ID ABLM2_HUMAN Reviewed; 611 AA. AC Q6H8Q1; E9PF39; Q08E71; Q19VH0; Q6H8Q0; Q6NX73; Q8N3C5; Q8N9E9; Q8N9G2; AC Q96JL7; DT 07-DEC-2004, integrated into UniProtKB/Swiss-Prot. DT 07-DEC-2004, sequence version 2. DT 28-JAN-2026, entry version 178. DE RecName: Full=Actin-binding LIM protein 2; DE Short=abLIM-2; DE AltName: Full=Actin-binding LIM protein family member 2; GN Name=ABLIM2; Synonyms=KIAA1808; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 7), FUNCTION, TISSUE SPECIFICITY, AND RP INTERACTION WITH ABRA AND F-ACTIN. RC TISSUE=Heart; RX PubMed=17194709; DOI=10.1074/jbc.m607549200; RA Barrientos T., Frank D., Kuwahara K., Bezprozvannaya S., Pipes G.C.T., RA Bassel-Duby R., Richardson J.A., Katus H.A., Olson E.N., Frey N.; RT "Two novel members of the ABLIM protein family, ABLIM-2 and -3, associate RT with STARS and directly bind F-actin."; RL J. Biol. Chem. 282:8393-8403(2007). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2). RA Klimov E.A., Rakhmanaliev E.R., Rudco O.I.; RT "Structure and transcriptional activity of the ABLIM2 gene of human, mouse RT and rat."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4). RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 6 AND 8). RC TISSUE=PNS; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 34-611 (ISOFORM 2). RC TISSUE=Brain; RX PubMed=11347906; DOI=10.1093/dnares/8.2.85; RA Nagase T., Nakayama M., Nakajima D., Kikuno R., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XX. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 8:85-95(2001). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 390-572 (ISOFORM 5). RC TISSUE=Amygdala; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-364, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [10] RP STRUCTURE BY NMR OF 73-140 AND 212-271, AND ZINC-BINDING SITES. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the LIM domain of the human actin binding LIM RT protein 2."; RL Submitted (FEB-2009) to the PDB data bank. RN [11] RP VARIANTS [LARGE SCALE ANALYSIS] ARG-227 AND MET-274. RX PubMed=18772397; DOI=10.1126/science.1164368; RA Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., RA Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., RA Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., RA Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., RA Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., RA Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., RA Velculescu V.E., Kinzler K.W.; RT "Core signaling pathways in human pancreatic cancers revealed by global RT genomic analyses."; RL Science 321:1801-1806(2008). CC -!- FUNCTION: May act as scaffold protein. May stimulate ABRA activity and CC ABRA-dependent SRF transcriptional activity. CC {ECO:0000269|PubMed:17194709}. CC -!- SUBUNIT: Interacts with F-actin and ABRA. CC {ECO:0000269|PubMed:17194709}. CC -!- INTERACTION: CC Q6H8Q1-8; A0A0S2Z5Z3: C6orf142; NbExp=3; IntAct=EBI-16436655, EBI-16435510; CC Q6H8Q1-8; A0A0S2Z6I7: C6orf142; NbExp=4; IntAct=EBI-16436655, EBI-16435493; CC Q6H8Q1-8; P28329-3: CHAT; NbExp=3; IntAct=EBI-16436655, EBI-25837549; CC Q6H8Q1-8; G5E9A7: DMWD; NbExp=3; IntAct=EBI-16436655, EBI-10976677; CC Q6H8Q1-8; P22607: FGFR3; NbExp=3; IntAct=EBI-16436655, EBI-348399; CC Q6H8Q1-8; P14136: GFAP; NbExp=3; IntAct=EBI-16436655, EBI-744302; CC Q6H8Q1-8; Q8WXH2: JPH3; NbExp=3; IntAct=EBI-16436655, EBI-1055254; CC Q6H8Q1-8; P02545: LMNA; NbExp=3; IntAct=EBI-16436655, EBI-351935; CC Q6H8Q1-8; P35240: NF2; NbExp=3; IntAct=EBI-16436655, EBI-1014472; CC Q6H8Q1-8; Q9BZ23-2: PANK2; NbExp=3; IntAct=EBI-16436655, EBI-25929070; CC Q6H8Q1-8; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-16436655, EBI-5235340; CC -!- SUBCELLULAR LOCATION: Cytoplasm. Note=In skeletal muscle, sarcomeric or CC cosarcomeric localization. {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=9; CC Name=1; CC IsoId=Q6H8Q1-1; Sequence=Displayed; CC Name=2; CC IsoId=Q6H8Q1-2; Sequence=VSP_012117; CC Name=3; CC IsoId=Q6H8Q1-3; Sequence=VSP_012113, VSP_012115, VSP_012117; CC Name=4; CC IsoId=Q6H8Q1-4; Sequence=VSP_012112, VSP_012113, VSP_012114, CC VSP_012116; CC Name=5; CC IsoId=Q6H8Q1-5; Sequence=VSP_012116, VSP_012117; CC Name=6; CC IsoId=Q6H8Q1-6; Sequence=VSP_012113, VSP_012115, VSP_012116, CC VSP_012118, VSP_012119; CC Name=7; CC IsoId=Q6H8Q1-7; Sequence=VSP_012115; CC Name=8; CC IsoId=Q6H8Q1-8; Sequence=VSP_012115, VSP_012116, VSP_012117; CC Name=9; CC IsoId=Q6H8Q1-9; Sequence=VSP_046646, VSP_012116; CC -!- TISSUE SPECIFICITY: Highly expressed in skeletal muscle. CC {ECO:0000269|PubMed:17194709}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH67214.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; DQ413177; ABD83330.1; -; mRNA. DR EMBL; AJ748600; CAG38375.1; -; mRNA. DR EMBL; AJ748601; CAG38376.1; -; mRNA. DR EMBL; AK094754; BAC04414.1; -; mRNA. DR EMBL; AK094798; BAC04427.1; -; mRNA. DR EMBL; AC097381; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC104650; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC114807; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC067214; AAH67214.1; ALT_INIT; mRNA. DR EMBL; BC122567; AAI22568.1; -; mRNA. DR EMBL; AB058711; BAB47437.1; -; mRNA. DR EMBL; AL834195; CAD38885.2; -; mRNA. DR CCDS; CCDS47011.1; -. [Q6H8Q1-7] DR CCDS; CCDS47012.1; -. [Q6H8Q1-2] DR CCDS; CCDS47013.1; -. [Q6H8Q1-1] DR CCDS; CCDS47014.1; -. [Q6H8Q1-9] DR CCDS; CCDS47015.1; -. [Q6H8Q1-3] DR CCDS; CCDS47016.1; -. [Q6H8Q1-6] DR CCDS; CCDS54719.1; -. [Q6H8Q1-8] DR CCDS; CCDS68669.1; -. [Q6H8Q1-4] DR RefSeq; NP_001123555.1; NM_001130083.2. [Q6H8Q1-9] DR RefSeq; NP_001123556.1; NM_001130084.2. [Q6H8Q1-1] DR RefSeq; NP_001123557.1; NM_001130085.2. [Q6H8Q1-2] DR RefSeq; NP_001123558.1; NM_001130086.2. [Q6H8Q1-7] DR RefSeq; NP_001123559.1; NM_001130087.2. [Q6H8Q1-3] DR RefSeq; NP_001123560.1; NM_001130088.2. [Q6H8Q1-6] DR RefSeq; NP_001273617.1; NM_001286688.2. [Q6H8Q1-4] DR RefSeq; NP_115808.3; NM_032432.4. [Q6H8Q1-8] DR PDB; 1V6G; NMR; -; A=73-140. DR PDB; 1WIG; NMR; -; A=212-271. DR PDB; 2L3X; NMR; -; A=546-611. DR PDBsum; 1V6G; -. DR PDBsum; 1WIG; -. DR PDBsum; 2L3X; -. DR AlphaFoldDB; Q6H8Q1; -. DR BMRB; Q6H8Q1; -. DR SMR; Q6H8Q1; -. DR BioGRID; 124086; 18. DR FunCoup; Q6H8Q1; 158. DR IntAct; Q6H8Q1; 26. DR STRING; 9606.ENSP00000393511; -. DR GlyCosmos; Q6H8Q1; 4 sites, 1 glycan. DR GlyGen; Q6H8Q1; 6 sites, 1 O-linked glycan (6 sites). DR iPTMnet; Q6H8Q1; -. DR PhosphoSitePlus; Q6H8Q1; -. DR SwissPalm; Q6H8Q1; -. DR BioMuta; ABLIM2; -. DR DMDM; 56404514; -. DR jPOST; Q6H8Q1; -. DR MassIVE; Q6H8Q1; -. DR PaxDb; 9606-ENSP00000393511; -. DR PeptideAtlas; Q6H8Q1; -. DR ProteomicsDB; 20020; -. DR ProteomicsDB; 66340; -. [Q6H8Q1-1] DR ProteomicsDB; 66341; -. [Q6H8Q1-2] DR ProteomicsDB; 66342; -. [Q6H8Q1-3] DR ProteomicsDB; 66343; -. [Q6H8Q1-4] DR ProteomicsDB; 66344; -. [Q6H8Q1-5] DR ProteomicsDB; 66345; -. [Q6H8Q1-6] DR ProteomicsDB; 66346; -. [Q6H8Q1-7] DR ProteomicsDB; 66347; -. [Q6H8Q1-8] DR Antibodypedia; 22725; 48 antibodies from 16 providers. DR DNASU; 84448; -. DR Ensembl; ENST00000341937.9; ENSP00000342813.5; ENSG00000163995.22. [Q6H8Q1-1] DR Ensembl; ENST00000361581.9; ENSP00000355003.5; ENSG00000163995.22. [Q6H8Q1-2] DR Ensembl; ENST00000361737.9; ENSP00000354887.5; ENSG00000163995.22. [Q6H8Q1-3] DR Ensembl; ENST00000407564.7; ENSP00000384658.3; ENSG00000163995.22. [Q6H8Q1-8] DR Ensembl; ENST00000428004.6; ENSP00000389410.2; ENSG00000163995.22. [Q6H8Q1-6] DR Ensembl; ENST00000447017.7; ENSP00000393511.2; ENSG00000163995.22. [Q6H8Q1-9] DR Ensembl; ENST00000505872.5; ENSP00000421283.1; ENSG00000163995.22. [Q6H8Q1-7] DR Ensembl; ENST00000514025.5; ENSP00000423661.1; ENSG00000163995.22. [Q6H8Q1-4] DR GeneID; 84448; -. DR KEGG; hsa:84448; -. DR MANE-Select; ENST00000447017.7; ENSP00000393511.2; NM_001130083.2; NP_001123555.1. [Q6H8Q1-9] DR UCSC; uc003gkj.5; human. [Q6H8Q1-1] DR AGR; HGNC:19195; -. DR ClinPGx; PA134940437; -. DR CTD; 84448; -. DR DisGeNET; 84448; -. DR GeneCards; ABLIM2; -. DR HGNC; HGNC:19195; ABLIM2. DR HPA; ENSG00000163995; Group enriched (skeletal muscle, tongue). DR MIM; 612544; gene. DR OpenTargets; ENSG00000163995; -. DR VEuPathDB; HostDB:ENSG00000163995; -. DR eggNOG; KOG1044; Eukaryota. DR GeneTree; ENSGT00950000182850; -. DR HOGENOM; CLU_001357_12_3_1; -. DR InParanoid; Q6H8Q1; -. DR OMA; NTNCAYL; -. DR OrthoDB; 1746725at2759; -. DR PAN-GO; Q6H8Q1; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q6H8Q1; -. DR PathwayCommons; Q6H8Q1; -. DR Reactome; R-HSA-418885; DCC mediated attractive signaling. DR SignaLink; Q6H8Q1; -. DR Agora; ENSG00000163995; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 84448; 10 hits in 1151 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; ABLIM2; human. DR EvolutionaryTrace; Q6H8Q1; -. DR GenomeRNAi; 84448; -. DR Pharos; Q6H8Q1; Tdark. DR PRO; PR:Q6H8Q1; -. DR Proteomes; UP000005640; Chromosome 4. DR RNAct; Q6H8Q1; protein. DR Bgee; ENSG00000163995; Expressed in tibialis anterior and 160 other cell types or tissues. DR ExpressionAtlas; Q6H8Q1; baseline and differential. DR GO; GO:0015629; C:actin cytoskeleton; IDA:MGI. DR GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0051015; F:actin filament binding; IBA:GO_Central. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0007010; P:cytoskeleton organization; IEA:InterPro. DR GO; GO:0030032; P:lamellipodium assembly; IBA:GO_Central. DR CDD; cd09327; LIM1_abLIM; 1. DR CDD; cd09328; LIM2_abLIM; 1. DR CDD; cd09329; LIM3_abLIM; 1. DR CDD; cd09330; LIM4_abLIM; 1. DR FunFam; 2.10.110.10:FF:000003; actin-binding LIM protein 1 isoform X1; 1. DR FunFam; 2.10.110.10:FF:000004; actin-binding LIM protein 1 isoform X1; 1. DR FunFam; 2.10.110.10:FF:000007; actin-binding LIM protein 1 isoform X1; 1. DR FunFam; 1.10.950.10:FF:000001; actin-binding LIM protein 1 isoform X2; 1. DR FunFam; 2.10.110.10:FF:000053; Actin-binding LIM protein family, member 2; 1. DR Gene3D; 2.10.110.10; Cysteine Rich Protein; 4. DR Gene3D; 1.10.950.10; Villin headpiece domain; 1. DR InterPro; IPR032402; AbLIM_anchor. DR InterPro; IPR051618; Actin-binding_LIM. DR InterPro; IPR003128; Villin_headpiece. DR InterPro; IPR036886; Villin_headpiece_dom_sf. DR InterPro; IPR001781; Znf_LIM. DR PANTHER; PTHR24213; ACTIN-BINDING LIM PROTEIN; 1. DR PANTHER; PTHR24213:SF6; ACTIN-BINDING LIM PROTEIN 2; 1. DR Pfam; PF16182; AbLIM_anchor; 2. DR Pfam; PF00412; LIM; 4. DR Pfam; PF02209; VHP; 1. DR SMART; SM00132; LIM; 4. DR SMART; SM00153; VHP; 1. DR SUPFAM; SSF57716; Glucocorticoid receptor-like (DNA-binding domain); 6. DR SUPFAM; SSF47050; VHP, Villin headpiece domain; 1. DR PROSITE; PS51089; HP; 1. DR PROSITE; PS00478; LIM_DOMAIN_1; 4. DR PROSITE; PS50023; LIM_DOMAIN_2; 4. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Cytoplasm; LIM domain; Metal-binding; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW Zinc. FT CHAIN 1..611 FT /note="Actin-binding LIM protein 2" FT /id="PRO_0000075699" FT DOMAIN 22..81 FT /note="LIM zinc-binding 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00125" FT DOMAIN 81..141 FT /note="LIM zinc-binding 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00125" FT DOMAIN 151..210 FT /note="LIM zinc-binding 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00125" FT DOMAIN 210..270 FT /note="LIM zinc-binding 4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00125" FT DOMAIN 543..611 FT /note="HP" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00595" FT REGION 269..295 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 336..527 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 269..278 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 279..295 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 363..372 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 393..404 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 473..488 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 83 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 86 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 103 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 106 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 109 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT BINDING 112 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT BINDING 131 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT BINDING 134 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT BINDING 212 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="3" FT BINDING 215 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="3" FT BINDING 232 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="3" FT BINDING 235 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="3" FT BINDING 238 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="4" FT BINDING 241 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="4" FT BINDING 260 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="4" FT BINDING 263 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="4" FT MOD_RES 282 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q6KC51" FT MOD_RES 294 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BL65" FT MOD_RES 364 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 367 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BL65" FT MOD_RES 452 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q6KC51" FT MOD_RES 472 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q8BL65" FT MOD_RES 476 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q6KC51" FT MOD_RES 578 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q6KC51" FT VAR_SEQ 1..243 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_012112" FT VAR_SEQ 349 FT /note="E -> ESPQLLSPTPTE (in isoform 3, isoform 4 and FT isoform 6)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_012113" FT VAR_SEQ 389..422 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_012114" FT VAR_SEQ 389 FT /note="P -> PAGTVSVGTSSCLSLSQHPSPTSVFRHHYIPYFR (in isoform FT 9)" FT /evidence="ECO:0000305" FT /id="VSP_046646" FT VAR_SEQ 390..441 FT /note="Missing (in isoform 3, isoform 6, isoform 7 and FT isoform 8)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:17194709" FT /id="VSP_012115" FT VAR_SEQ 459 FT /note="K -> KQ (in isoform 4, isoform 5, isoform 6, isoform FT 8 and isoform 9)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:17974005" FT /id="VSP_012116" FT VAR_SEQ 506..545 FT /note="RFPYSKSDPLPGHGKNGLDQRNANLAPCGADPDASWGMRE -> Q (in FT isoform 2, isoform 3, isoform 5 and isoform 8)" FT /evidence="ECO:0000303|PubMed:11347906, FT ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:17974005, ECO:0000303|Ref.2" FT /id="VSP_012117" FT VAR_SEQ 507..510 FT /note="FPYS -> EWFF (in isoform 6)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_012118" FT VAR_SEQ 511..611 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_012119" FT VARIANT 227 FT /note="G -> R (in a pancreatic ductal adenocarcinoma FT sample; somatic mutation; dbSNP:rs757430763)" FT /evidence="ECO:0000269|PubMed:18772397" FT /id="VAR_062665" FT VARIANT 274 FT /note="K -> M (in a pancreatic ductal adenocarcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:18772397" FT /id="VAR_062666" FT CONFLICT 240 FT /note="R -> G (in Ref. 3; BAC04414)" FT /evidence="ECO:0000305" FT CONFLICT 312 FT /note="D -> G (in Ref. 3; BAC04414)" FT /evidence="ECO:0000305" FT HELIX 75..77 FT /evidence="ECO:0007829|PDB:1V6G" FT TURN 84..86 FT /evidence="ECO:0007829|PDB:1V6G" FT STRAND 95..97 FT /evidence="ECO:0007829|PDB:1V6G" FT STRAND 100..102 FT /evidence="ECO:0007829|PDB:1V6G" FT TURN 104..106 FT /evidence="ECO:0007829|PDB:1V6G" FT STRAND 110..112 FT /evidence="ECO:0007829|PDB:1V6G" FT STRAND 118..120 FT /evidence="ECO:0007829|PDB:1V6G" FT STRAND 122..125 FT /evidence="ECO:0007829|PDB:1V6G" FT STRAND 128..131 FT /evidence="ECO:0007829|PDB:1V6G" FT HELIX 132..135 FT /evidence="ECO:0007829|PDB:1V6G" FT STRAND 213..215 FT /evidence="ECO:0007829|PDB:1WIG" FT TURN 233..235 FT /evidence="ECO:0007829|PDB:1WIG" FT STRAND 239..241 FT /evidence="ECO:0007829|PDB:1WIG" FT STRAND 252..254 FT /evidence="ECO:0007829|PDB:1WIG" FT STRAND 257..259 FT /evidence="ECO:0007829|PDB:1WIG" FT HELIX 263..266 FT /evidence="ECO:0007829|PDB:1WIG" FT STRAND 268..271 FT /evidence="ECO:0007829|PDB:1WIG" FT HELIX 551..554 FT /evidence="ECO:0007829|PDB:2L3X" FT HELIX 556..558 FT /evidence="ECO:0007829|PDB:2L3X" FT TURN 559..561 FT /evidence="ECO:0007829|PDB:2L3X" FT STRAND 570..572 FT /evidence="ECO:0007829|PDB:2L3X" FT HELIX 573..576 FT /evidence="ECO:0007829|PDB:2L3X" FT HELIX 579..586 FT /evidence="ECO:0007829|PDB:2L3X" FT HELIX 590..595 FT /evidence="ECO:0007829|PDB:2L3X" FT HELIX 598..607 FT /evidence="ECO:0007829|PDB:2L3X" SQ SEQUENCE 611 AA; 67812 MW; 225A4E25646B370B CRC64; MSAVSQPQAA PSPLEKSPST AILCNTCGNV CKGEVLRVQD KYFHIKCFVC KACGCDLAEG GFFVRQGEYI CTLDYQRLYG TRCFSCDQFI EGEVVSALGK TYHPDCFVCA VCRLPFPPGD RVTFNGKECM CQKCSLPVSV GSSAHLSQGL RSCGGCGTEI KNGQALVALD KHWHLGCFKC KSCGKLLNAE YISKDGLPYC EADYHAKFGI RCDSCEKYIT GRVLEAGEKH YHPSCALCVR CGQMFAEGEE MYLQGSSIWH PACRQAARTE DRNKETRTSS ESIISVPASS TSGSPSRVIY AKLGGEILDY RDLAALPKSK AIYDIDRPDM ISYSPYISHS AGDRQSYGEG DQDDRSYKQC RTSSPSSTGS VSLGRYTPTS RSPQHYSRPG SESGRSTPSL SVLSDSKPPP STYQQAPRHF HVPDTGVKDN IYRKPPIYRQ HAARRSDGED GSLDQDNRKK SSWLMLKGDA DTRTNSPDLD TQSLSHSSGT DRDPLQRMAG DSFHSRFPYS KSDPLPGHGK NGLDQRNANL APCGADPDAS WGMREYKIYP YDSLIVTNRI RVKLPKDVDR TRLERHLSPE EFQEVFGMSI EEFDRLALWK RNDLKKKALL F // ID ADA19_HUMAN Reviewed; 955 AA. AC Q9H013; Q9BZL5; Q9UHP2; DT 31-JAN-2002, integrated into UniProtKB/Swiss-Prot. DT 10-AUG-2010, sequence version 3. DT 28-JAN-2026, entry version 211. DE RecName: Full=Disintegrin and metalloproteinase domain-containing protein 19; DE Short=ADAM 19; DE EC=3.4.24.-; DE AltName: Full=Meltrin-beta; DE AltName: Full=Metalloprotease and disintegrin dendritic antigen marker; DE Short=MADDAM; DE Flags: Precursor; GN Name=ADAM19; Synonyms=MLTNB; ORFNames=FKSG34; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A). RA Wang Y.-G., Gong L.; RT "Identification of FKSG34, a novel human gene encoding for metalloprotease- RT disintegrin meltrin beta."; RL Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B), AND VARIANT SER-4. RC TISSUE=Lymph node; RX PubMed=10887142; RA Fritsche J., Moser M., Faust S., Peuker A., Buettner R., Andreesen R., RA Kreutz M.; RT "Molecular cloning and characterization of a human metalloprotease RT disintegrin a novel marker for dendritic cell differentiation."; RL Blood 96:732-739(2000). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B). RC TISSUE=Dendritic cell; RX PubMed=11162584; DOI=10.1006/bbrc.2000.4200; RA Wei P., Zhao Y.-G., Zhuang L., Ruben S., Sang Q.-X.A.; RT "Expression and enzymatic activity of human disintegrin and RT metalloproteinase ADAM19/meltrin beta."; RL Biochem. Biophys. Res. Commun. 280:744-755(2001). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 99-955 (ISOFORM A). RA Xu R., Cai J., Ying B., Wang F., Xu T., Zhao S., Li C.; RT "Partial sequence of Homo sapiens ADAM19."; RL Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases. RN [6] RP INTERACTION WITH SH3PXD2A. RX PubMed=12615925; DOI=10.1074/jbc.m300267200; RA Abram C.L., Seals D.F., Pass I., Salinsky D., Maurer L., Roth T.M., RA Courtneidge S.A.; RT "The adaptor protein fish associates with members of the ADAMs family and RT localizes to podosomes of Src-transformed cells."; RL J. Biol. Chem. 278:16844-16851(2003). RN [7] RP VARIANTS [LARGE SCALE ANALYSIS] GLN-133 AND THR-298. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [8] RP VARIANT [LARGE SCALE ANALYSIS] GLN-609. RX PubMed=18772397; DOI=10.1126/science.1164368; RA Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., RA Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., RA Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., RA Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., RA Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., RA Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., RA Velculescu V.E., Kinzler K.W.; RT "Core signaling pathways in human pancreatic cancers revealed by global RT genomic analyses."; RL Science 321:1801-1806(2008). CC -!- FUNCTION: Participates in the proteolytic processing of beta-type CC neuregulin isoforms which are involved in neurogenesis and CC synaptogenesis, suggesting a regulatory role in glial cell. Also CC cleaves alpha-2 macroglobulin. May be involved in osteoblast CC differentiation and/or osteoblast activity in bone (By similarity). CC {ECO:0000250}. CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250}; CC Note=Binds 1 zinc ion per subunit. {ECO:0000250}; CC -!- SUBUNIT: Interacts with SH3PXD2A. {ECO:0000269|PubMed:12615925}. CC -!- INTERACTION: CC Q9H013; Q9NYB9: ABI2; NbExp=2; IntAct=EBI-8567699, EBI-743598; CC Q9H013; Q8TE68: EPS8L1; NbExp=2; IntAct=EBI-8567699, EBI-7487998; CC Q9H013; Q5TCZ1: SH3PXD2A; NbExp=2; IntAct=EBI-8567699, EBI-2483234; CC Q9H013; O95153: TSPOAP1; NbExp=2; IntAct=EBI-8567699, EBI-5915931; CC -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=A; CC IsoId=Q9H013-1; Sequence=Displayed; CC Name=B; CC IsoId=Q9H013-2; Sequence=VSP_005481; CC -!- TISSUE SPECIFICITY: Expressed in many normal organ tissues and several CC cancer cell lines. CC -!- INDUCTION: By 1,25(OH)2VD3 in monocytes. CC -!- DOMAIN: The conserved cysteine present in the cysteine-switch motif CC binds the catalytic zinc ion, thus inhibiting the enzyme. The CC dissociation of the cysteine from the zinc ion upon the activation- CC peptide release activates the enzyme. CC -!- PTM: The precursor is cleaved by a furin endopeptidase. {ECO:0000250}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF326918; AAG50282.1; -; mRNA. DR EMBL; Y13786; CAC20585.1; -; mRNA. DR EMBL; AF311317; AAK07852.1; -; mRNA. DR EMBL; AC008676; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC008694; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC106801; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AF134707; AAF22162.1; -; mRNA. DR CCDS; CCDS4338.1; -. [Q9H013-2] DR RefSeq; NP_150377.1; NM_033274.5. [Q9H013-2] DR RefSeq; XP_047273814.1; XM_047417858.1. [Q9H013-1] DR RefSeq; XP_054209714.1; XM_054353739.1. [Q9H013-1] DR AlphaFoldDB; Q9H013; -. DR SMR; Q9H013; -. DR BioGRID; 114267; 52. DR FunCoup; Q9H013; 775. DR IntAct; Q9H013; 44. DR MINT; Q9H013; -. DR STRING; 9606.ENSP00000257527; -. DR MEROPS; M12.214; -. DR GlyCosmos; Q9H013; 4 sites, No reported glycans. DR GlyGen; Q9H013; 8 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (4 sites). DR iPTMnet; Q9H013; -. DR PhosphoSitePlus; Q9H013; -. DR SwissPalm; Q9H013; -. DR BioMuta; ADAM19; -. DR DMDM; 302393821; -. DR jPOST; Q9H013; -. DR MassIVE; Q9H013; -. DR PaxDb; 9606-ENSP00000257527; -. DR PeptideAtlas; Q9H013; -. DR ProteomicsDB; 80195; -. [Q9H013-1] DR ProteomicsDB; 80196; -. [Q9H013-2] DR Antibodypedia; 16547; 249 antibodies from 35 providers. DR DNASU; 8728; -. DR Ensembl; ENST00000257527.9; ENSP00000257527.5; ENSG00000135074.17. [Q9H013-2] DR Ensembl; ENST00000517905.1; ENSP00000428654.1; ENSG00000135074.17. [Q9H013-1] DR GeneID; 8728; -. DR KEGG; hsa:8728; -. DR MANE-Select; ENST00000257527.9; ENSP00000257527.5; NM_033274.5; NP_150377.1. [Q9H013-2] DR UCSC; uc003lwz.5; human. [Q9H013-1] DR AGR; HGNC:197; -. DR ClinPGx; PA24514; -. DR CTD; 8728; -. DR DisGeNET; 8728; -. DR GeneCards; ADAM19; -. DR HGNC; HGNC:197; ADAM19. DR HPA; ENSG00000135074; Low tissue specificity. DR MIM; 603640; gene. DR OpenTargets; ENSG00000135074; -. DR VEuPathDB; HostDB:ENSG00000135074; -. DR eggNOG; KOG3607; Eukaryota. DR GeneTree; ENSGT00940000159624; -. DR HOGENOM; CLU_012714_7_0_1; -. DR InParanoid; Q9H013; -. DR OMA; HGVCCEN; -. DR OrthoDB; 5951731at2759; -. DR PAN-GO; Q9H013; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q9H013; -. DR PathwayCommons; Q9H013; -. DR Reactome; R-HSA-8941237; Invadopodia formation. DR Reactome; R-HSA-9762292; Regulation of CDH11 function. DR SABIO-RK; Q9H013; -. DR SignaLink; Q9H013; -. DR SIGNOR; Q9H013; -. DR Agora; ENSG00000135074; -. DR BioGRID-ORCS; 8728; 9 hits in 1148 CRISPR screens. DR ChiTaRS; ADAM19; human. DR GeneWiki; ADAM19; -. DR GenomeRNAi; 8728; -. DR Pharos; Q9H013; Tbio. DR PRO; PR:Q9H013; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; Q9H013; protein. DR Bgee; ENSG00000135074; Expressed in oocyte and 180 other cell types or tissues. DR ExpressionAtlas; Q9H013; baseline and differential. DR GO; GO:0031012; C:extracellular matrix; HDA:BHF-UCL. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; TAS:Reactome. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0004222; F:metalloendopeptidase activity; IMP:UniProtKB. DR GO; GO:1902945; F:metalloendopeptidase activity involved in amyloid precursor protein catabolic process; IMP:ARUK-UCL. DR GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW. DR GO; GO:0042987; P:amyloid precursor protein catabolic process; IMP:ARUK-UCL. DR GO; GO:0006509; P:membrane protein ectodomain proteolysis; IBA:GO_Central. DR GO; GO:0001890; P:placenta development; IEP:UniProtKB. DR GO; GO:2000049; P:positive regulation of cell-cell adhesion mediated by cadherin; IDA:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB. DR GO; GO:0016485; P:protein processing; IMP:ARUK-UCL. DR CDD; cd04269; ZnMc_adamalysin_II_like; 1. DR FunFam; 3.40.390.10:FF:000002; Disintegrin and metalloproteinase domain-containing protein 22; 1. DR FunFam; 4.10.70.10:FF:000001; Disintegrin and metalloproteinase domain-containing protein 22; 1. DR Gene3D; 3.40.390.10; Collagenase (Catalytic Domain); 1. DR Gene3D; 4.10.70.10; Disintegrin domain; 1. DR InterPro; IPR006586; ADAM_Cys-rich. DR InterPro; IPR018358; Disintegrin_CS. DR InterPro; IPR001762; Disintegrin_dom. DR InterPro; IPR036436; Disintegrin_dom_sf. DR InterPro; IPR000742; EGF. DR InterPro; IPR024079; MetalloPept_cat_dom_sf. DR InterPro; IPR001590; Peptidase_M12B. DR InterPro; IPR002870; Peptidase_M12B_N. DR InterPro; IPR034027; Reprolysin_adamalysin. DR PANTHER; PTHR11905; ADAM A DISINTEGRIN AND METALLOPROTEASE DOMAIN; 1. DR PANTHER; PTHR11905:SF19; DISINTEGRIN AND METALLOPROTEINASE DOMAIN-CONTAINING PROTEIN 19; 1. DR Pfam; PF08516; ADAM_CR; 1. DR Pfam; PF00200; Disintegrin; 1. DR Pfam; PF01562; Pep_M12B_propep; 1. DR Pfam; PF01421; Reprolysin; 1. DR PRINTS; PR00289; DISINTEGRIN. DR SMART; SM00608; ACR; 1. DR SMART; SM00050; DISIN; 1. DR SUPFAM; SSF57552; Blood coagulation inhibitor (disintegrin); 1. DR SUPFAM; SSF55486; Metalloproteases ('zincins'), catalytic domain; 1. DR PROSITE; PS50215; ADAM_MEPRO; 1. DR PROSITE; PS00427; DISINTEGRIN_1; 1. DR PROSITE; PS50214; DISINTEGRIN_2; 1. DR PROSITE; PS01186; EGF_2; 1. DR PROSITE; PS50026; EGF_3; 1. DR PROSITE; PS00142; ZINC_PROTEASE; 1. PE 1: Evidence at protein level; KW Alternative splicing; Disulfide bond; EGF-like domain; Glycoprotein; KW Hydrolase; Membrane; Metal-binding; Metalloprotease; Protease; KW Proteomics identification; Reference proteome; SH3-binding; Signal; KW Transmembrane; Transmembrane helix; Zinc; Zymogen. FT SIGNAL 1..25 FT /evidence="ECO:0000255" FT PROPEP 26..202 FT /evidence="ECO:0000250" FT /id="PRO_0000029102" FT CHAIN 203..955 FT /note="Disintegrin and metalloproteinase domain-containing FT protein 19" FT /id="PRO_0000029103" FT TOPO_DOM 203..699 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 700..720 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 721..955 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 210..408 FT /note="Peptidase M12B" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00276" FT DOMAIN 416..502 FT /note="Disintegrin" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00068" FT DOMAIN 650..682 FT /note="EGF-like" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00076" FT REGION 753..917 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 130..137 FT /note="Cysteine switch" FT /evidence="ECO:0000250" FT MOTIF 833..844 FT /note="SH3-binding" FT /evidence="ECO:0000255" FT COMPBIAS 753..771 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 787..796 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 833..844 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 346 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00276, FT ECO:0000255|PROSITE-ProRule:PRU10095" FT BINDING 132 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_note="catalytic" FT /note="in inhibited form" FT /evidence="ECO:0000250" FT BINDING 345 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_note="catalytic" FT /evidence="ECO:0000250" FT BINDING 349 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_note="catalytic" FT /evidence="ECO:0000250" FT BINDING 355 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_note="catalytic" FT /evidence="ECO:0000250" FT CARBOHYD 144 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 444 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 447 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 645 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 320..403 FT /evidence="ECO:0000250" FT DISULFID 360..387 FT /evidence="ECO:0000250" FT DISULFID 361..370 FT /evidence="ECO:0000250" FT DISULFID 474..494 FT /evidence="ECO:0000250" FT DISULFID 654..664 FT /evidence="ECO:0000250" FT DISULFID 658..670 FT /evidence="ECO:0000250" FT DISULFID 672..681 FT /evidence="ECO:0000250" FT VAR_SEQ 902..955 FT /note="VSPREALKVKAGTRGLQGGRCRVEKTKQFMLLVVWTELPEQKPRAKHSCFLV FT PA -> FPEYRSQRAGGMISSKI (in isoform B)" FT /evidence="ECO:0000303|PubMed:10887142, FT ECO:0000303|PubMed:11162584" FT /id="VSP_005481" FT VARIANT 4 FT /note="G -> S (in dbSNP:rs11465228)" FT /evidence="ECO:0000269|PubMed:10887142" FT /id="VAR_057066" FT VARIANT 133 FT /note="R -> Q (in a colorectal cancer sample; somatic FT mutation; dbSNP:rs200894535)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036146" FT VARIANT 298 FT /note="A -> T (in a colorectal cancer sample; somatic FT mutation; dbSNP:rs1178207005)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036147" FT VARIANT 609 FT /note="H -> Q (in a pancreatic ductal adenocarcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:18772397" FT /id="VAR_062670" FT CONFLICT 32 FT /note="R -> SK (in Ref. 1; AAG50282)" FT /evidence="ECO:0000305" FT CONFLICT 557 FT /note="D -> V (in Ref. 1; AAG50282 and 5; AAF22162)" FT /evidence="ECO:0000305" FT CONFLICT 622 FT /note="D -> N (in Ref. 1; AAG50282 and 5; AAF22162)" FT /evidence="ECO:0000305" SQ SEQUENCE 955 AA; 104997 MW; 9C9D42BED18BF7F9 CRC64; MPGGAGAARL CLLAFALQPL RPRAAREPGW TRGSEEGSPK LQHELIIPQW KTSESPVREK HPLKAELRVM AEGRELILDL EKNEQLFAPS YTETHYTSSG NPQTTTRKLE DHCFYHGTVR ETELSSVTLS TCRGIRGLIT VSSNLSYVIE PLPDSKGQHL IYRSEHLKPP PGNCGFEHSK PTTRDWALQF TQQTKKRPRR MKREDLNSMK YVELYLVADY LEFQKNRRDQ DATKHKLIEI ANYVDKFYRS LNIRIALVGL EVWTHGNMCE VSENPYSTLW SFLSWRRKLL AQKYHDNAQL ITGMSFHGTT IGLAPLMAMC SVYQSGGVNM DHSENAIGVA ATMAHEMGHN FGMTHDSADC CSASAADGGC IMAAATGHPF PKVFNGCNRR ELDRYLQSGG GMCLSNMPDT RMLYGGRRCG NGYLEDGEEC DCGEEEECNN PCCNASNCTL RPGAECAHGS CCHQCKLLAP GTLCREQARQ CDLPEFCTGK SPHCPTNFYQ MDGTPCEGGQ AYCYNGMCLT YQEQCQQLWG PGARPAPDLC FEKVNVAGDT FGNCGKDMNG EHRKCNMRDA KCGKIQCQSS EARPLESNAV PIDTTIIMNG RQIQCRGTHV YRGPEEEGDM LDPGLVMTGT KCGYNHICFE GQCRNTSFFE TEGCGKKCNG HGVCNNNQNC HCLPGWAPPF CNTPGHGGSI DSGPMPPESV GPVVAGVLVA ILVLAVLMLM YYCCRQNNKL GQLKPSALPS KLRQQFSCPF RVSQNSGTGH ANPTFKLQTP QGKRKVINTP EILRKPSQPP PRPPPDYLRG GSPPAPLPAH LSRAARNSPG PGSQIERTES SRRPPPSRPI PPAPNCIVSQ DFSRPRPPQK ALPANPVPGR RSLPRPGGAS PLRPPGAGPQ QSRPLAALAP KVSPREALKV KAGTRGLQGG RCRVEKTKQF MLLVVWTELP EQKPRAKHSC FLVPA // ID BARD1_HUMAN Reviewed; 777 AA. AC Q99728; F6MDH7; F6MDH8; F6MDH9; O43574; Q53SS5; DT 21-FEB-2001, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 2. DT 28-JAN-2026, entry version 239. DE RecName: Full=BRCA1-associated RING domain protein 1; DE Short=BARD-1; DE EC=2.3.2.27 {ECO:0000269|PubMed:12890688, ECO:0000269|PubMed:20351172}; DE AltName: Full=RING-type E3 ubiquitin transferase BARD1 {ECO:0000305}; GN Name=BARD1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CHARACTERIZATION. RC TISSUE=B-cell; RX PubMed=8944023; DOI=10.1038/ng1296-430; RA Wu L.C., Wang Z.W., Tsan J.T., Spillman M.A., Phung A., Xu X.L., RA Yang M.-C.W., Hwang L.-Y., Bowcock A.M., Baer R.; RT "Identification of a RING protein that can interact in vivo with the BRCA1 RT gene product."; RL Nat. Genet. 14:430-440(1996). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-24; GLU-153; SER-378; RP MET-507; SER-557; HIS-564; CYS-658; LEU-695 AND ASN-761. RX PubMed=9425226; DOI=10.1093/hmg/7.2.195; RA Thai T.H., Du F., Tsan J.T., Jin Y., Phung A., Spillman M.A., Massa H.F., RA Muller C.Y., Ashfaq R., Mathis J.M., Miller D.S., Trask B.J., Baer R., RA Bowcock A.M.; RT "Mutations in the BRCA1-associated RING domain (BARD1) gene in primary RT breast, ovarian and uterine cancers."; RL Hum. Mol. Genet. 7:195-202(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA; BETA AND GAMMA), AND RP ALTERNATIVE SPLICING. RX PubMed=18089818; DOI=10.1158/0008-5472.can-07-2370; RA Li L., Ryser S., Dizin E., Pils D., Krainer M., Jefford C.E., Bertoni F., RA Zeillinger R., Irminger-Finger I.; RT "Oncogenic BARD1 isoforms expressed in gynecological cancers."; RL Cancer Res. 67:11876-11885(2007). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP DOMAINS. RX PubMed=10026184; DOI=10.1074/jbc.274.9.5659; RA Meza J.E., Brzovic P.S., King M.-C., Klevit R.E.; RT "Mapping the functional domains of BRCA1. Interaction of the ring finger RT domains of BRCA1 and BARD1."; RL J. Biol. Chem. 274:5659-5665(1999). RN [7] RP POSSIBLE FUNCTION. RX PubMed=10477523; DOI=10.1126/science.285.5433.1576; RA Kleiman F.E., Manley J.L.; RT "Functional interaction of BRCA1-associated BARD1 with polyadenylation RT factor CstF-50."; RL Science 285:1576-1579(1999). RN [8] RP FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH BRCA1. RX PubMed=12890688; DOI=10.1074/jbc.c300249200; RA Wu-Baer F., Lagrazon K., Yuan W., Baer R.; RT "The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an RT unconventional linkage involving lysine residue K6 of ubiquitin."; RL J. Biol. Chem. 278:34743-34746(2003). RN [9] RP FUNCTION, AND INTERACTION WITH BRCA1. RX PubMed=14976165; DOI=10.1093/hmg/ddh095; RA Morris J.R., Solomon E.; RT "BRCA1:BARD1 induces the formation of conjugated ubiquitin structures, RT dependent on K6 of ubiquitin, in cells during DNA replication and repair."; RL Hum. Mol. Genet. 13:807-817(2004). RN [10] RP IDENTIFICATION IN THE BRCA1-A COMPLEX. RX PubMed=17643122; DOI=10.1038/nsmb1277; RA Kim H., Huang J., Chen J.; RT "CCDC98 is a BRCA1-BRCT domain-binding protein involved in the DNA damage RT response."; RL Nat. Struct. Mol. Biol. 14:710-715(2007). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-391 AND THR-394, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [13] RP IDENTIFICATION IN THE BRCA1-A COMPLEX. RX PubMed=19261749; DOI=10.1101/gad.1770309; RA Wang B., Hurov K., Hofmann K., Elledge S.J.; RT "NBA1, a new player in the Brca1 A complex, is required for DNA damage RT resistance and checkpoint control."; RL Genes Dev. 23:729-739(2009). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [15] RP FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH BRCA1. RX PubMed=20351172; DOI=10.1128/mcb.01056-09; RA Wu-Baer F., Ludwig T., Baer R.; RT "The UBXN1 protein associates with autoubiquitinated forms of the BRCA1 RT tumor suppressor and inhibits its enzymatic function."; RL Mol. Cell. Biol. 30:2787-2798(2010). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-186 AND THR-299, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [17] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-170, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25755297; DOI=10.1074/mcp.o114.044792; RA Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V., RA Vertegaal A.C.; RT "System-wide analysis of SUMOylation dynamics in response to replication RT stress reveals novel small ubiquitin-like modified target proteins and RT acceptor lysines relevant for genome stability."; RL Mol. Cell. Proteomics 14:1419-1434(2015). RN [18] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-160; LYS-170; LYS-423 AND RP LYS-548, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [19] RP STRUCTURE BY NMR OF 26-140 IN COMPLEX WITH BRCA1 AND ZINC IONS, AND RP SUBUNIT. RX PubMed=11573085; DOI=10.1038/nsb1001-833; RA Brzovic P.S., Rajagopal P., Hoyt D.W., King M.C., Klevit R.E.; RT "Structure of a BRCA1-BARD1 heterodimeric RING-RING complex."; RL Nat. Struct. Biol. 8:833-837(2001). RN [20] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 568-777. RX PubMed=17550235; DOI=10.1021/bi700323t; RA Birrane G., Varma A.K., Soni A., Ladias J.A.; RT "Crystal structure of the BARD1 BRCT domains."; RL Biochemistry 46:7706-7712(2007). RN [21] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 569-777, INTERACTION WITH CSTF1, RP DOMAIN STRUCTURE, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=18842000; DOI=10.1021/bi801115g; RA Edwards R.A., Lee M.S., Tsutakawa S.E., Williams R.S., Nazeer I., RA Kleiman F.E., Tainer J.A., Glover J.N.; RT "The BARD1 C-terminal domain structure and interactions with RT polyadenylation factor CstF-50."; RL Biochemistry 47:11446-11456(2008). RN [22] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 425-555, IDENTIFICATION BY MASS RP SPECTROMETRY, DOMAINS ANK REPEATS, AND DOMAIN STRUCTURE. RX PubMed=18480049; DOI=10.1074/jbc.m802333200; RA Fox D. III, Le Trong I., Rajagopal P., Brzovic P.S., Stenkamp R.E., RA Klevit R.E.; RT "Crystal structure of the BARD1 ankyrin repeat domain and its functional RT consequences."; RL J. Biol. Chem. 283:21179-21186(2008). CC -!- FUNCTION: E3 ubiquitin-protein ligase. The BRCA1-BARD1 heterodimer CC specifically mediates the formation of 'Lys-6'-linked polyubiquitin CC chains and coordinates a diverse range of cellular pathways such as DNA CC damage repair, ubiquitination and transcriptional regulation to CC maintain genomic stability. Plays a central role in the control of the CC cell cycle in response to DNA damage. Acts by mediating ubiquitin E3 CC ligase activity that is required for its tumor suppressor function. CC Also forms a heterodimer with CSTF1/CSTF-50 to modulate mRNA processing CC and RNAP II stability by inhibiting pre-mRNA 3' cleavage. CC {ECO:0000269|PubMed:12890688, ECO:0000269|PubMed:14976165, CC ECO:0000269|PubMed:20351172}. CC -!- CATALYTIC ACTIVITY: CC Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine + CC [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L- CC cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.; CC EC=2.3.2.27; Evidence={ECO:0000269|PubMed:12890688, CC ECO:0000269|PubMed:20351172}; CC -!- PATHWAY: Protein modification; protein ubiquitination. CC -!- SUBUNIT: Homo- and heterodimer. Heterodimer (RING-type zinc finger) CC with BRCA1. Heterodimer (via ANK repeats and BRCT domains) with CC CSTF1/CSTF-50. Component of the BRCA1-A complex, at least composed of CC the BRCA1, BARD1, UIMC1/RAP80, ABRAXAS1, BRCC3/BRCC36, BABAM2 and CC BABAM1/NBA1. Interacts with UBXN1. {ECO:0000269|PubMed:11573085, CC ECO:0000269|PubMed:12890688, ECO:0000269|PubMed:14976165, CC ECO:0000269|PubMed:17643122, ECO:0000269|PubMed:18842000, CC ECO:0000269|PubMed:19261749, ECO:0000269|PubMed:20351172}. CC -!- INTERACTION: CC Q99728; P31749: AKT1; NbExp=3; IntAct=EBI-473181, EBI-296087; CC Q99728; Q9Y2T1: AXIN2; NbExp=3; IntAct=EBI-473181, EBI-4400025; CC Q99728; P38398: BRCA1; NbExp=20; IntAct=EBI-473181, EBI-349905; CC Q99728; P38398-1: BRCA1; NbExp=3; IntAct=EBI-473181, EBI-21498346; CC Q99728; Q9P2H0: CEP126; NbExp=2; IntAct=EBI-473181, EBI-473176; CC Q99728; Q8NHQ1: CEP70; NbExp=3; IntAct=EBI-473181, EBI-739624; CC Q99728; Q12873: CHD3; NbExp=2; IntAct=EBI-473181, EBI-523590; CC Q99728; Q05048: CSTF1; NbExp=4; IntAct=EBI-473181, EBI-1789619; CC Q99728; P33240: CSTF2; NbExp=8; IntAct=EBI-473181, EBI-711360; CC Q99728; O00471: EXOC5; NbExp=3; IntAct=EBI-473181, EBI-949824; CC Q99728; Q8IZU0: FAM9B; NbExp=3; IntAct=EBI-473181, EBI-10175124; CC Q99728; Q9Y2X7: GIT1; NbExp=2; IntAct=EBI-473181, EBI-466061; CC Q99728; Q08379: GOLGA2; NbExp=6; IntAct=EBI-473181, EBI-618309; CC Q99728; O75031: HSF2BP; NbExp=3; IntAct=EBI-473181, EBI-7116203; CC Q99728; Q13422-7: IKZF1; NbExp=3; IntAct=EBI-473181, EBI-11522367; CC Q99728; O95251: KAT7; NbExp=2; IntAct=EBI-473181, EBI-473199; CC Q99728; Q9BVG8-5: KIFC3; NbExp=3; IntAct=EBI-473181, EBI-14069005; CC Q99728; Q6A162: KRT40; NbExp=3; IntAct=EBI-473181, EBI-10171697; CC Q99728; O95751: LDOC1; NbExp=7; IntAct=EBI-473181, EBI-740738; CC Q99728; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-473181, EBI-11522433; CC Q99728; O95453: PARN; NbExp=4; IntAct=EBI-473181, EBI-372832; CC Q99728; Q15276: RABEP1; NbExp=3; IntAct=EBI-473181, EBI-447043; CC Q99728; O14776: TCERG1; NbExp=2; IntAct=EBI-473181, EBI-473271; CC Q99728; Q13077: TRAF1; NbExp=3; IntAct=EBI-473181, EBI-359224; CC Q99728; Q8N720: ZNF655; NbExp=3; IntAct=EBI-473181, EBI-625509; CC Q99728-1; Q13526: PIN1; NbExp=4; IntAct=EBI-21498323, EBI-714158; CC -!- SUBCELLULAR LOCATION: Nucleus. Note=During S phase of the cell cycle, CC colocalizes with BRCA1 into discrete subnuclear foci. Can translocate CC to the cytoplasm. Localizes at sites of DNA damage at double-strand CC breaks (DSBs); recruitment to DNA damage sites is mediated by the CC BRCA1-A complex. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; Synonyms=FL; CC IsoId=Q99728-1; Sequence=Displayed; CC Name=alpha; CC IsoId=Q99728-2; Sequence=VSP_055876; CC Name=beta; CC IsoId=Q99728-3; Sequence=VSP_055874, VSP_055875; CC Name=gamma; CC IsoId=Q99728-4; Sequence=VSP_055877, VSP_055878; CC -!- PTM: Processed during apoptosis. The homodimer is more susceptible to CC proteolytic cleavage than the BARD1/BRCA1 heterodimer. CC -!- CAUTION: It is uncertain whether Met-1 or Met-26 is the initiator. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/756/BARD1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U76638; AAB38316.1; -; mRNA. DR EMBL; AF038042; AAB99978.1; -; Genomic_DNA. DR EMBL; AF038034; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038035; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038036; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038037; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038038; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038039; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038040; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; AF038041; AAB99978.1; JOINED; Genomic_DNA. DR EMBL; JF790280; AEF57471.1; -; mRNA. DR EMBL; JF790281; AEF57472.1; -; mRNA. DR EMBL; JF790282; AEF57473.1; -; mRNA. DR EMBL; AC016708; AAX93130.1; -; Genomic_DNA. DR EMBL; BC126426; AAI26427.1; -; mRNA. DR CCDS; CCDS2397.1; -. [Q99728-1] DR CCDS; CCDS74646.1; -. [Q99728-2] DR RefSeq; NP_000456.2; NM_000465.4. [Q99728-1] DR RefSeq; NP_001269472.1; NM_001282543.2. [Q99728-2] DR PDB; 1JM7; NMR; -; B=26-140. DR PDB; 2NTE; X-ray; 1.90 A; A/B=568-777. DR PDB; 2R1Z; X-ray; 2.10 A; A/B=569-777. DR PDB; 3C5R; X-ray; 2.00 A; A/B=425-555. DR PDB; 3FA2; X-ray; 2.20 A; A/B=566-777. DR PDB; 6M14; X-ray; 1.88 A; A/B=568-777. DR PDB; 7E8I; EM; 3.10 A; K=425-777. DR PDB; 7JZV; EM; 3.90 A; B=26-140. DR PDB; 7LYB; EM; 3.28 A; N=26-122. DR PDB; 7LYC; EM; 2.94 A; N=415-777. DR PDB; 8GRQ; EM; 3.87 A; M=26-117. DR PDBsum; 1JM7; -. DR PDBsum; 2NTE; -. DR PDBsum; 2R1Z; -. DR PDBsum; 3C5R; -. DR PDBsum; 3FA2; -. DR PDBsum; 6M14; -. DR PDBsum; 7E8I; -. DR PDBsum; 7JZV; -. DR PDBsum; 7LYB; -. DR PDBsum; 7LYC; -. DR PDBsum; 8GRQ; -. DR AlphaFoldDB; Q99728; -. DR EMDB; EMD-22581; -. DR EMDB; EMD-23591; -. DR EMDB; EMD-23592; -. DR EMDB; EMD-31020; -. DR EMDB; EMD-34212; -. DR EMDB; EMD-6340; -. DR EMDB; EMD-6400; -. DR SMR; Q99728; -. DR BioGRID; 107056; 331. DR ComplexPortal; CPX-715; BRCA1-BARD1 complex. DR ComplexPortal; CPX-955; BRCC E3 ubiquitin ligase complex. DR CORUM; Q99728; -. DR DIP; DIP-5972N; -. DR FunCoup; Q99728; 1110. DR IntAct; Q99728; 68. DR MINT; Q99728; -. DR STRING; 9606.ENSP00000260947; -. DR BindingDB; Q99728; -. DR GlyGen; Q99728; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q99728; -. DR PhosphoSitePlus; Q99728; -. DR BioMuta; BARD1; -. DR DMDM; 116241265; -. DR jPOST; Q99728; -. DR MassIVE; Q99728; -. DR PaxDb; 9606-ENSP00000260947; -. DR PeptideAtlas; Q99728; -. DR ProteomicsDB; 78442; -. [Q99728-1] DR Pumba; Q99728; -. DR Antibodypedia; 20039; 288 antibodies from 35 providers. DR DNASU; 580; -. DR Ensembl; ENST00000260947.9; ENSP00000260947.4; ENSG00000138376.12. [Q99728-1] DR Ensembl; ENST00000617164.5; ENSP00000480470.1; ENSG00000138376.12. [Q99728-2] DR Ensembl; ENST00000620057.4; ENSP00000481988.1; ENSG00000138376.12. [Q99728-4] DR GeneID; 580; -. DR KEGG; hsa:580; -. DR MANE-Select; ENST00000260947.9; ENSP00000260947.4; NM_000465.4; NP_000456.2. DR UCSC; uc002veu.4; human. [Q99728-1] DR AGR; HGNC:952; -. DR CIViC; 580; 2 evidence items across 3 molecular profiles. DR ClinPGx; PA25256; -. DR CTD; 580; -. DR DisGeNET; 580; -. DR GeneCards; BARD1; -. DR HGNC; HGNC:952; BARD1. DR HPA; ENSG00000138376; Low tissue specificity. DR MalaCards; BARD1; -. DR MIM; 601593; gene. DR OpenTargets; ENSG00000138376; -. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR VEuPathDB; HostDB:ENSG00000138376; -. DR eggNOG; KOG0504; Eukaryota. DR eggNOG; KOG4362; Eukaryota. DR GeneTree; ENSGT00940000156532; -. DR HOGENOM; CLU_021642_0_0_1; -. DR InParanoid; Q99728; -. DR OMA; LGQCEHV; -. DR OrthoDB; 2384350at2759; -. DR PAN-GO; Q99728; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q99728; -. DR BRENDA; 2.3.2.27; 2681. DR PathwayCommons; Q99728; -. DR Reactome; R-HSA-5685938; HDR through Single Strand Annealing (SSA). DR Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR). DR Reactome; R-HSA-5689603; UCH proteinases. DR Reactome; R-HSA-5689901; Metalloprotease DUBs. DR Reactome; R-HSA-5693554; Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA). DR Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks. DR Reactome; R-HSA-5693568; Resolution of D-loop Structures through Holliday Junction Intermediates. DR Reactome; R-HSA-5693571; Nonhomologous End-Joining (NHEJ). DR Reactome; R-HSA-5693579; Homologous DNA Pairing and Strand Exchange. DR Reactome; R-HSA-5693607; Processing of DNA double-strand break ends. DR Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-9663199; Defective DNA double strand break response due to BRCA1 loss of function. DR Reactome; R-HSA-9699150; Defective DNA double strand break response due to BARD1 loss of function. DR Reactome; R-HSA-9701192; Defective homologous recombination repair (HRR) due to BRCA1 loss of function. DR Reactome; R-HSA-9704331; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function. DR Reactome; R-HSA-9704646; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function. DR Reactome; R-HSA-9709570; Impaired BRCA2 binding to RAD51. DR Reactome; R-HSA-9709603; Impaired BRCA2 binding to PALB2. DR SignaLink; Q99728; -. DR SIGNOR; Q99728; -. DR UniPathway; UPA00143; -. DR Agora; ENSG00000138376; -. DR BioGRID-ORCS; 580; 517 hits in 1215 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; BARD1; human. DR EvolutionaryTrace; Q99728; -. DR GeneWiki; BARD1; -. DR GenomeRNAi; 580; -. DR Pharos; Q99728; Tbio. DR PRO; PR:Q99728; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q99728; protein. DR Bgee; ENSG00000138376; Expressed in secondary oocyte and 204 other cell types or tissues. DR ExpressionAtlas; Q99728; baseline and differential. DR GO; GO:0070531; C:BRCA1-A complex; IDA:UniProtKB. DR GO; GO:0070532; C:BRCA1-B complex; IPI:ComplexPortal. DR GO; GO:0031436; C:BRCA1-BARD1 complex; IDA:UniProtKB. DR GO; GO:0070533; C:BRCA1-C complex; IPI:ComplexPortal. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0036464; C:cytoplasmic ribonucleoprotein granule; IDA:HPA. DR GO; GO:0016607; C:nuclear speck; IDA:HPA. DR GO; GO:0000152; C:nuclear ubiquitin ligase complex; IDA:ComplexPortal. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0000151; C:ubiquitin ligase complex; NAS:UniProtKB. DR GO; GO:0140863; F:histone H2AK127 ubiquitin ligase activity; TAS:ARUK-UCL. DR GO; GO:0140864; F:histone H2AK129 ubiquitin ligase activity; TAS:ARUK-UCL. DR GO; GO:0019900; F:kinase binding; NAS:UniProtKB. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB. DR GO; GO:0003723; F:RNA binding; IDA:MGI. DR GO; GO:0061649; F:ubiquitin-modified histone reader activity; TAS:ARUK-UCL. DR GO; GO:0004842; F:ubiquitin-protein transferase activity; NAS:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0071479; P:cellular response to ionizing radiation; IMP:ComplexPortal. DR GO; GO:0006338; P:chromatin remodeling; TAS:ARUK-UCL. DR GO; GO:0006974; P:DNA damage response; NAS:UniProtKB. DR GO; GO:0006281; P:DNA repair; NAS:ComplexPortal. DR GO; GO:0110025; P:DNA strand resection involved in replication fork processing; NAS:ComplexPortal. DR GO; GO:0035825; P:homologous recombination; NAS:ComplexPortal. DR GO; GO:0044818; P:mitotic G2/M transition checkpoint; NAS:ComplexPortal. DR GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:0045786; P:negative regulation of cell cycle; NAS:ComplexPortal. DR GO; GO:0031441; P:negative regulation of mRNA 3'-end processing; NAS:UniProtKB. DR GO; GO:0046826; P:negative regulation of protein export from nucleus; IDA:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:0045732; P:positive regulation of protein catabolic process; NAS:UniProtKB. DR GO; GO:0085020; P:protein K6-linked ubiquitination; IDA:UniProtKB. DR GO; GO:0016567; P:protein ubiquitination; NAS:UniProtKB. DR GO; GO:0051726; P:regulation of cell cycle; NAS:UniProtKB. DR GO; GO:2000001; P:regulation of DNA damage checkpoint; NAS:ComplexPortal. DR GO; GO:0006282; P:regulation of DNA repair; NAS:ComplexPortal. DR GO; GO:0042325; P:regulation of phosphorylation; IMP:UniProtKB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; TAS:ARUK-UCL. DR GO; GO:0001894; P:tissue homeostasis; TAS:UniProtKB. DR CDD; cd17734; BRCT_Bard1_rpt1; 1. DR CDD; cd17720; BRCT_Bard1_rpt2; 1. DR CDD; cd16496; RING-HC_BARD1; 1. DR FunFam; 1.25.40.20:FF:000032; BCL-6 corepressor isoform X1; 1. DR FunFam; 3.30.40.10:FF:000349; BRCA1 associated RING domain 1; 1. DR FunFam; 3.40.50.10190:FF:000013; BRCA1 associated RING domain 1; 1. DR FunFam; 3.40.50.10190:FF:000019; BRCA1 associated RING domain 1; 1. DR Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 1. DR Gene3D; 3.40.50.10190; BRCT domain; 2. DR Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1. DR InterPro; IPR002110; Ankyrin_rpt. DR InterPro; IPR036770; Ankyrin_rpt-contain_sf. DR InterPro; IPR039503; BARD1_Znf-RING. DR InterPro; IPR001357; BRCT_dom. DR InterPro; IPR036420; BRCT_dom_sf. DR InterPro; IPR001841; Znf_RING. DR InterPro; IPR013083; Znf_RING/FYVE/PHD. DR InterPro; IPR017907; Znf_RING_CS. DR PANTHER; PTHR24171; ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 39-RELATED; 1. DR PANTHER; PTHR24171:SF8; BRCA1-ASSOCIATED RING DOMAIN PROTEIN 1; 1. DR Pfam; PF12796; Ank_2; 1. DR Pfam; PF00533; BRCT; 1. DR Pfam; PF14835; zf-RING_6; 1. DR PRINTS; PR01415; ANKYRIN. DR SMART; SM00248; ANK; 3. DR SMART; SM00292; BRCT; 2. DR SUPFAM; SSF48403; Ankyrin repeat; 1. DR SUPFAM; SSF52113; BRCT domain; 2. DR SUPFAM; SSF57850; RING/U-box; 1. DR PROSITE; PS50297; ANK_REP_REGION; 1. DR PROSITE; PS50088; ANK_REPEAT; 3. DR PROSITE; PS50172; BRCT; 2. DR PROSITE; PS00518; ZF_RING_1; 1. DR PROSITE; PS50089; ZF_RING_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ANK repeat; DNA damage; DNA repair; KW Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; Transferase; KW Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger. FT CHAIN 1..777 FT /note="BRCA1-associated RING domain protein 1" FT /id="PRO_0000055819" FT REPEAT 427..459 FT /note="ANK 1" FT REPEAT 460..492 FT /note="ANK 2" FT REPEAT 493..525 FT /note="ANK 3" FT REPEAT 526..546 FT /note="ANK 4; degenerate" FT DOMAIN 560..653 FT /note="BRCT 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00033" FT DOMAIN 667..777 FT /note="BRCT 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00033" FT ZN_FING 50..87 FT /note="RING-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00175" FT REGION 1..32 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 26..119 FT /note="Interaction with BRCA1" FT REGION 167..211 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 356..404 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 554..558 FT /note="Flexible linker" FT COMPBIAS 197..209 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 389..404 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 186 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 299 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 391 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 394 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648" FT CROSSLNK 160 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 170 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25755297, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 423 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 548 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 1..24 FT /note="MPDNRQPRNRQPRIRSGNEPRSAP -> MVAVPGPTVAPRSTAWRSCCAARV FT (in isoform beta)" FT /evidence="ECO:0000303|PubMed:18089818" FT /id="VSP_055874" FT VAR_SEQ 25..121 FT /note="Missing (in isoform beta)" FT /evidence="ECO:0000303|PubMed:18089818" FT /id="VSP_055875" FT VAR_SEQ 54..72 FT /note="Missing (in isoform alpha)" FT /evidence="ECO:0000303|PubMed:18089818" FT /id="VSP_055876" FT VAR_SEQ 122..127 FT /note="DLKEDK -> GRHTFC (in isoform gamma)" FT /evidence="ECO:0000303|PubMed:18089818" FT /id="VSP_055877" FT VAR_SEQ 128..777 FT /note="Missing (in isoform gamma)" FT /evidence="ECO:0000303|PubMed:18089818" FT /id="VSP_055878" FT VARIANT 24 FT /note="P -> S (in dbSNP:rs1048108)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010354" FT VARIANT 153 FT /note="K -> E (in dbSNP:rs753377280)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010355" FT VARIANT 186 FT /note="S -> G (in dbSNP:rs16852741)" FT /id="VAR_038371" FT VARIANT 241 FT /note="S -> C (in dbSNP:rs3738885)" FT /id="VAR_020109" FT VARIANT 378 FT /note="R -> S (in dbSNP:rs2229571)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_024611" FT VARIANT 507 FT /note="V -> M (in dbSNP:rs2070094)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010356" FT VARIANT 557 FT /note="C -> S (in dbSNP:rs28997576)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010357" FT VARIANT 564 FT /note="Q -> H (in an ovarian clear cell adenocarcinoma; FT dbSNP:rs1168537193)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010358" FT VARIANT 645 FT /note="C -> R (in dbSNP:rs2228456)" FT /id="VAR_038372" FT VARIANT 658 FT /note="R -> C (in dbSNP:rs3738888)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010359" FT VARIANT 695 FT /note="V -> L (in a breast cancer sample; somatic mutation; FT dbSNP:rs111367604)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010360" FT VARIANT 728 FT /note="S -> F (in dbSNP:rs13389423)" FT /id="VAR_028309" FT VARIANT 761 FT /note="S -> N (in an uterine cancer sample; somatic FT mutation; dbSNP:rs142155101)" FT /evidence="ECO:0000269|PubMed:9425226" FT /id="VAR_010361" FT CONFLICT 85 FT /note="V -> A (in Ref. 3; AEF57473)" FT /evidence="ECO:0000305" FT CONFLICT 406 FT /note="R -> Q (in Ref. 1; AAB38316 and 3; AEF57471/ FT AEF57472)" FT /evidence="ECO:0000305" FT HELIX 35..45 FT /evidence="ECO:0007829|PDB:7LYB" FT TURN 51..53 FT /evidence="ECO:0007829|PDB:7LYB" FT STRAND 58..61 FT /evidence="ECO:0007829|PDB:7LYB" FT STRAND 64..67 FT /evidence="ECO:0007829|PDB:7LYB" FT HELIX 72..75 FT /evidence="ECO:0007829|PDB:7LYB" FT TURN 78..81 FT /evidence="ECO:0007829|PDB:7LYB" FT TURN 84..86 FT /evidence="ECO:0007829|PDB:7LYB" FT HELIX 99..115 FT /evidence="ECO:0007829|PDB:7LYB" FT HELIX 431..438 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 441..449 FT /evidence="ECO:0007829|PDB:3C5R" FT STRAND 459..461 FT /evidence="ECO:0007829|PDB:7LYC" FT HELIX 464..470 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 474..482 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 492..494 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 497..503 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 507..515 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 530..533 FT /evidence="ECO:0007829|PDB:3C5R" FT HELIX 537..543 FT /evidence="ECO:0007829|PDB:3C5R" FT STRAND 571..576 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 579..591 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 595..599 FT /evidence="ECO:0007829|PDB:2NTE" FT STRAND 606..613 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 618..625 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 629..632 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 634..642 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 648..651 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 656..665 FT /evidence="ECO:0007829|PDB:6M14" FT TURN 671..674 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 676..679 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 684..686 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 688..697 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 701..705 FT /evidence="ECO:0007829|PDB:2NTE" FT HELIX 709..711 FT /evidence="ECO:0007829|PDB:2NTE" FT HELIX 712..716 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 729..731 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 735..739 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 741..744 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 748..752 FT /evidence="ECO:0007829|PDB:6M14" FT STRAND 755..759 FT /evidence="ECO:0007829|PDB:6M14" FT HELIX 760..769 FT /evidence="ECO:0007829|PDB:6M14" SQ SEQUENCE 777 AA; 86648 MW; 95E2D904046B5646 CRC64; MPDNRQPRNR QPRIRSGNEP RSAPAMEPDG RGAWAHSRAA LDRLEKLLRC SRCTNILREP VCLGGCEHIF CSNCVSDCIG TGCPVCYTPA WIQDLKINRQ LDSMIQLCSK LRNLLHDNEL SDLKEDKPRK SLFNDAGNKK NSIKMWFSPR SKKVRYVVSK ASVQTQPAIK KDASAQQDSY EFVSPSPPAD VSERAKKASA RSGKKQKKKT LAEINQKWNL EAEKEDGEFD SKEESKQKLV SFCSQPSVIS SPQINGEIDL LASGSLTESE CFGSLTEVSL PLAEQIESPD TKSRNEVVTP EKVCKNYLTS KKSLPLENNG KRGHHNRLSS PISKRCRTSI LSTSGDFVKQ TVPSENIPLP ECSSPPSCKR KVGGTSGRKN SNMSDEFISL SPGTPPSTLS SSSYRRVMSS PSAMKLLPNM AVKRNHRGET LLHIASIKGD IPSVEYLLQN GSDPNVKDHA GWTPLHEACN HGHLKVVELL LQHKALVNTT GYQNDSPLHD AAKNGHVDIV KLLLSYGASR NAVNIFGLRP VDYTDDESMK SLLLLPEKNE SSSASHCSVM NTGQRRDGPL VLIGSGLSSE QQKMLSELAV ILKAKKYTEF DSTVTHVVVP GDAVQSTLKC MLGILNGCWI LKFEWVKACL RRKVCEQEEK YEIPEGPRRS RLNREQLLPK LFDGCYFYLW GTFKHHPKDN LIKLVTAGGG QILSRKPKPD SDVTQTINTV AYHARPDSDQ RFCTQYIIYE DLCNYHPERV RQGKVWKAPS SWFIDCVMSF ELLPLDS // ID DPOE1_HUMAN Reviewed; 2286 AA. AC Q07864; Q13533; Q86VH9; DT 01-OCT-1994, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 5. DT 28-JAN-2026, entry version 229. DE RecName: Full=DNA polymerase epsilon catalytic subunit A; DE EC=2.7.7.7 {ECO:0000250|UniProtKB:P21951}; DE AltName: Full=3'-5' exodeoxyribonuclease {ECO:0000305}; DE EC=3.1.11.- {ECO:0000250|UniProtKB:P21951}; DE AltName: Full=DNA polymerase II subunit A; GN Name=POLE {ECO:0000312|HGNC:HGNC:9177}; Synonyms=POLE1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 48-51; 876-886 AND RP 1338-1344. RC TISSUE=T-cell; RX PubMed=8486689; DOI=10.1016/s0021-9258(18)82195-0; RA Kesti T., Frantti H., Syvaeoja J.E.; RT "Molecular cloning of the cDNA for the catalytic subunit of human DNA RT polymerase epsilon."; RL J. Biol. Chem. 268:10238-10245(1993). RN [2] RP SEQUENCE REVISION. RA Syvaeoja J.E.; RL Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [MRNA]. RA Asahara H., Goldsmith J.S., Lee E., Linn S.; RL Submitted (FEB-1996) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 22-2286. RG NIEHS SNPs program; RL Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases. RN [5] RP FUNCTION, AND IDENTIFICATION IN EPSILON DNA POLYMERASE COMPLEX. RC TISSUE=Cervix carcinoma; RX PubMed=10801849; DOI=10.1074/jbc.m002548200; RA Li Y., Pursell Z.F., Linn S.; RT "Identification and cloning of two histone fold motif-containing subunits RT of HeLa DNA polymerase epsilon."; RL J. Biol. Chem. 275:23247-23252(2000). RN [6] RP INTERACTION WITH TOPBP1. RX PubMed=11395493; DOI=10.1074/jbc.m102245200; RA Maekiniemi M., Hillukkala T., Tuusa J., Reini K., Vaara M., Huang D., RA Pospiech H., Majuri I., Westerling T., Maekelae T.P., Syvaeoja J.E.; RT "BRCT domain-containing protein TopBP1 functions in DNA replication and RT damage response."; RL J. Biol. Chem. 276:30399-30406(2001). RN [7] RP INTERACTION WITH RAD17. RX PubMed=14500819; DOI=10.1093/nar/gkg765; RA Post S.M., Tomkinson A.E., Lee E.Y.-H.P.; RT "The human checkpoint Rad protein Rad17 is chromatin-associated throughout RT the cell cycle, localizes to DNA replication sites, and interacts with DNA RT polymerase epsilon."; RL Nucleic Acids Res. 31:5568-5575(2003). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1940, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [9] RP FUNCTION. RX PubMed=20227374; DOI=10.1016/j.molcel.2010.02.009; RA Ogi T., Limsirichaikul S., Overmeer R.M., Volker M., Takenaka K., RA Cloney R., Nakazawa Y., Niimi A., Miki Y., Jaspers N.G., Mullenders L.H., RA Yamashita S., Fousteri M.I., Lehmann A.R.; RT "Three DNA polymerases, recruited by different mechanisms, carry out NER RT repair synthesis in human cells."; RL Mol. Cell 37:714-727(2010). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1184, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [12] RP INVOLVEMENT IN FILS. RX PubMed=23230001; DOI=10.1084/jem.20121303; RA Pachlopnik Schmid J., Lemoine R., Nehme N., Cormier-Daire V., Revy P., RA Debeurme F., Debre M., Nitschke P., Bole-Feysot C., Legeai-Mallet L., RA Lim A., de Villartay J.P., Picard C., Durandy A., Fischer A., RA de Saint Basile G.; RT "Polymerase epsilon1 mutation in a human syndrome with facial dysmorphism, RT immunodeficiency, livedo, and short stature (FILS syndrome)."; RL J. Exp. Med. 209:2323-2330(2012). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1297 AND SER-1317, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [14] {ECO:0007744|PDB:7PFO} RP STRUCTURE BY ELECTRON MICROSCOPY (3.20 ANGSTROMS) IN COMPLEX WITH RP REPLISOME. RX PubMed=34694004; DOI=10.15252/embj.2021108819; RA Jones M.L., Baris Y., Taylor M.R.G., Yeeles J.T.P.; RT "Structure of a human replisome shows the organisation and interactions of RT a DNA replication machine."; RL EMBO J. 40:e108819-e108819(2021). RN [15] {ECO:0007744|PDB:7PLO} RP STRUCTURE BY ELECTRON MICROSCOPY (2.80 ANGSTROMS) IN COMPLEX WITH RP REPLISOME. RX PubMed=34700328; DOI=10.1038/s41586-021-04145-3; RA Jenkyn-Bedford M., Jones M.L., Baris Y., Labib K.P.M., Cannone G., RA Yeeles J.T.P., Deegan T.D.; RT "A conserved mechanism for regulating replisome disassembly in RT eukaryotes."; RL Nature 600:743-747(2021). RN [16] RP VARIANTS CRCS12 LEU-411 AND VAL-424, AND VARIANTS THR-189; HIS-231; RP HIS-286; SER-367; ARG-436; PHE-459; TRP-762; ASN-777; ASN-1008; VAL-1255; RP MET-1368; SER-1421; ASN-1752; ASN-2013; THR-2056 AND VAL-2213. RX PubMed=23263490; DOI=10.1038/ng.2503; RG CORGI Consortium; RG WGS500 Consortium; RA Palles C., Cazier J.B., Howarth K.M., Domingo E., Jones A.M., Broderick P., RA Kemp Z., Spain S.L., Guarino Almeida E., Salguero I., Sherborne A., RA Chubb D., Carvajal-Carmona L.G., Ma Y., Kaur K., Dobbins S., Barclay E., RA Gorman M., Martin L., Kovac M.B., Humphray S., Lucassen A., Holmes C.C., RA Bentley D., Donnelly P., Taylor J., Petridis C., Roylance R., Sawyer E.J., RA Kerr D.J., Clark S., Grimes J., Kearsey S.E., Thomas H.J., McVean G., RA Houlston R.S., Tomlinson I.; RT "Germline mutations affecting the proofreading domains of POLE and POLD1 RT predispose to colorectal adenomas and carcinomas."; RL Nat. Genet. 45:136-144(2013). RN [17] RP VARIANT CRCS12 VAL-424. RX PubMed=24501277; DOI=10.1093/hmg/ddu058; RA Valle L., Hernandez-Illan E., Bellido F., Aiza G., Castillejo A., RA Castillejo M.I., Navarro M., Segui N., Vargas G., Guarinos C., Juarez M., RA Sanjuan X., Iglesias S., Alenda C., Egoavil C., Segura A., Juan M.J., RA Rodriguez-Soler M., Brunet J., Gonzalez S., Jover R., Lazaro C., RA Capella G., Pineda M., Soto J.L., Blanco I.; RT "New insights into POLE and POLD1 germline mutations in familial colorectal RT cancer and polyposis."; RL Hum. Mol. Genet. 23:3506-3512(2014). RN [18] RP VARIANT CRCS12 PHE-458. RX PubMed=25860647; DOI=10.1007/s10689-015-9803-2; RA Hansen M.F., Johansen J., Bjoernevoll I., Sylvander A.E., Steinsbekk K.S., RA Saetrom P., Sandvik A.K., Drabloes F., Sjursen W.; RT "A novel POLE mutation associated with cancers of colon, pancreas, ovaries RT and small intestine."; RL Fam. Cancer 14:437-448(2015). RN [19] RP FUNCTION, AND VARIANT CRCS12 LEU-411. RX PubMed=27573199; DOI=10.1007/s10689-016-9925-1; RA Wimmer K., Beilken A., Nustede R., Ripperger T., Lamottke B., Ure B., RA Steinmann D., Reineke-Plaass T., Lehmann U., Zschocke J., Valle L., RA Fauth C., Kratz C.P.; RT "A novel germline POLE mutation causes an early onset cancer prone syndrome RT mimicking constitutional mismatch repair deficiency."; RL Fam. Cancer 16:67-71(2017). RN [20] RP VARIANTS ARG-286; CYS-1382 AND THR-1925. RX PubMed=27612425; DOI=10.18632/oncotarget.11862; RA Ahn S.M., Ansari A.A., Kim J., Kim D., Chun S.M., Kim J., Kim T.W., RA Park I., Yu C.S., Jang S.J.; RT "The somatic POLE P286R mutation defines a unique subclass of colorectal RT cancer featuring hypermutation, representing a potential genomic biomarker RT for immunotherapy."; RL Oncotarget 7:68638-68649(2016). RN [21] RP VARIANTS IMAGEI 683-TYR--HIS-2286 DEL; PRO-1007 AND 1980-TRP--HIS-2286 DEL, RP AND INVOLVEMENT IN IMAGEI. RX PubMed=30503519; DOI=10.1016/j.ajhg.2018.10.024; RG SGP Consortium; RA Logan C.V., Murray J.E., Parry D.A., Robertson A., Bellelli R., RA Tarnauskaite Z., Challis R., Cleal L., Borel V., Fluteau A., RA Santoyo-Lopez J., Aitman T., Barroso I., Basel D., Bicknell L.S., Goel H., RA Hu H., Huff C., Hutchison M., Joyce C., Knox R., Lacroix A.E., Langlois S., RA McCandless S., McCarrier J., Metcalfe K.A., Morrissey R., Murphy N., RA Netchine I., O'Connell S.M., Olney A.H., Paria N., Rosenfeld J.A., RA Sherlock M., Syverson E., White P.C., Wise C., Yu Y., Zacharin M., RA Banerjee I., Reijns M., Bober M.B., Semple R.K., Boulton S.J., Rios J.J., RA Jackson A.P.; RT "DNA polymerase epsilon deficiency causes IMAGe syndrome with variable RT immunodeficiency."; RL Am. J. Hum. Genet. 103:1038-1044(2018). CC -!- FUNCTION: Catalytic component of the DNA polymerase epsilon complex CC (PubMed:10801849). Participates in chromosomal DNA replication (By CC similarity). Required during synthesis of the leading DNA strands at CC the replication fork, binds at/or near replication origins and moves CC along DNA with the replication fork (By similarity). Has 3'-5' CC proofreading exonuclease activity that corrects errors arising during CC DNA replication (By similarity). Involved in DNA synthesis during DNA CC repair (PubMed:20227374, PubMed:27573199). Along with DNA polymerase CC POLD1 and DNA polymerase POLK, has a role in excision repair (NER) CC synthesis following UV irradiation (PubMed:20227374). CC {ECO:0000250|UniProtKB:P21951, ECO:0000269|PubMed:10801849, CC ECO:0000269|PubMed:20227374, ECO:0000269|PubMed:27573199}. CC -!- CATALYTIC ACTIVITY: CC Reaction=DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + CC diphosphate; Xref=Rhea:RHEA:22508, Rhea:RHEA-COMP:17339, Rhea:RHEA- CC COMP:17340, ChEBI:CHEBI:33019, ChEBI:CHEBI:61560, ChEBI:CHEBI:173112; CC EC=2.7.7.7; Evidence={ECO:0000250|UniProtKB:P21951}; CC -!- SUBUNIT: Component of the DNA polymerase epsilon complex consisting of CC four subunits: the catalytic subunit POLE and the accessory subunits CC POLE2, POLE3 and POLE4. Interacts with RAD17 and TOPBP1. CC {ECO:0000269|PubMed:10801849, ECO:0000269|PubMed:11395493, CC ECO:0000269|PubMed:14500819}. CC -!- INTERACTION: CC Q07864; O95870: ABHD16A; NbExp=3; IntAct=EBI-348526, EBI-348517; CC Q07864; P15056: BRAF; NbExp=6; IntAct=EBI-348526, EBI-365980; CC Q07864; P01106: MYC; NbExp=2; IntAct=EBI-348526, EBI-447544; CC Q07864; P56282: POLE2; NbExp=12; IntAct=EBI-348526, EBI-713847; CC -!- SUBCELLULAR LOCATION: Nucleus. CC -!- DOMAIN: The DNA polymerase activity domain resides in the N-terminal CC half of the protein, while the C-terminus is necessary for maintenance CC of the complex. {ECO:0000250|UniProtKB:P21951}. CC -!- DOMAIN: The CysA-type zinc finger is required for PCNA-binding. CC {ECO:0000250|UniProtKB:P15436}. CC -!- DOMAIN: The CysB motif binds 1 4Fe-4S cluster and is required for the CC formation of polymerase complexes. {ECO:0000250|UniProtKB:P15436}. CC -!- DISEASE: Colorectal cancer 12 (CRCS12) [MIM:615083]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. CRCS12 is characterized by a high-penetrance CC predisposition to the development of colorectal adenomas and CC carcinomas, with a variable tendency to develop multiple and large CC tumors. Onset is usually before age 40 years. The histologic features CC of the tumors are unremarkable. {ECO:0000269|PubMed:23263490, CC ECO:0000269|PubMed:24501277, ECO:0000269|PubMed:25860647, CC ECO:0000269|PubMed:27573199}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Facial dysmorphism, immunodeficiency, livedo, and short CC stature (FILS) [MIM:615139]: A syndrome characterized by mild facial CC dysmorphism, mainly malar hypoplasia, livedo on the skin since birth, CC and immunodeficiency resulting in recurrent infections. Growth CC impairment is observed during early childhood and results in variable CC short stature in adulthood. {ECO:0000269|PubMed:23230001}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Intrauterine growth retardation, metaphyseal dysplasia, CC adrenal hypoplasia congenita, genital anomalies, and immunodeficiency CC (IMAGEI) [MIM:618336]: An autosomal recessive disorder characterized by CC intrauterine growth retardation, postnatal growth failure, metaphyseal CC dysplasia, adrenal hypoplasia congenita, growth hormone deficiency, CC genital anomalies, and immunodeficiency resulting in increased CC infections. {ECO:0000269|PubMed:30503519}. Note=The disease is caused CC by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the DNA polymerase type-B family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA15448.1; Type=Frameshift; Evidence={ECO:0000305}; CC Sequence=AAA15448.1; Type=Miscellaneous discrepancy; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; S60080; AAA15448.1; ALT_SEQ; mRNA. DR EMBL; L09561; AAC19148.1; -; mRNA. DR EMBL; U49356; AAA90924.1; -; mRNA. DR EMBL; AY273166; AAP12650.1; -; Genomic_DNA. DR CCDS; CCDS9278.1; -. DR PIR; G02434; G02434. DR RefSeq; NP_006222.2; NM_006231.4. DR PDB; 5VBN; X-ray; 2.35 A; B/F=2142-2286. DR PDB; 7PFO; EM; 3.20 A; B=1-2286. DR PDB; 7PLO; EM; 2.80 A; B=1-2286. DR PDB; 9B8S; EM; 5.01 A; A=1-2286. DR PDB; 9B8T; EM; 2.95 A; A=1-2286. DR PDB; 9F6D; EM; 3.60 A; A=1-1200. DR PDB; 9F6E; EM; 3.74 A; A=1-1200. DR PDB; 9F6F; EM; 3.75 A; A=1-1200. DR PDB; 9F6I; EM; 3.30 A; A=1-1200. DR PDB; 9F6J; EM; 3.90 A; A=1-1200. DR PDB; 9F6K; EM; 4.20 A; A=1-1200. DR PDB; 9F6L; EM; 3.90 A; A=1-1200. DR PDB; 9NE6; EM; 3.11 A; A=1-1200. DR PDB; 9NE7; EM; 3.53 A; A=1-1200. DR PDB; 9NE8; EM; 3.60 A; A=1-1200. DR PDB; 9NE9; EM; 3.88 A; A=27-1198. DR PDB; 9NEA; EM; 3.81 A; A=1-2286. DR PDBsum; 5VBN; -. DR PDBsum; 7PFO; -. DR PDBsum; 7PLO; -. DR PDBsum; 9B8S; -. DR PDBsum; 9B8T; -. DR PDBsum; 9F6D; -. DR PDBsum; 9F6E; -. DR PDBsum; 9F6F; -. DR PDBsum; 9F6I; -. DR PDBsum; 9F6J; -. DR PDBsum; 9F6K; -. DR PDBsum; 9F6L; -. DR PDBsum; 9NE6; -. DR PDBsum; 9NE7; -. DR PDBsum; 9NE8; -. DR PDBsum; 9NE9; -. DR PDBsum; 9NEA; -. DR AlphaFoldDB; Q07864; -. DR EMDB; EMD-13375; -. DR EMDB; EMD-13494; -. DR EMDB; EMD-44357; -. DR EMDB; EMD-49299; -. DR EMDB; EMD-49300; -. DR EMDB; EMD-49301; -. DR EMDB; EMD-49302; -. DR EMDB; EMD-49303; -. DR EMDB; EMD-50222; -. DR EMDB; EMD-50223; -. DR EMDB; EMD-50224; -. DR EMDB; EMD-50225; -. DR EMDB; EMD-50226; -. DR EMDB; EMD-50227; -. DR EMDB; EMD-50228; -. DR SMR; Q07864; -. DR BioGRID; 111422; 164. DR ComplexPortal; CPX-2108; DNA polymerase epsilon complex. DR CORUM; Q07864; -. DR DIP; DIP-24243N; -. DR FunCoup; Q07864; 2368. DR IntAct; Q07864; 78. DR MINT; Q07864; -. DR STRING; 9606.ENSP00000322570; -. DR ChEMBL; CHEMBL2363042; -. DR DrugBank; DB00242; Cladribine. DR DrugCentral; Q07864; -. DR GlyGen; Q07864; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q07864; -. DR MetOSite; Q07864; -. DR PhosphoSitePlus; Q07864; -. DR SwissPalm; Q07864; -. DR BioMuta; POLE; -. DR DMDM; 116241339; -. DR jPOST; Q07864; -. DR MassIVE; Q07864; -. DR PaxDb; 9606-ENSP00000322570; -. DR PeptideAtlas; Q07864; -. DR ProteomicsDB; 58543; -. DR Pumba; Q07864; -. DR Antibodypedia; 32096; 184 antibodies from 23 providers. DR CPTC; Q07864; 1 antibody. DR DNASU; 5426; -. DR Ensembl; ENST00000320574.10; ENSP00000322570.5; ENSG00000177084.20. DR GeneID; 5426; -. DR KEGG; hsa:5426; -. DR MANE-Select; ENST00000320574.10; ENSP00000322570.5; NM_006231.4; NP_006222.2. DR UCSC; uc001uks.3; human. DR AGR; HGNC:9177; -. DR CIViC; 5426; 13 evidence items across 8 molecular profiles. DR ClinPGx; PA277; -. DR CTD; 5426; -. DR DisGeNET; 5426; -. DR GeneCards; POLE; -. DR HGNC; HGNC:9177; POLE. DR HPA; ENSG00000177084; Low tissue specificity. DR MalaCards; POLE; -. DR MIM; 174762; gene. DR MIM; 615083; phenotype. DR MIM; 615139; phenotype. DR MIM; 618336; phenotype. DR OpenTargets; ENSG00000177084; -. DR Orphanet; 352712; Facial dysmorphism-immunodeficiency-livedo-short stature syndrome. DR Orphanet; 440437; Familial colorectal cancer Type X. DR Orphanet; 85173; IMAGe syndrome. DR Orphanet; 447877; Polymerase proofreading-related polyposis. DR VEuPathDB; HostDB:ENSG00000177084; -. DR eggNOG; KOG1798; Eukaryota. DR GeneTree; ENSGT00390000010194; -. DR HOGENOM; CLU_000556_0_0_1; -. DR InParanoid; Q07864; -. DR OMA; MLDQCRY; -. DR OrthoDB; 10060449at2759; -. DR PAN-GO; Q07864; 9 GO annotations based on evolutionary models. DR PhylomeDB; Q07864; -. DR BRENDA; 2.7.7.7; 2681. DR PathwayCommons; Q07864; -. DR Reactome; R-HSA-110314; Recognition of DNA damage by PCNA-containing replication complex. DR Reactome; R-HSA-5651801; PCNA-Dependent Long Patch Base Excision Repair. DR Reactome; R-HSA-5656169; Termination of translesion DNA synthesis. DR Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR). DR Reactome; R-HSA-5696397; Gap-filling DNA repair synthesis and ligation in GG-NER. DR Reactome; R-HSA-5696400; Dual Incision in GG-NER. DR Reactome; R-HSA-6782135; Dual incision in TC-NER. DR Reactome; R-HSA-6782210; Gap-filling DNA repair synthesis and ligation in TC-NER. DR Reactome; R-HSA-68952; DNA replication initiation. DR Reactome; R-HSA-68962; Activation of the pre-replicative complex. DR SignaLink; Q07864; -. DR SIGNOR; Q07864; -. DR Agora; ENSG00000177084; -. DR BioGRID-ORCS; 5426; 795 hits in 1174 CRISPR screens. DR ChiTaRS; POLE; human. DR GeneWiki; POLE_(enzyme); -. DR GenomeRNAi; 5426; -. DR Pharos; Q07864; Tclin. DR PRO; PR:Q07864; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; Q07864; protein. DR Bgee; ENSG00000177084; Expressed in right hemisphere of cerebellum and 149 other cell types or tissues. DR ExpressionAtlas; Q07864; baseline and differential. DR GO; GO:0008622; C:epsilon DNA polymerase complex; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0051539; F:4 iron, 4 sulfur cluster binding; IEA:UniProtKB-KW. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0003887; F:DNA-directed DNA polymerase activity; IMP:UniProtKB. DR GO; GO:0000166; F:nucleotide binding; IEA:InterPro. DR GO; GO:0008310; F:single-stranded DNA 3'-5' DNA exonuclease activity; IBA:GO_Central. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0006287; P:base-excision repair, gap-filling; IDA:UniProtKB. DR GO; GO:0006260; P:DNA replication; IMP:UniProtKB. DR GO; GO:0045004; P:DNA replication proofreading; IBA:GO_Central. DR GO; GO:0000731; P:DNA synthesis involved in DNA repair; IMP:UniProtKB. DR GO; GO:0006261; P:DNA-templated DNA replication; IDA:ComplexPortal. DR GO; GO:0048568; P:embryonic organ development; IEA:Ensembl. DR GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0006272; P:leading strand elongation; IBA:GO_Central. DR GO; GO:0000278; P:mitotic cell cycle; IBA:GO_Central. DR GO; GO:0006297; P:nucleotide-excision repair, DNA gap filling; IMP:UniProtKB. DR CDD; cd05779; DNA_polB_epsilon_exo; 1. DR CDD; cd05535; POLBc_epsilon; 1. DR FunFam; 1.10.132.60:FF:000002; DNA polymerase epsilon catalytic subunit; 1. DR FunFam; 3.30.420.10:FF:000010; DNA polymerase epsilon catalytic subunit; 1. DR FunFam; 3.90.1600.10:FF:000006; DNA polymerase epsilon catalytic subunit; 1. DR Gene3D; 1.10.132.60; DNA polymerase family B, C-terminal domain; 1. DR Gene3D; 3.30.342.10; DNA Polymerase, chain B, domain 1; 1. DR Gene3D; 3.90.1600.10; Palm domain of DNA polymerase; 1. DR Gene3D; 3.30.420.10; Ribonuclease H-like superfamily/Ribonuclease H; 1. DR InterPro; IPR006172; DNA-dir_DNA_pol_B. DR InterPro; IPR006133; DNA-dir_DNA_pol_B_exonuc. DR InterPro; IPR043502; DNA/RNA_pol_sf. DR InterPro; IPR042087; DNA_pol_B_thumb. DR InterPro; IPR013697; DNA_pol_e_suA_C. DR InterPro; IPR023211; DNA_pol_palm_dom_sf. DR InterPro; IPR029703; POL2. DR InterPro; IPR055191; POL2_thumb. DR InterPro; IPR012337; RNaseH-like_sf. DR InterPro; IPR036397; RNaseH_sf. DR InterPro; IPR054475; Znf-DPOE. DR PANTHER; PTHR10670; DNA POLYMERASE EPSILON CATALYTIC SUBUNIT A; 1. DR PANTHER; PTHR10670:SF0; DNA POLYMERASE EPSILON CATALYTIC SUBUNIT A; 1. DR Pfam; PF03104; DNA_pol_B_exo1; 1. DR Pfam; PF08490; DUF1744; 1. DR Pfam; PF22634; POL2_thumb; 1. DR Pfam; PF22912; zf-DPOE; 1. DR Pfam; PF23250; zf_DPOE_2; 1. DR SMART; SM01159; DUF1744; 1. DR SMART; SM00486; POLBc; 1. DR SUPFAM; SSF56672; DNA/RNA polymerases; 1. DR SUPFAM; SSF53098; Ribonuclease H-like; 1. PE 1: Evidence at protein level; KW 3D-structure; 4Fe-4S; Direct protein sequencing; Disease variant; KW DNA damage; DNA repair; DNA replication; DNA-binding; KW DNA-directed DNA polymerase; Hydrolase; Iron; Iron-sulfur; Metal-binding; KW Nucleotidyltransferase; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Transferase; Zinc; Zinc-finger. FT CHAIN 1..2286 FT /note="DNA polymerase epsilon catalytic subunit A" FT /id="PRO_0000046455" FT ZN_FING 2158..2190 FT /note="CysA-type" FT /evidence="ECO:0000250|UniProtKB:P15436" FT REGION 1..30 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1939..1969 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 2221..2238 FT /note="CysB motif" FT /evidence="ECO:0000250|UniProtKB:P15436" FT COMPBIAS 9..24 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1946..1969 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 2158 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:P15436" FT BINDING 2161 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:P15436" FT BINDING 2187 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:P15436" FT BINDING 2190 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:P15436" FT BINDING 2221 FT /ligand="[4Fe-4S] cluster" FT /ligand_id="ChEBI:CHEBI:49883" FT /evidence="ECO:0000250|UniProtKB:P15436" FT BINDING 2224 FT /ligand="[4Fe-4S] cluster" FT /ligand_id="ChEBI:CHEBI:49883" FT /evidence="ECO:0000250|UniProtKB:P15436" FT BINDING 2236 FT /ligand="[4Fe-4S] cluster" FT /ligand_id="ChEBI:CHEBI:49883" FT /evidence="ECO:0000250|UniProtKB:P15436" FT BINDING 2238 FT /ligand="[4Fe-4S] cluster" FT /ligand_id="ChEBI:CHEBI:49883" FT /evidence="ECO:0000250|UniProtKB:P15436" FT MOD_RES 1184 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 1297 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1317 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1940 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17525332" FT VARIANT 31 FT /note="A -> S (in dbSNP:rs34047482)" FT /id="VAR_061138" FT VARIANT 99 FT /note="P -> L (in dbSNP:rs5744739)" FT /id="VAR_028429" FT VARIANT 189 FT /note="A -> T (found in a colorectal sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069339" FT VARIANT 231 FT /note="R -> H (found in a colorectal sample; somatic FT mutation; dbSNP:rs1060500835)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069340" FT VARIANT 252 FT /note="A -> V (in dbSNP:rs5744751)" FT /id="VAR_020276" FT VARIANT 260 FT /note="R -> Q (in dbSNP:rs5744752)" FT /id="VAR_028430" FT VARIANT 286 FT /note="P -> H (found in a colorectal sample; somatic FT mutation; dbSNP:rs1057519943)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069341" FT VARIANT 286 FT /note="P -> R (found in a colorectal sample; somatic FT mutation; dbSNP:rs1057519943)" FT /evidence="ECO:0000269|PubMed:27612425" FT /id="VAR_077349" FT VARIANT 336 FT /note="N -> S (in dbSNP:rs5744760)" FT /id="VAR_020277" FT VARIANT 367 FT /note="F -> S (found in a colorectal sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069342" FT VARIANT 411 FT /note="V -> L (in CRCS12; uncertain significance; FT dbSNP:rs1057519945)" FT /evidence="ECO:0000269|PubMed:23263490, FT ECO:0000269|PubMed:27573199" FT /id="VAR_069343" FT VARIANT 424 FT /note="L -> V (in CRCS12; dbSNP:rs483352909)" FT /evidence="ECO:0000269|PubMed:23263490, FT ECO:0000269|PubMed:24501277" FT /id="VAR_069344" FT VARIANT 436 FT /note="P -> R (found in a colorectal sample; somatic FT mutation; dbSNP:rs864622766)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069345" FT VARIANT 458 FT /note="Y -> F (in CRCS12; uncertain significance; FT dbSNP:rs2135996937)" FT /evidence="ECO:0000269|PubMed:25860647" FT /id="VAR_077350" FT VARIANT 459 FT /note="S -> F (found in a colorectal sample; somatic FT mutation; dbSNP:rs765702675)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069346" FT VARIANT 683..2286 FT /note="Missing (in IMAGEI)" FT /evidence="ECO:0000269|PubMed:30503519" FT /id="VAR_081996" FT VARIANT 695 FT /note="F -> I (in dbSNP:rs5744799)" FT /id="VAR_020278" FT VARIANT 762 FT /note="R -> W (found in a colorectal sample; somatic FT mutation; dbSNP:rs1064794759)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069347" FT VARIANT 777 FT /note="K -> N (found in a colorectal sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069348" FT VARIANT 1007 FT /note="A -> P (in IMAGEI; uncertain significance; FT dbSNP:rs747692201)" FT /evidence="ECO:0000269|PubMed:30503519" FT /id="VAR_081997" FT VARIANT 1008 FT /note="K -> N (found in a colorectal sample; somatic FT mutation; dbSNP:rs2138689242)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069349" FT VARIANT 1255 FT /note="L -> V (found in a colorectal sample; somatic FT mutation; dbSNP:rs745838504)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069350" FT VARIANT 1368 FT /note="V -> M (found in a colorectal sample; somatic FT mutation; dbSNP:rs770558983)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069351" FT VARIANT 1382 FT /note="R -> C (found in a colorectal sample; somatic FT mutation; dbSNP:rs5744904)" FT /evidence="ECO:0000269|PubMed:27612425" FT /id="VAR_028431" FT VARIANT 1395 FT /note="Y -> C (in dbSNP:rs5744933)" FT /id="VAR_020279" FT VARIANT 1396 FT /note="N -> S (in dbSNP:rs5744934)" FT /id="VAR_020280" FT VARIANT 1399 FT /note="E -> Q (in dbSNP:rs5744935)" FT /id="VAR_020281" FT VARIANT 1421 FT /note="P -> S (in dbSNP:rs2138558999)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069352" FT VARIANT 1577 FT /note="E -> A (in dbSNP:rs5744948)" FT /id="VAR_028432" FT VARIANT 1712 FT /note="A -> V (in dbSNP:rs5744950)" FT /id="VAR_028433" FT VARIANT 1752 FT /note="D -> N (found in a colorectal sample; somatic FT mutation; dbSNP:rs1335665224)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069353" FT VARIANT 1857 FT /note="K -> R (in dbSNP:rs5744971)" FT /id="VAR_028434" FT VARIANT 1925 FT /note="I -> T (found in a colorectal sample; somatic FT mutation; dbSNP:rs2138485353)" FT /evidence="ECO:0000269|PubMed:27612425" FT /id="VAR_077351" FT VARIANT 1935 FT /note="C -> Y (in dbSNP:rs5744991)" FT /id="VAR_028435" FT VARIANT 1980..2286 FT /note="Missing (in IMAGEI)" FT /evidence="ECO:0000269|PubMed:30503519" FT /id="VAR_081998" FT VARIANT 2013 FT /note="D -> N" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069354" FT VARIANT 2040 FT /note="A -> V (in dbSNP:rs5745021)" FT /id="VAR_020282" FT VARIANT 2056 FT /note="A -> T (found in a colorectal sample; somatic FT mutation; dbSNP:rs58916399)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069355" FT VARIANT 2140 FT /note="E -> K (in dbSNP:rs5745066)" FT /id="VAR_048881" FT VARIANT 2159 FT /note="R -> C (in dbSNP:rs5745067)" FT /id="VAR_048882" FT VARIANT 2165 FT /note="R -> H (in dbSNP:rs5745068)" FT /id="VAR_020283" FT VARIANT 2213 FT /note="A -> V (found in a colorectal sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069356" FT CONFLICT 2237 FT /note="S -> T (in Ref. 1; AAA15448/AAC19148)" FT /evidence="ECO:0000305" FT HELIX 25..47 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 57..65 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 68..72 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 78..87 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 93..99 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 103..111 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 114..121 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 125..127 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 128..137 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 142..145 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 150..159 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 160..179 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 213..217 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 218..223 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 228..235 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 243..248 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 251..253 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 256..260 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 271..273 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 275..278 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 288..290 FT /evidence="ECO:0007829|PDB:9F6I" FT STRAND 293..302 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 304..308 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 310..312 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 313..315 FT /evidence="ECO:0007829|PDB:9F6I" FT STRAND 333..335 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 340..354 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 357..363 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 364..367 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 368..379 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 383..387 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 400..402 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 404..406 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 408..414 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 419..421 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 424..430 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 443..447 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 452..473 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 475..482 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 485..487 FT /evidence="ECO:0007829|PDB:9F6I" FT HELIX 489..494 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 497..511 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 529..531 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 533..539 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 550..556 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 558..561 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 564..583 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 584..586 FT /evidence="ECO:0007829|PDB:9F6I" FT HELIX 590..592 FT /evidence="ECO:0007829|PDB:9F6I" FT STRAND 593..595 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 596..599 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 600..609 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 610..612 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 615..618 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 620..629 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 630..638 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 642..644 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 648..653 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 668..675 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 680..692 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 707..709 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 712..730 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 731..734 FT /evidence="ECO:0007829|PDB:9F6I" FT STRAND 736..743 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 745..747 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 753..782 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 783..785 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 791..817 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 818..820 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 821..823 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 829..850 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 851..853 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 854..859 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 861..869 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 876..881 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 886..890 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 892..904 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 911..915 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 916..919 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 921..923 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 931..942 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 956..959 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 965..979 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 980..988 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 991..994 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 995..998 FT /evidence="ECO:0007829|PDB:9F6I" FT HELIX 999..1018 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 1021..1024 FT /evidence="ECO:0007829|PDB:9F6I" FT HELIX 1026..1030 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 1035..1038 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 1044..1046 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 1052..1064 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 1066..1068 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 1070..1072 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 1075..1081 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 1090..1092 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 1093..1095 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 1096..1098 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 1099..1101 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 1104..1106 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 1107..1113 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 1124..1127 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 1130..1144 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 1146..1151 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 1159..1161 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 1165..1175 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 1176..1178 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 1183..1186 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 1189..1192 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 2152..2157 FT /evidence="ECO:0007829|PDB:5VBN" FT TURN 2159..2161 FT /evidence="ECO:0007829|PDB:5VBN" FT STRAND 2164..2168 FT /evidence="ECO:0007829|PDB:5VBN" FT TURN 2169..2171 FT /evidence="ECO:0007829|PDB:5VBN" FT STRAND 2188..2190 FT /evidence="ECO:0007829|PDB:5VBN" FT HELIX 2196..2216 FT /evidence="ECO:0007829|PDB:5VBN" FT STRAND 2219..2224 FT /evidence="ECO:0007829|PDB:5VBN" FT STRAND 2230..2232 FT /evidence="ECO:0007829|PDB:5VBN" FT STRAND 2237..2239 FT /evidence="ECO:0007829|PDB:5VBN" FT STRAND 2241..2246 FT /evidence="ECO:0007829|PDB:5VBN" FT HELIX 2248..2265 FT /evidence="ECO:0007829|PDB:5VBN" FT HELIX 2268..2279 FT /evidence="ECO:0007829|PDB:5VBN" SQ SEQUENCE 2286 AA; 261518 MW; A213AE1EA8437DEC CRC64; MSLRSGGRRR ADPGADGEAS RDDGATSSVS ALKRLERSQW TDKMDLRFGF ERLKEPGEKT GWLINMHPTE ILDEDKRLGS AVDYYFIQDD GSRFKVALPY KPYFYIATRK GCEREVSSFL SKKFQGKIAK VETVPKEDLD LPNHLVGLKR NYIRLSFHTV EDLVKVRKEI SPAVKKNREQ DHASDAYTAL LSSVLQRGGV ITDEEETSKK IADQLDNIVD MREYDVPYHI RLSIDLKIHV AHWYNVRYRG NAFPVEITRR DDLVERPDPV VLAFDIETTK LPLKFPDAET DQIMMISYMI DGQGYLITNR EIVSEDIEDF EFTPKPEYEG PFCVFNEPDE AHLIQRWFEH VQETKPTIMV TYNGDFFDWP FVEARAAVHG LSMQQEIGFQ KDSQGEYKAP QCIHMDCLRW VKRDSYLPVG SHNLKAAAKA KLGYDPVELD PEDMCRMATE QPQTLATYSV SDAVATYYLY MKYVHPFIFA LCTIIPMEPD EVLRKGSGTL CEALLMVQAF HANIIFPNKQ EQEFNKLTDD GHVLDSETYV GGHVEALESG VFRSDIPCRF RMNPAAFDFL LQRVEKTLRH ALEEEEKVPV EQVTNFEEVC DEIKSKLASL KDVPSRIECP LIYHLDVGAM YPNIILTNRL QPSAMVDEAT CAACDFNKPG ANCQRKMAWQ WRGEFMPASR SEYHRIQHQL ESEKFPPLFP EGPARAFHEL SREEQAKYEK RRLADYCRKA YKKIHITKVE ERLTTICQRE NSFYVDTVRA FRDRRYEFKG LHKVWKKKLS AAVEVGDAAE VKRCKNMEVL YDSLQLAHKC ILNSFYGYVM RKGARWYSME MAGIVCFTGA NIITQARELI EQIGRPLELD TDGIWCVLPN SFPENFVFKT TNVKKPKVTI SYPGAMLNIM VKEGFTNDQY QELAEPSSLT YVTRSENSIF FEVDGPYLAM ILPASKEEGK KLKKRYAVFN EDGSLAELKG FEVKRRGELQ LIKIFQSSVF EAFLKGSTLE EVYGSVAKVA DYWLDVLYSK AANMPDSELF ELISENRSMS RKLEDYGEQK STSISTAKRL AEFLGDQMVK DAGLSCRYII SRKPEGSPVT ERAIPLAIFQ AEPTVRKHFL RKWLKSSSLQ DFDIRAILDW DYYIERLGSA IQKIITIPAA LQQVKNPVPR VKHPDWLHKK LLEKNDVYKQ KKISELFTLE GRRQVTMAEA SEDSPRPSAP DMEDFGLVKL PHPAAPVTVK RKRVLWESQE ESQDLTPTVP WQEILGQPPA LGTSQEEWLV WLRFHKKKWQ LQARQRLARR KRQRLESAEG VLRPGAIRDG PATGLGSFLR RTARSILDLP WQIVQISETS QAGLFRLWAL VGSDLHCIRL SIPRVFYVNQ RVAKAEEGAS YRKVNRVLPR SNMVYNLYEY SVPEDMYQEH INEINAELSA PDIEGVYETQ VPLLFRALVH LGCVCVVNKQ LVRHLSGWEA ETFALEHLEM RSLAQFSYLE PGSIRHIYLY HHAQAHKALF GIFIPSQRRA SVFVLDTVRS NQMPSLGALY SAEHGLLLEK VGPELLPPPK HTFEVRAETD LKTICRAIQR FLLAYKEERR GPTLIAVQSS WELKRLASEI PVLEEFPLVP ICVADKINYG VLDWQRHGAR RMIRHYLNLD TCLSQAFEMS RYFHIPIGNL PEDISTFGSD LFFARHLQRH NHLLWLSPTA RPDLGGKEAD DNCLVMEFDD QATVEINSSG CYSTVCVELD LQNLAVNTIL QSHHVNDMEG ADSMGISFDV IQQASLEDMI TGGQAASAPA SYDETALCSN TFRILKSMVV GWVKEITQYH NIYADNQVMH FYRWLRSPSS LLHDPALHRT LHNMMKKLFL QLIAEFKRLG SSVIYANFNR IILCTKKRRV EDAIAYVEYI TSSIHSKETF HSLTISFSRC WEFLLWMDPS NYGGIKGKVS SRIHCGLQDS QKAGGAEDEQ ENEDDEEERD GEEEEEAEES NVEDLLENNW NILQFLPQAA SCQNYFLMIV SAYIVAVYHC MKDGLRRSAP GSTPVRRRGA SQLSQEAEGA VGALPGMITF SQDYVANELT QSFFTITQKI QKKVTGSRNS TELSEMFPVL PGSHLLLNNP ALEFIKYVCK VLSLDTNITN QVNKLNRDLL RLVDVGEFSE EAQFRDPCRS YVLPEVICRS CNFCRDLDLC KDSSFSEDGA VLPQWLCSNC QAPYDSSAIE MTLVEVLQKK LMAFTLQDLV CLKCRGVKET SMPVYCSCAG DFALTIHTQV FMEQIGIFRN IAQHYGMSYL LETLEWLLQK NPQLGH // ID EGFR_HUMAN Reviewed; 1210 AA. AC P00533; O00688; O00732; P06268; Q14225; Q68GS5; Q92795; Q9BZS2; Q9GZX1; AC Q9H2C9; Q9H3C9; Q9UMD7; Q9UMD8; Q9UMG5; DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1997, sequence version 2. DT 28-JAN-2026, entry version 299. DE RecName: Full=Epidermal growth factor receptor {ECO:0000305}; DE EC=2.7.10.1; DE AltName: Full=Proto-oncogene c-ErbB-1; DE AltName: Full=Receptor tyrosine-protein kinase erbB-1; DE Flags: Precursor; GN Name=EGFR {ECO:0000312|HGNC:HGNC:3236}; Synonyms=ERBB, ERBB1, HER1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PROTEIN SEQUENCE OF 25-32. RX PubMed=6328312; DOI=10.1038/309418a0; RA Ullrich A., Coussens L., Hayflick J.S., Dull T.J., Gray A., Tam A.W., RA Lee J., Yarden Y., Libermann T.A., Schlessinger J., Downward J., RA Mayes E.L.V., Whittle N., Waterfield M.D., Seeburg P.H.; RT "Human epidermal growth factor receptor cDNA sequence and aberrant RT expression of the amplified gene in A431 epidermoid carcinoma cells."; RL Nature 309:418-425(1984). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RC TISSUE=Placenta; RX PubMed=7654368; DOI=10.1002/mrd.1080410205; RA Ilekis J.V., Stark B.C., Scoccia B.; RT "Possible role of variant RNA transcripts in the regulation of epidermal RT growth factor receptor expression in human placenta."; RL Mol. Reprod. Dev. 41:149-156(1995). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 2). RC TISSUE=Placenta; RX PubMed=8918811; DOI=10.1093/nar/24.20.4050; RA Reiter J.L., Maihle N.J.; RT "A 1.8 kb alternative transcript from the human epidermal growth factor RT receptor gene encodes a truncated form of the receptor."; RL Nucleic Acids Res. 24:4050-4056(1996). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RC TISSUE=Placenta; RX PubMed=9103388; DOI=10.1006/gyno.1996.4526; RA Ilekis J.V., Gariti J., Niederberger C., Scoccia B.; RT "Expression of a truncated epidermal growth factor receptor-like protein RT (TEGFR) in ovarian cancer."; RL Gynecol. Oncol. 65:36-41(1997). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 3 AND 4). RC TISSUE=Placenta; RX PubMed=11161793; DOI=10.1006/geno.2000.6341; RA Reiter J.L., Threadgill D.W., Eley G.D., Strunk K.E., Danielsen A.J., RA Schehl Sinclair C., Pearsall R.S., Green P.J., Yee D., Lampland A.L., RA Balasubramaniam S., Crossley T.D., Magnuson T.R., James C.D., Maihle N.J.; RT "Comparative genomic sequence analysis and isolation of human and mouse RT alternative EGFR transcripts encoding truncated receptor isoforms."; RL Genomics 71:1-20(2001). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RA Xu L., Hong A., He X.; RT "Cloning of the cDNA for a short EGF receptor from human placenta."; RL Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLN-98; ARG-266; LYS-521; RP ILE-674; GLY-962 AND PRO-988. RG NIEHS SNPs program; RL Submitted (APR-2004) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 575-687. RA Reiter J.L., Threadgill D.W., Danielsen A.J., Schehl C.M., Lampland A.L., RA Balasubramaniam S., Crossley T.O., Magnuson T.R., Maihle N.J.; RT "Human and mouse alternative EGFR transcripts encoding only the RT extracellular domain of the receptor."; RL Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 713-924. RX PubMed=6326261; DOI=10.1126/science.6326261; RA Lin C.R., Chen W.S., Kruiger W., Stolarsky L.S., Weber W., Evans R.M., RA Verma I.M., Gill G.N., Rosenfeld M.G.; RT "Expression cloning of human EGF receptor complementary DNA: gene RT amplification and three related messenger RNA products in A431 cells."; RL Science 224:843-848(1984). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] OF 150-962. RX PubMed=6330563; DOI=10.1038/309806a0; RA Xu Y.H., Ishii S., Clark A.J.L., Sullivan M., Wilson R.K., Ma D.P., RA Roe B.A., Merlino G.T., Pastan I.; RT "Human epidermal growth factor receptor cDNA is homologous to a variety of RT RNAs overproduced in A431 carcinoma cells."; RL Nature 309:806-810(1984). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1028-1210. RX PubMed=6093780; DOI=10.1016/0006-291x(84)90926-4; RA Simmen F.A., Gope M.L., Schulz T.Z., Wright D.A., Carpenter G., RA O'Malley B.W.; RT "Isolation of an evolutionarily conserved epidermal growth factor receptor RT cDNA from human A431 carcinoma cells."; RL Biochem. Biophys. Res. Commun. 124:125-132(1984). RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-29. RX PubMed=3329716; RA Haley J.D., Whittle N., Bennett P., Kinchington D., Ullrich A., RA Waterfield M.D.; RT "The human EGF receptor gene: structure of the 110 kb locus and RT identification of sequences regulating its transcription."; RL Oncogene Res. 1:375-396(1987). RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-29. RX PubMed=1988448; DOI=10.1016/s0021-9258(18)52359-0; RA Haley J.D., Waterfield M.D.; RT "Contributory effects of de novo transcription and premature transcript RT termination in the regulation of human epidermal growth factor receptor RT proto-oncogene RNA synthesis."; RL J. Biol. Chem. 266:1746-1753(1991). RN [14] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-29. RX PubMed=2991899; DOI=10.1073/pnas.82.15.4920; RA Ishii S., Xu Y.H., Stratton R.H., Roe B.A., Merlino G.T., Pastan I.; RT "Characterization and sequence of the promoter region of the human RT epidermal growth factor receptor gene."; RL Proc. Natl. Acad. Sci. U.S.A. 82:4920-4924(1985). RN [15] RP NUCLEOTIDE SEQUENCE [MRNA] OF 25-49. RX PubMed=6324343; DOI=10.1126/science.6324343; RA Weber W., Gill G.N., Spiess J.; RT "Production of an epidermal growth factor receptor-related protein."; RL Science 224:294-297(1984). RN [16] RP PROTEIN SEQUENCE OF 540. RA Kohda D.; RL Submitted (SEP-1997) to UniProtKB. RN [17] RP PROTEIN SEQUENCE OF 687-705; 986-998; 1000-1023; 1026-1030 AND 1068-1077, RP AND PHOSPHORYLATION AT THR-693; SER-695; SER-1070 AND SER-1071. RX PubMed=3138233; DOI=10.1016/s0021-9258(18)37684-1; RA Heisermann G.J., Gill G.N.; RT "Epidermal growth factor receptor threonine and serine residues RT phosphorylated in vivo."; RL J. Biol. Chem. 263:13152-13158(1988). RN [18] RP PROTEIN SEQUENCE OF 25-39. RX PubMed=15340161; DOI=10.1110/ps.04682504; RA Zhang Z., Henzel W.J.; RT "Signal peptide prediction based on analysis of experimentally verified RT cleavage sites."; RL Protein Sci. 13:2819-2824(2004). RN [19] RP PROTEIN SEQUENCE OF 740-744 AND 746-747. RX PubMed=2985580; DOI=10.1016/s0021-9258(18)89002-0; RA Russo M.W., Lukas T.J., Cohen S., Staros J.V.; RT "Identification of residues in the nucleotide binding site of the epidermal RT growth factor receptor/kinase."; RL J. Biol. Chem. 260:5205-5208(1985). RN [20] RP PROTEIN SEQUENCE OF 861-875 AND 914-932, UBIQUITINATION AT LYS-716; RP LYS-737; LYS-754; LYS-867; LYS-929 AND LYS-970, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RX PubMed=16543144; DOI=10.1016/j.molcel.2006.02.018; RA Huang F., Kirkpatrick D., Jiang X., Gygi S.P., Sorkin A.; RT "Differential regulation of EGF receptor internalization and degradation by RT multiubiquitination within the kinase domain."; RL Mol. Cell 21:737-748(2006). RN [21] RP PARTIAL PROTEIN SEQUENCE, AND DISULFIDE BONDS. RX PubMed=9556602; DOI=10.1074/jbc.273.18.11150; RA Abe Y., Odaka M., Inagaki F., Lax I., Schlessinger J., Kohda D.; RT "Disulfide bond structure of human epidermal growth factor receptor."; RL J. Biol. Chem. 273:11150-11157(1998). RN [22] RP RECEPTOR ACTIVITY. RX PubMed=6325948; DOI=10.1038/309270a0; RA Mroczkowski B., Mosig G., Cohen S.; RT "ATP-stimulated interaction between epidermal growth factor receptor and RT supercoiled DNA."; RL Nature 309:270-273(1984). RN [23] RP REVIEW. RX PubMed=3039909; DOI=10.1146/annurev.bi.56.070187.004313; RA Carpenter G.; RT "Receptors for epidermal growth factor and other polypeptide mitogens."; RL Annu. Rev. Biochem. 56:881-914(1987). RN [24] RP FUNCTION, SUBCELLULAR LOCATION, AND LIGAND-BINDING. RX PubMed=2790960; DOI=10.1016/0092-8674(89)90867-2; RA Chen W.S., Lazar C.S., Lund K.A., Welsh J.B., Chang C.P., Walton G.M., RA Der C.J., Wiley H.S., Gill G.N., Rosenfeld M.G.; RT "Functional independence of the epidermal growth factor receptor from a RT domain required for ligand-induced internalization and calcium RT regulation."; RL Cell 59:33-43(1989). RN [25] RP PHOSPHORYLATION AT TYR-1110. RX PubMed=2543678; DOI=10.1016/s0021-9258(18)81674-x; RA Margolis B.L., Lax I., Kris R., Dombalagian M., Honegger A.M., Howk R., RA Givol D., Ullrich A., Schlessinger J.; RT "All autophosphorylation sites of epidermal growth factor (EGF) receptor RT and HER2/neu are located in their carboxyl-terminal tails. Identification RT of a novel site in EGF receptor."; RL J. Biol. Chem. 264:10667-10671(1989). RN [26] RP IDENTIFICATION OF AREG AS LIGAND, AND FUNCTION. RX PubMed=7679104; DOI=10.1016/s0021-9258(18)53862-x; RA Johnson G.R., Kannan B., Shoyab M., Stromberg K.; RT "Amphiregulin induces tyrosine phosphorylation of the epidermal growth RT factor receptor and p185erbB2. Evidence that amphiregulin acts exclusively RT through the epidermal growth factor receptor at the surface of human RT epithelial cells."; RL J. Biol. Chem. 268:2924-2931(1993). RN [27] RP INTERACTION WITH ZPR1. RX PubMed=8650580; DOI=10.1126/science.272.5269.1797; RA Galcheva-Gargova Z., Konstantinov K.N., Wu I.-H., Klier F.G., Barrett T., RA Davis R.J.; RT "Binding of zinc finger protein ZPR1 to the epidermal growth factor RT receptor."; RL Science 272:1797-1802(1996). RN [28] RP INTERACTION WITH ZPR1. RX PubMed=9852145; DOI=10.1083/jcb.143.6.1471; RA Gangwani L., Mikrut M., Galcheva-Gargova Z., Davis R.J.; RT "Interaction of ZPR1 with translation elongation factor-1alpha in RT proliferating cells."; RL J. Cell Biol. 143:1471-1484(1998). RN [29] RP PHOSPHORYLATION AT THR-678 AND THR-693. RX PubMed=10523301; DOI=10.1093/emboj/18.20.5567; RA Bagowski C.P., Stein-Gerlach M., Choidas A., Ullrich A.; RT "Cell-type specific phosphorylation of threonines T654 and T669 by PKD RT defines the signal capacity of the EGF receptor."; RL EMBO J. 18:5567-5576(1999). RN [30] RP IDENTIFICATION OF BETACELLULIN/BTC AS LIGAND. RX PubMed=8144591; DOI=10.1016/s0021-9258(17)36977-6; RA Watanabe T., Shintani A., Nakata M., Shing Y., Folkman J., Igarashi K., RA Sasada R.; RT "Recombinant human betacellulin. Molecular structure, biological RT activities, and receptor interaction."; RL J. Biol. Chem. 269:9966-9973(1994). RN [31] RP FUNCTION IN PHOSPHORYLATION OF CBL, AND INTERACTION WITH CBL. RX PubMed=7657591; DOI=10.1074/jbc.270.35.20242; RA Galisteo M.L., Dikic I., Batzer A.G., Langdon W.Y., Schlessinger J.; RT "Tyrosine phosphorylation of the c-cbl proto-oncogene protein product and RT association with epidermal growth factor (EGF) receptor upon EGF RT stimulation."; RL J. Biol. Chem. 270:20242-20245(1995). RN [32] RP GLYCOSYLATION AT ASN-128; ASN-175; ASN-413; ASN-444 AND ASN-528. RX PubMed=8962717; DOI=10.3109/08977199609034572; RA Smith K.D., Davies M.J., Bailey D., Renouf D.V., Hounsell E.F.; RT "Analysis of the glycosylation patterns of the extracellular domain of the RT epidermal growth factor receptor expressed in Chinese hamster ovary RT fibroblasts."; RL Growth Factors 13:121-132(1996). RN [33] RP IDENTIFICATION OF EPIREGULIN/EREG AS LIGAND, AND FUNCTION. RX PubMed=9419975; DOI=10.1038/sj.onc.1201458; RA Komurasaki T., Toyoda H., Uchida D., Morimoto S.; RT "Epiregulin binds to epidermal growth factor receptor and ErbB-4 and RT induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB- RT 2, ErbB-3 and ErbB-4."; RL Oncogene 15:2841-2848(1997). RN [34] RP PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPN1 AND PTPN2. RX PubMed=9488479; DOI=10.1128/mcb.18.3.1622; RA Tiganis T., Bennett A.M., Ravichandran K.S., Tonks N.K.; RT "Epidermal growth factor receptor and the adaptor protein p52Shc are RT specific substrates of T-cell protein tyrosine phosphatase."; RL Mol. Cell. Biol. 18:1622-1634(1998). RN [35] RP INTERACTION WITH AP2M1. RX PubMed=10228163; DOI=10.1093/emboj/18.9.2489; RA Nesterov A., Carter R.E., Sorkina T., Gill G.N., Sorkin A.; RT "Inhibition of the receptor-binding function of clathrin adaptor protein RT AP-2 by dominant-negative mutant mu2 subunit and its effects on RT endocytosis."; RL EMBO J. 18:2489-2499(1999). RN [36] RP INTERACTION WITH GRB2; NCK1 AND NCK2. RX PubMed=10026169; DOI=10.1074/jbc.274.9.5542; RA Braverman L.E., Quilliam L.A.; RT "Identification of Grb4/Nckbeta, a src homology 2 and 3 domain-containing RT adapter protein having similar binding and biological properties to Nck."; RL J. Biol. Chem. 274:5542-5549(1999). RN [37] RP GLYCOSYLATION AT ASN-56; ASN-352; ASN-361; ASN-568 AND ASN-603. RX PubMed=10731668; DOI=10.1093/oxfordjournals.jbchem.a022585; RA Sato C., Kim J.-H., Abe Y., Saito K., Yokoyama S., Kohda D.; RT "Characterization of the N-oligosaccharides attached to the atypical Asn-X- RT Cys sequence of recombinant human epidermal growth factor receptor."; RL J. Biochem. 127:65-72(2000). RN [38] RP FUNCTION IN PHOSPHORYLATION OF RGS16. RX PubMed=11602604; DOI=10.1074/jbc.m108862200; RA Derrien A., Druey K.M.; RT "RGS16 function is regulated by epidermal growth factor receptor-mediated RT tyrosine phosphorylation."; RL J. Biol. Chem. 276:48532-48538(2001). RN [39] RP GLYCOSYLATION AT ASN-56; ASN-128; ASN-175; ASN-196; ASN-352; ASN-361; RP ASN-413; ASN-444; ASN-528; ASN-568; ASN-603 AND ASN-623. RX PubMed=12731890; DOI=10.1021/bi027101p; RA Zhen Y., Caprioli R.M., Staros J.V.; RT "Characterization of glycosylation sites of the epidermal growth factor RT receptor."; RL Biochemistry 42:5478-5492(2003). RN [40] RP FUNCTION IN CELL PROLIFERATION, INTERACTION WITH STAT3, AND PHOSPHORYLATION RP AT TYR-1092 AND TYR-1110. RX PubMed=12873986; RA Shao H., Cheng H.Y., Cook R.G., Tweardy D.J.; RT "Identification and characterization of signal transducer and activator of RT transcription 3 recruitment sites within the epidermal growth factor RT receptor."; RL Cancer Res. 63:3923-3930(2003). RN [41] RP ACTIVITY REGULATION, AND INTERACTION WITH LRIG1. RX PubMed=15282549; DOI=10.1038/sj.emboj.7600342; RA Gur G., Rubin C., Katz M., Amit I., Citri A., Nilsson J., Amariglio N., RA Henriksson R., Rechavi G., Hedman H., Wides R., Yarden Y.; RT "LRIG1 restricts growth factor signaling by enhancing receptor RT ubiquitylation and degradation."; RL EMBO J. 23:3270-3281(2004). RN [42] RP FUNCTION IN EGFR SIGNALING, IDENTIFICATION IN A COMPLEX WITH PIK3C2A AND RP ERBB2, IDENTIFICATION IN A COMPLEX WITH PIK3C2B AND ERBB2, INTERACTION WITH RP PIK3C2B, AND MUTAGENESIS OF TYR-1016; TYR-1092; TYR-1110; TYR-1172 AND RP TYR-1197. RX PubMed=10805725; DOI=10.1128/mcb.20.11.3817-3830.2000; RA Arcaro A., Zvelebil M.J., Wallasch C., Ullrich A., Waterfield M.D., RA Domin J.; RT "Class II phosphoinositide 3-kinases are downstream targets of activated RT polypeptide growth factor receptors."; RL Mol. Cell. Biol. 20:3817-3830(2000). RN [43] RP FUNCTION IN NF-KAPPA-B ACTIVATION, AND INTERACTION WITH RIPK1. RX PubMed=11116146; DOI=10.1074/jbc.m008458200; RA Habib A.A., Chatterjee S., Park S.-K., Ratan R.R., Lefebvre S., RA Vartanian T.; RT "The epidermal growth factor receptor engages receptor interacting protein RT and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF- RT kappa B. Identification of a novel receptor-tyrosine kinase signalosome."; RL J. Biol. Chem. 276:8865-8874(2001). RN [44] RP FUNCTION IN PHOSPHORYLATION OF MUC1, AND INTERACTION WITH MUC1. RX PubMed=11483589; DOI=10.1074/jbc.c100359200; RA Li Y., Ren J., Yu W., Li Q., Kuwahara H., Yin L., Carraway K.L. III, RA Kufe D.; RT "The epidermal growth factor receptor regulates interaction of the human RT DF3/MUC1 carcinoma antigen with c-Src and beta-catenin."; RL J. Biol. Chem. 276:35239-35242(2001). RN [45] RP FUNCTION, ACTIVITY REGULATION, AND INTERACTION WITH SOCS5. RX PubMed=15590694; DOI=10.1074/jbc.m408575200; RA Kario E., Marmor M.D., Adamsky K., Citri A., Amit I., Amariglio N., RA Rechavi G., Yarden Y.; RT "Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor RT receptor signaling."; RL J. Biol. Chem. 280:7038-7048(2005). RN [46] RP IDENTIFICATION OF EPIGEN/EPGN AS A LIGAND, AND FUNCTION. RX PubMed=15611079; DOI=10.1074/jbc.m413919200; RA Kochupurakkal B.S., Harari D., Di-Segni A., Maik-Rachline G., Lyass L., RA Gur G., Kerber G., Citri A., Lavi S., Eilam R., Chalifa-Caspi V., RA Eshhar Z., Pikarsky E., Pinkas-Kramarski R., Bacus S.S., Yarden Y.; RT "Epigen, the last ligand of ErbB receptors, reveals intricate relationships RT between affinity and mitogenicity."; RL J. Biol. Chem. 280:8503-8512(2005). RN [47] RP GLYCOSYLATION AT ASN-56; ASN-128; ASN-175; ASN-196; ASN-352; ASN-361; RP ASN-413; ASN-444; ASN-528; ASN-568 AND ASN-603, PHOSPHORYLATION AT THR-693; RP SER-991 AND SER-1026, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=16083266; DOI=10.1021/pr050113n; RA Wu S.L., Kim J., Hancock W.S., Karger B.; RT "Extended Range Proteomic Analysis (ERPA): a new and sensitive LC-MS RT platform for high sequence coverage of complex proteins with extensive RT post-translational modifications-comprehensive analysis of beta-casein and RT epidermal growth factor receptor (EGFR)."; RL J. Proteome Res. 4:1155-1170(2005). RN [48] RP INTERACTION WITH PELP1. RX PubMed=16140940; DOI=10.1158/0008-5472.can-05-0614; RA Vadlamudi R.K., Manavathi B., Balasenthil S., Nair S.S., Yang Z., RA Sahin A.A., Kumar R.; RT "Functional implications of altered subcellular localization of PELP1 in RT breast cancer cells."; RL Cancer Res. 65:7724-7732(2005). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1172 AND TYR-1197, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [50] RP FUNCTION IN CELL PROLIFERATION, FUNCTION IN PCNA PHOSPHORYLATION, RP INTERACTION WITH PCNA, AND SUBCELLULAR LOCATION. RX PubMed=17115032; DOI=10.1038/ncb1501; RA Wang S.C., Nakajima Y., Yu Y.L., Xia W., Chen C.T., Yang C.C., RA McIntush E.W., Li L.Y., Hawke D.H., Kobayashi R., Hung M.C.; RT "Tyrosine phosphorylation controls PCNA function through protein RT stability."; RL Nat. Cell Biol. 8:1359-1368(2006). RN [51] RP INTERACTION WITH STX19. RX PubMed=16420529; DOI=10.1111/j.1600-0854.2005.00378.x; RA Wang Y., Foo L.Y., Guo K., Gan B.Q., Zeng Q., Hong W., Tang B.L.; RT "Syntaxin 9 is enriched in skin hair follicle epithelium and interacts with RT the epidermal growth factor receptor."; RL Traffic 7:216-226(2006). RN [52] RP INTERACTION WITH PIKFYVE, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=17909029; DOI=10.1158/0008-5472.can-07-1333; RA Kim J., Jahng W.J., Di Vizio D., Lee J.S., Jhaveri R., Rubin M.A., RA Shisheva A., Freeman M.R.; RT "The phosphoinositide kinase PIKfyve mediates epidermal growth factor RT receptor trafficking to the nucleus."; RL Cancer Res. 67:9229-9237(2007). RN [53] RP TISSUE SPECIFICITY. RX PubMed=17671655; DOI=10.1172/jci31680; RA Groenestege W.M.T., Thebault S., van der Wijst J., van den Berg D., RA Janssen R., Tejpar S., van den Heuvel L.P., van Cutsem E., Hoenderop J.G., RA Knoers N.V., Bindels R.J.; RT "Impaired basolateral sorting of pro-EGF causes isolated recessive renal RT hypomagnesemia."; RL J. Clin. Invest. 117:2260-2267(2007). RN [54] RP INTERACTION WITH TNF2, AND SUBCELLULAR LOCATION. RX PubMed=17182860; DOI=10.1091/mbc.e06-02-0142; RA Shen F., Lin Q., Gu Y., Childress C., Yang W.; RT "Activated Cdc42-associated kinase 1 is a component of EGF receptor RT signaling complex and regulates EGF receptor degradation."; RL Mol. Biol. Cell 18:732-742(2007). RN [55] RP INTERACTION WITH NEU3, AND ACTIVITY REGULATION. RX PubMed=17334392; DOI=10.1038/sj.onc.1210341; RA Wada T., Hata K., Yamaguchi K., Shiozaki K., Koseki K., Moriya S., RA Miyagi T.; RT "A crucial role of plasma membrane-associated sialidase in the survival of RT human cancer cells."; RL Oncogene 26:2483-2490(2007). RN [56] RP INTERACTION WITH ATXN2. RX PubMed=18602463; DOI=10.1016/j.cellsig.2008.05.018; RA Nonis D., Schmidt M.H., van de Loo S., Eich F., Dikic I., Nowock J., RA Auburger G.; RT "Ataxin-2 associates with the endocytosis complex and affects EGF receptor RT trafficking."; RL Cell. Signal. 20:1725-1739(2008). RN [57] RP INTERACTION WITH GAB2. RX PubMed=19172738; DOI=10.1038/emboj.2008.159; RA Brummer T., Larance M., Herrera Abreu M.T., Lyons R.J., Timpson P., RA Emmerich C.H., Fleuren E.D.G., Lehrbach G.M., Schramek D., Guilhaus M., RA James D.E., Daly R.J.; RT "Phosphorylation-dependent binding of 14-3-3 terminates signalling by the RT Gab2 docking protein."; RL EMBO J. 27:2305-2316(2008). RN [58] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [59] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-693; SER-695; SER-1064; RP SER-1081; SER-1166 AND TYR-1197, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [60] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-991; SER-995; TYR-998; RP SER-1039; THR-1041; SER-1042; SER-1064 AND SER-1166, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [61] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [62] RP ACTIVITY REGULATION BY PTPRJ AND PTPRK, PHOSPHORYLATION AT TYR-1197, RP DEPHOSPHORYLATION BY PTPRJ, SUBCELLULAR LOCATION, AND INTERACTION WITH CBL RP AND GRB2. RX PubMed=19836242; DOI=10.1016/j.cub.2009.09.048; RA Tarcic G., Boguslavsky S.K., Wakim J., Kiuchi T., Liu A., Reinitz F., RA Nathanson D., Takahashi T., Mischel P.S., Ng T., Yarden Y.; RT "An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase RT controlling EGFR endocytosis."; RL Curr. Biol. 19:1788-1798(2009). RN [63] RP INTERACTION WITH GAREM1. RX PubMed=19509291; DOI=10.1074/jbc.m109.021139; RA Tashiro K., Tsunematsu T., Okubo H., Ohta T., Sano E., Yamauchi E., RA Taniguchi H., Konishi H.; RT "GAREM, a novel adaptor protein for growth factor receptor-bound protein 2, RT contributes to cellular transformation through the activation of RT extracellular signal-regulated kinase signaling."; RL J. Biol. Chem. 284:20206-20214(2009). RN [64] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-352; ASN-413 AND ASN-568. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). RN [65] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [66] RP INTERACTION WITH GPER1. RX PubMed=19749156; DOI=10.1210/me.2009-0120; RA Vivacqua A., Lappano R., De Marco P., Sisci D., Aquila S., De Amicis F., RA Fuqua S.A., Ando S., Maggiolini M.; RT "G protein-coupled receptor 30 expression is up-regulated by EGF and TGF RT alpha in estrogen receptor alpha-positive cancer cells."; RL Mol. Endocrinol. 23:1815-1826(2009). RN [67] RP MUTAGENESIS OF 525-SER--ALA-1210; ASP-587; HIS-590 AND LYS-609. RX PubMed=19718021; DOI=10.1038/nature08297; RA Alvarado D., Klein D.E., Lemmon M.A.; RT "ErbB2 resembles an autoinhibited invertebrate epidermal growth factor RT receptor."; RL Nature 461:287-291(2009). RN [68] RP INTERACTION WITH COPG1, SUBCELLULAR LOCATION, AND TOPOLOGY. RX PubMed=20674546; DOI=10.1016/j.bbrc.2010.07.096; RA Wang Y.N., Wang H., Yamaguchi H., Lee H.J., Lee H.H., Hung M.C.; RT "COPI-mediated retrograde trafficking from the Golgi to the ER regulates RT EGFR nuclear transport."; RL Biochem. Biophys. Res. Commun. 399:498-504(2010). RN [69] RP INTERACTION WITH GPER1, AND SUBCELLULAR LOCATION. RX PubMed=20551055; DOI=10.1158/0008-5472.can-10-0408; RA Madeo A., Maggiolini M.; RT "Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol- RT induced gene expression and migration in breast cancer-associated RT fibroblasts."; RL Cancer Res. 70:6036-6046(2010). RN [70] RP FUNCTION, IDENTIFICATION IN COMPLEX WITH CCDC88A AND GNAI3, SUBCELLULAR RP LOCATION, AND PHOSPHORYLATION. RX PubMed=20462955; DOI=10.1091/mbc.e10-01-0028; RA Ghosh P., Beas A.O., Bornheimer S.J., Garcia-Marcos M., Forry E.P., RA Johannson C., Ear J., Jung B.H., Cabrera B., Carethers J.M., Farquhar M.G.; RT "A G{alpha}i-GIV molecular complex binds epidermal growth factor receptor RT and determines whether cells migrate or proliferate."; RL Mol. Biol. Cell 21:2338-2354(2010). RN [71] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-693; SER-991; SER-1064 AND RP TYR-1197, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [72] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [73] RP PHOSPHORYLATION AT SER-229. RX PubMed=21487020; DOI=10.1074/jbc.m111.240796; RA Huang W.C., Chen Y.J., Li L.Y., Wei Y.L., Hsu S.C., Tsai S.L., Chiu P.C., RA Huang W.P., Wang Y.N., Chen C.H., Chang W.C., Chang W.C., Chen A.J., RA Tsai C.H., Hung M.C.; RT "Nuclear translocation of epidermal growth factor receptor by Akt-dependent RT phosphorylation enhances breast cancer-resistant protein expression in RT gefitinib-resistant cells."; RL J. Biol. Chem. 286:20558-20568(2011). RN [74] RP FUNCTION IN CELL PROLIFERATION AND CELL MIGRATION, METHYLATION AT ARG-1199 RP BY PRMT5, AND INTERACTION WITH PRMT5 AND PTPN6. RX PubMed=21258366; DOI=10.1038/ncb2158; RA Hsu J.M., Chen C.T., Chou C.K., Kuo H.P., Li L.Y., Lin C.Y., Lee H.J., RA Wang Y.N., Liu M., Liao H.W., Shi B., Lai C.C., Bedford M.T., Tsai C.H., RA Hung M.C.; RT "Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation RT negatively modulates EGFR-mediated ERK activation."; RL Nat. Cell Biol. 13:174-181(2011). RN [75] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=21516087; DOI=10.1038/nm.2341; RA Lupberger J., Zeisel M.B., Xiao F., Thumann C., Fofana I., Zona L., RA Davis C., Mee C.J., Turek M., Gorke S., Royer C., Fischer B., Zahid M.N., RA Lavillette D., Fresquet J., Cosset F.L., Rothenberg S.M., Pietschmann T., RA Patel A.H., Pessaux P., Doffoel M., Raffelsberger W., Poch O., RA McKeating J.A., Brino L., Baumert T.F.; RT "EGFR and EphA2 are host factors for hepatitis C virus entry and possible RT targets for antiviral therapy."; RL Nat. Med. 17:589-595(2011). RN [76] RP INTERACTION WITH FER, AND PHOSPHORYLATION. RX PubMed=21518868; DOI=10.1073/pnas.1105369108; RA Guo C., Stark G.R.; RT "FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine RT through EGF-dependent activation of NF-kappaB."; RL Proc. Natl. Acad. Sci. U.S.A. 108:7968-7973(2011). RN [77] RP INTERACTION WITH ANKRD13A; ANKRD13B AND ANKRD13D, UBIQUITINATION, AND RP SUBCELLULAR LOCATION. RX PubMed=22298428; DOI=10.1091/mbc.e11-09-0817; RA Tanno H., Yamaguchi T., Goto E., Ishido S., Komada M.; RT "The Ankrd 13 family of UIM-bearing proteins regulates EGF receptor RT endocytosis from the plasma membrane."; RL Mol. Biol. Cell 23:1343-1353(2012). RN [78] RP UBIQUITINATION, AND DEUBIQUITINATION BY OTUD7B. RX PubMed=22179831; DOI=10.1038/onc.2011.587; RA Pareja F., Ferraro D.A., Rubin C., Cohen-Dvashi H., Zhang F., Aulmann S., RA Ben-Chetrit N., Pines G., Navon R., Crosetto N., Kostler W., Carvalho S., RA Lavi S., Schmitt F., Dikic I., Yakhini Z., Sinn P., Mills G.B., Yarden Y.; RT "Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression."; RL Oncogene 31:4599-4608(2012). RN [79] RP INTERACTION WITH CBL, AND PHOSPHORYLATION AT TYR-869; TYR-1016; TYR-1069; RP TYR-1092 AND TYR-1197. RX PubMed=23774213; DOI=10.1158/0008-5472.can-12-4441; RA Hong S.Y., Shih Y.P., Li T., Carraway K.L. III, Lo S.H.; RT "CTEN prolongs signaling by EGFR through reducing its ligand-induced RT degradation."; RL Cancer Res. 73:5266-5276(2013). RN [80] RP INTERACTION WITH RNF115 AND RNF126. RX PubMed=23418353; DOI=10.1242/jcs.116129; RA Smith C.J., Berry D.M., McGlade C.J.; RT "The E3 ubiquitin ligases RNF126 and Rabring7 regulate endosomal sorting of RT the epidermal growth factor receptor."; RL J. Cell Sci. 126:1366-1380(2013). RN [81] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-693 AND SER-1064, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [82] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-693; SER-991; SER-1026 AND RP SER-1166, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [83] RP INTERACTION WITH CCDC88A AND GNAI3. RX PubMed=25187647; DOI=10.1091/mbc.e14-05-0978; RA Lin C., Ear J., Midde K., Lopez-Sanchez I., Aznar N., Garcia-Marcos M., RA Kufareva I., Abagyan R., Ghosh P.; RT "Structural basis for activation of trimeric Gi proteins by multiple growth RT factor receptors via GIV/Girdin."; RL Mol. Biol. Cell 25:3654-3671(2014). RN [84] RP SUBCELLULAR LOCATION, AND INTERACTION WITH CD44. RX PubMed=23589287; DOI=10.1074/jbc.m113.451336; RA Midgley A.C., Rogers M., Hallett M.B., Clayton A., Bowen T., Phillips A.O., RA Steadman R.; RT "Transforming growth factor-beta1 (TGF-beta1)-stimulated fibroblast to RT myofibroblast differentiation is mediated by hyaluronan (HA)-facilitated RT epidermal growth factor receptor (EGFR) and CD44 co-localization in lipid RT rafts."; RL J. Biol. Chem. 288:14824-14838(2013). RN [85] RP INTERACTION WITH GPRC5A. RX PubMed=25311788; DOI=10.1186/1476-4598-13-233; RA Lin X., Zhong S., Ye X., Liao Y., Yao F., Yang X., Sun B., Zhang J., Li Q., RA Gao Y., Wang Y., Liu J., Han B., Chin Y.E., Zhou B.P., Deng J.; RT "EGFR phosphorylates and inhibits lung tumor suppressor GPRC5A in lung RT cancer."; RL Mol. Cancer 13:233-233(2014). RN [86] RP INTERACTION WITH FAM83B. RX PubMed=23912460; DOI=10.1038/onc.2013.293; RA Cipriano R., Bryson B.L., Miskimen K.L., Bartel C.A., Hernandez-Sanchez W., RA Bruntz R.C., Scott S.A., Lindsley C.W., Brown H.A., Jackson M.W.; RT "Hyperactivation of EGFR and downstream effector phospholipase D1 by RT oncogenic FAM83B."; RL Oncogene 33:3298-3306(2014). RN [87] RP GLYCOSYLATION AT ASN-528, AND ACTIVITY REGULATION. RX PubMed=25922362; DOI=10.1093/glycob/cwv026; RA Mozzi A., Forcella M., Riva A., Difrancesco C., Molinari F., Martin V., RA Papini N., Bernasconi B., Nonnis S., Tedeschi G., Mazzucchelli L., RA Monti E., Fusi P., Frattini M.; RT "NEU3 activity enhances EGFR activation without affecting EGFR expression RT and acts on its sialylation levels."; RL Glycobiology 25:855-868(2015). RN [88] RP FUNCTION, PALMITOYLATION AT CYS-1049 AND CYS-1146, IDENTIFICATION BY MASS RP SPECTROMETRY, UBIQUITINATION, PHOSPHORYLATION AT TYR-1092; TYR-1172 AND RP TYR-1197, SUBCELLULAR LOCATION, AND MUTAGENESIS OF 1048-ALA--ALA-1210; RP CYS-1049 AND CYS-1146. RX PubMed=27153536; DOI=10.1016/j.molcel.2016.04.003; RA Runkle K.B., Kharbanda A., Stypulkowski E., Cao X.J., Wang W., Garcia B.A., RA Witze E.S.; RT "Inhibition of DHHC20-Mediated EGFR Palmitoylation Creates a Dependence on RT EGFR Signaling."; RL Mol. Cell 62:385-396(2016). RN [89] RP INTERACTION WITH PGRMC1. RX PubMed=26988023; DOI=10.1038/ncomms11030; RA Kabe Y., Nakane T., Koike I., Yamamoto T., Sugiura Y., Harada E., RA Sugase K., Shimamura T., Ohmura M., Muraoka K., Yamamoto A., Uchida T., RA Iwata S., Yamaguchi Y., Krayukhina E., Noda M., Handa H., Ishimori K., RA Uchiyama S., Kobayashi T., Suematsu M.; RT "Haem-dependent dimerization of PGRMC1/Sigma-2 receptor facilitates cancer RT proliferation and chemoresistance."; RL Nat. Commun. 7:11030-11030(2016). RN [90] RP SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT TYR-1172. RX PubMed=26918609; DOI=10.18632/oncotarget.7675; RA Overmiller A.M., McGuinn K.P., Roberts B.J., Cooper F., RA Brennan-Crispi D.M., Deguchi T., Peltonen S., Wahl J.K. III, Mahoney M.G.; RT "c-Src/Cav1-dependent activation of the EGFR by Dsg2."; RL Oncotarget 7:37536-37555(2016). RN [91] RP INTERACTION WITH LAPTM4B. RX PubMed=28479384; DOI=10.1016/j.gene.2017.05.006; RA Tian M., Chen Y., Tian D., Qiao X., Ma Z., Li J.; RT "Beclin1 antagonizes LAPTM4B-mediated EGFR overactivation in gastric cancer RT cells."; RL Gene 626:48-53(2017). RN [92] RP HYDROXYBUTYRYLATION AT LYS-745. RX PubMed=29192674; DOI=10.1038/cr.2017.149; RA Huang H., Luo Z., Qi S., Huang J., Xu P., Wang X., Gao L., Li F., Wang J., RA Zhao W., Gu W., Chen Z., Dai L., Dai J., Zhao Y.; RT "Landscape of the regulatory elements for lysine 2-hydroxyisobutyrylation RT pathway."; RL Cell Res. 28:111-125(2018). RN [93] RP INTERACTION WITH TRAF4. RX PubMed=30352854; DOI=10.1073/pnas.1809599115; RA Cai G., Zhu L., Chen X., Sun K., Liu C., Sen G.C., Stark G.R., Qin J., RA Li X.; RT "TRAF4 binds to the juxtamembrane region of EGFR directly and promotes RT kinase activation."; RL Proc. Natl. Acad. Sci. U.S.A. 115:11531-11536(2018). RN [94] RP UBIQUITINATION BY ZNRF1 AND CBL. RX PubMed=33996800; DOI=10.3389/fcell.2021.642625; RA Shen C.H., Chou C.C., Lai T.Y., Hsu J.E., Lin Y.S., Liu H.Y., Chen Y.K., RA Ho I.L., Hsu P.H., Chuang T.H., Lee C.Y., Hsu L.C.; RT "ZNRF1 Mediates Epidermal Growth Factor Receptor Ubiquitination to Control RT Receptor Lysosomal Trafficking and Degradation."; RL Front. Cell Dev. Biol. 9:642625-642625(2021). RN [95] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CD82. RX PubMed=35538033; DOI=10.3724/abbs.2022011; RA Bu J., Zhong W., Li M., He S., Zhang M., Zhang Y., Li Y.; RT "CD82 palmitoylation site mutations at Cys5+Cys74 affect EGFR RT internalization and metabolism through recycling pathway."; RL Acta Biochim. Biophys. Sin. 54:400-408(2022). RN [96] RP INTERACTION WITH SNX32. RX PubMed=39073202; DOI=10.1111/tra.12952; RA Wang D., Zhao X., Wang P., Liu J.J.; RT "SNX32 regulates sorting and trafficking of activated EGFR to the lysosomal RT degradation pathway."; RL Traffic 25:e12952-e12952(2024). RN [97] {ECO:0007744|PDB:1MOX} RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 25-525 IN COMPLEX WITH TGFA, RP FUNCTION, GLYCOSYLATION AT ASN-56; ASN-196 AND ASN-352, AND DISULFIDE RP BONDS. RX PubMed=12297049; DOI=10.1016/s0092-8674(02)00940-6; RA Garrett T.P., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., RA Zhu H.J., Walker F., Frenkel M.J., Hoyne P.A., Jorissen R.N., Nice E.C., RA Burgess A.W., Ward C.W.; RT "Crystal structure of a truncated epidermal growth factor receptor RT extracellular domain bound to transforming growth factor alpha."; RL Cell 110:763-773(2002). RN [98] {ECO:0007744|PDB:1IVO} RP X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 25-646 IN COMPLEX WITH EGF, RP FUNCTION IN MAPK1 AND/OR MAPK3 ACTIVATION, SUBUNIT, SUBCELLULAR LOCATION, RP MUTAGENESIS OF TYR-275; PHE-287; ARG-309 AND ARG-429, DISULFIDE BONDS, AND RP GLYCOSYLATION AT ASN-56; ASN-175; ASN-196; ASN-352; ASN-361 AND ASN-444. RX PubMed=12297050; DOI=10.1016/s0092-8674(02)00963-7; RA Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J.H., RA Saito K., Sakamoto A., Inoue M., Shirouzu M., Yokoyama S.; RT "Crystal structure of the complex of human epidermal growth factor and RT receptor extracellular domains."; RL Cell 110:775-787(2002). RN [99] {ECO:0007744|PDB:1NQL} RP X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 25-642 IN COMPLEX WITH EGF, RP FUNCTION, SUBUNIT, MUTAGENESIS OF 587-ASP--HIS-590 AND LYS-609, DISULFIDE RP BONDS, AND GLYCOSYLATION AT ASN-352; ASN-361; ASN-444; ASN-528; ASN-568 AND RP ASN-603. RX PubMed=12620237; DOI=10.1016/s1097-2765(03)00047-9; RA Ferguson K.M., Berger M.B., Mendrola J.M., Cho H.S., Leahy D.J., RA Lemmon M.A.; RT "EGF activates its receptor by removing interactions that autoinhibit RT ectodomain dimerization."; RL Mol. Cell 11:507-517(2003). RN [100] {ECO:0007744|PDB:1XKK} RP X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 695-1022 IN COMPLEX WITH RP GW572016, CATALYTIC ACTIVITY, AND FUNCTION. RX PubMed=15374980; DOI=10.1158/0008-5472.can-04-1168; RA Wood E.R., Truesdale A.T., McDonald O.B., Yuan D., Hassell A., RA Dickerson S.H., Ellis B., Pennisi C., Horne E., Lackey K., Alligood K.J., RA Rusnak D.W., Gilmer T.M., Shewchuk L.; RT "A unique structure for epidermal growth factor receptor bound to GW572016 RT (Lapatinib): relationships among protein conformation, inhibitor off-rate, RT and receptor activity in tumor cells."; RL Cancer Res. 64:6652-6659(2004). RN [101] {ECO:0007744|PDB:1YY9} RP X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 25-642 IN COMPLEX WITH CETUXIMAB. RX PubMed=15837620; DOI=10.1016/j.ccr.2005.03.003; RA Li S., Schmitz K.R., Jeffrey P.D., Wiltzius J.J., Kussie P., Ferguson K.M.; RT "Structural basis for inhibition of the epidermal growth factor receptor by RT cetuximab."; RL Cancer Cell 7:301-311(2005). RN [102] RP STRUCTURE BY NMR OF 669-721. RX PubMed=15840573; DOI=10.1074/jbc.m502698200; RA Choowongkomon K., Carlin C.R., Sonnichsen F.D.; RT "A structural model for the membrane-bound form of the juxtamembrane domain RT of the epidermal growth factor receptor."; RL J. Biol. Chem. 280:24043-24052(2005). RN [103] {ECO:0007744|PDB:2ITN, ECO:0007744|PDB:2ITO, ECO:0007744|PDB:2ITP, ECO:0007744|PDB:2ITQ, ECO:0007744|PDB:2ITT, ECO:0007744|PDB:2ITU, ECO:0007744|PDB:2ITV, ECO:0007744|PDB:2J6M} RP X-RAY CRYSTALLOGRAPHY (2.47 ANGSTROMS) OF 696-1022 OF WILD-TYPE AND RP VARIANTS SER-719 AND ARG-858 IN COMPLEXES WITH ATP ANALOGS AND SYNTHETIC RP INHIBITORS, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND CHARACTERIZATION RP OF VARIANTS SER-719 AND ARG-858. RX PubMed=17349580; DOI=10.1016/j.ccr.2006.12.017; RA Yun C.H., Boggon T.J., Li Y., Woo M.S., Greulich H., Meyerson M., Eck M.J.; RT "Structures of lung cancer-derived EGFR mutants and inhibitor complexes: RT mechanism of activation and insights into differential inhibitor RT sensitivity."; RL Cancer Cell 11:217-227(2007). RN [104] RP X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 702-1022 IN COMPLEX WITH ERRFI1, RP ACTIVITY REGULATION, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, SUBUNIT, AND RP INTERACTION WITH ERRFI1. RX PubMed=18046415; DOI=10.1038/nature05998; RA Zhang X., Pickin K.A., Bose R., Jura N., Cole P.A., Kuriyan J.; RT "Inhibition of the EGF receptor by binding of MIG6 to an activating kinase RT domain interface."; RL Nature 450:741-744(2007). RN [105] {ECO:0007744|PDB:2JIT, ECO:0007744|PDB:2JIU, ECO:0007744|PDB:2JIV} RP X-RAY CRYSTALLOGRAPHY (3.05 ANGSTROMS) OF 695-1022 OF VARIANT MET-790, RP CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANT MET-790. RX PubMed=18227510; DOI=10.1073/pnas.0709662105; RA Yun C.H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., Wong K.K., RA Meyerson M., Eck M.J.; RT "The T790M mutation in EGFR kinase causes drug resistance by increasing the RT affinity for ATP."; RL Proc. Natl. Acad. Sci. U.S.A. 105:2070-2075(2008). RN [106] {ECO:0007744|PDB:3GT8} RP X-RAY CRYSTALLOGRAPHY (2.96 ANGSTROMS) OF 696-1022, CATALYTIC ACTIVITY, RP PHOSPHORYLATION AT TYR-998; TYR-1016 AND TYR-1197, MUTAGENESIS OF LEU-688; RP GLU-690; LEU-692; ARG-977 AND 1005-GLU-ASP-1006, AND SUBUNIT. RX PubMed=19563760; DOI=10.1016/j.cell.2009.04.025; RA Jura N., Endres N.F., Engel K., Deindl S., Das R., Lamers M.H., RA Wemmer D.E., Zhang X., Kuriyan J.; RT "Mechanism for activation of the EGF receptor catalytic domain by the RT juxtamembrane segment."; RL Cell 137:1293-1307(2009). RN [107] RP X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 669-1022 OF MUTANT MET-745, RP CATALYTIC ACTIVITY, FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, RP AUTOPHOSPHORYLATION, AND MUTAGENESIS OF LEU-688; VAL-689; GLU-690; LEU-692; RP THR-693; PRO-694; PRO-699; ASN-700; LEU-704; ARG-705; ILE-706 AND LYS-745. RX PubMed=19560417; DOI=10.1016/j.molcel.2009.04.034; RA Red Brewer M., Choi S.H., Alvarado D., Moravcevic K., Pozzi A., RA Lemmon M.A., Carpenter G.; RT "The juxtamembrane region of the EGF receptor functions as an activation RT domain."; RL Mol. Cell 34:641-651(2009). RN [108] RP STRUCTURE BY NMR OF 634-677 IN COMPLEX WITH ERBB2, AND SUBUNIT. RX PubMed=20471394; DOI=10.1016/j.jmb.2010.05.016; RA Mineev K.S., Bocharov E.V., Pustovalova Y.E., Bocharova O.V., Chupin V.V., RA Arseniev A.S.; RT "Spatial structure of the transmembrane domain heterodimer of ErbB1 and RT ErbB2 receptor tyrosine kinases."; RL J. Mol. Biol. 400:231-243(2010). RN [109] {ECO:0007744|PDB:3NJP} RP X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 25-638 IN COMPLEX WITH EGF, RP FUNCTION, SUBUNIT, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-56; ASN-73; RP ASN-175; ASN-196; ASN-352; ASN-361; ASN-444 AND ASN-528. RX PubMed=20837704; DOI=10.1128/mcb.00742-10; RA Lu C., Mi L.Z., Grey M.J., Zhu J., Graef E., Yokoyama S., Springer T.A.; RT "Structural evidence for loose linkage between ligand binding and kinase RT activation in the epidermal growth factor receptor."; RL Mol. Cell. Biol. 30:5432-5443(2010). RN [110] RP X-RAY CRYSTALLOGRAPHY (2.27 ANGSTROMS) OF 1066-1076 IN COMPLEX WITH CBLB, RP AND INTERACTION WITH CBLB. RG Structural genomics consortium; RT "Crystal structure of Cbl-b TKB domain in complex with EGFR pY1069 RT peptide."; RL Submitted (OCT-2010) to the PDB data bank. RN [111] RP X-RAY CRYSTALLOGRAPHY (1.52 ANGSTROMS) OF 1062-1074 IN COMPLEX WITH CBLC, RP PHOSPHORYLATION AT TYR-1069, INTERACTION WITH CBLC, AND MUTAGENESIS OF RP GLN-1067; ARG-1068 AND TYR-1069. RX PubMed=22888118; DOI=10.1093/jb/mvs085; RA Takeshita K., Tezuka T., Isozaki Y., Yamashita E., Suzuki M., Kim M., RA Yamanashi Y., Yamamoto T., Nakagawa A.; RT "Structural flexibility regulates phosphopeptide-binding activity of the RT tyrosine kinase binding domain of Cbl-c."; RL J. Biochem. 152:487-495(2012). RN [112] RP VARIANTS ALA-709; GLY-709; CYS-719; SER-719; 746-GLU--ALA-750 DEL; RP 746-GLU--THR-751 DELINS ALA; 746-GLU--SER-752 DELINS ASP; 747-LEU--THR-751 RP DEL; ILE-768; MET-769; VAL-833; LEU-835; VAL-838; ARG-858 AND GLN-861. RX PubMed=15623594; DOI=10.1158/1078-0432.ccr-04-1245; RA Huang S.F., Liu H.P., Li L.H., Ku Y.C., Fu Y.N., Tsai H.Y., Chen Y.T., RA Lin Y.F., Chang W.C., Kuo H.P., Wu Y.C., Chen Y.R., Tsai S.F.; RT "High frequency of epidermal growth factor receptor mutations with complex RT patterns in non-small cell lung cancers related to gefitinib responsiveness RT in Taiwan."; RL Clin. Cancer Res. 10:8195-8203(2004). RN [113] RP VARIANTS SER-719 AND ARG-858, AND POSSIBLE INVOLVEMENT IN LUNG CANCER. RX PubMed=15118125; DOI=10.1126/science.1099314; RA Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., RA Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., RA Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M.; RT "EGFR mutations in lung cancer: correlation with clinical response to RT gefitinib therapy."; RL Science 304:1497-1500(2004). RN [114] RP VARIANTS ALA-709; LYS-709; ALA-719; ASP-719; CYS-719; SER-719; SER-724; RP LYS-734; GLU-746 DEL; PHE-747; 747-LEU--GLU-749 DEL; PRO-748; RP 752-SER--ILE-759 DEL; ARG-787; MET-790; VAL-833; LEU-834; MET-858; ARG-858; RP GLN-861 AND GLU-873, AND POSSIBLE INVOLVEMENT IN LUNG CANCER. RX PubMed=16533793; DOI=10.1158/1078-0432.ccr-05-1981; RA Tam I.Y.S., Chung L.P., Suen W.S., Wang E., Wong M.C.M., Ho K.K., Lam W.K., RA Chiu S.W., Girard L., Minna J.D., Gazdar A.F., Wong M.P.; RT "Distinct epidermal growth factor receptor and KRAS mutation patterns in RT non-small cell lung cancer patients with different tobacco exposure and RT clinicopathologic features."; RL Clin. Cancer Res. 12:1647-1653(2006). RN [115] RP CHARACTERIZATION OF VARIANTS ALA-709; GLY-709; SER-719; ILE-768; VAL-833; RP LEU-835; VAL-838; ARG-858 AND GLN-861. RX PubMed=16205628; DOI=10.1038/sj.onc.1209159; RA Chen Y.R., Fu Y.N., Lin C.H., Yang S.T., Hu S.F., Chen Y.T., Tsai S.F., RA Huang S.F.; RT "Distinctive activation patterns in constitutively active and gefitinib- RT sensitive EGFR mutants."; RL Oncogene 25:1205-1215(2006). RN [116] RP VARIANT 30-VAL--ARG-297 DEL, AND POSSIBLE INVOLVEMENT IN LUNG CANCER. RX PubMed=16672372; DOI=10.1073/pnas.0510284103; RA Ji H., Zhao X., Yuza Y., Shimamura T., Li D., Protopopov A., Jung B.L., RA McNamara K., Xia H., Glatt K.A., Thomas R.K., Sasaki H., Horner J.W., RA Eck M., Mitchell A., Sun Y., Al-Hashem R., Bronson R.T., Rabindran S.K., RA Discafani C.M., Maher E., Shapiro G.I., Meyerson M., Wong K.K.; RT "Epidermal growth factor receptor variant III mutations in lung RT tumorigenesis and sensitivity to tyrosine kinase inhibitors."; RL Proc. Natl. Acad. Sci. U.S.A. 103:7817-7822(2006). RN [117] RP VARIANTS [LARGE SCALE ANALYSIS] LYS-521; ARG-1034 AND VAL-1210. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [118] RP VARIANT NNCIS ASP-428, CHARACTERIZATION OF VARIANT NNCIS ASP-428, AND RP INVOLVEMENT IN NNCIS. RX PubMed=24691054; DOI=10.1038/jid.2014.164; RA Campbell P., Morton P.E., Takeichi T., Salam A., Roberts N., RA Proudfoot L.E., Mellerio J.E., Aminu K., Wellington C., Patil S.N., RA Akiyama M., Liu L., McMillan J.R., Aristodemou S., Ishida-Yamamoto A., RA Abdul-Wahab A., Petrof G., Fong K., Harnchoowong S., Stone K.L., RA Harper J.I., McLean W.H., Simpson M.A., Parsons M., McGrath J.A.; RT "Epithelial inflammation resulting from an inherited loss-of-function RT mutation in EGFR."; RL J. Invest. Dermatol. 134:2570-2578(2014). CC -!- FUNCTION: Receptor tyrosine kinase binding ligands of the EGF family CC and activating several signaling cascades to convert extracellular cues CC into appropriate cellular responses (PubMed:10805725, PubMed:27153536, CC PubMed:2790960, PubMed:35538033). Known ligands include EGF, TGFA/TGF- CC alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and CC HBEGF/heparin-binding EGF (PubMed:12297049, PubMed:15611079, CC PubMed:17909029, PubMed:20837704, PubMed:27153536, PubMed:2790960, CC PubMed:7679104, PubMed:8144591, PubMed:9419975). Ligand binding CC triggers receptor homo- and/or heterodimerization and CC autophosphorylation on key cytoplasmic residues. The phosphorylated CC receptor recruits adapter proteins like GRB2 which in turn activates CC complex downstream signaling cascades. Activates at least 4 major CC downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 CC kinase-AKT, PLCgamma-PKC and STATs modules (PubMed:27153536). May also CC activate the NF-kappa-B signaling cascade (PubMed:11116146). Also CC directly phosphorylates other proteins like RGS16, activating its CC GTPase activity and probably coupling the EGF receptor signaling to the CC G protein-coupled receptor signaling (PubMed:11602604). Also CC phosphorylates MUC1 and increases its interaction with SRC and CC CTNNB1/beta-catenin (PubMed:11483589). Positively regulates cell CC migration via interaction with CCDC88A/GIV which retains EGFR at the CC cell membrane following ligand stimulation, promoting EGFR signaling CC which triggers cell migration (PubMed:20462955). Plays a role in CC enhancing learning and memory performance (By similarity). Plays a role CC in mammalian pain signaling (long-lasting hypersensitivity) (By CC similarity). {ECO:0000250|UniProtKB:Q01279, CC ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:11116146, CC ECO:0000269|PubMed:11483589, ECO:0000269|PubMed:11602604, CC ECO:0000269|PubMed:12297049, ECO:0000269|PubMed:12297050, CC ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:12873986, CC ECO:0000269|PubMed:15374980, ECO:0000269|PubMed:15590694, CC ECO:0000269|PubMed:15611079, ECO:0000269|PubMed:17115032, CC ECO:0000269|PubMed:17909029, ECO:0000269|PubMed:19560417, CC ECO:0000269|PubMed:20462955, ECO:0000269|PubMed:20837704, CC ECO:0000269|PubMed:21258366, ECO:0000269|PubMed:27153536, CC ECO:0000269|PubMed:2790960, ECO:0000269|PubMed:35538033, CC ECO:0000269|PubMed:7679104, ECO:0000269|PubMed:8144591, CC ECO:0000269|PubMed:9419975}. CC -!- FUNCTION: Isoform 2 may act as an antagonist of EGF action. CC -!- FUNCTION: (Microbial infection) Acts as a receptor for hepatitis C CC virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV CC entry by promoting the formation of the CD81-CLDN1 receptor complexes CC that are essential for HCV entry and by enhancing membrane fusion of CC cells expressing HCV envelope glycoproteins. CC {ECO:0000269|PubMed:21516087}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:15374980, ECO:0000269|PubMed:17349580, CC ECO:0000269|PubMed:18046415, ECO:0000269|PubMed:18227510, CC ECO:0000269|PubMed:19560417, ECO:0000269|PubMed:19563760}; CC -!- ACTIVITY REGULATION: Endocytosis and inhibition of the activated EGFR CC by phosphatases like PTPRJ and PTPRK constitute immediate regulatory CC mechanisms. Upon EGF-binding phosphorylates EPS15 that regulates EGFR CC endocytosis and activity. Moreover, inducible feedback inhibitors CC including LRIG1, SOCS4, SOCS5 and ERRFI1 constitute alternative CC regulatory mechanisms for the EGFR signaling. Up-regulated by NEU3- CC mediated desialylation of N-linked glycan at Asn-528. CC {ECO:0000269|PubMed:15282549, ECO:0000269|PubMed:15590694, CC ECO:0000269|PubMed:17334392, ECO:0000269|PubMed:18046415, CC ECO:0000269|PubMed:19836242, ECO:0000269|PubMed:25922362}. CC -!- SUBUNIT: Binding of the ligand triggers homo- and/or heterodimerization CC of the receptor triggering its autophosphorylation. Heterodimer with CC ERBB2 (PubMed:10805725). Forms a complex with CCDC88A/GIV (via SH2-like CC regions) and GNAI3 which leads to enhanced EGFR signaling and CC triggering of cell migration; binding to CCDC88A requires CC autophosphorylation of the EGFR C-terminal region, and ligand CC stimulation is required for recruitment of GNAI3 to the complex CC (PubMed:20462955, PubMed:25187647). Interacts with ERRFI1; inhibits CC dimerization of the kinase domain and autophosphorylation CC (PubMed:18046415). Part of a complex with ERBB2 and either PIK3C2A or CC PIK3C2B (PubMed:10805725). Interacts with GRB2; an adapter protein CC coupling the receptor to downstream signaling pathways. Interacts with CC GAB2; involved in signaling downstream of EGFR. Interacts with STAT3; CC mediates EGFR downstream signaling in cell proliferation. Interacts CC with RIPK1; involved in NF-kappa-B activation. Interacts CC (autophosphorylated) with CBL, CBLB and CBLC; involved in EGFR CC ubiquitination and regulation; interaction with CBL is reduced in the CC presence of tensin TNS4 (PubMed:23774213). Interacts with SOCS5; CC regulates EGFR degradation through ELOC- and ELOB-mediated CC ubiquitination and proteasomal degradation. Interacts with PRMT5; CC methylates EGFR and enhances interaction with PTPN6. Interacts CC (phosphorylated) with PTPN6; inhibits EGFR-dependent activation of CC MAPK/ERK. Interacts with COPG1; essential for regulation of EGF- CC dependent nuclear transport of EGFR by retrograde trafficking from the CC Golgi to the ER. Interacts with TNK2; this interaction is dependent on CC EGF stimulation and kinase activity of EGFR. Interacts with PCNA; CC positively regulates PCNA (PubMed:17115032). Interacts with PELP1. CC Interacts with MUC1. Interacts with AP2M1. Interacts with FER. May CC interact with EPS8; mediates EPS8 phosphorylation. Interacts (via SH2 CC domains) with GRB2, NCK1 and NCK2 (PubMed:10026169). Interacts with CC ATXN2. Interacts with GAREM1. Interacts (ubiquitinated) with CC ANKRD13A/B/D; the interaction is direct and may regulate EGFR CC internalization after EGF stimulation. Interacts with GPER1; the CC interaction occurs in an estrogen-dependent manner. Interacts (via C- CC terminal cytoplasmic kinase domain) with ZPR1 (via zinc fingers). CC Interacts with RNF115 and RNF126 (PubMed:23418353). Interacts with CC GPRC5A (via its transmembrane domain) (PubMed:25311788). Interacts with CC FAM83B; positively regulates EGFR inducing its autophosphorylation in CC absence of stimulation by EGF (PubMed:23912460). Interacts with CC LAPTM4B; positively correlates with EGFR activation (PubMed:28479384). CC Interacts with STX19 (PubMed:16420529). Interacts with CD44 CC (PubMed:23589287). Interacts with PGRMC1; the interaction requires CC PGRMC1 homodimerization (PubMed:26988023). Interacts with PIKFYVE CC (PubMed:17909029). Interacts with NEU3. Interacts with TRAF4 CC (PubMed:30352854). Interacts with the ant venom OMEGA- CC myrmeciitoxin(02)-Mg1a (By similarity). Interacts with CD82; this CC interaction facilitates ligand-induced endocytosis of the receptor and CC its subsequent desensitization (PubMed:35538033). Interacts with SNX32; CC the interaction is required for endolysosomal EGFR trafficking CC (PubMed:39073202). {ECO:0000250|UniProtKB:Q01279, CC ECO:0000269|PubMed:10026169, ECO:0000269|PubMed:10228163, CC ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:11116146, CC ECO:0000269|PubMed:11483589, ECO:0000269|PubMed:12297050, CC ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:12873986, CC ECO:0000269|PubMed:15282549, ECO:0000269|PubMed:15374980, CC ECO:0000269|PubMed:15590694, ECO:0000269|PubMed:15837620, CC ECO:0000269|PubMed:16140940, ECO:0000269|PubMed:16420529, CC ECO:0000269|PubMed:17115032, ECO:0000269|PubMed:17182860, CC ECO:0000269|PubMed:17334392, ECO:0000269|PubMed:17909029, CC ECO:0000269|PubMed:18046415, ECO:0000269|PubMed:18602463, CC ECO:0000269|PubMed:19172738, ECO:0000269|PubMed:19509291, CC ECO:0000269|PubMed:19560417, ECO:0000269|PubMed:19563760, CC ECO:0000269|PubMed:19749156, ECO:0000269|PubMed:19836242, CC ECO:0000269|PubMed:20462955, ECO:0000269|PubMed:20471394, CC ECO:0000269|PubMed:20551055, ECO:0000269|PubMed:20674546, CC ECO:0000269|PubMed:20837704, ECO:0000269|PubMed:21258366, CC ECO:0000269|PubMed:21518868, ECO:0000269|PubMed:22298428, CC ECO:0000269|PubMed:22888118, ECO:0000269|PubMed:23418353, CC ECO:0000269|PubMed:23589287, ECO:0000269|PubMed:23774213, CC ECO:0000269|PubMed:23912460, ECO:0000269|PubMed:25187647, CC ECO:0000269|PubMed:25311788, ECO:0000269|PubMed:26988023, CC ECO:0000269|PubMed:28479384, ECO:0000269|PubMed:35538033, CC ECO:0000269|PubMed:39073202, ECO:0000269|PubMed:7657591, CC ECO:0000269|PubMed:8650580, ECO:0000269|PubMed:9852145, CC ECO:0000269|Ref.110}. CC -!- INTERACTION: CC P00533; P00519: ABL1; NbExp=3; IntAct=EBI-297353, EBI-375543; CC P00533; P42684: ABL2; NbExp=9; IntAct=EBI-297353, EBI-1102694; CC P00533; Q15109: AGER; NbExp=2; IntAct=EBI-297353, EBI-1646426; CC P00533; Q9UKV8: AGO2; NbExp=11; IntAct=EBI-297353, EBI-528269; CC P00533; Q09666: AHNAK; NbExp=4; IntAct=EBI-297353, EBI-2555881; CC P00533; O00170: AIP; NbExp=2; IntAct=EBI-297353, EBI-704197; CC P00533; Q02952: AKAP12; NbExp=3; IntAct=EBI-297353, EBI-2562430; CC P00533; P31749: AKT1; NbExp=4; IntAct=EBI-297353, EBI-296087; CC P00533; P49418: AMPH; NbExp=2; IntAct=EBI-297353, EBI-7121510; CC P00533; Q92625: ANKS1A; NbExp=7; IntAct=EBI-297353, EBI-1048612; CC P00533; P04083: ANXA1; NbExp=5; IntAct=EBI-297353, EBI-354007; CC P00533; P07355: ANXA2; NbExp=4; IntAct=EBI-297353, EBI-352622; CC P00533; Q10567: AP1B1; NbExp=4; IntAct=EBI-297353, EBI-1171303; CC P00533; Q96CW1: AP2M1; NbExp=8; IntAct=EBI-297353, EBI-297683; CC P00533; O00213: APBB1; NbExp=4; IntAct=EBI-297353, EBI-81694; CC P00533; Q92870: APBB2; NbExp=7; IntAct=EBI-297353, EBI-79277; CC P00533; O95704: APBB3; NbExp=2; IntAct=EBI-297353, EBI-286427; CC P00533; Q9UKG1: APPL1; NbExp=3; IntAct=EBI-297353, EBI-741243; CC P00533; P49407: ARRB1; NbExp=3; IntAct=EBI-297353, EBI-743313; CC P00533; P32121: ARRB2; NbExp=3; IntAct=EBI-297353, EBI-714559; CC P00533; O14965: AURKA; NbExp=5; IntAct=EBI-297353, EBI-448680; CC P00533; P30530: AXL; NbExp=5; IntAct=EBI-297353, EBI-2850927; CC P00533; Q9UQB8: BAIAP2; NbExp=4; IntAct=EBI-297353, EBI-525456; CC P00533; Q9BXH1: BBC3; NbExp=10; IntAct=EBI-297353, EBI-519884; CC P00533; Q14457: BECN1; NbExp=8; IntAct=EBI-297353, EBI-949378; CC P00533; P51451: BLK; NbExp=3; IntAct=EBI-297353, EBI-2105445; CC P00533; P62158: CALM3; NbExp=6; IntAct=EBI-297353, EBI-397435; CC P00533; P49069: CAMLG; NbExp=3; IntAct=EBI-297353, EBI-1748958; CC P00533; Q03135: CAV1; NbExp=7; IntAct=EBI-297353, EBI-603614; CC P00533; P51636: CAV2; NbExp=3; IntAct=EBI-297353, EBI-603607; CC P00533; P22681: CBL; NbExp=26; IntAct=EBI-297353, EBI-518228; CC P00533; Q16543: CDC37; NbExp=13; IntAct=EBI-297353, EBI-295634; CC P00533; P12830: CDH1; NbExp=4; IntAct=EBI-297353, EBI-727477; CC P00533; P06493: CDK1; NbExp=3; IntAct=EBI-297353, EBI-444308; CC P00533; P23528: CFL1; NbExp=3; IntAct=EBI-297353, EBI-352733; CC P00533; Q9BZP6: CHIA; NbExp=2; IntAct=EBI-297353, EBI-14357960; CC P00533; Q9NSE2: CISH; NbExp=4; IntAct=EBI-297353, EBI-617866; CC P00533; Q7Z7G1: CLNK; NbExp=2; IntAct=EBI-297353, EBI-7878194; CC P00533; Q8IZV2: CMTM8; NbExp=3; IntAct=EBI-297353, EBI-7868911; CC P00533; Q8WXI2: CNKSR2; NbExp=2; IntAct=EBI-297353, EBI-1045119; CC P00533; P46108: CRK; NbExp=4; IntAct=EBI-297353, EBI-886; CC P00533; P46108-1: CRK; NbExp=3; IntAct=EBI-297353, EBI-287556; CC P00533; P46109: CRKL; NbExp=5; IntAct=EBI-297353, EBI-910; CC P00533; P41240: CSK; NbExp=3; IntAct=EBI-297353, EBI-1380630; CC P00533; O60716: CTNND1; NbExp=5; IntAct=EBI-297353, EBI-701927; CC P00533; Q14247: CTTN; NbExp=4; IntAct=EBI-297353, EBI-351886; CC P00533; Q7L591: DOK3; NbExp=2; IntAct=EBI-297353, EBI-2834978; CC P00533; Q6PKX4: DOK6; NbExp=2; IntAct=EBI-297353, EBI-2880244; CC P00533; P01133: EGF; NbExp=29; IntAct=EBI-297353, EBI-640857; CC P00533; P00533: EGFR; NbExp=31; IntAct=EBI-297353, EBI-297353; CC P00533; Q6UW88: EPGN; NbExp=3; IntAct=EBI-297353, EBI-15482510; CC P00533; Q12929: EPS8; NbExp=4; IntAct=EBI-297353, EBI-375576; CC P00533; P04626: ERBB2; NbExp=25; IntAct=EBI-297353, EBI-641062; CC P00533; P21860: ERBB3; NbExp=15; IntAct=EBI-297353, EBI-720706; CC P00533; Q15303: ERBB4; NbExp=4; IntAct=EBI-297353, EBI-80371; CC P00533; P07992: ERCC1; NbExp=21; IntAct=EBI-297353, EBI-750962; CC P00533; O14944: EREG; NbExp=3; IntAct=EBI-297353, EBI-17272224; CC P00533; Q9UJM3: ERRFI1; NbExp=16; IntAct=EBI-297353, EBI-2941912; CC P00533; P03372: ESR1; NbExp=3; IntAct=EBI-297353, EBI-78473; CC P00533; P03372-4: ESR1; NbExp=4; IntAct=EBI-297353, EBI-4309277; CC P00533; Q92731: ESR2; NbExp=8; IntAct=EBI-297353, EBI-78505; CC P00533; Q96A65: EXOC4; NbExp=2; IntAct=EBI-297353, EBI-355383; CC P00533; P15311: EZR; NbExp=3; IntAct=EBI-297353, EBI-1056902; CC P00533; Q9BXW9: FANCD2; NbExp=3; IntAct=EBI-297353, EBI-359343; CC P00533; P09769: FGR; NbExp=3; IntAct=EBI-297353, EBI-1383732; CC P00533; Q13451: FKBP5; NbExp=2; IntAct=EBI-297353, EBI-306914; CC P00533; Q14318: FKBP8; NbExp=4; IntAct=EBI-297353, EBI-724839; CC P00533; Q13480: GAB1; NbExp=5; IntAct=EBI-297353, EBI-517684; CC P00533; Q9UQC2: GAB2; NbExp=3; IntAct=EBI-297353, EBI-975200; CC P00533; P60520: GABARAPL2; NbExp=3; IntAct=EBI-297353, EBI-720116; CC P00533; P47869: GABRA2; NbExp=2; IntAct=EBI-297353, EBI-2685723; CC P00533; P04406: GAPDH; NbExp=7; IntAct=EBI-297353, EBI-354056; CC P00533; Q8NBJ4: GOLM1; NbExp=13; IntAct=EBI-297353, EBI-712073; CC P00533; P17174: GOT1; NbExp=3; IntAct=EBI-297353, EBI-727329; CC P00533; Q14956: GPNMB; NbExp=3; IntAct=EBI-297353, EBI-7250369; CC P00533; Q14956-1: GPNMB; NbExp=2; IntAct=EBI-297353, EBI-16191078; CC P00533; O75791: GRAP2; NbExp=3; IntAct=EBI-297353, EBI-740418; CC P00533; Q13322: GRB10; NbExp=4; IntAct=EBI-297353, EBI-80275; CC P00533; P62993: GRB2; NbExp=59; IntAct=EBI-297353, EBI-401755; CC P00533; P25098: GRK2; NbExp=3; IntAct=EBI-297353, EBI-3904795; CC P00533; Q99075: HBEGF; NbExp=3; IntAct=EBI-297353, EBI-7211558; CC P00533; P08631: HCK; NbExp=3; IntAct=EBI-297353, EBI-346340; CC P00533; Q9UBN7: HDAC6; NbExp=12; IntAct=EBI-297353, EBI-301697; CC P00533; Q8WUI4: HDAC7; NbExp=3; IntAct=EBI-297353, EBI-1048378; CC P00533; P07900: HSP90AA1; NbExp=8; IntAct=EBI-297353, EBI-296047; CC P00533; P08238: HSP90AB1; NbExp=10; IntAct=EBI-297353, EBI-352572; CC P00533; Q6PK50: HSP90AB1; NbExp=2; IntAct=EBI-297353, EBI-9356629; CC P00533; P08107: HSPA1B; NbExp=6; IntAct=EBI-297353, EBI-629985; CC P00533; P34932: HSPA4; NbExp=3; IntAct=EBI-297353, EBI-356933; CC P00533; P11142: HSPA8; NbExp=7; IntAct=EBI-297353, EBI-351896; CC P00533; P38646: HSPA9; NbExp=5; IntAct=EBI-297353, EBI-354932; CC P00533; P17936: IGFBP3; NbExp=3; IntAct=EBI-297353, EBI-715709; CC P00533; P46940: IQGAP1; NbExp=4; IntAct=EBI-297353, EBI-297509; CC P00533; O14654: IRS4; NbExp=2; IntAct=EBI-297353, EBI-356594; CC P00533; Q9NZM3: ITSN2; NbExp=3; IntAct=EBI-297353, EBI-308689; CC P00533; P14923: JUP; NbExp=3; IntAct=EBI-297353, EBI-702484; CC P00533; Q86VI4: LAPTM4B; NbExp=10; IntAct=EBI-297353, EBI-3267258; CC P00533; O43561: LAT; NbExp=3; IntAct=EBI-297353, EBI-1222766; CC P00533; Q13094: LCP2; NbExp=3; IntAct=EBI-297353, EBI-346946; CC P00533; Q96FE5: LINGO1; NbExp=2; IntAct=EBI-297353, EBI-719955; CC P00533; Q96JA1: LRIG1; NbExp=6; IntAct=EBI-297353, EBI-2865191; CC P00533; O94898: LRIG2; NbExp=4; IntAct=EBI-297353, EBI-2830372; CC P00533; Q38SD2: LRRK1; NbExp=2; IntAct=EBI-297353, EBI-1050422; CC P00533; P07948: LYN; NbExp=7; IntAct=EBI-297353, EBI-79452; CC P00533; P07948-1: LYN; NbExp=2; IntAct=EBI-297353, EBI-6895930; CC P00533; Q9BRK4: LZTS2; NbExp=2; IntAct=EBI-297353, EBI-741037; CC P00533; Q12852: MAP3K12; NbExp=3; IntAct=EBI-297353, EBI-710223; CC P00533; Q9UQF2: MAPK8IP1; NbExp=3; IntAct=EBI-297353, EBI-78404; CC P00533; Q13387: MAPK8IP2; NbExp=5; IntAct=EBI-297353, EBI-722813; CC P00533; Q9Y2H9: MAST1; NbExp=3; IntAct=EBI-297353, EBI-3385920; CC P00533; Q9NS73: MBIP; NbExp=3; IntAct=EBI-297353, EBI-741953; CC P00533; P08581: MET; NbExp=8; IntAct=EBI-297353, EBI-1039152; CC P00533; P14174: MIF; NbExp=3; IntAct=EBI-297353, EBI-372712; CC P00533; P15941: MUC1; NbExp=6; IntAct=EBI-297353, EBI-2804728; CC P00533; P16333: NCK1; NbExp=6; IntAct=EBI-297353, EBI-389883; CC P00533; P46934: NEDD4; NbExp=3; IntAct=EBI-297353, EBI-726944; CC P00533; P04150: NR3C1; NbExp=3; IntAct=EBI-297353, EBI-493507; CC P00533; Q16620: NTRK2; NbExp=3; IntAct=EBI-297353, EBI-3904881; CC P00533; P49757: NUMB; NbExp=2; IntAct=EBI-297353, EBI-915016; CC P00533; Q9Y6R0: NUMBL; NbExp=2; IntAct=EBI-297353, EBI-945925; CC P00533; Q13438: OS9; NbExp=3; IntAct=EBI-297353, EBI-725454; CC P00533; Q8WUM4: PDCD6IP; NbExp=4; IntAct=EBI-297353, EBI-310624; CC P00533; P16234: PDGFRA; NbExp=4; IntAct=EBI-297353, EBI-2861522; CC P00533; O00750: PIK3C2B; NbExp=10; IntAct=EBI-297353, EBI-641107; CC P00533; P27986: PIK3R1; NbExp=7; IntAct=EBI-297353, EBI-79464; CC P00533; O00459: PIK3R2; NbExp=5; IntAct=EBI-297353, EBI-346930; CC P00533; Q92569: PIK3R3; NbExp=7; IntAct=EBI-297353, EBI-79893; CC P00533; P19174: PLCG1; NbExp=6; IntAct=EBI-297353, EBI-79387; CC P00533; P16885: PLCG2; NbExp=7; IntAct=EBI-297353, EBI-617403; CC P00533; P35813: PPM1A; NbExp=2; IntAct=EBI-297353, EBI-989143; CC P00533; P17252: PRKCA; NbExp=3; IntAct=EBI-297353, EBI-1383528; CC P00533; Q05397: PTK2; NbExp=7; IntAct=EBI-297353, EBI-702142; CC P00533; Q13882: PTK6; NbExp=2; IntAct=EBI-297353, EBI-1383632; CC P00533; P18031: PTPN1; NbExp=9; IntAct=EBI-297353, EBI-968788; CC P00533; Q06124: PTPN11; NbExp=10; IntAct=EBI-297353, EBI-297779; CC P00533; Q05209: PTPN12; NbExp=5; IntAct=EBI-297353, EBI-2266035; CC P00533; Q9Y2R2: PTPN22; NbExp=3; IntAct=EBI-297353, EBI-1211241; CC P00533; P18433: PTPRA; NbExp=3; IntAct=EBI-297353, EBI-2609645; CC P00533; P23467: PTPRB; NbExp=3; IntAct=EBI-297353, EBI-1265766; CC P00533; P08575: PTPRC; NbExp=2; IntAct=EBI-297353, EBI-1341; CC P00533; P23470: PTPRG; NbExp=3; IntAct=EBI-297353, EBI-2258115; CC P00533; Q9HD43: PTPRH; NbExp=3; IntAct=EBI-297353, EBI-1267176; CC P00533; Q9UJ41: RABGEF1; NbExp=4; IntAct=EBI-297353, EBI-913954; CC P00533; P04049: RAF1; NbExp=3; IntAct=EBI-297353, EBI-365996; CC P00533; Q70E73: RAPH1; NbExp=2; IntAct=EBI-297353, EBI-3940924; CC P00533; P20936: RASA1; NbExp=7; IntAct=EBI-297353, EBI-1026476; CC P00533; Q13671: RIN1; NbExp=3; IntAct=EBI-297353, EBI-366017; CC P00533; Q01973: ROR1; NbExp=8; IntAct=EBI-297353, EBI-6082337; CC P00533; Q92622: RUBCN; NbExp=4; IntAct=EBI-297353, EBI-2952709; CC P00533; P26447: S100A4; NbExp=6; IntAct=EBI-297353, EBI-717058; CC P00533; P61619: SEC61A1; NbExp=2; IntAct=EBI-297353, EBI-358919; CC P00533; Q9UBV2: SEL1L; NbExp=2; IntAct=EBI-297353, EBI-358766; CC P00533; P31947: SFN; NbExp=9; IntAct=EBI-297353, EBI-476295; CC P00533; Q9NRF2: SH2B1; NbExp=4; IntAct=EBI-297353, EBI-310491; CC P00533; Q9UQQ2: SH2B3; NbExp=2; IntAct=EBI-297353, EBI-7879749; CC P00533; Q9BRG2: SH2D3A; NbExp=3; IntAct=EBI-297353, EBI-2339271; CC P00533; O75368: SH3BGRL; NbExp=3; IntAct=EBI-297353, EBI-2854777; CC P00533; Q99962: SH3GL2; NbExp=4; IntAct=EBI-297353, EBI-77938; CC P00533; Q96B97: SH3KBP1; NbExp=4; IntAct=EBI-297353, EBI-346595; CC P00533; P29353: SHC1; NbExp=44; IntAct=EBI-297353, EBI-78835; CC P00533; P29353-7: SHC1; NbExp=4; IntAct=EBI-297353, EBI-9691288; CC P00533; P98077: SHC2; NbExp=3; IntAct=EBI-297353, EBI-7256023; CC P00533; Q6S5L8: SHC4; NbExp=3; IntAct=EBI-297353, EBI-9453524; CC P00533; O75563: SKAP2; NbExp=2; IntAct=EBI-297353, EBI-2483161; CC P00533; Q13239: SLA; NbExp=3; IntAct=EBI-297353, EBI-726214; CC P00533; P13866: SLC5A1; NbExp=3; IntAct=EBI-297353, EBI-1772443; CC P00533; Q07889: SOS1; NbExp=3; IntAct=EBI-297353, EBI-297487; CC P00533; P12931: SRC; NbExp=10; IntAct=EBI-297353, EBI-621482; CC P00533; P42224: STAT1; NbExp=7; IntAct=EBI-297353, EBI-1057697; CC P00533; P40763: STAT3; NbExp=16; IntAct=EBI-297353, EBI-518675; CC P00533; P42229: STAT5A; NbExp=4; IntAct=EBI-297353, EBI-749537; CC P00533; P51692: STAT5B; NbExp=2; IntAct=EBI-297353, EBI-1186119; CC P00533; P31948: STIP1; NbExp=3; IntAct=EBI-297353, EBI-1054052; CC P00533; Q9UNE7: STUB1; NbExp=4; IntAct=EBI-297353, EBI-357085; CC P00533; O43752: STX6; NbExp=3; IntAct=EBI-297353, EBI-2695795; CC P00533; P43405: SYK; NbExp=7; IntAct=EBI-297353, EBI-78302; CC P00533; Q15750: TAB1; NbExp=3; IntAct=EBI-297353, EBI-358643; CC P00533; Q9Y6A5: TACC3; NbExp=3; IntAct=EBI-297353, EBI-2554984; CC P00533; P01135: TGFA; NbExp=4; IntAct=EBI-297353, EBI-1034374; CC P00533; Q9Y490: TLN1; NbExp=2; IntAct=EBI-297353, EBI-2462036; CC P00533; O60603: TLR2; NbExp=3; IntAct=EBI-297353, EBI-973722; CC P00533; Q9Y6Q6-2: TNFRSF11A; NbExp=3; IntAct=EBI-297353, EBI-20899422; CC P00533; Q68CZ2: TNS3; NbExp=5; IntAct=EBI-297353, EBI-1220488; CC P00533; Q8IZW8: TNS4; NbExp=2; IntAct=EBI-297353, EBI-7543499; CC P00533; O75674: TOM1L1; NbExp=6; IntAct=EBI-297353, EBI-712991; CC P00533; Q12933: TRAF2; NbExp=4; IntAct=EBI-297353, EBI-355744; CC P00533; Q71U36: TUBA1A; NbExp=4; IntAct=EBI-297353, EBI-302552; CC P00533; Q13885: TUBB2A; NbExp=2; IntAct=EBI-297353, EBI-711595; CC P00533; P10599: TXN; NbExp=5; IntAct=EBI-297353, EBI-594644; CC P00533; P09936: UCHL1; NbExp=3; IntAct=EBI-297353, EBI-714860; CC P00533; Q8TEY7: USP33; NbExp=2; IntAct=EBI-297353, EBI-719283; CC P00533; Q9P0L0: VAPA; NbExp=4; IntAct=EBI-297353, EBI-1059156; CC P00533; Q9UPY6: WASF3; NbExp=3; IntAct=EBI-297353, EBI-3907133; CC P00533; P07947: YES1; NbExp=3; IntAct=EBI-297353, EBI-515331; CC P00533; P27348: YWHAQ; NbExp=7; IntAct=EBI-297353, EBI-359854; CC P00533; P63104: YWHAZ; NbExp=6; IntAct=EBI-297353, EBI-347088; CC P00533; P43403: ZAP70; NbExp=3; IntAct=EBI-297353, EBI-1211276; CC P00533; Q53FC7; NbExp=3; IntAct=EBI-297353, EBI-9356749; CC P00533; Q96BE0; NbExp=2; IntAct=EBI-297353, EBI-9356686; CC P00533; P62161: Calm3; Xeno; NbExp=6; IntAct=EBI-297353, EBI-397530; CC P00533; P22682: Cbl; Xeno; NbExp=2; IntAct=EBI-297353, EBI-640919; CC P00533; P62994: Grb2; Xeno; NbExp=5; IntAct=EBI-297353, EBI-401775; CC P00533; Q9QZC5: Grb7; Xeno; NbExp=7; IntAct=EBI-297353, EBI-22085551; CC P00533; P97313: Prkdc; Xeno; NbExp=4; IntAct=EBI-297353, EBI-2272005; CC P00533; P20417: Ptpn1; Xeno; NbExp=11; IntAct=EBI-297353, EBI-916819; CC P00533; Q80U62: Rubcn; Xeno; NbExp=2; IntAct=EBI-297353, EBI-3506572; CC P00533; P0DTC2: S; Xeno; NbExp=4; IntAct=EBI-297353, EBI-25474821; CC P00533; Q8K424: Trpv3; Xeno; NbExp=2; IntAct=EBI-297353, EBI-2650739; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:17182860, CC ECO:0000269|PubMed:20462955, ECO:0000269|PubMed:23589287, CC ECO:0000269|PubMed:26918609, ECO:0000269|PubMed:27153536, CC ECO:0000269|PubMed:2790960, ECO:0000269|PubMed:35538033}; Single-pass CC type I membrane protein {ECO:0000269|PubMed:27153536}. Endoplasmic CC reticulum membrane {ECO:0000269|PubMed:27153536}; Single-pass type I CC membrane protein. Golgi apparatus membrane; Single-pass type I membrane CC protein. Nucleus membrane; Single-pass type I membrane protein. CC Endosome {ECO:0000269|PubMed:17182860, ECO:0000269|PubMed:27153536}. CC Endosome membrane. Nucleus {ECO:0000269|PubMed:17115032, CC ECO:0000269|PubMed:17909029, ECO:0000269|PubMed:20551055, CC ECO:0000269|PubMed:20674546}. Note=In response to EGF, translocated CC from the cell membrane to the nucleus via Golgi and ER CC (PubMed:17909029, PubMed:20674546). Endocytosed upon activation by CC ligand (PubMed:17182860, PubMed:17909029, PubMed:27153536, CC PubMed:2790960). Colocalized with GPER1 in the nucleus of estrogen CC agonist-induced cancer-associated fibroblasts (CAF) (PubMed:20551055). CC {ECO:0000269|PubMed:17182860, ECO:0000269|PubMed:17909029, CC ECO:0000269|PubMed:20674546, ECO:0000269|PubMed:27153536, CC ECO:0000269|PubMed:2790960}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; Synonyms=p170; CC IsoId=P00533-1; Sequence=Displayed; CC Name=2; Synonyms=p60, Truncated, TEGFR; CC IsoId=P00533-2; Sequence=VSP_002887, VSP_002888; CC Name=3; Synonyms=p110; CC IsoId=P00533-3; Sequence=VSP_002889, VSP_002890; CC Name=4; CC IsoId=P00533-4; Sequence=VSP_002891, VSP_002892; CC -!- TISSUE SPECIFICITY: Ubiquitously expressed. Isoform 2 is also expressed CC in ovarian cancers. {ECO:0000269|PubMed:17671655}. CC -!- PTM: Phosphorylated on Tyr residues in response to EGF CC (PubMed:20462955, PubMed:27153536). Phosphorylation at Ser-695 is CC partial and occurs only if Thr-693 is phosphorylated. Phosphorylation CC at Thr-678 and Thr-693 by PRKD1 inhibits EGF-induced MAPK8/JNK1 CC activation. Dephosphorylation by PTPRJ prevents endocytosis and CC stabilizes the receptor at the plasma membrane. Autophosphorylation at CC Tyr-1197 is stimulated by methylation at Arg-1199 and enhances CC interaction with PTPN6. Autophosphorylation at Tyr-1092 and/or Tyr-1110 CC recruits STAT3. Dephosphorylated by PTPN1 and PTPN2. CC {ECO:0000269|PubMed:10523301, ECO:0000269|PubMed:12873986, CC ECO:0000269|PubMed:16083266, ECO:0000269|PubMed:19563760, CC ECO:0000269|PubMed:19836242, ECO:0000269|PubMed:20462955, CC ECO:0000269|PubMed:21258366, ECO:0000269|PubMed:2543678, CC ECO:0000269|PubMed:27153536, ECO:0000269|PubMed:3138233}. CC -!- PTM: Monoubiquitinated and polyubiquitinated upon EGF stimulation; CC which does not affect tyrosine kinase activity or signaling capacity CC but may play a role in lysosomal targeting (PubMed:27153536). CC Polyubiquitin linkage is mainly through 'Lys-63', but linkage through CC 'Lys-48', 'Lys-11' and 'Lys-29' also occurs. Deubiquitination by OTUD7B CC prevents degradation. Ubiquitinated by RNF115 and RNF126 (By CC similarity). Ubiquitinated by ZNRF1 or CBL at different lysines in CC response to EGF stimulation; leading to recruitment of the ESCRT CC machinery and subsequent degradation in the lysosomes CC (PubMed:33996800). Deubiquitinated by UCHL1 leading to the inhibition CC of its degradation (By similarity). {ECO:0000250|UniProtKB:Q01279, CC ECO:0000269|PubMed:16543144, ECO:0000269|PubMed:22179831, CC ECO:0000269|PubMed:22298428, ECO:0000269|PubMed:27153536, CC ECO:0000269|PubMed:33996800}. CC -!- PTM: Palmitoylated on Cys residues by ZDHHC20. Palmitoylation inhibits CC internalization after ligand binding, and increases the persistence of CC tyrosine-phosphorylated EGFR at the cell membrane. Palmitoylation CC increases the amplitude and duration of EGFR signaling. CC {ECO:0000269|PubMed:27153536}. CC -!- PTM: Methylated. Methylation at Arg-1199 by PRMT5 stimulates CC phosphorylation at Tyr-1197. {ECO:0000269|PubMed:19563760, CC ECO:0000269|PubMed:19836242, ECO:0000269|PubMed:21258366}. CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. {ECO:0000269|PubMed:15118125, ECO:0000269|PubMed:16533793, CC ECO:0000269|PubMed:16672372}. Note=The gene represented in this entry CC is involved in disease pathogenesis. CC -!- DISEASE: Neonatal nephrocutaneous inflammatory syndrome (NNCIS) CC [MIM:616069]: An autosomal recessive disorder characterized by CC intrauterine growth retardation, premature birth, fragile skin, CC recurrent skin infections and sepsis, failure to thrive, CC nephrocalcinosis, and nephromegaly with tubular dysfunction. Some CC patients have chronic diarrhea, and necrotizing enterocolitis. CC {ECO:0000269|PubMed:24691054}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Wikipedia; Note=EGFR entry; CC URL="https://en.wikipedia.org/wiki/Epidermal_growth_factor_receptor"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X00588; CAA25240.1; -; mRNA. DR EMBL; U95089; AAB53063.1; -; mRNA. DR EMBL; U48722; AAC50802.1; -; mRNA. DR EMBL; U48723; AAC50804.1; -; Genomic_DNA. DR EMBL; U48724; AAC50796.1; -; Genomic_DNA. DR EMBL; U48725; AAC50797.1; -; Genomic_DNA. DR EMBL; U48726; AAC50798.1; -; Genomic_DNA. DR EMBL; U48727; AAC50799.1; -; Genomic_DNA. DR EMBL; U48728; AAC50800.1; -; Genomic_DNA. DR EMBL; U48729; AAC50801.1; -; Genomic_DNA. DR EMBL; AF288738; AAG35786.1; -; Genomic_DNA. DR EMBL; AF288738; AAG35787.1; -; Genomic_DNA. DR EMBL; AF288738; AAG35788.1; -; Genomic_DNA. DR EMBL; AF288738; AAG35789.1; -; Genomic_DNA. DR EMBL; AF288738; AAG35790.1; -; Genomic_DNA. DR EMBL; AY698024; AAT97979.1; -; mRNA. DR EMBL; AY588246; AAS83109.1; -; Genomic_DNA. DR EMBL; AF277897; AAK01080.1; -; mRNA. DR EMBL; AF125253; AAG43240.1; -; mRNA. DR EMBL; AF125539; AAG43243.1; -; Genomic_DNA. DR EMBL; AF125538; AAG43243.1; JOINED; Genomic_DNA. DR EMBL; X06370; CAA29668.1; -; Genomic_DNA. DR EMBL; X00663; CAA25282.1; -; mRNA. DR EMBL; M38425; AAA63171.1; -; Genomic_DNA. DR EMBL; M11234; AAA52370.1; -; Genomic_DNA. DR CCDS; CCDS47587.1; -. [P00533-2] DR CCDS; CCDS5514.1; -. [P00533-1] DR CCDS; CCDS5515.1; -. [P00533-3] DR CCDS; CCDS5516.1; -. [P00533-4] DR PIR; A00641; GQHUE. DR RefSeq; NP_005219.2; NM_005228.4. [P00533-1] DR RefSeq; NP_958439.1; NM_201282.2. [P00533-4] DR RefSeq; NP_958440.1; NM_201283.2. [P00533-2] DR RefSeq; NP_958441.1; NM_201284.2. [P00533-3] DR PDB; 1IVO; X-ray; 3.30 A; A/B=25-646. DR PDB; 1M14; X-ray; 2.60 A; A=695-1022. DR PDB; 1M17; X-ray; 2.60 A; A=695-1022. DR PDB; 1MOX; X-ray; 2.50 A; A/B=25-525. DR PDB; 1NQL; X-ray; 2.80 A; A=25-642. DR PDB; 1XKK; X-ray; 2.40 A; A=695-1022. DR PDB; 1YY9; X-ray; 2.60 A; A=25-642. DR PDB; 1Z9I; NMR; -; A=669-721. DR PDB; 2EB2; X-ray; 2.50 A; A=695-1022. DR PDB; 2EB3; X-ray; 2.84 A; A=695-1022. DR PDB; 2GS2; X-ray; 2.80 A; A=696-1022. DR PDB; 2GS6; X-ray; 2.60 A; A=696-1022. DR PDB; 2GS7; X-ray; 2.60 A; A/B=696-1022. DR PDB; 2ITN; X-ray; 2.47 A; A=696-1022. DR PDB; 2ITO; X-ray; 3.25 A; A=696-1022. DR PDB; 2ITP; X-ray; 2.74 A; A=696-1022. DR PDB; 2ITQ; X-ray; 2.68 A; A=696-1022. DR PDB; 2ITT; X-ray; 2.73 A; A=696-1022. DR PDB; 2ITU; X-ray; 2.80 A; A=696-1022. DR PDB; 2ITV; X-ray; 2.47 A; A=696-1022. DR PDB; 2ITW; X-ray; 2.88 A; A=696-1022. DR PDB; 2ITX; X-ray; 2.98 A; A=696-1022. DR PDB; 2ITY; X-ray; 3.42 A; A=696-1022. DR PDB; 2ITZ; X-ray; 2.72 A; A=696-1022. DR PDB; 2J5E; X-ray; 3.10 A; A=696-1022. DR PDB; 2J5F; X-ray; 3.00 A; A=696-1022. DR PDB; 2J6M; X-ray; 3.10 A; A=696-1022. DR PDB; 2JIT; X-ray; 3.10 A; A/B=696-1022. DR PDB; 2JIU; X-ray; 3.05 A; A/B=695-1022. DR PDB; 2JIV; X-ray; 3.50 A; A/B=695-1022. DR PDB; 2KS1; NMR; -; B=634-677. DR PDB; 2M0B; NMR; -; A/B=634-677. DR PDB; 2M20; NMR; -; A/B=642-697. DR PDB; 2N5S; NMR; -; A=642-690. DR PDB; 2RF9; X-ray; 3.50 A; A/B=696-1022. DR PDB; 2RFD; X-ray; 3.60 A; A/B=702-1022. DR PDB; 2RFE; X-ray; 2.90 A; A/B/C/D=702-1022. DR PDB; 2RGP; X-ray; 2.00 A; A=702-1016. DR PDB; 3B2U; X-ray; 2.58 A; A/B/E/I/M/P/S/V=335-538. DR PDB; 3B2V; X-ray; 3.30 A; A=25-642. DR PDB; 3BEL; X-ray; 2.30 A; A=702-1016. DR PDB; 3BUO; X-ray; 2.60 A; A/C=1063-1075. DR PDB; 3C09; X-ray; 3.20 A; A/D=336-538. DR PDB; 3G5V; X-ray; 2.00 A; C=311-326. DR PDB; 3G5Y; X-ray; 1.59 A; E=311-326. DR PDB; 3GOP; X-ray; 2.80 A; A=669-1022. DR PDB; 3GT8; X-ray; 2.96 A; A/B/C/D=696-1022. DR PDB; 3IKA; X-ray; 2.90 A; A/B=694-1022. DR PDB; 3LZB; X-ray; 2.70 A; A/B/C/D/E/F/G/H=696-983. DR PDB; 3NJP; X-ray; 3.30 A; A/B=25-638. DR PDB; 3OB2; X-ray; 2.10 A; A=1063-1074. DR PDB; 3OP0; X-ray; 2.52 A; C/D=1066-1076. DR PDB; 3P0Y; X-ray; 1.80 A; A=334-538. DR PDB; 3PFV; X-ray; 2.27 A; C/D=1066-1076. DR PDB; 3POZ; X-ray; 1.50 A; A=696-1022. DR PDB; 3QWQ; X-ray; 2.75 A; A=1-642. DR PDB; 3UG1; X-ray; 2.75 A; A=695-1022. DR PDB; 3UG2; X-ray; 2.50 A; A=695-1022. DR PDB; 3VJN; X-ray; 2.34 A; A=695-1022. DR PDB; 3VJO; X-ray; 2.64 A; A=695-1022. DR PDB; 3VRP; X-ray; 1.52 A; B=1062-1074. DR PDB; 3VRR; X-ray; 2.00 A; C=1062-1074. DR PDB; 3W2O; X-ray; 2.35 A; A=698-1022. DR PDB; 3W2P; X-ray; 2.05 A; A=698-1022. DR PDB; 3W2Q; X-ray; 2.20 A; A=698-1022. DR PDB; 3W2R; X-ray; 2.05 A; A=698-1022. DR PDB; 3W2S; X-ray; 1.90 A; A=696-1022. DR PDB; 3W32; X-ray; 1.80 A; A=696-1022. DR PDB; 3W33; X-ray; 1.70 A; A=696-1022. DR PDB; 4G5J; X-ray; 2.80 A; A=696-1022. DR PDB; 4G5P; X-ray; 3.17 A; A/B=696-1022. DR PDB; 4HJO; X-ray; 2.75 A; A=696-1022. DR PDB; 4I1Z; X-ray; 3.00 A; A=695-1022. DR PDB; 4I20; X-ray; 3.34 A; A=695-1022. DR PDB; 4I21; X-ray; 3.37 A; A/B=695-1022. DR PDB; 4I22; X-ray; 1.71 A; A=695-1022. DR PDB; 4I23; X-ray; 2.80 A; A=695-1022. DR PDB; 4I24; X-ray; 1.80 A; A/B=695-1022. DR PDB; 4JQ7; X-ray; 2.73 A; A=696-1021. DR PDB; 4JQ8; X-ray; 2.83 A; A=696-1021. DR PDB; 4JR3; X-ray; 2.70 A; A=696-1021. DR PDB; 4JRV; X-ray; 2.80 A; A=696-1021. DR PDB; 4KRL; X-ray; 2.85 A; A=335-538. DR PDB; 4KRM; X-ray; 2.66 A; A/C/E/G/I/K=335-538. DR PDB; 4KRO; X-ray; 3.05 A; A=25-642. DR PDB; 4KRP; X-ray; 2.82 A; A=25-642. DR PDB; 4LI5; X-ray; 2.64 A; A=696-1020. DR PDB; 4LL0; X-ray; 4.00 A; A/B=694-1022. DR PDB; 4LQM; X-ray; 2.50 A; A=694-1022. DR PDB; 4LRM; X-ray; 3.53 A; A/B/C/D/E=694-1022. DR PDB; 4R3P; X-ray; 2.90 A; A=696-1018. DR PDB; 4R3R; X-ray; 3.25 A; A=696-1018. DR PDB; 4R5S; X-ray; 3.00 A; A=696-1022. DR PDB; 4RIW; X-ray; 3.10 A; B/D=682-1022. DR PDB; 4RIX; X-ray; 3.10 A; B/D=682-1022. DR PDB; 4RIY; X-ray; 2.98 A; B/D=682-1022. DR PDB; 4RJ4; X-ray; 2.78 A; A=695-1022. DR PDB; 4RJ5; X-ray; 3.10 A; A=695-1022. DR PDB; 4RJ6; X-ray; 2.70 A; A=695-1022. DR PDB; 4RJ7; X-ray; 2.55 A; A=695-1022. DR PDB; 4RJ8; X-ray; 2.50 A; A=695-1022. DR PDB; 4TKS; X-ray; 3.20 A; A=695-1022. DR PDB; 4UIP; X-ray; 2.95 A; A=26-637. DR PDB; 4UV7; X-ray; 2.10 A; A=25-645. DR PDB; 4WD5; X-ray; 3.30 A; A/B=694-1022. DR PDB; 4WKQ; X-ray; 1.85 A; A=696-1022. DR PDB; 4WRG; X-ray; 1.90 A; A=696-1022. DR PDB; 4ZAU; X-ray; 2.80 A; A=696-1022. DR PDB; 4ZJV; X-ray; 2.70 A; A/B=695-1022. DR PDB; 4ZSE; X-ray; 1.97 A; A/B/C/D=695-1022. DR PDB; 5C8K; X-ray; 3.00 A; A=695-1022. DR PDB; 5C8M; X-ray; 2.90 A; A=695-1022. DR PDB; 5C8N; X-ray; 2.40 A; A=695-1022. DR PDB; 5CAL; X-ray; 2.70 A; A=695-1022. DR PDB; 5CAN; X-ray; 2.80 A; A=695-1022. DR PDB; 5CAO; X-ray; 2.60 A; A=695-1022. DR PDB; 5CAP; X-ray; 2.40 A; A=695-1022. DR PDB; 5CAQ; X-ray; 2.50 A; A=695-1022. DR PDB; 5CAS; X-ray; 2.10 A; A=695-1022. DR PDB; 5CAU; X-ray; 2.25 A; A=695-1022. DR PDB; 5CAV; X-ray; 2.73 A; A=695-1022. DR PDB; 5CNN; X-ray; 1.90 A; A/B=696-1042. DR PDB; 5CNO; X-ray; 1.55 A; A/B/X=696-1022. DR PDB; 5CZH; X-ray; 2.80 A; A=694-1022. DR PDB; 5CZI; X-ray; 2.60 A; A=694-1022. DR PDB; 5D41; X-ray; 2.31 A; A/B=695-1022. DR PDB; 5EDP; X-ray; 2.90 A; A=695-1022. DR PDB; 5EDQ; X-ray; 2.80 A; A=695-1022. DR PDB; 5EDR; X-ray; 2.60 A; A=695-1022. DR PDB; 5EM5; X-ray; 2.65 A; A=695-1022. DR PDB; 5EM6; X-ray; 2.78 A; A=695-1022. DR PDB; 5EM7; X-ray; 2.81 A; A=695-1022. DR PDB; 5EM8; X-ray; 2.80 A; A=695-1022. DR PDB; 5FED; X-ray; 2.65 A; A=696-1022. DR PDB; 5FEE; X-ray; 2.70 A; A=696-1022. DR PDB; 5FEQ; X-ray; 3.40 A; A=696-1022. DR PDB; 5GMP; X-ray; 2.80 A; A=696-1022. DR PDB; 5GNK; X-ray; 1.80 A; A=696-988. DR PDB; 5GTY; X-ray; 3.14 A; A/B/C/D/E/F/G/H=696-1022. DR PDB; 5GTZ; X-ray; 3.00 A; A=696-1022. DR PDB; 5HCX; X-ray; 2.60 A; A=696-1022. DR PDB; 5HCY; X-ray; 2.46 A; A=696-1022. DR PDB; 5HCZ; X-ray; 2.62 A; A=696-1022. DR PDB; 5HG5; X-ray; 1.52 A; A=695-1022. DR PDB; 5HG7; X-ray; 1.85 A; A=695-1022. DR PDB; 5HG8; X-ray; 1.42 A; A=695-1022. DR PDB; 5HG9; X-ray; 2.15 A; A=695-1022. DR PDB; 5HIB; X-ray; 2.85 A; A=695-1022. DR PDB; 5HIC; X-ray; 2.60 A; A=695-1022. DR PDB; 5J9Y; X-ray; 2.80 A; A=697-1019. DR PDB; 5J9Z; X-ray; 2.50 A; A=696-1020. DR PDB; 5JEB; X-ray; 3.30 A; A=696-1022. DR PDB; 5LV6; NMR; -; A/B=634-677. DR PDB; 5SX4; X-ray; 2.80 A; M/N=335-525. DR PDB; 5SX5; X-ray; 2.50 A; M/N=335-525. DR PDB; 5U8L; X-ray; 1.60 A; A=695-1022. DR PDB; 5UG8; X-ray; 1.46 A; A=695-1022. DR PDB; 5UG9; X-ray; 1.33 A; A=695-1022. DR PDB; 5UGA; X-ray; 1.82 A; A=695-1022. DR PDB; 5UGB; X-ray; 2.53 A; A=695-1022. DR PDB; 5UGC; X-ray; 1.58 A; A=695-1022. DR PDB; 5UWD; X-ray; 3.06 A; A=695-1022. DR PDB; 5WB7; X-ray; 2.94 A; A/B/C/D=25-525. DR PDB; 5WB8; X-ray; 3.00 A; A/D=25-525. DR PDB; 5X26; X-ray; 2.95 A; A=696-1022. DR PDB; 5X27; X-ray; 2.95 A; A=696-1022. DR PDB; 5X28; X-ray; 2.95 A; A=696-1022. DR PDB; 5X2A; X-ray; 1.85 A; A/B/C/D=696-1022. DR PDB; 5X2C; X-ray; 2.05 A; A/B=696-1022. DR PDB; 5X2F; X-ray; 2.20 A; A/B/C/D=696-1022. DR PDB; 5X2K; X-ray; 3.20 A; A=696-1022. DR PDB; 5XDK; X-ray; 2.35 A; A=696-1022. DR PDB; 5XDL; X-ray; 2.70 A; A=696-1022. DR PDB; 5XGM; X-ray; 2.95 A; A=696-1022. DR PDB; 5XGN; X-ray; 3.00 A; A/B=696-1022. DR PDB; 5XWD; X-ray; 2.89 A; A=1-643. DR PDB; 5Y25; X-ray; 3.10 A; A=698-1022. DR PDB; 5Y9T; X-ray; 3.25 A; A=695-1022. DR PDB; 5YU9; X-ray; 1.95 A; A/B/C/D=696-1022. DR PDB; 5ZTO; X-ray; 2.65 A; A=696-1022. DR PDB; 5ZWJ; X-ray; 2.90 A; A=675-1022. DR PDB; 6ARU; X-ray; 3.20 A; A=25-640. DR PDB; 6B3S; X-ray; 2.80 A; A/B/E/I=335-538. DR PDB; 6D8E; X-ray; 2.54 A; A=696-1022. DR PDB; 6DUK; X-ray; 2.20 A; A/B/C/D/E/F=695-1022. DR PDB; 6JRJ; X-ray; 2.94 A; A=696-1022. DR PDB; 6JRK; X-ray; 2.80 A; A=696-1022. DR PDB; 6JRX; X-ray; 2.20 A; A=696-1022. DR PDB; 6JWL; X-ray; 2.55 A; A=696-1022. DR PDB; 6JX0; X-ray; 2.53 A; A=696-1022. DR PDB; 6JX4; X-ray; 2.53 A; A=696-1022. DR PDB; 6JXT; X-ray; 2.31 A; A=696-1022. DR PDB; 6JZ0; X-ray; 2.86 A; A=696-1021. DR PDB; 6LUB; X-ray; 2.31 A; A=695-1022. DR PDB; 6LUD; X-ray; 2.05 A; A=695-1022. DR PDB; 6P1D; X-ray; 2.40 A; A/B/C/D=696-1022. DR PDB; 6P1L; X-ray; 2.80 A; A/B/C/D=696-1022. DR PDB; 6P8Q; X-ray; 1.90 A; A/B/C/D=696-1022. DR PDB; 6S89; X-ray; 2.70 A; A=695-1022. DR PDB; 6S8A; X-ray; 2.60 A; A=695-1022. DR PDB; 6S9B; X-ray; 3.25 A; A=697-1022. DR PDB; 6S9C; X-ray; 2.73 A; A=696-1022. DR PDB; 6S9D; X-ray; 2.67 A; A=696-1022. DR PDB; 6TFU; X-ray; 2.00 A; A/B=695-1022. DR PDB; 6TFV; X-ray; 1.50 A; A/B=695-1022. DR PDB; 6TFW; X-ray; 2.00 A; A/B=695-1022. DR PDB; 6TFY; X-ray; 1.70 A; A/B=695-1022. DR PDB; 6TFZ; X-ray; 1.80 A; A/B=695-1022. DR PDB; 6TG0; X-ray; 1.50 A; A/B=695-1022. DR PDB; 6TG1; X-ray; 1.60 A; A/B=695-1022. DR PDB; 6V5N; X-ray; 2.40 A; A/B/C/D=695-1022. DR PDB; 6V5P; X-ray; 2.30 A; A/B/C/D=695-1022. DR PDB; 6V66; X-ray; 1.79 A; A/B/C/D=696-1022. DR PDB; 6V6K; X-ray; 2.20 A; A/B/C/D/E/F/G/H=696-1022. DR PDB; 6V6O; X-ray; 2.10 A; A/B/C/D/E/F/G/H=696-1022. DR PDB; 6VH4; X-ray; 2.80 A; A=696-1022. DR PDB; 6VHN; X-ray; 2.40 A; A=696-1022. DR PDB; 6VHP; X-ray; 3.60 A; A=696-1022. DR PDB; 6WA2; X-ray; 2.40 A; A/B/C/D=695-1022. DR PDB; 6WAK; X-ray; 2.40 A; A/B/C/D=695-1022. DR PDB; 6WXN; X-ray; 1.76 A; A/B/C/D=695-1022. DR PDB; 6XL4; X-ray; 2.06 A; A/B/C/D=695-1022. DR PDB; 6Z4B; X-ray; 2.50 A; A/B=695-1022. DR PDB; 6Z4D; X-ray; 2.00 A; A/B=695-1022. DR PDB; 7A2A; X-ray; 1.90 A; A/B=695-1022. DR PDB; 7A6I; X-ray; 2.40 A; A=695-1022. DR PDB; 7A6J; X-ray; 2.00 A; A/B=695-1022. DR PDB; 7A6K; X-ray; 2.00 A; A/B/C/D=695-1022. DR PDB; 7AEI; X-ray; 2.65 A; A=695-1022. DR PDB; 7AEM; X-ray; 2.65 A; A=695-1022. DR PDB; 7B85; X-ray; 2.50 A; A=695-1022. DR PDB; 7ER2; X-ray; 2.66 A; A=696-1022. DR PDB; 7JXI; X-ray; 3.00 A; A/B/C/D=695-1022. DR PDB; 7JXK; X-ray; 3.10 A; A/B/C/D/E/F=695-1022. DR PDB; 7JXL; X-ray; 2.40 A; A/B/C/D=695-1022. DR PDB; 7JXM; X-ray; 2.19 A; A/B/C/D=695-1022. DR PDB; 7JXP; X-ray; 2.16 A; A/B/C/D/E/F=695-1022. DR PDB; 7JXQ; X-ray; 1.83 A; A/B/C/D=695-1022. DR PDB; 7JXW; X-ray; 2.50 A; A/B/C/D=695-1022. DR PDB; 7K1H; X-ray; 2.60 A; A/B/C/D/E/F=695-1022. DR PDB; 7K1I; X-ray; 3.20 A; A=695-1022. DR PDB; 7KXZ; X-ray; 2.40 A; A=695-1022. DR PDB; 7KY0; X-ray; 3.10 A; A/B/C/D=695-1022. DR PDB; 7LEN; X-ray; 2.90 A; A/B=25-525. DR PDB; 7LFR; X-ray; 3.20 A; A/B=25-525. DR PDB; 7LFS; X-ray; 3.50 A; A/B/C/D=25-525. DR PDB; 7LG8; X-ray; 2.93 A; A/B/C/D=695-1022. DR PDB; 7LGS; X-ray; 3.10 A; A/B/C/D=696-1022. DR PDB; 7LTX; X-ray; 2.30 A; A/B/C/D=695-1022. DR PDB; 7OM4; X-ray; 6.05 A; A=25-645. DR PDB; 7OXB; X-ray; 2.56 A; A=696-1020. DR PDB; 7SI1; X-ray; 1.60 A; A=695-1022. DR PDB; 7SYD; EM; 3.10 A; A/B=1-1210. DR PDB; 7SYE; EM; 3.30 A; A/B=1-1210. DR PDB; 7SZ0; EM; 3.30 A; A/B=1-1210. DR PDB; 7SZ1; EM; 3.40 A; A/B=1-1210. DR PDB; 7SZ5; EM; 3.60 A; A/B=1-1210. DR PDB; 7SZ7; EM; 3.40 A; A/B=1-1210. DR PDB; 7T4I; X-ray; 2.61 A; A=696-1022. DR PDB; 7T4J; X-ray; 2.20 A; A/B=696-1022. DR PDB; 7TVD; X-ray; 2.96 A; A=696-1022. DR PDB; 7U98; X-ray; 3.42 A; A/B/C/D=695-1022. DR PDB; 7U99; X-ray; 2.50 A; A=695-1022. DR PDB; 7U9A; X-ray; 2.60 A; A=695-1022. DR PDB; 7UKV; X-ray; 2.40 A; A=695-1022. DR PDB; 7UKW; X-ray; 2.60 A; A/B/C/D=695-1022. DR PDB; 7VRA; X-ray; 2.41 A; A=696-1022. DR PDB; 7VRE; X-ray; 2.51 A; A=696-1022. DR PDB; 7ZYM; X-ray; 2.50 A; A=695-1022. DR PDB; 7ZYN; X-ray; 2.30 A; A=695-1022. DR PDB; 7ZYP; X-ray; 2.80 A; A=695-1022. DR PDB; 7ZYQ; X-ray; 2.10 A; A/B=695-1022. DR PDB; 8A27; X-ray; 1.07 A; A=700-1022. DR PDB; 8A2A; X-ray; 1.43 A; A=700-1022. DR PDB; 8A2B; X-ray; 1.69 A; A=700-1022. DR PDB; 8A2D; X-ray; 1.11 A; A=700-1022. DR PDB; 8D73; X-ray; 2.17 A; A/B=695-1022. DR PDB; 8D76; X-ray; 2.40 A; A/B=695-1022. DR PDB; 8DSW; X-ray; 2.39 A; A=696-1022. DR PDB; 8EME; X-ray; 3.32 A; A/B=695-1022. DR PDB; 8F1H; X-ray; 2.80 A; A=695-1022. DR PDB; 8F1W; X-ray; 3.20 A; A/B/C/D=695-1022. DR PDB; 8F1X; X-ray; 2.30 A; A=695-1022. DR PDB; 8F1Y; X-ray; 2.75 A; A=695-1022. DR PDB; 8F1Z; X-ray; 2.40 A; A=695-1022. DR PDB; 8FV3; X-ray; 2.10 A; A/B/C/D=695-1022. DR PDB; 8FV4; X-ray; 2.20 A; A/B/C/D=695-1022. DR PDB; 8G63; X-ray; 2.50 A; A=696-1022. DR PDB; 8GB4; X-ray; 2.59 A; A/B/C/D=695-1022. DR PDB; 8GK5; X-ray; 2.30 A; A/B/C/D=695-1022. DR PDB; 8H7X; X-ray; 3.40 A; A/B=696-1022. DR PDB; 8HGO; EM; 3.31 A; A=1-683. DR PDB; 8HGP; EM; 4.53 A; A=1-683. DR PDB; 8HGS; EM; 3.81 A; A/B=1-683. DR PDB; 8HV1; X-ray; 2.40 A; A=695-1022. DR PDB; 8HV2; X-ray; 2.80 A; A=694-1022. DR PDB; 8HV3; X-ray; 2.40 A; A=695-1022. DR PDB; 8HV4; X-ray; 2.20 A; A=695-1022. DR PDB; 8HV5; X-ray; 2.20 A; A=695-1022. DR PDB; 8HV6; X-ray; 2.20 A; A=695-1022. DR PDB; 8HV7; X-ray; 2.69 A; A=695-1022. DR PDB; 8HV8; X-ray; 2.40 A; A=695-1022. DR PDB; 8HV9; X-ray; 2.50 A; A=695-1022. DR PDB; 8HVA; X-ray; 2.77 A; A=695-1022. DR PDB; 8HY7; X-ray; 2.91 A; A=695-1022. DR PDB; 8KFQ; X-ray; 3.22 A; A=697-1018. DR PDB; 8PNZ; X-ray; 2.51 A; A=695-1022. DR PDB; 8PO0; X-ray; 2.52 A; A=695-1022. DR PDB; 8PO1; X-ray; 2.11 A; A=695-1022. DR PDB; 8PO2; X-ray; 2.28 A; A/B/D=695-1022. DR PDB; 8PO3; X-ray; 2.13 A; A=695-1022. DR PDB; 8PO4; X-ray; 1.62 A; A/B=695-1022. DR PDB; 8S1M; X-ray; 2.05 A; A=1076-1099. DR PDB; 8SC7; X-ray; 1.98 A; A=696-1022. DR PDB; 8TJL; X-ray; 2.70 A; A=695-1022. DR PDB; 8TO3; X-ray; 2.49 A; A/B/C/D=695-1022. DR PDB; 8TO4; X-ray; 2.99 A; A/B/C/D=695-1022. DR PDB; 8UKV; X-ray; 2.94 A; A/B=298-642. DR PDB; 8UKW; X-ray; 2.39 A; A/B=298-642. DR PDB; 8UKX; X-ray; 3.30 A; A=298-642. DR PDB; 8WD4; X-ray; 2.55 A; A=696-1022. DR PDB; 9BY4; X-ray; 2.31 A; A=696-1022. DR PDB; 9BY6; X-ray; 2.55 A; A=696-1022. DR PDB; 9D3V; X-ray; 2.32 A; A=696-1022. DR PDB; 9D3W; X-ray; 2.53 A; A=696-1022. DR PDB; 9DF2; X-ray; 2.50 A; A=696-1022. DR PDB; 9DF3; X-ray; 1.68 A; A=696-1022. DR PDB; 9DF4; X-ray; 1.78 A; A=696-1022. DR PDB; 9EWS; X-ray; 2.44 A; A=695-1022. DR PDB; 9EWT; X-ray; 3.02 A; A/B=695-1022. DR PDB; 9FQP; X-ray; 2.50 A; A=695-1022. DR PDB; 9FQS; X-ray; 1.78 A; A=695-1022. DR PDB; 9FRD; X-ray; 2.06 A; A=696-1022. DR PDB; 9GC4; X-ray; 2.42 A; A/B/D=695-1022. DR PDB; 9GC5; X-ray; 1.91 A; A/B=695-1022. DR PDB; 9GC6; X-ray; 1.90 A; A/B=695-1022. DR PDB; 9GDV; X-ray; 2.22 A; A/B=695-1022. DR PDB; 9GI9; X-ray; 3.12 A; A=696-1022. DR PDB; 9GL7; X-ray; 1.88 A; A=695-1022. DR PDB; 9GL8; X-ray; 1.63 A; A=695-1022. DR PDB; 9GL9; X-ray; 2.15 A; A=696-1022. DR PDB; 9H46; X-ray; 3.16 A; A=696-1022. DR PDB; 9HBO; X-ray; 2.45 A; A/B=695-1022. DR PDB; 9IP7; EM; 3.21 A; A=25-645. DR PDB; 9IP8; EM; 3.91 A; A=25-645. DR PDB; 9IP9; EM; 3.64 A; A=25-645. DR PDB; 9IPA; EM; 3.85 A; A=25-645. DR PDB; 9IPB; EM; 2.93 A; A=25-645. DR PDB; 9IPC; EM; 3.40 A; A=25-645. DR PDB; 9IPD; EM; 3.29 A; A=25-645. DR PDB; 9IPE; EM; 3.31 A; A=25-645. DR PDBsum; 1IVO; -. DR PDBsum; 1M14; -. DR PDBsum; 1M17; -. DR PDBsum; 1MOX; -. DR PDBsum; 1NQL; -. DR PDBsum; 1XKK; -. DR PDBsum; 1YY9; -. DR PDBsum; 1Z9I; -. DR PDBsum; 2EB2; -. DR PDBsum; 2EB3; -. DR PDBsum; 2GS2; -. DR PDBsum; 2GS6; -. DR PDBsum; 2GS7; -. DR PDBsum; 2ITN; -. DR PDBsum; 2ITO; -. DR PDBsum; 2ITP; -. DR PDBsum; 2ITQ; -. DR PDBsum; 2ITT; -. DR PDBsum; 2ITU; -. DR PDBsum; 2ITV; -. DR PDBsum; 2ITW; -. DR PDBsum; 2ITX; -. DR PDBsum; 2ITY; -. DR PDBsum; 2ITZ; -. DR PDBsum; 2J5E; -. DR PDBsum; 2J5F; -. DR PDBsum; 2J6M; -. DR PDBsum; 2JIT; -. DR PDBsum; 2JIU; -. DR PDBsum; 2JIV; -. DR PDBsum; 2KS1; -. DR PDBsum; 2M0B; -. DR PDBsum; 2M20; -. DR PDBsum; 2N5S; -. DR PDBsum; 2RF9; -. DR PDBsum; 2RFD; -. DR PDBsum; 2RFE; -. DR PDBsum; 2RGP; -. DR PDBsum; 3B2U; -. DR PDBsum; 3B2V; -. DR PDBsum; 3BEL; -. DR PDBsum; 3BUO; -. DR PDBsum; 3C09; -. DR PDBsum; 3G5V; -. DR PDBsum; 3G5Y; -. DR PDBsum; 3GOP; -. DR PDBsum; 3GT8; -. DR PDBsum; 3IKA; -. DR PDBsum; 3LZB; -. DR PDBsum; 3NJP; -. DR PDBsum; 3OB2; -. DR PDBsum; 3OP0; -. DR PDBsum; 3P0Y; -. DR PDBsum; 3PFV; -. DR PDBsum; 3POZ; -. DR PDBsum; 3QWQ; -. DR PDBsum; 3UG1; -. DR PDBsum; 3UG2; -. DR PDBsum; 3VJN; -. DR PDBsum; 3VJO; -. DR PDBsum; 3VRP; -. DR PDBsum; 3VRR; -. DR PDBsum; 3W2O; -. DR PDBsum; 3W2P; -. DR PDBsum; 3W2Q; -. DR PDBsum; 3W2R; -. DR PDBsum; 3W2S; -. DR PDBsum; 3W32; -. DR PDBsum; 3W33; -. DR PDBsum; 4G5J; -. DR PDBsum; 4G5P; -. DR PDBsum; 4HJO; -. DR PDBsum; 4I1Z; -. DR PDBsum; 4I20; -. DR PDBsum; 4I21; -. DR PDBsum; 4I22; -. DR PDBsum; 4I23; -. DR PDBsum; 4I24; -. DR PDBsum; 4JQ7; -. DR PDBsum; 4JQ8; -. DR PDBsum; 4JR3; -. DR PDBsum; 4JRV; -. DR PDBsum; 4KRL; -. DR PDBsum; 4KRM; -. DR PDBsum; 4KRO; -. DR PDBsum; 4KRP; -. DR PDBsum; 4LI5; -. DR PDBsum; 4LL0; -. DR PDBsum; 4LQM; -. DR PDBsum; 4LRM; -. DR PDBsum; 4R3P; -. DR PDBsum; 4R3R; -. DR PDBsum; 4R5S; -. DR PDBsum; 4RIW; -. DR PDBsum; 4RIX; -. DR PDBsum; 4RIY; -. DR PDBsum; 4RJ4; -. DR PDBsum; 4RJ5; -. DR PDBsum; 4RJ6; -. DR PDBsum; 4RJ7; -. DR PDBsum; 4RJ8; -. DR PDBsum; 4TKS; -. DR PDBsum; 4UIP; -. DR PDBsum; 4UV7; -. DR PDBsum; 4WD5; -. DR PDBsum; 4WKQ; -. DR PDBsum; 4WRG; -. DR PDBsum; 4ZAU; -. DR PDBsum; 4ZJV; -. DR PDBsum; 4ZSE; -. DR PDBsum; 5C8K; -. DR PDBsum; 5C8M; -. DR PDBsum; 5C8N; -. DR PDBsum; 5CAL; -. DR PDBsum; 5CAN; -. DR PDBsum; 5CAO; -. DR PDBsum; 5CAP; -. DR PDBsum; 5CAQ; -. DR PDBsum; 5CAS; -. DR PDBsum; 5CAU; -. DR PDBsum; 5CAV; -. DR PDBsum; 5CNN; -. DR PDBsum; 5CNO; -. DR PDBsum; 5CZH; -. DR PDBsum; 5CZI; -. DR PDBsum; 5D41; -. DR PDBsum; 5EDP; -. DR PDBsum; 5EDQ; -. DR PDBsum; 5EDR; -. DR PDBsum; 5EM5; -. DR PDBsum; 5EM6; -. DR PDBsum; 5EM7; -. DR PDBsum; 5EM8; -. DR PDBsum; 5FED; -. DR PDBsum; 5FEE; -. DR PDBsum; 5FEQ; -. DR PDBsum; 5GMP; -. DR PDBsum; 5GNK; -. DR PDBsum; 5GTY; -. DR PDBsum; 5GTZ; -. DR PDBsum; 5HCX; -. DR PDBsum; 5HCY; -. DR PDBsum; 5HCZ; -. DR PDBsum; 5HG5; -. DR PDBsum; 5HG7; -. DR PDBsum; 5HG8; -. DR PDBsum; 5HG9; -. DR PDBsum; 5HIB; -. DR PDBsum; 5HIC; -. DR PDBsum; 5J9Y; -. DR PDBsum; 5J9Z; -. DR PDBsum; 5JEB; -. DR PDBsum; 5LV6; -. DR PDBsum; 5SX4; -. DR PDBsum; 5SX5; -. DR PDBsum; 5U8L; -. DR PDBsum; 5UG8; -. DR PDBsum; 5UG9; -. DR PDBsum; 5UGA; -. DR PDBsum; 5UGB; -. DR PDBsum; 5UGC; -. DR PDBsum; 5UWD; -. DR PDBsum; 5WB7; -. DR PDBsum; 5WB8; -. DR PDBsum; 5X26; -. DR PDBsum; 5X27; -. DR PDBsum; 5X28; -. DR PDBsum; 5X2A; -. DR PDBsum; 5X2C; -. DR PDBsum; 5X2F; -. DR PDBsum; 5X2K; -. DR PDBsum; 5XDK; -. DR PDBsum; 5XDL; -. DR PDBsum; 5XGM; -. DR PDBsum; 5XGN; -. DR PDBsum; 5XWD; -. DR PDBsum; 5Y25; -. DR PDBsum; 5Y9T; -. DR PDBsum; 5YU9; -. DR PDBsum; 5ZTO; -. DR PDBsum; 5ZWJ; -. DR PDBsum; 6ARU; -. DR PDBsum; 6B3S; -. DR PDBsum; 6D8E; -. DR PDBsum; 6DUK; -. DR PDBsum; 6JRJ; -. DR PDBsum; 6JRK; -. DR PDBsum; 6JRX; -. DR PDBsum; 6JWL; -. DR PDBsum; 6JX0; -. DR PDBsum; 6JX4; -. DR PDBsum; 6JXT; -. DR PDBsum; 6JZ0; -. DR PDBsum; 6LUB; -. DR PDBsum; 6LUD; -. DR PDBsum; 6P1D; -. DR PDBsum; 6P1L; -. DR PDBsum; 6P8Q; -. DR PDBsum; 6S89; -. DR PDBsum; 6S8A; -. DR PDBsum; 6S9B; -. DR PDBsum; 6S9C; -. DR PDBsum; 6S9D; -. DR PDBsum; 6TFU; -. DR PDBsum; 6TFV; -. DR PDBsum; 6TFW; -. DR PDBsum; 6TFY; -. DR PDBsum; 6TFZ; -. DR PDBsum; 6TG0; -. DR PDBsum; 6TG1; -. DR PDBsum; 6V5N; -. DR PDBsum; 6V5P; -. DR PDBsum; 6V66; -. DR PDBsum; 6V6K; -. DR PDBsum; 6V6O; -. DR PDBsum; 6VH4; -. DR PDBsum; 6VHN; -. DR PDBsum; 6VHP; -. DR PDBsum; 6WA2; -. DR PDBsum; 6WAK; -. DR PDBsum; 6WXN; -. DR PDBsum; 6XL4; -. DR PDBsum; 6Z4B; -. DR PDBsum; 6Z4D; -. DR PDBsum; 7A2A; -. DR PDBsum; 7A6I; -. DR PDBsum; 7A6J; -. DR PDBsum; 7A6K; -. DR PDBsum; 7AEI; -. DR PDBsum; 7AEM; -. DR PDBsum; 7B85; -. DR PDBsum; 7ER2; -. DR PDBsum; 7JXI; -. DR PDBsum; 7JXK; -. DR PDBsum; 7JXL; -. DR PDBsum; 7JXM; -. DR PDBsum; 7JXP; -. DR PDBsum; 7JXQ; -. DR PDBsum; 7JXW; -. DR PDBsum; 7K1H; -. DR PDBsum; 7K1I; -. DR PDBsum; 7KXZ; -. DR PDBsum; 7KY0; -. DR PDBsum; 7LEN; -. DR PDBsum; 7LFR; -. DR PDBsum; 7LFS; -. DR PDBsum; 7LG8; -. DR PDBsum; 7LGS; -. DR PDBsum; 7LTX; -. DR PDBsum; 7OM4; -. DR PDBsum; 7OXB; -. DR PDBsum; 7SI1; -. DR PDBsum; 7SYD; -. DR PDBsum; 7SYE; -. DR PDBsum; 7SZ0; -. DR PDBsum; 7SZ1; -. DR PDBsum; 7SZ5; -. DR PDBsum; 7SZ7; -. DR PDBsum; 7T4I; -. DR PDBsum; 7T4J; -. DR PDBsum; 7TVD; -. DR PDBsum; 7U98; -. DR PDBsum; 7U99; -. DR PDBsum; 7U9A; -. DR PDBsum; 7UKV; -. DR PDBsum; 7UKW; -. DR PDBsum; 7VRA; -. DR PDBsum; 7VRE; -. DR PDBsum; 7ZYM; -. DR PDBsum; 7ZYN; -. DR PDBsum; 7ZYP; -. DR PDBsum; 7ZYQ; -. DR PDBsum; 8A27; -. DR PDBsum; 8A2A; -. DR PDBsum; 8A2B; -. DR PDBsum; 8A2D; -. DR PDBsum; 8D73; -. DR PDBsum; 8D76; -. DR PDBsum; 8DSW; -. DR PDBsum; 8EME; -. DR PDBsum; 8F1H; -. DR PDBsum; 8F1W; -. DR PDBsum; 8F1X; -. DR PDBsum; 8F1Y; -. DR PDBsum; 8F1Z; -. DR PDBsum; 8FV3; -. DR PDBsum; 8FV4; -. DR PDBsum; 8G63; -. DR PDBsum; 8GB4; -. DR PDBsum; 8GK5; -. DR PDBsum; 8H7X; -. DR PDBsum; 8HGO; -. DR PDBsum; 8HGP; -. DR PDBsum; 8HGS; -. DR PDBsum; 8HV1; -. DR PDBsum; 8HV2; -. DR PDBsum; 8HV3; -. DR PDBsum; 8HV4; -. DR PDBsum; 8HV5; -. DR PDBsum; 8HV6; -. DR PDBsum; 8HV7; -. DR PDBsum; 8HV8; -. DR PDBsum; 8HV9; -. DR PDBsum; 8HVA; -. DR PDBsum; 8HY7; -. DR PDBsum; 8KFQ; -. DR PDBsum; 8PNZ; -. DR PDBsum; 8PO0; -. DR PDBsum; 8PO1; -. DR PDBsum; 8PO2; -. DR PDBsum; 8PO3; -. DR PDBsum; 8PO4; -. DR PDBsum; 8S1M; -. DR PDBsum; 8SC7; -. DR PDBsum; 8TJL; -. DR PDBsum; 8TO3; -. DR PDBsum; 8TO4; -. DR PDBsum; 8UKV; -. DR PDBsum; 8UKW; -. DR PDBsum; 8UKX; -. DR PDBsum; 8WD4; -. DR PDBsum; 9BY4; -. DR PDBsum; 9BY6; -. DR PDBsum; 9D3V; -. DR PDBsum; 9D3W; -. DR PDBsum; 9DF2; -. DR PDBsum; 9DF3; -. DR PDBsum; 9DF4; -. DR PDBsum; 9EWS; -. DR PDBsum; 9EWT; -. DR PDBsum; 9FQP; -. DR PDBsum; 9FQS; -. DR PDBsum; 9FRD; -. DR PDBsum; 9GC4; -. DR PDBsum; 9GC5; -. DR PDBsum; 9GC6; -. DR PDBsum; 9GDV; -. DR PDBsum; 9GI9; -. DR PDBsum; 9GL7; -. DR PDBsum; 9GL8; -. DR PDBsum; 9GL9; -. DR PDBsum; 9H46; -. DR PDBsum; 9HBO; -. DR PDBsum; 9IP7; -. DR PDBsum; 9IP8; -. DR PDBsum; 9IP9; -. DR PDBsum; 9IPA; -. DR PDBsum; 9IPB; -. DR PDBsum; 9IPC; -. DR PDBsum; 9IPD; -. DR PDBsum; 9IPE; -. DR AlphaFoldDB; P00533; -. DR BMRB; P00533; -. DR EMDB; EMD-25522; -. DR EMDB; EMD-25523; -. DR EMDB; EMD-25558; -. DR EMDB; EMD-25559; -. DR EMDB; EMD-25561; -. DR EMDB; EMD-25563; -. DR EMDB; EMD-34744; -. DR EMDB; EMD-34745; -. DR EMDB; EMD-34746; -. DR EMDB; EMD-60764; -. DR EMDB; EMD-60765; -. DR EMDB; EMD-60766; -. DR EMDB; EMD-60767; -. DR EMDB; EMD-60768; -. DR EMDB; EMD-60769; -. DR EMDB; EMD-60770; -. DR EMDB; EMD-60771; -. DR SMR; P00533; -. DR BioGRID; 108276; 3218. DR CORUM; P00533; -. DR DIP; DIP-405N; -. DR ELM; P00533; -. DR FunCoup; P00533; 3104. DR IntAct; P00533; 1179. DR MINT; P00533; -. DR STRING; 9606.ENSP00000275493; -. DR BindingDB; P00533; -. DR ChEMBL; CHEMBL203; -. DR DrugBank; DB15327; Abivertinib. DR DrugBank; DB08916; Afatinib. DR DrugBank; DB18840; Allitinib. DR DrugBank; DB16640; Almonertinib. DR DrugBank; DB03496; Alvocidib. DR DrugBank; DB16695; Amivantamab. DR DrugBank; DB06021; AV-412. DR DrugBank; DB12318; BMS-599626. DR DrugBank; DB11665; BMS-690514. DR DrugBank; DB12267; Brigatinib. DR DrugBank; DB05424; Canertinib. DR DrugBank; DB00002; Cetuximab. DR DrugBank; DB12174; CUDC-101. DR DrugBank; DB11963; Dacomitinib. DR DrugBank; DB11731; Depatuxizumab mafodotin. DR DrugBank; DB00530; Erlotinib. DR DrugBank; DB12966; Falnidamol. DR DrugBank; DB10772; Foreskin keratinocyte (neonatal). DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB00317; Gefitinib. DR DrugBank; DB11737; Icotinib. DR DrugBank; DB04988; IGN311. DR DrugBank; DB01259; Lapatinib. DR DrugBank; DB16768; Lavendustin A. DR DrugBank; DB16216; Lazertinib. DR DrugBank; DB00281; Lidocaine. DR DrugBank; DB05101; Matuzumab. DR DrugBank; DB06110; MDX-214. DR DrugBank; DB04862; Merimepodib. DR DrugBank; DB16390; Mobocertinib. DR DrugBank; DB12682; Mubritinib. DR DrugBank; DB08462; N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE. DR DrugBank; DB12036; Naquotinib. DR DrugBank; DB16250; Nazartinib. DR DrugBank; DB09559; Necitumumab. DR DrugBank; DB11828; Neratinib. DR DrugBank; DB00727; Nitroglycerin. DR DrugBank; DB13164; Olmutinib. DR DrugBank; DB09330; Osimertinib. DR DrugBank; DB01269; Panitumumab. DR DrugBank; DB08339; PD-166326. DR DrugBank; DB07662; PD-168393. DR DrugBank; DB05524; Pelitinib. DR DrugBank; DB12114; Poziotinib. DR DrugBank; DB08052; PP-121. DR DrugBank; DB14993; Pyrotinib. DR DrugBank; DB05374; Rindopepimut. DR DrugBank; DB11907; Rociletinib. DR DrugBank; DB07602; S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB14944; Tarloxotinib. DR DrugBank; DB05294; Vandetanib. DR DrugBank; DB05944; Varlitinib. DR DrugBank; DB04879; Vatalanib. DR DrugBank; DB12202; Zalutumumab. DR DrugBank; DB15035; Zanubrutinib. DR DrugCentral; P00533; -. DR GuidetoPHARMACOLOGY; 1797; -. DR MoonDB; P00533; Predicted. DR TCDB; 8.A.23.1.46; the basigin (basigin) family. DR GlyConnect; 137; 81 N-Linked glycans (10 sites). DR GlyCosmos; P00533; 17 sites, 102 glycans. DR GlyGen; P00533; 27 sites, 148 N-linked glycans (18 sites), 1 O-linked glycan (7 sites). DR iPTMnet; P00533; -. DR MetOSite; P00533; -. DR PhosphoSitePlus; P00533; -. DR SwissPalm; P00533; -. DR BioMuta; EGFR; -. DR DMDM; 2811086; -. DR CPTAC; CPTAC-1043; -. DR CPTAC; CPTAC-1560; -. DR CPTAC; CPTAC-1781; -. DR CPTAC; CPTAC-3043; -. DR CPTAC; CPTAC-3044; -. DR CPTAC; CPTAC-5784; -. DR CPTAC; CPTAC-5785; -. DR CPTAC; CPTAC-5830; -. DR CPTAC; CPTAC-5831; -. DR CPTAC; CPTAC-5832; -. DR CPTAC; CPTAC-5833; -. DR CPTAC; CPTAC-5834; -. DR CPTAC; CPTAC-5835; -. DR CPTAC; CPTAC-802; -. DR CPTAC; non-CPTAC-5380; -. DR CPTAC; non-CPTAC-5381; -. DR CPTAC; non-CPTAC-5382; -. DR CPTAC; non-CPTAC-5545; -. DR CPTAC; non-CPTAC-5546; -. DR CPTAC; non-CPTAC-5735; -. DR CPTAC; non-CPTAC-5736; -. DR CPTAC; non-CPTAC-5737; -. DR CPTAC; non-CPTAC-5738; -. DR jPOST; P00533; -. DR MassIVE; P00533; -. DR PaxDb; 9606-ENSP00000275493; -. DR PeptideAtlas; P00533; -. DR ProteomicsDB; 51261; -. [P00533-1] DR ProteomicsDB; 51262; -. [P00533-2] DR ProteomicsDB; 51263; -. [P00533-3] DR ProteomicsDB; 51264; -. [P00533-4] DR ABCD; P00533; 128 sequenced antibodies. DR Antibodypedia; 718; 10780 antibodies from 66 providers. DR CPTC; P00533; 13 antibodies. DR DNASU; 1956; -. DR Ensembl; ENST00000275493.7; ENSP00000275493.2; ENSG00000146648.22. [P00533-1] DR Ensembl; ENST00000342916.7; ENSP00000342376.3; ENSG00000146648.22. [P00533-4] DR Ensembl; ENST00000344576.7; ENSP00000345973.2; ENSG00000146648.22. [P00533-3] DR Ensembl; ENST00000420316.6; ENSP00000413843.2; ENSG00000146648.22. [P00533-2] DR GeneID; 1956; -. DR KEGG; hsa:1956; -. DR MANE-Select; ENST00000275493.7; ENSP00000275493.2; NM_005228.5; NP_005219.2. DR UCSC; uc003tqh.4; human. [P00533-1] DR AGR; HGNC:3236; -. DR CIViC; 1956; 4 clinical assertions and 612 evidence items across 318 molecular profiles. DR ClinPGx; PA7360; -. DR CTD; 1956; -. DR DisGeNET; 1956; -. DR GeneCards; EGFR; -. DR HGNC; HGNC:3236; EGFR. DR HPA; ENSG00000146648; Tissue enhanced (placenta). DR MalaCards; EGFR; -. DR MIM; 131550; gene. DR MIM; 211980; phenotype. DR MIM; 616069; phenotype. DR OpenTargets; ENSG00000146648; -. DR Orphanet; 251579; Giant cell glioblastoma. DR Orphanet; 251576; Gliosarcoma. DR Orphanet; 294023; Neonatal inflammatory skin and bowel disease. DR VEuPathDB; HostDB:ENSG00000146648; -. DR eggNOG; KOG1025; Eukaryota. DR GeneTree; ENSGT00940000155450; -. DR HOGENOM; CLU_003384_0_2_1; -. DR InParanoid; P00533; -. DR OMA; GYYYEWV; -. DR OrthoDB; 6219513at2759; -. DR PAN-GO; P00533; 11 GO annotations based on evolutionary models. DR PhylomeDB; P00533; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P00533; -. DR Reactome; R-HSA-1227986; Signaling by ERBB2. DR Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants. DR Reactome; R-HSA-1236394; Signaling by ERBB4. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1251932; PLCG1 events in ERBB2 signaling. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-177929; Signaling by EGFR. DR Reactome; R-HSA-179812; GRB2 events in EGFR signaling. DR Reactome; R-HSA-180292; GAB1 signalosome. DR Reactome; R-HSA-180336; SHC1 events in EGFR signaling. DR Reactome; R-HSA-182971; EGFR downregulation. DR Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling. DR Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling. DR Reactome; R-HSA-212718; EGFR interacts with phospholipase C-gamma. DR Reactome; R-HSA-2179392; EGFR Transactivation by Gastrin. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-445144; Signal transduction by L1. DR Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII. DR Reactome; R-HSA-5638303; Inhibition of Signaling by Overexpressed EGFR. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6785631; ERBB2 Regulates Cell Motility. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling. DR Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis. DR Reactome; R-HSA-8856828; Clathrin-mediated endocytosis. DR Reactome; R-HSA-8857538; PTK6 promotes HIF1A stabilization. DR Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling. DR Reactome; R-HSA-8866910; TFAP2 (AP-2) family regulates transcription of growth factors and their receptors. DR Reactome; R-HSA-9009391; Extra-nuclear estrogen signaling. DR Reactome; R-HSA-9013507; NOTCH3 Activation and Transmission of Signal to the Nucleus. DR Reactome; R-HSA-9609690; HCMV Early Events. DR Reactome; R-HSA-9634638; Estrogen-dependent nuclear events downstream of ESR-membrane signaling. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665348; Signaling by ERBB2 ECD mutants. DR Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants. DR Reactome; R-HSA-9820960; Respiratory syncytial virus (RSV) attachment and entry. DR Reactome; R-HSA-9927432; Developmental Lineage of Mammary Gland Myoepithelial Cells. DR SignaLink; P00533; -. DR SIGNOR; P00533; -. DR Agora; ENSG00000146648; -. DR BioGRID-ORCS; 1956; 155 hits in 1222 CRISPR screens. DR ChiTaRS; EGFR; human. DR EvolutionaryTrace; P00533; -. DR GeneWiki; Epidermal_growth_factor_receptor; -. DR GenomeRNAi; 1956; -. DR Pharos; P00533; Tclin. DR PRO; PR:P00533; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; P00533; protein. DR Bgee; ENSG00000146648; Expressed in nipple and 206 other cell types or tissues. DR ExpressionAtlas; P00533; baseline and differential. DR GO; GO:0009925; C:basal plasma membrane; IBA:GO_Central. DR GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL. DR GO; GO:0030054; C:cell junction; IDA:HPA. DR GO; GO:0009986; C:cell surface; IDA:UniProtKB. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0031901; C:early endosome membrane; IDA:UniProtKB. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005768; C:endosome; IDA:UniProtKB. DR GO; GO:0010008; C:endosome membrane; IDA:UniProtKB. DR GO; GO:0005615; C:extracellular space; NAS:UniProtKB. DR GO; GO:0005925; C:focal adhesion; HDA:UniProtKB. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell. DR GO; GO:0097708; C:intracellular vesicle; IDA:ARUK-UCL. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0045121; C:membrane raft; IDA:UniProtKB. DR GO; GO:0097489; C:multivesicular body, internal vesicle lumen; IDA:UniProtKB. DR GO; GO:0031965; C:nuclear membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IMP:ARUK-UCL. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0032587; C:ruffle membrane; IDA:ARUK-UCL. DR GO; GO:0070435; C:Shc-EGFR complex; ISS:BHF-UCL. DR GO; GO:0097229; C:sperm end piece; IDA:HPA. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0051015; F:actin filament binding; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0051117; F:ATPase binding; ISS:ARUK-UCL. DR GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0003690; F:double-stranded DNA binding; NAS:UniProtKB. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0048408; F:epidermal growth factor binding; IBA:GO_Central. DR GO; GO:0005006; F:epidermal growth factor receptor activity; IDA:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0019900; F:kinase binding; IPI:UniProtKB. DR GO; GO:0004709; F:MAP kinase kinase kinase activity; NAS:UniProtKB. DR GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB. DR GO; GO:0030296; F:protein tyrosine kinase activator activity; IDA:MGI. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0004888; F:transmembrane signaling receptor activity; IDA:MGI. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB. DR GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW. DR GO; GO:0000902; P:cell morphogenesis; IEA:Ensembl. DR GO; GO:0007166; P:cell surface receptor signaling pathway; IDA:MGI. DR GO; GO:0098609; P:cell-cell adhesion; IMP:UniProtKB. DR GO; GO:0071230; P:cellular response to amino acid stimulus; IEA:Ensembl. DR GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; ISS:UniProtKB. DR GO; GO:0071392; P:cellular response to estradiol stimulus; IDA:UniProtKB. DR GO; GO:0021795; P:cerebral cortex cell migration; IEA:Ensembl. DR GO; GO:0048546; P:digestive tract morphogenesis; IEA:Ensembl. DR GO; GO:0001892; P:embryonic placenta development; IEA:Ensembl. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0050673; P:epithelial cell proliferation; IEA:Ensembl. DR GO; GO:0038134; P:ERBB2-EGFR signaling pathway; IDA:MGI. DR GO; GO:0061029; P:eyelid development in camera-type eye; IEA:Ensembl. DR GO; GO:0010467; P:gene expression; IEA:Ensembl. DR GO; GO:0001942; P:hair follicle development; IEA:Ensembl. DR GO; GO:0007611; P:learning or memory; ISS:UniProtKB. DR GO; GO:0060571; P:morphogenesis of an epithelial fold; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:1905208; P:negative regulation of cardiocyte differentiation; IMP:BHF-UCL. DR GO; GO:0042059; P:negative regulation of epidermal growth factor receptor signaling pathway; TAS:Reactome. DR GO; GO:0042177; P:negative regulation of protein catabolic process; IDA:UniProtKB. DR GO; GO:0030182; P:neuron differentiation; IBA:GO_Central. DR GO; GO:0001503; P:ossification; NAS:UniProtKB. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:BHF-UCL. DR GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:BHF-UCL. DR GO; GO:0030307; P:positive regulation of cell growth; IDA:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:MGI. DR GO; GO:0045739; P:positive regulation of DNA repair; IDA:UniProtKB. DR GO; GO:0045740; P:positive regulation of DNA replication; IDA:UniProtKB. DR GO; GO:0045742; P:positive regulation of epidermal growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IDA:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB. DR GO; GO:0048146; P:positive regulation of fibroblast proliferation; IEA:Ensembl. DR GO; GO:1900087; P:positive regulation of G1/S transition of mitotic cell cycle; IMP:BHF-UCL. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:ARUK-UCL. DR GO; GO:1902895; P:positive regulation of miRNA transcription; IMP:BHF-UCL. DR GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IMP:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:BHF-UCL. DR GO; GO:0042327; P:positive regulation of phosphorylation; IDA:UniProtKB. DR GO; GO:0090037; P:positive regulation of protein kinase C signaling; IDA:ParkinsonsUK-UCL. DR GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IDA:ParkinsonsUK-UCL. DR GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0051205; P:protein insertion into membrane; TAS:UniProtKB. DR GO; GO:0016567; P:protein ubiquitination; IEA:Ensembl. DR GO; GO:0050730; P:regulation of peptidyl-tyrosine phosphorylation; IMP:UniProtKB. DR GO; GO:0070141; P:response to UV-A; IDA:BHF-UCL. DR GO; GO:0007435; P:salivary gland morphogenesis; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; IDA:UniProtKB. DR GO; GO:0070086; P:ubiquitin-dependent endocytosis; IEA:Ensembl. DR GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IEA:Ensembl. DR GO; GO:0042908; P:xenobiotic transport; IEA:Ensembl. DR CDD; cd00064; FU; 3. DR CDD; cd05108; PTKc_EGFR; 1. DR CDD; cd12093; TM_ErbB1; 1. DR DisProt; DP00309; -. DR FunFam; 1.10.510.10:FF:000027; Receptor protein-tyrosine kinase; 1. DR FunFam; 2.10.220.10:FF:000001; Receptor protein-tyrosine kinase; 1. DR FunFam; 2.10.220.10:FF:000008; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.30.200.20:FF:000044; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000005; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000006; Receptor protein-tyrosine kinase; 1. DR Gene3D; 2.10.220.10; Hormone Receptor, Insulin-like Growth Factor Receptor 1, Chain A, domain 2; 3. DR Gene3D; 1.20.5.420; Immunoglobulin FC, subunit C; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.20.20; Receptor L-domain; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00262; -. DR InterPro; IPR006211; Furin-like_Cys-rich_dom. DR InterPro; IPR006212; Furin_repeat. DR InterPro; IPR032778; GF_recep_IV. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR000494; Rcpt_L-dom. DR InterPro; IPR036941; Rcpt_L-dom_sf. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR049328; TM_ErbB1. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt. DR PANTHER; PTHR24416:SF91; EPIDERMAL GROWTH FACTOR RECEPTOR; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00757; Furin-like; 1. DR Pfam; PF14843; GF_recep_IV; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF01030; Recep_L_domain; 2. DR Pfam; PF21314; TM_ErbB1; 1. DR PIRSF; PIRSF000619; TyrPK_EGF-R; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00261; FU; 3. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 2. DR SUPFAM; SSF52058; L domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; KW Developmental protein; Direct protein sequencing; Disease variant; KW Disulfide bond; Endoplasmic reticulum; Endosome; Glycoprotein; KW Golgi apparatus; Host cell receptor for virus entry; KW Host-virus interaction; Hydroxylation; Isopeptide bond; Kinase; KW Lipoprotein; Membrane; Methylation; Nucleotide-binding; Nucleus; Palmitate; KW Phosphoprotein; Proteomics identification; Proto-oncogene; Receptor; KW Reference proteome; Repeat; Secreted; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..24 FT /evidence="ECO:0000269|PubMed:15340161, FT ECO:0000269|PubMed:6328312, ECO:0000269|Ref.16" FT CHAIN 25..1210 FT /note="Epidermal growth factor receptor" FT /id="PRO_0000016665" FT TOPO_DOM 25..645 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 646..668 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 669..1210 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT REPEAT 75..300 FT /note="Approximate" FT REPEAT 390..600 FT /note="Approximate" FT DOMAIN 712..979 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 688..704 FT /note="Important for dimerization, phosphorylation and FT activation" FT REGION 1097..1137 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1104..1115 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1128..1137 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 837 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 718..726 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:19563760, FT ECO:0007744|PDB:2GS7, ECO:0007744|PDB:3GT8, FT ECO:0007744|PDB:4ZSE, ECO:0007744|PDB:5CNN, FT ECO:0007744|PDB:5CNO, ECO:0007744|PDB:5D41" FT BINDING 745 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:17349580, FT ECO:0000269|PubMed:19563760, ECO:0007744|PDB:2EB3, FT ECO:0007744|PDB:2GS7, ECO:0007744|PDB:2ITN, FT ECO:0007744|PDB:3GT8, ECO:0007744|PDB:3VJN, FT ECO:0007744|PDB:3VJO, ECO:0007744|PDB:4RIW, FT ECO:0007744|PDB:4RIY, ECO:0007744|PDB:4ZSE, FT ECO:0007744|PDB:5CNN, ECO:0007744|PDB:5CNO, FT ECO:0007744|PDB:5D41" FT BINDING 790..791 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:17349580, FT ECO:0000269|PubMed:19563760, ECO:0007744|PDB:2EB3, FT ECO:0007744|PDB:2GS7, ECO:0007744|PDB:2ITN, FT ECO:0007744|PDB:2ITV, ECO:0007744|PDB:2ITX, FT ECO:0007744|PDB:3GT8, ECO:0007744|PDB:3VJN, FT ECO:0007744|PDB:3VJO, ECO:0007744|PDB:4RIW, FT ECO:0007744|PDB:4RIX, ECO:0007744|PDB:4RIY, FT ECO:0007744|PDB:4ZSE, ECO:0007744|PDB:5CNN, FT ECO:0007744|PDB:5CNO, ECO:0007744|PDB:5D41" FT BINDING 855 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:17349580, FT ECO:0000269|PubMed:19563760, ECO:0007744|PDB:2EB3, FT ECO:0007744|PDB:2GS7, ECO:0007744|PDB:2ITN, FT ECO:0007744|PDB:2ITV, ECO:0007744|PDB:2ITX, FT ECO:0007744|PDB:3GT8, ECO:0007744|PDB:3VJN, FT ECO:0007744|PDB:4RIW, ECO:0007744|PDB:4RIX, FT ECO:0007744|PDB:4RIY, ECO:0007744|PDB:4ZSE, FT ECO:0007744|PDB:5CNN, ECO:0007744|PDB:5CNO, FT ECO:0007744|PDB:5D41" FT SITE 1016 FT /note="Important for interaction with PIK3C2B" FT MOD_RES 229 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:21487020" FT MOD_RES 678 FT /note="Phosphothreonine; by PKC and PKD/PRKD1" FT /evidence="ECO:0000269|PubMed:10523301" FT MOD_RES 693 FT /note="Phosphothreonine; by PKD/PRKD1" FT /evidence="ECO:0000269|PubMed:10523301, FT ECO:0000269|PubMed:16083266, ECO:0000269|PubMed:3138233, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 695 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:3138233, FT ECO:0007744|PubMed:18691976" FT MOD_RES 745 FT /note="N6-(2-hydroxyisobutyryl)lysine" FT /evidence="ECO:0000269|PubMed:29192674" FT MOD_RES 869 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:23774213" FT MOD_RES 991 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:16083266, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:24275569" FT MOD_RES 995 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 998 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:19563760, FT ECO:0007744|PubMed:18669648" FT MOD_RES 1016 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:19563760, FT ECO:0000269|PubMed:23774213" FT MOD_RES 1026 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:16083266, FT ECO:0007744|PubMed:24275569" FT MOD_RES 1039 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 1041 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 1042 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 1064 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1069 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:23774213, FT ECO:0000305|PubMed:22888118" FT MOD_RES 1070 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:3138233" FT MOD_RES 1071 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:3138233" FT MOD_RES 1081 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 1092 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12873986, FT ECO:0000269|PubMed:23774213, ECO:0000269|PubMed:27153536" FT MOD_RES 1110 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12873986, FT ECO:0000269|PubMed:2543678" FT MOD_RES 1166 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:24275569" FT MOD_RES 1172 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:26918609, FT ECO:0000269|PubMed:27153536, ECO:0007744|PubMed:17081983" FT MOD_RES 1197 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:19563760, FT ECO:0000269|PubMed:19836242, ECO:0000269|PubMed:23774213, FT ECO:0000269|PubMed:27153536, ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:20068231" FT MOD_RES 1199 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000269|PubMed:21258366" FT LIPID 1049 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000269|PubMed:27153536" FT LIPID 1146 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000269|PubMed:27153536" FT CARBOHYD 56 FT /note="N-linked (GlcNAc...) (complex) asparagine; atypical; FT partial" FT /evidence="ECO:0000269|PubMed:10731668, FT ECO:0000269|PubMed:12297049, ECO:0000269|PubMed:12297050, FT ECO:0000269|PubMed:12731890, ECO:0000269|PubMed:16083266, FT ECO:0000269|PubMed:20837704, ECO:0007744|PDB:1IVO, FT ECO:0007744|PDB:1MOX, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ" FT /id="CAR_000227" FT CARBOHYD 73 FT /note="N-linked (GlcNAc...) asparagine; atypical" FT /evidence="ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:3NJP" FT CARBOHYD 128 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:12731890, FT ECO:0000269|PubMed:16083266, ECO:0000269|PubMed:8962717" FT CARBOHYD 175 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:12297050, FT ECO:0000269|PubMed:12731890, ECO:0000269|PubMed:16083266, FT ECO:0000269|PubMed:20837704, ECO:0000269|PubMed:8962717, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:3NJP" FT CARBOHYD 196 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12731890, FT ECO:0000269|PubMed:16083266, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:3NJP" FT CARBOHYD 352 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:10731668, FT ECO:0000269|PubMed:12297049, ECO:0000269|PubMed:12297050, FT ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:12731890, FT ECO:0000269|PubMed:16083266, ECO:0000269|PubMed:19159218, FT ECO:0000269|PubMed:20837704, ECO:0007744|PDB:1IVO, FT ECO:0007744|PDB:1MOX, ECO:0007744|PDB:1NQL, FT ECO:0007744|PDB:1YY9, ECO:0007744|PDB:3B2U, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3P0Y, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRL, ECO:0007744|PDB:4KRM, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7" FT CARBOHYD 361 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:10731668, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:12731890, ECO:0000269|PubMed:16083266, FT ECO:0000269|PubMed:20837704, ECO:0007744|PDB:1IVO, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2U, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRL, FT ECO:0007744|PDB:4KRM, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UV7" FT CARBOHYD 413 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:12731890, FT ECO:0000269|PubMed:16083266, ECO:0000269|PubMed:19159218, FT ECO:0000269|PubMed:8962717, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2U, ECO:0007744|PDB:3B2V, FT ECO:0007744|PDB:3P0Y, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP" FT CARBOHYD 444 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:12297050, FT ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:12731890, FT ECO:0000269|PubMed:16083266, ECO:0000269|PubMed:20837704, FT ECO:0000269|PubMed:8962717, ECO:0007744|PDB:1IVO, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2U, ECO:0007744|PDB:3B2V, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3P0Y, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRL, FT ECO:0007744|PDB:4KRM, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7" FT CARBOHYD 528 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:12731890, ECO:0000269|PubMed:16083266, FT ECO:0000269|PubMed:20837704, ECO:0000269|PubMed:25922362, FT ECO:0000269|PubMed:8962717, ECO:0007744|PDB:1NQL, FT ECO:0007744|PDB:1YY9, ECO:0007744|PDB:3B2V, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7" FT CARBOHYD 568 FT /note="N-linked (GlcNAc...) asparagine; partial" FT /evidence="ECO:0000269|PubMed:10731668, FT ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:12731890, FT ECO:0000269|PubMed:16083266, ECO:0000269|PubMed:19159218, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9" FT CARBOHYD 603 FT /note="N-linked (GlcNAc...) asparagine; partial" FT /evidence="ECO:0000269|PubMed:10731668, FT ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:12731890, FT ECO:0000269|PubMed:16083266, ECO:0007744|PDB:1NQL, FT ECO:0007744|PDB:1YY9" FT CARBOHYD 623 FT /note="N-linked (GlcNAc...) (high mannose) asparagine" FT /evidence="ECO:0000305|PubMed:12731890" FT DISULFID 31..58 FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD" FT DISULFID 157..187 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:5WB7, FT ECO:0007744|PDB:5WB8, ECO:0007744|PDB:5XWD" FT DISULFID 190..199 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5WB7, FT ECO:0007744|PDB:5WB8, ECO:0007744|PDB:5XWD" FT DISULFID 194..207 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5WB7, FT ECO:0007744|PDB:5WB8, ECO:0007744|PDB:5XWD" FT DISULFID 215..223 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD" FT DISULFID 219..231 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD" FT DISULFID 232..240 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD" FT DISULFID 236..248 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD" FT DISULFID 251..260 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD" FT DISULFID 264..291 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5WB7, FT ECO:0007744|PDB:5WB8, ECO:0007744|PDB:5XWD" FT DISULFID 295..307 FT /evidence="ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5WB7, FT ECO:0007744|PDB:5WB8, ECO:0007744|PDB:5XWD" FT DISULFID 311..326 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3G5V, FT ECO:0007744|PDB:3G5Y, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD" FT DISULFID 329..333 FT /evidence="ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5WB7, FT ECO:0007744|PDB:5WB8, ECO:0007744|PDB:5XWD" FT DISULFID 337..362 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2U, ECO:0007744|PDB:3B2V, FT ECO:0007744|PDB:3C09, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3P0Y, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRL, ECO:0007744|PDB:4KRM, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5SX4, ECO:0007744|PDB:5SX5, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD, ECO:0007744|PDB:6B3S" FT DISULFID 470..499 FT /evidence="ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2U, ECO:0007744|PDB:3B2V, FT ECO:0007744|PDB:3C09, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3P0Y, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRL, ECO:0007744|PDB:4KRM, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5SX4, ECO:0007744|PDB:5SX5, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD, ECO:0007744|PDB:6B3S" FT DISULFID 506..515 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2U, ECO:0007744|PDB:3B2V, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3P0Y, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRL, FT ECO:0007744|PDB:4KRM, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5SX4, FT ECO:0007744|PDB:5SX5, ECO:0007744|PDB:5WB7, FT ECO:0007744|PDB:5WB8, ECO:0007744|PDB:5XWD, FT ECO:0007744|PDB:6B3S" FT DISULFID 510..523 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2U, ECO:0007744|PDB:3B2V, FT ECO:0007744|PDB:3C09, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3P0Y, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRL, ECO:0007744|PDB:4KRM, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5SX4, ECO:0007744|PDB:5SX5, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD, ECO:0007744|PDB:6B3S" FT DISULFID 526..535 FT /evidence="ECO:0000269|PubMed:12297050, FT ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:15837620, FT ECO:0000269|PubMed:20837704, ECO:0007744|PDB:1IVO, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRL, FT ECO:0007744|PDB:4KRM, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5XWD" FT DISULFID 539..555 FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5XWD" FT DISULFID 558..571 FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5XWD" FT DISULFID 562..579 FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5XWD" FT DISULFID 582..591 FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5XWD" FT DISULFID 595..617 FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5XWD" FT DISULFID 620..628 FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5XWD" FT DISULFID 624..636 FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5XWD" FT CROSSLNK 716 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:16543144, FT ECO:0000269|PubMed:33996800" FT CROSSLNK 737 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:16543144, FT ECO:0000269|PubMed:33996800" FT CROSSLNK 754 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:16543144, FT ECO:0000269|PubMed:33996800" FT CROSSLNK 757 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:33996800" FT CROSSLNK 867 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:16543144, FT ECO:0000269|PubMed:33996800" FT CROSSLNK 929 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:16543144" FT CROSSLNK 960 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:33996800" FT CROSSLNK 970 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:16543144" FT VAR_SEQ 404..405 FT /note="FL -> LS (in isoform 2)" FT /evidence="ECO:0000303|PubMed:7654368, FT ECO:0000303|PubMed:8918811, ECO:0000303|PubMed:9103388, FT ECO:0000303|Ref.6" FT /id="VSP_002887" FT VAR_SEQ 406..1210 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:7654368, FT ECO:0000303|PubMed:8918811, ECO:0000303|PubMed:9103388, FT ECO:0000303|Ref.6" FT /id="VSP_002888" FT VAR_SEQ 628..705 FT /note="CTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTL FT RRLLQERELVEPLTPSGEAPNQALLR -> PGNESLKAMLFCLFKLSSCNQSNDGSVSH FT QSGSPAAQESCLGWIPSLLPSEFQLGWGGCSHLHAWPSASVIITASSCH (in FT isoform 3)" FT /evidence="ECO:0000303|PubMed:11161793" FT /id="VSP_002889" FT VAR_SEQ 628 FT /note="C -> S (in isoform 4)" FT /evidence="ECO:0000303|PubMed:11161793" FT /id="VSP_002891" FT VAR_SEQ 629..1210 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:11161793" FT /id="VSP_002892" FT VAR_SEQ 706..1210 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:11161793" FT /id="VSP_002890" FT VARIANT 30..297 FT /note="Missing (variant EGFR vIII; found in a lung cancer FT sample; somatic mutation; induces lung cancer when FT exogenously expressed)" FT /evidence="ECO:0000269|PubMed:16672372" FT /id="VAR_066493" FT VARIANT 98 FT /note="R -> Q (in dbSNP:rs17289589)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_019293" FT VARIANT 266 FT /note="P -> R (in dbSNP:rs17336639)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_019294" FT VARIANT 428 FT /note="G -> D (in NNCIS; loss of function; the mutant does FT not localize to the cell membrane; has diffuse cytoplasmic FT localization; dbSNP:rs606231253)" FT /evidence="ECO:0000269|PubMed:24691054" FT /id="VAR_072435" FT VARIANT 521 FT /note="R -> K (in dbSNP:rs2227983)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.7" FT /id="VAR_019295" FT VARIANT 674 FT /note="V -> I (in dbSNP:rs17337079)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_019296" FT VARIANT 709 FT /note="E -> A (found in a lung cancer sample; more FT sensitive to gefitinib than wild-type; dbSNP:rs397517085)" FT /evidence="ECO:0000269|PubMed:15623594, FT ECO:0000269|PubMed:16205628, ECO:0000269|PubMed:16533793" FT /id="VAR_026084" FT VARIANT 709 FT /note="E -> G (found in a lung cancer sample; FT constitutively activated kinase with higher levels of basal FT autophosphorylation; more sensitive to gefitinib than wild- FT type; dbSNP:rs397517085)" FT /evidence="ECO:0000269|PubMed:15623594, FT ECO:0000269|PubMed:16205628" FT /id="VAR_069498" FT VARIANT 709 FT /note="E -> K (found in a lung cancer sample; FT dbSNP:rs727504256)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026085" FT VARIANT 719 FT /note="G -> A (found in a lung cancer sample; FT dbSNP:rs121913428)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026086" FT VARIANT 719 FT /note="G -> C (found in a lung cancer sample; FT dbSNP:rs28929495)" FT /evidence="ECO:0000269|PubMed:15623594, FT ECO:0000269|PubMed:16533793" FT /id="VAR_026087" FT VARIANT 719 FT /note="G -> D (found in a lung cancer sample; FT dbSNP:rs121913428)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026088" FT VARIANT 719 FT /note="G -> S (found in a lung cancer sample; somatic FT mutation; strongly increased kinase activity; FT constitutively activated kinase with higher levels of basal FT autophosphorylation; more sensitive to gefitinib than wild- FT type; dbSNP:rs28929495)" FT /evidence="ECO:0000269|PubMed:15118125, FT ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628, FT ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:17349580" FT /id="VAR_019297" FT VARIANT 724 FT /note="G -> S (found in a lung cancer sample; FT dbSNP:rs1051753269)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026089" FT VARIANT 734 FT /note="E -> K (found in a lung cancer sample; FT dbSNP:rs121913420)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026090" FT VARIANT 746..752 FT /note="ELREATS -> D (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:15623594" FT /id="VAR_069499" FT VARIANT 746..751 FT /note="ELREAT -> A (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:15623594" FT /id="VAR_069500" FT VARIANT 746..750 FT /note="Missing (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:15623594" FT /id="VAR_026092" FT VARIANT 746 FT /note="Missing (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026091" FT VARIANT 747..751 FT /note="Missing (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:15623594" FT /id="VAR_069501" FT VARIANT 747..749 FT /note="Missing (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026094" FT VARIANT 747 FT /note="L -> F (found in a lung cancer sample; FT dbSNP:rs2128954811)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026093" FT VARIANT 748 FT /note="R -> P (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026095" FT VARIANT 752..759 FT /note="Missing (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026096" FT VARIANT 768 FT /note="S -> I (found in a lung cancer sample; FT constitutively activated kinase with higher levels of basal FT autophosphorylation; more sensitive to gefitinib than wild- FT type; dbSNP:rs121913465)" FT /evidence="ECO:0000269|PubMed:15623594, FT ECO:0000269|PubMed:16205628" FT /id="VAR_069502" FT VARIANT 769 FT /note="V -> M (found in a lung cancer sample; FT dbSNP:rs147149347)" FT /evidence="ECO:0000269|PubMed:15623594" FT /id="VAR_069503" FT VARIANT 787 FT /note="Q -> R (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026097" FT VARIANT 790 FT /note="T -> M (found in a lung cancer sample; increased FT kinase activity; dbSNP:rs121434569)" FT /evidence="ECO:0000269|PubMed:16533793, FT ECO:0000269|PubMed:18227510" FT /id="VAR_026098" FT VARIANT 833 FT /note="L -> V (found in a lung cancer sample; more FT sensitive to gefitinib than wild-type; dbSNP:rs397517126)" FT /evidence="ECO:0000269|PubMed:15623594, FT ECO:0000269|PubMed:16205628, ECO:0000269|PubMed:16533793" FT /id="VAR_026099" FT VARIANT 834 FT /note="V -> L (found in a lung cancer sample; FT dbSNP:rs397517127)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026100" FT VARIANT 835 FT /note="H -> L (found in a lung cancer sample; more FT sensitive to gefitinib than wild-type; dbSNP:rs397517128)" FT /evidence="ECO:0000269|PubMed:15623594, FT ECO:0000269|PubMed:16205628" FT /id="VAR_069504" FT VARIANT 838 FT /note="L -> V (found in a lung cancer sample; more FT sensitive to gefitinib than wild-type; dbSNP:rs864621996)" FT /evidence="ECO:0000269|PubMed:15623594, FT ECO:0000269|PubMed:16205628" FT /id="VAR_069505" FT VARIANT 858 FT /note="L -> M (found in a lung cancer sample; FT dbSNP:rs121913443)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026101" FT VARIANT 858 FT /note="L -> R (found in a lung cancer sample; somatic FT mutation; constitutively activated enzyme with strongly FT increased kinase activity; more sensitive to gefitinib than FT wild-type; dbSNP:rs121434568)" FT /evidence="ECO:0000269|PubMed:15118125, FT ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628, FT ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:17349580" FT /id="VAR_019298" FT VARIANT 861 FT /note="L -> Q (found in a lung cancer sample; FT constitutively activated kinase with higher levels of basal FT autophosphorylation; more sensitive to gefitinib than wild- FT type; dbSNP:rs121913444)" FT /evidence="ECO:0000269|PubMed:15623594, FT ECO:0000269|PubMed:16205628, ECO:0000269|PubMed:16533793" FT /id="VAR_026102" FT VARIANT 873 FT /note="G -> E (found in a lung cancer sample; FT dbSNP:rs2128964711)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026103" FT VARIANT 962 FT /note="R -> G (in dbSNP:rs17337451)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_019299" FT VARIANT 988 FT /note="H -> P (in dbSNP:rs17290699)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_019300" FT VARIANT 1034 FT /note="L -> R (in dbSNP:rs34352568)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042095" FT VARIANT 1210 FT /note="A -> V (in dbSNP:rs35918369)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042096" FT MUTAGEN 275 FT /note="Y->A: Strongly reduced autophosphorylation and FT activation of downstream kinases; when associated with A- FT 309." FT /evidence="ECO:0000269|PubMed:12297050" FT MUTAGEN 287 FT /note="F->A: Strongly reduced autophosphorylation and FT activation of downstream kinases; when associated with A- FT 309." FT /evidence="ECO:0000269|PubMed:12297050" FT MUTAGEN 309 FT /note="R->S: Strongly reduced autophosphorylation and FT activation of downstream kinases; when associated with A- FT 275. Strongly reduced autophosphorylation and activation of FT downstream kinases; when associated with A-287." FT /evidence="ECO:0000269|PubMed:12297050" FT MUTAGEN 429 FT /note="R->E: Abolishes autophosphorylation and activation FT of downstream kinases." FT /evidence="ECO:0000269|PubMed:12297050" FT MUTAGEN 525..1210 FT /note="Missing: Increased EGF binding." FT /evidence="ECO:0000269|PubMed:19718021" FT MUTAGEN 587..590 FT /note="DGPH->AGPA: Decreases intramolecular interactions FT and facilitates EGF binding." FT /evidence="ECO:0000269|PubMed:12620237" FT MUTAGEN 587 FT /note="D->A: Increased EGF binding; when associated with A- FT 590 and A-609." FT /evidence="ECO:0000269|PubMed:19718021" FT MUTAGEN 590 FT /note="H->A: Increased EGF binding; when associated with A- FT 587; A-590 and A-609." FT /evidence="ECO:0000269|PubMed:19718021" FT MUTAGEN 609 FT /note="K->A: Decreases intramolecular interactions and FT facilitates EGF binding. Increased EGF binding; when FT associated with A-587; A-590 and A-609." FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:19718021" FT MUTAGEN 688 FT /note="L->A: Strongly reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417, FT ECO:0000269|PubMed:19563760" FT MUTAGEN 689 FT /note="V->A: Reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 689 FT /note="V->M: Constitutively activated kinase." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 690 FT /note="E->A: Reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417, FT ECO:0000269|PubMed:19563760" FT MUTAGEN 692 FT /note="L->A,P: Strongly reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417, FT ECO:0000269|PubMed:19563760" FT MUTAGEN 693 FT /note="T->A: Increased phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 693 FT /note="T->D: Strongly reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 694 FT /note="P->A: Strongly reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 699 FT /note="P->A: Reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 700 FT /note="N->A: Abolishes phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 704 FT /note="L->A: Abolishes phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 705 FT /note="R->A: Abolishes phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 706 FT /note="I->A: Abolishes phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 745 FT /note="K->A,M: Abolishes kinase activity." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 974 FT /note="D->A: Strongly reduced phosphorylation." FT MUTAGEN 977 FT /note="R->A: Reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:19563760" FT MUTAGEN 1005..1006 FT /note="ED->RK: Constitutively activated kinase." FT /evidence="ECO:0000269|PubMed:19563760" FT MUTAGEN 1016 FT /note="Y->F: 50% decrease in interaction with PIK3C2B. 65% FT decrease in interaction with PIK3C2B; when associated with FT F-1197. Abolishes interaction with PIK3C2B; when associated FT with F-1197 and F-1092." FT /evidence="ECO:0000269|PubMed:10805725" FT MUTAGEN 1048..1210 FT /note="Missing: Abolishes palmitoylation." FT /evidence="ECO:0000269|PubMed:27153536" FT MUTAGEN 1049 FT /note="C->A: Decreased palmitoylation." FT /evidence="ECO:0000269|PubMed:27153536" FT MUTAGEN 1067 FT /note="Q->G: No effect on interaction with CBLC." FT /evidence="ECO:0000269|PubMed:22888118" FT MUTAGEN 1068 FT /note="R->G: Strongly decreases interaction with CBLC." FT /evidence="ECO:0000269|PubMed:22888118" FT MUTAGEN 1069 FT /note="Y->F: Abolishes interaction with CBLC." FT /evidence="ECO:0000269|PubMed:22888118" FT MUTAGEN 1092 FT /note="Y->F: No change in interaction with PIK3C2B. FT Abolishes interaction with PIK3C2B; when associated with F- FT 1197 and F-1016." FT /evidence="ECO:0000269|PubMed:10805725" FT MUTAGEN 1110 FT /note="Y->F: No change in interaction with PIK3C2B." FT /evidence="ECO:0000269|PubMed:10805725" FT MUTAGEN 1146 FT /note="C->A: Decreased palmitoylation." FT /evidence="ECO:0000269|PubMed:27153536" FT MUTAGEN 1172 FT /note="Y->F: No change in interaction with PIK3C2B." FT /evidence="ECO:0000269|PubMed:10805725" FT MUTAGEN 1197 FT /note="Y->F: No change in interaction with PIK3C2B. 65% FT decrease in interaction with PIK3C2B; when associated with FT F-1016. Abolishes interaction with PIK3C2B; when associated FT with F-1092 and F-1016." FT /evidence="ECO:0000269|PubMed:10805725" FT CONFLICT 540 FT /note="N -> K (in Ref. 1; CAA25240)" FT /evidence="ECO:0000305" FT STRAND 40..43 FT /evidence="ECO:0007829|PDB:3QWQ" FT HELIX 44..55 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 60..69 FT /evidence="ECO:0007829|PDB:4UV7" FT HELIX 77..81 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 84..87 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 89..93 FT /evidence="ECO:0007829|PDB:4UV7" FT HELIX 101..103 FT /evidence="ECO:0007829|PDB:1IVO" FT TURN 114..116 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 117..122 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 125..129 FT /evidence="ECO:0007829|PDB:1MOX" FT STRAND 145..152 FT /evidence="ECO:0007829|PDB:4UV7" FT HELIX 159..161 FT /evidence="ECO:0007829|PDB:4UV7" FT HELIX 164..166 FT /evidence="ECO:0007829|PDB:4UV7" FT HELIX 170..173 FT /evidence="ECO:0007829|PDB:1MOX" FT STRAND 183..185 FT /evidence="ECO:0007829|PDB:5XWD" FT HELIX 195..197 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 199..204 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 211..214 FT /evidence="ECO:0007829|PDB:1MOX" FT STRAND 217..221 FT /evidence="ECO:0007829|PDB:5XWD" FT STRAND 223..227 FT /evidence="ECO:0007829|PDB:4UV7" FT HELIX 228..230 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 236..238 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 240..244 FT /evidence="ECO:0007829|PDB:4UV7" FT TURN 245..247 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 248..256 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 259..263 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 267..271 FT /evidence="ECO:0007829|PDB:4UV7" FT TURN 272..275 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 276..279 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 285..287 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 290..294 FT /evidence="ECO:0007829|PDB:4UV7" FT TURN 296..298 FT /evidence="ECO:0007829|PDB:3B2V" FT STRAND 299..301 FT /evidence="ECO:0007829|PDB:7LEN" FT STRAND 303..305 FT /evidence="ECO:0007829|PDB:4KRP" FT STRAND 306..310 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 313..315 FT /evidence="ECO:0007829|PDB:3B2V" FT STRAND 318..320 FT /evidence="ECO:0007829|PDB:3G5Y" FT STRAND 323..325 FT /evidence="ECO:0007829|PDB:3G5Y" FT STRAND 330..332 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 336..338 FT /evidence="ECO:0007829|PDB:3P0Y" FT TURN 340..342 FT /evidence="ECO:0007829|PDB:3QWQ" FT HELIX 343..345 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 349..351 FT /evidence="ECO:0007829|PDB:3P0Y" FT TURN 353..355 FT /evidence="ECO:0007829|PDB:3P0Y" FT HELIX 356..359 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 363..367 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 369..371 FT /evidence="ECO:0007829|PDB:3P0Y" FT HELIX 373..377 FT /evidence="ECO:0007829|PDB:3P0Y" FT TURN 380..383 FT /evidence="ECO:0007829|PDB:3P0Y" FT HELIX 389..397 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 400..403 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 405..407 FT /evidence="ECO:0007829|PDB:3P0Y" FT HELIX 418..420 FT /evidence="ECO:0007829|PDB:3P0Y" FT TURN 433..435 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 436..442 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 458..464 FT /evidence="ECO:0007829|PDB:3P0Y" FT HELIX 472..474 FT /evidence="ECO:0007829|PDB:3P0Y" FT HELIX 477..480 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 481..483 FT /evidence="ECO:0007829|PDB:1YY9" FT STRAND 488..494 FT /evidence="ECO:0007829|PDB:3P0Y" FT HELIX 496..501 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 508..510 FT /evidence="ECO:0007829|PDB:5SX4" FT STRAND 515..519 FT /evidence="ECO:0007829|PDB:3P0Y" FT HELIX 520..522 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 523..526 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 531..533 FT /evidence="ECO:0007829|PDB:4KRL" FT STRAND 534..537 FT /evidence="ECO:0007829|PDB:8UKW" FT STRAND 540..546 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 548..551 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 554..557 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 560..562 FT /evidence="ECO:0007829|PDB:4KRO" FT STRAND 566..568 FT /evidence="ECO:0007829|PDB:8UKW" FT STRAND 570..575 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 578..587 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 590..594 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 597..602 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 606..611 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 615..619 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 622..624 FT /evidence="ECO:0007829|PDB:7SYE" FT STRAND 629..632 FT /evidence="ECO:0007829|PDB:4UV7" FT HELIX 633..635 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 643..646 FT /evidence="ECO:0007829|PDB:2KS1" FT HELIX 648..669 FT /evidence="ECO:0007829|PDB:2KS1" FT STRAND 671..673 FT /evidence="ECO:0007829|PDB:1Z9I" FT HELIX 679..684 FT /evidence="ECO:0007829|PDB:3GOP" FT HELIX 685..687 FT /evidence="ECO:0007829|PDB:3GOP" FT STRAND 688..692 FT /evidence="ECO:0007829|PDB:1Z9I" FT STRAND 694..697 FT /evidence="ECO:0007829|PDB:1Z9I" FT STRAND 703..706 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 709..711 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 712..720 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 722..731 FT /evidence="ECO:0007829|PDB:8A27" FT TURN 734..736 FT /evidence="ECO:0007829|PDB:5UG9" FT STRAND 740..749 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 753..767 FT /evidence="ECO:0007829|PDB:8A27" FT TURN 771..773 FT /evidence="ECO:0007829|PDB:8PO2" FT STRAND 777..781 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 783..785 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 787..791 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 794..797 FT /evidence="ECO:0007829|PDB:5ZWJ" FT HELIX 798..804 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 806..808 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 811..830 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 840..842 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 843..847 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 850..853 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 856..858 FT /evidence="ECO:0007829|PDB:7VRA" FT TURN 859..865 FT /evidence="ECO:0007829|PDB:8A2A" FT HELIX 866..868 FT /evidence="ECO:0007829|PDB:8A2D" FT STRAND 871..873 FT /evidence="ECO:0007829|PDB:6V66" FT STRAND 875..877 FT /evidence="ECO:0007829|PDB:5CZH" FT HELIX 878..880 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 883..888 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 893..908 FT /evidence="ECO:0007829|PDB:8A27" FT TURN 909..911 FT /evidence="ECO:0007829|PDB:7JXW" FT TURN 914..917 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 920..922 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 923..928 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 937..939 FT /evidence="ECO:0007829|PDB:8PO0" FT HELIX 941..950 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 951..953 FT /evidence="ECO:0007829|PDB:5JEB" FT HELIX 955..957 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 961..972 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 975..977 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 984..986 FT /evidence="ECO:0007829|PDB:5HG8" FT TURN 992..998 FT /evidence="ECO:0007829|PDB:5HG8" FT TURN 999..1003 FT /evidence="ECO:0007829|PDB:6S89" FT STRAND 1004..1010 FT /evidence="ECO:0007829|PDB:3W2S" FT HELIX 1013..1016 FT /evidence="ECO:0007829|PDB:8A2A" FT STRAND 1068..1070 FT /evidence="ECO:0007829|PDB:3PFV" FT STRAND 1091..1094 FT /evidence="ECO:0007829|PDB:8S1M" SQ SEQUENCE 1210 AA; 134277 MW; D8A2A50B4EFB6ED2 CRC64; MRPSGTAGAA LLALLAALCP ASRALEEKKV CQGTSNKLTQ LGTFEDHFLS LQRMFNNCEV VLGNLEITYV QRNYDLSFLK TIQEVAGYVL IALNTVERIP LENLQIIRGN MYYENSYALA VLSNYDANKT GLKELPMRNL QEILHGAVRF SNNPALCNVE SIQWRDIVSS DFLSNMSMDF QNHLGSCQKC DPSCPNGSCW GAGEENCQKL TKIICAQQCS GRCRGKSPSD CCHNQCAAGC TGPRESDCLV CRKFRDEATC KDTCPPLMLY NPTTYQMDVN PEGKYSFGAT CVKKCPRNYV VTDHGSCVRA CGADSYEMEE DGVRKCKKCE GPCRKVCNGI GIGEFKDSLS INATNIKHFK NCTSISGDLH ILPVAFRGDS FTHTPPLDPQ ELDILKTVKE ITGFLLIQAW PENRTDLHAF ENLEIIRGRT KQHGQFSLAV VSLNITSLGL RSLKEISDGD VIISGNKNLC YANTINWKKL FGTSGQKTKI ISNRGENSCK ATGQVCHALC SPEGCWGPEP RDCVSCRNVS RGRECVDKCN LLEGEPREFV ENSECIQCHP ECLPQAMNIT CTGRGPDNCI QCAHYIDGPH CVKTCPAGVM GENNTLVWKY ADAGHVCHLC HPNCTYGCTG PGLEGCPTNG PKIPSIATGM VGALLLLLVV ALGIGLFMRR RHIVRKRTLR RLLQERELVE PLTPSGEAPN QALLRILKET EFKKIKVLGS GAFGTVYKGL WIPEGEKVKI PVAIKELREA TSPKANKEIL DEAYVMASVD NPHVCRLLGI CLTSTVQLIT QLMPFGCLLD YVREHKDNIG SQYLLNWCVQ IAKGMNYLED RRLVHRDLAA RNVLVKTPQH VKITDFGLAK LLGAEEKEYH AEGGKVPIKW MALESILHRI YTHQSDVWSY GVTVWELMTF GSKPYDGIPA SEISSILEKG ERLPQPPICT IDVYMIMVKC WMIDADSRPK FRELIIEFSK MARDPQRYLV IQGDERMHLP SPTDSNFYRA LMDEEDMDDV VDADEYLIPQ QGFFSSPSTS RTPLLSSLSA TSNNSTVACI DRNGLQSCPI KEDSFLQRYS SDPTGALTED SIDDTFLPVP EYINQSVPKR PAGSVQNPVY HNQPLNPAPS RDPHYQDPHS TAVGNPEYLN TVQPTCVNST FDSPAHWAQK GSHQISLDNP DYQQDFFPKE AKPNGIFKGS TAENAEYLRV APQSSEFIGA // ID ITK_HUMAN Reviewed; 620 AA. AC Q08881; B2R752; Q32ML7; DT 01-OCT-1994, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-1994, sequence version 1. DT 28-JAN-2026, entry version 239. DE RecName: Full=Tyrosine-protein kinase ITK/TSK; DE EC=2.7.10.2; DE AltName: Full=Interleukin-2-inducible T-cell kinase; DE Short=IL-2-inducible T-cell kinase; DE AltName: Full=Kinase EMT; DE AltName: Full=T-cell-specific kinase; DE AltName: Full=Tyrosine-protein kinase Lyk; GN Name=ITK; Synonyms=EMT, LYK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND INDUCTION. RX PubMed=8504851; DOI=10.1016/0014-5793(93)81520-a; RA Tanaka N., Asao H., Ohtani K., Nakamura M., Sugamura K.; RT "A novel human tyrosine kinase gene inducible in T cells by interleukin RT 2."; RL FEBS Lett. 324:1-5(1993). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Thymus; RX PubMed=8364206; RA Gibson S., Leung B., Squire J.A., Hill M., Arima N., Goss P., Hogg D., RA Mills G.B.; RT "Identification, cloning, and characterization of a novel human T-cell- RT specific tyrosine kinase located at the hematopoietin complex on chromosome RT 5q."; RL Blood 82:1561-1572(1993). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Thymus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP PROTEIN SEQUENCE OF 171-192, AND PHOSPHORYLATION AT TYR-180. RX PubMed=12573241; DOI=10.1016/s1570-9639(02)00524-1; RA Nore B.F., Mattsson P.T., Antonsson P., Backesjo C.-M., Westlund A., RA Lennartsson J., Hansson H., Low P., Ronnstrand L., Smith C.I.E.; RT "Identification of phosphorylation sites within the SH3 domains of Tec RT family tyrosine kinases."; RL Biochim. Biophys. Acta 1645:123-132(2003). RN [7] RP PHOSPHORYLATION BY LCK. RX PubMed=9312162; DOI=10.1074/jbc.272.40.25401; RA Heyeck S.D., Wilcox H.M., Bunnell S.C., Berg L.J.; RT "Lck phosphorylates the activation loop tyrosine of the Itk kinase domain RT and activates Itk kinase activity."; RL J. Biol. Chem. 272:25401-25408(1997). RN [8] RP INDUCTION. RX PubMed=9701039; DOI=10.1093/intimm/10.7.1009; RA King P.D., Sadra A., Teng J.M., Bell G.M., Dupont B.; RT "CD2-mediated activation of the Tec-family tyrosine kinase ITK is RT controlled by proline-rich stretch-4 of the CD2 cytoplasmic tail."; RL Int. Immunol. 10:1009-1016(1998). RN [9] RP DOMAIN. RX PubMed=10795735; DOI=10.1016/s1074-7613(00)80189-2; RA Yang W.C., Collette Y., Nunes J.A., Olive D.; RT "Tec kinases: a family with multiple roles in immunity."; RL Immunity 12:373-382(2000). RN [10] RP FUNCTION IN PHOSPHORYLATION OF LAT. RX PubMed=12186560; DOI=10.1021/bi025554o; RA Perez-Villar J.J., Whitney G.S., Sitnick M.T., Dunn R.J., Venkatesan S., RA O'Day K., Schieven G.L., Lin T.A., Kanner S.B.; RT "Phosphorylation of the linker for activation of T-cells by Itk promotes RT recruitment of Vav."; RL Biochemistry 41:10732-10740(2002). RN [11] RP FUNCTION. RX PubMed=12682224; DOI=10.4049/jimmunol.170.8.3971; RA Grasis J.A., Browne C.D., Tsoukas C.D.; RT "Inducible T cell tyrosine kinase regulates actin-dependent cytoskeletal RT events induced by the T cell antigen receptor."; RL J. Immunol. 170:3971-3976(2003). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=15144186; DOI=10.1021/ac035352d; RA Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M., RA Peters E.C.; RT "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from RT human T cells using immobilized metal affinity chromatography and tandem RT mass spectrometry."; RL Anal. Chem. 76:2763-2772(2004). RN [13] RP INTERACTION WITH PPIA/CYPA, AND MUTAGENESIS OF PRO-288. RX PubMed=15308100; DOI=10.1016/j.immuni.2004.07.005; RA Colgan J., Asmal M., Neagu M., Yu B., Schneidkraut J., Lee Y., RA Sokolskaja E., Andreotti A., Luban J.; RT "Cyclophilin A regulates TCR signal strength in CD4+ T cells via a proline- RT directed conformational switch in Itk."; RL Immunity 21:189-201(2004). RN [14] RP INTERACTION WITH VAV1. RX PubMed=15661896; DOI=10.4049/jimmunol.174.3.1385; RA Dombroski D., Houghtling R.A., Labno C.M., Precht P., Takesono A., RA Caplen N.J., Billadeau D.D., Wange R.L., Burkhardt J.K., Schwartzberg P.L.; RT "Kinase-independent functions for Itk in TCR-induced regulation of Vav and RT the actin cytoskeleton."; RL J. Immunol. 174:1385-1392(2005). RN [15] RP SUBCELLULAR LOCATION. RX PubMed=17060314; DOI=10.1074/jbc.m609180200; RA Qi Q., Sahu N., August A.; RT "Tec kinase Itk forms membrane clusters specifically in the vicinity of RT recruiting receptors."; RL J. Biol. Chem. 281:38529-38534(2006). RN [16] RP INTERACTION WITH FASLG. RX PubMed=19807924; DOI=10.1186/1471-2172-10-53; RA Voss M., Lettau M., Janssen O.; RT "Identification of SH3 domain interaction partners of human FasL (CD178) by RT phage display screening."; RL BMC Immunol. 10:53-53(2009). RN [17] RP AUTOPHOSPHORYLATION. RX PubMed=19523959; DOI=10.1016/j.jmb.2009.06.023; RA Joseph R.E., Severin A., Min L., Fulton D.B., Andreotti A.H.; RT "SH2-dependent autophosphorylation within the Tec family kinase Itk."; RL J. Mol. Biol. 391:164-177(2009). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-512 AND SER-565, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [19] RP UBIQUITINATION. RX PubMed=20596523; DOI=10.1371/journal.pone.0011332; RA Del Rincon S.V., Rogers J., Widschwendter M., Sun D., Sieburg H.B., RA Spruck C.; RT "Development and validation of a method for profiling post-translational RT modification activities using protein microarrays."; RL PLoS ONE 5:E11332-E11332(2010). RN [20] RP FUNCTION IN PHOSPHORYLATION OF LCP2. RX PubMed=21725281; DOI=10.1038/emboj.2011.213; RA Sela M., Bogin Y., Beach D., Oellerich T., Lehne J., Smith-Garvin J.E., RA Okumura M., Starosvetsky E., Kosoff R., Libman E., Koretzky G., RA Kambayashi T., Urlaub H., Wienands J., Chernoff J., Yablonski D.; RT "Sequential phosphorylation of SLP-76 at tyrosine 173 is required for RT activation of T and mast cells."; RL EMBO J. 30:3160-3172(2011). RN [21] RP STRUCTURE BY NMR OF 113-239. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the BTK motif and the SH3 domain of tyrosine-protein RT kinase ITK from human."; RL Submitted (OCT-2007) to the PDB data bank. RN [22] RP VARIANTS [LARGE SCALE ANALYSIS] LYS-19; LEU-23; GLN-451; TRP-581 AND RP ILE-587. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [23] RP VARIANT LPFS1 TRP-335, AND CHARACTERIZATION OF VARIANT LPSA1 TRP-335. RX PubMed=19425169; DOI=10.1172/jci37901; RA Huck K., Feyen O., Niehues T., Rueschendorf F., Huebner N., Laws H.-J., RA Telieps T., Knapp S., Wacker H.-H., Meindl A., Jumaa H., Borkhardt A.; RT "Girls homozygous for an IL-2-inducible T cell kinase mutation that leads RT to protein deficiency develop fatal EBV-associated lymphoproliferation."; RL J. Clin. Invest. 119:1350-1358(2009). CC -!- FUNCTION: Tyrosine kinase that plays an essential role in regulation of CC the adaptive immune response. Regulates the development, function and CC differentiation of conventional T-cells and nonconventional NKT-cells. CC When antigen presenting cells (APC) activate T-cell receptor (TCR), a CC series of phosphorylation lead to the recruitment of ITK to the cell CC membrane, in the vicinity of the stimulated TCR receptor, where it is CC phosphorylated by LCK. Phosphorylation leads to ITK autophosphorylation CC and full activation. Once activated, phosphorylates PLCG1, leading to CC the activation of this lipase and subsequent cleavage of its CC substrates. In turn, the endoplasmic reticulum releases calcium in the CC cytoplasm and the nuclear activator of activated T-cells (NFAT) CC translocates into the nucleus to perform its transcriptional duty. CC Phosphorylates 2 essential adapter proteins: the linker for activation CC of T-cells/LAT protein and LCP2. Then, a large number of signaling CC molecules such as VAV1 are recruited and ultimately lead to lymphokine CC production, T-cell proliferation and differentiation (PubMed:12186560, CC PubMed:12682224, PubMed:21725281). Required for TCR-mediated calcium CC response in gamma-delta T-cells, may also be involved in the modulation CC of the transcriptomic signature in the Vgamma2-positive subset of CC immature gamma-delta T-cells (By similarity). Phosphorylates TBX21 at CC 'Tyr-530' and mediates its interaction with GATA3 (By similarity). CC {ECO:0000250|UniProtKB:Q03526, ECO:0000269|PubMed:12186560, CC ECO:0000269|PubMed:12682224, ECO:0000269|PubMed:21725281}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250}; CC Note=Binds 1 zinc ion per subunit. {ECO:0000250}; CC -!- SUBUNIT: Homooligomerizes; this association negatively regulates kinase CC activity (By similarity). Interacts with PPIA/CYPA; this interaction CC regulates TCR signal strength via a proline-directed conformational CC switch in ITK. Interacts with THEMIS (By similarity). Interacts with CC FASLG. Interacts with VAV1; this interaction is important for VAV1 CC localization and TCR-induced actin polarization. Interacts with TBX21 CC (By similarity). {ECO:0000250|UniProtKB:Q03526, CC ECO:0000269|PubMed:15308100, ECO:0000269|PubMed:15661896, CC ECO:0000269|PubMed:19807924}. CC -!- INTERACTION: CC Q08881; P04626: ERBB2; NbExp=2; IntAct=EBI-968552, EBI-641062; CC Q08881; P48023: FASLG; NbExp=3; IntAct=EBI-968552, EBI-495538; CC Q08881; P08238: HSP90AB1; NbExp=3; IntAct=EBI-968552, EBI-352572; CC Q08881; Q13094: LCP2; NbExp=4; IntAct=EBI-968552, EBI-346946; CC Q08881; P31947: SFN; NbExp=2; IntAct=EBI-968552, EBI-476295; CC Q08881; P62258: YWHAE; NbExp=2; IntAct=EBI-968552, EBI-356498; CC Q08881; P10686: Plcg1; Xeno; NbExp=2; IntAct=EBI-968552, EBI-520788; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17060314}. Nucleus CC {ECO:0000250|UniProtKB:Q03526}. Note=Localizes in the vicinity of cell CC surface receptors in the plasma membrane after receptor stimulation. CC -!- TISSUE SPECIFICITY: T-cell lines and natural killer cell lines. CC -!- INDUCTION: Through a myriad of surface receptors including the TCR/CD3 CC signaling complex, coreceptors, or chemokine receptors. CC {ECO:0000269|PubMed:8504851, ECO:0000269|PubMed:9701039}. CC -!- DOMAIN: The N-terminal PH domain allows ITK to be recruited to the CC plasma membrane by an activated PI3 kinase. This domain also contains a CC proline-rich region (PRR). The adjoining domain is a SH3 domain, which CC binds to PRR (from itself or from other proteins). Next, a SH2 domain CC is required for binding tyrosine-phosphorylated substrates. In the C- CC terminal region, the kinase domain is required for tyrosine CC phosphorylation. {ECO:0000269|PubMed:10795735}. CC -!- PTM: Phosphorylated at Tyr-512 in the activation loop of the kinase CC domain by LCK. Subsequent autophosphorylation at Tyr-180 leads to the CC kinase activation. The autophosphorylated Tyr-180 lies within the CC substrate binding sequence of the SH3 domain. CC {ECO:0000269|PubMed:12573241, ECO:0000269|PubMed:9312162}. CC -!- PTM: Ubiquitinated. {ECO:0000269|PubMed:20596523}. CC -!- DISEASE: Lymphoproliferative syndrome 1 (LPFS1) [MIM:613011]: A rare CC immunodeficiency characterized by extreme susceptibility to infection CC with Epstein-Barr virus (EBV). Inadequate immune response to EBV can CC have a fatal outcome. Clinical features include splenomegaly, CC lymphadenopathy, anemia, thrombocytopenia, pancytopenia, recurrent CC infections. There is an increased risk for lymphoma. CC {ECO:0000269|PubMed:19425169}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. TEC subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/43329/ITK"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D13720; BAA02873.1; -; mRNA. DR EMBL; L10717; AAA36748.1; -; mRNA. DR EMBL; S65186; AAB28072.2; -; mRNA. DR EMBL; AK312846; BAG35699.1; -; mRNA. DR EMBL; CH471062; EAW61608.1; -; Genomic_DNA. DR EMBL; BC109077; AAI09078.1; -; mRNA. DR EMBL; BC109078; AAI09079.1; -; mRNA. DR CCDS; CCDS4336.1; -. DR PIR; S33253; S33253. DR RefSeq; NP_005537.3; NM_005546.3. DR PDB; 1SM2; X-ray; 2.30 A; A/B=357-620. DR PDB; 1SNU; X-ray; 2.50 A; A/B=357-620. DR PDB; 1SNX; X-ray; 3.20 A; A/B=357-620. DR PDB; 2E6I; NMR; -; A=113-169. DR PDB; 2LMJ; NMR; -; A=171-231. DR PDB; 2YUQ; NMR; -; A=162-239. DR PDB; 3MIY; X-ray; 1.67 A; A/B=357-620. DR PDB; 3MJ1; X-ray; 1.72 A; A=357-620. DR PDB; 3MJ2; X-ray; 1.90 A; A=357-620. DR PDB; 3QGW; X-ray; 2.10 A; A/B=357-620. DR PDB; 3QGY; X-ray; 2.10 A; A/B=357-620. DR PDB; 3T9T; X-ray; 1.65 A; A=354-620. DR PDB; 3V5J; X-ray; 2.59 A; A/B=357-620. DR PDB; 3V5L; X-ray; 1.86 A; A/B/C/D=357-620. DR PDB; 3V8T; X-ray; 2.00 A; A/B=357-620. DR PDB; 3V8W; X-ray; 2.27 A; A/B=357-620. DR PDB; 4HCT; X-ray; 1.48 A; A=354-620. DR PDB; 4HCU; X-ray; 1.43 A; A=354-620. DR PDB; 4HCV; X-ray; 1.48 A; A=354-620. DR PDB; 4KIO; X-ray; 2.18 A; A/B/C/D=357-620. DR PDB; 4L7S; X-ray; 2.03 A; A/B=357-620. DR PDB; 4M0Y; X-ray; 1.70 A; A=354-620. DR PDB; 4M0Z; X-ray; 2.00 A; A=354-620. DR PDB; 4M12; X-ray; 2.15 A; A=354-620. DR PDB; 4M13; X-ray; 1.85 A; A=354-620. DR PDB; 4M14; X-ray; 1.55 A; A=354-620. DR PDB; 4M15; X-ray; 1.52 A; A=354-620. DR PDB; 4MF0; X-ray; 2.67 A; A/B=357-620. DR PDB; 4MF1; X-ray; 2.11 A; A/B=357-620. DR PDB; 4PP9; X-ray; 2.58 A; A/B=357-620. DR PDB; 4PPA; X-ray; 2.67 A; A/B=357-620. DR PDB; 4PPB; X-ray; 2.82 A; A/B=357-620. DR PDB; 4PPC; X-ray; 2.95 A; A/B=357-620. DR PDB; 4PQN; X-ray; 1.71 A; A=357-620. DR PDB; 4QD6; X-ray; 2.45 A; A/B=357-620. DR PDB; 4RFM; X-ray; 2.10 A; A=357-620. DR PDBsum; 1SM2; -. DR PDBsum; 1SNU; -. DR PDBsum; 1SNX; -. DR PDBsum; 2E6I; -. DR PDBsum; 2LMJ; -. DR PDBsum; 2YUQ; -. DR PDBsum; 3MIY; -. DR PDBsum; 3MJ1; -. DR PDBsum; 3MJ2; -. DR PDBsum; 3QGW; -. DR PDBsum; 3QGY; -. DR PDBsum; 3T9T; -. DR PDBsum; 3V5J; -. DR PDBsum; 3V5L; -. DR PDBsum; 3V8T; -. DR PDBsum; 3V8W; -. DR PDBsum; 4HCT; -. DR PDBsum; 4HCU; -. DR PDBsum; 4HCV; -. DR PDBsum; 4KIO; -. DR PDBsum; 4L7S; -. DR PDBsum; 4M0Y; -. DR PDBsum; 4M0Z; -. DR PDBsum; 4M12; -. DR PDBsum; 4M13; -. DR PDBsum; 4M14; -. DR PDBsum; 4M15; -. DR PDBsum; 4MF0; -. DR PDBsum; 4MF1; -. DR PDBsum; 4PP9; -. DR PDBsum; 4PPA; -. DR PDBsum; 4PPB; -. DR PDBsum; 4PPC; -. DR PDBsum; 4PQN; -. DR PDBsum; 4QD6; -. DR PDBsum; 4RFM; -. DR AlphaFoldDB; Q08881; -. DR BMRB; Q08881; -. DR SMR; Q08881; -. DR BioGRID; 109907; 55. DR CORUM; Q08881; -. DR DIP; DIP-29974N; -. DR FunCoup; Q08881; 1866. DR IntAct; Q08881; 45. DR MINT; Q08881; -. DR STRING; 9606.ENSP00000398655; -. DR BindingDB; Q08881; -. DR ChEMBL; CHEMBL2959; -. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB06589; Pazopanib. DR DrugBank; DB14924; Ritlecitinib. DR DrugBank; DB02010; Staurosporine. DR DrugBank; DB15035; Zanubrutinib. DR DrugCentral; Q08881; -. DR GuidetoPHARMACOLOGY; 2046; -. DR GlyGen; Q08881; 1 site. DR iPTMnet; Q08881; -. DR PhosphoSitePlus; Q08881; -. DR BioMuta; ITK; -. DR DMDM; 585361; -. DR CPTAC; CPTAC-2862; -. DR CPTAC; CPTAC-2863; -. DR jPOST; Q08881; -. DR MassIVE; Q08881; -. DR PaxDb; 9606-ENSP00000398655; -. DR PeptideAtlas; Q08881; -. DR ProteomicsDB; 58650; -. DR Pumba; Q08881; -. DR ABCD; Q08881; 4 sequenced antibodies. DR Antibodypedia; 16533; 527 antibodies from 42 providers. DR DNASU; 3702; -. DR Ensembl; ENST00000422843.8; ENSP00000398655.4; ENSG00000113263.15. DR GeneID; 3702; -. DR KEGG; hsa:3702; -. DR MANE-Select; ENST00000422843.8; ENSP00000398655.4; NM_005546.4; NP_005537.3. DR UCSC; uc003lwo.2; human. DR AGR; HGNC:6171; -. DR ClinPGx; PA29968; -. DR CTD; 3702; -. DR DisGeNET; 3702; -. DR GeneCards; ITK; -. DR HGNC; HGNC:6171; ITK. DR HPA; ENSG00000113263; Tissue enriched (lymphoid). DR MalaCards; ITK; -. DR MIM; 186973; gene. DR MIM; 613011; phenotype. DR OpenTargets; ENSG00000113263; -. DR Orphanet; 538963; Combined immunodeficiency due to ITK deficiency. DR VEuPathDB; HostDB:ENSG00000113263; -. DR eggNOG; KOG0197; Eukaryota. DR GeneTree; ENSGT00940000158850; -. DR HOGENOM; CLU_000288_7_2_1; -. DR InParanoid; Q08881; -. DR OMA; GYWLEKT; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; Q08881; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q08881; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; Q08881; -. DR Reactome; R-HSA-202433; Generation of second messenger molecules. DR Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization. DR SignaLink; Q08881; -. DR SIGNOR; Q08881; -. DR Agora; ENSG00000113263; -. DR BioGRID-ORCS; 3702; 17 hits in 1184 CRISPR screens. DR CD-CODE; F345034F; Signaling cluster. DR ChiTaRS; ITK; human. DR EvolutionaryTrace; Q08881; -. DR GeneWiki; ITK_(gene); -. DR GenomeRNAi; 3702; -. DR Pharos; Q08881; Tclin. DR PRO; PR:Q08881; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; Q08881; protein. DR Bgee; ENSG00000113263; Expressed in granulocyte and 129 other cell types or tissues. DR ExpressionAtlas; Q08881; baseline and differential. DR GO; GO:0005911; C:cell-cell junction; IEA:Ensembl. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0002250; P:adaptive immune response; ISS:UniProtKB. DR GO; GO:0050853; P:B cell receptor signaling pathway; IBA:GO_Central. DR GO; GO:0006968; P:cellular defense response; TAS:ProtInc. DR GO; GO:0046629; P:gamma-delta T cell activation; ISS:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro. DR GO; GO:0001865; P:NK T cell differentiation; IBA:GO_Central. DR GO; GO:0001819; P:positive regulation of cytokine production; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0042110; P:T cell activation; TAS:UniProtKB. DR GO; GO:0050852; P:T cell receptor signaling pathway; ISS:UniProtKB. DR CDD; cd01238; PH_Btk; 1. DR CDD; cd05112; PTKc_Itk; 1. DR CDD; cd10396; SH2_Tec_Itk; 1. DR CDD; cd11908; SH3_ITK; 1. DR FunFam; 1.10.510.10:FF:000052; Tyrosine-protein kinase; 1. DR FunFam; 2.30.29.30:FF:000244; Tyrosine-protein kinase; 1. DR FunFam; 2.30.30.40:FF:000176; Tyrosine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000053; Tyrosine-protein kinase; 1. DR FunFam; 3.30.505.10:FF:000061; Tyrosine-protein kinase; 1. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR Gene3D; 3.30.505.10; SH2 domain; 1. DR Gene3D; 2.30.30.40; SH3 Domains; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR042785; ITK_PTKc. DR InterPro; IPR035583; ITK_SH3. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR050198; Non-receptor_tyrosine_kinases. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR001849; PH_domain. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR000980; SH2. DR InterPro; IPR036860; SH2_dom_sf. DR InterPro; IPR036028; SH3-like_dom_sf. DR InterPro; IPR001452; SH3_domain. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR001562; Znf_Btk_motif. DR PANTHER; PTHR24418; TYROSINE-PROTEIN KINASE; 1. DR Pfam; PF00779; BTK; 1. DR Pfam; PF00169; PH; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00017; SH2; 1. DR Pfam; PF00018; SH3_1; 1. DR PRINTS; PR00401; SH2DOMAIN. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00107; BTK; 1. DR SMART; SM00233; PH; 1. DR SMART; SM00252; SH2; 1. DR SMART; SM00326; SH3; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF50729; PH domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF55550; SH2 domain; 1. DR SUPFAM; SSF50044; SH3-domain; 1. DR PROSITE; PS50003; PH_DOMAIN; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS50001; SH2; 1. DR PROSITE; PS50002; SH3; 1. DR PROSITE; PS51113; ZF_BTK; 1. PE 1: Evidence at protein level; KW 3D-structure; Adaptive immunity; ATP-binding; Cytoplasm; KW Direct protein sequencing; Disease variant; Immunity; Kinase; KW Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; SH2 domain; SH3 domain; KW Transferase; Tyrosine-protein kinase; Ubl conjugation; Zinc; Zinc-finger. FT CHAIN 1..620 FT /note="Tyrosine-protein kinase ITK/TSK" FT /id="PRO_0000088106" FT DOMAIN 4..111 FT /note="PH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00145" FT DOMAIN 171..231 FT /note="SH3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00192" FT DOMAIN 239..338 FT /note="SH2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00191" FT DOMAIN 363..615 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ZN_FING 113..149 FT /note="Btk-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT ACT_SITE 482 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 121 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT BINDING 132 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT BINDING 133 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT BINDING 143 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT BINDING 369..377 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 391 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 180 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12573241" FT MOD_RES 512 FT /note="Phosphotyrosine; by LCK" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 565 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332" FT VARIANT 19 FT /note="R -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1753502279)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041710" FT VARIANT 23 FT /note="P -> L (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041711" FT VARIANT 193 FT /note="R -> Q (in dbSNP:rs17054374)" FT /id="VAR_051696" FT VARIANT 335 FT /note="R -> W (in LPFS1; shows nearly undetectable mutant FT ITK protein consistent with severe protein instability; FT dbSNP:rs121908191)" FT /evidence="ECO:0000269|PubMed:19425169" FT /id="VAR_063424" FT VARIANT 451 FT /note="R -> Q (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs779372373)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041712" FT VARIANT 581 FT /note="R -> W (in dbSNP:rs34482255)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041713" FT VARIANT 587 FT /note="V -> I (in dbSNP:rs56005928)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041714" FT MUTAGEN 288 FT /note="P->G: Complete loss of interaction with PPIA/CYPA." FT /evidence="ECO:0000269|PubMed:15308100" FT CONFLICT 171..172 FT /note="PE -> GS (in Ref. 6; AA sequence)" FT /evidence="ECO:0000305" FT CONFLICT 331 FT /note="V -> W (in Ref. 2; AAB28072)" FT /evidence="ECO:0000305" FT STRAND 127..133 FT /evidence="ECO:0007829|PDB:2E6I" FT STRAND 148..152 FT /evidence="ECO:0007829|PDB:2E6I" FT STRAND 171..173 FT /evidence="ECO:0007829|PDB:2YUQ" FT STRAND 175..180 FT /evidence="ECO:0007829|PDB:2LMJ" FT STRAND 187..189 FT /evidence="ECO:0007829|PDB:2YUQ" FT STRAND 197..205 FT /evidence="ECO:0007829|PDB:2LMJ" FT STRAND 208..212 FT /evidence="ECO:0007829|PDB:2LMJ" FT STRAND 214..216 FT /evidence="ECO:0007829|PDB:2LMJ" FT STRAND 218..221 FT /evidence="ECO:0007829|PDB:2LMJ" FT HELIX 223..225 FT /evidence="ECO:0007829|PDB:2LMJ" FT STRAND 226..228 FT /evidence="ECO:0007829|PDB:2LMJ" FT HELIX 360..362 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 363..371 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 373..375 FT /evidence="ECO:0007829|PDB:4KIO" FT STRAND 376..382 FT /evidence="ECO:0007829|PDB:4HCU" FT TURN 383..385 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 386..393 FT /evidence="ECO:0007829|PDB:4HCU" FT TURN 395..397 FT /evidence="ECO:0007829|PDB:3T9T" FT HELIX 400..411 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 421..425 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 427..436 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 443..448 FT /evidence="ECO:0007829|PDB:4HCU" FT TURN 449..452 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 456..475 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 485..487 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 488..490 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 492..494 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 496..498 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 503..506 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 510..513 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 522..524 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 527..532 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 537..552 FT /evidence="ECO:0007829|PDB:4HCU" FT TURN 553..555 FT /evidence="ECO:0007829|PDB:4PQN" FT TURN 558..561 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 564..572 FT /evidence="ECO:0007829|PDB:4HCU" FT STRAND 581..583 FT /evidence="ECO:0007829|PDB:3V8W" FT HELIX 585..594 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 599..601 FT /evidence="ECO:0007829|PDB:4HCU" FT HELIX 605..617 FT /evidence="ECO:0007829|PDB:4HCU" SQ SEQUENCE 620 AA; 71831 MW; DAE396BD2309319D CRC64; MNNFILLEEQ LIKKSQQKRR TSPSNFKVRF FVLTKASLAY FEDRHGKKRT LKGSIELSRI KCVEIVKSDI SIPCHYKYPF QVVHDNYLLY VFAPDRESRQ RWVLALKEET RNNNSLVPKY HPNFWMDGKW RCCSQLEKLA TGCAQYDPTK NASKKPLPPT PEDNRRPLWE PEETVVIALY DYQTNDPQEL ALRRNEEYCL LDSSEIHWWR VQDRNGHEGY VPSSYLVEKS PNNLETYEWY NKSISRDKAE KLLLDTGKEG AFMVRDSRTA GTYTVSVFTK AVVSENNPCI KHYHIKETND NPKRYYVAEK YVFDSIPLLI NYHQHNGGGL VTRLRYPVCF GRQKAPVTAG LRYGKWVIDP SELTFVQEIG SGQFGLVHLG YWLNKDKVAI KTIREGAMSE EDFIEEAEVM MKLSHPKLVQ LYGVCLEQAP ICLVFEFMEH GCLSDYLRTQ RGLFAAETLL GMCLDVCEGM AYLEEACVIH RDLAARNCLV GENQVIKVSD FGMTRFVLDD QYTSSTGTKF PVKWASPEVF SFSRYSSKSD VWSFGVLMWE VFSEGKIPYE NRSNSEVVED ISTGFRLYKP RLASTHVYQI MNHCWKERPE DRPAFSRLLR QLAEIAESGL // ID KC1E_HUMAN Reviewed; 416 AA. AC P49674; DT 01-FEB-1996, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1996, sequence version 1. DT 28-JAN-2026, entry version 234. DE RecName: Full=Casein kinase I isoform epsilon; DE Short=CKI-epsilon; DE Short=CKIe; DE EC=2.7.11.1 {ECO:0000269|PubMed:29222110}; GN Name=CSNK1E; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Placenta; RX PubMed=7797465; DOI=10.1074/jbc.270.25.14875; RA Fish K.J., Cegielska A., Getman M.E., Landes G.M., Virshup D.M.; RT "Isolation and characterization of human casein kinase I epsilon (CKI), a RT novel member of the CKI gene family."; RL J. Biol. Chem. 270:14875-14883(1995). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RA Ono K., Murata-Hori M., Hosoya H.; RT "Casein kinase I epsilon from HeLa cell."; RL Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH SOCS3, INDUCTION, AND RP FUNCTION. RC TISSUE=Hematopoietic stem cell; RX PubMed=15070676; DOI=10.1182/blood-2003-08-2768; RA Okamura A., Iwata N., Nagata A., Tamekane A., Shimoyama M., Gomyo H., RA Yakushijin K., Urahama N., Hamaguchi M., Fukui C., Chihara K., Ito M., RA Matsui T.; RT "Involvement of casein kinase Iepsilon in cytokine-induced granulocytic RT differentiation."; RL Blood 103:2997-3004(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84; RA Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A., RA Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J., RA Beare D.M., Dunham I.; RT "A genome annotation-driven approach to cloning the human ORFeome."; RL Genome Biol. 5:R84.1-R84.11(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=10591208; DOI=10.1038/990031; RA Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M., Clamp M., RA Smink L.J., Ainscough R., Almeida J.P., Babbage A.K., Bagguley C., RA Bailey J., Barlow K.F., Bates K.N., Beasley O.P., Bird C.P., Blakey S.E., RA Bridgeman A.M., Buck D., Burgess J., Burrill W.D., Burton J., Carder C., RA Carter N.P., Chen Y., Clark G., Clegg S.M., Cobley V.E., Cole C.G., RA Collier R.E., Connor R., Conroy D., Corby N.R., Coville G.J., Cox A.V., RA Davis J., Dawson E., Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., RA Ellington A.G., Evans K.L., Fey J.M., Fleming K., French L., Garner A.A., RA Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C., RA Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S., Hunt S.E., RA Jones M.C., Kershaw J., Kimberley A.M., King A., Laird G.K., Langford C.F., RA Leversha M.A., Lloyd C., Lloyd D.M., Martyn I.D., Mashreghi-Mohammadi M., RA Matthews L.H., Mccann O.T., Mcclay J., Mclaren S., McMurray A.A., RA Milne S.A., Mortimore B.J., Odell C.N., Pavitt R., Pearce A.V., Pearson D., RA Phillimore B.J.C.T., Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., RA Rogers L., Ross M.T., Scott C.E., Sehra H.K., Skuce C.D., Smalley S., RA Smith M.L., Soderlund C., Spragon L., Steward C.A., Sulston J.E., RA Swann R.M., Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L., RA Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L., RA Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N., RA Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J., Shintani A., RA Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S., Roe B.A., Chen F., Chu L., RA Crabtree J., Deschamps S., Do A., Do T., Dorman A., Fang F., Fu Y., Hu P., RA Hua A., Kenton S., Lai H., Lao H.I., Lewis J., Lewis S., Lin S.-P., Loh P., RA Malaj E., Nguyen T., Pan H., Phan S., Qi S., Qian Y., Ray L., Ren Q., RA Shaull S., Sloan D., Song L., Wang Q., Wang Y., Wang Z., White J., RA Willingham D., Wu H., Yao Z., Zhan M., Zhang G., Chissoe S., Murray J., RA Miller N., Minx P., Fulton R., Johnson D., Bemis G., Bentley D., RA Bradshaw H., Bourne S., Cordes M., Du Z., Fulton L., Goela D., Graves T., RA Hawkins J., Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., RA Rohlfing T., Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., RA Nelson J., Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R., RA Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S., Budarf M.L., RA McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E., Edelmann L., Kim U.J., RA Shizuya H., Simon M.I., Dumanski J.P., Peyrard M., Kedra D., Seroussi E., RA Fransson I., Tapia I., Bruder C.E., O'Brien K.P., Wilkinson P., RA Bodenteich A., Hartman K., Hu X., Khan A.S., Lane L., Tilahun Y., RA Wright H.; RT "The DNA sequence of human chromosome 22."; RL Nature 402:489-495(1999). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP INTERACTION WITH PER1. RX PubMed=10790862; DOI=10.1097/00001756-200004070-00011; RA Keesler G.A., Camacho F., Guo Y., Virshup D., Mondadori C., Yao Z.; RT "Phosphorylation and destabilization of human period I clock protein by RT human casein kinase I epsilon."; RL NeuroReport 11:951-955(2000). RN [8] RP ROLE IN WNT SIGNALING. RX PubMed=12556519; DOI=10.1074/jbc.m213265200; RA Hino S., Michiue T., Asashima M., Kikuchi A.; RT "Casein kinase I epsilon enhances the binding of Dvl-1 to Frat-1 and is RT essential for Wnt-3a-induced accumulation of beta-catenin."; RL J. Biol. Chem. 278:14066-14073(2003). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Lymphoblast; RX PubMed=14654843; DOI=10.1038/nature02166; RA Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.; RT "Proteomic characterization of the human centrosome by protein correlation RT profiling."; RL Nature 426:570-574(2003). RN [10] RP FUNCTION AS PER1 KINASE. RX PubMed=15917222; DOI=10.1074/jbc.m502862200; RA Shirogane T., Jin J., Ang X.L., Harper J.W.; RT "SCFbeta-TRCP controls clock-dependent transcription via casein kinase 1- RT dependent degradation of the mammalian period-1 (Per1) protein."; RL J. Biol. Chem. 280:26863-26872(2005). RN [11] RP INTERACTION WITH DBNDD2. RX PubMed=16618118; DOI=10.1021/bi052354e; RA Yin H., Laguna K.A., Li G., Kuret J.; RT "Dysbindin structural homologue CK1BP is an isoform-selective binding RT partner of human casein kinase-1."; RL Biochemistry 45:5297-5308(2006). RN [12] RP INTERACTION WITH LRP5 AND LRP6. RX PubMed=16513652; DOI=10.1074/jbc.m510580200; RA Swiatek W., Kang H., Garcia B.A., Shabanowitz J., Coombs G.S., Hunt D.F., RA Virshup D.M.; RT "Negative regulation of LRP6 function by casein kinase I epsilon RT phosphorylation."; RL J. Biol. Chem. 281:12233-12241(2006). RN [13] RP FUNCTION, AUTOPHOSPHORYLATION, DEPHOSPHORYLATION BY PPP5C, AND ACTIVITY RP REGULATION. RX PubMed=16790549; DOI=10.1073/pnas.0604138103; RA Partch C.L., Shields K.F., Thompson C.L., Selby C.P., Sancar A.; RT "Posttranslational regulation of the mammalian circadian clock by RT cryptochrome and protein phosphatase 5."; RL Proc. Natl. Acad. Sci. U.S.A. 103:10467-10472(2006). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-343; SER-354; THR-362 AND RP SER-363, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-363, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [16] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-343 AND SER-354, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-389, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [19] RP INTERACTION WITH SNAI1. RX PubMed=20305697; DOI=10.1038/onc.2010.77; RA Xu Y., Lee S.H., Kim H.S., Kim N.H., Piao S., Park S.H., Jung Y.S., RA Yook J.I., Park B.J., Ha N.C.; RT "Role of CK1 in GSK3beta-mediated phosphorylation and degradation of RT snail."; RL Oncogene 29:3124-3133(2010). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-363, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-389; SER-405 AND SER-408, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [23] RP FUNCTION, AND INTERACTION WITH DDX3X. RX PubMed=23413191; DOI=10.1126/science.1231499; RA Cruciat C.M., Dolde C., de Groot R.E., Ohkawara B., Reinhard C., RA Korswagen H.C., Niehrs C.; RT "RNA helicase DDX3 is a regulatory subunit of casein kinase 1 in Wnt-beta- RT catenin signaling."; RL Science 339:1436-1441(2013). RN [24] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [25] RP INTERACTION WITH DDX3X, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-38. RX PubMed=29222110; DOI=10.1242/jcs.207316; RA Dolde C., Bischof J., Grueter S., Montada A., Halekotte J., Peifer C., RA Kalbacher H., Baumann U., Knippschild U., Suter B.; RT "A CK1 FRET biosensor reveals that DDX3X is an essential activator of RT CK1epsilon."; RL J. Cell Sci. 131:0-0(2018). RN [26] RP INTERACTION WITH FAM83A; FAM83B; FAM83E AND FAM83H. RX PubMed=29789297; DOI=10.1126/scisignal.aao2341; RA Fulcher L.J., Bozatzi P., Tachie-Menson T., Wu K.Z.L., Cummins T.D., RA Bufton J.C., Pinkas D.M., Dunbar K., Shrestha S., Wood N.T., Weidlich S., RA Macartney T.J., Varghese J., Gourlay R., Campbell D.G., Dingwell K.S., RA Smith J.C., Bullock A.N., Sapkota G.P.; RT "The DUF1669 domain of FAM83 family proteins anchor casein kinase 1 RT isoforms."; RL Sci. Signal. 11:0-0(2018). RN [27] RP X-RAY CRYSTALLOGRAPHY (2.74 ANGSTROMS) OF 1-294 ALONE AND IN COMPLEX WITH RP INHIBITOR, AND SUBUNIT. RX PubMed=23106386; DOI=10.1021/jm301336n; RA Long A.M., Zhao H., Huang X.; RT "Structural basis for the potent and selective inhibition of casein kinase RT 1 epsilon."; RL J. Med. Chem. 55:10307-10311(2012). RN [28] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-256 AND ARG-413. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Casein kinases are operationally defined by their CC preferential utilization of acidic proteins such as caseins as CC substrates (Probable). Participates in Wnt signaling (PubMed:12556519, CC PubMed:23413191). Phosphorylates DVL1 (PubMed:12556519). Phosphorylates CC DVL2 (PubMed:23413191). Phosphorylates NEDD9/HEF1 (By similarity). CC Central component of the circadian clock (PubMed:16790549). In balance CC with PP1, determines the circadian period length, through the CC regulation of the speed and rhythmicity of PER1 and PER2 CC phosphorylation (PubMed:15917222, PubMed:16790549). Controls PER1 and CC PER2 nuclear transport and degradation (By similarity). Inhibits CC cytokine-induced granuloytic differentiation (PubMed:15070676). CC {ECO:0000250|UniProtKB:Q9JMK2, ECO:0000269|PubMed:12556519, CC ECO:0000269|PubMed:15070676, ECO:0000269|PubMed:15917222, CC ECO:0000269|PubMed:16790549, ECO:0000269|PubMed:23413191, CC ECO:0000305|PubMed:7797465}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:29222110}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609; CC Evidence={ECO:0000269|PubMed:29222110}; CC -!- ACTIVITY REGULATION: Phosphorylation leads to a decrease of the CC catalytic activity. {ECO:0000269|PubMed:16790549}. CC -!- SUBUNIT: Monomer (PubMed:23106386). Component of the circadian core CC oscillator, which includes the CRY proteins, CLOCK, or NPAS2, CC ARTNL/BMAL1 or ARTNL2/BMAL2, CSNK1D and/or CSNK1E, TIMELESS and the PER CC proteins (By similarity). Interacts with PER1 (PubMed:10790862). CC Interacts with ANKRD6 (By similarity). Interacts with DBNDD2 CC (PubMed:16618118). Interacts with LRP5 and LRP6 (PubMed:16513652). CC Interacts with SOCS3 (PubMed:15070676). Interacts with SNAI1 (via zinc CC fingers) (PubMed:20305697). Interacts with DDX3X; this interaction CC greatly enhances CSNK1E affinity for ATP and DVL2 phosphorylation, but CC inhibits DDX3X ATPase/helicase activity. In the presence of RNA, the CC interaction is decreased (PubMed:23413191, PubMed:29222110). Interacts CC with FAM83A, FAM83B, FAM83E and FAM83H (via DUF1669) (PubMed:29789297). CC {ECO:0000250|UniProtKB:Q9JMK2, ECO:0000269|PubMed:10790862, CC ECO:0000269|PubMed:15070676, ECO:0000269|PubMed:16513652, CC ECO:0000269|PubMed:16618118, ECO:0000269|PubMed:20305697, CC ECO:0000269|PubMed:23106386, ECO:0000269|PubMed:23413191, CC ECO:0000269|PubMed:29222110, ECO:0000269|PubMed:29789297}. CC -!- INTERACTION: CC P49674; P25054: APC; NbExp=8; IntAct=EBI-749343, EBI-727707; CC P49674; O15169: AXIN1; NbExp=5; IntAct=EBI-749343, EBI-710484; CC P49674; O14640: DVL1; NbExp=6; IntAct=EBI-749343, EBI-723489; CC P49674; O14641: DVL2; NbExp=4; IntAct=EBI-749343, EBI-740850; CC P49674; Q92997: DVL3; NbExp=9; IntAct=EBI-749343, EBI-739789; CC P49674; Q9BQ89: FAM110A; NbExp=3; IntAct=EBI-749343, EBI-1752811; CC P49674; Q1W6H9: FAM110C; NbExp=4; IntAct=EBI-749343, EBI-3942563; CC P49674; Q86UY5: FAM83A; NbExp=5; IntAct=EBI-749343, EBI-1384254; CC P49674; P08238: HSP90AB1; NbExp=2; IntAct=EBI-749343, EBI-352572; CC P49674; P23508: MCC; NbExp=9; IntAct=EBI-749343, EBI-307531; CC P49674; Q00987: MDM2; NbExp=3; IntAct=EBI-749343, EBI-389668; CC P49674; Q16625: OCLN; NbExp=10; IntAct=EBI-749343, EBI-2903088; CC P49674; O15055: PER2; NbExp=9; IntAct=EBI-749343, EBI-1054296; CC P49674; O75382: TRIM3; NbExp=3; IntAct=EBI-749343, EBI-2129889; CC P49674; P62258: YWHAE; NbExp=3; IntAct=EBI-749343, EBI-356498; CC P49674; Q04917: YWHAH; NbExp=3; IntAct=EBI-749343, EBI-306940; CC P49674; Q5T7W0: ZNF618; NbExp=7; IntAct=EBI-749343, EBI-6255994; CC P49674; O70239: Axin1; Xeno; NbExp=7; IntAct=EBI-749343, EBI-6857773; CC P49674; Q60838: Dvl2; Xeno; NbExp=3; IntAct=EBI-749343, EBI-641940; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Expressed in all tissues examined, including brain, CC heart, lung, liver, pancreas, kidney, placenta and skeletal muscle. CC Expressed in monocytes and lymphocytes but not in granulocytes. CC -!- INDUCTION: Down-regulated during granulocytic differentiation. CC {ECO:0000269|PubMed:15070676}. CC -!- PTM: Autophosphorylated. Partially dephosphorylated by PPP5C. May be CC dephosphorylated by PP1. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CK1 Ser/Thr CC protein kinase family. Casein kinase I subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L37043; AAC41761.1; -; mRNA. DR EMBL; AB024597; BAA92345.1; -; mRNA. DR EMBL; AB091043; BAC10902.1; -; mRNA. DR EMBL; CR456429; CAG30315.1; -; mRNA. DR EMBL; AL020993; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC006490; AAH06490.1; -; mRNA. DR PIR; I61744; I61744. DR RefSeq; NP_001885.1; NM_001894.5. DR RefSeq; NP_689407.1; NM_152221.3. DR PDB; 4HNI; X-ray; 2.74 A; A/B=1-294. DR PDB; 4HOK; X-ray; 2.77 A; A/C/E/G/I/K/M/O/Q/S/U/W=1-294. DR PDBsum; 4HNI; -. DR PDBsum; 4HOK; -. DR AlphaFoldDB; P49674; -. DR SMR; P49674; -. DR BioGRID; 107838; 342. DR BioGRID; 3196631; 5. DR CORUM; P49674; -. DR DIP; DIP-38050N; -. DR FunCoup; P49674; 4515. DR IntAct; P49674; 209. DR MINT; P49674; -. DR STRING; 9606.ENSP00000380044; -. DR BindingDB; P49674; -. DR ChEMBL; CHEMBL4937; -. DR DrugBank; DB03083; IC261. DR DrugBank; DB06195; Seliciclib. DR DrugBank; DB14989; Umbralisib. DR DrugCentral; P49674; -. DR GuidetoPHARMACOLOGY; 1998; -. DR GlyGen; P49674; 2 sites, 1 N-linked glycan (1 site). DR iPTMnet; P49674; -. DR PhosphoSitePlus; P49674; -. DR BioMuta; CSNK1E; -. DR DMDM; 1346369; -. DR CPTAC; CPTAC-3155; -. DR jPOST; P49674; -. DR MassIVE; P49674; -. DR PaxDb; 9606-ENSP00000380044; -. DR PeptideAtlas; P49674; -. DR ProteomicsDB; 56045; -. DR Pumba; P49674; -. DR Antibodypedia; 4043; 488 antibodies from 37 providers. DR DNASU; 1454; -. DR Ensembl; ENST00000359867.7; ENSP00000352929.3; ENSG00000213923.14. DR Ensembl; ENST00000396832.6; ENSP00000380044.1; ENSG00000213923.14. DR Ensembl; ENST00000403904.5; ENSP00000384074.1; ENSG00000213923.14. DR GeneID; 1454; -. DR KEGG; hsa:102800317; -. DR KEGG; hsa:1454; -. DR MANE-Select; ENST00000396832.6; ENSP00000380044.1; NM_152221.3; NP_689407.1. DR AGR; HGNC:2453; -. DR AGR; HGNC:53829; -. DR ClinPGx; PA26953; -. DR CTD; 1454; -. DR DisGeNET; 102800317; -. DR DisGeNET; 1454; -. DR GeneCards; CSNK1E; -. DR HGNC; HGNC:2453; CSNK1E. DR HPA; ENSG00000213923; Low tissue specificity. DR MalaCards; CSNK1E; -. DR MIM; 600863; gene. DR OpenTargets; ENSG00000213923; -. DR VEuPathDB; HostDB:ENSG00000213923; -. DR eggNOG; KOG1164; Eukaryota. DR GeneTree; ENSGT00940000153536; -. DR HOGENOM; CLU_019279_2_2_1; -. DR InParanoid; P49674; -. DR OMA; HDSKTRQ; -. DR OrthoDB; 5800476at2759; -. DR PAN-GO; P49674; 8 GO annotations based on evolutionary models. DR PhylomeDB; P49674; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; P49674; -. DR Reactome; R-HSA-201688; WNT mediated activation of DVL. DR Reactome; R-HSA-2565942; Regulation of PLK1 Activity at G2/M Transition. DR Reactome; R-HSA-380259; Loss of Nlp from mitotic centrosomes. DR Reactome; R-HSA-380270; Recruitment of mitotic centrosome proteins and complexes. DR Reactome; R-HSA-380284; Loss of proteins required for interphase microtubule organization from the centrosome. DR Reactome; R-HSA-380320; Recruitment of NuMA to mitotic centrosomes. DR Reactome; R-HSA-5620912; Anchoring of the basal body to the plasma membrane. DR Reactome; R-HSA-6791226; Major pathway of rRNA processing in the nucleolus and cytosol. DR Reactome; R-HSA-8854518; AURKA Activation by TPX2. DR Reactome; R-HSA-9931521; The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex. DR Reactome; R-HSA-9931530; Phosphorylation and nuclear translocation of the CRY:PER:kinase complex. DR SABIO-RK; P49674; -. DR SignaLink; P49674; -. DR SIGNOR; P49674; -. DR Agora; ENSG00000213923; -. DR BioGRID-ORCS; 102800317; 1 hit in 108 CRISPR screens. DR BioGRID-ORCS; 1454; 11 hits in 1186 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; CSNK1E; human. DR EvolutionaryTrace; P49674; -. DR GeneWiki; CSNK1E; -. DR Pharos; P49674; Tclin. DR PRO; PR:P49674; -. DR Proteomes; UP000005640; Chromosome 22. DR RNAct; P49674; protein. DR Bgee; ENSG00000213923; Expressed in cortical plate and 199 other cell types or tissues. DR ExpressionAtlas; P49674; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:ParkinsonsUK-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0030426; C:growth cone; IEA:Ensembl. DR GO; GO:0043025; C:neuronal cell body; IEA:Ensembl. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:1990904; C:ribonucleoprotein complex; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004672; F:protein kinase activity; IDA:WormBase. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0003723; F:RNA binding; HDA:UniProtKB. DR GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:WormBase. DR GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IEA:Ensembl. DR GO; GO:0048512; P:circadian behavior; IEA:Ensembl. DR GO; GO:0032922; P:circadian regulation of gene expression; ISS:UniProtKB. DR GO; GO:0006281; P:DNA repair; TAS:ProtInc. DR GO; GO:0006897; P:endocytosis; IBA:GO_Central. DR GO; GO:0008104; P:intracellular protein localization; IEA:Ensembl. DR GO; GO:0051058; P:negative regulation of small GTPase mediated signal transduction; IDA:ARUK-UCL. DR GO; GO:0030178; P:negative regulation of Wnt signaling pathway; IEA:Ensembl. DR GO; GO:0035567; P:non-canonical Wnt signaling pathway; IDA:ARUK-UCL. DR GO; GO:1902004; P:positive regulation of amyloid-beta formation; IEA:Ensembl. DR GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IBA:GO_Central. DR GO; GO:2000052; P:positive regulation of non-canonical Wnt signaling pathway; IC:ParkinsonsUK-UCL. DR GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; ISS:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB. DR GO; GO:0032880; P:regulation of protein localization; IDA:ParkinsonsUK-UCL. DR GO; GO:0007165; P:signal transduction; IBA:GO_Central. DR CDD; cd14125; STKc_CK1_delta_epsilon; 1. DR FunFam; 1.10.510.10:FF:000194; Casein kinase I isoform delta; 1. DR FunFam; 3.30.200.20:FF:000538; Putative Casein kinase I; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR050235; CK1_Ser-Thr_kinase. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR11909; CASEIN KINASE-RELATED; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Biological rhythms; Cytoplasm; Kinase; KW Methylation; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..416 FT /note="Casein kinase I isoform epsilon" FT /id="PRO_0000192837" FT DOMAIN 9..277 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 301..416 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 301..318 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 351..365 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 128 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 15..23 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 38 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 343 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195" FT MOD_RES 354 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195" FT MOD_RES 362 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 363 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:21406692" FT MOD_RES 382 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q9JMK2" FT MOD_RES 389 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:23186163" FT MOD_RES 405 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 408 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VARIANT 256 FT /note="R -> L (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042082" FT VARIANT 413 FT /note="H -> R (in dbSNP:rs35665927)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042083" FT MUTAGEN 38 FT /note="K->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:29222110" FT TURN 6..8 FT /evidence="ECO:0007829|PDB:4HNI" FT STRAND 14..16 FT /evidence="ECO:0007829|PDB:4HNI" FT STRAND 22..28 FT /evidence="ECO:0007829|PDB:4HNI" FT TURN 29..31 FT /evidence="ECO:0007829|PDB:4HNI" FT STRAND 35..41 FT /evidence="ECO:0007829|PDB:4HNI" FT HELIX 51..56 FT /evidence="ECO:0007829|PDB:4HNI" FT TURN 57..61 FT /evidence="ECO:0007829|PDB:4HNI" FT STRAND 68..74 FT /evidence="ECO:0007829|PDB:4HNI" FT STRAND 77..83 FT /evidence="ECO:0007829|PDB:4HNI" FT HELIX 89..95 FT /evidence="ECO:0007829|PDB:4HNI" FT TURN 96..98 FT /evidence="ECO:0007829|PDB:4HNI" FT HELIX 102..120 FT /evidence="ECO:0007829|PDB:4HNI" FT TURN 121..123 FT /evidence="ECO:0007829|PDB:4HNI" FT HELIX 131..133 FT /evidence="ECO:0007829|PDB:4HNI" FT STRAND 134..136 FT /evidence="ECO:0007829|PDB:4HNI" FT HELIX 139..141 FT /evidence="ECO:0007829|PDB:4HNI" FT STRAND 145..147 FT /evidence="ECO:0007829|PDB:4HNI" FT STRAND 154..157 FT /evidence="ECO:0007829|PDB:4HNI" FT TURN 159..161 FT /evidence="ECO:0007829|PDB:4HNI" FT HELIX 177..179 FT /evidence="ECO:0007829|PDB:4HNI" FT HELIX 182..185 FT /evidence="ECO:0007829|PDB:4HNI" FT HELIX 192..208 FT /evidence="ECO:0007829|PDB:4HNI" FT TURN 212..215 FT /evidence="ECO:0007829|PDB:4HOK" FT HELIX 221..234 FT /evidence="ECO:0007829|PDB:4HNI" FT HELIX 237..240 FT /evidence="ECO:0007829|PDB:4HNI" FT TURN 241..243 FT /evidence="ECO:0007829|PDB:4HNI" FT HELIX 246..255 FT /evidence="ECO:0007829|PDB:4HNI" FT HELIX 266..280 FT /evidence="ECO:0007829|PDB:4HNI" FT HELIX 289..291 FT /evidence="ECO:0007829|PDB:4HNI" SQ SEQUENCE 416 AA; 47315 MW; EE1B1698AE914324 CRC64; MELRVGNKYR LGRKIGSGSF GDIYLGANIA SGEEVAIKLE CVKTKHPQLH IESKFYKMMQ GGVGIPSIKW CGAEGDYNVM VMELLGPSLE DLFNFCSRKF SLKTVLLLAD QMISRIEYIH SKNFIHRDVK PDNFLMGLGK KGNLVYIIDF GLAKKYRDAR THQHIPYREN KNLTGTARYA SINTHLGIEQ SRRDDLESLG YVLMYFNLGS LPWQGLKAAT KRQKYERISE KKMSTPIEVL CKGYPSEFST YLNFCRSLRF DDKPDYSYLR QLFRNLFHRQ GFSYDYVFDW NMLKFGAARN PEDVDRERRE HEREERMGQL RGSATRALPP GPPTGATANR LRSAAEPVAS TPASRIQPAG NTSPRAISRV DRERKVSMRL HRGAPANVSS SDLTGRQEVS RIPASQTSVP FDHLGK // ID KLF6_HUMAN Reviewed; 283 AA. AC Q99612; B2RE86; B4DDN0; D3DRR1; F5H3M5; Q5VUT7; Q5VUT8; Q9BT79; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 30-MAY-2000, sequence version 3. DT 28-JAN-2026, entry version 221. DE RecName: Full=Krueppel-like factor 6; DE AltName: Full=B-cell-derived protein 1; DE AltName: Full=Core promoter element-binding protein; DE AltName: Full=GC-rich sites-binding factor GBF; DE AltName: Full=Proto-oncogene BCD1; DE AltName: Full=Suppressor of tumorigenicity 12 protein; DE AltName: Full=Transcription factor Zf9; GN Name=KLF6; Synonyms=BCD1, COPEB, CPBP, ST12; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP PRELIMINARY NUCLEOTIDE SEQUENCE (ISOFORM 1). RX PubMed=9000136; RA El Rouby S., Newcomb E.W.; RT "Identification of Bcd, a novel proto-oncogene expressed in B-cells."; RL Oncogene 13:2623-2630(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Placenta; RX PubMed=9083102; DOI=10.1074/jbc.272.14.9573; RA Koritschoner N.P., Bocco J.L., Panzetta-Dutari G.M., Dumur C.I., Flury A., RA Patrito L.C.; RT "A novel human zinc finger protein that interacts with the core promoter RT element of a TATA box-less gene."; RL J. Biol. Chem. 272:9573-9580(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Hepatic stellate cell; RX PubMed=9689109; DOI=10.1073/pnas.95.16.9500; RA Ratziu V., Lalazar A., Wong L., Dang Q., Collins C., Shaulian E., RA Jensen S., Friedman S.L.; RT "Zf9, a Kruppel-like transcription factor up-regulated in vivo during early RT hepatic fibrosis."; RL Proc. Natl. Acad. Sci. U.S.A. 95:9500-9505(1998). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CHARACTERIZATION. RC TISSUE=Leukocyte; RX PubMed=9685731; DOI=10.1093/oxfordjournals.jbchem.a022124; RA Suzuki T., Yamamoto T., Kurabayashi M., Nagai R., Yazaki Y., Horikoshi M.; RT "Isolation and initial characterization of GBF, a novel DNA-binding zinc RT finger protein that binds to the GC-rich binding sites of the HIV-1 RT promoter."; RL J. Biochem. 124:389-395(1998). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Koritschoner N.P.; RT "Genomic organization of the human COPEB/CPBP locus."; RL Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164054; DOI=10.1038/nature02462; RA Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L., RA Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K., RA Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L., RA Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P., RA Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P., RA Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N., RA Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A., RA Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C., RA Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D., RA Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C., RA Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K., RA Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A., RA Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S., RA McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S., RA Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., RA Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., RA Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., RA Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A., RA Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P., RA Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y., RA Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D., RA Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 10."; RL Nature 429:375-381(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP INACTIVATION OF 9AATAD MOTIF. RX PubMed=31375868; DOI=10.1007/s00018-019-03251-w; RA Piskacek M., Havelka M., Jendruchova K., Knight A., Keegan L.P.; RT "The evolution of the 9aaTAD domain in Sp2 proteins: inactivation with RT valines and intron reservoirs."; RL Cell. Mol. Life Sci. 77:1793-1810(2020). RN [12] RP INVOLVEMENT IN PC, VARIANTS ARG-64; PRO-116; ASP-123 AND PRO-169, AND RP CHARACTERIZATION OF VARIANTS ARG-64; PRO-116; ASP-123 AND PRO-169. RX PubMed=11752579; DOI=10.1126/science.1066326; RA Narla G., Heath K.E., Reeves H.L., Li D., Giono L.E., Kimmelman A.C., RA Glucksman M.J., Narla J., Eng F.J., Chan A.M., Ferrari A.C., RA Martignetti J.A., Friedman S.L.; RT "KLF6, a candidate tumor suppressor gene mutated in prostate cancer."; RL Science 294:2563-2566(2001). RN [13] RP INVOLVEMENT IN GASC, AND VARIANTS ARG-155; THR-172; LEU-180 AND LYS-198. RX PubMed=15824733; DOI=10.1038/sj.onc.1208670; RA Cho Y.G., Kim C.J., Park C.H., Yang Y.M., Kim S.Y., Nam S.W., Lee S.H., RA Yoo N.J., Lee J.Y., Park W.S.; RT "Genetic alterations of the KLF6 gene in gastric cancer."; RL Oncogene 24:4588-4590(2005). RN [14] RP INTERACTION WITH ZZEF1. RX PubMed=33227311; DOI=10.1016/j.jmb.2020.11.021; RA Yu Y., Tencer A., Xuan H., Kutateladze T.G., Shi X.; RT "ZZEF1 is a Histone Reader and Transcriptional Coregulator of Krueppel-Like RT Factors."; RL J. Mol. Biol. 433:166722-166722(2021). CC -!- FUNCTION: Transcriptional activator (By similarity). Binds a GC box CC motif. Could play a role in B-cell growth and development. CC {ECO:0000250}. CC -!- SUBUNIT: Interacts with ZZEF1. {ECO:0000269|PubMed:33227311}. CC -!- INTERACTION: CC Q99612; P41250: GARS1; NbExp=3; IntAct=EBI-714994, EBI-724143; CC Q99612; P02545: LMNA; NbExp=3; IntAct=EBI-714994, EBI-351935; CC Q99612; Q04206: RELA; NbExp=6; IntAct=EBI-714994, EBI-73886; CC Q99612; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-714994, EBI-5235340; CC -!- SUBCELLULAR LOCATION: Nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q99612-1; Sequence=Displayed; CC Name=2; CC IsoId=Q99612-2; Sequence=VSP_015715; CC Name=3; CC IsoId=Q99612-3; Sequence=VSP_045808; CC -!- TISSUE SPECIFICITY: Highly expressed in placenta followed by spleen, CC thymus, prostate, testis, small intestine and colon. Weakly expressed CC in pancreas, lung, liver, heart and skeletal muscle. Also expressed in CC fetal brain, spleen and thymus. CC -!- DOMAIN: The acidic N-terminal part may favor interaction with the basic CC domain of transcription factors. CC -!- DOMAIN: The 9aaTAD motif is a transactivation domain present in a large CC number of yeast and animal transcription factors. In KLF6, the motif is CC inactive. {ECO:0000269|PubMed:31375868}. CC -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which CC starts in the stomach, can spread to the esophagus or the small CC intestine, and can extend through the stomach wall to nearby lymph CC nodes and organs. It also can metastasize to other parts of the body. CC The term gastric cancer or gastric carcinoma refers to adenocarcinoma CC of the stomach that accounts for most of all gastric malignant tumors. CC Two main histologic types are recognized, diffuse type and intestinal CC type carcinomas. Diffuse tumors are poorly differentiated infiltrating CC lesions, resulting in thickening of the stomach. In contrast, CC intestinal tumors are usually exophytic, often ulcerating, and CC associated with intestinal metaplasia of the stomach, most often CC observed in sporadic disease. {ECO:0000269|PubMed:15824733}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in CC tissues of the prostate. Most prostate cancers are adenocarcinomas that CC develop in the acini of the prostatic ducts. Other rare histopathologic CC types of prostate cancer that occur in approximately 5% of patients CC include small cell carcinoma, mucinous carcinoma, prostatic ductal CC carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal CC cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:11752579}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- SIMILARITY: Belongs to the krueppel C2H2-type zinc-finger protein CC family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC23699.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAA33050.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/44002/KLF6"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U44975; AAC23699.1; ALT_INIT; mRNA. DR EMBL; AF001461; AAC39929.1; -; mRNA. DR EMBL; AB017493; BAA33050.1; ALT_INIT; mRNA. DR EMBL; AF284036; AAM73548.1; -; Genomic_DNA. DR EMBL; BT006778; AAP35424.1; -; mRNA. DR EMBL; AL513303; CAH74049.1; -; Genomic_DNA. DR EMBL; AL450322; CAH74049.1; JOINED; Genomic_DNA. DR EMBL; AK293259; BAG56791.1; -; mRNA. DR EMBL; AK316596; BAG38183.1; -; mRNA. DR EMBL; AL513303; CAH74050.1; -; Genomic_DNA. DR EMBL; AL450322; CAH74050.1; JOINED; Genomic_DNA. DR EMBL; AL450322; CAH71010.1; -; Genomic_DNA. DR EMBL; AL513303; CAH71010.1; JOINED; Genomic_DNA. DR EMBL; AL450322; CAH71011.1; -; Genomic_DNA. DR EMBL; AL513303; CAH71011.1; JOINED; Genomic_DNA. DR EMBL; CH471072; EAW86477.1; -; Genomic_DNA. DR EMBL; CH471072; EAW86479.1; -; Genomic_DNA. DR EMBL; BC000311; AAH00311.1; -; mRNA. DR CCDS; CCDS53490.1; -. [Q99612-3] DR CCDS; CCDS7060.1; -. [Q99612-1] DR PIR; JE0235; JE0235. DR RefSeq; NP_001153596.1; NM_001160124.1. DR RefSeq; NP_001153597.1; NM_001160125.2. [Q99612-3] DR RefSeq; NP_001291.3; NM_001300.5. [Q99612-1] DR AlphaFoldDB; Q99612; -. DR SMR; Q99612; -. DR BioGRID; 107711; 94. DR FunCoup; Q99612; 2033. DR IntAct; Q99612; 81. DR STRING; 9606.ENSP00000419923; -. DR GlyGen; Q99612; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q99612; -. DR PhosphoSitePlus; Q99612; -. DR BioMuta; KLF6; -. DR DMDM; 7387592; -. DR jPOST; Q99612; -. DR MassIVE; Q99612; -. DR PaxDb; 9606-ENSP00000419923; -. DR PeptideAtlas; Q99612; -. DR ProteomicsDB; 26317; -. DR ProteomicsDB; 78355; -. [Q99612-1] DR ProteomicsDB; 78356; -. [Q99612-2] DR Antibodypedia; 4619; 229 antibodies from 37 providers. DR DNASU; 1316; -. DR Ensembl; ENST00000469435.1; ENSP00000419079.1; ENSG00000067082.16. [Q99612-2] DR Ensembl; ENST00000497571.6; ENSP00000419923.1; ENSG00000067082.16. [Q99612-1] DR Ensembl; ENST00000542957.1; ENSP00000445301.1; ENSG00000067082.16. [Q99612-3] DR GeneID; 1316; -. DR KEGG; hsa:1316; -. DR MANE-Select; ENST00000497571.6; ENSP00000419923.1; NM_001300.6; NP_001291.3. DR UCSC; uc001iha.4; human. [Q99612-1] DR AGR; HGNC:2235; -. DR ClinPGx; PA26751; -. DR CTD; 1316; -. DR DisGeNET; 1316; -. DR GeneCards; KLF6; -. DR HGNC; HGNC:2235; KLF6. DR HPA; ENSG00000067082; Tissue enhanced (bone). DR MalaCards; KLF6; -. DR MIM; 176807; phenotype. DR MIM; 602053; gene. DR MIM; 613659; phenotype. DR OpenTargets; ENSG00000067082; -. DR VEuPathDB; HostDB:ENSG00000067082; -. DR eggNOG; KOG1721; Eukaryota. DR GeneTree; ENSGT00940000158085; -. DR HOGENOM; CLU_002678_33_4_1; -. DR InParanoid; Q99612; -. DR OMA; HKCHFNG; -. DR OrthoDB; 4748970at2759; -. DR PAN-GO; Q99612; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q99612; -. DR PathwayCommons; Q99612; -. DR SignaLink; Q99612; -. DR SIGNOR; Q99612; -. DR Agora; ENSG00000067082; -. DR BioGRID-ORCS; 1316; 31 hits in 1184 CRISPR screens. DR ChiTaRS; KLF6; human. DR GeneWiki; KLF6; -. DR GenomeRNAi; 1316; -. DR Pharos; Q99612; Tbio. DR PRO; PR:Q99612; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; Q99612; protein. DR Bgee; ENSG00000067082; Expressed in nipple and 214 other cell types or tissues. DR GO; GO:0000785; C:chromatin; ISA:NTNU_SB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0001650; C:fibrillar center; IDA:HPA. DR GO; GO:0005730; C:nucleolus; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; TAS:UniProtKB. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:NTNU_SB. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:NTNU_SB. DR GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0030183; P:B cell differentiation; NAS:UniProtKB. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; TAS:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:NTNU_SB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central. DR CDD; cd21586; KLF6_N; 1. DR FunFam; 3.30.160.60:FF:000021; Basic krueppel-like factor 3; 1. DR FunFam; 3.30.160.60:FF:000018; Krueppel-like factor 15; 1. DR FunFam; 3.30.160.60:FF:000624; zinc finger protein 697; 1. DR Gene3D; 3.30.160.60; Classic Zinc Finger; 3. DR InterPro; IPR036236; Znf_C2H2_sf. DR InterPro; IPR013087; Znf_C2H2_type. DR PANTHER; PTHR23235:SF50; KRUEPPEL-LIKE FACTOR 6; 1. DR PANTHER; PTHR23235; KRUEPPEL-LIKE TRANSCRIPTION FACTOR; 1. DR Pfam; PF00096; zf-C2H2; 3. DR SMART; SM00355; ZnF_C2H2; 3. DR SUPFAM; SSF57667; beta-beta-alpha zinc fingers; 2. DR PROSITE; PS00028; ZINC_FINGER_C2H2_1; 3. DR PROSITE; PS50157; ZINC_FINGER_C2H2_2; 3. PE 1: Evidence at protein level; KW Activator; Alternative splicing; DNA-binding; Metal-binding; Nucleus; KW Proteomics identification; Reference proteome; Repeat; Transcription; KW Transcription regulation; Zinc; Zinc-finger. FT CHAIN 1..283 FT /note="Krueppel-like factor 6" FT /id="PRO_0000047171" FT ZN_FING 200..224 FT /note="C2H2-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00042" FT ZN_FING 230..254 FT /note="C2H2-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00042" FT ZN_FING 260..282 FT /note="C2H2-type 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00042" FT REGION 106..198 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 62..70 FT /note="9aaTAD; inactive" FT /evidence="ECO:0000269|PubMed:31375868" FT COMPBIAS 133..148 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 183..196 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT VAR_SEQ 227..283 FT /note="EKPYRCSWEGCEWRFARSDELTRHFRKHTGAKPFKCSHCDRCFSRSDHLALH FT MKRHL -> QCPRGPRRAAAGGRHCIAPALEGAGPGCTGCGQGRQILTSSDVFHQSIRS FT FWSSE (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_015715" FT VAR_SEQ 227..283 FT /note="EKPYRCSWEGCEWRFARSDELTRHFRKHTGAKPFKCSHCDRCFSRSDHLALH FT MKRHL -> VFPGLTTWPCT (in isoform 3)" FT /evidence="ECO:0000305" FT /id="VSP_045808" FT VARIANT 64 FT /note="W -> R (found in prostate cancer samples; somatic FT mutation; does not up-regulates CDKN1A in a p53-independent FT manner and significantly reduces cell proliferation; FT dbSNP:rs121909142)" FT /evidence="ECO:0000269|PubMed:11752579" FT /id="VAR_065136" FT VARIANT 116 FT /note="S -> P (found in prostate cancer samples; somatic FT mutation; does not up-regulates CDKN1A in a p53-independent FT manner and significantly reduces cell proliferation; FT dbSNP:rs121909139)" FT /evidence="ECO:0000269|PubMed:11752579" FT /id="VAR_065137" FT VARIANT 123 FT /note="A -> D (found in prostate cancer samples; somatic FT mutation; does not up-regulates CDKN1A in a p53-independent FT manner and significantly reduces cell proliferation; FT dbSNP:rs121909141)" FT /evidence="ECO:0000269|PubMed:11752579" FT /id="VAR_065138" FT VARIANT 155 FT /note="S -> R (found in gastric cancer samples; somatic FT mutation; dbSNP:rs121909144)" FT /evidence="ECO:0000269|PubMed:15824733" FT /id="VAR_065139" FT VARIANT 169 FT /note="L -> P (found in prostate cancer samples; somatic FT mutation; does not up-regulates CDKN1A in a p53-independent FT manner and significantly reduces cell proliferation; FT dbSNP:rs121909143)" FT /evidence="ECO:0000269|PubMed:11752579" FT /id="VAR_065140" FT VARIANT 172 FT /note="P -> T (found in gastric cancer samples; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:15824733" FT /id="VAR_065141" FT VARIANT 180 FT /note="S -> L (found in gastric cancer samples; somatic FT mutation; dbSNP:rs372338890)" FT /evidence="ECO:0000269|PubMed:15824733" FT /id="VAR_065142" FT VARIANT 198 FT /note="R -> K (found in gastric cancer samples; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:15824733" FT /id="VAR_065143" FT CONFLICT 276 FT /note="A -> G (in Ref. 3; AAC39929)" FT /evidence="ECO:0000305" SQ SEQUENCE 283 AA; 31865 MW; 84294A7E6D0A0231 CRC64; MDVLPMCSIF QELQIVHETG YFSALPSLEE YWQQTCLELE RYLQSEPCYV SASEIKFDSQ EDLWTKIILA REKKEESELK ISSSPPEDTL ISPSFCYNLE TNSLNSDVSS ESSDSSEELS PTAKFTSDPI GEVLVSSGKL SSSVTSTPPS SPELSREPSQ LWGCVPGELP SPGKVRSGTS GKPGDKGNGD ASPDGRRRVH RCHFNGCRKV YTKSSHLKAH QRTHTGEKPY RCSWEGCEWR FARSDELTRH FRKHTGAKPF KCSHCDRCFS RSDHLALHMK RHL // ID LN28B_HUMAN Reviewed; 250 AA. AC Q6ZN17; A1L165; B2RPN6; Q5TCM4; DT 17-OCT-2006, integrated into UniProtKB/Swiss-Prot. DT 05-JUL-2004, sequence version 1. DT 28-JAN-2026, entry version 181. DE RecName: Full=Protein lin-28 homolog B; DE Short=Lin-28B; GN Name=LIN28B; Synonyms=CSDD2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Moss E.G., Kemper K.; RT "Expression of Lin28A and Lin28B in post-implantation mouse embryos."; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Teratocarcinoma; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP ALTERNATIVE SPLICING (ISOFORMS 1 AND 2), SUBCELLULAR LOCATION, TISSUE RP SPECIFICITY, AND INDUCTION. RX PubMed=16971064; DOI=10.1016/j.gene.2006.07.011; RA Guo Y., Chen Y., Ito H., Watanabe A., Ge X., Kodama T., Aburatani H.; RT "Identification and characterization of lin-28 homolog B (LIN28B) in human RT hepatocellular carcinoma."; RL Gene 384:51-61(2006). RN [7] RP FUNCTION, SUBCELLULAR LOCATION, AND RNA-BINDING. RX PubMed=18951094; DOI=10.1016/j.molcel.2008.09.014; RA Heo I., Joo C., Cho J., Ha M., Han J., Kim V.N.; RT "Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA."; RL Mol. Cell 32:276-284(2008). RN [8] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [9] RP FUNCTION, AND RNA-BINDING. RX PubMed=19703396; DOI=10.1016/j.cell.2009.08.002; RA Heo I., Joo C., Kim Y.-K., Ha M., Yoon M.-J., Cho J., Yeom K.-H., Han J., RA Kim V.N.; RT "TUT4 in concert with Lin28 suppresses MicroRNA biogenesis through pre- RT microRNA uridylation."; RL Cell 138:696-708(2009). RN [10] RP POSSIBLE INVOLVEMENT IN CANCERS. RX PubMed=19483683; DOI=10.1038/ng.392; RA Viswanathan S.R., Powers J.T., Einhorn W., Hoshida Y., Ng T.L., RA Toffanin S., O'Sullivan M., Lu J., Phillips L.A., Lockhart V.L., Shah S.P., RA Tanwar P.S., Mermel C.H., Beroukhim R., Azam M., Teixeira J., Meyerson M., RA Hughes T.P., Llovet J.M., Radich J., Mullighan C.G., Golub T.R., RA Sorensen P.H., Daley G.Q.; RT "Lin28 promotes transformation and is associated with advanced human RT malignancies."; RL Nat. Genet. 41:843-848(2009). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [12] RP FUNCTION IN PRE-LET-7 REPRESSION, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=22118463; DOI=10.1016/j.cell.2011.10.039; RA Piskounova E., Polytarchou C., Thornton J.E., LaPierre R.J., RA Pothoulakis C., Hagan J.P., Iliopoulos D., Gregory R.I.; RT "Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct RT mechanisms."; RL Cell 147:1066-1079(2011). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-54; SER-96; SER-105; SER-110 RP AND SER-203, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [15] RP X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 24-111, AND ZINC KNUCKLE DOMAIN. RX PubMed=22570413; DOI=10.1093/nar/gks355; RA Mayr F., Schutz A., Doge N., Heinemann U.; RT "The Lin28 cold-shock domain remodels pre-let-7 microRNA."; RL Nucleic Acids Res. 40:7492-7506(2012). CC -!- FUNCTION: Suppressor of microRNA (miRNA) biogenesis, including that of CC let-7 and possibly of miR107, miR-143 and miR-200c. Binds primary let-7 CC transcripts (pri-let-7), including pri-let-7g and pri-let-7a-1, and CC sequester them in the nucleolus, away from the microprocessor complex, CC hence preventing their processing into mature miRNA (PubMed:22118463). CC Does not act on pri-miR21 (PubMed:22118463). The repression of let-7 CC expression is required for normal development and contributes to CC maintain the pluripotent state of embryonic stem cells by preventing CC let-7-mediated differentiation. When overexpressed, recruits CC ZCCHC11/TUT4 uridylyltransferase to pre-let-7 transcripts, leading to CC their terminal uridylation and degradation (PubMed:19703396). This CC activity might not be relevant in vivo, as LIN28B-mediated inhibition CC of let-7 miRNA maturation appears to be ZCCHC11-independent CC (PubMed:22118463). Interaction with target pre-miRNAs occurs via an 5'- CC GGAG-3' motif in the pre-miRNA terminal loop. Mediates MYC-induced let- CC 7 repression (By similarity). When overexpressed, isoform 1 stimulates CC growth of the breast adenocarcinoma cell line MCF-7. Isoform 2 has no CC effect on cell growth. {ECO:0000250|UniProtKB:Q45KJ6, CC ECO:0000269|PubMed:16971064, ECO:0000269|PubMed:18951094, CC ECO:0000269|PubMed:19703396, ECO:0000269|PubMed:22118463}. CC -!- SUBCELLULAR LOCATION: Nucleus. Nucleus, nucleolus CC {ECO:0000269|PubMed:22118463}. Cytoplasm {ECO:0000269|PubMed:16971064}. CC Note=Predominantly nucleolar (PubMed:22118463). In Huh7 cells, CC predominantly cytoplasmic, with only a subset of cells exhibiting CC strong nuclear staining; however, the specificity of the polyclonal CC antibody used in these experiments has not been not documented CC (PubMed:16971064). {ECO:0000269|PubMed:16971064, CC ECO:0000269|PubMed:22118463}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q6ZN17-1; Sequence=Displayed; CC Name=2; Synonyms=LIN28BS; CC IsoId=Q6ZN17-2; Sequence=VSP_027207; CC -!- TISSUE SPECIFICITY: Expressed at high levels in the placenta and, at CC mucher lower, in testis and fetal liver (PubMed:16971064). Isoform 1 is CC only detected in placenta and in moderately and poorly differentiated CC hepatocellular carcinoma cells (at protein level). Isoform 2 is CC detected in fetal liver, non-tumor liver tissues, as well as well- CC differentiated tumor tissues (at protein level). Tends to be up- CC regulated in triple-negative (ER-,PR-,HER2-) breast tumors, as well as CC in liver, ovarian, and thyroid carcinomas (PubMed:22118463). CC {ECO:0000269|PubMed:16971064, ECO:0000269|PubMed:22118463}. CC -!- INDUCTION: Might be negatively regulated by the microRNA let-7b. CC {ECO:0000269|PubMed:16971064}. CC -!- DOMAIN: The tandem zinc fingers, also referred as zinc knuckle domain CC (ZKD), mediate specific binding to the GGAG/GGUG motif while the CSD CC shows only limited pyrimidine-rich sequence specificity. Both domains CC bind single-stranded nucleic acids. CC -!- SIMILARITY: Belongs to the lin-28 family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/45723/LIN28B"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; DQ127228; AAZ38897.1; -; mRNA. DR EMBL; AK131411; BAD18558.1; -; mRNA. DR EMBL; AL135911; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z95329; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471051; EAW48434.1; -; Genomic_DNA. DR EMBL; BC127712; AAI27713.1; -; mRNA. DR EMBL; BC127713; AAI27714.1; -; mRNA. DR EMBL; BC137526; AAI37527.1; -; mRNA. DR EMBL; BC137527; AAI37528.1; -; mRNA. DR EMBL; BC141960; AAI41961.1; -; mRNA. DR CCDS; CCDS34504.1; -. [Q6ZN17-1] DR RefSeq; NP_001004317.1; NM_001004317.4. [Q6ZN17-1] DR PDB; 4A4I; X-ray; 1.95 A; A/B=24-111. DR PDBsum; 4A4I; -. DR AlphaFoldDB; Q6ZN17; -. DR SMR; Q6ZN17; -. DR BioGRID; 133142; 363. DR FunCoup; Q6ZN17; 1779. DR IntAct; Q6ZN17; 813. DR MINT; Q6ZN17; -. DR STRING; 9606.ENSP00000344401; -. DR ChEMBL; CHEMBL4295873; -. DR GlyGen; Q6ZN17; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q6ZN17; -. DR PhosphoSitePlus; Q6ZN17; -. DR BioMuta; LIN28B; -. DR DMDM; 74758701; -. DR jPOST; Q6ZN17; -. DR MassIVE; Q6ZN17; -. DR PaxDb; 9606-ENSP00000344401; -. DR PeptideAtlas; Q6ZN17; -. DR ProteomicsDB; 67959; -. [Q6ZN17-1] DR ProteomicsDB; 67960; -. [Q6ZN17-2] DR Pumba; Q6ZN17; -. DR Antibodypedia; 32105; 310 antibodies from 36 providers. DR DNASU; 389421; -. DR Ensembl; ENST00000345080.5; ENSP00000344401.4; ENSG00000187772.8. [Q6ZN17-1] DR GeneID; 389421; -. DR KEGG; hsa:389421; -. DR MANE-Select; ENST00000345080.5; ENSP00000344401.4; NM_001004317.4; NP_001004317.1. DR UCSC; uc003pqv.2; human. [Q6ZN17-1] DR AGR; HGNC:32207; -. DR ClinPGx; PA142671543; -. DR CTD; 389421; -. DR DisGeNET; 389421; -. DR GeneCards; LIN28B; -. DR HGNC; HGNC:32207; LIN28B. DR HPA; ENSG00000187772; Tissue enriched (placenta). DR MalaCards; LIN28B; -. DR MIM; 611044; gene. DR OpenTargets; ENSG00000187772; -. DR Orphanet; 635; Neuroblastoma. DR VEuPathDB; HostDB:ENSG00000187772; -. DR eggNOG; KOG3070; Eukaryota. DR GeneTree; ENSGT00940000153295; -. DR HOGENOM; CLU_089169_1_1_1; -. DR InParanoid; Q6ZN17; -. DR OMA; WGNMAEG; -. DR OrthoDB; 422005at2759; -. DR PAN-GO; Q6ZN17; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q6ZN17; -. DR PathwayCommons; Q6ZN17; -. DR SignaLink; Q6ZN17; -. DR SIGNOR; Q6ZN17; -. DR Agora; ENSG00000187772; -. DR BioGRID-ORCS; 389421; 55 hits in 1180 CRISPR screens. DR CD-CODE; 232F8A39; P-body. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; LIN28B; human. DR EvolutionaryTrace; Q6ZN17; -. DR GenomeRNAi; 389421; -. DR Pharos; Q6ZN17; Tbio. DR PRO; PR:Q6ZN17; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q6ZN17; protein. DR Bgee; ENSG00000187772; Expressed in placenta and 37 other cell types or tissues. DR ExpressionAtlas; Q6ZN17; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005730; C:nucleolus; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0003729; F:mRNA binding; IBA:GO_Central. DR GO; GO:0003723; F:RNA binding; IDA:UniProtKB. DR GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0010587; P:miRNA catabolic process; IMP:UniProtKB. DR GO; GO:2000632; P:negative regulation of pre-miRNA processing; IDA:CACAO. DR GO; GO:2000635; P:negative regulation of primary miRNA processing; IDA:CACAO. DR GO; GO:2000627; P:positive regulation of miRNA catabolic process; IMP:CACAO. DR GO; GO:0031054; P:pre-miRNA processing; IMP:UniProtKB. DR GO; GO:0031123; P:RNA 3'-end processing; IMP:UniProtKB. DR GO; GO:0050779; P:RNA destabilization; IDA:CACAO. DR CDD; cd04458; CSP_CDS; 1. DR FunFam; 4.10.60.10:FF:000007; Protein lin-28 homolog A; 1. DR FunFam; 2.40.50.140:FF:000087; Protein lin-28 homolog B; 1. DR Gene3D; 2.40.50.140; Nucleic acid-binding proteins; 1. DR Gene3D; 4.10.60.10; Zinc finger, CCHC-type; 1. DR InterPro; IPR011129; CSD. DR InterPro; IPR002059; CSP_DNA-bd. DR InterPro; IPR051373; Lin-28_RNA-binding. DR InterPro; IPR054081; Lin-28A-like_Znf-CCHC_2. DR InterPro; IPR012340; NA-bd_OB-fold. DR InterPro; IPR001878; Znf_CCHC. DR InterPro; IPR036875; Znf_CCHC_sf. DR PANTHER; PTHR46109; PROTEIN LIN-28; 1. DR PANTHER; PTHR46109:SF3; PROTEIN LIN-28 HOMOLOG B; 1. DR Pfam; PF00313; CSD; 1. DR Pfam; PF21890; Lin-28A-like_zf-CCHC_2; 1. DR Pfam; PF00098; zf-CCHC; 1. DR PRINTS; PR00050; COLDSHOCK. DR SMART; SM00357; CSP; 1. DR SMART; SM00343; ZnF_C2HC; 2. DR SUPFAM; SSF50249; Nucleic acid-binding proteins; 1. DR SUPFAM; SSF57756; Retrovirus zinc finger-like domains; 1. DR PROSITE; PS51857; CSD_2; 1. DR PROSITE; PS50158; ZF_CCHC; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Cytoplasm; Metal-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW RNA-binding; RNA-mediated gene silencing; Zinc; Zinc-finger. FT CHAIN 1..250 FT /note="Protein lin-28 homolog B" FT /id="PRO_0000253793" FT DOMAIN 29..102 FT /note="CSD" FT ZN_FING 127..144 FT /note="CCHC-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00047" FT ZN_FING 149..166 FT /note="CCHC-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00047" FT REGION 1..26 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 98..126 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 169..250 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 112..125 FT /note="Bipartite nuclear localization signal" FT /evidence="ECO:0000269|PubMed:22118463" FT MOTIF 239..250 FT /note="Nucleolar localization signal" FT /evidence="ECO:0000269|PubMed:22118463" FT COMPBIAS 114..125 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 173..191 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 210..219 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 220..231 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 129 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 132 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 137 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 142 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 151 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 154 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 159 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 164 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT MOD_RES 54 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 96 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 105 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 110 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 203 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..70 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_027207" FT STRAND 28..38 FT /evidence="ECO:0007829|PDB:4A4I" FT TURN 39..42 FT /evidence="ECO:0007829|PDB:4A4I" FT STRAND 43..51 FT /evidence="ECO:0007829|PDB:4A4I" FT STRAND 54..65 FT /evidence="ECO:0007829|PDB:4A4I" FT HELIX 66..68 FT /evidence="ECO:0007829|PDB:4A4I" FT STRAND 71..74 FT /evidence="ECO:0007829|PDB:4A4I" FT STRAND 82..88 FT /evidence="ECO:0007829|PDB:4A4I" FT STRAND 95..101 FT /evidence="ECO:0007829|PDB:4A4I" FT HELIX 102..104 FT /evidence="ECO:0007829|PDB:4A4I" SQ SEQUENCE 250 AA; 27084 MW; DEF2920C5F1D0BBD CRC64; MAEGGASKGG GEEPGKLPEP AEEESQVLRG TGHCKWFNVR MGFGFISMIN REGSPLDIPV DVFVHQSKLF MEGFRSLKEG EPVEFTFKKS SKGLESIRVT GPGGSPCLGS ERRPKGKTLQ KRKPKGDRCY NCGGLDHHAK ECSLPPQPKK CHYCQSIMHM VANCPHKNVA QPPASSQGRQ EAESQPCTST LPREVGGGHG CTSPPFPQEA RAEISERSGR SPQEASSTKS SIAPEEQSKK GPSVQKRKKT // ID NEK11_HUMAN Reviewed; 645 AA. AC Q8NG66; A6NHD7; Q5JPC0; Q8NG65; Q8TBY1; Q9H5F4; DT 13-SEP-2005, integrated into UniProtKB/Swiss-Prot. DT 30-NOV-2010, sequence version 2. DT 28-JAN-2026, entry version 181. DE RecName: Full=Serine/threonine-protein kinase Nek11; DE EC=2.7.11.1 {ECO:0000269|PubMed:12154088, ECO:0000269|PubMed:15161910}; DE AltName: Full=Never in mitosis A-related kinase 11; DE Short=NimA-related protein kinase 11; GN Name=NEK11 {ECO:0000312|HGNC:HGNC:18593}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305, ECO:0000312|EMBL:BAC06350.1} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, CATALYTIC RP ACTIVITY, COFACTOR, ACTIVITY REGULATION, DEVELOPMENTAL STAGE, TISSUE RP SPECIFICITY, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-61, AND VARIANT RP VAL-488. RC TISSUE=Cervix carcinoma; RX PubMed=12154088; DOI=10.1074/jbc.m204599200; RA Noguchi K., Fukazawa H., Murakami Y., Uehara Y.; RT "Nek11, a new member of the NIMA family of kinases, involved in DNA RT replication and genotoxic stress responses."; RL J. Biol. Chem. 277:39655-39665(2002). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4), AND VARIANT VAL-488. RC TISSUE=Cervix; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [4] {ECO:0000305, ECO:0000312|EMBL:CAI46114.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] {ECO:0000305, ECO:0000312|EMBL:AAH28587.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Testis {ECO:0000312|EMBL:AAH28587.1}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] {ECO:0000305, ECO:0000312|EMBL:BAB15672.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 162-645 (ISOFORM 1), AND VARIANT RP VAL-488. RC TISSUE=Lung {ECO:0000312|EMBL:BAB15672.1}; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] {ECO:0000305} RP CATALYTIC ACTIVITY, COFACTOR, SUBCELLULAR LOCATION, ACTIVITY REGULATION, RP AND INTERACTION WITH NEK2. RX PubMed=15161910; DOI=10.1074/jbc.m404104200; RA Noguchi K., Fukazawa H., Murakami Y., Uehara Y.; RT "Nucleolar Nek11 is a novel target of Nek2A in G1/S-arrested cells."; RL J. Biol. Chem. 279:32716-32727(2004). RN [8] RP FUNCTION, AND PHOSPHORYLATION AT SER-273. RX PubMed=19734889; DOI=10.1038/ncb1969; RA Melixetian M., Klein D.K., Soerensen C.S., Helin K.; RT "NEK11 regulates CDC25A degradation and the IR-induced G2/M checkpoint."; RL Nat. Cell Biol. 11:1247-1253(2009). RN [9] RP FUNCTION, AND PHOSPHORYLATION AT SER-273. RX PubMed=20090422; DOI=10.4161/cc.9.3.10513; RA Soerensen C.S., Melixetian M., Klein D.K., Helin K.; RT "NEK11: linking CHK1 and CDC25A in DNA damage checkpoint signaling."; RL Cell Cycle 9:450-455(2010). RN [10] RP VARIANTS [LARGE SCALE ANALYSIS] MET-108; CYS-123; LEU-213; VAL-263; RP LYS-451; VAL-488; LYS-492; THR-548; ALA-562; LYS-606 AND ASN-617. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Protein kinase which plays an important role in the G2/M CC checkpoint response to DNA damage. Controls degradation of CDC25A by CC directly phosphorylating it on residues whose phosphorylation is CC required for BTRC-mediated polyubiquitination and degradation. CC {ECO:0000269|PubMed:12154088, ECO:0000269|PubMed:19734889, CC ECO:0000269|PubMed:20090422}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12154088, ECO:0000269|PubMed:15161910}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12154088, ECO:0000269|PubMed:15161910}; CC -!- COFACTOR: CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; CC Evidence={ECO:0000269|PubMed:12154088, ECO:0000269|PubMed:15161910}; CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:12154088, ECO:0000269|PubMed:15161910}; CC -!- ACTIVITY REGULATION: Autorepressed by intramolecular binding of the C- CC terminus which dissociates following phosphorylation by NEK2 isoform 1 CC in G1/S-arrested cells. NEK2 isoform 2 is largely not present in the CC nucleolus, and does not appear to phosphorylate NEK11. Activated in CC response to DNA damage. Inhibited by zinc. CC {ECO:0000269|PubMed:12154088, ECO:0000269|PubMed:15161910}. CC -!- SUBUNIT: Interacts with isoform 1 of NEK2. CC {ECO:0000269|PubMed:15161910}. CC -!- INTERACTION: CC Q8NG66; P08238: HSP90AB1; NbExp=2; IntAct=EBI-633195, EBI-352572; CC Q8NG66; P51955: NEK2; NbExp=5; IntAct=EBI-633195, EBI-633182; CC Q8NG66; P51955-1: NEK2; NbExp=2; IntAct=EBI-633195, EBI-687792; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12154088}. Nucleus, CC nucleolus {ECO:0000269|PubMed:15161910}. Note=Nuclear during interphase CC but moves to the polar microtubules during prometaphase and metaphase CC (PubMed:12154088). Accumulates in the nucleolus in G1/S-arrested cells CC (PubMed:15161910). {ECO:0000269|PubMed:12154088, CC ECO:0000269|PubMed:15161910}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1 {ECO:0000269|PubMed:12154088}; Synonyms=Long CC {ECO:0000303|PubMed:12154088}; CC IsoId=Q8NG66-1; Sequence=Displayed; CC Name=2 {ECO:0000269|PubMed:12154088}; Synonyms=Short CC {ECO:0000303|PubMed:12154088}; CC IsoId=Q8NG66-2; Sequence=VSP_051821, VSP_051822; CC Name=3 {ECO:0000305}; CC IsoId=Q8NG66-3; Sequence=VSP_051820, VSP_051823; CC Name=4; CC IsoId=Q8NG66-4; Sequence=VSP_040080, VSP_040081; CC -!- TISSUE SPECIFICITY: Poorly expressed in cerebellum, trachea, lung, CC appendix, and uterus. {ECO:0000269|PubMed:12154088}. CC -!- DEVELOPMENTAL STAGE: Predominantly expressed at S/G2/M phase. CC {ECO:0000269|PubMed:12154088}. CC -!- PTM: Phosphorylated by NEK2. Phosphorylation at Ser-273 is important CC for its activation. {ECO:0000269|PubMed:19734889, CC ECO:0000269|PubMed:20090422}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. NEK Ser/Thr CC protein kinase family. NIMA subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAB15672.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB071996; BAC06350.1; -; mRNA. DR EMBL; AB071997; BAC06351.1; -; mRNA. DR EMBL; AL833472; CAI46114.1; -; mRNA. DR EMBL; AC055733; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471052; EAW79213.1; -; Genomic_DNA. DR EMBL; BC028587; AAH28587.1; -; mRNA. DR EMBL; AK027148; BAB15672.1; ALT_INIT; mRNA. DR CCDS; CCDS3069.1; -. [Q8NG66-1] DR CCDS; CCDS46915.1; -. [Q8NG66-2] DR CCDS; CCDS54639.1; -. [Q8NG66-4] DR CCDS; CCDS82836.1; -. [Q8NG66-3] DR RefSeq; NP_001139475.1; NM_001146003.2. [Q8NG66-4] DR RefSeq; NP_001308149.1; NM_001321220.2. [Q8NG66-1] DR RefSeq; NP_001308150.1; NM_001321221.1. DR RefSeq; NP_001308151.1; NM_001321222.1. DR RefSeq; NP_001308152.1; NM_001321223.1. [Q8NG66-3] DR RefSeq; NP_001308153.1; NM_001321224.1. DR RefSeq; NP_001339952.1; NM_001353023.2. [Q8NG66-1] DR RefSeq; NP_001339957.1; NM_001353028.2. [Q8NG66-4] DR RefSeq; NP_001339958.1; NM_001353029.2. [Q8NG66-4] DR RefSeq; NP_079076.3; NM_024800.4. [Q8NG66-1] DR RefSeq; NP_665917.1; NM_145910.4. [Q8NG66-2] DR RefSeq; XP_047304926.1; XM_047448970.1. [Q8NG66-1] DR RefSeq; XP_047304927.1; XM_047448971.1. [Q8NG66-1] DR RefSeq; XP_047304928.1; XM_047448972.1. [Q8NG66-1] DR RefSeq; XP_047304935.1; XM_047448979.1. [Q8NG66-2] DR RefSeq; XP_054203914.1; XM_054347939.1. [Q8NG66-2] DR AlphaFoldDB; Q8NG66; -. DR SMR; Q8NG66; -. DR BioGRID; 122947; 36. DR CORUM; Q8NG66; -. DR FunCoup; Q8NG66; 986. DR IntAct; Q8NG66; 16. DR STRING; 9606.ENSP00000372857; -. DR BindingDB; Q8NG66; -. DR ChEMBL; CHEMBL5638; -. DR DrugBank; DB08912; Dabrafenib. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q8NG66; -. DR GuidetoPHARMACOLOGY; 2116; -. DR iPTMnet; Q8NG66; -. DR PhosphoSitePlus; Q8NG66; -. DR BioMuta; NEK11; -. DR DMDM; 313104142; -. DR CPTAC; non-CPTAC-5648; -. DR CPTAC; non-CPTAC-5649; -. DR jPOST; Q8NG66; -. DR MassIVE; Q8NG66; -. DR PaxDb; 9606-ENSP00000372857; -. DR PeptideAtlas; Q8NG66; -. DR ProteomicsDB; 73438; -. [Q8NG66-1] DR ProteomicsDB; 73439; -. [Q8NG66-2] DR ProteomicsDB; 73440; -. [Q8NG66-3] DR ProteomicsDB; 73441; -. [Q8NG66-4] DR Antibodypedia; 2071; 293 antibodies from 25 providers. DR DNASU; 79858; -. DR Ensembl; ENST00000356918.8; ENSP00000349389.5; ENSG00000114670.15. [Q8NG66-2] DR Ensembl; ENST00000383366.9; ENSP00000372857.4; ENSG00000114670.15. [Q8NG66-1] DR Ensembl; ENST00000507910.5; ENSP00000426662.1; ENSG00000114670.15. [Q8NG66-3] DR Ensembl; ENST00000508196.5; ENSP00000421851.1; ENSG00000114670.15. [Q8NG66-1] DR Ensembl; ENST00000510688.5; ENSP00000423458.1; ENSG00000114670.15. [Q8NG66-4] DR Ensembl; ENST00000511262.5; ENSP00000425114.1; ENSG00000114670.15. [Q8NG66-2] DR GeneID; 79858; -. DR KEGG; hsa:79858; -. DR MANE-Select; ENST00000383366.9; ENSP00000372857.4; NM_024800.5; NP_079076.3. DR UCSC; uc003enx.4; human. [Q8NG66-1] DR AGR; HGNC:18593; -. DR ClinPGx; PA38595; -. DR CTD; 79858; -. DR DisGeNET; 79858; -. DR GeneCards; NEK11; -. DR HGNC; HGNC:18593; NEK11. DR HPA; ENSG00000114670; Tissue enhanced (choroid). DR MIM; 609779; gene. DR OpenTargets; ENSG00000114670; -. DR VEuPathDB; HostDB:ENSG00000114670; -. DR eggNOG; KOG0589; Eukaryota. DR GeneTree; ENSGT00940000160525; -. DR HOGENOM; CLU_000288_63_39_1; -. DR InParanoid; Q8NG66; -. DR OrthoDB; 248923at2759; -. DR PAN-GO; Q8NG66; 8 GO annotations based on evolutionary models. DR PhylomeDB; Q8NG66; -. DR PathwayCommons; Q8NG66; -. DR SignaLink; Q8NG66; -. DR SIGNOR; Q8NG66; -. DR Agora; ENSG00000114670; -. DR BioGRID-ORCS; 79858; 11 hits in 1182 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; NEK11; human. DR GenomeRNAi; 79858; -. DR Pharos; Q8NG66; Tchem. DR PRO; PR:Q8NG66; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q8NG66; protein. DR Bgee; ENSG00000114670; Expressed in right uterine tube and 137 other cell types or tissues. DR ExpressionAtlas; Q8NG66; baseline and differential. DR GO; GO:0005730; C:nucleolus; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0031573; P:mitotic intra-S DNA damage checkpoint signaling; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:1901990; P:regulation of mitotic cell cycle phase transition; IMP:CACAO. DR CDD; cd08222; STKc_Nek11; 1. DR FunFam; 1.10.510.10:FF:000436; NIMA related kinase 11; 1. DR FunFam; 3.30.200.20:FF:000332; NIMA related kinase 11; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR051131; NEK_Ser/Thr_kinase_NIMA. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR44899; CAMK FAMILY PROTEIN KINASE; 1. DR PANTHER; PTHR44899:SF8; NIMA-RELATED KINASE 11; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cell cycle; Coiled coil; Kinase; KW Magnesium; Manganese; Metal-binding; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..645 FT /note="Serine/threonine-protein kinase Nek11" FT /id="PRO_0000086438" FT DOMAIN 29..287 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 399..445 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 346..385 FT /evidence="ECO:0000250|UniProtKB:P51957, ECO:0000255" FT ACT_SITE 158 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:P51957, FT ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE- FT ProRule:PRU10027" FT BINDING 35..43 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:P51957, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 61 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:12154088" FT MOD_RES 273 FT /note="Phosphoserine; by CHEK1" FT /evidence="ECO:0000269|PubMed:19734889, FT ECO:0000269|PubMed:20090422" FT VAR_SEQ 467..482 FT /note="EIPEDPLVAEEYYADA -> GDCNLISLDEYWKNEK (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_051820" FT VAR_SEQ 467..470 FT /note="EIPE -> ATHS (in isoform 2)" FT /evidence="ECO:0000303|PubMed:12154088" FT /id="VSP_051821" FT VAR_SEQ 471..645 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:12154088" FT /id="VSP_051822" FT VAR_SEQ 483..645 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_051823" FT VAR_SEQ 542..599 FT /note="TKTITTMAEDMSPGPPIFNSVMARTKMKRMRESAMQKLGTEVFEEVYNYLKR FT ARHQNA -> QPCRSWGQKYLKRSIITSREQGIRMLAKQRSASVWKKWCLKPATVLKWT FT SSCTLKSSC (in isoform 4)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_040080" FT VAR_SEQ 600..645 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_040081" FT VARIANT 108 FT /note="T -> M (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs200709914)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040935" FT VARIANT 123 FT /note="Y -> C (in dbSNP:rs55806123)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040936" FT VARIANT 213 FT /note="S -> L (in dbSNP:rs55920129)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040937" FT VARIANT 263 FT /note="I -> V (in dbSNP:rs35567155)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040938" FT VARIANT 451 FT /note="E -> K (in dbSNP:rs35409692)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040939" FT VARIANT 488 FT /note="E -> V (in dbSNP:rs3738000)" FT /evidence="ECO:0000269|PubMed:12154088, FT ECO:0000269|PubMed:14702039, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:17974005" FT /id="VAR_040940" FT VARIANT 492 FT /note="E -> K (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs140599545)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040941" FT VARIANT 548 FT /note="M -> T (in dbSNP:rs55813244)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040942" FT VARIANT 562 FT /note="V -> A (in dbSNP:rs16836266)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_033907" FT VARIANT 606 FT /note="E -> K (in dbSNP:rs55944737)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040943" FT VARIANT 617 FT /note="D -> N (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs765563230)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040944" FT MUTAGEN 61 FT /note="K->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:12154088" SQ SEQUENCE 645 AA; 74192 MW; 7D11AE1D89711DEC CRC64; MLKFQEAAKC VSGSTAISTY PKTLIARRYV LQQKLGSGSF GTVYLVSDKK AKRGEELKVL KEISVGELNP NETVQANLEA QLLSKLDHPA IVKFHASFVE QDNFCIITEY CEGRDLDDKI QEYKQAGKIF PENQIIEWFI QLLLGVDYMH ERRILHRDLK SKNVFLKNNL LKIGDFGVSR LLMGSCDLAT TLTGTPHYMS PEALKHQGYD TKSDIWSLAC ILYEMCCMNH AFAGSNFLSI VLKIVEGDTP SLPERYPKEL NAIMESMLNK NPSLRPSAIE ILKIPYLDEQ LQNLMCRYSE MTLEDKNLDC QKEAAHIINA MQKRIHLQTL RALSEVQKMT PRERMRLRKL QAADEKARKL KKIVEEKYEE NSKRMQELRS RNFQQLSVDV LHEKTHLKGM EEKEEQPEGR LSCSPQDEDE ERWQGREEES DEPTLENLPE SQPIPSMDLH ELESIVEDAT SDLGYHEIPE DPLVAEEYYA DAFDSYCEES DEEEEEIALE RPEKEIRNEG SQPAYRTNQQ DSDIEALARC LENVLGCTSL DTKTITTMAE DMSPGPPIFN SVMARTKMKR MRESAMQKLG TEVFEEVYNY LKRARHQNAS EAEIRECLEK VVPQASDCFE VDQLLYFEEQ LLITMGKEPT LQNHL // ID P53_HUMAN Reviewed; 393 AA. AC P04637; Q15086; Q15087; Q15088; Q16535; Q16807; Q16808; Q16809; Q16810; AC Q16811; Q16848; Q2XN98; Q3LRW1; Q3LRW2; Q3LRW3; Q3LRW4; Q3LRW5; Q86UG1; AC Q8J016; Q99659; Q9BTM4; Q9HAQ8; Q9NP68; Q9NPJ2; Q9NZD0; Q9UBI2; Q9UQ61; DT 13-AUG-1987, integrated into UniProtKB/Swiss-Prot. DT 24-NOV-2009, sequence version 4. DT 28-JAN-2026, entry version 313. DE RecName: Full=Cellular tumor antigen p53; DE AltName: Full=Antigen NY-CO-13; DE AltName: Full=Phosphoprotein p53; DE AltName: Full=Tumor suppressor p53; GN Name=TP53; Synonyms=P53; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=4006916; DOI=10.1002/j.1460-2075.1985.tb03768.x; RA Zakut-Houri R., Bienz-Tadmor B., Givol D., Oren M.; RT "Human p53 cellular tumor antigen: cDNA sequence and expression in COS RT cells."; RL EMBO J. 4:1251-1255(1985). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT GLY-76. RX PubMed=2946935; DOI=10.1128/mcb.6.5.1379-1385.1986; RA Lamb P., Crawford L.; RT "Characterization of the human p53 gene."; RL Mol. Cell. Biol. 6:1379-1385(1986). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3894933; DOI=10.1128/mcb.5.7.1601-1610.1985; RA Harlow E., Williamson N.M., Ralston R., Helfman D.M., Adams T.E.; RT "Molecular cloning and in vitro expression of a cDNA clone for human RT cellular tumor antigen p53."; RL Mol. Cell. Biol. 5:1601-1610(1985). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3025664; DOI=10.1128/mcb.6.12.4650-4656.1986; RA Harris N., Brill E., Shohat O., Prokocimer M., Wolf D., Arai N., Rotter V.; RT "Molecular basis for heterogeneity of the human p53 protein."; RL Mol. Cell. Biol. 6:4650-4656(1986). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=2905688; DOI=10.1016/0378-1119(88)90196-5; RA Buchman V.L., Chumakov P.M., Ninkina N.N., Samarina O.P., Georgiev G.P.; RT "A variation in the structure of the protein-coding region of the human p53 RT gene."; RL Gene 70:245-252(1988). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS SPORADIC CANCERS. RX PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x; RA Farrell P.J., Allan G., Shanahan F., Vousden K.H., Crook T.; RT "p53 is frequently mutated in Burkitt's lymphoma cell lines."; RL EMBO J. 10:2879-2887(1991). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286. RX PubMed=8316628; DOI=10.2307/3578196; RA Allalunis-Turner M.J., Barron G.M., Day R.S. III, Dobler K.D., RA Mirzayans R.; RT "Isolation of two cell lines from a human malignant glioma specimen RT differing in sensitivity to radiation and chemotherapeutic drugs."; RL Radiat. Res. 134:349-354(1993). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH WWOX. RX PubMed=11058590; DOI=10.1074/jbc.m007140200; RA Chang N.-S., Pratt N., Heath J., Schultz L., Sleve D., Carey G.B., RA Zevotek N.; RT "Hyaluronidase induction of a WW domain-containing oxidoreductase that RT enhances tumor necrosis factor cytotoxicity."; RL J. Biol. Chem. 276:3361-3370(2001). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 7; 8 AND 9), SUBCELLULAR RP LOCATION, TISSUE SPECIFICITY, ALTERNATIVE PROMOTER USAGE, ALTERNATIVE RP SPLICING, INDUCTION, AND VARIANT ARG-72. RC TISSUE=Colon; RX PubMed=16131611; DOI=10.1101/gad.1339905; RA Bourdon J.C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A., RA Xirodimas D.P., Saville M.K., Lane D.P.; RT "p53 isoforms can regulate p53 transcriptional activity."; RL Genes Dev. 19:2122-2137(2005). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Chumakov P.M., Almazov V.P., Jenkins J.R.; RL Submitted (JUN-1991) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Rozemuller E.H., Tilanus M.G.J.; RT "P53 genomic sequence. Corrections and polymorphism."; RL Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-47; LYS-339 AND RP ALA-366. RG NIEHS SNPs program; RL Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases. RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286. RX PubMed=11023613; DOI=10.1667/0033-7587(2000)154[0473:htftmg]2.0.co;2; RA Anderson C.W., Allalunis-Turner M.J.; RT "Human TP53 from the malignant glioma-derived cell lines M059J and M059K RT has a cancer-associated mutation in exon 8."; RL Radiat. Res. 154:473-476(2000). RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS HIS-273 AND SER-309. RA Azuma K., Shichijo S., Itoh K.; RT "Identification of a tumor-rejection antigen recognized by HLA-B46 RT restricted CTL."; RL Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases. RN [15] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-72. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [16] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [17] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-72. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [18] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ALA-278. RC TISSUE=Kidney; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [19] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-379 (ISOFORM 1), AND VARIANTS ASN-139 AND RP PRO-155. RC TISSUE=Lung carcinoma; RX PubMed=14660794; DOI=10.1073/pnas.2536558100; RA Kanashiro C.A., Schally A.V., Groot K., Armatis P., Bernardino A.L., RA Varga J.L.; RT "Inhibition of mutant p53 expression and growth of DMS-153 small cell lung RT carcinoma by antagonists of growth hormone-releasing hormone and RT bombesin."; RL Proc. Natl. Acad. Sci. U.S.A. 100:15836-15841(2003). RN [20] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 101-393. RX PubMed=6396087; DOI=10.1002/j.1460-2075.1984.tb02287.x; RA Matlashewski G., Lamb P., Pim D., Peacock J., Crawford L., Benchimol S.; RT "Isolation and characterization of a human p53 cDNA clone: expression of RT the human p53 gene."; RL EMBO J. 3:3257-3262(1984). RN [21] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 126-185. RA Pan X.L., Zhang A.H.; RT "Study on the effect of tumor suppressor gene p53 in arsenism patients."; RL Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases. RN [22] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 261-298, AND VARIANT GLN-282. RC TISSUE=Blood; RA Nimri L.F., Owais W., Momani E.; RT "Detection of P53 gene mutations and serum p53 antibodies associated with RT cigarette smoking."; RL Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases. RN [23] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 262-306, AND VARIANT VAL-262. RC TISSUE=Ovarian adenocarcinoma; RA Filippini G., Soldati G.; RL Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases. RN [24] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260. RC TISSUE=Glial cell, and Glial tumor; RA Thompson-Hehir J., Davies M.P.A., Green J.A., Halliwell N., Joyce K.A., RA Salisbury J., Sibson D.R., Vergote I., Walker C.; RT "Mutation detection utilizing a novel PCR approach for amplification of the RT p53 gene from microdissected tissue: application to archival tumor RT samples."; RL Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases. RN [25] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260. RA Yavuz A.S., Farner N.L., Yavuz S., Grammer A.C., Girschick H.J., RA Lipsky P.E.; RT "Bcl6 and P53 gene mutations in tonsillar B cells."; RL Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases. RN [26] RP PROTEIN SEQUENCE OF 320-337, SUBUNIT, INTERACTION WITH PRMT5, SUBCELLULAR RP LOCATION, METHYLATION AT ARG-333; ARG-335 AND ARG-337 BY PRMT5, RP IDENTIFICATION BY MASS SPECTROMETRY, AND MUTAGENESIS OF 333-ARG--ARG-337. RX PubMed=19011621; DOI=10.1038/ncb1802; RA Jansson M., Durant S.T., Cho E.C., Sheahan S., Edelmann M., Kessler B., RA La Thangue N.B.; RT "Arginine methylation regulates the p53 response."; RL Nat. Cell Biol. 10:1431-1439(2008). RN [27] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 332-366. RA Pinto E.M., Mendonca B.B., Latronico A.C.; RT "Allelic variant in intron 9 of TP53 gene."; RL Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases. RN [28] RP INTERACTION WITH HUMAN PAPILLOMAVIRUS TYPE 6 AND 11 PROTEIN E6 (MICROBIAL RP INFECTION). RX PubMed=2175676; DOI=10.1016/0092-8674(90)90409-8; RA Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M.; RT "The E6 oncoprotein encoded by human papillomavirus types 16 and 18 RT promotes the degradation of p53."; RL Cell 63:1129-1136(1990). RN [29] RP NUCLEAR LOCALIZATION SIGNAL, AND MUTAGENESIS OF LYS-319; LYS-320 AND RP LYS-321. RX PubMed=2156209; RA Addison C., Jenkins J.R., Sturzbecher H.-W.; RT "The p53 nuclear localisation signal is structurally linked to a p34cdc2 RT kinase motif."; RL Oncogene 5:423-426(1990). RN [30] RP PHOSPHORYLATION BY P60/CDC2 AND CYCLIN B/CDC2. RX PubMed=2141171; DOI=10.1073/pnas.87.12.4766; RA Bischoff J.R., Friedman P.N., Marshak D.R., Prives C., Beach D.; RT "Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2."; RL Proc. Natl. Acad. Sci. U.S.A. 87:4766-4770(1990). RN [31] RP PHOSPHORYLATION. RX PubMed=1705009; DOI=10.1128/mcb.11.3.1598-1606.1991; RA Samad A., Carroll R.B.; RT "The tumor suppressor p53 is bound to RNA by a stable covalent linkage."; RL Mol. Cell. Biol. 11:1598-1606(1991). RN [32] RP DEPHOSPHORYLATION BY PP2A. RX PubMed=1848668; DOI=10.1128/mcb.11.4.1996-2003.1991; RA Scheidtmann K.H., Mumby M.C., Rundell K., Walter G.; RT "Dephosphorylation of simian virus 40 large-T antigen and p53 protein by RT protein phosphatase 2A: inhibition by small-t antigen."; RL Mol. Cell. Biol. 11:1996-2003(1991). RN [33] RP ALTERNATIVE SPLICING. RX PubMed=8632903; RA Flaman J.-M., Waridel F., Estreicher A., Vannier A., Limacher J.-M., RA Gilbert D., Iggo R., Frebourg T.; RT "The human tumour suppressor gene p53 is alternatively spliced in normal RT cells."; RL Oncogene 12:813-818(1996). RN [34] RP GLYCOSYLATION. RX PubMed=8632915; RA Shaw P., Freeman J., Bovey R., Iggo R.; RT "Regulation of specific DNA binding by p53: evidence for a role for O- RT glycosylation and charged residues at the carboxy-terminus."; RL Oncogene 12:921-930(1996). RN [35] RP PHOSPHORYLATION AT SER-33. RX PubMed=9372954; DOI=10.1128/mcb.17.12.7220; RA Ko L.J., Shieh S.-Y., Chen X., Jayaraman L., Tamai K., Taya Y., Prives C., RA Pan Z.-Q.; RT "p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner."; RL Mol. Cell. Biol. 17:7220-7229(1997). RN [36] RP FUNCTION, AND IDENTIFICATION IN COMPLEX WITH CAK. RX PubMed=9840937; DOI=10.1038/sj.onc.1202504; RA Schneider E., Montenarh M., Wagner P.; RT "Regulation of CAK kinase activity by p53."; RL Oncogene 17:2733-2741(1998). RN [37] RP SUMOYLATION AT LYS-386, AND MUTAGENESIS OF LYS-386. RA Gostissa M., Hengstermann A., Fogal V., Sandy P., Schwarz S.E., RA Scheffner M., Del Sal G.; RT "Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1."; RL EMBO J. 18:6462-6471(1999). RN [38] RP PHOSPHORYLATION AT THR-18 BY CSNK1D/CK1. RX PubMed=10606744; DOI=10.1016/s0014-5793(99)01647-6; RA Dumaz N., Milne D.M., Meek D.W.; RT "Protein kinase CK1 is a p53-threonine 18 kinase which requires prior RT phosphorylation of serine 15."; RL FEBS Lett. 463:312-316(1999). RN [39] RP BIPARTITE NUCLEAR LOCALIZATION SIGNAL, AND CHARACTERIZATION OF VARIANT RP ASN-305. RX PubMed=10551826; DOI=10.1074/jbc.274.46.32699; RA Liang S.H., Clarke M.F.; RT "A bipartite nuclear localization signal is required for p53 nuclear import RT regulated by a carboxyl-terminal domain."; RL J. Biol. Chem. 274:32699-32703(1999). RN [40] RP PHOSPHORYLATION AT SER-15 AND SER-20, INDUCTION BY DNA DAMAGE, RP CHARACTERIZATION OF LFS VARIANT HIS-273, MUTAGENESIS OF THR-18; SER-20 AND RP 22-LEU-TRP-23, SUBCELLULAR LOCATION, AND INTERACTION WITH PML AND MDM2. RX PubMed=10570149; DOI=10.1073/pnas.96.24.13777; RA Chehab N.H., Malikzay A., Stavridi E.S., Halazonetis T.D.; RT "Phosphorylation of Ser-20 mediates stabilization of human p53 in response RT to DNA damage."; RL Proc. Natl. Acad. Sci. U.S.A. 96:13777-13782(1999). RN [41] RP UBIQUITINATION. RX PubMed=10722742; DOI=10.1074/jbc.275.12.8945; RA Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., Weissman A.M.; RT "Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and RT p53."; RL J. Biol. Chem. 275:8945-8951(2000). RN [42] RP ACETYLATION AT LYS-373 AND LYS-382. RX PubMed=10656795; DOI=10.1006/jmbi.1999.3415; RA Abraham J., Kelly J., Thibault P., Benchimol S.; RT "Post-translational modification of p53 protein in response to ionizing RT radiation analyzed by mass spectrometry."; RL J. Mol. Biol. 295:853-864(2000). RN [43] RP PHOSPHORYLATION AT SER-315 AND SER-392 BY CDK2, AND MUTAGENESIS OF LYS-382; RP LEU-383 AND PHE-385. RX PubMed=10884347; DOI=10.1006/jmbi.2000.3830; RA Luciani M.G., Hutchins J.R.A., Zheleva D., Hupp T.R.; RT "The C-terminal regulatory domain of p53 contains a functional docking site RT for cyclin A."; RL J. Mol. Biol. 300:503-518(2000). RN [44] RP FUNCTION, INTERACTION WITH PML, AND SUBCELLULAR LOCATION. RX PubMed=11025664; DOI=10.1038/35036365; RA Guo A., Salomoni P., Luo J., Shih A., Zhong S., Gu W., Pandolfi P.P.; RT "The function of PML in p53-dependent apoptosis."; RL Nat. Cell Biol. 2:730-736(2000). RN [45] RP INTERACTION WITH E4F1. RX PubMed=10644996; DOI=10.1038/sj.onc.1203250; RA Sandy P., Gostissa M., Fogal V., Cecco L.D., Szalay K., Rooney R.J., RA Schneider C., Del Sal G.; RT "p53 is involved in the p120E4F-mediated growth arrest."; RL Oncogene 19:188-199(2000). RN [46] RP PHOSPHORYLATION AT THR-18. RX PubMed=10951572; DOI=10.1038/sj.onc.1203709; RA Lopez-Borges S., Lazo P.A.; RT "The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 RT within the mdm-2 binding site of the p53 tumour suppressor protein."; RL Oncogene 19:3656-3664(2000). RN [47] RP REVIEW ON ZINC-BINDING PROPERTIES. RX PubMed=11554448; DOI=10.1089/15230860152542961; RA Hainaut P., Mann K.; RT "Zinc binding and redox control of p53 structure and function."; RL Antioxid. Redox Signal. 3:611-623(2001). RN [48] RP PHOSPHORYLATION AT SER-15. RX PubMed=11554766; DOI=10.1006/bbrc.2001.5627; RA Imamura K., Ogura T., Kishimoto A., Kaminishi M., Esumi H.; RT "Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated RT protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D- RT ribofuranoside, in a human hepatocellular carcinoma cell line."; RL Biochem. Biophys. Res. Commun. 287:562-567(2001). RN [49] RP DEACETYLATION AT LYS-382 BY SIRT1. RX PubMed=11672523; DOI=10.1016/s0092-8674(01)00527-x; RA Vaziri H., Dessain S.K., Ng Eaton E., Imai S., Frye R.A., Pandita T.K., RA Guarente L., Weinberg R.A.; RT "hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase."; RL Cell 107:149-159(2001). RN [50] RP MINIMAL REPRESSION DOMAIN. RX PubMed=11007800; DOI=10.1074/jbc.m008231200; RA Hong T.M., Chen J.J., Peck K., Yang P.C., Wu C.W.; RT "p53 amino acids 339-346 represent the minimal p53 repression domain."; RL J. Biol. Chem. 276:1510-1515(2001). RN [51] RP PHOSPHORYLATION AT SER-20 BY PLK3. RX PubMed=11447225; DOI=10.1074/jbc.m104157200; RA Xie S., Wang Q., Wu H., Cogswell J., Lu L., Jhanwar-Uniyal M., Dai W.; RT "Reactive oxygen species-induced phosphorylation of p53 on serine 20 is RT mediated in part by polo-like kinase-3."; RL J. Biol. Chem. 276:36194-36199(2001). RN [52] RP PHOSPHORYLATION AT SER-20 BY PLK3. RX PubMed=11551930; DOI=10.1074/jbc.m106050200; RA Xie S., Wu H., Wang Q., Cogswell J.P., Husain I., Conn C., Stambrook P., RA Jhanwar-Uniyal M., Dai W.; RT "Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at RT least in part via the p53 pathway."; RL J. Biol. Chem. 276:43305-43312(2001). RN [53] RP SUMOYLATION AT LYS-386, SUBCELLULAR LOCATION, AND MUTAGENESIS OF PHE-385; RP LYS-386; THR-387 AND GLU-388. RX PubMed=11124955; DOI=10.1074/jbc.m009476200; RA Rodriguez M.S., Dargemont C., Hay R.T.; RT "SUMO-1 conjugation in vivo requires both a consensus modification motif RT and nuclear targeting."; RL J. Biol. Chem. 276:12654-12659(2001). RN [54] RP PHOSPHORYLATION BY PRPK. RX PubMed=11546806; DOI=10.1074/jbc.m105669200; RA Abe Y., Matsumoto S., Wei S., Nezu K., Miyoshi A., Kito K., Ueda N., RA Shigemoto K., Hitsumoto Y., Nikawa J., Enomoto Y.; RT "Cloning and characterization of a p53-related protein kinase expressed in RT interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and RT the testes."; RL J. Biol. Chem. 276:44003-44011(2001). RN [55] RP PHOSPHORYLATION AT SER-392. RX PubMed=11239457; DOI=10.1016/s1097-2765(01)00176-9; RA Keller D.M., Zeng X., Wang Y., Zhang Q.H., Kapoor M., Shu H., Goodman R., RA Lozano G., Zhao Y., Lu H.; RT "A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, RT and SSRP1."; RL Mol. Cell 7:283-292(2001). RN [56] RP INTERACTION WITH USP7. RX PubMed=12507430; DOI=10.1016/s0092-8674(02)01199-6; RA Hu M., Li P., Li M., Li W., Yao T., Wu J.-W., Gu W., Cohen R.E., Shi Y.; RT "Crystal structure of a UBP-family deubiquitinating enzyme in isolation and RT in complex with ubiquitin aldehyde."; RL Cell 111:1041-1054(2002). RN [57] RP IDENTIFICATION IN A COMPLEX WITH CABLES1 AND TP73. RX PubMed=11706030; DOI=10.1074/jbc.m108535200; RA Tsuji K., Mizumoto K., Yamochi T., Nishimoto I., Matsuoka M.; RT "Differential effect of ik3-1/cables on p53- and p73-induced cell death."; RL J. Biol. Chem. 277:2951-2957(2002). RN [58] RP INTERACTION WITH HIPK2. RX PubMed=11925430; DOI=10.1074/jbc.m200153200; RA Kim E.-J., Park J.-S., Um S.-J.; RT "Identification and characterization of HIPK2 interacting with p73 and RT modulating functions of the p53 family in vivo."; RL J. Biol. Chem. 277:32020-32028(2002). RN [59] RP INTERACTION WITH HIPK2, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF RP SER-46 AND LYS-382. RX PubMed=11740489; DOI=10.1038/ncb715; RA Hofmann T.G., Moeller A., Sirma H., Zentgraf H., Taya Y., Droege W., RA Will H., Schmitz M.L.; RT "Regulation of p53 activity by its interaction with homeodomain-interacting RT protein kinase-2."; RL Nat. Cell Biol. 4:1-10(2002). RN [60] RP INTERACTION WITH HIPK2, AND PHOSPHORYLATION AT SER-46. RX PubMed=11780126; DOI=10.1038/ncb714; RA D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y., Saito S., RA Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G., Fanciulli M., RA Appella E., Soddu S.; RT "Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and RT mediates apoptosis."; RL Nat. Cell Biol. 4:11-19(2002). RN [61] RP INTERACTION WITH ING4. RX PubMed=12750254; RA Shiseki M., Nagashima M., Pedeux R.M., Kitahama-Shiseki M., Miura K., RA Okamura S., Onogi H., Higashimoto Y., Appella E., Yokota J., Harris C.C.; RT "p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity."; RL Cancer Res. 63:2373-2378(2003). RN [62] RP ACETYLATION AT LYS-305. RX PubMed=12724314; DOI=10.1074/jbc.m212574200; RA Wang Y.H., Tsay Y.G., Tan B.C., Lo W.Y., Lee S.C.; RT "Identification and characterization of a novel p300-mediated p53 RT acetylation site, lysine 305."; RL J. Biol. Chem. 278:25568-25576(2003). RN [63] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH CHEK2 AND PML, RP UBIQUITINATION BY MDM2, AND PHOSPHORYLATION AT SER-20. RX PubMed=12810724; DOI=10.1074/jbc.m301264200; RA Louria-Hayon I., Grossman T., Sionov R.V., Alsheich O., Pandolfi P.P., RA Haupt Y.; RT "The promyelocytic leukemia protein protects p53 from Mdm2-mediated RT inhibition and degradation."; RL J. Biol. Chem. 278:33134-33141(2003). RN [64] RP INTERACTION WITH TP53INP1. RX PubMed=12851404; DOI=10.1074/jbc.m301979200; RA Tomasini R., Samir A.A., Carrier A., Isnardon D., Cecchinelli B., Soddu S., RA Malissen B., Dagorn J.-C., Iovanna J.L., Dusetti N.J.; RT "TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are RT partners in regulating p53 activity."; RL J. Biol. Chem. 278:37722-37729(2003). RN [65] RP NUCLEOCYTOPLASMIC SHUTTLING, AND NUCLEAR EXPORT SIGNAL. RX PubMed=12944468; DOI=10.1128/mcb.23.18.6396-6405.2003; RA O'Keefe K., Li H., Zhang Y.; RT "Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated RT cytoplasmic degradation but not ubiquitination."; RL Mol. Cell. Biol. 23:6396-6405(2003). RN [66] RP FUNCTION, AND INTERACTION WITH PPP1R13L; PPP1R13B AND TP53BP2. RX PubMed=12524540; DOI=10.1038/ng1070; RA Bergamaschi D., Samuels Y., O'Neil N.J., Trigiante G., Crook T., RA Hsieh J.-K., O'Connor D.J., Zhong S., Campargue I., Tomlinson M.L., RA Kuwabara P.E., Lu X.; RT "iASPP oncoprotein is a key inhibitor of p53 conserved from worm to RT human."; RL Nat. Genet. 33:162-167(2003). RN [67] RP INTERACTION WITH HIPK1. RX PubMed=12702766; DOI=10.1073/pnas.0530308100; RA Kondo S., Lu Y., Debbas M., Lin A.W., Sarosi I., Itie A., Wakeham A., RA Tuan J., Saris C., Elliott G., Ma W., Benchimol S., Lowe S.W., Mak T.W., RA Thukral S.K.; RT "Characterization of cells and gene-targeted mice deficient for the p53- RT binding kinase homeodomain-interacting protein kinase 1 (HIPK1)."; RL Proc. Natl. Acad. Sci. U.S.A. 100:5431-5436(2003). RN [68] RP INTERACTION WITH CDKN2AIP. RX PubMed=15109303; DOI=10.1042/bj20040337; RA Hasan M.K., Yaguchi T., Minoda Y., Hirano T., Taira K., Wadhwa R., RA Kaul S.C.; RT "Alternative reading frame protein (ARF)-independent function of CARF RT (collaborator of ARF) involves its interactions with p53: evidence for a RT novel p53-activation pathway and its negative feedback control."; RL Biochem. J. 380:605-610(2004). RN [69] RP INTERACTION WITH HRMT1L2; EP300 AND CARM1, AND FUNCTION. RX PubMed=15186775; DOI=10.1016/j.cell.2004.05.009; RA An W., Kim J., Roeder R.G.; RT "Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional RT activation by p53."; RL Cell 117:735-748(2004). RN [70] RP INTERACTION WITH ANKRD2. RX PubMed=15136035; DOI=10.1016/j.jmb.2004.03.071; RA Kojic S., Medeot E., Guccione E., Krmac H., Zara I., Martinelli V., RA Valle G., Faulkner G.; RT "The Ankrd2 protein, a link between the sarcomere and the nucleus in RT skeletal muscle."; RL J. Mol. Biol. 339:313-325(2004). RN [71] RP PHOSPHORYLATION AT THR-55, MUTAGENESIS OF THR-55, AND INTERACTION WITH RP TAF1. RX PubMed=15053879; DOI=10.1016/s1097-2765(04)00123-6; RA Li H.-H., Li A.G., Sheppard H.M., Liu X.; RT "Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for RT TAF1 in cell G1 progression."; RL Mol. Cell 13:867-878(2004). RN [72] RP DEUBIQUITINATION BY USP7. RX PubMed=15053880; DOI=10.1016/s1097-2765(04)00157-1; RA Li M., Brooks C.L., Kon N., Gu W.; RT "A dynamic role of HAUSP in the p53-Mdm2 pathway."; RL Mol. Cell 13:879-886(2004). RN [73] RP ALTERNATIVE SPLICING (ISOFORM 4), FUNCTION, SUBCELLULAR LOCATION, AND RP UBIQUITINATION. RX PubMed=15340061; DOI=10.1128/mcb.24.18.7987-7997.2004; RA Ghosh A., Stewart D., Matlashewski G.; RT "Regulation of human p53 activity and cell localization by alternative RT splicing."; RL Mol. Cell. Biol. 24:7987-7997(2004). RN [74] RP METHYLATION AT LYS-372, AND MUTAGENESIS OF LYS-372. RX PubMed=15525938; DOI=10.1038/nature03117; RA Chuikov S., Kurash J.K., Wilson J.R., Xiao B., Justin N., Ivanov G.S., RA McKinney K., Tempst P., Prives C., Gamblin S.J., Barlev N.A., Reinberg D.; RT "Regulation of p53 activity through lysine methylation."; RL Nature 432:353-360(2004). RN [75] RP ACETYLATION AT LYS-382. RX PubMed=15448695; DOI=10.1038/ncb1170; RA Demonacos C., Krstic-Demonacos M., Smith L., Xu D., O'Connor D.P., RA Jansson M., La Thangue N.B.; RT "A new effector pathway links ATM kinase with the DNA damage response."; RL Nat. Cell Biol. 6:968-976(2004). RN [76] RP INTERACTION WITH AURKA, AND PHOSPHORYLATION AT SER-315. RX PubMed=14702041; DOI=10.1038/ng1279; RA Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F., RA Fujii S., Arlinghaus R.B., Czerniak B.A., Sen S.; RT "Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization RT and inhibition of p53."; RL Nat. Genet. 36:55-62(2004). RN [77] RP INTERACTION WITH NQO1. RX PubMed=15687255; DOI=10.1101/gad.319905; RA Asher G., Tsvetkov P., Kahana C., Shaul Y.; RT "A mechanism of ubiquitin-independent proteasomal degradation of the tumor RT suppressors p53 and p73."; RL Genes Dev. 19:316-321(2005). RN [78] RP INTERACTION WITH NOC2L. RX PubMed=16322561; DOI=10.1101/gad.351205; RA Hublitz P., Kunowska N., Mayer U.P., Muller J.M., Heyne K., Yin N., RA Fritzsche C., Poli C., Miguet L., Schupp I.W., van Grunsven L.A., RA Potiers N., van Dorsselaer A., Metzger E., Roemer K., Schule R.; RT "NIR is a novel INHAT repressor that modulates the transcriptional activity RT of p53."; RL Genes Dev. 19:2912-2924(2005). RN [79] RP RETRACTED PAPER. RX PubMed=15701641; DOI=10.1074/jbc.m413200200; RA Jalota-Badhwar A., Singh K., Pavithra L., Kaul-Ghanekar R., Jameel S., RA Chattopadhyay S.; RT "Tumor suppressor SMAR1 activates and stabilizes p53 through its arginine- RT serine-rich motif."; RL J. Biol. Chem. 280:16019-16029(2005). RN [80] RP RETRACTION NOTICE OF PUBMED:15701641. RX PubMed=32144153; DOI=10.1074/jbc.w120.012894; RA Jalota A., Singh K., Pavithra L., Kaul-Ghanekar R., Jameel S., RA Chattopadhyay S.; RL J. Biol. Chem. 295:3390-3390(2020). RN [81] RP INTERACTION WITH PTK2/FAK1. RX PubMed=15855171; DOI=10.1074/jbc.m414172200; RA Golubovskaya V.M., Finch R., Cance W.G.; RT "Direct interaction of the N-terminal domain of focal adhesion kinase with RT the N-terminal transactivation domain of p53."; RL J. Biol. Chem. 280:25008-25021(2005). RN [82] RP INTERACTION WITH WWOX, AND MUTAGENESIS OF SER-46. RX PubMed=16219768; DOI=10.1074/jbc.m505590200; RA Chang N.-S., Doherty J., Ensign A., Schultz L., Hsu L.-J., Hong Q.; RT "WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, RT and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds RT and stabilizes serine 46-phosphorylated p53."; RL J. Biol. Chem. 280:43100-43108(2005). RN [83] RP PHOSPHORYLATION AT SER-15. RX PubMed=15866171; DOI=10.1016/j.molcel.2005.03.027; RA Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J., RA Thompson C.B.; RT "AMP-activated protein kinase induces a p53-dependent metabolic RT checkpoint."; RL Mol. Cell 18:283-293(2005). RN [84] RP INTERACTION WITH STK11/LKB1, AND PHOSPHORYLATION AT SER-15 AND SER-392. RX PubMed=17108107; DOI=10.1158/0008-5472.can-06-0999; RA Zeng P.Y., Berger S.L.; RT "LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate RT transcriptional activation."; RL Cancer Res. 66:10701-10708(2006). RN [85] RP PHOSPHORYLATION AT THR-18. RX PubMed=16704422; DOI=10.1111/j.1742-4658.2006.05256.x; RA Blanco S., Klimcakova L., Vega F.M., Lazo P.A.; RT "The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms RT determines their different effect on p53 stability in tumour cell lines."; RL FEBS J. 273:2487-2504(2006). RN [86] RP INTERACTION WITH YWHAZ. RX PubMed=16376338; DOI=10.1016/j.febslet.2005.12.024; RA Gu Y.-M., Jin Y.-H., Choi J.-K., Baek K.-H., Yeo C.-Y., Lee K.-Y.; RT "Protein kinase A phosphorylates and regulates dimerization of 14-3-3 RT epsilon."; RL FEBS Lett. 580:305-310(2006). RN [87] RP PHOSPHORYLATION AT SER-46, AND INTERACTION WITH PRKCG. RX PubMed=16377624; DOI=10.1074/jbc.m512074200; RA Yoshida K., Liu H., Miki Y.; RT "Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor RT suppressor in the apoptotic response to DNA damage."; RL J. Biol. Chem. 281:5734-5740(2006). RN [88] RP FUNCTION, ACETYLATION AT LYS-120, VARIANTS ARG-120; GLU-120 AND MET-120, RP AND CHARACTERIZATION OF VARIANTS ARG-120; GLU-120 AND MET-120. RX PubMed=17189187; DOI=10.1016/j.molcel.2006.11.026; RA Sykes S.M., Mellert H.S., Holbert M.A., Li K., Marmorstein R., Lane W.S., RA McMahon S.B.; RT "Acetylation of the p53 DNA-binding domain regulates apoptosis induction."; RL Mol. Cell 24:841-851(2006). RN [89] RP METHYLATION AT LYS-370, AND MUTAGENESIS OF LYS-370. RX PubMed=17108971; DOI=10.1038/nature05287; RA Huang J., Perez-Burgos L., Placek B.J., Sengupta R., Richter M., RA Dorsey J.A., Kubicek S., Opravil S., Jenuwein T., Berger S.L.; RT "Repression of p53 activity by Smyd2-mediated methylation."; RL Nature 444:629-632(2006). RN [90] RP INTERACTION WITH DAXX. RX PubMed=16845383; DOI=10.1038/ncb1442; RA Tang J., Qu L.K., Zhang J., Wang W., Michaelson J.S., Degenhardt Y.Y., RA El-Deiry W.S., Yang X.; RT "Critical role for Daxx in regulating Mdm2."; RL Nat. Cell Biol. 8:855-862(2006). RN [91] RP MOTIF, AND METHYLATION AT LYS-372. RX PubMed=16415881; DOI=10.1038/nsmb1045; RA Couture J.-F., Collazo E., Hauk G., Trievel R.C.; RT "Structural basis for the methylation site specificity of SET7/9."; RL Nat. Struct. Mol. Biol. 13:140-146(2006). RN [92] RP INTERACTION WITH POU4F2. RX PubMed=17145718; DOI=10.1093/nar/gkl878; RA Budhram-Mahadeo V.S., Bowen S., Lee S., Perez-Sanchez C., Ensor E., RA Morris P.J., Latchman D.S.; RT "Brn-3b enhances the pro-apoptotic effects of p53 but not its induction of RT cell cycle arrest by cooperating in trans-activation of bax expression."; RL Nucleic Acids Res. 34:6640-6652(2006). RN [93] RP PHOSPHORYLATION AT SER-37, AND MUTAGENESIS OF SER-37. RX PubMed=17254968; DOI=10.1016/j.cell.2006.11.050; RA Sun P., Yoshizuka N., New L., Moser B.A., Li Y., Liao R., Xie C., Chen J., RA Deng Q., Yamout M., Dong M.Q., Frangou C.G., Yates J.R. III, Wright P.E., RA Han J.; RT "PRAK is essential for ras-induced senescence and tumor suppression."; RL Cell 128:295-308(2007). RN [94] RP INTERACTION WITH ZNF385A, AND CHARACTERIZATION OF VARIANTS ALA-143; HIS-175 RP AND PRO-175. RX PubMed=17719541; DOI=10.1016/j.cell.2007.06.013; RA Das S., Raj L., Zhao B., Kimura Y., Bernstein A., Aaronson S.A., Lee S.W.; RT "Hzf Determines cell survival upon genotoxic stress by modulating p53 RT transactivation."; RL Cell 130:624-637(2007). RN [95] RP UBIQUITINATION, INTERACTION WITH SYVN1, AND SUBCELLULAR LOCATION. RX PubMed=17170702; DOI=10.1038/sj.emboj.7601490; RA Yamasaki S., Yagishita N., Sasaki T., Nakazawa M., Kato Y., Yamadera T., RA Bae E., Toriyama S., Ikeda R., Zhang L., Fujitani K., Yoo E., RA Tsuchimochi K., Ohta T., Araya N., Fujita H., Aratani S., Eguchi K., RA Komiya S., Maruyama I., Higashi N., Sato M., Senoo H., Ochi T., RA Yokoyama S., Amano T., Kim J., Gay S., Fukamizu A., Nishioka K., Tanaka K., RA Nakajima T.; RT "Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident RT ubiquitin ligase 'Synoviolin'."; RL EMBO J. 26:113-122(2007). RN [96] RP INTERACTION WITH PPP2CA; PPP2R1A; PPP2R2A AND PPP2R5C. RX PubMed=17245430; DOI=10.1038/sj.emboj.7601519; RA Li H.H., Cai X., Shouse G.P., Piluso L.G., Liu X.; RT "A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced RT dephosphorylation of p53 at Thr55."; RL EMBO J. 26:402-411(2007). RN [97] RP INTERACTION WITH ARMC10. RX PubMed=17904127; DOI=10.1016/j.febslet.2007.09.025; RA Zhou X., Yang G., Huang R., Chen X., Hu G.; RT "SVH-B interacts directly with p53 and suppresses the transcriptional RT activity of p53."; RL FEBS Lett. 581:4943-4948(2007). RN [98] RP PHOSPHORYLATION AT SER-9. RX PubMed=18022393; DOI=10.1016/j.febslet.2007.11.022; RA Arai S., Matsushita A., Du K., Yagi K., Okazaki Y., Kurokawa R.; RT "Novel homeodomain-interacting protein kinase family member, HIPK4, RT phosphorylates human p53 at serine 9."; RL FEBS Lett. 581:5649-5657(2007). RN [99] RP DOMAIN. RX PubMed=17467953; DOI=10.1016/j.ygeno.2007.02.003; RA Piskacek S., Gregor M., Nemethova M., Grabner M., Kovarik P., Piskacek M.; RT "Nine-amino-acid transactivation domain: establishment and prediction RT utilities."; RL Genomics 89:756-768(2007). RN [100] RP INTERACTION WITH RFFL AND RNF34. RX PubMed=17121812; DOI=10.1074/jbc.m610793200; RA Yang W., Rozan L.M., McDonald E.R. III, Navaraj A., Liu J.J., Matthew E.M., RA Wang W., Dicker D.T., El-Deiry W.S.; RT "CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho- RT p53ser20 degradation."; RL J. Biol. Chem. 282:3273-3281(2007). RN [101] RP FUNCTION, AND INTERACTION WITH MAML1. RX PubMed=17317671; DOI=10.1074/jbc.m608974200; RA Zhao Y., Katzman R.B., Delmolino L.M., Bhat I., Zhang Y., Gurumurthy C.B., RA Germaniuk-Kurowska A., Reddi H.V., Solomon A., Zeng M.S., Kung A., Ma H., RA Gao Q., Dimri G., Stanculescu A., Miele L., Wu L., Griffin J.D., RA Wazer D.E., Band H., Band V.; RT "The notch regulator MAML1 interacts with p53 and functions as a RT coactivator."; RL J. Biol. Chem. 282:11969-11981(2007). RN [102] RP PHOSPHORYLATION AT SER-15; SER-33 AND SER-46, INTERACTION WITH CDK5, AND RP SUBCELLULAR LOCATION. RX PubMed=17591690; DOI=10.1242/jcs.03468; RA Lee J.-H., Kim H.-S., Lee S.-J., Kim K.-T.; RT "Stabilization and activation of p53 induced by Cdk5 contributes to RT neuronal cell death."; RL J. Cell Sci. 120:2259-2271(2007). RN [103] RP INTERACTION WITH MORC3. RX PubMed=17332504; DOI=10.1091/mbc.e06-08-0747; RA Takahashi K., Yoshida N., Murakami N., Kawata K., Ishizaki H., RA Tanaka-Okamoto M., Miyoshi J., Zinn A.R., Shime H., Inoue N.; RT "Dynamic regulation of p53 subnuclear localization and senescence by RT MORC3."; RL Mol. Biol. Cell 18:1701-1709(2007). RN [104] RP FUNCTION, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF SER-46. RX PubMed=17349958; DOI=10.1016/j.molcel.2007.02.007; RA Taira N., Nihira K., Yamaguchi T., Miki Y., Yoshida K.; RT "DYRK2 is targeted to the nucleus and controls p53 via Ser46 RT phosphorylation in the apoptotic response to DNA damage."; RL Mol. Cell 25:725-738(2007). RN [105] RP DEMETHYLATION BY KDM1A. RX PubMed=17805299; DOI=10.1038/nature06092; RA Huang J., Sengupta R., Espejo A.B., Lee M.G., Dorsey J.A., Richter M., RA Opravil S., Shiekhattar R., Bedford M.T., Jenuwein T., Berger S.L.; RT "p53 is regulated by the lysine demethylase LSD1."; RL Nature 449:105-108(2007). RN [106] RP METHYLATION AT LYS-382, AND MUTAGENESIS OF LYS-382. RX PubMed=17707234; DOI=10.1016/j.molcel.2007.07.012; RA Shi X., Kachirskaia I., Yamaguchi H., West L.E., Wen H., Wang E.W., RA Dutta S., Appella E., Gozani O.; RT "Modulation of p53 function by SET8-mediated methylation at lysine 382."; RL Mol. Cell 27:636-646(2007). RN [107] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [108] RP ACETYLATION, AND DEACETYLATION BY SIRT2. RX PubMed=18249187; DOI=10.1016/j.bbrc.2008.01.114; RA Jin Y.H., Kim Y.J., Kim D.W., Baek K.H., Kang B.Y., Yeo C.Y., Lee K.Y.; RT "Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of RT p53."; RL Biochem. Biophys. Res. Commun. 368:690-695(2008). RN [109] RP INTERACTION WITH SETD2. RX PubMed=18585004; DOI=10.1016/j.cellsig.2008.05.012; RA Xie P., Tian C., An L., Nie J., Lu K., Xing G., Zhang L., He F.; RT "Histone methyltransferase protein SETD2 interacts with p53 and selectively RT regulates its downstream genes."; RL Cell. Signal. 20:1671-1678(2008). RN [110] RP INTERACTION WITH NUPR1. RX PubMed=18690848; DOI=10.2174/156800908785133196; RA Clark D.W., Mitra A., Fillmore R.A., Jiang W.G., Samant R.S., Fodstad O., RA Shevde L.A.; RT "NUPR1 interacts with p53, transcriptionally regulates p21 and rescues RT breast epithelial cells from doxorubicin-induced genotoxic stress."; RL Curr. Cancer Drug Targets 8:421-430(2008). RN [111] RP UBIQUITINATION, AND SUBCELLULAR LOCATION. RX PubMed=18206965; DOI=10.1016/j.molcel.2007.11.031; RA Lim S.T., Chen X.L., Lim Y., Hanson D.A., Vo T.T., Howerton K., RA Larocque N., Fisher S.J., Schlaepfer D.D., Ilic D.; RT "Nuclear FAK promotes cell proliferation and survival through FERM-enhanced RT p53 degradation."; RL Mol. Cell 29:9-22(2008). RN [112] RP INTERACTION WITH KAT7. RX PubMed=17954561; DOI=10.1128/mcb.00662-07; RA Iizuka M., Sarmento O.F., Sekiya T., Scrable H., Allis C.D., Smith M.M.; RT "Hbo1 Links p53-dependent stress signaling to DNA replication licensing."; RL Mol. Cell. Biol. 28:140-153(2008). RN [113] RP INTERACTION WITH PPP2CA; PPP2R1A AND PPP2R5C, PHOSPHORYLATION AT SER-15 BY RP ATM, AND MUTAGENESIS OF SER-15. RX PubMed=17967874; DOI=10.1128/mcb.00983-07; RA Shouse G.P., Cai X., Liu X.; RT "Serine 15 phosphorylation of p53 directs its interaction with B56gamma and RT the tumor suppressor activity of B56gamma-specific protein phosphatase RT 2A."; RL Mol. Cell. Biol. 28:448-456(2008). RN [114] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [115] RP INTERACTION WITH MKRN1, MUTAGENESIS OF 291-LYS-LYS-292, AND UBIQUITINATION RP AT LYS-291 AND LYS-292 BY MKRN1. RX PubMed=19536131; DOI=10.1038/emboj.2009.164; RA Lee E.-W., Lee M.-S., Camus S., Ghim J., Yang M.-R., Oh W., Ha N.-C., RA Lane D.P., Song J.; RT "Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell RT cycle arrest and apoptosis."; RL EMBO J. 28:2100-2113(2009). RN [116] RP UBIQUITINATION BY TOPORS. RX PubMed=19473992; DOI=10.1074/jbc.c109.001560; RA Yang X., Li H., Zhou Z., Wang W.H., Deng A., Andrisani O., Liu X.; RT "Plk1-mediated phosphorylation of Topors regulates p53 stability."; RL J. Biol. Chem. 284:18588-18592(2009). RN [117] RP UBIQUITINATION AT LYS-351 AND LYS-357, AND SUBCELLULAR LOCATION. RX PubMed=19033443; DOI=10.1074/jbc.m805658200; RA Kruse J.P., Gu W.; RT "MSL2 promotes Mdm2-independent cytoplasmic localization of p53."; RL J. Biol. Chem. 284:3250-3263(2009). RN [118] RP INTERACTION WITH MTA1 AND COP1, AND UBIQUITINATION. RX PubMed=19837670; DOI=10.1074/jbc.m109.056499; RA Li D.Q., Divijendra Natha Reddy S., Pakala S.B., Wu X., Zhang Y., RA Rayala S.K., Kumar R.; RT "MTA1 coregulator regulates p53 stability and function."; RL J. Biol. Chem. 284:34545-34552(2009). RN [119] RP INTERACTION WITH HHV-5 PROTEIN UL123 (MICROBIAL INFECTION). RX PubMed=19776115; DOI=10.1128/jvi.00304-09; RA Hwang E.S., Zhang Z., Cai H., Huang D.Y., Huong S.M., Cha C.Y., Huang E.S.; RT "Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53- RT dependent transactivation by a mechanism different from that of IE2-86 RT protein."; RL J. Virol. 83:12388-12398(2009). RN [120] RP ACETYLATION AT LYS-120. RX PubMed=19854137; DOI=10.1016/j.molcel.2009.07.031; RA Li X., Wu L., Corsa C.A., Kunkel S., Dou Y.; RT "Two mammalian MOF complexes regulate transcription activation by distinct RT mechanisms."; RL Mol. Cell 36:290-301(2009). RN [121] RP INTERACTION WITH FBXO42. RX PubMed=19509332; DOI=10.1073/pnas.0901864106; RA Sun L., Shi L., Li W., Yu W., Liang J., Zhang H., Yang X., Wang Y., Li R., RA Yao X., Yi X., Shang Y.; RT "JFK, a Kelch domain-containing F-box protein, links the SCF complex to p53 RT regulation."; RL Proc. Natl. Acad. Sci. U.S.A. 106:10195-10200(2009). RN [122] RP FUNCTION, UBIQUITINATION, AND INTERACTION WITH TRIM24. RX PubMed=19556538; DOI=10.1073/pnas.0813177106; RA Allton K., Jain A.K., Herz H.M., Tsai W.W., Jung S.Y., Qin J., Bergmann A., RA Johnson R.L., Barton M.C.; RT "Trim24 targets endogenous p53 for degradation."; RL Proc. Natl. Acad. Sci. U.S.A. 106:11612-11616(2009). RN [123] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-381 AND LYS-382, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [124] RP INTERACTION WITH TAF6 ISOFORMS 1 AND 4. RX PubMed=20096117; DOI=10.1186/1471-2199-11-10; RA Wilhelm E., Kornete M., Targat B., Vigneault-Edwards J., Frontini M., RA Tora L., Benecke A., Bell B.; RT "TAF6delta orchestrates an apoptotic transcriptome profile and interacts RT functionally with p53."; RL BMC Mol. Biol. 11:10-10(2010). RN [125] RP UBIQUITINATION, AND DEUBIQUITINATION BY USP10. RX PubMed=20096447; DOI=10.1016/j.cell.2009.12.032; RA Yuan J., Luo K., Zhang L., Cheville J.C., Lou Z.; RT "USP10 regulates p53 localization and stability by deubiquitinating p53."; RL Cell 140:384-396(2010). RN [126] RP FUNCTION. RX PubMed=20673990; DOI=10.1016/j.cell.2010.06.040; RA Huarte M., Guttman M., Feldser D., Garber M., Koziol M.J., RA Kenzelmann-Broz D., Khalil A.M., Zuk O., Amit I., Rabani M., Attardi L.D., RA Regev A., Lander E.S., Jacks T., Rinn J.L.; RT "A large intergenic noncoding RNA induced by p53 mediates global gene RT repression in the p53 response."; RL Cell 142:409-419(2010). RN [127] RP PHOSPHORYLATION AT SER-20 BY CSNK1D/CK1. RX PubMed=20041275; DOI=10.1007/s00018-009-0236-7; RA Venerando A., Marin O., Cozza G., Bustos V.H., Sarno S., Pinna L.A.; RT "Isoform specific phosphorylation of p53 by protein kinase CK1."; RL Cell. Mol. Life Sci. 67:1105-1118(2010). RN [128] RP INTERACTION WITH SNAI1, CHARACTERIZATION OF VARIANTS LEU-110; PRO-155; RP HIS-175; SER-232; SER-249; HIS-273 AND TRP-282, AND MUTAGENESIS OF ARG-248. RX PubMed=20385133; DOI=10.1016/j.febslet.2010.04.006; RA Lim S.O., Kim H., Jung G.; RT "p53 inhibits tumor cell invasion via the degradation of snail protein in RT hepatocellular carcinoma."; RL FEBS Lett. 584:2231-2236(2010). RN [129] RP INTERACTION WITH PTK2B/PYK2 AND MDM2, UBIQUITINATION, AND SUBCELLULAR RP LOCATION. RX PubMed=19880522; DOI=10.1074/jbc.m109.064212; RA Lim S.T., Miller N.L., Nam J.O., Chen X.L., Lim Y., Schlaepfer D.D.; RT "Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating RT cell proliferation and survival."; RL J. Biol. Chem. 285:1743-1753(2010). RN [130] RP METHYLATION AT LYS-373, AND MUTAGENESIS OF LYS-373. RX PubMed=20118233; DOI=10.1074/jbc.m109.062588; RA Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X., Jenuwein T., RA Reinberg D., Berger S.L.; RT "G9a and Glp methylate lysine 373 in the tumor suppressor p53."; RL J. Biol. Chem. 285:9636-9641(2010). RN [131] RP ERRATUM OF PUBMED:20118233. RA Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X., Jenuwein T., RA Reinberg D., Berger S.L.; RL J. Biol. Chem. 285:18122-18122(2010). RN [132] RP PHOSPHORYLATION AT THR-55, AND INTERACTION WITH GRK5. RX PubMed=20124405; DOI=10.1074/jbc.m109.094243; RA Chen X., Zhu H., Yuan M., Fu J., Zhou Y., Ma L.; RT "G-protein-coupled receptor kinase 5 phosphorylates p53 and inhibits DNA RT damage-induced apoptosis."; RL J. Biol. Chem. 285:12823-12830(2010). RN [133] RP INTERACTION WITH BRD7, AND ACETYLATION AT LYS-382. RX PubMed=20228809; DOI=10.1038/ncb2038; RA Drost J., Mantovani F., Tocco F., Elkon R., Comel A., Holstege H., RA Kerkhoven R., Jonkers J., Voorhoeve P.M., Agami R., Del Sal G.; RT "BRD7 is a candidate tumour suppressor gene required for p53 function."; RL Nat. Cell Biol. 12:380-389(2010). RN [134] RP UBIQUITINATION BY RFWD3. RX PubMed=20173098; DOI=10.1073/pnas.0912094107; RA Fu X., Yucer N., Liu S., Li M., Yi P., Mu J.J., Yang T., Chu J., Jung S.Y., RA O'Malley B.W., Gu W., Qin J., Wang Y.; RT "RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in RT response to DNA damage."; RL Proc. Natl. Acad. Sci. U.S.A. 107:4579-4584(2010). RN [135] RP INTERACTION WITH BRD7. RX PubMed=20660729; DOI=10.1073/pnas.1009559107; RA Burrows A.E., Smogorzewska A., Elledge S.J.; RT "Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are RT critical regulators of p53 required for induction of replicative RT senescence."; RL Proc. Natl. Acad. Sci. U.S.A. 107:14280-14285(2010). RN [136] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [137] RP INTERACTION WITH UHRF2. RX PubMed=21952639; DOI=10.4161/cc.10.19.17176; RA Mori T., Ikeda D.D., Fukushima T., Takenoshita S., Kochi H.; RT "NIRF constitutes a nodal point in the cell cycle network and is a RT candidate tumor suppressor."; RL Cell Cycle 10:3284-3299(2011). RN [138] RP INTERACTION WITH MUL1, SUBCELLULAR LOCATION, UBIQUITINATION AT LYS-24 BY RP MUL1, AND MUTAGENESIS OF LYS-24. RX PubMed=21597459; DOI=10.1038/cdd.2011.57; RA Jung J.H., Bae S., Lee J.Y., Woo S.R., Cha H.J., Yoon Y., Suh K.S., RA Lee S.J., Park I.C., Jin Y.W., Lee K.H., An S., Lee J.H.; RT "E3 ubiquitin ligase Hades negatively regulates the exonuclear function of RT p53."; RL Cell Death Differ. 18:1865-1875(2011). RN [139] RP FUNCTION, INTERACTION WITH AURKB AND NOC2L, PHOSPHORYLATION AT SER-183; RP SER-269 AND THR-284, CHARACTERIZATION OF VARIANT ALA-284, MUTAGENESIS OF RP SER-183; SER-269 AND THR-284, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=20959462; DOI=10.1074/jbc.m110.174755; RA Wu L., Ma C.A., Zhao Y., Jain A.; RT "Aurora B interacts with NIR-p53, leading to p53 phosphorylation in its RT DNA-binding domain and subsequent functional suppression."; RL J. Biol. Chem. 286:2236-2244(2011). RN [140] RP INTERACTION WITH ALDOB AND G6PD. RX PubMed=35122041; DOI=10.1038/s43018-020-0086-7; RA Li M., He X., Guo W., Yu H., Zhang S., Wang N., Liu G., Sa R., Shen X., RA Jiang Y., Tang Y., Zhuo Y., Yin C., Tu Q., Li N., Nie X., Li Y., Hu Z., RA Zhu H., Ding J., Li Z., Liu T., Zhang F., Zhou H., Li S., Yue J., Yan Z., RA Cheng S., Tao Y., Yin H.; RT "Aldolase B suppresses hepatocellular carcinogenesis by inhibiting G6PD and RT pentose phosphate pathways."; RL Nat. Cancer 1:735-747(2020). RN [141] RP INVOLVEMENT IN BCC7. RX PubMed=21946351; DOI=10.1038/ng.926; RA Stacey S.N., Sulem P., Jonasdottir A., Masson G., Gudmundsson J., RA Gudbjartsson D.F., Magnusson O.T., Gudjonsson S.A., Sigurgeirsson B., RA Thorisdottir K., Ragnarsson R., Benediktsdottir K.R., Nexo B.A., RA Tjonneland A., Overvad K., Rudnai P., Gurzau E., Koppova K., Hemminki K., RA Corredera C., Fuentelsaz V., Grasa P., Navarrete S., Fuertes F., RA Garcia-Prats M.D., Sanambrosio E., Panadero A., De Juan A., Garcia A., RA Rivera F., Planelles D., Soriano V., Requena C., Aben K.K., RA van Rossum M.M., Cremers R.G., van Oort I.M., van Spronsen D.J., RA Schalken J.A., Peters W.H., Helfand B.T., Donovan J.L., Hamdy F.C., RA Badescu D., Codreanu O., Jinga M., Csiki I.E., Constantinescu V., Badea P., RA Mates I.N., Dinu D.E., Constantin A., Mates D., Kristjansdottir S., RA Agnarsson B.A., Jonsson E., Barkardottir R.B., Einarsson G.V., RA Sigurdsson F., Moller P.H., Stefansson T., Valdimarsson T., RA Johannsson O.T., Sigurdsson H., Jonsson T., Jonasson J.G., RA Tryggvadottir L., Rice T., Hansen H.M., Xiao Y., Lachance D.H., RA O'Neill B.P., Kosel M.L., Decker P.A., Thorleifsson G., Johannsdottir H., RA Helgadottir H.T., Sigurdsson A., Steinthorsdottir V., Lindblom A., RA Sandler R.S., Keku T.O., Banasik K., Jorgensen T., Witte D.R., Hansen T., RA Pedersen O., Jinga V., Neal D.E., Catalona W.J., Wrensch M., Wiencke J., RA Jenkins R.B., Nagore E., Vogel U., Kiemeney L.A., Kumar R., Mayordomo J.I., RA Olafsson J.H., Kong A., Thorsteinsdottir U., Rafnar T., Stefansson K.; RT "A germline variant in the TP53 polyadenylation signal confers cancer RT susceptibility."; RL Nat. Genet. 43:1098-1103(2011). RN [142] RP INTERACTION WITH NUAK1, AND PHOSPHORYLATION AT SER-15 AND SER-392. RX PubMed=21317932; DOI=10.1038/onc.2011.19; RA Hou X., Liu J.E., Liu W., Liu C.Y., Liu Z.Y., Sun Z.Y.; RT "A new role of NUAK1: directly phosphorylating p53 and regulating cell RT proliferation."; RL Oncogene 30:2933-2942(2011). RN [143] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PPIF. RX PubMed=22726440; DOI=10.1016/j.cell.2012.05.014; RA Vaseva A.V., Marchenko N.D., Ji K., Tsirka S.E., Holzmann S., Moll U.M.; RT "p53 opens the mitochondrial permeability transition pore to trigger RT necrosis."; RL Cell 149:1536-1548(2012). RN [144] RP INTERACTION WITH UBC9, PHOSPHORYLATION AT SER-392, AND SUMOYLATION AT RP LYS-386. RX PubMed=22214662; DOI=10.4161/cc.11.2.18999; RA Bennett R.L., Pan Y., Christian J., Hui T., May W.S. Jr.; RT "The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and RT activation, leading to G(1) arrest."; RL Cell Cycle 11:407-417(2012). RN [145] RP INTERACTION WITH NOP53. RX PubMed=22522597; DOI=10.1038/cdd.2012.40; RA Lee S., Kim J.Y., Kim Y.J., Seok K.O., Kim J.H., Chang Y.J., Kang H.Y., RA Park J.H.; RT "Nucleolar protein GLTSCR2 stabilizes p53 in response to ribosomal RT stresses."; RL Cell Death Differ. 19:1613-1622(2012). RN [146] RP INTERACTION WITH ZNF385B. RX PubMed=22945289; DOI=10.1002/eji.201242530; RA Iijima K., Yamada H., Miharu M., Imadome K., Miyagawa Y., Akimoto S., RA Kobayashi K., Okita H., Nakazawa A., Fujiwara S., Fujimoto J., Kiyokawa N.; RT "ZNF385B is characteristically expressed in germinal center B cells and RT involved in B-cell apoptosis."; RL Eur. J. Immunol. 42:3405-3415(2012). RN [147] RP METHYLATION AT LYS-370 AND LYS-382. RX PubMed=22864287; DOI=10.1038/nsmb.2353; RA Cui G., Park S., Badeaux A.I., Kim D., Lee J., Thompson J.R., Yan F., RA Kaneko S., Yuan Z., Botuyan M.V., Bedford M.T., Cheng J.Q., Mer G.; RT "PHF20 is an effector protein of p53 double lysine methylation that RT stabilizes and activates p53."; RL Nat. Struct. Mol. Biol. 19:916-924(2012). RN [148] RP FUNCTION. RX PubMed=24051492; DOI=10.1038/ncomms3444; RA Miki T., Matsumoto T., Zhao Z., Lee C.C.; RT "p53 regulates Period2 expression and the circadian clock."; RL Nat. Commun. 4:2444-2444(2013). RN [149] RP ACETYLATION AT LYS-120 AND LYS-382. RX PubMed=23431171; DOI=10.1073/pnas.1300490110; RA Rokudai S., Laptenko O., Arnal S.M., Taya Y., Kitabayashi I., Prives C.; RT "MOZ increases p53 acetylation and premature senescence through its complex RT formation with PML."; RL Proc. Natl. Acad. Sci. U.S.A. 110:3895-3900(2013). RN [150] RP INTERACTION WITH HSPA9, AND SUBCELLULAR LOCATION. RX PubMed=24625977; DOI=10.1038/cddis.2014.100; RA Sane S., Abdullah A., Boudreau D.A., Autenried R.K., Gupta B.K., Wang X., RA Wang H., Schlenker E.H., Zhang D., Telleria C., Huang L., Chauhan S.C., RA Rezvani K.; RT "Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell RT death by interfering with the p53-Mortalin interactions in colon cancer RT cells."; RL Cell Death Dis. 5:e1118-e1118(2014). RN [151] RP INTERACTION WITH S100A4, AND SUBCELLULAR LOCATION. RX PubMed=23752197; DOI=10.1038/onc.2013.213; RA Orre L.M., Panizza E., Kaminskyy V.O., Vernet E., Graeslund T., RA Zhivotovsky B., Lehtioe J.; RT "S100A4 interacts with p53 in the nucleus and promotes p53 degradation."; RL Oncogene 32:5531-5540(2013). RN [152] RP FUNCTION. RX PubMed=24652652; DOI=10.1093/jnci/dju053; RA Polato F., Rusconi P., Zangrossi S., Morelli F., Boeri M., Musi A., RA Marchini S., Castiglioni V., Scanziani E., Torri V., Broggini M.; RT "DRAGO (KIAA0247), a new DNA damage-responsive, p53-inducible gene that RT cooperates with p53 as oncosuppressor. [Corrected]."; RL J. Natl. Cancer Inst. 106:1-10(2014). RN [153] RP INTERACTION WITH UBD. RX PubMed=25422469; DOI=10.1073/pnas.1403383111; RA Theng S.S., Wang W., Mah W.C., Chan C., Zhuo J., Gao Y., Qin H., Lim L., RA Chong S.S., Song J., Lee C.G.; RT "Disruption of FAT10-MAD2 binding inhibits tumor progression."; RL Proc. Natl. Acad. Sci. U.S.A. 111:E5282-E5291(2014). RN [154] RP INTERACTION WITH TTC5, AND SUBCELLULAR LOCATION. RX PubMed=25168243; DOI=10.1038/cdd.2014.135; RA Maniam S., Coutts A.S., Stratford M.R., McGouran J., Kessler B., RA La Thangue N.B.; RT "Cofactor Strap regulates oxidative phosphorylation and mitochondrial p53 RT activity through ATP synthase."; RL Cell Death Differ. 22:156-163(2015). RN [155] RP SUBCELLULAR LOCATION. RX PubMed=26634371; DOI=10.1007/s12192-015-0661-5; RA Sane S., Abdullah A., Nelson M.E., Wang H., Chauhan S.C., Newton S.S., RA Rezvani K.; RT "Structural studies of UBXN2A and mortalin interaction and the putative RT role of silenced UBXN2A in preventing response to chemotherapy."; RL Cell Stress Chaperones 21:313-326(2016). RN [156] RP UBIQUITINATION. RX PubMed=25591766; DOI=10.1159/000369691; RA Yang L., Zhou B., Li X., Lu Z., Li W., Huo X., Miao Z.; RT "RNF125 is a ubiquitin-protein ligase that promotes p53 degradation."; RL Cell. Physiol. Biochem. 35:237-245(2015). RN [157] RP INTERACTION WITH HADV5 E1B-55K (MICROBIAL INFECTION). RX PubMed=25772236; DOI=10.1038/onc.2015.63; RA Wimmer P., Berscheminski J., Blanchette P., Groitl P., Branton P.E., RA Hay R.T., Dobner T., Schreiner S.; RT "PML isoforms IV and V contribute to adenovirus-mediated oncogenic RT transformation by functionally inhibiting the tumor-suppressor p53."; RL Oncogene 35:69-82(2016). RN [158] RP INTERACTION WITH FBXO22, AND UBIQUITINATION. RX PubMed=26868148; DOI=10.1038/ncomms10574; RA Johmura Y., Sun J., Kitagawa K., Nakanishi K., Kuno T., Naiki-Ito A., RA Sawada Y., Miyamoto T., Okabe A., Aburatani H., Li S., Miyoshi I., RA Takahashi S., Kitagawa M., Nakanishi M.; RT "SCF(Fbxo22)-KDM4A targets methylated p53 for degradation and regulates RT senescence."; RL Nat. Commun. 7:10574-10574(2016). RN [159] RP INTERACTION WITH AFG1L, AND SUBCELLULAR LOCATION. RX PubMed=27323408; DOI=10.18632/oncotarget.9959; RA Cesnekova J., Spacilova J., Hansikova H., Houstek J., Zeman J., RA Stiburek L.; RT "LACE1 interacts with p53 and mediates its mitochondrial translocation and RT apoptosis."; RL Oncotarget 7:47687-47698(2016). RN [160] RP INTERACTION WITH DDX3X AND GAMMA-TUBULIN, SUBCELLULAR LOCATION, AND RP PHOSPHORYLATION AT SER-15. RX PubMed=28842590; DOI=10.1038/s41598-017-09779-w; RA Chen W.J., Wang W.T., Tsai T.Y., Li H.K., Lee Y.W.; RT "DDX3 localizes to the centrosome and prevents multipolar mitosis by RT epigenetically and translationally modulating p53 expression."; RL Sci. Rep. 7:9411-9411(2017). RN [161] RP DEUBIQUITINATION BY USP3. RX PubMed=28807825; DOI=10.1016/j.bbrc.2017.08.036; RA Fu S., Shao S., Wang L., Liu H., Hou H., Wang Y., Wang H., Huang X., Lv R.; RT "USP3 stabilizes p53 protein through its deubiquitinase activity."; RL Biochem. Biophys. Res. Commun. 492:178-183(2017). RN [162] RP INTERACTION WITH DAZAP2. RX PubMed=33591310; DOI=10.1093/nar/gkab084; RA Liebl M.C., Moehlenbrink J., Becker H., Raddatz G., Abdeen S.K., RA Aqeilan R.I., Lyko F., Hofmann T.G.; RT "DAZAP2 acts as specifier of the p53 response to DNA damage."; RL Nucleic Acids Res. 49:2759-2776(2021). RN [163] RP INVOLVEMENT IN BMFS5. RX PubMed=30146126; DOI=10.1016/j.ajhg.2018.07.020; RA Toki T., Yoshida K., Wang R., Nakamura S., Maekawa T., Goi K., Katoh M.C., RA Mizuno S., Sugiyama F., Kanezaki R., Uechi T., Nakajima Y., Sato Y., RA Okuno Y., Sato-Otsubo A., Shiozawa Y., Kataoka K., Shiraishi Y., Sanada M., RA Chiba K., Tanaka H., Terui K., Sato T., Kamio T., Sakaguchi H., Ohga S., RA Kuramitsu M., Hamaguchi I., Ohara A., Kanno H., Miyano S., Kojima S., RA Ishiguro A., Sugita K., Kenmochi N., Takahashi S., Eto K., Ogawa S., RA Ito E.; RT "De novo mutations activating germline TP53 in an inherited bone-marrow- RT failure syndrome."; RL Am. J. Hum. Genet. 103:440-447(2018). RN [164] RP INTERACTION WITH MORN3, DEACETYLATION AT LYS-382, AND UBQIQUITINATION. RX PubMed=29681526; DOI=10.1016/j.chembiol.2018.03.010; RA Liang L., Wang H., Shi H., Li Z., Yao H., Bu Z., Song N., Li C., Xiang D., RA Zhang Y., Wang J., Hu Y., Xu Q., Ma Y., Cheng Z., Wang Y., Zhao S., RA Qian J., Chen Y., Fang J.Y., Xu J.; RT "A Designed Peptide Targets Two Types of Modifications of p53 with Anti- RT cancer Activity."; RL Cell Chem. Biol. 25:761-774.e5(2018). RN [165] RP ACETYLATION AT LYS-381, DEACETYLATION BY SIRT6, AND MUTAGENESIS OF LYS-381. RX PubMed=29474172; DOI=10.7554/elife.32127; RA Ghosh S., Wong S.K., Jiang Z., Liu B., Wang Y., Hao Q., Gorbunova V., RA Liu X., Zhou Z.; RT "Haploinsufficiency of Trp53 dramatically extends the lifespan of Sirt6- RT deficient mice."; RL Elife 7:0-0(2018). RN [166] RP PHOSPHORYLATION AT THR-18 BY VRK1. RX PubMed=31527692; DOI=10.1038/s41598-019-49821-7; RA Martin-Doncel E., Rojas A.M., Cantarero L., Lazo P.A.; RT "VRK1 functional insufficiency due to alterations in protein stability or RT kinase activity of human VRK1 pathogenic variants implicated in neuromotor RT syndromes."; RL Sci. Rep. 9:13381-13381(2019). RN [167] RP DOMAIN, AND MUTAGENESIS OF SER-392. RX PubMed=31953488; DOI=10.1038/s41598-020-57521-w; RA Kamagata K., Kanbayashi S., Honda M., Itoh Y., Takahashi H., Kameda T., RA Nagatsugi F., Takahashi S.; RT "Liquid-like droplet formation by tumor suppressor p53 induced by RT multivalent electrostatic interactions between two disordered domains."; RL Sci. Rep. 10:580-580(2020). RN [168] RP INTERACTION WITH KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS/HHV-8 PROTEIN RP ORF45 (MICROBIAL INFECTION). RX PubMed=34523970; DOI=10.1128/jvi.01459-21; RA Alzhanova D., Meyo J.O., Juarez A., Dittmer D.P.; RT "The ORF45 protein of Kaposi Sarcoma-associated Herpesvirus (KSHV) is an RT inhibitor of p53 signaling during viral reactivation."; RL J. Virol. 0:0-0(2021). RN [169] RP INTERACTION WITH ZNF768. RX PubMed=34404770; DOI=10.1038/s41467-021-24932-w; RA Villot R., Poirier A., Bakan I., Boulay K., Fernandez E., Devillers R., RA Gama-Braga L., Tribouillard L., Gagne A., Duchesne E., Caron D., RA Berube J.S., Berube J.C., Coulombe Y., Orain M., Gelinas Y., Gobeil S., RA Bosse Y., Masson J.Y., Elowe S., Bilodeau S., Manem V., Joubert P., RA Mallette F.A., Laplante M.; RT "ZNF768 links oncogenic RAS to cellular senescence."; RL Nat. Commun. 12:4841-4841(2021). RN [170] RP FUNCTION, DOMAIN, PHOSPHORYLATION AT SER-392, AND MUTAGENESIS OF SER-392. RX PubMed=35618207; DOI=10.1016/j.bbagrm.2022.194827; RA Dai Z., Li G., Chen Q., Yang X.; RT "Ser392 phosphorylation modulated a switch between p53 and transcriptional RT condensates."; RL Biochim. Biophys. Acta 1865:194827-194827(2022). RN [171] RP DOMAIN, SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANTS LFS CYS-337; RP HIS-337 AND PRO-344, AND CHARACTERIZATION OF VARIANT PRO-337. RX PubMed=36108750; DOI=10.1016/j.ijbiomac.2022.09.087; RA Chen C., Fu G., Guo Q., Xue S., Luo S.Z.; RT "Phase separation of p53 induced by its unstructured basic region and RT prevented by oncogenic mutations in tetramerization domain."; RL Int. J. Biol. Macromol. 222:207-216(2022). RN [172] RP FUNCTION, AND DOMAIN. RX PubMed=36634798; DOI=10.1016/j.ijbiomac.2023.123221; RA Chen Q., Wu Y., Dai Z., Zhang Z., Yang X.; RT "Phosphorylation and specific DNA improved the incorporation ability of p53 RT into functional condensates."; RL Int. J. Biol. Macromol. 230:123221-123221(2023). RN [173] RP FUNCTION, DOMAIN, LACTYLATION AT LYS-120 AND LYS-139, AND CHARACTERIZATION RP OF VARIANTS GLU-120; GLN-120; ASN-139; THR-139; GLN-139 AND GLU-139. RX PubMed=38653238; DOI=10.1016/j.cell.2024.04.002; RA Zong Z., Xie F., Wang S., Wu X., Zhang Z., Yang B., Zhou F.; RT "Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase RT that lactylates p53 and contributes to tumorigenesis."; RL Cell 187:2375-2392(2024). RN [174] RP STRUCTURE BY NMR OF 319-360. RX PubMed=8023159; DOI=10.1126/science.8023159; RA Clore G.M., Omichinski J.G., Sakaguchi K., Zambrano N., Sakamoto H., RA Appella E., Gronenborn A.M.; RT "High-resolution structure of the oligomerization domain of p53 by RT multidimensional NMR."; RL Science 265:386-391(1994). RN [175] RP STRUCTURE BY NMR OF 325-355. RX PubMed=7773777; DOI=10.1038/nsb1294-877; RA Lee W., Harvey T.S., Yin Y., Yau P., Litchfield D., Arrowsmith C.H.; RT "Solution structure of the tetrameric minimum transforming domain of p53."; RL Nat. Struct. Biol. 1:877-890(1994). RN [176] RP STRUCTURE BY NMR OF 326-354. RX PubMed=9321402; DOI=10.1093/emboj/16.20.6230; RA McCoy M., Stavridi E.S., Waterman J.L., Wieczorek A.M., Opella S.J., RA Halazonetis T.D.; RT "Hydrophobic side-chain size is a determinant of the three-dimensional RT structure of the p53 oligomerization domain."; RL EMBO J. 16:6230-6236(1997). RN [177] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 94-289. RX PubMed=8023157; DOI=10.1126/science.8023157; RA Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P.; RT "Crystal structure of a p53 tumor suppressor-DNA complex: understanding RT tumorigenic mutations."; RL Science 265:346-355(1994). RN [178] RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 325-356. RX PubMed=7878469; DOI=10.1126/science.7878469; RA Jeffrey P.D., Gorina S., Pavletich N.P.; RT "Crystal structure of the tetramerization domain of the p53 tumor RT suppressor at 1.7 angstroms."; RL Science 267:1498-1502(1995). RN [179] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 13-29 IN COMPLEX WITH MDM2. RX PubMed=8875929; DOI=10.1126/science.274.5289.948; RA Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., RA Pavletich N.P.; RT "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor RT transactivation domain."; RL Science 274:948-953(1996). RN [180] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 97-287 IN COMPLEX WITH 53BP2. RX PubMed=8875926; DOI=10.1126/science.274.5289.1001; RA Gorina S., Pavletich N.P.; RT "Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains RT of 53BP2."; RL Science 274:1001-1005(1996). RN [181] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC IONS, RP AND SUBUNIT. RX PubMed=14534297; DOI=10.1074/jbc.m309732200; RA Joerger A.C., Allen M.D., Fersht A.R.; RT "Crystal structure of a superstable mutant of human p53 core domain. RT Insights into the mechanism of rescuing oncogenic mutations."; RL J. Biol. Chem. 279:1291-1296(2004). RN [182] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA AND RP ZINC IONS, AND SUBUNIT. RX PubMed=16793544; DOI=10.1016/j.molcel.2006.05.015; RA Kitayner M., Rozenberg H., Kessler N., Rabinovich D., Shaulov L., RA Haran T.E., Shakked Z.; RT "Structural basis of DNA recognition by p53 tetramers."; RL Mol. Cell 22:741-753(2006). RN [183] RP X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 358-367 IN COMPLEX WITH USP7, AND RP INTERACTION WITH USP7. RX PubMed=16474402; DOI=10.1038/nsmb1067; RA Sheng Y., Saridakis V., Sarkari F., Duan S., Wu T., Arrowsmith C.H., RA Frappier L.; RT "Molecular recognition of p53 and MDM2 by USP7/HAUSP."; RL Nat. Struct. Mol. Biol. 13:285-291(2006). RN [184] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 360-368 IN COMPLEX WITH USP7, RP MUTAGENESIS OF PRO-359; GLY-361 AND SER-362, AND INTERACTION WITH USP7. RX PubMed=16402859; DOI=10.1371/journal.pbio.0040027; RA Hu M., Gu L., Li M., Jeffrey P.D., Gu W., Shi Y.; RT "Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: RT implications for the regulation of the p53-MDM2 pathway."; RL PLoS Biol. 4:228-239(2006). RN [185] RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 377-386, METHYLATION AT LYS-382, RP MUTAGENESIS OF LYS-382, AND INTERACTION WITH L3MBTL1. RX PubMed=20870725; DOI=10.1074/jbc.m110.139527; RA West L.E., Roy S., Lachmi-Weiner K., Hayashi R., Shi X., Appella E., RA Kutateladze T.G., Gozani O.; RT "The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine RT 382 to target gene repression."; RL J. Biol. Chem. 285:37725-37732(2010). RN [186] RP REVIEW. RX PubMed=8266092; DOI=10.1126/science.8266092; RA Harris C.C.; RT "p53: at the crossroads of molecular carcinogenesis and risk assessment."; RL Science 262:1980-1981(1993). RN [187] RP REVIEW ON VARIANTS. RX PubMed=1905840; DOI=10.1126/science.1905840; RA Hoolstein M., Sidransky D., Vogelstein B., Harris C.C.; RT "p53 mutations in human cancers."; RL Science 253:49-53(1991). RN [188] RP REVIEW ON VARIANTS. RX PubMed=8829653; RX DOI=10.1002/(sici)1098-1004(1996)7:3<202::aid-humu4>3.0.co;2-c; RA de Vries E.M.G., Ricke D.O., de Vries T.N., Hartmann A., Blaszyk H., RA Liao D., Soussi T., Kovach J.S., Sommer S.S.; RT "Database of mutations in the p53 and APC tumor suppressor genes designed RT to facilitate molecular epidemiological analyses."; RL Hum. Mutat. 7:202-213(1996). RN [189] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC IONS. RX PubMed=17015838; DOI=10.1073/pnas.0607286103; RA Joerger A.C., Ang H.C., Fersht A.R.; RT "Structural basis for understanding oncogenic p53 mutations and designing RT rescue drugs."; RL Proc. Natl. Acad. Sci. U.S.A. 103:15056-15061(2006). RN [190] RP X-RAY CRYSTALLOGRAPHY (1.54 ANGSTROMS) OF 94-292 OF VARIANT GLN-282. RX PubMed=18453682; DOI=10.1107/s0907444908003338; RA Tu C., Tan Y.H., Shaw G., Zhou Z., Bai Y., Luo R., Ji X.; RT "Impact of low-frequency hotspot mutation R282Q on the structure of p53 RT DNA-binding domain as revealed by crystallography at 1.54 angstroms RT resolution."; RL Acta Crystallogr. D 64:471-477(2008). RN [191] RP X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 94-312 OF VARIANT CYS-202 IN RP COMPLEX WITH ZINC IONS AND PHIKAN083. RX PubMed=18650397; DOI=10.1073/pnas.0805326105; RA Boeckler F.M., Joerger A.C., Jaggi G., Rutherford T.J., Veprintsev D.B., RA Fersht A.R.; RT "Targeted rescue of a destabilized mutant of p53 by an in silico screened RT drug."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10360-10365(2008). RN [192] RP X-RAY CRYSTALLOGRAPHY (1.2 ANGSTROMS) OF 94-293 OF VARIANT SER-249 IN RP COMPLEX WITH DNA. RX PubMed=18996393; DOI=10.1016/j.jmb.2008.10.063; RA Suad O., Rozenberg H., Brosh R., Diskin-Posner Y., Kessler N., Shimon L.J., RA Frolow F., Liran A., Rotter V., Shakked Z.; RT "Structural basis of restoring sequence-specific DNA binding and RT transactivation to mutant p53 by suppressor mutations."; RL J. Mol. Biol. 385:249-265(2009). RN [193] RP X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 94-310 IN COMPLEX WITH ZINC IONS. RX PubMed=19515728; DOI=10.1093/protein/gzp018; RA Khoo K.H., Joerger A.C., Freund S.M., Fersht A.R.; RT "Stabilising the DNA-binding domain of p53 by rational design of its RT hydrophobic core."; RL Protein Eng. Des. Sel. 22:421-430(2009). RN [194] RP X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 94-312 OF VARIANT CYS-220 IN RP COMPLEX WITH ZINC IONS. RX PubMed=20142040; DOI=10.1016/j.chembiol.2009.12.011; RA Basse N., Kaar J.L., Settanni G., Joerger A.C., Rutherford T.J., RA Fersht A.R.; RT "Toward the rational design of p53-stabilizing drugs: probing the surface RT of the oncogenic Y220C mutant."; RL Chem. Biol. 17:46-56(2010). RN [195] RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA AND RP ZINC IONS, AND SUBUNIT. RX PubMed=20364130; DOI=10.1038/nsmb.1800; RA Kitayner M., Rozenberg H., Rohs R., Suad O., Rabinovich D., Honig B., RA Shakked Z.; RT "Diversity in DNA recognition by p53 revealed by crystal structures with RT Hoogsteen base pairs."; RL Nat. Struct. Mol. Biol. 17:423-429(2010). RN [196] {ECO:0007744|PDB:6T58} RP X-RAY CRYSTALLOGRAPHY (3.10 ANGSTROMS) OF 17-56, AND INTERACTION WITH RP S100A4. RX PubMed=32442400; DOI=10.1016/j.str.2020.05.001; RA Ecsedi P., Gogl G., Hof H., Kiss B., Harmat V., Nyitray L.; RT "Structure Determination of the Transactivation Domain of p53 in Complex RT with S100A4Using Annexin A2 as a Crystallization Chaperone."; RL Structure 28:943-953.e4(2020). RN [197] RP VARIANT ARG-72. RX PubMed=1999338; DOI=10.1007/bf00201836; RA Olschwang S., Laurent-Puig P., Vassal A., Salmon R.-J., Thomas G.; RT "Characterization of a frequent polymorphism in the coding sequence of the RT Tp53 gene in colonic cancer patients and a control population."; RL Hum. Genet. 86:369-370(1991). RN [198] RP VARIANT LFS THR-133. RX PubMed=1933902; RA Law J.C., Strong L.C., Chidambaram A., Ferrell R.E.; RT "A germ line mutation in exon 5 of the p53 gene in an extended cancer RT family."; RL Cancer Res. 51:6385-6387(1991). RN [199] RP VARIANTS LFS CYS-245; TRP-248; PRO-252 AND LYS-258. RX PubMed=1978757; DOI=10.1126/science.1978757; RA Malkin D., Li F.P., Strong L.C., Fraumeni J.F. Jr., Nelson C.E., Kim D.H., RA Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A., Friend S.H.; RT "Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, RT and other neoplasms."; RL Science 250:1233-1238(1990). RN [200] RP VARIANT LFS ASP-245. RX PubMed=2259385; DOI=10.1038/348747a0; RA Srivastava S., Zou Z., Pirollo K., Blattner W., Chang E.H.; RT "Germ-line transmission of a mutated p53 gene in a cancer-prone family with RT Li-Fraumeni syndrome."; RL Nature 348:747-749(1990). RN [201] RP VARIANT LFS LEU-272. RX PubMed=1737852; DOI=10.1172/jci115630; RA Felix C.A., Nau M.M., Takahashi T., Mitsudomi T., Chiba I., Poplack D.G., RA Reaman G.H., Cole D.E., Letterio J.J., Whang-Peng J., Knutsen T., RA Minna J.D.; RT "Hereditary and acquired p53 gene mutations in childhood acute RT lymphoblastic leukemia."; RL J. Clin. Invest. 89:640-647(1992). RN [202] RP VARIANTS LFS HIS-273 AND VAL-325. RX PubMed=1565144; DOI=10.1056/nejm199205143262002; RA Malkin D., Jolly K.W., Barbier N., Look A.T., Friend S.H., Gebhardt M.C., RA Andersen T.I., Boerresen A.-L., Li F.P., Garber J., Strong L.C.; RT "Germline mutations of the p53 tumor-suppressor gene in children and young RT adults with second malignant neoplasms."; RL N. Engl. J. Med. 326:1309-1315(1992). RN [203] RP VARIANTS SPORADIC CANCERS GLN-132; SER-249; LYS-280 AND LYS-285. RX PubMed=1694291; RA Bartek J., Iggo R., Gannon J., Lane D.P.; RT "Genetic and immunochemical analysis of mutant p53 in human breast cancer RT cell lines."; RL Oncogene 5:893-899(1990). RN [204] RP VARIANTS SPORADIC CANCERS PHE-241 AND HIS-273. RX PubMed=1699228; DOI=10.1073/pnas.87.19.7555; RA Rodrigues N.R., Rowan A., Smith M.E.F., Kerr I.B., Bodmer W.F., RA Gannon J.V., Lane D.P.; RT "p53 mutations in colorectal cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 87:7555-7559(1990). RN [205] RP VARIANTS SPORADIC CANCER VAL-154; VAL-245; GLN-248; LEU-278 AND SER-278. RX PubMed=2263646; DOI=10.1073/pnas.87.24.9958; RA Hollstein M.C., Metcalf R.A., Welsh J.A., Montesano R., Harris C.C.; RT "Frequent mutation of the p53 gene in human esophageal cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 87:9958-9961(1990). RN [206] RP VARIANTS SPORADIC CANCERS. RX PubMed=1647768; DOI=10.1016/0006-291x(91)90623-f; RA Ishioka C., Sato T., Gamoh M., Suzuki T., Shibata H., Kanamaru R., RA Wakui A., Yamazaki T.; RT "Mutations of the P53 gene, including an intronic point mutation, in RT colorectal tumors."; RL Biochem. Biophys. Res. Commun. 177:901-906(1991). RN [207] RP VARIANTS SPORADIC CANCERS LEU-152; ALA-155; HIS-175; PHE-176 AND HIS-273. RX PubMed=1868473; RA Casson A.G., Mukhopadhyay T., Cleary K.R., Ro J.Y., Levin B., Roth J.A.; RT "p53 gene mutations in Barrett's epithelium and esophageal cancer."; RL Cancer Res. 51:4495-4499(1991). RN [208] RP VARIANTS SPORADIC CANCERS IN CHINA. RX PubMed=1849234; DOI=10.1038/350427a0; RA Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C.; RT "Mutational hotspot in the p53 gene in human hepatocellular carcinomas."; RL Nature 350:427-428(1991). RN [209] RP VARIANTS SPORADIC CANCERS IN SOUTH AFRICA. RX PubMed=1672732; DOI=10.1038/350429a0; RA Bressac B., Kew M., Wands J., Ozturk M.; RT "Selective G to T mutations of p53 gene in hepatocellular carcinoma from RT southern Africa."; RL Nature 350:429-431(1991). RN [210] RP VARIANTS SPORADIC CANCERS PHE-176; PHE-242; CYS-245; LEU-248 AND HIS-273. RX PubMed=1394225; RA Somers K.D., Merrick M.A., Lopez M.E., Incognito L.S., Schechter G.L., RA Casey G.; RT "Frequent p53 mutations in head and neck cancer."; RL Cancer Res. 52:5997-6000(1992). RN [211] RP VARIANTS SPORADIC CANCERS. RX PubMed=1327751; DOI=10.1002/j.1460-2075.1992.tb05487.x; RA Crook T., Vousden K.H.; RT "Properties of p53 mutations detected in primary and secondary cervical RT cancers suggest mechanisms of metastasis and involvement of environmental RT carcinogens."; RL EMBO J. 11:3935-3940(1992). RN [212] RP VARIANTS SPORADIC CANCERS CYS-205; GLU-281 AND LYS-285. RX PubMed=1459726; DOI=10.1002/ijc.2910520606; RA Sakai E., Rikimaru K., Ueda M., Matsumoto Y., Ishii N., Enomoto S., RA Yamamoto H., Tsuchida N.; RT "The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous- RT cell carcinoma."; RL Int. J. Cancer 52:867-872(1992). RN [213] RP VARIANT PRO-HIS-PRO-178 INS. RX PubMed=1303181; DOI=10.1093/hmg/1.3.207; RA Bhatia K., Guiterrez M.I., Magrath I.T.; RT "A novel mutation in the p53 gene in a Burkitt's lymphoma cell line."; RL Hum. Mol. Genet. 1:207-208(1992). RN [214] RP VARIANTS SPORADIC CANCERS. RX PubMed=1437144; RA Duthu A., Debuire B., Romano J.W., Ehrhart J.C., Fiscella M., May E., RA Appella E., May P.; RT "p53 mutations in Raji cells: characterization and localization relative to RT other Burkitt's lymphomas."; RL Oncogene 7:2161-2167(1992). RN [215] RP VARIANT SPORADIC CANCER THR-280. RX PubMed=1631151; DOI=10.1073/pnas.89.14.6516; RA Sun Y., Hegamyer G., Heng Y.-J., Hildesheim A., Chen J.-Y., Chen I.-H., RA Cao Y., Yao K.-T., Colburn N.H.; RT "An infrequent point mutation of the p53 gene in human nasopharyngeal RT carcinoma."; RL Proc. Natl. Acad. Sci. U.S.A. 89:6516-6520(1992). RN [216] RP VARIANTS SPORADIC CANCERS SER-151; PRO-156; LYS-174; ARG-194; CYS-220; RP GLN-248; LEU-248 AND HIS-273. RX PubMed=7682763; RA Caamano J., Zhang S.Y., Rosvold E.A., Bauer B., Klein-Szanto A.J.P.; RT "p53 alterations in human squamous cell carcinomas and carcinoma cell RT lines."; RL Am. J. Pathol. 142:1131-1139(1993). RN [217] RP VARIANTS SPORADIC CANCERS. RX PubMed=8402617; RA Boyle J.O., Hakim J., Koch W., van der Riet P., Hruban R.H., Roa R.A., RA Correo R., Eby Y.J., Ruppert J.M., Sidransky D.; RT "The incidence of p53 mutations increases with progression of head and neck RT cancer."; RL Cancer Res. 53:4477-4480(1993). RN [218] RP VARIANTS SPORADIC CANCERS. RX PubMed=8336944; RA Hamelin R., Jego N., Laurent-Puig P., Vidaud M., Thomas G.; RT "Efficient screening of p53 mutations by denaturing gradient gel RT electrophoresis in colorectal tumors."; RL Oncogene 8:2213-2220(1993). RN [219] RP VARIANTS, AND INVOLVEMENT IN LFL. RX PubMed=8118819; RA Birch J.M., Hartley A.L., Tricker K.J., Prosser J., Condie A., Kelsey A.M., RA Harris M., Jones P.H., Binchy A., Crowther D., Craft A.W., Eden O.B., RA Evans D.G.R., Thompson E., Mann J.R., Martin J., Mitchell E.L.D., RA Santibanez-Koref M.F.; RT "Prevalence and diversity of constitutional mutations in the p53 gene among RT 21 Li-Fraumeni families."; RL Cancer Res. 54:1298-1304(1994). RN [220] RP CHARACTERIZATION OF VARIANT ALA-143. RX PubMed=8013454; DOI=10.1002/j.1460-2075.1994.tb06543.x; RA Zhang W., Guo X.-Y., Hu G.-Y., Liu W.-B., Shay J.W., Deisseroth A.B.; RT "A temperature-sensitive mutant of human p53."; RL EMBO J. 13:2535-2544(1994). RN [221] RP VARIANTS LFS HIS-175; ARG-193; GLN-248; CYS-273 AND TYR-275. RX PubMed=7887414; RA Frebourg T., Barbier N., Yan Y.-X., Garber J.E., Dreyfus M., RA Fraumeni J.F. Jr., Li F.P., Friend S.H.; RT "Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome."; RL Am. J. Hum. Genet. 56:608-615(1995). RN [222] RP VARIANTS, AND INVOLVEMENT IN LFL. RX PubMed=8718514; RA Eeles R.A.; RT "Germline mutations in the TP53 gene."; RL Cancer Surv. 25:101-124(1995). RN [223] RP VARIANT LFS HIS-175. RX PubMed=8825920; DOI=10.1136/jmg.32.12.942; RA Varley J.M., McGrown G., Thorncroft M., Tricker K.J., Teare M.D., RA Santibanez-Koref M.F., Houlston R.S., Martin J., Birch J.M., Evans D.G.R.; RT "An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 RT mutation in TP53."; RL J. Med. Genet. 32:942-945(1995). RN [224] RP VARIANTS SPORADIC CANCERS PHE-176; SER-245; TRP-248; TRP-282 AND GLN-286. RX PubMed=8829627; RX DOI=10.1002/(sici)1098-1004(1996)7:2<109::aid-humu4>3.0.co;2-7; RA Audrezet M.-P., Robaszkiewicz M., Mercier B., Nousbaum J.-B., Hardy E., RA Bail J.-P., Volant A., Lozac'H P., Gouerou H., Ferec C.; RT "Molecular analysis of the TP53 gene in Barrett's adenocarcinoma."; RL Hum. Mutat. 7:109-113(1996). RN [225] RP VARIANTS SPORADIC CANCERS. RX PubMed=9101296; RX DOI=10.1002/(sici)1098-1004(1997)9:4<348::aid-humu8>3.0.co;2-1; RA Guldberg P., Nedergaard T., Nielsen H.J., Olsen A.C., Ahrenkiel V., RA Zeuthen J.; RT "Single-step DGGE-based mutation scanning of the p53 gene: application to RT genetic diagnosis of colorectal cancer."; RL Hum. Mutat. 9:348-355(1997). RN [226] RP VARIANT SPORADIC CANCER ILE-157. RX PubMed=9419979; DOI=10.1038/sj.onc.1201668; RA Miyaki M., Nishio J., Konishi M., Kikuchi-Yanoshita R., Tanaka K., RA Muraoka M., Nagato M., Chong J.-M., Koike M., Terada T., Kawahara Y., RA Fukutome A., Tomiyama J., Chuganji Y., Momoi M., Utsunomiya J.; RT "Drastic genetic instability of tumors and normal tissues in Turcot RT syndrome."; RL Oncogene 15:2877-2881(1997). RN [227] RP VARIANTS SER-152; ILE-169; PHE-176; THR-195; CYS-220; ILE-230; CYS-273 AND RP SER-278. RX PubMed=9450901; RX DOI=10.1002/(sici)1098-1004(1998)11:1<39::aid-humu6>3.0.co;2-g; RA van Rensburg E.J., Engelbrecht S., van Heerden W.F.P., Kotze M.J., RA Raubenheimer E.J.; RT "Detection of p53 gene mutations in oral squamous cell carcinomas of a RT black African population sample."; RL Hum. Mutat. 11:39-44(1998). RN [228] RP VARIANT NON-CLASSICAL LFS CYS-337. RX PubMed=9452042; DOI=10.1002/humu.1380110121; RA Luca J.W., Strong L.C., Hansen M.F.; RT "A germline missense mutation R337C in exon 10 of the human p53 gene."; RL Hum. Mutat. Suppl. 1:S58-S61(1998). RN [229] RP VARIANT LFS ILE-292. RX PubMed=10484981; DOI=10.1016/s0165-4608(98)00276-3; RA Gueran S., Tunca Y., Imirzalioglu N.; RT "Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in a Li- RT Fraumeni syndrome family."; RL Cancer Genet. Cytogenet. 113:145-151(1999). RN [230] RP VARIANTS. RX PubMed=10549356; DOI=10.1016/s0065-230x(08)60785-x; RA Hainaut P., Hollstein M.; RT "p53 and human cancer: the first ten thousand mutations."; RL Adv. Cancer Res. 77:81-137(2000). RN [231] RP VARIANT ADCC HIS-337. RX PubMed=11481490; DOI=10.1073/pnas.161479898; RA Ribeiro R.C., Sandrini F., Figueiredo B., Zambetti G.P., Michalkiewicz E., RA Lafferty A.R., DeLacerda L., Rabin M., Cadwell C., Sampaio G., Cat I., RA Stratakis C.A., Sandrini R.; RT "An inherited p53 mutation that contributes in a tissue-specific manner to RT pediatric adrenal cortical carcinoma."; RL Proc. Natl. Acad. Sci. U.S.A. 98:9330-9335(2001). RN [232] RP INVOLVEMENT IN CPP. RX PubMed=12085209; DOI=10.1038/sj.bjc.6600269; RA Rutherford J., Chu C.E., Duddy P.M., Charlton R.S., Chumas P., Taylor G.R., RA Lu X., Barnes D.M., Camplejohn R.S.; RT "Investigations on a clinically and functionally unusual and novel germline RT p53 mutation."; RL Br. J. Cancer 86:1592-1596(2002). RN [233] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-134; PHE-157; CYS-163; HIS-175; RP ARG-177; ARG-193; PRO-213; PHE-241; PHE-242; GLN-248; TRP-248; SER-249; RP TRP-267; LYS-271; CYS-273; HIS-273; LEU-273; SER-278; ILE-280 AND HIS-281. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [234] RP VARIANTS PRO-110; VAL-113; VAL-138; CYS-163; HIS-163; THR-195; MET-216; RP ALA-241; MET-249; SER-251; TYR-259 AND CYS-273. RX PubMed=17224074; DOI=10.1186/bcr1637; RA Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A., Presswalla S., RA Kaaresen R., Strausberg R.L., Gerhard D.S., Kristensen V., Perou C.M., RA Boerresen-Dale A.-L.; RT "Somatic sequence alterations in twenty-one genes selected by expression RT profile analysis of breast carcinomas."; RL Breast Cancer Res. 9:R5-R5(2007). RN [235] RP VARIANTS. RX PubMed=17311302; DOI=10.1002/humu.20495; RA Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., RA Olivier M.; RT "Impact of mutant p53 functional properties on TP53 mutation patterns and RT tumor phenotype: lessons from recent developments in the IARC TP53 RT database."; RL Hum. Mutat. 28:622-629(2007). RN [236] RP CHARACTERIZATION OF VARIANT SPORADIC CANCER LYS-280, UBIQUITINATION, RP PROTEASOMAL DEGRADATION, AND INTERACTION WITH CCAR2. RX PubMed=25732823; DOI=10.1016/j.celrep.2015.01.066; RA Qin B., Minter-Dykhouse K., Yu J., Zhang J., Liu T., Zhang H., Lee S., RA Kim J., Wang L., Lou Z.; RT "DBC1 functions as a tumor suppressor by regulating p53 stability."; RL Cell Rep. 10:1324-1334(2015). RN [237] RP VARIANTS VAL-138; HIS-175; ILE-237; TRP-248 AND PRO-273. RX PubMed=27657329; DOI=10.1371/journal.pbio.1002555; RA Guan Y., Huang D., Chen F., Gao C., Tao T., Shi H., Zhao S., Liao Z., RA Lo L.J., Wang Y., Chen J., Peng J.; RT "Phosphorylation of Def Regulates Nucleolar p53 Turnover and Cell Cycle RT Progression through Def Recruitment of Calpain3."; RL PLoS Biol. 14:e1002555-e1002555(2016). CC -!- FUNCTION: Multifunctional transcription factor that induces cell cycle CC arrest, DNA repair or apoptosis upon binding to its target DNA sequence CC (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, CC PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, CC PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, CC PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, CC PubMed:9840937). Acts as a tumor suppressor in many tumor types; CC induces growth arrest or apoptosis depending on the physiological CC circumstances and cell type (PubMed:11025664, PubMed:12524540, CC PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17189187, CC PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, CC PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, CC PubMed:38653238, PubMed:9840937). Negatively regulates cell division by CC controlling expression of a set of genes required for this process CC (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, CC PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, CC PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, CC PubMed:24652652, PubMed:9840937). One of the activated genes is an CC inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be CC mediated either by stimulation of BAX and FAS antigen expression, or by CC repression of Bcl-2 expression (PubMed:12524540, PubMed:17189187). Its CC pro-apoptotic activity is activated via its interaction with CC PPP1R13B/ASPP1 or TP53BP2/ASPP2 (PubMed:12524540). However, this CC activity is inhibited when the interaction with PPP1R13B/ASPP1 or CC TP53BP2/ASPP2 is displaced by PPP1R13L/iASPP (PubMed:12524540). In CC cooperation with mitochondrial PPIF is involved in activating oxidative CC stress-induced necrosis; the function is largely independent of CC transcription. Induces the transcription of long intergenic non-coding CC RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in CC TP53-dependent transcriptional repression leading to apoptosis and CC seems to have an effect on cell-cycle regulation. Implicated in Notch CC signaling cross-over. Prevents CDK7 kinase activity when associated to CC CAK complex in response to DNA damage, thus stopping cell cycle CC progression. Isoform 2 enhances the transactivation activity of isoform CC 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses CC transactivation activity and impairs growth suppression mediated by CC isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates CC the circadian clock by repressing CLOCK-BMAL1-mediated transcriptional CC activation of PER2 (PubMed:24051492). {ECO:0000269|PubMed:11025664, CC ECO:0000269|PubMed:12524540, ECO:0000269|PubMed:12810724, CC ECO:0000269|PubMed:15186775, ECO:0000269|PubMed:15340061, CC ECO:0000269|PubMed:17189187, ECO:0000269|PubMed:17317671, CC ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:19556538, CC ECO:0000269|PubMed:20673990, ECO:0000269|PubMed:20959462, CC ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:24051492, CC ECO:0000269|PubMed:24652652, ECO:0000269|PubMed:35618207, CC ECO:0000269|PubMed:36634798, ECO:0000269|PubMed:38653238, CC ECO:0000269|PubMed:9840937}. CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; CC Evidence={ECO:0000269|PubMed:14534297, ECO:0000269|PubMed:16793544, CC ECO:0000269|PubMed:17015838, ECO:0000269|PubMed:18650397, CC ECO:0000269|PubMed:19515728, ECO:0000269|PubMed:20142040, CC ECO:0000269|PubMed:20364130}; CC Note=Binds 1 zinc ion per subunit. {ECO:0000269|PubMed:14534297, CC ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, CC ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, CC ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130}; CC -!- SUBUNIT: Forms homodimers and homotetramers (PubMed:19011621). Binds CC DNA as a homotetramer (PubMed:36108750). Interacts with AXIN1. Probably CC part of a complex consisting of TP53, HIPK2 and AXIN1 (By similarity). CC Interacts with histone acetyltransferases EP300 and methyltransferases CC HRMT1L2 and CARM1, and recruits them to promoters. Interacts (via C- CC terminus) with TAF1; when TAF1 is part of the TFIID complex. Interacts CC with ING4; this interaction may be indirect. Found in a complex with CC CABLES1 and TP73. Interacts with HIPK1, HIPK2, and TP53INP1. Interacts CC with WWOX. May interact with HCV core protein. Interacts with USP7 and CC SYVN1. Interacts with HSP90AB1. Interacts with CHD8; leading to recruit CC histone H1 and prevent transactivation activity (By similarity). CC Interacts with ARMC10, CDKN2AIP, NUAK1, STK11/LKB1, UHRF2 and E4F1. CC Interacts with YWHAZ; the interaction enhances TP53 transcriptional CC activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this CC interaction. Interacts (via DNA-binding domain) with MAML1 (via N- CC terminus). Interacts with MKRN1. Interacts with PML (via C-terminus). CC Interacts with MDM2; leading to ubiquitination and proteasomal CC degradation of TP53. Directly interacts with FBXO42; leading to CC ubiquitination and degradation of TP53. Interacts (phosphorylated at CC Ser-15 by ATM) with the phosphatase PP2A-PPP2R5C holoenzyme; regulates CC stress-induced TP53-dependent inhibition of cell proliferation. CC Interacts with PPP2R2A. Interacts with AURKA, DAXX, BRD7 and TRIM24. CC Interacts (when monomethylated at Lys-382) with L3MBTL1. Isoform 1 CC interacts with isoform 2 and with isoform 4. Interacts with GRK5. Binds CC to the CAK complex (CDK7, cyclin H and MAT1) in response to DNA damage. CC Interacts with CDK5 in neurons. Interacts with AURKB, SETD2, UHRF2 and CC NOC2L. Interacts (via N-terminus) with PTK2/FAK1; this promotes CC ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes CC ubiquitination by MDM2. Interacts with PRKCG. Interacts with PPIF; the CC association implicates preferentially tetrameric TP53, is induced by CC oxidative stress and is impaired by cyclosporin A (CsA). Interacts with CC SNAI1; the interaction induces SNAI1 degradation via MDM2-mediated CC ubiquitination and inhibits SNAI1-induced cell invasion. Interacts with CC UBC9. Interacts with ZNF385B; the interaction is direct. Interacts (via CC DNA-binding domain) with ZNF385A; the interaction is direct and CC enhances p53/TP53 transactivation functions on cell-cycle arrest target CC genes, resulting in growth arrest. Interacts with ANKRD2. Interacts CC with RFFL and RNF34; involved in p53/TP53 ubiquitination. Interacts CC with MTA1 and COP1. Interacts with CCAR2 (via N-terminus). Interacts CC with MORC3 (PubMed:17332504). Interacts (via C-terminus) with POU4F2 CC isoform 1 (via C-terminus) (PubMed:17145718). Interacts (via CC oligomerization region) with NOP53; the interaction is direct and may CC prevent the MDM2-mediated proteasomal degradation of TP53 CC (PubMed:22522597). Interacts with AFG1L; mediates mitochondrial CC translocation of TP53 (PubMed:27323408). Interacts with UBD CC (PubMed:25422469). Interacts with TAF6 isoform 1 and isoform 4 CC (PubMed:20096117). Interacts with C10orf90/FATS; the interaction CC inhibits binding of TP53 and MDM2 (By similarity). Interacts with CC NUPR1; interaction is stress-dependent (PubMed:18690848). Forms a CC complex with EP300 and NUPR1; this complex binds CDKN1A promoter CC leading to transcriptional induction of CDKN1A (PubMed:18690848). CC Interacts with PRMT5 in response to DNA damage; the interaction is CC TTC5/STRAP dependent (PubMed:19011621). Interacts with PPP1R13L (via CC SH3 domain and ANK repeats); the interaction inhibits pro-apoptotic CC activity of p53/TP53 (PubMed:12524540). Interacts with PPP1R13B/ASPP1 CC and TP53BP2/ASPP2; the interactions promotes pro-apoptotic activity CC (PubMed:12524540). When phosphorylated at Ser-15, interacts with DDX3X CC and gamma-tubulin (PubMed:28842590). Interacts with KAT7/HBO1; leading CC to inhibit histone acetyltransferase activity of KAT7/HBO1 CC (PubMed:17954561). Interacts (via N-terminus) with E3 ubiquitin-protein CC ligase MUL1; the interaction results in ubiquitination of cytoplasmic CC TP53 at Lys-24 and subsequent proteasomal degradation CC (PubMed:21597459). Interacts with S100A4; this interaction promotes CC TP53 degradation (PubMed:23752197, PubMed:32442400). Interacts with CC BANP (By similarity). Interacts with TTC5/STRAP; the interaction may CC result in increased mitochondrial-dependent apoptosis CC (PubMed:25168243). Interacts with NQO1; this interaction is NADH- CC dependent, stabilizes TP53 in response to oxidative stress and protects CC it from ubiquitin-independent degradation by the 20S proteasome CC (PubMed:15687255). Interacts with DAZAP2 at TP53 target gene promoters; CC the interaction is triggered by DNA damage and leads to modulation of CC the expression of a subset of TP53 target genes, reducing DNA damage- CC induced cell death by limiting the expression of cell death-mediating CC TP53 target genes (PubMed:33591310). Interacts (via N-terminus) with CC ZNF768 (via zinc-finger domains); interaction might be facilitated by CC TP53 oligomerization state (PubMed:34404770). Forms a ternary complex CC with ALDOB and G6PD; this interaction is direct. ALDOB stabilizes the CC complex inhibiting G6PD activity and keeping oxidative pentose CC phosphate metabolism in check. Interacts with MORN3; the interactions CC mediate post-transcriptional modifications of TP53 by MDM2 and SIRT1 CC (PubMed:29681526). Interacts with HSPA9/MOT-2; the interaction promotes CC the degradation of TP53 (PubMed:24625977). Interacts with FBXO22; this CC interaction promotes TP53 proteasomal degradation (PubMed:26868148). CC {ECO:0000250|UniProtKB:P02340, ECO:0000250|UniProtKB:P10361, CC ECO:0000269|PubMed:12524540, ECO:0000269|PubMed:12750254, CC ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:12851404, CC ECO:0000269|PubMed:14534297, ECO:0000269|PubMed:14702041, CC ECO:0000269|PubMed:15053879, ECO:0000269|PubMed:15109303, CC ECO:0000269|PubMed:15136035, ECO:0000269|PubMed:15186775, CC ECO:0000269|PubMed:15687255, ECO:0000269|PubMed:15855171, CC ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:16322561, CC ECO:0000269|PubMed:16376338, ECO:0000269|PubMed:16377624, CC ECO:0000269|PubMed:16402859, ECO:0000269|PubMed:16474402, CC ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:16845383, CC ECO:0000269|PubMed:17015838, ECO:0000269|PubMed:17108107, CC ECO:0000269|PubMed:17121812, ECO:0000269|PubMed:17145718, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17245430, CC ECO:0000269|PubMed:17317671, ECO:0000269|PubMed:17332504, CC ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17719541, CC ECO:0000269|PubMed:17904127, ECO:0000269|PubMed:17954561, CC ECO:0000269|PubMed:17967874, ECO:0000269|PubMed:18585004, CC ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:18690848, CC ECO:0000269|PubMed:18996393, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:19509332, ECO:0000269|PubMed:19515728, CC ECO:0000269|PubMed:19536131, ECO:0000269|PubMed:19556538, CC ECO:0000269|PubMed:19837670, ECO:0000269|PubMed:19880522, CC ECO:0000269|PubMed:20096117, ECO:0000269|PubMed:20124405, CC ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20228809, CC ECO:0000269|PubMed:20364130, ECO:0000269|PubMed:20385133, CC ECO:0000269|PubMed:20660729, ECO:0000269|PubMed:20870725, CC ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:21317932, CC ECO:0000269|PubMed:21952639, ECO:0000269|PubMed:22214662, CC ECO:0000269|PubMed:22522597, ECO:0000269|PubMed:22726440, CC ECO:0000269|PubMed:22945289, ECO:0000269|PubMed:23431171, CC ECO:0000269|PubMed:23752197, ECO:0000269|PubMed:24625977, CC ECO:0000269|PubMed:25168243, ECO:0000269|PubMed:25422469, CC ECO:0000269|PubMed:25732823, ECO:0000269|PubMed:26868148, CC ECO:0000269|PubMed:27323408, ECO:0000269|PubMed:28842590, CC ECO:0000269|PubMed:29681526, ECO:0000269|PubMed:32442400, CC ECO:0000269|PubMed:33591310, ECO:0000269|PubMed:34404770, CC ECO:0000269|PubMed:35122041, ECO:0000269|PubMed:8875926, CC ECO:0000269|PubMed:8875929, ECO:0000269|PubMed:9840937}. CC -!- SUBUNIT: (Microbial infection) Interacts with cancer-associated/HPV E6 CC viral proteins leading to ubiquitination and degradation of TP53 giving CC a possible model for cell growth regulation. This complex formation CC requires an additional factor, E6-AP, which stably associates with TP53 CC in the presence of E6. {ECO:0000269|PubMed:2175676}. CC -!- SUBUNIT: (Microbial infection) Interacts with human CC cytomegalovirus/HHV-5 protein UL123. {ECO:0000269|PubMed:19776115}. CC -!- SUBUNIT: (Microbial infection) Interacts (via N-terminus) with human CC adenovirus 5 E1B-55K protein; this interaction leads to the inhibition CC of TP53 function and/or its degradation. {ECO:0000269|PubMed:25772236}. CC -!- SUBUNIT: (Microbial infection) Interacts with Kaposi's sarcoma- CC associated herpesvirus/HHV-8 protein ORF45; this interaction results in CC the cytoplasmic localization of TP53 thereby decreasing its CC transcriptional activity. {ECO:0000269|PubMed:34523970}. CC -!- INTERACTION: CC P04637; P00519: ABL1; NbExp=2; IntAct=EBI-366083, EBI-375543; CC P04637; Q13155: AIMP2; NbExp=6; IntAct=EBI-366083, EBI-745226; CC P04637; O95376: ARIH2; NbExp=5; IntAct=EBI-366083, EBI-711158; CC P04637; P49407: ARRB1; NbExp=5; IntAct=EBI-366083, EBI-743313; CC P04637; Q9UBL3: ASH2L; NbExp=8; IntAct=EBI-366083, EBI-540797; CC P04637; O95352-2: ATG7; NbExp=4; IntAct=EBI-366083, EBI-15980880; CC P04637; O15169: AXIN1; NbExp=4; IntAct=EBI-366083, EBI-710484; CC P04637; Q8N9N5: BANP; NbExp=3; IntAct=EBI-366083, EBI-744695; CC P04637; P10415: BCL2; NbExp=5; IntAct=EBI-366083, EBI-77694; CC P04637; Q07817-1: BCL2L1; NbExp=26; IntAct=EBI-366083, EBI-287195; CC P04637; O14503: BHLHE40; NbExp=11; IntAct=EBI-366083, EBI-711810; CC P04637; P15056: BRAF; NbExp=4; IntAct=EBI-366083, EBI-365980; CC P04637; P38398: BRCA1; NbExp=2; IntAct=EBI-366083, EBI-349905; CC P04637; P51587: BRCA2; NbExp=7; IntAct=EBI-366083, EBI-79792; CC P04637; Q9NPI1: BRD7; NbExp=9; IntAct=EBI-366083, EBI-711221; CC P04637; Q9BX70: BTBD2; NbExp=2; IntAct=EBI-366083, EBI-710091; CC P04637; Q9Y297: BTRC; NbExp=2; IntAct=EBI-366083, EBI-307461; CC P04637; P55212: CASP6; NbExp=3; IntAct=EBI-366083, EBI-718729; CC P04637; Q9BWC9: CCDC106; NbExp=3; IntAct=EBI-366083, EBI-711501; CC P04637; P48643: CCT5; NbExp=3; IntAct=EBI-366083, EBI-355710; CC P04637; P38936: CDKN1A; NbExp=6; IntAct=EBI-366083, EBI-375077; CC P04637; P17676: CEBPB; NbExp=4; IntAct=EBI-366083, EBI-969696; CC P04637; Q03701: CEBPZ; NbExp=2; IntAct=EBI-366083, EBI-1046778; CC P04637; O14757: CHEK1; NbExp=2; IntAct=EBI-366083, EBI-974488; CC P04637; O96017: CHEK2; NbExp=3; IntAct=EBI-366083, EBI-1180783; CC P04637; Q8NHY2: COP1; NbExp=5; IntAct=EBI-366083, EBI-1176214; CC P04637; Q92793: CREBBP; NbExp=17; IntAct=EBI-366083, EBI-81215; CC P04637; P55060: CSE1L; NbExp=5; IntAct=EBI-366083, EBI-286709; CC P04637; Q14999: CUL7; NbExp=19; IntAct=EBI-366083, EBI-308606; CC P04637; Q8IWT3: CUL9; NbExp=16; IntAct=EBI-366083, EBI-311123; CC P04637; Q9P0U4: CXXC1; NbExp=7; IntAct=EBI-366083, EBI-949911; CC P04637; Q9UER7: DAXX; NbExp=13; IntAct=EBI-366083, EBI-77321; CC P04637; Q92841: DDX17; NbExp=3; IntAct=EBI-366083, EBI-746012; CC P04637; P17844: DDX5; NbExp=6; IntAct=EBI-366083, EBI-351962; CC P04637; Q9NRR4: DROSHA; NbExp=5; IntAct=EBI-366083, EBI-528367; CC P04637; Q9BV47: DUSP26; NbExp=9; IntAct=EBI-366083, EBI-2924519; CC P04637; O14641: DVL2; NbExp=6; IntAct=EBI-366083, EBI-740850; CC P04637; Q09472: EP300; NbExp=22; IntAct=EBI-366083, EBI-447295; CC P04637; P15036: ETS2; NbExp=4; IntAct=EBI-366083, EBI-1646991; CC P04637; Q86XK2: FBXO11; NbExp=4; IntAct=EBI-366083, EBI-1047804; CC P04637; P21333-2: FLNA; NbExp=3; IntAct=EBI-366083, EBI-9641086; CC P04637; P51114: FXR1; NbExp=2; IntAct=EBI-366083, EBI-713291; CC P04637; P49841: GSK3B; NbExp=3; IntAct=EBI-366083, EBI-373586; CC P04637; P32780: GTF2H1; NbExp=12; IntAct=EBI-366083, EBI-715539; CC P04637; Q13547: HDAC1; NbExp=8; IntAct=EBI-366083, EBI-301834; CC P04637; Q86Z02: HIPK1; NbExp=2; IntAct=EBI-366083, EBI-692891; CC P04637; Q9H2X6: HIPK2; NbExp=3; IntAct=EBI-366083, EBI-348345; CC P04637; P09429: HMGB1; NbExp=9; IntAct=EBI-366083, EBI-389432; CC P04637; P41235: HNF4A; NbExp=3; IntAct=EBI-366083, EBI-1049011; CC P04637; P61978: HNRNPK; NbExp=2; IntAct=EBI-366083, EBI-304185; CC P04637; P61978-2: HNRNPK; NbExp=2; IntAct=EBI-366083, EBI-7060731; CC P04637; Q9BUJ2: HNRNPUL1; NbExp=12; IntAct=EBI-366083, EBI-1018153; CC P04637; P38646: HSPA9; NbExp=6; IntAct=EBI-366083, EBI-354932; CC P04637; P04792: HSPB1; NbExp=3; IntAct=EBI-366083, EBI-352682; CC P04637; P42858: HTT; NbExp=19; IntAct=EBI-366083, EBI-466029; CC P04637; Q7Z6Z7: HUWE1; NbExp=3; IntAct=EBI-366083, EBI-625934; CC P04637; Q16666-2: IFI16; NbExp=6; IntAct=EBI-366083, EBI-6273540; CC P04637; O14920: IKBKB; NbExp=3; IntAct=EBI-366083, EBI-81266; CC P04637; Q9UHH9: IP6K2; NbExp=4; IntAct=EBI-366083, EBI-747509; CC P04637; Q6NYC1: JMJD6; NbExp=7; IntAct=EBI-366083, EBI-8464037; CC P04637; Q92993: KAT5; NbExp=3; IntAct=EBI-366083, EBI-399080; CC P04637; Q9H7Z6: KAT8; NbExp=2; IntAct=EBI-366083, EBI-896414; CC P04637; O60341-1: KDM1A; NbExp=6; IntAct=EBI-366083, EBI-15599570; CC P04637; Q8IZD2: KMT2E; NbExp=4; IntAct=EBI-366083, EBI-2689959; CC P04637; P13473-2: LAMP2; NbExp=3; IntAct=EBI-366083, EBI-21591415; CC P04637; P43356: MAGEA2B; NbExp=7; IntAct=EBI-366083, EBI-5650739; CC P04637; Q96M61: MAGEB18; NbExp=3; IntAct=EBI-366083, EBI-741835; CC P04637; Q9UBF1: MAGEC2; NbExp=3; IntAct=EBI-366083, EBI-5651487; CC P04637; P46821: MAP1B; NbExp=6; IntAct=EBI-366083, EBI-764611; CC P04637; Q15759: MAPK11; NbExp=2; IntAct=EBI-366083, EBI-298304; CC P04637; Q8IW41: MAPKAPK5; NbExp=2; IntAct=EBI-366083, EBI-1201460; CC P04637; Q00987: MDM2; NbExp=119; IntAct=EBI-366083, EBI-389668; CC P04637; O15151: MDM4; NbExp=24; IntAct=EBI-366083, EBI-398437; CC P04637; Q15648: MED1; NbExp=3; IntAct=EBI-366083, EBI-394459; CC P04637; Q9UHC7: MKRN1; NbExp=8; IntAct=EBI-366083, EBI-373524; CC P04637; O75970: MPDZ; NbExp=3; IntAct=EBI-366083, EBI-821405; CC P04637; P04731: MT1A; NbExp=3; IntAct=EBI-366083, EBI-8045030; CC P04637; P19338: NCL; NbExp=2; IntAct=EBI-366083, EBI-346967; CC P04637; Q9Y618: NCOR2; NbExp=7; IntAct=EBI-366083, EBI-80830; CC P04637; Q99608: NDN; NbExp=4; IntAct=EBI-366083, EBI-718177; CC P04637; P23511: NFYA; NbExp=11; IntAct=EBI-366083, EBI-389739; CC P04637; P25208: NFYB; NbExp=6; IntAct=EBI-366083, EBI-389728; CC P04637; Q9Y3T9: NOC2L; NbExp=8; IntAct=EBI-366083, EBI-751547; CC P04637; O60936: NOL3; NbExp=3; IntAct=EBI-366083, EBI-740992; CC P04637; P06748: NPM1; NbExp=6; IntAct=EBI-366083, EBI-78579; CC P04637; P06748-1: NPM1; NbExp=3; IntAct=EBI-366083, EBI-354150; CC P04637; Q15466: NR0B2; NbExp=3; IntAct=EBI-366083, EBI-3910729; CC P04637; P22736: NR4A1; NbExp=6; IntAct=EBI-366083, EBI-721550; CC P04637; O43847: NRDC; NbExp=6; IntAct=EBI-366083, EBI-2371631; CC P04637; O60285: NUAK1; NbExp=5; IntAct=EBI-366083, EBI-1046789; CC P04637; P49757: NUMB; NbExp=5; IntAct=EBI-366083, EBI-915016; CC P04637; Q96FW1: OTUB1; NbExp=8; IntAct=EBI-366083, EBI-1058491; CC P04637; Q8TEW0: PARD3; NbExp=3; IntAct=EBI-366083, EBI-81968; CC P04637; P09874: PARP1; NbExp=5; IntAct=EBI-366083, EBI-355676; CC P04637; Q96KB5: PBK; NbExp=7; IntAct=EBI-366083, EBI-536853; CC P04637; Q7Z412: PEX26; NbExp=3; IntAct=EBI-366083, EBI-752057; CC P04637; P35232: PHB1; NbExp=6; IntAct=EBI-366083, EBI-354213; CC P04637; O75925: PIAS1; NbExp=4; IntAct=EBI-366083, EBI-629434; CC P04637; Q8N2W9: PIAS4; NbExp=2; IntAct=EBI-366083, EBI-473160; CC P04637; Q92569: PIK3R3; NbExp=5; IntAct=EBI-366083, EBI-79893; CC P04637; Q13526: PIN1; NbExp=14; IntAct=EBI-366083, EBI-714158; CC P04637; P53350: PLK1; NbExp=6; IntAct=EBI-366083, EBI-476768; CC P04637; P29590: PML; NbExp=4; IntAct=EBI-366083, EBI-295890; CC P04637; A0A6Q8PF08: PMP22; NbExp=3; IntAct=EBI-366083, EBI-50433196; CC P04637; P30405: PPIF; NbExp=4; IntAct=EBI-366083, EBI-5544229; CC P04637; P36873-1: PPP1CC; NbExp=2; IntAct=EBI-366083, EBI-356289; CC P04637; Q8WUF5: PPP1R13L; NbExp=12; IntAct=EBI-366083, EBI-5550163; CC P04637; P30153: PPP2R1A; NbExp=3; IntAct=EBI-366083, EBI-302388; CC P04637; Q13362: PPP2R5C; NbExp=4; IntAct=EBI-366083, EBI-1266156; CC P04637; O43741: PRKAB2; NbExp=3; IntAct=EBI-366083, EBI-1053424; CC P04637; Q05655: PRKCD; NbExp=4; IntAct=EBI-366083, EBI-704279; CC P04637; P61289: PSME3; NbExp=7; IntAct=EBI-366083, EBI-355546; CC P04637; Q05397: PTK2; NbExp=13; IntAct=EBI-366083, EBI-702142; CC P04637; Q06609: RAD51; NbExp=2; IntAct=EBI-366083, EBI-297202; CC P04637; Q06330: RBPJ; NbExp=5; IntAct=EBI-366083, EBI-632552; CC P04637; Q96PM5: RCHY1; NbExp=13; IntAct=EBI-366083, EBI-947779; CC P04637; Q6PCD5: RFWD3; NbExp=5; IntAct=EBI-366083, EBI-2129159; CC P04637; Q06587: RING1; NbExp=7; IntAct=EBI-366083, EBI-752313; CC P04637; P23396: RPS3; NbExp=4; IntAct=EBI-366083, EBI-351193; CC P04637; Q9Y265: RUVBL1; NbExp=10; IntAct=EBI-366083, EBI-353675; CC P04637; Q8N488: RYBP; NbExp=4; IntAct=EBI-366083, EBI-752324; CC P04637; P23297: S100A1; NbExp=3; IntAct=EBI-366083, EBI-743686; CC P04637; P31949: S100A11; NbExp=2; IntAct=EBI-366083, EBI-701862; CC P04637; P29034: S100A2; NbExp=4; IntAct=EBI-366083, EBI-752230; CC P04637; P33764: S100A3; NbExp=2; IntAct=EBI-366083, EBI-1044747; CC P04637; P26447: S100A4; NbExp=9; IntAct=EBI-366083, EBI-717058; CC P04637; P33763: S100A5; NbExp=2; IntAct=EBI-366083, EBI-7211732; CC P04637; P06703: S100A6; NbExp=3; IntAct=EBI-366083, EBI-352877; CC P04637; P04271: S100B; NbExp=3; IntAct=EBI-366083, EBI-458391; CC P04637; P25815: S100P; NbExp=2; IntAct=EBI-366083, EBI-743700; CC P04637; Q15424: SAFB; NbExp=5; IntAct=EBI-366083, EBI-348298; CC P04637; Q8WTS6: SETD7; NbExp=11; IntAct=EBI-366083, EBI-1268586; CC P04637; P31947: SFN; NbExp=5; IntAct=EBI-366083, EBI-476295; CC P04637; Q96ST3: SIN3A; NbExp=2; IntAct=EBI-366083, EBI-347218; CC P04637; Q96EB6: SIRT1; NbExp=18; IntAct=EBI-366083, EBI-1802965; CC P04637; Q15796: SMAD2; NbExp=7; IntAct=EBI-366083, EBI-1040141; CC P04637; Q9NRG4: SMYD2; NbExp=6; IntAct=EBI-366083, EBI-1055671; CC P04637; O95863: SNAI1; NbExp=2; IntAct=EBI-366083, EBI-1045459; CC P04637; Q06945: SOX4; NbExp=4; IntAct=EBI-366083, EBI-6672525; CC P04637; P08047: SP1; NbExp=6; IntAct=EBI-366083, EBI-298336; CC P04637; Q12772: SREBF2; NbExp=3; IntAct=EBI-366083, EBI-465059; CC P04637; Q96SB4: SRPK1; NbExp=3; IntAct=EBI-366083, EBI-539478; CC P04637; P31948: STIP1; NbExp=4; IntAct=EBI-366083, EBI-1054052; CC P04637; P63165: SUMO1; NbExp=3; IntAct=EBI-366083, EBI-80140; CC P04637; Q86TM6: SYVN1; NbExp=5; IntAct=EBI-366083, EBI-947849; CC P04637; Q9HBM6: TAF9B; NbExp=2; IntAct=EBI-366083, EBI-751601; CC P04637; P20226: TBP; NbExp=2; IntAct=EBI-366083, EBI-355371; CC P04637; P15884: TCF4; NbExp=2; IntAct=EBI-366083, EBI-533224; CC P04637; Q96GM8: TOE1; NbExp=3; IntAct=EBI-366083, EBI-717460; CC P04637; P04637: TP53; NbExp=34; IntAct=EBI-366083, EBI-366083; CC P04637; Q12888: TP53BP1; NbExp=8; IntAct=EBI-366083, EBI-396540; CC P04637; Q12888-1: TP53BP1; NbExp=17; IntAct=EBI-366083, EBI-8022649; CC P04637; Q13625: TP53BP2; NbExp=9; IntAct=EBI-366083, EBI-77642; CC P04637; Q9H3D4: TP63; NbExp=5; IntAct=EBI-366083, EBI-2337775; CC P04637; P13693: TPT1; NbExp=7; IntAct=EBI-366083, EBI-1783169; CC P04637; O15164: TRIM24; NbExp=3; IntAct=EBI-366083, EBI-2130378; CC P04637; Q15672: TWIST1; NbExp=10; IntAct=EBI-366083, EBI-1797287; CC P04637; P0CG48: UBC; NbExp=15; IntAct=EBI-366083, EBI-3390054; CC P04637; P63279: UBE2I; NbExp=5; IntAct=EBI-366083, EBI-80168; CC P04637; Q05086: UBE3A; NbExp=6; IntAct=EBI-366083, EBI-954357; CC P04637; P09936: UCHL1; NbExp=3; IntAct=EBI-366083, EBI-714860; CC P04637; Q96PU4: UHRF2; NbExp=3; IntAct=EBI-366083, EBI-625304; CC P04637; Q9H9J4: USP42; NbExp=2; IntAct=EBI-366083, EBI-2513638; CC P04637; Q9H9J4-2: USP42; NbExp=2; IntAct=EBI-366083, EBI-9118105; CC P04637; Q93009: USP7; NbExp=23; IntAct=EBI-366083, EBI-302474; CC P04637; P11473: VDR; NbExp=6; IntAct=EBI-366083, EBI-286357; CC P04637; Q99986: VRK1; NbExp=11; IntAct=EBI-366083, EBI-1769146; CC P04637; Q14191: WRN; NbExp=5; IntAct=EBI-366083, EBI-368417; CC P04637; Q9NZC7: WWOX; NbExp=2; IntAct=EBI-366083, EBI-4320739; CC P04637; O14980: XPO1; NbExp=3; IntAct=EBI-366083, EBI-355867; CC P04637; P12956: XRCC6; NbExp=2; IntAct=EBI-366083, EBI-353208; CC P04637; P61981: YWHAG; NbExp=5; IntAct=EBI-366083, EBI-359832; CC P04637; P63104: YWHAZ; NbExp=3; IntAct=EBI-366083, EBI-347088; CC P04637; Q8TAQ5: ZNF420; NbExp=4; IntAct=EBI-366083, EBI-3923307; CC P04637; Q7L7W2; NbExp=2; IntAct=EBI-366083, EBI-7210801; CC P04637; P29066: Arrb1; Xeno; NbExp=3; IntAct=EBI-366083, EBI-4303019; CC P04637; Q9ESJ1: Cables1; Xeno; NbExp=3; IntAct=EBI-366083, EBI-604411; CC P04637; P45481: Crebbp; Xeno; NbExp=10; IntAct=EBI-366083, EBI-296306; CC P04637; P03120: E2; Xeno; NbExp=3; IntAct=EBI-366083, EBI-1779322; CC P04637; P03126: E6; Xeno; NbExp=5; IntAct=EBI-366083, EBI-1177242; CC P04637; P04019: E6; Xeno; NbExp=2; IntAct=EBI-366083, EBI-1177232; CC P04637; P06463: E6; Xeno; NbExp=5; IntAct=EBI-366083, EBI-1186926; CC P04637; P02829: HSP82; Xeno; NbExp=8; IntAct=EBI-366083, EBI-8659; CC P04637; Q08619: Ifi205b; Xeno; NbExp=2; IntAct=EBI-366083, EBI-8064290; CC P04637; P89055: NSP1; Xeno; NbExp=6; IntAct=EBI-366083, EBI-9522973; CC P04637; Q923E4: Sirt1; Xeno; NbExp=4; IntAct=EBI-366083, EBI-1802585; CC P04637; Q8R5A0: Smyd2; Xeno; NbExp=3; IntAct=EBI-366083, EBI-15612527; CC P04637; P32776: TFB1; Xeno; NbExp=7; IntAct=EBI-366083, EBI-19146; CC P04637; O88898: Tp63; Xeno; NbExp=2; IntAct=EBI-366083, EBI-2338025; CC P04637; P26687: Twist1; Xeno; NbExp=4; IntAct=EBI-366083, EBI-6123119; CC P04637; Q9PST7: znf585b.S; Xeno; NbExp=3; IntAct=EBI-366083, EBI-1782562; CC P04637; P03070; Xeno; NbExp=25; IntAct=EBI-366083, EBI-617698; CC P04637; PRO_0000037536 [P26663]; Xeno; NbExp=9; IntAct=EBI-366083, EBI-6838571; CC P04637; Q8QW27; Xeno; NbExp=2; IntAct=EBI-366083, EBI-6863726; CC P04637-1; P17844: DDX5; NbExp=2; IntAct=EBI-3895849, EBI-351962; CC P04637-1; P55209: NAP1L1; NbExp=2; IntAct=EBI-3895849, EBI-356392; CC P04637-1; P03126: E6; Xeno; NbExp=2; IntAct=EBI-3895849, EBI-1177242; CC P04637-7; P17844: DDX5; NbExp=2; IntAct=EBI-3895873, EBI-351962; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15340061, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:19033443, ECO:0000269|PubMed:21597459, CC ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:24625977, CC ECO:0000269|PubMed:26634371}. Nucleus {ECO:0000269|PubMed:15340061, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17591690, CC ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:21597459, ECO:0000269|PubMed:24625977, CC ECO:0000269|PubMed:26634371}. Nucleus, PML body CC {ECO:0000269|PubMed:11025664, ECO:0000269|PubMed:12810724, CC ECO:0000269|PubMed:36108750}. Endoplasmic reticulum CC {ECO:0000269|PubMed:17170702}. Mitochondrion matrix CC {ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:25168243, CC ECO:0000269|PubMed:27323408}. Cytoplasm, cytoskeleton, microtubule CC organizing center, centrosome {ECO:0000269|PubMed:28842590}. CC Note=Recruited into PML bodies together with CHEK2 (PubMed:12810724). CC Translocates to mitochondria upon oxidative stress (PubMed:22726440). CC Translocates to mitochondria in response to mitomycin C treatment CC (PubMed:27323408). Competitive inhibition of TP53 interaction with CC HSPA9/MOT-2 by UBXN2A results in increased protein abundance and CC subsequent translocation of TP53 to the nucleus (PubMed:24625977). CC {ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:22726440, CC ECO:0000269|PubMed:24625977, ECO:0000269|PubMed:27323408}. CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Nucleus CC {ECO:0000269|PubMed:23752197}. Cytoplasm. Note=Predominantly nuclear CC but localizes to the cytoplasm when expressed with isoform 4. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus. Cytoplasm. Note=Localized CC mainly in the nucleus with minor staining in the cytoplasm. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Nucleus. Cytoplasm. Note=Localized CC in the nucleus in most cells but found in the cytoplasm in some cells. CC -!- SUBCELLULAR LOCATION: [Isoform 4]: Nucleus. Cytoplasm. CC Note=Predominantly nuclear but translocates to the cytoplasm following CC cell stress. CC -!- SUBCELLULAR LOCATION: [Isoform 7]: Nucleus. Cytoplasm. Note=Localized CC mainly in the nucleus with minor staining in the cytoplasm. CC -!- SUBCELLULAR LOCATION: [Isoform 8]: Nucleus. Cytoplasm. Note=Localized CC in both nucleus and cytoplasm in most cells. In some cells, forms foci CC in the nucleus that are different from nucleoli. CC -!- SUBCELLULAR LOCATION: [Isoform 9]: Cytoplasm. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=9; CC Name=1; Synonyms=p53, p53alpha; CC IsoId=P04637-1; Sequence=Displayed; CC Name=2; Synonyms=I9RET, p53beta; CC IsoId=P04637-2; Sequence=VSP_006535, VSP_006536; CC Name=3; Synonyms=p53gamma; CC IsoId=P04637-3; Sequence=VSP_040560, VSP_040561; CC Name=4; Synonyms=Del40-p53, Del40-p53alpha, p47; CC IsoId=P04637-4; Sequence=VSP_040832; CC Name=5; Synonyms=Del40-p53beta; CC IsoId=P04637-5; Sequence=VSP_040832, VSP_006535, VSP_006536; CC Name=6; Synonyms=Del40-p53gamma; CC IsoId=P04637-6; Sequence=VSP_040832, VSP_040560, VSP_040561; CC Name=7; Synonyms=Del133-p53, Del133-p53alpha; CC IsoId=P04637-7; Sequence=VSP_040833; CC Name=8; Synonyms=Del133-p53beta; CC IsoId=P04637-8; Sequence=VSP_040833, VSP_006535, VSP_006536; CC Name=9; Synonyms=Del133-p53gamma; CC IsoId=P04637-9; Sequence=VSP_040833, VSP_040560, VSP_040561; CC -!- TISSUE SPECIFICITY: Ubiquitous. Isoforms are expressed in a wide range CC of normal tissues but in a tissue-dependent manner. Isoform 2 is CC expressed in most normal tissues but is not detected in brain, lung, CC prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 CC is expressed in most normal tissues but is not detected in lung, CC spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is CC expressed in most normal tissues but is not detected in prostate, CC uterus, skeletal muscle and breast. Isoform 8 is detected only in CC colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is CC expressed in most normal tissues but is not detected in brain, heart, CC lung, fetal liver, salivary gland, breast or intestine. CC {ECO:0000269|PubMed:16131611}. CC -!- INDUCTION: Up-regulated in response to DNA damage. Isoform 2 is not CC induced in tumor cells in response to stress. CC {ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:16131611}. CC -!- DOMAIN: The N-terminal and C-terminal disordered regions undergo CC liquid-liquid phase separation (LLPS) following homotetramerization and CC activation (PubMed:31953488, PubMed:35618207, PubMed:36108750, CC PubMed:36634798, PubMed:38653238). Post-translational modifications, CC such as phosphorylation or lactylation affect the ability to undergo CC LLPS (PubMed:31953488, PubMed:35618207, PubMed:36634798, CC PubMed:38653238). {ECO:0000269|PubMed:31953488, CC ECO:0000269|PubMed:35618207, ECO:0000269|PubMed:36108750, CC ECO:0000269|PubMed:36634798, ECO:0000269|PubMed:38653238}. CC -!- DOMAIN: The nuclear export signal acts as a transcriptional repression CC domain. The TADI and TADII motifs (residues 17 to 25 and 48 to 56) CC correspond both to 9aaTAD motifs which are transactivation domains CC present in a large number of yeast and animal transcription factors. CC {ECO:0000269|PubMed:17467953}. CC -!- PTM: Acetylation of Lys-382 by CREBBP enhances transcriptional activity CC (PubMed:10656795, PubMed:15448695, PubMed:20228809, PubMed:23431171). CC Acetylation of Lys-382 by EP300 (PubMed:10656795, PubMed:15448695, CC PubMed:20228809, PubMed:23431171). Deacetylation of Lys-382 by SIRT1 CC impairs its ability to induce proapoptotic program and modulate cell CC senescence (PubMed:10656795, PubMed:15448695, PubMed:20228809, CC PubMed:23431171). Deacetylation by SIRT2 impairs its ability to induce CC transcription activation in a AKT-dependent manner (PubMed:10656795, CC PubMed:15448695, PubMed:20228809, PubMed:23431171, PubMed:29681526). CC Acetylation at Lys-381 increases stability (PubMed:29474172). CC Deacetylation at Lys-381 by SIRT6 decreases its stability, thereby CC regulating cell senescence (PubMed:29474172). Acetylated at Lys-120 by CC KAT5, KAT6A and KAT8; regulating its ability to induce proapoptotic CC program (PubMed:17189187, PubMed:19854137, PubMed:23431171). CC {ECO:0000269|PubMed:10656795, ECO:0000269|PubMed:15448695, CC ECO:0000269|PubMed:17189187, ECO:0000269|PubMed:19854137, CC ECO:0000269|PubMed:20228809, ECO:0000269|PubMed:23431171, CC ECO:0000269|PubMed:29474172, ECO:0000269|PubMed:29681526}. CC -!- PTM: Lactylation by AARS1 prevents ability to undergo liquid-liquid CC phase separation (LLPS), thereby inhibiting transcription factor CC activity. {ECO:0000269|PubMed:38653238}. CC -!- PTM: Phosphorylation on Ser residues mediates transcriptional CC activation. Phosphorylated by HIPK1 (By similarity). Phosphorylation at CC Ser-9 by HIPK4 increases repression activity on BIRC5 promoter. CC Phosphorylated on Thr-18 by VRK1, which may prevent the interaction CC with MDM2 (PubMed:10951572, PubMed:31527692). Phosphorylated on Ser-20 CC by CHEK2 in response to DNA damage, which prevents ubiquitination by CC MDM2. Phosphorylated on Ser-20 by PLK3 in response to reactive oxygen CC species (ROS), promoting p53/TP53-mediated apoptosis. Phosphorylated on CC Thr-55 by TAF1, which promotes MDM2-mediated degradation. CC Phosphorylated on Ser-33 by CDK7 in a CAK complex in response to DNA CC damage. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. CC Phosphorylation on Ser-46 is required for acetylation by CREBBP. CC Phosphorylated on Ser-392 following UV but not gamma irradiation. CC Phosphorylated by NUAK1 at Ser-15 and Ser-392; was initially thought to CC be mediated by STK11/LKB1 but it was later shown that it is indirect CC and that STK11/LKB1-dependent phosphorylation is probably mediated by CC downstream NUAK1 (PubMed:21317932). It is unclear whether AMP directly CC mediates phosphorylation at Ser-15. Phosphorylated on Thr-18 by isoform CC 1 and isoform 2 of VRK2. Phosphorylation on Thr-18 by isoform 2 of VRK2 CC results in a reduction in ubiquitination by MDM2 and an increase in CC acetylation by EP300. Stabilized by CDK5-mediated phosphorylation in CC response to genotoxic and oxidative stresses at Ser-15, Ser-33 and Ser- CC 46, leading to accumulation of p53/TP53, particularly in the nucleus, CC thus inducing the transactivation of p53/TP53 target genes. CC Phosphorylated by DYRK2 at Ser-46 in response to genotoxic stress. CC Phosphorylated at Ser-315 and Ser-392 by CDK2 in response to DNA- CC damage. Phosphorylation at Ser-15 is required for interaction with CC DDX3X and gamma-tubulin (PubMed:28842590). Phosphorylation at Ser-392 CC regulates its ability to undergo liquid-liquid phase separation by CC increasing fluidity of TP53/p53 condensates (PubMed:35618207). CC {ECO:0000250, ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:10606744, CC ECO:0000269|PubMed:10884347, ECO:0000269|PubMed:10951572, CC ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:11447225, CC ECO:0000269|PubMed:11546806, ECO:0000269|PubMed:11551930, CC ECO:0000269|PubMed:11554766, ECO:0000269|PubMed:11740489, CC ECO:0000269|PubMed:11780126, ECO:0000269|PubMed:12810724, CC ECO:0000269|PubMed:14702041, ECO:0000269|PubMed:15053879, CC ECO:0000269|PubMed:15866171, ECO:0000269|PubMed:16377624, CC ECO:0000269|PubMed:16704422, ECO:0000269|PubMed:1705009, CC ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:17254968, CC ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:17591690, CC ECO:0000269|PubMed:17967874, ECO:0000269|PubMed:18022393, CC ECO:0000269|PubMed:20041275, ECO:0000269|PubMed:20124405, CC ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:21317932, CC ECO:0000269|PubMed:2141171, ECO:0000269|PubMed:22214662, CC ECO:0000269|PubMed:28842590, ECO:0000269|PubMed:31527692, CC ECO:0000269|PubMed:9372954}. CC -!- PTM: Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small CC T antigen inhibits the dephosphorylation by the AC form of PP2A. CC -!- PTM: May be O-glycosylated in the C-terminal basic region. Studied in CC EB-1 cell line. {ECO:0000269|PubMed:8632915}. CC -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal CC degradation (PubMed:10722742, PubMed:12810724, PubMed:15340061, CC PubMed:17170702, PubMed:19880522, PubMed:29681526). Ubiquitinated by CC RFWD3, which works in cooperation with MDM2 and may catalyze the CC formation of short polyubiquitin chains on p53/TP53 that are not CC targeted to the proteasome (PubMed:10722742, PubMed:12810724, CC PubMed:20173098). Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which CC leads to proteasomal degradation (PubMed:19536131). Deubiquitinated by CC USP10, leading to its stabilization (PubMed:20096447). Ubiquitinated by CC TRIM24, RFFL, RNF34 and RNF125, which leads to proteasomal degradation CC (PubMed:19556538). Ubiquitination by TOPORS induces degradation CC (PubMed:19473992). Deubiquitination by USP7, leading to stabilization CC (PubMed:15053880). Isoform 4 is monoubiquitinated in an MDM2- CC independent manner (PubMed:15340061). Ubiquitinated by COP1, which CC leads to proteasomal degradation (PubMed:19837670). Ubiquitination and CC subsequent proteasomal degradation is negatively regulated by CCAR2 CC (PubMed:25732823). Polyubiquitinated by C10orf90/FATS, CC polyubiquitination is 'Lys-48'-linkage independent and non-proteolytic, CC leading to TP53 stabilization (By similarity). Polyubiquitinated by CC MUL1 at Lys-24 which leads to proteasomal degradation CC (PubMed:21597459). Deubiquitinated by USP3, leading to stabilization CC (PubMed:28807825). Ubiquitinated by MSL2, promoting its cytoplasmic CC localization (PubMed:19033443). Also ubiquitinated by the SCF(FBXO22)- CC KDMA4A complex; leading to proteasomal degradation (PubMed:26868148). CC {ECO:0000250|UniProtKB:P02340, ECO:0000269|PubMed:10722742, CC ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:15053880, CC ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:17170702, CC ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19033443, CC ECO:0000269|PubMed:19473992, ECO:0000269|PubMed:19536131, CC ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:19837670, CC ECO:0000269|PubMed:19880522, ECO:0000269|PubMed:20096447, CC ECO:0000269|PubMed:20173098, ECO:0000269|PubMed:21597459, CC ECO:0000269|PubMed:25591766, ECO:0000269|PubMed:25732823, CC ECO:0000269|PubMed:26868148, ECO:0000269|PubMed:28807825, CC ECO:0000269|PubMed:29681526}. CC -!- PTM: Monomethylated at Lys-372 by SETD7, leading to stabilization and CC increased transcriptional activation (PubMed:15525938, CC PubMed:16415881). Monomethylated at Lys-370 by SMYD2, leading to CC decreased DNA-binding activity and subsequent transcriptional CC regulation activity (PubMed:17108971). Lys-372 monomethylation prevents CC interaction with SMYD2 and subsequent monomethylation at Lys-370 CC (PubMed:17108971). Dimethylated at Lys-373 by EHMT1 and EHMT2 CC (PubMed:20118233). Monomethylated at Lys-382 by KMT5A, promoting CC interaction with L3MBTL1 and leading to repress transcriptional CC activity (PubMed:17707234). Dimethylation at Lys-370 and Lys-382 CC diminishes p53 ubiquitination, through stabilizing association with the CC methyl reader PHF20 (PubMed:22864287). Demethylation of dimethylated CC Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53- CC mediated transcriptional activation (PubMed:17805299). Monomethylated CC at Arg-333 and dimethylated at Arg-335 and Arg-337 by PRMT5; CC methylation is increased after DNA damage and might possibly affect CC TP53 target gene specificity (PubMed:19011621). CC {ECO:0000269|PubMed:15525938, ECO:0000269|PubMed:16415881, CC ECO:0000269|PubMed:17108971, ECO:0000269|PubMed:17707234, CC ECO:0000269|PubMed:17805299, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:20118233, ECO:0000269|PubMed:22864287}. CC -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-386 by UBC9. CC {ECO:0000269|PubMed:11124955, ECO:0000269|PubMed:22214662, CC ECO:0000269|Ref.37}. CC -!- DISEASE: Note=TP53 is found in increased amounts in a wide variety of CC transformed cells. TP53 is frequently mutated or inactivated in about CC 60% of cancers. TP53 defects are found in Barrett metaplasia a CC condition in which the normally stratified squamous epithelium of the CC lower esophagus is replaced by a metaplastic columnar epithelium. The CC condition develops as a complication in approximately 10% of patients CC with chronic gastroesophageal reflux disease and predisposes to the CC development of esophageal adenocarcinoma. CC -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the CC esophagus. The most common types are esophageal squamous cell carcinoma CC and adenocarcinoma. Cancer of the esophagus remains a devastating CC disease because it is usually not detected until it has progressed to CC an advanced incurable stage. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Li-Fraumeni syndrome (LFS) [MIM:151623]: An autosomal dominant CC familial cancer syndrome that in its classic form is defined by the CC existence of a proband affected by a sarcoma before 45 years with a CC first degree relative affected by any tumor before 45 years and another CC first degree relative with any tumor before 45 years or a sarcoma at CC any age. Other clinical definitions for LFS have been proposed and CC called Li-Fraumeni like syndrome (LFL). In these families affected CC relatives develop a diverse set of malignancies at unusually early CC ages. Four types of cancers account for 80% of tumors occurring in TP53 CC germline mutation carriers: breast cancers, soft tissue and bone CC sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. CC Less frequent tumors include choroid plexus carcinoma or papilloma CC before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, CC Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers. CC {ECO:0000269|PubMed:10484981, ECO:0000269|PubMed:1565144, CC ECO:0000269|PubMed:1737852, ECO:0000269|PubMed:1933902, CC ECO:0000269|PubMed:1978757, ECO:0000269|PubMed:2259385, CC ECO:0000269|PubMed:36108750, ECO:0000269|PubMed:7887414, CC ECO:0000269|PubMed:8825920, ECO:0000269|PubMed:9452042}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) CC [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. CC The hallmark of cutaneous SCC is malignant transformation of normal CC epidermal keratinocytes. Note=The gene represented in this entry is CC involved in disease pathogenesis. CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. Note=The disease is caused by variants affecting the gene CC represented in this entry. CC -!- DISEASE: Papilloma of choroid plexus (CPP) [MIM:260500]: A benign tumor CC of neuroectodermal origin that generally occurs in childhood, but has CC also been reported in adults. Although generally found within the CC ventricular system, choroid plexus papillomas can arise ectopically in CC the brain parenchyma or disseminate throughout the neuraxis. Patients CC present with signs and symptoms of increased intracranial pressure CC including headache, hydrocephalus, papilledema, nausea, vomiting, CC cranial nerve deficits, gait impairment, and seizures. CC {ECO:0000269|PubMed:12085209}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Adrenocortical carcinoma (ADCC) [MIM:202300]: A malignant CC neoplasm of the adrenal cortex and a rare childhood tumor. It occurs CC with increased frequency in patients with Beckwith-Wiedemann syndrome CC and Li-Fraumeni syndrome. {ECO:0000269|PubMed:11481490}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Basal cell carcinoma 7 (BCC7) [MIM:614740]: A common malignant CC skin neoplasm that typically appears on hair-bearing skin, most CC commonly on sun-exposed areas. It is slow growing and rarely CC metastasizes, but has potentialities for local invasion and CC destruction. It usually develops as a flat, firm, pale area that is CC small, raised, pink or red, translucent, shiny, and waxy, and the area CC may bleed following minor injury. Tumor size can vary from a few CC millimeters to several centimeters in diameter. CC {ECO:0000269|PubMed:21946351}. Note=Disease susceptibility is CC associated with variants affecting the gene represented in this entry. CC -!- DISEASE: Bone marrow failure syndrome 5 (BMFS5) [MIM:618165]: A form of CC bone marrow failure syndrome, a heterogeneous group of life-threatening CC disorders characterized by hematopoietic defects in association with a CC range of variable extra-hematopoietic manifestations. BMFS5 is an CC autosomal dominant form characterized by infantile onset of severe red CC cell anemia requiring transfusion. Additional features include CC hypogammaglobulinemia, poor growth with microcephaly, developmental CC delay, and seizures. {ECO:0000269|PubMed:30146126}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 2]: Expressed in quiescent lymphocytes. Seems CC to be non-functional. May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 3]: Expressed in quiescent lymphocytes. Seems CC to be non-functional. May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 7]: Produced by alternative promoter usage. CC {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 8]: Produced by alternative promoter usage and CC alternative splicing. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 9]: Produced by alternative promoter usage and CC alternative splicing. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}. CC -!- CAUTION: Interaction with BANP was reported to enhance phosphorylation CC on Ser-15 upon ultraviolet irradiation (PubMed:15701641). However, the CC publication has been retracted due to image duplication and CC manipulation. Interaction with BANP has been confirmed in mouse studies CC (By similarity). Phosphorylation at Ser-15 has been confirmed by other CC studies (PubMed:10570149, PubMed:11554766, PubMed:15866171, CC PubMed:16219768, PubMed:17317671, PubMed:17954561, PubMed:20959462, CC PubMed:25772236). Its nuclear and cytoplasmic localization has been CC confirmed by other studies (PubMed:15340061, PubMed:17170702, CC PubMed:17591690, PubMed:18206965, PubMed:19011621, PubMed:21597459, CC PubMed:22726440). {ECO:0000250|UniProtKB:P02340, CC ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:11554766, CC ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:15701641, CC ECO:0000269|PubMed:15866171, ECO:0000269|PubMed:16219768, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17317671, CC ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17954561, CC ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:21597459, CC ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:25772236, CC ECO:0000305|PubMed:32144153}. CC -!- WEB RESOURCE: Name=The TP53 Database; CC URL="https://tp53.cancer.gov/"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/88/P53"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=P53 entry; CC URL="https://en.wikipedia.org/wiki/P53"; CC -!- WEB RESOURCE: Name=Protein Spotlight; Note=On the right track - Issue CC 206 of August 2018; CC URL="https://www.proteinspotlight.org/back_issues/206/"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X02469; CAA26306.1; -; mRNA. DR EMBL; M13121; AAA59987.1; -; Genomic_DNA. DR EMBL; M13112; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13113; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13114; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13115; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13116; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13117; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13118; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13119; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13120; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; K03199; AAA59989.1; -; mRNA. DR EMBL; M14694; AAA61211.1; -; mRNA. DR EMBL; M14695; AAA61212.1; -; mRNA. DR EMBL; M22898; AAA59988.1; -; Genomic_DNA. DR EMBL; M22882; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22883; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22884; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22887; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22888; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22894; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22895; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22896; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22897; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; X01405; CAA25652.1; -; mRNA. DR EMBL; X60011; CAA42626.1; -; mRNA. DR EMBL; X60012; CAA42627.1; ALT_TERM; mRNA. DR EMBL; X60013; CAA42628.1; -; mRNA. DR EMBL; X60014; CAA42629.1; -; mRNA. DR EMBL; X60015; CAA42630.1; -; mRNA. DR EMBL; X60016; CAA42631.1; -; mRNA. DR EMBL; X60017; CAA42632.1; -; mRNA. DR EMBL; X60018; CAA42633.1; -; mRNA. DR EMBL; X60019; CAA42634.1; -; mRNA. DR EMBL; X60020; CAA42635.1; -; mRNA. DR EMBL; AF307851; AAG28785.1; -; mRNA. DR EMBL; DQ186648; ABA29753.1; -; mRNA. DR EMBL; DQ186649; ABA29754.1; -; mRNA. DR EMBL; DQ186650; ABA29755.1; -; mRNA. DR EMBL; DQ186651; ABA29756.1; -; mRNA. DR EMBL; DQ186652; ABA29757.1; -; mRNA. DR EMBL; DQ191317; ABB80262.1; -; mRNA. DR EMBL; DQ286964; ABB80266.1; -; mRNA. DR EMBL; X54156; CAA38095.1; -; Genomic_DNA. DR EMBL; U94788; AAC12971.1; -; Genomic_DNA. DR EMBL; AY838896; AAV80424.1; -; Genomic_DNA. DR EMBL; AF135121; AAD28535.1; -; Genomic_DNA. DR EMBL; AF135120; AAD28535.1; JOINED; Genomic_DNA. DR EMBL; AF136271; AAD28628.1; -; Genomic_DNA. DR EMBL; AF136270; AAD28628.1; JOINED; Genomic_DNA. DR EMBL; AB082923; BAC16799.1; -; mRNA. DR EMBL; AK312568; BAG35463.1; -; mRNA. DR EMBL; AC007421; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC087388; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471108; EAW90143.1; -; Genomic_DNA. DR EMBL; CH471108; EAW90144.1; -; Genomic_DNA. DR EMBL; BC003596; AAH03596.1; -; mRNA. DR EMBL; AY429684; AAR10356.1; -; mRNA. DR EMBL; AY390341; AAQ90158.1; -; Genomic_DNA. DR EMBL; AY359814; AAR13239.1; -; Genomic_DNA. DR EMBL; U63714; AAB39322.1; -; Genomic_DNA. DR EMBL; AF209136; AAF36362.1; -; Genomic_DNA. DR EMBL; AF209128; AAF36354.1; -; Genomic_DNA. DR EMBL; AF209129; AAF36355.1; -; Genomic_DNA. DR EMBL; AF209130; AAF36356.1; -; Genomic_DNA. DR EMBL; AF209131; AAF36357.1; -; Genomic_DNA. DR EMBL; AF209132; AAF36358.1; -; Genomic_DNA. DR EMBL; AF209133; AAF36359.1; -; Genomic_DNA. DR EMBL; AF209134; AAF36360.1; -; Genomic_DNA. DR EMBL; AF209135; AAF36361.1; -; Genomic_DNA. DR EMBL; AF209148; AAF36374.1; -; Genomic_DNA. DR EMBL; AF209149; AAF36375.1; -; Genomic_DNA. DR EMBL; AF209150; AAF36376.1; -; Genomic_DNA. DR EMBL; AF209151; AAF36377.1; -; Genomic_DNA. DR EMBL; AF209152; AAF36378.1; -; Genomic_DNA. DR EMBL; AF209153; AAF36379.1; -; Genomic_DNA. DR EMBL; AF209154; AAF36380.1; -; Genomic_DNA. DR EMBL; AF209155; AAF36381.1; -; Genomic_DNA. DR EMBL; AF209156; AAF36382.1; -; Genomic_DNA. DR EMBL; AF210309; AAF63442.1; -; Genomic_DNA. DR EMBL; AF210308; AAF63442.1; JOINED; Genomic_DNA. DR EMBL; AF210310; AAF63443.1; -; Genomic_DNA. DR EMBL; AF240684; AAK76358.1; -; Genomic_DNA. DR EMBL; AF240685; AAK76359.1; -; Genomic_DNA. DR EMBL; AY270155; AAP30003.1; -; Genomic_DNA. DR CCDS; CCDS11118.1; -. [P04637-1] DR CCDS; CCDS45605.1; -. [P04637-3] DR CCDS; CCDS45606.1; -. [P04637-2] DR CCDS; CCDS73966.1; -. [P04637-7] DR CCDS; CCDS73967.1; -. [P04637-9] DR CCDS; CCDS73968.1; -. [P04637-8] DR CCDS; CCDS73969.1; -. [P04637-4] DR CCDS; CCDS73970.1; -. [P04637-6] DR CCDS; CCDS73971.1; -. [P04637-5] DR PIR; A25224; DNHU53. DR RefSeq; NP_000537.3; NM_000546.5. [P04637-1] DR RefSeq; NP_001119584.1; NM_001126112.3. [P04637-1] DR RefSeq; NP_001119585.1; NM_001126113.3. [P04637-3] DR RefSeq; NP_001119586.1; NM_001126114.3. [P04637-2] DR RefSeq; NP_001119587.1; NM_001126115.2. [P04637-7] DR RefSeq; NP_001119588.1; NM_001126116.2. [P04637-8] DR RefSeq; NP_001119589.1; NM_001126117.2. [P04637-9] DR RefSeq; NP_001119590.1; NM_001126118.2. [P04637-4] DR RefSeq; NP_001263624.1; NM_001276695.3. [P04637-6] DR RefSeq; NP_001263625.1; NM_001276696.3. [P04637-5] DR RefSeq; NP_001263626.1; NM_001276697.1. DR RefSeq; NP_001263627.1; NM_001276698.1. DR RefSeq; NP_001263628.1; NM_001276699.1. DR RefSeq; NP_001263689.1; NM_001276760.3. [P04637-4] DR RefSeq; NP_001263690.1; NM_001276761.3. [P04637-4] DR RefSeq; NP_001394191.1; NM_001407262.1. [P04637-1] DR RefSeq; NP_001394192.1; NM_001407263.1. [P04637-4] DR RefSeq; NP_001394193.1; NM_001407264.1. [P04637-1] DR RefSeq; NP_001394194.1; NM_001407265.1. [P04637-4] DR RefSeq; NP_001394195.1; NM_001407266.1. [P04637-1] DR RefSeq; NP_001394196.1; NM_001407267.1. [P04637-4] DR RefSeq; NP_001394197.1; NM_001407268.1. [P04637-2] DR RefSeq; NP_001394198.1; NM_001407269.1. [P04637-5] DR RefSeq; NP_001394199.1; NM_001407270.1. [P04637-2] DR RefSeq; NP_001394200.1; NM_001407271.1. [P04637-5] DR PDB; 1A1U; NMR; -; A/C=324-358. DR PDB; 1AIE; X-ray; 1.50 A; A=326-356. DR PDB; 1C26; X-ray; 1.70 A; A=325-356. DR PDB; 1DT7; NMR; -; X/Y=367-388. DR PDB; 1GZH; X-ray; 2.60 A; A/C=95-292. DR PDB; 1H26; X-ray; 2.24 A; E=376-386. DR PDB; 1HS5; NMR; -; A/B=324-357. DR PDB; 1JSP; NMR; -; A=367-386. DR PDB; 1KZY; X-ray; 2.50 A; A/B=95-289. DR PDB; 1MA3; X-ray; 2.00 A; B=372-389. DR PDB; 1OLG; NMR; -; A/B/C/D=319-360. DR PDB; 1OLH; NMR; -; A/B/C/D=319-360. DR PDB; 1PES; NMR; -; A/B/C/D=325-355. DR PDB; 1PET; NMR; -; A/B/C/D=325-355. DR PDB; 1SAE; NMR; -; A/B/C/D=319-360. DR PDB; 1SAF; NMR; -; A/B/C/D=319-360. DR PDB; 1SAK; NMR; -; A/B/C/D=319-360. DR PDB; 1SAL; NMR; -; A/B/C/D=319-360. DR PDB; 1TSR; X-ray; 2.20 A; A/B/C=94-312. DR PDB; 1TUP; X-ray; 2.20 A; A/B/C=94-312. DR PDB; 1UOL; X-ray; 1.90 A; A/B=94-312. DR PDB; 1XQH; X-ray; 1.75 A; B/F=369-377. DR PDB; 1YC5; X-ray; 1.40 A; B=372-389. DR PDB; 1YCQ; X-ray; 2.30 A; B=13-29. DR PDB; 1YCR; X-ray; 2.60 A; B=15-29. DR PDB; 1YCS; X-ray; 2.20 A; A=94-292. DR PDB; 2AC0; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 2ADY; X-ray; 2.50 A; A/B=94-293. DR PDB; 2AHI; X-ray; 1.85 A; A/B/C/D=94-293. DR PDB; 2ATA; X-ray; 2.20 A; A/B/C/D=94-293. DR PDB; 2B3G; X-ray; 1.60 A; B=33-60. DR PDB; 2BIM; X-ray; 1.98 A; A/B=94-312. DR PDB; 2BIN; X-ray; 1.90 A; A=94-312. DR PDB; 2BIO; X-ray; 1.90 A; A=94-312. DR PDB; 2BIP; X-ray; 1.80 A; A=94-312. DR PDB; 2BIQ; X-ray; 1.80 A; A=94-312. DR PDB; 2F1X; X-ray; 2.30 A; A/B=359-368. DR PDB; 2FEJ; NMR; -; A=94-297. DR PDB; 2FOJ; X-ray; 1.60 A; B=361-367. DR PDB; 2FOO; X-ray; 2.20 A; B=358-363. DR PDB; 2GS0; NMR; -; B=20-73. DR PDB; 2H1L; X-ray; 3.16 A; M/N/O/P/Q/R/S/T/U/V/W/X=92-292. DR PDB; 2H2D; X-ray; 1.70 A; B=372-389. DR PDB; 2H2F; X-ray; 2.20 A; B=372-389. DR PDB; 2H4F; X-ray; 2.00 A; D=372-389. DR PDB; 2H4H; X-ray; 1.99 A; B=372-389. DR PDB; 2H4J; X-ray; 2.10 A; D=372-389. DR PDB; 2H59; X-ray; 1.90 A; D/E=372-389. DR PDB; 2J0Z; NMR; -; A/B/C/D=326-356. DR PDB; 2J10; NMR; -; A/B/C/D=326-356. DR PDB; 2J11; NMR; -; A/B/C/D=326-356. DR PDB; 2J1W; X-ray; 1.80 A; A/B=94-312. DR PDB; 2J1X; X-ray; 1.65 A; A/B=94-312. DR PDB; 2J1Y; X-ray; 1.69 A; A/B/C/D=94-293. DR PDB; 2J1Z; X-ray; 1.80 A; A/B=94-312. DR PDB; 2J20; X-ray; 1.80 A; A/B=94-312. DR PDB; 2J21; X-ray; 1.60 A; A/B=94-312. DR PDB; 2K8F; NMR; -; B=1-39. DR PDB; 2L14; NMR; -; B=13-61. DR PDB; 2LY4; NMR; -; B=1-93. DR PDB; 2MEJ; NMR; -; B=96-312. DR PDB; 2MWO; NMR; -; B=363-377. DR PDB; 2MWP; NMR; -; B=376-387. DR PDB; 2MWY; NMR; -; B=15-29. DR PDB; 2MZD; NMR; -; B=35-59. DR PDB; 2OCJ; X-ray; 2.05 A; A/B/C/D=94-312. DR PDB; 2PCX; X-ray; 1.54 A; A=94-292. DR PDB; 2RUK; NMR; -; A=41-62. DR PDB; 2VUK; X-ray; 1.50 A; A/B=94-312. DR PDB; 2WGX; X-ray; 1.75 A; A/B=94-312. DR PDB; 2X0U; X-ray; 1.60 A; A/B=94-312. DR PDB; 2X0V; X-ray; 1.80 A; A/B=94-312. DR PDB; 2X0W; X-ray; 2.10 A; A/B=94-312. DR PDB; 2XWR; X-ray; 1.68 A; A/B=89-293. DR PDB; 2YBG; X-ray; 1.90 A; A/B/C/D=94-293. DR PDB; 2YDR; X-ray; 2.75 A; P=144-154. DR PDB; 2Z5S; X-ray; 2.30 A; P/Q/R=15-29. DR PDB; 2Z5T; X-ray; 2.30 A; P/Q/R=15-29. DR PDB; 3D05; X-ray; 1.70 A; A=94-293. DR PDB; 3D06; X-ray; 1.20 A; A=94-293. DR PDB; 3D07; X-ray; 2.20 A; A/B=94-293. DR PDB; 3D08; X-ray; 1.40 A; A=94-293. DR PDB; 3D09; X-ray; 1.90 A; A=94-293. DR PDB; 3D0A; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 3DAB; X-ray; 1.90 A; B/D/F/H=15-29. DR PDB; 3DAC; X-ray; 1.80 A; B/P=17-37. DR PDB; 3IGK; X-ray; 1.70 A; A=94-293. DR PDB; 3IGL; X-ray; 1.80 A; A=94-293. DR PDB; 3KMD; X-ray; 2.15 A; A/B/C/D=92-291. DR PDB; 3KZ8; X-ray; 1.91 A; A/B=94-293. DR PDB; 3LW1; X-ray; 1.28 A; P=385-393. DR PDB; 3OQ5; X-ray; 2.50 A; D/E=377-386. DR PDB; 3PDH; X-ray; 1.80 A; D=372-389. DR PDB; 3Q01; X-ray; 2.10 A; A/B=94-356. DR PDB; 3Q05; X-ray; 2.40 A; A/B/C/D=94-356. DR PDB; 3Q06; X-ray; 3.20 A; A/B/C/D=96-354. DR PDB; 3SAK; NMR; -; A/B/C/D=319-360. DR PDB; 3TG5; X-ray; 2.30 A; B=365-375. DR PDB; 3TS8; X-ray; 2.80 A; A/B/C/D=94-356. DR PDB; 3ZME; X-ray; 1.35 A; A/B=94-312. DR PDB; 4AGL; X-ray; 1.70 A; A/B=94-312. DR PDB; 4AGM; X-ray; 1.52 A; A/B=94-312. DR PDB; 4AGN; X-ray; 1.60 A; A/B=94-312. DR PDB; 4AGO; X-ray; 1.45 A; A/B=94-312. DR PDB; 4AGP; X-ray; 1.50 A; A/B=94-312. DR PDB; 4AGQ; X-ray; 1.42 A; A/B=94-312. DR PDB; 4BUZ; X-ray; 1.90 A; P=379-386. DR PDB; 4BV2; X-ray; 3.30 A; E/H=376-388. DR PDB; 4HFZ; X-ray; 2.69 A; B/D=15-29. DR PDB; 4HJE; X-ray; 1.91 A; A/B/C/D=92-291. DR PDB; 4IBQ; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 4IBS; X-ray; 1.78 A; A/B/C/D=94-293. DR PDB; 4IBT; X-ray; 1.70 A; A/B/C/D=94-293. DR PDB; 4IBU; X-ray; 1.70 A; A/B/C/D=94-293. DR PDB; 4IBV; X-ray; 2.10 A; A=94-293. DR PDB; 4IBW; X-ray; 1.79 A; A=94-293. DR PDB; 4IBY; X-ray; 1.45 A; A/B=94-293. DR PDB; 4IBZ; X-ray; 1.92 A; A/B/C/D=94-293. DR PDB; 4IJT; X-ray; 1.78 A; A=94-293. DR PDB; 4KVP; X-ray; 1.50 A; A/B/C/D=94-312. DR PDB; 4LO9; X-ray; 2.50 A; A/B/C/D=94-312. DR PDB; 4LOE; X-ray; 1.85 A; A/B/C/D=94-312. DR PDB; 4LOF; X-ray; 2.00 A; A=94-312. DR PDB; 4MZI; X-ray; 1.25 A; A=94-292. DR PDB; 4MZR; X-ray; 2.90 A; A/B/C/D=94-358. DR PDB; 4QO1; X-ray; 1.92 A; B=92-312. DR PDB; 4RP6; X-ray; 1.70 A; Z=252-258. DR PDB; 4RP7; X-ray; 1.58 A; Z=253-258. DR PDB; 4X34; X-ray; 1.80 A; C/D=377-386. DR PDB; 4XR8; X-ray; 2.25 A; C/D=94-292. DR PDB; 4ZZJ; X-ray; 2.74 A; B=379-383. DR PDB; 5A7B; X-ray; 1.40 A; A/B=94-312. DR PDB; 5AB9; X-ray; 1.36 A; A/B=94-312. DR PDB; 5ABA; X-ray; 1.62 A; A/B=94-312. DR PDB; 5AOI; X-ray; 1.78 A; A/B=94-312. DR PDB; 5AOJ; X-ray; 1.47 A; A/B=94-312. DR PDB; 5AOK; X-ray; 1.35 A; A/B=94-312. DR PDB; 5AOL; X-ray; 1.50 A; A/B=94-312. DR PDB; 5AOM; X-ray; 1.74 A; A/B=94-312. DR PDB; 5BUA; X-ray; 1.81 A; A=94-293. DR PDB; 5ECG; X-ray; 3.00 A; A/B=95-312. DR PDB; 5G4M; X-ray; 1.38 A; A/B=94-312. DR PDB; 5G4N; X-ray; 1.35 A; A/B=94-312. DR PDB; 5G4O; X-ray; 1.48 A; A/B=94-312. DR PDB; 5HOU; NMR; -; A=1-61. DR PDB; 5HP0; NMR; -; A=37-61. DR PDB; 5HPD; NMR; -; A=2-61. DR PDB; 5LAP; X-ray; 1.42 A; A/B=94-312. DR PDB; 5LGY; X-ray; 2.92 A; A/B/C/D=94-291. DR PDB; 5MCT; X-ray; 1.45 A; A/B=94-293. DR PDB; 5MCU; X-ray; 1.70 A; A/B=94-293. DR PDB; 5MCV; X-ray; 1.60 A; A/B=94-293. DR PDB; 5MCW; X-ray; 1.90 A; A/B=94-293. DR PDB; 5MF7; X-ray; 1.59 A; A/B=94-293. DR PDB; 5MG7; X-ray; 1.45 A; A/B=94-293. DR PDB; 5MHC; X-ray; 1.20 A; P=382-393. DR PDB; 5MOC; X-ray; 1.80 A; P=382-393. DR PDB; 5O1A; X-ray; 1.44 A; A/B=94-312. DR PDB; 5O1B; X-ray; 1.43 A; A/B=94-312. DR PDB; 5O1C; X-ray; 1.32 A; A/B=94-312. DR PDB; 5O1D; X-ray; 1.36 A; A/B=94-312. DR PDB; 5O1E; X-ray; 1.30 A; A/B=94-312. DR PDB; 5O1F; X-ray; 1.38 A; A/B=94-312. DR PDB; 5O1G; X-ray; 1.35 A; A/B=94-312. DR PDB; 5O1H; X-ray; 1.32 A; A/B=94-312. DR PDB; 5O1I; X-ray; 1.40 A; A/B=94-312. DR PDB; 5OL0; X-ray; 1.99 A; C/D=372-389. DR PDB; 5UN8; X-ray; 2.13 A; E/F/G/H=144-154. DR PDB; 5XZC; EM; 10.70 A; B/C/D/E=92-356. DR PDB; 6FF9; X-ray; 2.00 A; A/B/C/D=97-289. DR PDB; 6FJ5; X-ray; 2.05 A; A/B/C/D=94-293. DR PDB; 6GGA; X-ray; 1.55 A; A/B=94-312. DR PDB; 6GGB; X-ray; 1.32 A; A/B=94-312. DR PDB; 6GGC; X-ray; 1.24 A; A/B=94-312. DR PDB; 6GGD; X-ray; 1.40 A; A/B=94-312. DR PDB; 6GGE; X-ray; 1.25 A; A/B=94-312. DR PDB; 6GGF; X-ray; 1.32 A; A/B=94-312. DR PDB; 6LHD; X-ray; 2.50 A; A/B=96-292. DR PDB; 6R5L; X-ray; 1.88 A; P=382-393. DR PDB; 6RJZ; X-ray; 1.58 A; P=382-393. DR PDB; 6RK8; X-ray; 1.60 A; P=382-393. DR PDB; 6RKI; X-ray; 1.88 A; P=382-393. DR PDB; 6RKK; X-ray; 1.88 A; P=382-393. DR PDB; 6RKM; X-ray; 1.88 A; P=382-393. DR PDB; 6RL3; X-ray; 1.30 A; P=382-393. DR PDB; 6RL4; X-ray; 1.60 A; P=382-393. DR PDB; 6RL6; X-ray; 1.60 A; P=382-393. DR PDB; 6RM5; X-ray; 1.88 A; P=382-393. DR PDB; 6RM7; X-ray; 1.60 A; P=382-393. DR PDB; 6RWH; X-ray; 1.68 A; P=382-393. DR PDB; 6RWI; X-ray; 1.65 A; P=382-393. DR PDB; 6RWS; X-ray; 1.53 A; P=382-393. DR PDB; 6RWU; X-ray; 1.46 A; P=382-393. DR PDB; 6RX2; X-ray; 1.82 A; P=382-393. DR PDB; 6RZ3; X-ray; 4.23 A; A=62-292. DR PDB; 6S39; X-ray; 1.88 A; P=382-393. DR PDB; 6S3C; X-ray; 2.00 A; P=382-393. DR PDB; 6S40; X-ray; 1.90 A; P=382-393. DR PDB; 6S9Q; X-ray; 1.69 A; P=382-393. DR PDB; 6SHZ; X-ray; 1.24 A; A/B=94-311. DR PDB; 6SI0; X-ray; 1.53 A; A/B=94-312. DR PDB; 6SI1; X-ray; 1.44 A; A/B=94-312. DR PDB; 6SI2; X-ray; 1.50 A; A/B=94-312. DR PDB; 6SI3; X-ray; 1.40 A; A/B=94-312. DR PDB; 6SI4; X-ray; 1.80 A; A/B=94-312. DR PDB; 6SIN; X-ray; 1.64 A; P=382-393. DR PDB; 6SIO; X-ray; 1.60 A; P=382-393. DR PDB; 6SIP; X-ray; 1.60 A; P=382-393. DR PDB; 6SIQ; X-ray; 1.60 A; P=382-393. DR PDB; 6SL6; X-ray; 1.67 A; A=89-311. DR PDB; 6SLV; X-ray; 1.90 A; P=382-393. DR PDB; 6T58; X-ray; 3.10 A; A/B=17-56. DR PDB; 6V4F; X-ray; 1.35 A; B=14-29. DR PDB; 6V4H; X-ray; 1.53 A; B/D=14-29. DR PDB; 6VQO; X-ray; 3.00 A; P/Q=168-176. DR PDB; 6VR1; X-ray; 2.37 A; P/Q=168-176. DR PDB; 6VR5; X-ray; 2.38 A; P/Q=168-176. DR PDB; 6VRM; X-ray; 2.61 A; P=168-176. DR PDB; 6VRN; X-ray; 2.46 A; P=168-176. DR PDB; 6W51; X-ray; 3.53 A; C/F/I/L=168-176. DR PDB; 6XRE; EM; 4.60 A; M=1-393. DR PDB; 6ZNC; X-ray; 1.64 A; A=94-293. DR PDB; 7B46; X-ray; 2.02 A; A/B/C/D=94-293. DR PDB; 7B47; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 7B48; X-ray; 2.05 A; A/B/C/D=94-293. DR PDB; 7B49; X-ray; 1.42 A; A/B=94-293. DR PDB; 7B4A; X-ray; 1.90 A; A/B=94-293. DR PDB; 7B4B; X-ray; 1.76 A; A/B/C/D=94-293. DR PDB; 7B4C; X-ray; 1.71 A; A/B/C/D=94-293. DR PDB; 7B4D; X-ray; 1.85 A; A=94-293. DR PDB; 7B4E; X-ray; 1.58 A; A=94-293. DR PDB; 7B4F; X-ray; 1.78 A; A=94-293. DR PDB; 7B4G; X-ray; 1.86 A; A=94-293. DR PDB; 7B4H; X-ray; 1.39 A; A=94-293. DR PDB; 7B4N; X-ray; 1.32 A; A=94-293. DR PDB; 7BWN; X-ray; 2.40 A; B/D/G/I/K/L/N/P=326-356. DR PDB; 7DHY; X-ray; 2.15 A; A/B/C/D=94-293. DR PDB; 7DHZ; X-ray; 1.74 A; A/B=94-293. DR PDB; 7DVD; X-ray; 2.59 A; A/B/C/D=92-290. DR PDB; 7EAX; X-ray; 2.55 A; A/B/C/D=96-289. DR PDB; 7EDS; X-ray; 1.77 A; A=94-293. DR PDB; 7EEU; X-ray; 2.90 A; A/B/C/D/E/F/G/H=94-293. DR PDB; 7EL4; X-ray; 2.11 A; A=23-29. DR PDB; 7NMI; X-ray; 2.10 A; A=17-56. DR PDB; 7RM4; X-ray; 3.33 A; C/H/M/R=168-176. DR PDB; 7V97; X-ray; 2.02 A; A/B/C/D=94-293. DR PDB; 7XZX; EM; 4.53 A; K/L/M/N=94-293. DR PDB; 7XZZ; EM; 4.07 A; K/L/M/N=1-393. DR PDB; 7YGI; X-ray; 2.10 A; A/B=92-289. DR PDB; 8A31; X-ray; 1.46 A; A/B=94-312. DR PDB; 8A32; X-ray; 1.47 A; A/B=94-312. DR PDB; 8A92; X-ray; 1.37 A; A/B=94-312. DR PDB; 8CG7; X-ray; 1.53 A; A/B=94-312. DR PDB; 8DC4; X-ray; 2.40 A; A/B/C/D=94-312. DR PDB; 8DC6; X-ray; 1.60 A; A/B/C/D=94-312. DR PDB; 8DC7; X-ray; 1.99 A; A=94-312. DR PDB; 8DC8; X-ray; 1.72 A; A=94-312. DR PDB; 8E7A; X-ray; 1.30 A; A=93-312. DR PDB; 8E7B; X-ray; 2.50 A; A/B=93-312. DR PDB; 8GCR; EM; 3.38 A; B=94-312. DR PDB; 8HLL; X-ray; 2.62 A; A=95-290. DR PDB; 8HLM; X-ray; 2.52 A; A=95-290. DR PDB; 8HLN; X-ray; 2.35 A; A=95-290. DR PDB; 8J8N; EM; 9.02 A; A/B/C/D=92-292. DR PDB; 8OXM; EM; 3.30 A; E/F=11-22. DR PDB; 8OXO; EM; 3.00 A; E/F=11-22. DR PDB; 8QWK; X-ray; 1.69 A; A=94-312. DR PDB; 8QWL; X-ray; 1.65 A; A=94-312. DR PDB; 8QWM; X-ray; 1.54 A; A/B=94-312. DR PDB; 8QWN; X-ray; 1.44 A; A=94-312. DR PDB; 8QWO; X-ray; 1.38 A; A/B=94-312. DR PDB; 8QWP; X-ray; 2.10 A; A/B=94-312. DR PDB; 8R1F; EM; 3.67 A; C=1-393. DR PDB; 8R1G; EM; 3.99 A; C/F=1-393. DR PDB; 8RBA; X-ray; 1.57 A; A/B=94-312. DR PDB; 8RBB; X-ray; 1.69 A; A/B=94-312. DR PDB; 8RBC; X-ray; 2.06 A; A/B=94-312. DR PDB; 8RCI; X-ray; 1.50 A; A=94-294. DR PDB; 8UQR; X-ray; 1.22 A; A/B/C/D=326-356. DR PDB; 8WD2; X-ray; 1.85 A; A/B=94-312. DR PDB; 8XP5; X-ray; 2.55 A; A/B=95-292. DR PDB; 9BR3; X-ray; 1.90 A; A/B=94-312. DR PDB; 9BR4; X-ray; 1.70 A; A/B=94-312. DR PDB; 9C5S; X-ray; 1.01 A; A/B/C/D=17-30. DR PDB; 9CHT; EM; 3.54 A; B=1-312. DR PDB; 9FZB; X-ray; 1.44 A; A=94-294. DR PDBsum; 1A1U; -. DR PDBsum; 1AIE; -. DR PDBsum; 1C26; -. DR PDBsum; 1DT7; -. DR PDBsum; 1GZH; -. DR PDBsum; 1H26; -. DR PDBsum; 1HS5; -. DR PDBsum; 1JSP; -. DR PDBsum; 1KZY; -. DR PDBsum; 1MA3; -. DR PDBsum; 1OLG; -. DR PDBsum; 1OLH; -. DR PDBsum; 1PES; -. DR PDBsum; 1PET; -. DR PDBsum; 1SAE; -. DR PDBsum; 1SAF; -. DR PDBsum; 1SAK; -. DR PDBsum; 1SAL; -. DR PDBsum; 1TSR; -. DR PDBsum; 1TUP; -. DR PDBsum; 1UOL; -. DR PDBsum; 1XQH; -. DR PDBsum; 1YC5; -. DR PDBsum; 1YCQ; -. DR PDBsum; 1YCR; -. DR PDBsum; 1YCS; -. DR PDBsum; 2AC0; -. DR PDBsum; 2ADY; -. DR PDBsum; 2AHI; -. DR PDBsum; 2ATA; -. DR PDBsum; 2B3G; -. DR PDBsum; 2BIM; -. DR PDBsum; 2BIN; -. DR PDBsum; 2BIO; -. DR PDBsum; 2BIP; -. DR PDBsum; 2BIQ; -. DR PDBsum; 2F1X; -. DR PDBsum; 2FEJ; -. DR PDBsum; 2FOJ; -. DR PDBsum; 2FOO; -. DR PDBsum; 2GS0; -. DR PDBsum; 2H1L; -. DR PDBsum; 2H2D; -. DR PDBsum; 2H2F; -. DR PDBsum; 2H4F; -. DR PDBsum; 2H4H; -. DR PDBsum; 2H4J; -. DR PDBsum; 2H59; -. DR PDBsum; 2J0Z; -. DR PDBsum; 2J10; -. DR PDBsum; 2J11; -. DR PDBsum; 2J1W; -. DR PDBsum; 2J1X; -. DR PDBsum; 2J1Y; -. DR PDBsum; 2J1Z; -. DR PDBsum; 2J20; -. DR PDBsum; 2J21; -. DR PDBsum; 2K8F; -. DR PDBsum; 2L14; -. DR PDBsum; 2LY4; -. DR PDBsum; 2MEJ; -. DR PDBsum; 2MWO; -. DR PDBsum; 2MWP; -. DR PDBsum; 2MWY; -. DR PDBsum; 2MZD; -. DR PDBsum; 2OCJ; -. DR PDBsum; 2PCX; -. DR PDBsum; 2RUK; -. DR PDBsum; 2VUK; -. DR PDBsum; 2WGX; -. DR PDBsum; 2X0U; -. DR PDBsum; 2X0V; -. DR PDBsum; 2X0W; -. DR PDBsum; 2XWR; -. DR PDBsum; 2YBG; -. DR PDBsum; 2YDR; -. DR PDBsum; 2Z5S; -. DR PDBsum; 2Z5T; -. DR PDBsum; 3D05; -. DR PDBsum; 3D06; -. DR PDBsum; 3D07; -. DR PDBsum; 3D08; -. DR PDBsum; 3D09; -. DR PDBsum; 3D0A; -. DR PDBsum; 3DAB; -. DR PDBsum; 3DAC; -. DR PDBsum; 3IGK; -. DR PDBsum; 3IGL; -. DR PDBsum; 3KMD; -. DR PDBsum; 3KZ8; -. DR PDBsum; 3LW1; -. DR PDBsum; 3OQ5; -. DR PDBsum; 3PDH; -. DR PDBsum; 3Q01; -. DR PDBsum; 3Q05; -. DR PDBsum; 3Q06; -. DR PDBsum; 3SAK; -. DR PDBsum; 3TG5; -. DR PDBsum; 3TS8; -. DR PDBsum; 3ZME; -. DR PDBsum; 4AGL; -. DR PDBsum; 4AGM; -. DR PDBsum; 4AGN; -. DR PDBsum; 4AGO; -. DR PDBsum; 4AGP; -. DR PDBsum; 4AGQ; -. DR PDBsum; 4BUZ; -. DR PDBsum; 4BV2; -. DR PDBsum; 4HFZ; -. DR PDBsum; 4HJE; -. DR PDBsum; 4IBQ; -. DR PDBsum; 4IBS; -. DR PDBsum; 4IBT; -. DR PDBsum; 4IBU; -. DR PDBsum; 4IBV; -. DR PDBsum; 4IBW; -. DR PDBsum; 4IBY; -. DR PDBsum; 4IBZ; -. DR PDBsum; 4IJT; -. DR PDBsum; 4KVP; -. DR PDBsum; 4LO9; -. DR PDBsum; 4LOE; -. DR PDBsum; 4LOF; -. DR PDBsum; 4MZI; -. DR PDBsum; 4MZR; -. DR PDBsum; 4QO1; -. DR PDBsum; 4RP6; -. DR PDBsum; 4RP7; -. DR PDBsum; 4X34; -. DR PDBsum; 4XR8; -. DR PDBsum; 4ZZJ; -. DR PDBsum; 5A7B; -. DR PDBsum; 5AB9; -. DR PDBsum; 5ABA; -. DR PDBsum; 5AOI; -. DR PDBsum; 5AOJ; -. DR PDBsum; 5AOK; -. DR PDBsum; 5AOL; -. DR PDBsum; 5AOM; -. DR PDBsum; 5BUA; -. DR PDBsum; 5ECG; -. DR PDBsum; 5G4M; -. DR PDBsum; 5G4N; -. DR PDBsum; 5G4O; -. DR PDBsum; 5HOU; -. DR PDBsum; 5HP0; -. DR PDBsum; 5HPD; -. DR PDBsum; 5LAP; -. DR PDBsum; 5LGY; -. DR PDBsum; 5MCT; -. DR PDBsum; 5MCU; -. DR PDBsum; 5MCV; -. DR PDBsum; 5MCW; -. DR PDBsum; 5MF7; -. DR PDBsum; 5MG7; -. DR PDBsum; 5MHC; -. DR PDBsum; 5MOC; -. DR PDBsum; 5O1A; -. DR PDBsum; 5O1B; -. DR PDBsum; 5O1C; -. DR PDBsum; 5O1D; -. DR PDBsum; 5O1E; -. DR PDBsum; 5O1F; -. DR PDBsum; 5O1G; -. DR PDBsum; 5O1H; -. DR PDBsum; 5O1I; -. DR PDBsum; 5OL0; -. DR PDBsum; 5UN8; -. DR PDBsum; 5XZC; -. DR PDBsum; 6FF9; -. DR PDBsum; 6FJ5; -. DR PDBsum; 6GGA; -. DR PDBsum; 6GGB; -. DR PDBsum; 6GGC; -. DR PDBsum; 6GGD; -. DR PDBsum; 6GGE; -. DR PDBsum; 6GGF; -. DR PDBsum; 6LHD; -. DR PDBsum; 6R5L; -. DR PDBsum; 6RJZ; -. DR PDBsum; 6RK8; -. DR PDBsum; 6RKI; -. DR PDBsum; 6RKK; -. DR PDBsum; 6RKM; -. DR PDBsum; 6RL3; -. DR PDBsum; 6RL4; -. DR PDBsum; 6RL6; -. DR PDBsum; 6RM5; -. DR PDBsum; 6RM7; -. DR PDBsum; 6RWH; -. DR PDBsum; 6RWI; -. DR PDBsum; 6RWS; -. DR PDBsum; 6RWU; -. DR PDBsum; 6RX2; -. DR PDBsum; 6RZ3; -. DR PDBsum; 6S39; -. DR PDBsum; 6S3C; -. DR PDBsum; 6S40; -. DR PDBsum; 6S9Q; -. DR PDBsum; 6SHZ; -. DR PDBsum; 6SI0; -. DR PDBsum; 6SI1; -. DR PDBsum; 6SI2; -. DR PDBsum; 6SI3; -. DR PDBsum; 6SI4; -. DR PDBsum; 6SIN; -. DR PDBsum; 6SIO; -. DR PDBsum; 6SIP; -. DR PDBsum; 6SIQ; -. DR PDBsum; 6SL6; -. DR PDBsum; 6SLV; -. DR PDBsum; 6T58; -. DR PDBsum; 6V4F; -. DR PDBsum; 6V4H; -. DR PDBsum; 6VQO; -. DR PDBsum; 6VR1; -. DR PDBsum; 6VR5; -. DR PDBsum; 6VRM; -. DR PDBsum; 6VRN; -. DR PDBsum; 6W51; -. DR PDBsum; 6XRE; -. DR PDBsum; 6ZNC; -. DR PDBsum; 7B46; -. DR PDBsum; 7B47; -. DR PDBsum; 7B48; -. DR PDBsum; 7B49; -. DR PDBsum; 7B4A; -. DR PDBsum; 7B4B; -. DR PDBsum; 7B4C; -. DR PDBsum; 7B4D; -. DR PDBsum; 7B4E; -. DR PDBsum; 7B4F; -. DR PDBsum; 7B4G; -. DR PDBsum; 7B4H; -. DR PDBsum; 7B4N; -. DR PDBsum; 7BWN; -. DR PDBsum; 7DHY; -. DR PDBsum; 7DHZ; -. DR PDBsum; 7DVD; -. DR PDBsum; 7EAX; -. DR PDBsum; 7EDS; -. DR PDBsum; 7EEU; -. DR PDBsum; 7EL4; -. DR PDBsum; 7NMI; -. DR PDBsum; 7RM4; -. DR PDBsum; 7V97; -. DR PDBsum; 7XZX; -. DR PDBsum; 7XZZ; -. DR PDBsum; 7YGI; -. DR PDBsum; 8A31; -. DR PDBsum; 8A32; -. DR PDBsum; 8A92; -. DR PDBsum; 8CG7; -. DR PDBsum; 8DC4; -. DR PDBsum; 8DC6; -. DR PDBsum; 8DC7; -. DR PDBsum; 8DC8; -. DR PDBsum; 8E7A; -. DR PDBsum; 8E7B; -. DR PDBsum; 8GCR; -. DR PDBsum; 8HLL; -. DR PDBsum; 8HLM; -. DR PDBsum; 8HLN; -. DR PDBsum; 8J8N; -. DR PDBsum; 8OXM; -. DR PDBsum; 8OXO; -. DR PDBsum; 8QWK; -. DR PDBsum; 8QWL; -. DR PDBsum; 8QWM; -. DR PDBsum; 8QWN; -. DR PDBsum; 8QWO; -. DR PDBsum; 8QWP; -. DR PDBsum; 8R1F; -. DR PDBsum; 8R1G; -. DR PDBsum; 8RBA; -. DR PDBsum; 8RBB; -. DR PDBsum; 8RBC; -. DR PDBsum; 8RCI; -. DR PDBsum; 8UQR; -. DR PDBsum; 8WD2; -. DR PDBsum; 8XP5; -. DR PDBsum; 9BR3; -. DR PDBsum; 9BR4; -. DR PDBsum; 9C5S; -. DR PDBsum; 9CHT; -. DR PDBsum; 9FZB; -. DR AlphaFoldDB; P04637; -. DR BMRB; P04637; -. DR EMDB; EMD-0378; -. DR EMDB; EMD-17265; -. DR EMDB; EMD-17266; -. DR EMDB; EMD-18809; -. DR EMDB; EMD-18810; -. DR EMDB; EMD-22294; -. DR EMDB; EMD-22827; -. DR EMDB; EMD-29941; -. DR EMDB; EMD-33533; -. DR EMDB; EMD-33535; -. DR EMDB; EMD-36075; -. DR EMDB; EMD-45601; -. DR EMDB; EMD-53478; -. DR EMDB; EMD-53532; -. DR EMDB; EMD-53536; -. DR EMDB; EMD-53537; -. DR EMDB; EMD-6791; -. DR EMDB; EMD-8926; -. DR EMDB; EMD-8927; -. DR SMR; P04637; -. DR BioGRID; 113010; 2577. DR ComplexPortal; CPX-6093; p53-MDM2-MDM4 transcriptional regulation complex. DR ComplexPortal; CPX-663; p53-MDM4 transcriptional regulation complex. DR ComplexPortal; CPX-759; p53-MDM2 transcriptional regulation complex. DR CORUM; P04637; -. DR DIP; DIP-368N; -. DR ELM; P04637; -. DR FunCoup; P04637; 3248. DR IntAct; P04637; 850. DR MINT; P04637; -. DR STRING; 9606.ENSP00000269305; -. DR BindingDB; P04637; -. DR ChEMBL; CHEMBL4096; -. DR DrugBank; DB08363; 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine. DR DrugBank; DB13010; 4-isothioureidobutyronitrile. DR DrugBank; DB00945; Acetylsalicylic acid. DR DrugBank; DB17549; Alrizomadlin. DR DrugBank; DB05404; AZD 3355. DR DrugBank; DB17507; COTI-2. DR DrugBank; DB11684; Eprenetapopt. DR DrugBank; DB17039; Nutlin-3. DR DrugBank; DB12541; SAR-405838. DR DrugBank; DB16331; Siremadlin. DR DrugBank; DB16447; Thymoquinone. DR DrugBank; DB03347; Triethyl phosphate. DR DrugBank; DB01593; Zinc. DR DrugBank; DB14487; Zinc acetate. DR DrugBank; DB14533; Zinc chloride. DR DrugBank; DB14548; Zinc sulfate, unspecified form. DR MoonDB; P04637; Predicted. DR TCDB; 1.C.110.1.1; the pore-forming pnc-27 peptide of 32 aas from the p53 tumor suppressor protein (pnc-27) family. DR GlyCosmos; P04637; 1 site, 1 glycan. DR GlyGen; P04637; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; P04637; -. DR MetOSite; P04637; -. DR PhosphoSitePlus; P04637; -. DR SwissPalm; P04637; -. DR BioMuta; TP53; -. DR DMDM; 269849759; -. DR CPTAC; CPTAC-5895; -. DR CPTAC; CPTAC-5896; -. DR CPTAC; CPTAC-951; -. DR jPOST; P04637; -. DR MassIVE; P04637; -. DR PaxDb; 9606-ENSP00000269305; -. DR PeptideAtlas; P04637; -. DR ProteomicsDB; 51728; -. [P04637-1] DR ProteomicsDB; 51729; -. [P04637-2] DR ProteomicsDB; 51730; -. [P04637-3] DR ProteomicsDB; 51731; -. [P04637-4] DR ProteomicsDB; 51732; -. [P04637-5] DR ProteomicsDB; 51733; -. [P04637-6] DR ProteomicsDB; 51734; -. [P04637-7] DR ProteomicsDB; 51735; -. [P04637-8] DR ProteomicsDB; 51736; -. [P04637-9] DR Pumba; P04637; -. DR ABCD; P04637; 67 sequenced antibodies. DR Antibodypedia; 3525; 9660 antibodies from 66 providers. DR CPTC; P04637; 2 antibodies. DR DNASU; 7157; -. DR Ensembl; ENST00000269305.9; ENSP00000269305.4; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000420246.6; ENSP00000391127.2; ENSG00000141510.20. [P04637-2] DR Ensembl; ENST00000445888.6; ENSP00000391478.2; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000455263.6; ENSP00000398846.2; ENSG00000141510.20. [P04637-3] DR Ensembl; ENST00000503591.2; ENSP00000426252.2; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000504290.5; ENSP00000484409.1; ENSG00000141510.20. [P04637-9] DR Ensembl; ENST00000504937.5; ENSP00000481179.1; ENSG00000141510.20. [P04637-7] DR Ensembl; ENST00000508793.6; ENSP00000424104.2; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000509690.6; ENSP00000425104.2; ENSG00000141510.20. [P04637-7] DR Ensembl; ENST00000510385.5; ENSP00000478499.1; ENSG00000141510.20. [P04637-8] DR Ensembl; ENST00000610292.4; ENSP00000478219.1; ENSG00000141510.20. [P04637-4] DR Ensembl; ENST00000610538.4; ENSP00000480868.1; ENSG00000141510.20. [P04637-6] DR Ensembl; ENST00000619485.4; ENSP00000482537.1; ENSG00000141510.20. [P04637-4] DR Ensembl; ENST00000620739.4; ENSP00000481638.1; ENSG00000141510.20. [P04637-4] DR Ensembl; ENST00000622645.4; ENSP00000482222.1; ENSG00000141510.20. [P04637-5] DR Ensembl; ENST00000714357.1; ENSP00000519624.1; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000714359.1; ENSP00000519626.1; ENSG00000141510.20. [P04637-1] DR GeneID; 7157; -. DR KEGG; hsa:7157; -. DR MANE-Select; ENST00000269305.9; ENSP00000269305.4; NM_000546.6; NP_000537.3. DR UCSC; uc002gij.4; human. [P04637-1] DR AGR; HGNC:11998; -. DR CIViC; 7157; 387 evidence items across 280 molecular profiles. DR ClinPGx; PA36679; -. DR CTD; 7157; -. DR DisGeNET; 7157; -. DR GeneCards; TP53; -. DR GeneReviews; TP53; -. DR HGNC; HGNC:11998; TP53. DR HPA; ENSG00000141510; Low tissue specificity. DR MalaCards; TP53; -. DR MIM; 133239; phenotype. DR MIM; 151623; phenotype. DR MIM; 191170; gene+phenotype. DR MIM; 202300; phenotype. DR MIM; 211980; phenotype. DR MIM; 260500; phenotype. DR MIM; 275355; phenotype. DR MIM; 614740; phenotype. DR MIM; 618165; phenotype. DR OpenTargets; ENSG00000141510; -. DR Orphanet; 1501; Adrenocortical carcinoma. DR Orphanet; 210159; Adult hepatocellular carcinoma. DR Orphanet; 99756; Alveolar rhabdomyosarcoma. DR Orphanet; 67038; B-cell chronic lymphocytic leukemia. DR Orphanet; 585909; B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2). DR Orphanet; 667662; Breast implant-associated anaplastic large cell lymphoma. DR Orphanet; 251899; Choroid plexus carcinoma. DR Orphanet; 96253; Cushing disease. DR Orphanet; 99757; Embryonal rhabdomyosarcoma. DR Orphanet; 3318; Essential thrombocythemia. DR Orphanet; 1333; Familial pancreatic carcinoma. DR Orphanet; 251579; Giant cell glioblastoma. DR Orphanet; 251576; Gliosarcoma. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR Orphanet; 524; Li-Fraumeni syndrome. DR Orphanet; 52688; Myelodysplastic syndrome. DR Orphanet; 668; Osteosarcoma. DR Orphanet; 2807; Papilloma of choroid plexus. DR Orphanet; 293199; Pleomorphic rhabdomyosarcoma. DR Orphanet; 70573; Small cell lung cancer. DR VEuPathDB; HostDB:ENSG00000141510; -. DR eggNOG; ENOG502QVY3; Eukaryota. DR GeneTree; ENSGT00950000183153; -. DR InParanoid; P04637; -. DR OMA; HKKGEPC; -. DR OrthoDB; 5915660at2759; -. DR PAN-GO; P04637; 3 GO annotations based on evolutionary models. DR PhylomeDB; P04637; -. DR PathwayCommons; P04637; -. DR Reactome; R-HSA-111448; Activation of NOXA and translocation to mitochondria. DR Reactome; R-HSA-139915; Activation of PUMA and translocation to mitochondria. DR Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation. DR Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence. DR Reactome; R-HSA-2559584; Formation of Senescence-Associated Heterochromatin Foci (SAHF). DR Reactome; R-HSA-2559585; Oncogene Induced Senescence. DR Reactome; R-HSA-2559586; DNA Damage/Telomere Stress Induced Senescence. DR Reactome; R-HSA-3232118; SUMOylation of transcription factors. DR Reactome; R-HSA-349425; Autodegradation of the E3 ubiquitin ligase COP1. DR Reactome; R-HSA-390471; Association of TriC/CCT with target proteins during biosynthesis. DR Reactome; R-HSA-5620971; Pyroptosis. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-5689896; Ovarian tumor domain proteases. DR Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks. DR Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release. DR Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain. DR Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases. DR Reactome; R-HSA-6803211; TP53 Regulates Transcription of Death Receptors and Ligands. DR Reactome; R-HSA-6804114; TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest. DR Reactome; R-HSA-6804115; TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain. DR Reactome; R-HSA-6804116; TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest. DR Reactome; R-HSA-6804754; Regulation of TP53 Expression. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-6804758; Regulation of TP53 Activity through Acetylation. DR Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors. DR Reactome; R-HSA-6804760; Regulation of TP53 Activity through Methylation. DR Reactome; R-HSA-6811555; PI5P Regulates TP53 Acetylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-69481; G2/M Checkpoints. DR Reactome; R-HSA-69541; Stabilization of p53. DR Reactome; R-HSA-69895; Transcriptional activation of cell cycle inhibitor p21. DR Reactome; R-HSA-8852276; The role of GTSE1 in G2/M progression after G2 checkpoint. DR Reactome; R-HSA-8853884; Transcriptional Regulation by VENTX. DR Reactome; R-HSA-8941855; RUNX3 regulates CDKN1A transcription. DR Reactome; R-HSA-8943724; Regulation of PTEN gene transcription. DR Reactome; R-HSA-9723905; Loss of function of TP53 in cancer due to loss of tetramerization ability. DR Reactome; R-HSA-9725370; Signaling by ALK fusions and activated point mutants. DR Reactome; R-HSA-9758274; Regulation of NF-kappa B signaling. DR Reactome; R-HSA-9819196; Zygotic genome activation (ZGA). DR Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production. DR Reactome; R-HSA-9833482; PKR-mediated signaling. DR SABIO-RK; P04637; -. DR SignaLink; P04637; -. DR SIGNOR; P04637; -. DR Agora; ENSG00000141510; -. DR BioGRID-ORCS; 7157; 66 hits in 1218 CRISPR screens. DR CD-CODE; 1A18FFC4; Paraspeckle. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; A1A97FAB; Synthetic Condensate 000191. DR CD-CODE; B5B9A610; PML body. DR CD-CODE; E11B6BAB; Synthetic Condensate 000195. DR ChiTaRS; TP53; human. DR EvolutionaryTrace; P04637; -. DR GeneWiki; P53; -. DR GenomeRNAi; 7157; -. DR Pharos; P04637; Tchem. DR PRO; PR:P04637; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P04637; protein. DR Bgee; ENSG00000141510; Expressed in ventricular zone and 144 other cell types or tissues. DR ExpressionAtlas; P04637; baseline and differential. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0000785; C:chromatin; IDA:BHF-UCL. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell. DR GO; GO:0043073; C:germ cell nucleus; IEA:Ensembl. DR GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0016363; C:nuclear matrix; IDA:UniProtKB. DR GO; GO:0005730; C:nucleolus; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0016605; C:PML body; IDA:UniProtKB. DR GO; GO:0032991; C:protein-containing complex; IDA:CAFA. DR GO; GO:0005657; C:replication fork; IEA:Ensembl. DR GO; GO:0035861; C:site of double-strand break; IEA:Ensembl. DR GO; GO:0005667; C:transcription regulator complex; IGI:ARUK-UCL. DR GO; GO:0017053; C:transcription repressor complex; IPI:ComplexPortal. DR GO; GO:0071889; F:14-3-3 protein binding; EXP:DisProt. DR GO; GO:0036310; F:ATP-dependent DNA/DNA annealing activity; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; IDA:ARUK-UCL. DR GO; GO:0005507; F:copper ion binding; IDA:UniProtKB. DR GO; GO:0001046; F:core promoter sequence-specific DNA binding; IDA:CAFA. DR GO; GO:0097718; F:disordered domain specific binding; IPI:CAFA. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:GO_Central. DR GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:UniProtKB. DR GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:ARUK-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL. DR GO; GO:0140296; F:general transcription initiation factor binding; IPI:BHF-UCL. DR GO; GO:0042826; F:histone deacetylase binding; IPI:CAFA. DR GO; GO:0035033; F:histone deacetylase regulator activity; IEA:Ensembl. DR GO; GO:0042802; F:identical protein binding; IPI:UniProtKB. DR GO; GO:0097371; F:MDM2/MDM4 family protein binding; IEA:Ensembl. DR GO; GO:0140693; F:molecular condensate scaffold activity; IDA:UniProtKB. DR GO; GO:0140677; F:molecular function activator activity; IPI:DisProt. DR GO; GO:0003730; F:mRNA 3'-UTR binding; IDA:CAFA. DR GO; GO:0002039; F:p53 binding; IPI:CAFA. DR GO; GO:1990841; F:promoter-specific chromatin binding; IDA:UniProtKB. DR GO; GO:0002020; F:protease binding; IPI:UniProtKB. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB. DR GO; GO:0051721; F:protein phosphatase 2A binding; IPI:UniProtKB. DR GO; GO:0051087; F:protein-folding chaperone binding; IPI:UniProtKB. DR GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:BHF-UCL. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:ARUK-UCL. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:UniProtKB. DR GO; GO:0001094; F:TFIID-class transcription factor complex binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:BHF-UCL. DR GO; GO:0001223; F:transcription coactivator binding; IPI:BHF-UCL. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; TAS:UniProtKB. DR GO; GO:0006914; P:autophagy; IMP:CAFA. DR GO; GO:0002326; P:B cell lineage commitment; IEA:Ensembl. DR GO; GO:0048539; P:bone marrow development; IMP:UniProtKB. DR GO; GO:0010659; P:cardiac muscle cell apoptotic process; IEA:Ensembl. DR GO; GO:0060411; P:cardiac septum morphogenesis; IEA:Ensembl. DR GO; GO:0072717; P:cellular response to actinomycin D; IDA:CAFA. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:CAFA. DR GO; GO:0042149; P:cellular response to glucose starvation; IDA:UniProtKB. DR GO; GO:0071456; P:cellular response to hypoxia; IEP:UniProtKB. DR GO; GO:0071479; P:cellular response to ionizing radiation; IMP:BHF-UCL. DR GO; GO:0034644; P:cellular response to UV; IDA:CAFA. DR GO; GO:0071494; P:cellular response to UV-C; IEA:Ensembl. DR GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEP:UniProtKB. DR GO; GO:0090398; P:cellular senescence; IMP:GO_Central. DR GO; GO:0021549; P:cerebellum development; IEA:Ensembl. DR GO; GO:0051276; P:chromosome organization; IEA:Ensembl. DR GO; GO:0048512; P:circadian behavior; ISS:UniProtKB. DR GO; GO:0008340; P:determination of adult lifespan; ISS:BHF-UCL. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; IDA:BHF-UCL. DR GO; GO:0006302; P:double-strand break repair; IEA:Ensembl. DR GO; GO:0048568; P:embryonic organ development; IEA:Ensembl. DR GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB. DR GO; GO:0006983; P:ER overload response; IDA:MGI. DR GO; GO:0048144; P:fibroblast proliferation; IEA:Ensembl. DR GO; GO:0007369; P:gastrulation; IEA:Ensembl. DR GO; GO:0014009; P:glial cell proliferation; IEA:Ensembl. DR GO; GO:0019661; P:glucose catabolic process to lactate via pyruvate; IEA:Ensembl. DR GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IMP:UniProtKB. DR GO; GO:0060218; P:hematopoietic stem cell differentiation; IMP:UniProtKB. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0008104; P:intracellular protein localization; IDA:UniProtKB. DR GO; GO:0097193; P:intrinsic apoptotic signaling pathway; TAS:HGNC-UCL. DR GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IMP:UniProtKB. DR GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IDA:UniProtKB. DR GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; IEA:Ensembl. DR GO; GO:1990144; P:intrinsic apoptotic signaling pathway in response to hypoxia; IEA:Ensembl. DR GO; GO:0043504; P:mitochondrial DNA repair; IEA:Ensembl. DR GO; GO:0000423; P:mitophagy; IEA:Ensembl. DR GO; GO:0031571; P:mitotic G1 DNA damage checkpoint signaling; IMP:BHF-UCL. DR GO; GO:0009299; P:mRNA transcription; IMP:UniProtKB. DR GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl. DR GO; GO:0070266; P:necroptotic process; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0030308; P:negative regulation of cell growth; IMP:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:CACAO. DR GO; GO:0008156; P:negative regulation of DNA replication; IEA:Ensembl. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0048147; P:negative regulation of fibroblast proliferation; IMP:UniProtKB. DR GO; GO:1903451; P:negative regulation of G1 to G0 transition; IDA:CAFA. DR GO; GO:0060253; P:negative regulation of glial cell proliferation; IEA:Ensembl. DR GO; GO:1904024; P:negative regulation of glucose catabolic process to lactate via pyruvate; IEA:Ensembl. DR GO; GO:0051097; P:negative regulation of helicase activity; TAS:UniProtKB. DR GO; GO:1903799; P:negative regulation of miRNA processing; IEA:Ensembl. DR GO; GO:1901525; P:negative regulation of mitophagy; IEA:Ensembl. DR GO; GO:0007406; P:negative regulation of neuroblast proliferation; IEA:Ensembl. DR GO; GO:1905856; P:negative regulation of pentose-phosphate shunt; IMP:CACAO. DR GO; GO:0045861; P:negative regulation of proteolysis; IEA:Ensembl. DR GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IEA:Ensembl. DR GO; GO:2000647; P:negative regulation of stem cell proliferation; IEA:Ensembl. DR GO; GO:0032211; P:negative regulation of telomere maintenance via telomerase; IDA:BHF-UCL. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:ARUK-UCL. DR GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IEA:Ensembl. DR GO; GO:0007405; P:neuroblast proliferation; IEA:Ensembl. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0006289; P:nucleotide-excision repair; IMP:UniProtKB. DR GO; GO:0097252; P:oligodendrocyte apoptotic process; IDA:UniProtKB. DR GO; GO:0090403; P:oxidative stress-induced premature senescence; IMP:BHF-UCL. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0010666; P:positive regulation of cardiac muscle cell apoptotic process; IEA:Ensembl. DR GO; GO:2000774; P:positive regulation of cellular senescence; IDA:UniProt. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IMP:AgBase. DR GO; GO:0010628; P:positive regulation of gene expression; IDA:CAFA. DR GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB. DR GO; GO:1902895; P:positive regulation of miRNA transcription; IDA:BHF-UCL. DR GO; GO:0035794; P:positive regulation of mitochondrial membrane permeability; IEA:Ensembl. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0062100; P:positive regulation of programmed necrotic cell death; IEA:Ensembl. DR GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IMP:BHF-UCL. DR GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; IDA:UniProtKB. DR GO; GO:0045899; P:positive regulation of RNA polymerase II transcription preinitiation complex assembly; IDA:BHF-UCL. DR GO; GO:0070245; P:positive regulation of thymocyte apoptotic process; ISS:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0006606; P:protein import into nucleus; IEA:Ensembl. DR GO; GO:0050821; P:protein stabilization; IEA:Ensembl. DR GO; GO:0051262; P:protein tetramerization; IEA:InterPro. DR GO; GO:0065003; P:protein-containing complex assembly; IDA:UniProtKB. DR GO; GO:0007265; P:Ras protein signal transduction; IEP:BHF-UCL. DR GO; GO:0072593; P:reactive oxygen species metabolic process; IEA:Ensembl. DR GO; GO:0042981; P:regulation of apoptotic process; IDA:MGI. DR GO; GO:0051726; P:regulation of cell cycle; IDA:BHF-UCL. DR GO; GO:1902749; P:regulation of cell cycle G2/M phase transition; IMP:UniProtKB. DR GO; GO:0043516; P:regulation of DNA damage response, signal transduction by p53 class mediator; IEA:Ensembl. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:2000269; P:regulation of fibroblast apoptotic process; IEA:Ensembl. DR GO; GO:1902253; P:regulation of intrinsic apoptotic signaling pathway by p53 class mediator; IEA:Ensembl. DR GO; GO:1902108; P:regulation of mitochondrial membrane permeability involved in apoptotic process; IEA:Ensembl. DR GO; GO:0034103; P:regulation of tissue remodeling; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:ARUK-UCL. DR GO; GO:0001836; P:release of cytochrome c from mitochondria; IEA:Ensembl. DR GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL. DR GO; GO:0046677; P:response to antibiotic; IEP:UniProtKB. DR GO; GO:0010332; P:response to gamma radiation; IMP:BHF-UCL. DR GO; GO:0002931; P:response to ischemia; IEA:Ensembl. DR GO; GO:0009651; P:response to salt stress; IEA:Ensembl. DR GO; GO:0010165; P:response to X-ray; IEA:Ensembl. DR GO; GO:0009303; P:rRNA transcription; IEA:Ensembl. DR GO; GO:0072331; P:signal transduction by p53 class mediator; IDA:CAFA. DR GO; GO:0001756; P:somitogenesis; IEA:Ensembl. DR GO; GO:0072089; P:stem cell proliferation; IEA:Ensembl. DR GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl. DR GO; GO:0002360; P:T cell lineage commitment; IEA:Ensembl. DR GO; GO:0002309; P:T cell proliferation involved in immune response; IEA:Ensembl. DR GO; GO:0070242; P:thymocyte apoptotic process; IEA:Ensembl. DR GO; GO:0045815; P:transcription initiation-coupled chromatin remodeling; IDA:GO_Central. DR GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IEA:Ensembl. DR GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IGI:BHF-UCL. DR GO; GO:0060333; P:type II interferon-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0016032; P:viral process; IMP:CACAO. DR CDD; cd08367; P53; 1. DR DisProt; DP00086; -. DR FunFam; 2.60.40.720:FF:000003; Cellular tumor antigen p53; 1. DR FunFam; 4.10.170.10:FF:000003; Cellular tumor antigen p53; 1. DR Gene3D; 2.60.40.720; -; 1. DR Gene3D; 6.10.50.20; -; 1. DR Gene3D; 4.10.170.10; p53-like tetramerisation domain; 1. DR IDEAL; IID00015; -. DR InterPro; IPR008967; p53-like_TF_DNA-bd_sf. DR InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf. DR InterPro; IPR057064; P53_central_site. DR InterPro; IPR011615; p53_DNA-bd. DR InterPro; IPR040926; p53_TAD2. DR InterPro; IPR036674; p53_tetramer_sf. DR InterPro; IPR010991; p53_tetrameristn. DR InterPro; IPR013872; p53_transactivation_domain. DR InterPro; IPR002117; p53_tumour_suppressor. DR PANTHER; PTHR11447; CELLULAR TUMOR ANTIGEN P53; 1. DR PANTHER; PTHR11447:SF6; CELLULAR TUMOR ANTIGEN P53; 1. DR Pfam; PF00870; P53; 1. DR Pfam; PF08563; P53_TAD; 1. DR Pfam; PF07710; P53_tetramer; 1. DR Pfam; PF18521; TAD2; 1. DR PRINTS; PR00386; P53SUPPRESSR. DR SUPFAM; SSF47719; p53 tetramerization domain; 1. DR SUPFAM; SSF49417; p53-like transcription factors; 1. DR PROSITE; PS00348; P53; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Activator; Alternative promoter usage; KW Alternative splicing; Apoptosis; Biological rhythms; Cell cycle; Cytoplasm; KW Cytoskeleton; Direct protein sequencing; Disease variant; DNA-binding; KW Endoplasmic reticulum; Glycoprotein; Host-virus interaction; KW Isopeptide bond; Li-Fraumeni syndrome; Metal-binding; Methylation; KW Mitochondrion; Necrosis; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repressor; Transcription; KW Transcription regulation; Tumor suppressor; Ubl conjugation; Zinc. FT CHAIN 1..393 FT /note="Cellular tumor antigen p53" FT /id="PRO_0000185703" FT DNA_BIND 102..292 FT /evidence="ECO:0000269|PubMed:16793544, FT ECO:0000269|PubMed:18996393, ECO:0000269|PubMed:20364130" FT REGION 1..320 FT /note="Interaction with CCAR2" FT /evidence="ECO:0000269|PubMed:25732823" FT REGION 1..83 FT /note="Interaction with HRMT1L2" FT /evidence="ECO:0000269|PubMed:15186775" FT REGION 1..44 FT /note="Transcription activation (acidic)" FT REGION 50..96 FT /note="Disordered" FT /evidence="ECO:0000269|PubMed:31953488" FT REGION 66..110 FT /note="Interaction with WWOX" FT REGION 100..370 FT /note="Interaction with HIPK1" FT /evidence="ECO:0000250" FT REGION 100..300 FT /note="Required for interaction with ZNF385A" FT /evidence="ECO:0000269|PubMed:17719541" FT REGION 113..236 FT /note="Required for interaction with FBXO42" FT /evidence="ECO:0000269|PubMed:19509332" FT REGION 116..292 FT /note="Interaction with AXIN1" FT /evidence="ECO:0000250" FT REGION 241..248 FT /note="Interaction with the 53BP2 SH3 domain" FT REGION 256..294 FT /note="Interaction with E4F1" FT /evidence="ECO:0000269|PubMed:10644996" FT REGION 273..280 FT /note="Interaction with DNA" FT REGION 282..325 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 300..393 FT /note="Interaction with CARM1" FT /evidence="ECO:0000269|PubMed:15186775" FT REGION 319..360 FT /note="Interaction with HIPK2" FT REGION 325..356 FT /note="Oligomerization" FT REGION 351..393 FT /note="Disordered" FT /evidence="ECO:0000269|PubMed:31953488, FT ECO:0000269|PubMed:36108750" FT REGION 359..363 FT /note="Interaction with USP7" FT REGION 368..387 FT /note="Basic (repression of DNA-binding)" FT REGION 374..393 FT /note="Interaction with MORN3" FT /evidence="ECO:0000269|PubMed:29681526" FT MOTIF 17..25 FT /note="TADI" FT MOTIF 48..56 FT /note="TADII" FT MOTIF 305..321 FT /note="Bipartite nuclear localization signal" FT MOTIF 339..350 FT /note="Nuclear export signal" FT MOTIF 370..372 FT /note="[KR]-[STA]-K motif" FT COMPBIAS 69..90 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 282..299 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 365..384 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 176 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT BINDING 179 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT BINDING 238 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT BINDING 242 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT SITE 120 FT /note="Interaction with DNA" FT /evidence="ECO:0000269|PubMed:16793544, FT ECO:0000269|PubMed:18996393, ECO:0000269|PubMed:20364130" FT MOD_RES 9 FT /note="Phosphoserine; by HIPK4" FT /evidence="ECO:0000269|PubMed:18022393" FT MOD_RES 15 FT /note="Phosphoserine; by CDK5, PRPK, AMPK, NUAK1 and ATM" FT /evidence="ECO:0000269|PubMed:10570149, FT ECO:0000269|PubMed:11554766, ECO:0000269|PubMed:15866171, FT ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:17591690, FT ECO:0000269|PubMed:17967874, ECO:0000269|PubMed:21317932, FT ECO:0000269|PubMed:28842590" FT MOD_RES 18 FT /note="Phosphothreonine; by CK1, VRK1 and VRK2" FT /evidence="ECO:0000269|PubMed:10606744, FT ECO:0000269|PubMed:10951572, ECO:0000269|PubMed:16704422, FT ECO:0000269|PubMed:31527692" FT MOD_RES 20 FT /note="Phosphoserine; by CHEK2, CK1 and PLK3" FT /evidence="ECO:0000269|PubMed:10570149, FT ECO:0000269|PubMed:11447225, ECO:0000269|PubMed:11551930, FT ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:20041275" FT MOD_RES 33 FT /note="Phosphoserine; by CDK5 and CDK7" FT /evidence="ECO:0000269|PubMed:17591690, FT ECO:0000269|PubMed:9372954" FT MOD_RES 37 FT /note="Phosphoserine; by MAPKAPK5" FT /evidence="ECO:0000269|PubMed:17254968" FT MOD_RES 46 FT /note="Phosphoserine; by CDK5, DYRK2, HIPK2 and PKC/PRKCG" FT /evidence="ECO:0000269|PubMed:11740489, FT ECO:0000269|PubMed:11780126, ECO:0000269|PubMed:16377624, FT ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:17591690" FT MOD_RES 55 FT /note="Phosphothreonine; by TAF1 and GRK5" FT /evidence="ECO:0000269|PubMed:15053879, FT ECO:0000269|PubMed:20124405" FT MOD_RES 120 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:17189187, FT ECO:0000269|PubMed:19854137, ECO:0000269|PubMed:23431171" FT MOD_RES 120 FT /note="N6-lactoyllysine" FT /evidence="ECO:0000269|PubMed:38653238" FT MOD_RES 139 FT /note="N6-lactoyllysine" FT /evidence="ECO:0000269|PubMed:38653238" FT MOD_RES 183 FT /note="Phosphoserine; by AURKB" FT /evidence="ECO:0000269|PubMed:20959462" FT MOD_RES 269 FT /note="Phosphoserine; by AURKB" FT /evidence="ECO:0000269|PubMed:20959462" FT MOD_RES 284 FT /note="Phosphothreonine; by AURKB" FT /evidence="ECO:0000269|PubMed:20959462" FT MOD_RES 305 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:12724314" FT MOD_RES 315 FT /note="Phosphoserine; by AURKA, CDK1 and CDK2" FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:14702041" FT MOD_RES 321 FT /note="N6-acetyllysine" FT /evidence="ECO:0000250|UniProtKB:P02340" FT MOD_RES 333 FT /note="Omega-N-methylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:19011621" FT MOD_RES 335 FT /note="Symmetric dimethylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:19011621" FT MOD_RES 337 FT /note="Symmetric dimethylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:19011621" FT MOD_RES 370 FT /note="N6,N6-dimethyllysine; alternate" FT /evidence="ECO:0000269|PubMed:17108971, FT ECO:0000269|PubMed:22864287" FT MOD_RES 370 FT /note="N6-methyllysine; by SMYD2; alternate" FT /evidence="ECO:0000269|PubMed:17108971, FT ECO:0000269|PubMed:22864287" FT MOD_RES 372 FT /note="N6-methyllysine; by SETD7" FT /evidence="ECO:0000269|PubMed:15525938, FT ECO:0000269|PubMed:16415881" FT MOD_RES 373 FT /note="N6,N6-dimethyllysine; by EHMT1 and EHMT2; alternate" FT /evidence="ECO:0000269|PubMed:20118233" FT MOD_RES 373 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0000269|PubMed:10656795" FT MOD_RES 381 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:29474172, FT ECO:0007744|PubMed:19608861" FT MOD_RES 382 FT /note="N6,N6-dimethyllysine; alternate" FT /evidence="ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725, ECO:0000269|PubMed:22864287" FT MOD_RES 382 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0000269|PubMed:10656795, FT ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:20228809, FT ECO:0000269|PubMed:23431171, ECO:0000269|PubMed:29681526, FT ECO:0007744|PubMed:19608861" FT MOD_RES 382 FT /note="N6-methyllysine; by KMT5A; alternate" FT /evidence="ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725, ECO:0000269|PubMed:22864287" FT MOD_RES 392 FT /note="Phosphoserine; by CK2, CDK2 and NUAK1" FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:17108107, FT ECO:0000269|PubMed:21317932, ECO:0000269|PubMed:22214662, FT ECO:0000269|PubMed:35618207" FT CROSSLNK 24 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:21597459" FT CROSSLNK 291 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19536131" FT CROSSLNK 292 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19536131" FT CROSSLNK 351 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19033443" FT CROSSLNK 357 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19033443" FT CROSSLNK 386 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO)" FT /evidence="ECO:0000269|PubMed:11124955, FT ECO:0000269|PubMed:22214662, ECO:0000269|Ref.37" FT VAR_SEQ 1..132 FT /note="Missing (in isoform 7, isoform 8 and isoform 9)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_040833" FT VAR_SEQ 1..39 FT /note="Missing (in isoform 4, isoform 5 and isoform 6)" FT /evidence="ECO:0000305" FT /id="VSP_040832" FT VAR_SEQ 332..346 FT /note="IRGRERFEMFRELNE -> MLLDLRWCYFLINSS (in isoform 3, FT isoform 6 and isoform 9)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_040560" FT VAR_SEQ 332..341 FT /note="IRGRERFEMF -> DQTSFQKENC (in isoform 2, isoform 5 FT and isoform 8)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_006535" FT VAR_SEQ 342..393 FT /note="Missing (in isoform 2, isoform 5 and isoform 8)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_006536" FT VAR_SEQ 347..393 FT /note="Missing (in isoform 3, isoform 6 and isoform 9)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_040561" FT VARIANT 5 FT /note="Q -> H (in a sporadic cancer; somatic mutation; FT abolishes strongly phosphorylation)" FT /id="VAR_044543" FT VARIANT 6 FT /note="S -> L (in a sporadic cancer; somatic mutation; FT reduces interaction with ZNF385A)" FT /id="VAR_044544" FT VARIANT 7 FT /note="D -> H (in a sporadic cancer; somatic mutation; FT dbSNP:rs587782646)" FT /id="VAR_005851" FT VARIANT 8 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_044545" FT VARIANT 10 FT /note="V -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs535274413)" FT /id="VAR_044546" FT VARIANT 11 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs201382018)" FT /id="VAR_044547" FT VARIANT 11 FT /note="E -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs201382018)" FT /id="VAR_044548" FT VARIANT 15 FT /note="S -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044549" FT VARIANT 16 FT /note="Q -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044550" FT VARIANT 17 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044551" FT VARIANT 24 FT /note="K -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_044552" FT VARIANT 28 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044553" FT VARIANT 29..30 FT /note="NN -> KD (in a sporadic cancer; somatic mutation)" FT /id="VAR_047158" FT VARIANT 31 FT /note="V -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs201753350)" FT /id="VAR_044554" FT VARIANT 33 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044555" FT VARIANT 34 FT /note="P -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044556" FT VARIANT 35 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs121912661)" FT /id="VAR_005852" FT VARIANT 36 FT /note="P -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs587781866)" FT /id="VAR_044557" FT VARIANT 37 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044558" FT VARIANT 37 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044559" FT VARIANT 39 FT /note="A -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044560" FT VARIANT 39 FT /note="A -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs1353016807)" FT /id="VAR_044561" FT VARIANT 42 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044562" FT VARIANT 43 FT /note="L -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_005853" FT VARIANT 44 FT /note="M -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501190)" FT /id="VAR_044563" FT VARIANT 44 FT /note="M -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044564" FT VARIANT 44 FT /note="M -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044565" FT VARIANT 45 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044566" FT VARIANT 46 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044567" FT VARIANT 46 FT /note="S -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs876659630)" FT /id="VAR_044568" FT VARIANT 47 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044569" FT VARIANT 47 FT /note="P -> S (in dbSNP:rs1800371)" FT /evidence="ECO:0000269|Ref.12" FT /id="VAR_014632" FT VARIANT 48 FT /note="D -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044570" FT VARIANT 49 FT /note="D -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587780728)" FT /id="VAR_044571" FT VARIANT 49 FT /note="D -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs587780728)" FT /id="VAR_044572" FT VARIANT 49 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044573" FT VARIANT 52 FT /note="Q -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044574" FT VARIANT 53 FT /note="W -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_005854" FT VARIANT 53 FT /note="W -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044575" FT VARIANT 54 FT /note="F -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555526742)" FT /id="VAR_044576" FT VARIANT 54 FT /note="F -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044577" FT VARIANT 56 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044578" FT VARIANT 56 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044579" FT VARIANT 58 FT /note="P -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044580" FT VARIANT 58 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044581" FT VARIANT 59 FT /note="G -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1237722021)" FT /id="VAR_044582" FT VARIANT 59 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044583" FT VARIANT 59 FT /note="G -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045783" FT VARIANT 60 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044584" FT VARIANT 60 FT /note="P -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044585" FT VARIANT 60 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_005855" FT VARIANT 61 FT /note="D -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1460793472)" FT /id="VAR_044586" FT VARIANT 61 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_044587" FT VARIANT 62 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044588" FT VARIANT 63 FT /note="A -> T (in a sporadic cancer; somatic mutation; FT dbSNP:rs876658902)" FT /id="VAR_044589" FT VARIANT 63 FT /note="A -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs372201428)" FT /id="VAR_044590" FT VARIANT 65 FT /note="R -> T (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501210)" FT /id="VAR_044591" FT VARIANT 66 FT /note="M -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555526711)" FT /id="VAR_044592" FT VARIANT 66 FT /note="M -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044593" FT VARIANT 67 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044594" FT VARIANT 67 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044595" FT VARIANT 67 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044596" FT VARIANT 68 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044597" FT VARIANT 68 FT /note="E -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044598" FT VARIANT 69 FT /note="A -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044599" FT VARIANT 69 FT /note="A -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs756233241)" FT /id="VAR_044600" FT VARIANT 69 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044601" FT VARIANT 69 FT /note="A -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs756233241)" FT /id="VAR_044602" FT VARIANT 70 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044603" FT VARIANT 71 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044604" FT VARIANT 72 FT /note="P -> C (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions; dbSNP:rs730882014)" FT /id="VAR_045784" FT VARIANT 72 FT /note="P -> G (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045785" FT VARIANT 72 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1042522)" FT /id="VAR_045786" FT VARIANT 72 FT /note="P -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045787" FT VARIANT 72 FT /note="P -> R (in dbSNP:rs1042522)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:16131611, ECO:0000269|PubMed:1999338, FT ECO:0000269|Ref.17" FT /id="VAR_005856" FT VARIANT 73 FT /note="V -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_044605" FT VARIANT 73 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044606" FT VARIANT 73 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs587782423)" FT /id="VAR_044607" FT VARIANT 74 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044608" FT VARIANT 75 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044609" FT VARIANT 75 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044610" FT VARIANT 75 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_044611" FT VARIANT 76 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /evidence="ECO:0000269|PubMed:2946935" FT /id="VAR_044612" FT VARIANT 76 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044613" FT VARIANT 77 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044614" FT VARIANT 78 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044615" FT VARIANT 79 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044616" FT VARIANT 79 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_005857" FT VARIANT 79 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044617" FT VARIANT 80 FT /note="P -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044618" FT VARIANT 80 FT /note="P -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501204)" FT /id="VAR_044619" FT VARIANT 81 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044620" FT VARIANT 82 FT /note="P -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs534447939)" FT /id="VAR_044621" FT VARIANT 82 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044622" FT VARIANT 83 FT /note="A -> E (in a sporadic cancer; somatic mutation; FT dbSNP:rs201717599)" FT /id="VAR_044623" FT VARIANT 83 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs201717599)" FT /id="VAR_044624" FT VARIANT 84 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044625" FT VARIANT 84 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044626" FT VARIANT 85 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044627" FT VARIANT 85 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044628" FT VARIANT 86 FT /note="A -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044629" FT VARIANT 87 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005858" FT VARIANT 88 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044630" FT VARIANT 88 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526631)" FT /id="VAR_044631" FT VARIANT 89 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730881994)" FT /id="VAR_044632" FT VARIANT 89 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044633" FT VARIANT 90 FT /note="S -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526625)" FT /id="VAR_044634" FT VARIANT 90 FT /note="S -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044635" FT VARIANT 91 FT /note="W -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044636" FT VARIANT 92 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044637" FT VARIANT 92 FT /note="P -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1210700121)" FT /id="VAR_044638" FT VARIANT 92 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_044639" FT VARIANT 93 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044640" FT VARIANT 93 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044641" FT VARIANT 94 FT /note="S -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044642" FT VARIANT 94 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005859" FT VARIANT 95 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044643" FT VARIANT 95 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044644" FT VARIANT 96 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044645" FT VARIANT 96 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044646" FT VARIANT 96 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044647" FT VARIANT 97 FT /note="V -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044648" FT VARIANT 97 FT /note="V -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044649" FT VARIANT 97 FT /note="V -> I (in familial cancer not matching LFS; FT germline mutation and in a sporadic cancer; somatic FT mutation; dbSNP:rs730882023)" FT /id="VAR_044650" FT VARIANT 98 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1245723119)" FT /id="VAR_044651" FT VARIANT 98 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044652" FT VARIANT 99 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044653" FT VARIANT 99 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044654" FT VARIANT 100 FT /note="Q -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044655" FT VARIANT 101 FT /note="K -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs878854069)" FT /id="VAR_044656" FT VARIANT 101 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044657" FT VARIANT 102 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs786202717)" FT /id="VAR_044658" FT VARIANT 104 FT /note="Q -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044659" FT VARIANT 104 FT /note="Q -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044660" FT VARIANT 105 FT /note="G -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_044661" FT VARIANT 105 FT /note="G -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs587781504)" FT /id="VAR_044662" FT VARIANT 105 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501195)" FT /id="VAR_044663" FT VARIANT 105 FT /note="G -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501195)" FT /id="VAR_044664" FT VARIANT 105 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044665" FT VARIANT 106 FT /note="S -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044666" FT VARIANT 106 FT /note="S -> R (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs1555526581)" FT /id="VAR_044667" FT VARIANT 107 FT /note="Y -> C (in a sporadic cancer; somatic mutation; FT dbSNP:rs587782447)" FT /id="VAR_044668" FT VARIANT 107 FT /note="Y -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044669" FT VARIANT 107 FT /note="Y -> H (in a sporadic cancer; somatic mutation; FT dbSNP:rs368771578)" FT /id="VAR_044670" FT VARIANT 108 FT /note="G -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044671" FT VARIANT 108 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587782461)" FT /id="VAR_044672" FT VARIANT 109 FT /note="F -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_044673" FT VARIANT 109 FT /note="F -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044674" FT VARIANT 109 FT /note="F -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1064796722)" FT /id="VAR_044675" FT VARIANT 110 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs587781371)" FT /id="VAR_005860" FT VARIANT 110 FT /note="R -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044676" FT VARIANT 110 FT /note="R -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs11540654)" FT /id="VAR_044677" FT VARIANT 110 FT /note="R -> L (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; does not induce SNAI1 degradation; FT dbSNP:rs11540654)" FT /evidence="ECO:0000269|PubMed:20385133" FT /id="VAR_005861" FT VARIANT 110 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs11540654)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_005862" FT VARIANT 110 FT /note="R -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs587781371)" FT /id="VAR_044678" FT VARIANT 111 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044679" FT VARIANT 111 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519997)" FT /id="VAR_044680" FT VARIANT 111 FT /note="L -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519997)" FT /id="VAR_044681" FT VARIANT 111 FT /note="L -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519997)" FT /id="VAR_044682" FT VARIANT 112 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044683" FT VARIANT 112 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1423803759)" FT /id="VAR_044684" FT VARIANT 113 FT /note="F -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_005863" FT VARIANT 113 FT /note="F -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045788" FT VARIANT 113 FT /note="F -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_044685" FT VARIANT 113 FT /note="F -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044686" FT VARIANT 113 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044687" FT VARIANT 113 FT /note="F -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs587781642)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033033" FT VARIANT 115 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044688" FT VARIANT 116 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_044689" FT VARIANT 116 FT /note="S -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044690" FT VARIANT 116 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044691" FT VARIANT 117 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs755238756)" FT /id="VAR_044692" FT VARIANT 117 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526518)" FT /id="VAR_044693" FT VARIANT 118 FT /note="T -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044694" FT VARIANT 118 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1064794141)" FT /id="VAR_044695" FT VARIANT 118 FT /note="T -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044696" FT VARIANT 119 FT /note="A -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044697" FT VARIANT 119 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044698" FT VARIANT 120 FT /note="K -> E (in sporadic cancers; somatic mutation; FT abolished acetylation; impaired ability to induce FT proapoptotic program; mimics lactylation, leading to FT decreased ability to undergo liquid-liquid phase separation FT and activate the transcription factor activity; FT dbSNP:rs121912658)" FT /evidence="ECO:0000269|PubMed:17189187, FT ECO:0000269|PubMed:38653238" FT /id="VAR_044699" FT VARIANT 120 FT /note="K -> M (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17189187" FT /id="VAR_044700" FT VARIANT 120 FT /note="K -> Q (in a sporadic cancer; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity; dbSNP:rs121912658)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044701" FT VARIANT 120 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17189187" FT /id="VAR_044702" FT VARIANT 121 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044703" FT VARIANT 122 FT /note="V -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044704" FT VARIANT 123 FT /note="T -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555526486)" FT /id="VAR_044705" FT VARIANT 123 FT /note="T -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_044706" FT VARIANT 124 FT /note="C -> G (in a sporadic cancer; somatic mutation; FT dbSNP:rs730881997)" FT /id="VAR_044707" FT VARIANT 124 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044708" FT VARIANT 124 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs730881997)" FT /id="VAR_044709" FT VARIANT 124 FT /note="C -> W (in a sporadic cancer; somatic mutation)" FT /id="VAR_044710" FT VARIANT 124 FT /note="C -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044711" FT VARIANT 125 FT /note="T -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044712" FT VARIANT 125 FT /note="T -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs786201057)" FT /id="VAR_044713" FT VARIANT 125 FT /note="T -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs786201057)" FT /id="VAR_005864" FT VARIANT 125 FT /note="T -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1057520003)" FT /id="VAR_044714" FT VARIANT 125 FT /note="T -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs786201057)" FT /id="VAR_044715" FT VARIANT 126 FT /note="Y -> C (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs1555526335)" FT /id="VAR_044716" FT VARIANT 126 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs886039483)" FT /id="VAR_005865" FT VARIANT 126 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044717" FT VARIANT 126 FT /note="Y -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045789" FT VARIANT 126 FT /note="Y -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044718" FT VARIANT 126 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs886039483)" FT /id="VAR_005866" FT VARIANT 126 FT /note="Y -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044719" FT VARIANT 127 FT /note="S -> C (in a sporadic cancer; somatic mutation; FT dbSNP:rs730881999)" FT /id="VAR_044720" FT VARIANT 127 FT /note="S -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs730881999)" FT /id="VAR_005867" FT VARIANT 127 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044721" FT VARIANT 127 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044722" FT VARIANT 127 FT /note="S -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044723" FT VARIANT 128 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044724" FT VARIANT 128 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044725" FT VARIANT 128 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044726" FT VARIANT 128 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005868" FT VARIANT 129 FT /note="A -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005869" FT VARIANT 129 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044727" FT VARIANT 129 FT /note="A -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs1438095083)" FT /id="VAR_044728" FT VARIANT 129 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs137852792)" FT /id="VAR_044729" FT VARIANT 130 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs863224683)" FT /id="VAR_044730" FT VARIANT 130 FT /note="L -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044731" FT VARIANT 130 FT /note="L -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_044732" FT VARIANT 130 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691013)" FT /id="VAR_044733" FT VARIANT 130 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_005870" FT VARIANT 130 FT /note="L -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs863224683)" FT /id="VAR_044734" FT VARIANT 131 FT /note="N -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044735" FT VARIANT 131 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044736" FT VARIANT 131 FT /note="N -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691037)" FT /id="VAR_044737" FT VARIANT 131 FT /note="N -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs769270327)" FT /id="VAR_005872" FT VARIANT 131 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005871" FT VARIANT 131 FT /note="N -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044738" FT VARIANT 131 FT /note="N -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs587782160)" FT /id="VAR_044739" FT VARIANT 132..133 FT /note="KM -> NL (in a sporadic cancer; somatic mutation)" FT /id="VAR_047159" FT VARIANT 132 FT /note="K -> E (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs747342068)" FT /id="VAR_044740" FT VARIANT 132 FT /note="K -> L (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045790" FT VARIANT 132 FT /note="K -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519996)" FT /id="VAR_005873" FT VARIANT 132 FT /note="K -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs866775781)" FT /id="VAR_044741" FT VARIANT 132 FT /note="K -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs747342068)" FT /evidence="ECO:0000269|PubMed:1694291" FT /id="VAR_005874" FT VARIANT 132 FT /note="K -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519996)" FT /id="VAR_044742" FT VARIANT 132 FT /note="K -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519996)" FT /id="VAR_044743" FT VARIANT 132 FT /note="K -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045791" FT VARIANT 133 FT /note="M -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795139)" FT /id="VAR_044744" FT VARIANT 133 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044745" FT VARIANT 133 FT /note="M -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044746" FT VARIANT 133 FT /note="M -> R (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_044747" FT VARIANT 133 FT /note="M -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934873)" FT /evidence="ECO:0000269|PubMed:1933902" FT /id="VAR_005875" FT VARIANT 133 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1057280220)" FT /id="VAR_044748" FT VARIANT 134 FT /note="F -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs780442292)" FT /id="VAR_044749" FT VARIANT 134 FT /note="F -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044750" FT VARIANT 134 FT /note="F -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs267605077)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036504" FT VARIANT 134 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044751" FT VARIANT 134 FT /note="F -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044752" FT VARIANT 135 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs587781991)" FT /id="VAR_005877" FT VARIANT 135 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519975)" FT /id="VAR_044753" FT VARIANT 135 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519975)" FT /id="VAR_044754" FT VARIANT 135 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519975)" FT /id="VAR_005876" FT VARIANT 135 FT /note="C -> T (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045792" FT VARIANT 135 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519976)" FT /id="VAR_044755" FT VARIANT 135 FT /note="C -> Y (in sporadic cancers; somatic mutation; FT decreased E6-mediated binding to E6-AP; dbSNP:rs587781991)" FT /id="VAR_044756" FT VARIANT 136 FT /note="Q -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526268)" FT /id="VAR_005878" FT VARIANT 136 FT /note="Q -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs758781593)" FT /id="VAR_044757" FT VARIANT 136 FT /note="Q -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_005879" FT VARIANT 136 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044758" FT VARIANT 136 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044759" FT VARIANT 137 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044760" FT VARIANT 137 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044761" FT VARIANT 137 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005880" FT VARIANT 137 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044762" FT VARIANT 138 FT /note="A -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044763" FT VARIANT 138 FT /note="A -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934875)" FT /id="VAR_005881" FT VARIANT 138 FT /note="A -> S (in LFS; germline mutation)" FT /id="VAR_044764" FT VARIANT 138 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044765" FT VARIANT 138 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs750600586)" FT /evidence="ECO:0000269|PubMed:17224074, FT ECO:0000269|PubMed:27657329" FT /id="VAR_033034" FT VARIANT 139 FT /note="K -> E (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity; dbSNP:rs1212996409)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044766" FT VARIANT 139 FT /note="K -> N (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity)" FT /evidence="ECO:0000269|PubMed:14660794, FT ECO:0000269|PubMed:38653238" FT /id="VAR_005882" FT VARIANT 139 FT /note="K -> Q (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044767" FT VARIANT 139 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044768" FT VARIANT 139 FT /note="K -> T (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044769" FT VARIANT 140 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044770" FT VARIANT 140 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044771" FT VARIANT 140 FT /note="T -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs786202561)" FT /id="VAR_044772" FT VARIANT 140 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044773" FT VARIANT 140 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044774" FT VARIANT 141 FT /note="C -> A (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045793" FT VARIANT 141 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs587781288)" FT /id="VAR_005885" FT VARIANT 141 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519978)" FT /id="VAR_005884" FT VARIANT 141 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519978)" FT /id="VAR_044775" FT VARIANT 141 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519978)" FT /id="VAR_044776" FT VARIANT 141 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519977)" FT /id="VAR_044777" FT VARIANT 141 FT /note="C -> Y (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587781288)" FT /id="VAR_005886" FT VARIANT 142 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044778" FT VARIANT 142 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045794" FT VARIANT 142 FT /note="P -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044779" FT VARIANT 142 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs779196500)" FT /id="VAR_044780" FT VARIANT 142 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044781" FT VARIANT 142 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044782" FT VARIANT 142 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044783" FT VARIANT 143 FT /note="V -> A (in sporadic cancers; somatic mutation; FT strong DNA binding ability at 32.5 degrees Celsius; strong FT reduction of transcriptional activity at 37.5 degrees FT Celsius; severely represses interaction with ZNF385A)" FT /evidence="ECO:0000269|PubMed:17719541, FT ECO:0000269|PubMed:8013454" FT /id="VAR_005887" FT VARIANT 143 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044784" FT VARIANT 143 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526241)" FT /id="VAR_044785" FT VARIANT 143 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587782620)" FT /id="VAR_044786" FT VARIANT 143 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs587782620)" FT /id="VAR_044787" FT VARIANT 144 FT /note="Q -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs786201419)" FT /id="VAR_044788" FT VARIANT 144 FT /note="Q -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044789" FT VARIANT 144 FT /note="Q -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786203071)" FT /id="VAR_044790" FT VARIANT 144 FT /note="Q -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs786203071)" FT /id="VAR_005888" FT VARIANT 144 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044791" FT VARIANT 145 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044792" FT VARIANT 145 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs587782197)" FT /id="VAR_005889" FT VARIANT 145 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005890" FT VARIANT 145 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044793" FT VARIANT 145 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044794" FT VARIANT 146 FT /note="W -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044795" FT VARIANT 146 FT /note="W -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs786203064)" FT /id="VAR_044796" FT VARIANT 146 FT /note="W -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044797" FT VARIANT 146 FT /note="W -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044798" FT VARIANT 146 FT /note="W -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044799" FT VARIANT 147 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044800" FT VARIANT 147 FT /note="V -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005891" FT VARIANT 147 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044801" FT VARIANT 147 FT /note="V -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044802" FT VARIANT 147 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1453167097)" FT /id="VAR_005892" FT VARIANT 147 FT /note="V -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526226)" FT /id="VAR_044803" FT VARIANT 148 FT /note="D -> A (in a sporadic cancer; somatic mutation; FT dbSNP:rs1046611742)" FT /id="VAR_044804" FT VARIANT 148 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044805" FT VARIANT 148 FT /note="D -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044806" FT VARIANT 148 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_044807" FT VARIANT 148 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044808" FT VARIANT 148 FT /note="D -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691007)" FT /id="VAR_044809" FT VARIANT 149 FT /note="S -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526214)" FT /id="VAR_044810" FT VARIANT 149 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_005893" FT VARIANT 149 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044811" FT VARIANT 150 FT /note="T -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044812" FT VARIANT 150 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044813" FT VARIANT 150 FT /note="T -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044814" FT VARIANT 150 FT /note="T -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_044815" FT VARIANT 150 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044816" FT VARIANT 150 FT /note="T -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044817" FT VARIANT 151 FT /note="P -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs28934874)" FT /id="VAR_005894" FT VARIANT 151 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520000)" FT /id="VAR_044818" FT VARIANT 151 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044819" FT VARIANT 151 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520000)" FT /id="VAR_044820" FT VARIANT 151 FT /note="P -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934874)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005895" FT VARIANT 151 FT /note="P -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934874)" FT /id="VAR_005896" FT VARIANT 152 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044821" FT VARIANT 152 FT /note="P -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782705)" FT /evidence="ECO:0000269|PubMed:1868473" FT /id="VAR_005897" FT VARIANT 152 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044822" FT VARIANT 152 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044823" FT VARIANT 152 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs767328513)" FT /evidence="ECO:0000269|PubMed:9450901" FT /id="VAR_005898" FT VARIANT 152 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044824" FT VARIANT 153 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044825" FT VARIANT 153 FT /note="P -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045795" FT VARIANT 153 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044826" FT VARIANT 153 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044827" FT VARIANT 153 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044828" FT VARIANT 153 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795860)" FT /id="VAR_044829" FT VARIANT 153 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005899" FT VARIANT 154 FT /note="G -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044830" FT VARIANT 154 FT /note="G -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044831" FT VARIANT 154 FT /note="G -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs762846821)" FT /id="VAR_044832" FT VARIANT 154 FT /note="G -> I (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045796" FT VARIANT 154 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs137852789)" FT /id="VAR_044833" FT VARIANT 154 FT /note="G -> V (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs762846821)" FT /evidence="ECO:0000269|PubMed:2263646" FT /id="VAR_005900" FT VARIANT 155 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs772683278)" FT /evidence="ECO:0000269|PubMed:1868473" FT /id="VAR_005901" FT VARIANT 155 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044834" FT VARIANT 155 FT /note="T -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044835" FT VARIANT 155 FT /note="T -> N (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786202752)" FT /id="VAR_044836" FT VARIANT 155 FT /note="T -> P (in sporadic cancers; somatic mutation; does FT not induce SNAI1 degradation)" FT /evidence="ECO:0000269|PubMed:14660794, FT ECO:0000269|PubMed:20385133" FT /id="VAR_044837" FT VARIANT 155 FT /note="T -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs786202752)" FT /id="VAR_044838" FT VARIANT 156 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs563378859)" FT /id="VAR_044839" FT VARIANT 156 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044840" FT VARIANT 156 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs371524413)" FT /id="VAR_044841" FT VARIANT 156 FT /note="R -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044842" FT VARIANT 156 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005902" FT VARIANT 156 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044843" FT VARIANT 157 FT /note="V -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691023)" FT /id="VAR_044844" FT VARIANT 157 FT /note="V -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005903" FT VARIANT 157 FT /note="V -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs121912654)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_005904" FT VARIANT 157 FT /note="V -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044845" FT VARIANT 157 FT /note="V -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs121912654)" FT /evidence="ECO:0000269|PubMed:9419979" FT /id="VAR_012977" FT VARIANT 157 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044846" FT VARIANT 158 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs587780068)" FT /id="VAR_005905" FT VARIANT 158 FT /note="R -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045797" FT VARIANT 158 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_005906" FT VARIANT 158 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782144)" FT /id="VAR_005907" FT VARIANT 158 FT /note="R -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044847" FT VARIANT 158 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs587782144)" FT /id="VAR_044848" FT VARIANT 158 FT /note="R -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044849" FT VARIANT 158 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044850" FT VARIANT 158 FT /note="R -> Y (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045798" FT VARIANT 159 FT /note="A -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044851" FT VARIANT 159 FT /note="A -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions; dbSNP:rs730882022)" FT /id="VAR_045799" FT VARIANT 159 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044852" FT VARIANT 159 FT /note="A -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs730882000)" FT /id="VAR_044853" FT VARIANT 159 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044854" FT VARIANT 159 FT /note="A -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs730882000)" FT /id="VAR_044855" FT VARIANT 159 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526131)" FT /id="VAR_044856" FT VARIANT 160..161 FT /note="MA -> IP (in a sporadic cancer; somatic mutation)" FT /id="VAR_047160" FT VARIANT 160..161 FT /note="MA -> IS (in sporadic cancers; somatic mutation)" FT /id="VAR_047161" FT VARIANT 160..161 FT /note="MA -> IT (in a sporadic cancer; somatic mutation)" FT /id="VAR_047162" FT VARIANT 160 FT /note="M -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs772354334)" FT /id="VAR_005908" FT VARIANT 160 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044857" FT VARIANT 160 FT /note="M -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044858" FT VARIANT 160 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs377274728)" FT /id="VAR_044859" FT VARIANT 161 FT /note="A -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795691)" FT /id="VAR_044860" FT VARIANT 161 FT /note="A -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045800" FT VARIANT 161 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044861" FT VARIANT 161 FT /note="A -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044862" FT VARIANT 161 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005909" FT VARIANT 161 FT /note="A -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs193920817)" FT /id="VAR_044863" FT VARIANT 161 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044864" FT VARIANT 162 FT /note="I -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044865" FT VARIANT 162 FT /note="I -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044866" FT VARIANT 162 FT /note="I -> N (in a breast cancer with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_044867" FT VARIANT 162 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587780069)" FT /id="VAR_005910" FT VARIANT 162 FT /note="I -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044868" FT VARIANT 162 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_005911" FT VARIANT 163 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs148924904)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17224074" FT /id="VAR_033035" FT VARIANT 163 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs786203436)" FT /id="VAR_044869" FT VARIANT 163 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044870" FT VARIANT 163 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs786203436)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_005912" FT VARIANT 163 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs786203436)" FT /id="VAR_044871" FT VARIANT 163 FT /note="Y -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044872" FT VARIANT 164 FT /note="K -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs879254249)" FT /id="VAR_044873" FT VARIANT 164 FT /note="K -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044874" FT VARIANT 164 FT /note="K -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691034)" FT /id="VAR_005913" FT VARIANT 164 FT /note="K -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005914" FT VARIANT 164 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044875" FT VARIANT 164 FT /note="K -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044876" FT VARIANT 165 FT /note="Q -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044877" FT VARIANT 165 FT /note="Q -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044878" FT VARIANT 165 FT /note="Q -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_005915" FT VARIANT 165 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044879" FT VARIANT 165 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_005916" FT VARIANT 166 FT /note="S -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044880" FT VARIANT 166 FT /note="S -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044881" FT VARIANT 166 FT /note="S -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526101)" FT /id="VAR_005917" FT VARIANT 166 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044882" FT VARIANT 166 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044883" FT VARIANT 167..168 FT /note="QH -> HD (in a sporadic cancer; somatic mutation)" FT /id="VAR_047163" FT VARIANT 167..168 FT /note="QH -> YL (in a sporadic cancer; somatic mutation)" FT /id="VAR_047164" FT VARIANT 167 FT /note="Q -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044884" FT VARIANT 167 FT /note="Q -> K (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_044885" FT VARIANT 167 FT /note="Q -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044886" FT VARIANT 167 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044887" FT VARIANT 168..169 FT /note="HM -> LI (in a sporadic cancer; somatic mutation)" FT /id="VAR_047165" FT VARIANT 168 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044888" FT VARIANT 168 FT /note="H -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044889" FT VARIANT 168 FT /note="H -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_044890" FT VARIANT 168 FT /note="H -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044891" FT VARIANT 168 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044892" FT VARIANT 168 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs867114783)" FT /id="VAR_005918" FT VARIANT 168 FT /note="H -> V (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045801" FT VARIANT 168 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044893" FT VARIANT 169..170 FT /note="MT -> IS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047166" FT VARIANT 169 FT /note="M -> I (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:9450901" FT /id="VAR_005919" FT VARIANT 169 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044894" FT VARIANT 169 FT /note="M -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005920" FT VARIANT 169 FT /note="M -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044895" FT VARIANT 170 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs587780729)" FT /id="VAR_044896" FT VARIANT 170 FT /note="T -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_044897" FT VARIANT 170 FT /note="T -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs779000871)" FT /id="VAR_005921" FT VARIANT 170 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044898" FT VARIANT 170 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005922" FT VARIANT 171 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044899" FT VARIANT 171 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044900" FT VARIANT 171 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044901" FT VARIANT 171 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs587781845)" FT /id="VAR_044902" FT VARIANT 171 FT /note="E -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044903" FT VARIANT 171 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044904" FT VARIANT 172 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_005923" FT VARIANT 172 FT /note="V -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044905" FT VARIANT 172 FT /note="V -> F (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1131691043)" FT /id="VAR_044906" FT VARIANT 172 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691021)" FT /id="VAR_044907" FT VARIANT 172 FT /note="V -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044908" FT VARIANT 173 FT /note="V -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519747)" FT /id="VAR_044909" FT VARIANT 173 FT /note="V -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519747)" FT /id="VAR_005924" FT VARIANT 173 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519747)" FT /id="VAR_044910" FT VARIANT 173 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs876660754)" FT /id="VAR_005925" FT VARIANT 173 FT /note="V -> M (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs876660754)" FT /id="VAR_005926" FT VARIANT 173 FT /note="V -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045802" FT VARIANT 174 FT /note="R -> G (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation; dbSNP:rs864622115)" FT /id="VAR_044911" FT VARIANT 174 FT /note="R -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1064796681)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005927" FT VARIANT 174 FT /note="R -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044912" FT VARIANT 174 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044913" FT VARIANT 174 FT /note="R -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044914" FT VARIANT 174 FT /note="R -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_044915" FT VARIANT 175 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs138729528)" FT /id="VAR_005928" FT VARIANT 175 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs138729528)" FT /id="VAR_005929" FT VARIANT 175 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; does not induce SNAI1 FT degradation; reduces interaction with ZNF385A; FT dbSNP:rs28934578)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17719541, ECO:0000269|PubMed:1868473, FT ECO:0000269|PubMed:20385133, ECO:0000269|PubMed:27657329, FT ECO:0000269|PubMed:7887414, ECO:0000269|PubMed:8825920" FT /id="VAR_005932" FT VARIANT 175 FT /note="R -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934578)" FT /id="VAR_005930" FT VARIANT 175 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17719541" FT /id="VAR_005931" FT VARIANT 175 FT /note="R -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044916" FT VARIANT 175 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044917" FT VARIANT 176..177 FT /note="CP -> FS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047167" FT VARIANT 176 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs786202962)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:1868473, ECO:0000269|PubMed:8829627, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005933" FT VARIANT 176 FT /note="C -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044918" FT VARIANT 176 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044919" FT VARIANT 176 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs967461896)" FT /id="VAR_044920" FT VARIANT 176 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519980)" FT /id="VAR_005934" FT VARIANT 176 FT /note="C -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs786202962)" FT /id="VAR_044921" FT VARIANT 177 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044922" FT VARIANT 177 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045803" FT VARIANT 177 FT /note="P -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044923" FT VARIANT 177 FT /note="P -> I (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045804" FT VARIANT 177 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs751477326)" FT /id="VAR_005935" FT VARIANT 177 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs751477326)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036505" FT VARIANT 177 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs147002414)" FT /id="VAR_044924" FT VARIANT 177 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044925" FT VARIANT 178..179 FT /note="HH -> QS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047168" FT VARIANT 178 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044926" FT VARIANT 178 FT /note="H -> HPHP (in a Burkitt lymphoma)" FT /evidence="ECO:0000269|PubMed:1303181" FT /id="VAR_005936" FT VARIANT 178 FT /note="H -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044927" FT VARIANT 178 FT /note="H -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795203)" FT /id="VAR_044928" FT VARIANT 178 FT /note="H -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526004)" FT /id="VAR_044929" FT VARIANT 178 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044930" FT VARIANT 178 FT /note="H -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044931" FT VARIANT 178 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044932" FT VARIANT 179 FT /note="H -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs587780070)" FT /id="VAR_044933" FT VARIANT 179 FT /note="H -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519991)" FT /id="VAR_044934" FT VARIANT 179 FT /note="H -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs587780070)" FT /id="VAR_044935" FT VARIANT 179 FT /note="H -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519991)" FT /id="VAR_044936" FT VARIANT 179 FT /note="H -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs876660821)" FT /id="VAR_044937" FT VARIANT 179 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519991)" FT /id="VAR_044938" FT VARIANT 179 FT /note="H -> Y (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587780070)" FT /id="VAR_044939" FT VARIANT 180 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044940" FT VARIANT 180 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044941" FT VARIANT 180 FT /note="E -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044942" FT VARIANT 180 FT /note="E -> K (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs879253911)" FT /id="VAR_044943" FT VARIANT 180 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044944" FT VARIANT 180 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044945" FT VARIANT 181 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782596)" FT /id="VAR_044946" FT VARIANT 181 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044947" FT VARIANT 181 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs397514495)" FT /id="VAR_044948" FT VARIANT 181 FT /note="R -> L (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs397514495)" FT /id="VAR_005937" FT VARIANT 181 FT /note="R -> P (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_044949" FT VARIANT 181 FT /note="R -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587782596)" FT /id="VAR_044950" FT VARIANT 182 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044951" FT VARIANT 182 FT /note="C -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005938" FT VARIANT 182 FT /note="C -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044952" FT VARIANT 183 FT /note="S -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525970)" FT /id="VAR_044953" FT VARIANT 183 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044954" FT VARIANT 184 FT /note="D -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501209)" FT /id="VAR_044955" FT VARIANT 184 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044956" FT VARIANT 184 FT /note="D -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs72661117)" FT /id="VAR_047169" FT VARIANT 184 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044957" FT VARIANT 184 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_005939" FT VARIANT 185 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044958" FT VARIANT 185 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044959" FT VARIANT 185 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044960" FT VARIANT 185 FT /note="S -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs150607408)" FT /id="VAR_044961" FT VARIANT 185 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044962" FT VARIANT 185 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044963" FT VARIANT 186 FT /note="D -> E (in a sporadic cancer; somatic mutation; FT dbSNP:rs375275361)" FT /id="VAR_044964" FT VARIANT 186 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044965" FT VARIANT 186 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044966" FT VARIANT 186 FT /note="D -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501206)" FT /id="VAR_044967" FT VARIANT 186 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044968" FT VARIANT 186 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_005940" FT VARIANT 187 FT /note="G -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_005941" FT VARIANT 187 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044969" FT VARIANT 187 FT /note="G -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045805" FT VARIANT 187 FT /note="G -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044970" FT VARIANT 187 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs776167460)" FT /id="VAR_005942" FT VARIANT 187 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044971" FT VARIANT 188 FT /note="L -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1199893366)" FT /id="VAR_044972" FT VARIANT 188 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044973" FT VARIANT 189 FT /note="A -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044974" FT VARIANT 189 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044975" FT VARIANT 189 FT /note="A -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_005943" FT VARIANT 189 FT /note="A -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555525921)" FT /id="VAR_044976" FT VARIANT 189 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044977" FT VARIANT 189 FT /note="A -> V (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121912665)" FT /id="VAR_044978" FT VARIANT 190 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044979" FT VARIANT 190 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044980" FT VARIANT 190 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs876660825)" FT /id="VAR_005944" FT VARIANT 190 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs876660825)" FT /id="VAR_044981" FT VARIANT 190 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044982" FT VARIANT 190 FT /note="P -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs876660254)" FT /id="VAR_044983" FT VARIANT 191 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587778718)" FT /id="VAR_044984" FT VARIANT 191 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587778718)" FT /id="VAR_044985" FT VARIANT 191 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs587778718)" FT /id="VAR_044986" FT VARIANT 191 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs868590738)" FT /id="VAR_044987" FT VARIANT 191 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005945" FT VARIANT 192..193 FT /note="QH -> HN (in a sporadic cancer; somatic mutation)" FT /id="VAR_047170" FT VARIANT 192..193 FT /note="QH -> HY (in a sporadic cancer; somatic mutation)" FT /id="VAR_047171" FT VARIANT 192 FT /note="Q -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044988" FT VARIANT 192 FT /note="Q -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_044989" FT VARIANT 192 FT /note="Q -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044990" FT VARIANT 192 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044991" FT VARIANT 192 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs730882002)" FT /id="VAR_005946" FT VARIANT 193 FT /note="H -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs876658468)" FT /id="VAR_005947" FT VARIANT 193 FT /note="H -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs786201838)" FT /id="VAR_044992" FT VARIANT 193 FT /note="H -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs876658468)" FT /id="VAR_044993" FT VARIANT 193 FT /note="H -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs786201838)" FT /id="VAR_044994" FT VARIANT 193 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044995" FT VARIANT 193 FT /note="H -> R (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786201838)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:7887414" FT /id="VAR_005948" FT VARIANT 193 FT /note="H -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs876658468)" FT /id="VAR_044996" FT VARIANT 194 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs587780071)" FT /id="VAR_044997" FT VARIANT 194 FT /note="L -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519998)" FT /id="VAR_044998" FT VARIANT 194 FT /note="L -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044999" FT VARIANT 194 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519998)" FT /id="VAR_005949" FT VARIANT 194 FT /note="L -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519998)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005950" FT VARIANT 194 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045000" FT VARIANT 195 FT /note="I -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs942158624)" FT /id="VAR_045001" FT VARIANT 195 FT /note="I -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_047172" FT VARIANT 195 FT /note="I -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs760043106)" FT /id="VAR_045002" FT VARIANT 195 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs760043106)" FT /id="VAR_045003" FT VARIANT 195 FT /note="I -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs760043106)" FT /evidence="ECO:0000269|PubMed:17224074, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005951" FT VARIANT 195 FT /note="I -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045004" FT VARIANT 195 FT /note="I -> Y (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045806" FT VARIANT 196 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs397516435)" FT /id="VAR_045005" FT VARIANT 196 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs483352697)" FT /id="VAR_045006" FT VARIANT 196 FT /note="R -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs483352697)" FT /id="VAR_045007" FT VARIANT 196 FT /note="R -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs483352697)" FT /id="VAR_045008" FT VARIANT 196 FT /note="R -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045009" FT VARIANT 197 FT /note="V -> E (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045010" FT VARIANT 197 FT /note="V -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045011" FT VARIANT 197 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs786204041)" FT /id="VAR_045012" FT VARIANT 197 FT /note="V -> M (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786204041)" FT /id="VAR_045013" FT VARIANT 198 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045014" FT VARIANT 198 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045015" FT VARIANT 198 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_005952" FT VARIANT 198 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045016" FT VARIANT 198 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045017" FT VARIANT 199 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045018" FT VARIANT 199 FT /note="G -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045019" FT VARIANT 199 FT /note="G -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045020" FT VARIANT 199 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525857)" FT /id="VAR_045021" FT VARIANT 200 FT /note="N -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045022" FT VARIANT 200 FT /note="N -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045023" FT VARIANT 200 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045024" FT VARIANT 200 FT /note="N -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045807" FT VARIANT 200 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045025" FT VARIANT 200 FT /note="N -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045026" FT VARIANT 201..202 FT /note="LR -> FC (in a sporadic cancer; somatic mutation)" FT /id="VAR_047173" FT VARIANT 201 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs730882024)" FT /id="VAR_045027" FT VARIANT 201 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045028" FT VARIANT 201 FT /note="L -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045029" FT VARIANT 202 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs587780072)" FT /id="VAR_045030" FT VARIANT 202 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs587780072)" FT /id="VAR_045031" FT VARIANT 202 FT /note="R -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587778719)" FT /id="VAR_045032" FT VARIANT 202 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587778719)" FT /id="VAR_045033" FT VARIANT 202 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045034" FT VARIANT 202 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045035" FT VARIANT 203..204 FT /note="VE -> LV (in a sporadic cancer; somatic mutation)" FT /id="VAR_047174" FT VARIANT 203 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045036" FT VARIANT 203 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045037" FT VARIANT 203 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045038" FT VARIANT 203 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs730882003)" FT /id="VAR_045039" FT VARIANT 203 FT /note="V -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045808" FT VARIANT 204 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045040" FT VARIANT 204 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045041" FT VARIANT 204 FT /note="E -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1260903787)" FT /id="VAR_045042" FT VARIANT 204 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045043" FT VARIANT 204 FT /note="E -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045044" FT VARIANT 204 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045045" FT VARIANT 205 FT /note="Y -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520007)" FT /evidence="ECO:0000269|PubMed:1459726" FT /id="VAR_005953" FT VARIANT 205 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520008)" FT /id="VAR_005954" FT VARIANT 205 FT /note="Y -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520007)" FT /id="VAR_047175" FT VARIANT 205 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520008)" FT /id="VAR_045046" FT VARIANT 205 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520008)" FT /id="VAR_045047" FT VARIANT 205 FT /note="Y -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520007)" FT /id="VAR_045048" FT VARIANT 206 FT /note="L -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045049" FT VARIANT 206 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_045050" FT VARIANT 207..208 FT /note="DD -> EY (in a sporadic cancer; somatic mutation)" FT /id="VAR_047176" FT VARIANT 207 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045051" FT VARIANT 207 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045052" FT VARIANT 207 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045053" FT VARIANT 207 FT /note="D -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs923100890)" FT /id="VAR_045054" FT VARIANT 207 FT /note="D -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045055" FT VARIANT 207 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045056" FT VARIANT 208 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045057" FT VARIANT 208 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045058" FT VARIANT 208 FT /note="D -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045059" FT VARIANT 208 FT /note="D -> I (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045809" FT VARIANT 208 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045060" FT VARIANT 208 FT /note="D -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1464727668)" FT /id="VAR_045061" FT VARIANT 208 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045062" FT VARIANT 209 FT /note="R -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045063" FT VARIANT 209 FT /note="R -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045064" FT VARIANT 209 FT /note="R -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045065" FT VARIANT 209 FT /note="R -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045066" FT VARIANT 210 FT /note="N -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045067" FT VARIANT 210 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045068" FT VARIANT 210 FT /note="N -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045069" FT VARIANT 210 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045070" FT VARIANT 210 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045071" FT VARIANT 210 FT /note="N -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045072" FT VARIANT 210 FT /note="N -> Y (in a familial cancer not matching LFS; FT germline mutation; dbSNP:rs1060501200)" FT /id="VAR_045073" FT VARIANT 211 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501198)" FT /id="VAR_045074" FT VARIANT 211 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045075" FT VARIANT 211 FT /note="T -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045076" FT VARIANT 211 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045077" FT VARIANT 211 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045078" FT VARIANT 212 FT /note="F -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795766)" FT /id="VAR_045079" FT VARIANT 212 FT /note="F -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045080" FT VARIANT 212 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045081" FT VARIANT 212 FT /note="F -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045082" FT VARIANT 212 FT /note="F -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045083" FT VARIANT 213 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs397516436)" FT /id="VAR_045084" FT VARIANT 213 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587778720)" FT /id="VAR_045085" FT VARIANT 213 FT /note="R -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587778720)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036506" FT VARIANT 213 FT /note="R -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587778720)" FT /id="VAR_005955" FT VARIANT 213 FT /note="R -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_045086" FT VARIANT 214 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045087" FT VARIANT 214 FT /note="H -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1057519992)" FT /id="VAR_045088" FT VARIANT 214 FT /note="H -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs587781386)" FT /id="VAR_047177" FT VARIANT 214 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519992)" FT /id="VAR_045089" FT VARIANT 214 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045090" FT VARIANT 215 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045091" FT VARIANT 215 FT /note="S -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs886039484)" FT /id="VAR_045092" FT VARIANT 215 FT /note="S -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs587782177)" FT /id="VAR_045093" FT VARIANT 215 FT /note="S -> K (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045810" FT VARIANT 215 FT /note="S -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs587782177)" FT /id="VAR_045094" FT VARIANT 215 FT /note="S -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520001)" FT /id="VAR_045095" FT VARIANT 215 FT /note="S -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587782177)" FT /id="VAR_045096" FT VARIANT 216 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045097" FT VARIANT 216 FT /note="V -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520004)" FT /id="VAR_045098" FT VARIANT 216 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520004)" FT /id="VAR_045099" FT VARIANT 216 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730882025)" FT /id="VAR_045100" FT VARIANT 216 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs730882025)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_005956" FT VARIANT 216 FT /note="V -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045811" FT VARIANT 217 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045101" FT VARIANT 217 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045102" FT VARIANT 217 FT /note="V -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045103" FT VARIANT 217 FT /note="V -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045104" FT VARIANT 217 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045105" FT VARIANT 217 FT /note="V -> M (in dbSNP:rs35163653)" FT /id="VAR_047178" FT VARIANT 218 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045106" FT VARIANT 218 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045107" FT VARIANT 218 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525743)" FT /id="VAR_045108" FT VARIANT 218 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045109" FT VARIANT 218 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs878854072)" FT /id="VAR_045110" FT VARIANT 219 FT /note="P -> C (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045812" FT VARIANT 219 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045111" FT VARIANT 219 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1420675064)" FT /id="VAR_045112" FT VARIANT 219 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045113" FT VARIANT 219 FT /note="P -> S (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs879253894)" FT /id="VAR_045114" FT VARIANT 219 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045115" FT VARIANT 220 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912666)" FT /evidence="ECO:0000269|PubMed:7682763, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005957" FT VARIANT 220 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs530941076)" FT /id="VAR_045116" FT VARIANT 220 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045117" FT VARIANT 220 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs530941076)" FT /id="VAR_005958" FT VARIANT 220 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs530941076)" FT /id="VAR_045118" FT VARIANT 220 FT /note="Y -> S (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121912666)" FT /id="VAR_005959" FT VARIANT 221 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045119" FT VARIANT 221 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045120" FT VARIANT 221 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045121" FT VARIANT 221 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs786201592)" FT /id="VAR_045122" FT VARIANT 221 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045123" FT VARIANT 222 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045124" FT VARIANT 222 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs146340390)" FT /id="VAR_045125" FT VARIANT 222 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045126" FT VARIANT 222 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045127" FT VARIANT 222 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501203)" FT /id="VAR_045128" FT VARIANT 222 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045129" FT VARIANT 223 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_047179" FT VARIANT 223 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs138983188)" FT /id="VAR_045130" FT VARIANT 223 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs138983188)" FT /id="VAR_045131" FT VARIANT 223 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045132" FT VARIANT 223 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045133" FT VARIANT 223 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045134" FT VARIANT 224 FT /note="E -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs267605076)" FT /id="VAR_045135" FT VARIANT 224 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045136" FT VARIANT 224 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525707)" FT /id="VAR_045137" FT VARIANT 224 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045138" FT VARIANT 225 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045139" FT VARIANT 225 FT /note="V -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045140" FT VARIANT 225 FT /note="V -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045141" FT VARIANT 225 FT /note="V -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045142" FT VARIANT 225 FT /note="V -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045143" FT VARIANT 225 FT /note="V -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs746504075)" FT /id="VAR_045144" FT VARIANT 226 FT /note="G -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045145" FT VARIANT 226 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_047180" FT VARIANT 226 FT /note="G -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045844" FT VARIANT 226 FT /note="G -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045146" FT VARIANT 226 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs970212462)" FT /id="VAR_045147" FT VARIANT 227 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045148" FT VARIANT 227 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045149" FT VARIANT 227 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045150" FT VARIANT 227 FT /note="S -> T (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_045151" FT VARIANT 228 FT /note="D -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045152" FT VARIANT 228 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_005960" FT VARIANT 228 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045153" FT VARIANT 228 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045154" FT VARIANT 228 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045155" FT VARIANT 228 FT /note="D -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045845" FT VARIANT 228 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045156" FT VARIANT 228 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045157" FT VARIANT 229 FT /note="C -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045158" FT VARIANT 229 FT /note="C -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045846" FT VARIANT 229 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1064794312)" FT /id="VAR_045159" FT VARIANT 229 FT /note="C -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045160" FT VARIANT 229 FT /note="C -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs1064793603)" FT /id="VAR_045161" FT VARIANT 230 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045162" FT VARIANT 230 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:9450901" FT /id="VAR_005961" FT VARIANT 230 FT /note="T -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045163" FT VARIANT 230 FT /note="T -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045164" FT VARIANT 230 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045165" FT VARIANT 231 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045166" FT VARIANT 231 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525564)" FT /id="VAR_045167" FT VARIANT 231 FT /note="T -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045168" FT VARIANT 231 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045169" FT VARIANT 232 FT /note="I -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045170" FT VARIANT 232 FT /note="I -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525562)" FT /id="VAR_045171" FT VARIANT 232 FT /note="I -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045172" FT VARIANT 232 FT /note="I -> S (in sporadic cancers; somatic mutation; does FT not induce SNAI1 degradation)" FT /evidence="ECO:0000269|PubMed:20385133" FT /id="VAR_045173" FT VARIANT 232 FT /note="I -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587781589)" FT /id="VAR_005962" FT VARIANT 232 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045174" FT VARIANT 233 FT /note="H -> D (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_045175" FT VARIANT 233 FT /note="H -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045176" FT VARIANT 233 FT /note="H -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045177" FT VARIANT 233 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045178" FT VARIANT 233 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs879254233)" FT /id="VAR_047181" FT VARIANT 233 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045179" FT VARIANT 234 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587780073)" FT /id="VAR_005963" FT VARIANT 234 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs864622237)" FT /id="VAR_045180" FT VARIANT 234 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045181" FT VARIANT 234 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs864622237)" FT /id="VAR_005964" FT VARIANT 234 FT /note="Y -> K (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045847" FT VARIANT 234 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs864622237)" FT /id="VAR_045182" FT VARIANT 234 FT /note="Y -> Q (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045848" FT VARIANT 234 FT /note="Y -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587780073)" FT /id="VAR_045183" FT VARIANT 235 FT /note="N -> D (in an adrenocortical carcinoma with no FT family history; germline mutation and in sporadic cancers; FT somatic mutation)" FT /id="VAR_047182" FT VARIANT 235 FT /note="N -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045184" FT VARIANT 235 FT /note="N -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs144340710)" FT /id="VAR_045185" FT VARIANT 235 FT /note="N -> M (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045849" FT VARIANT 235 FT /note="N -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs144340710)" FT /id="VAR_045186" FT VARIANT 235 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045187" FT VARIANT 235 FT /note="N -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs786204145)" FT /id="VAR_045188" FT VARIANT 236 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs730882026)" FT /id="VAR_045189" FT VARIANT 236 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs587782289)" FT /id="VAR_045190" FT VARIANT 236 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045191" FT VARIANT 236 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587782289)" FT /id="VAR_045192" FT VARIANT 236 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs587782289)" FT /id="VAR_045193" FT VARIANT 236 FT /note="Y -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs730882026)" FT /id="VAR_045194" FT VARIANT 237 FT /note="M -> I (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782664)" FT /evidence="ECO:0000269|PubMed:27657329" FT /id="VAR_005965" FT VARIANT 237 FT /note="M -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs765848205)" FT /id="VAR_045195" FT VARIANT 237 FT /note="M -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045196" FT VARIANT 237 FT /note="M -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs765848205)" FT /id="VAR_045197" FT VARIANT 237 FT /note="M -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045198" FT VARIANT 237 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs730882004)" FT /id="VAR_045199" FT VARIANT 238 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs730882005)" FT /id="VAR_005966" FT VARIANT 238 FT /note="C -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1057519981)" FT /id="VAR_045200" FT VARIANT 238 FT /note="C -> H (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045850" FT VARIANT 238 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519981)" FT /id="VAR_045201" FT VARIANT 238 FT /note="C -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs730882005)" FT /id="VAR_045202" FT VARIANT 238 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs193920789)" FT /id="VAR_045203" FT VARIANT 238 FT /note="C -> Y (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs730882005)" FT /id="VAR_005967" FT VARIANT 239 FT /note="N -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs876660807)" FT /id="VAR_045204" FT VARIANT 239 FT /note="N -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045205" FT VARIANT 239 FT /note="N -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045206" FT VARIANT 239 FT /note="N -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1057522275)" FT /id="VAR_045207" FT VARIANT 239 FT /note="N -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519999)" FT /id="VAR_045208" FT VARIANT 239 FT /note="N -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519999)" FT /id="VAR_045209" FT VARIANT 239 FT /note="N -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045210" FT VARIANT 240 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045211" FT VARIANT 240 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045212" FT VARIANT 240 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_005968" FT VARIANT 240 FT /note="S -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045213" FT VARIANT 240 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045214" FT VARIANT 240 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045215" FT VARIANT 240 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045216" FT VARIANT 241 FT /note="S -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520002)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033036" FT VARIANT 241 FT /note="S -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs28934573)" FT /id="VAR_045217" FT VARIANT 241 FT /note="S -> F (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934573)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:1699228" FT /id="VAR_005969" FT VARIANT 241 FT /note="S -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520002)" FT /id="VAR_045218" FT VARIANT 241 FT /note="S -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_047183" FT VARIANT 241 FT /note="S -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs28934573)" FT /id="VAR_045219" FT VARIANT 242 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs121912655)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:16959974" FT /id="VAR_005970" FT VARIANT 242 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519982)" FT /id="VAR_045220" FT VARIANT 242 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045221" FT VARIANT 242 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs121912655)" FT /id="VAR_045222" FT VARIANT 242 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs375874539)" FT /id="VAR_045223" FT VARIANT 242 FT /note="C -> Y (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121912655)" FT /id="VAR_045224" FT VARIANT 243..244 FT /note="MG -> IC (in a sporadic cancer; somatic mutation)" FT /id="VAR_047184" FT VARIANT 243..244 FT /note="MG -> IS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047185" FT VARIANT 243 FT /note="M -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045225" FT VARIANT 243 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045226" FT VARIANT 243 FT /note="M -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs786203117)" FT /id="VAR_045227" FT VARIANT 243 FT /note="M -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045228" FT VARIANT 243 FT /note="M -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs730882006)" FT /id="VAR_045229" FT VARIANT 243 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs786203117)" FT /id="VAR_045230" FT VARIANT 244 FT /note="G -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs985033810)" FT /id="VAR_047186" FT VARIANT 244 FT /note="G -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519989)" FT /id="VAR_045231" FT VARIANT 244 FT /note="G -> D (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1057517983)" FT /id="VAR_045232" FT VARIANT 244 FT /note="G -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045233" FT VARIANT 244 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519989)" FT /id="VAR_045234" FT VARIANT 244 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519989)" FT /id="VAR_045235" FT VARIANT 244 FT /note="G -> V (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs985033810)" FT /id="VAR_045236" FT VARIANT 245 FT /note="G -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs121912656)" FT /id="VAR_005971" FT VARIANT 245 FT /note="G -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934575)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:1978757" FT /id="VAR_005972" FT VARIANT 245 FT /note="G -> D (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912656)" FT /evidence="ECO:0000269|PubMed:2259385" FT /id="VAR_005973" FT VARIANT 245 FT /note="G -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045237" FT VARIANT 245 FT /note="G -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045851" FT VARIANT 245 FT /note="G -> H (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045852" FT VARIANT 245 FT /note="G -> L (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045853" FT VARIANT 245 FT /note="G -> N (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045854" FT VARIANT 245 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs28934575)" FT /id="VAR_045238" FT VARIANT 245 FT /note="G -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934575)" FT /evidence="ECO:0000269|PubMed:8829627" FT /id="VAR_005974" FT VARIANT 245 FT /note="G -> V (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912656)" FT /evidence="ECO:0000269|PubMed:2263646" FT /id="VAR_005975" FT VARIANT 246 FT /note="M -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1019340046)" FT /id="VAR_045239" FT VARIANT 246 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045240" FT VARIANT 246 FT /note="M -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs483352695)" FT /id="VAR_044020" FT VARIANT 246 FT /note="M -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs587780074)" FT /id="VAR_005976" FT VARIANT 246 FT /note="M -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587780074)" FT /id="VAR_005977" FT VARIANT 246 FT /note="M -> V (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs483352695)" FT /id="VAR_005978" FT VARIANT 247..248 FT /note="NR -> IP (in a sporadic cancer; somatic mutation)" FT /id="VAR_047187" FT VARIANT 247..248 FT /note="NR -> KW (in sporadic cancers; somatic mutation)" FT /id="VAR_047188" FT VARIANT 247 FT /note="N -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1452189221)" FT /id="VAR_045241" FT VARIANT 247 FT /note="N -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045855" FT VARIANT 247 FT /note="N -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs786201762)" FT /id="VAR_005980" FT VARIANT 247 FT /note="N -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045242" FT VARIANT 247 FT /note="N -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs786201762)" FT /id="VAR_045243" FT VARIANT 247 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_047189" FT VARIANT 247 FT /note="N -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045244" FT VARIANT 248 FT /note="R -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045245" FT VARIANT 248 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs121912651)" FT /id="VAR_005981" FT VARIANT 248 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs11540652)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:7682763" FT /id="VAR_005982" FT VARIANT 248 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs11540652)" FT /id="VAR_045246" FT VARIANT 248 FT /note="R -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs11540652)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:2263646, ECO:0000269|PubMed:7682763, FT ECO:0000269|PubMed:7887414" FT /id="VAR_005983" FT VARIANT 248 FT /note="R -> W (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912651)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:1978757, ECO:0000269|PubMed:27657329, FT ECO:0000269|PubMed:8829627" FT /id="VAR_005984" FT VARIANT 249..250 FT /note="RP -> SA (in a sporadic cancer; somatic mutation)" FT /id="VAR_047190" FT VARIANT 249..250 FT /note="RP -> SS (in sporadic cancers; somatic mutation)" FT /id="VAR_047191" FT VARIANT 249 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs587782082)" FT /id="VAR_005985" FT VARIANT 249 FT /note="R -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045247" FT VARIANT 249 FT /note="R -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs587782329)" FT /id="VAR_045248" FT VARIANT 249 FT /note="R -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs587782329)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033037" FT VARIANT 249 FT /note="R -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045856" FT VARIANT 249 FT /note="R -> S (in sporadic cancers; somatic mutation; does FT not induce SNAI1 degradation; dbSNP:rs28934571)" FT /evidence="ECO:0000269|PubMed:1694291, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:20385133" FT /id="VAR_005986" FT VARIANT 249 FT /note="R -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587782329)" FT /id="VAR_045249" FT VARIANT 249 FT /note="R -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs587782082)" FT /id="VAR_045250" FT VARIANT 250 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045251" FT VARIANT 250 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045857" FT VARIANT 250 FT /note="P -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045252" FT VARIANT 250 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1064794311)" FT /id="VAR_047192" FT VARIANT 250 FT /note="P -> N (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045858" FT VARIANT 250 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045253" FT VARIANT 250 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045254" FT VARIANT 250 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045255" FT VARIANT 251 FT /note="I -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045256" FT VARIANT 251 FT /note="I -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730882007)" FT /id="VAR_045257" FT VARIANT 251 FT /note="I -> M (in LFS; germline mutation; FT dbSNP:rs878854074)" FT /id="VAR_045258" FT VARIANT 251 FT /note="I -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_005987" FT VARIANT 251 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs730882027)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033038" FT VARIANT 251 FT /note="I -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045259" FT VARIANT 251 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045260" FT VARIANT 252 FT /note="L -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045261" FT VARIANT 252 FT /note="L -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045262" FT VARIANT 252 FT /note="L -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045263" FT VARIANT 252 FT /note="L -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912653)" FT /evidence="ECO:0000269|PubMed:1978757" FT /id="VAR_005988" FT VARIANT 252 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045264" FT VARIANT 253 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045265" FT VARIANT 253 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045266" FT VARIANT 253 FT /note="T -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525465)" FT /id="VAR_045267" FT VARIANT 253 FT /note="T -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_047193" FT VARIANT 253 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045268" FT VARIANT 254 FT /note="I -> D (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045859" FT VARIANT 254 FT /note="I -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045269" FT VARIANT 254 FT /note="I -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045270" FT VARIANT 254 FT /note="I -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_045271" FT VARIANT 254 FT /note="I -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_017908" FT VARIANT 254 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1330865474)" FT /id="VAR_045272" FT VARIANT 254 FT /note="I -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_017909" FT VARIANT 254 FT /note="I -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs746601313)" FT /id="VAR_045273" FT VARIANT 255 FT /note="I -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519995)" FT /id="VAR_045274" FT VARIANT 255 FT /note="I -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045275" FT VARIANT 255 FT /note="I -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs876659675)" FT /id="VAR_045276" FT VARIANT 255 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs876659675)" FT /id="VAR_045277" FT VARIANT 255 FT /note="I -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs876659675)" FT /id="VAR_045278" FT VARIANT 255 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045279" FT VARIANT 256 FT /note="T -> I (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045280" FT VARIANT 256 FT /note="T -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045281" FT VARIANT 256 FT /note="T -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045282" FT VARIANT 256 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045283" FT VARIANT 257 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_005989" FT VARIANT 257 FT /note="L -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934577)" FT /id="VAR_045284" FT VARIANT 257 FT /note="L -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs28934577)" FT /id="VAR_045285" FT VARIANT 257 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045286" FT VARIANT 258 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045287" FT VARIANT 258 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005990" FT VARIANT 258 FT /note="E -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501201)" FT /id="VAR_045288" FT VARIANT 258 FT /note="E -> K (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912652)" FT /evidence="ECO:0000269|PubMed:1978757" FT /id="VAR_005991" FT VARIANT 258 FT /note="E -> L (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045860" FT VARIANT 258 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045289" FT VARIANT 258 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045290" FT VARIANT 259 FT /note="D -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_047194" FT VARIANT 259 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045291" FT VARIANT 259 FT /note="D -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs745425759)" FT /id="VAR_045292" FT VARIANT 259 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045293" FT VARIANT 259 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045294" FT VARIANT 259 FT /note="D -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045861" FT VARIANT 259 FT /note="D -> S (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045862" FT VARIANT 259 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045295" FT VARIANT 259 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033039" FT VARIANT 260 FT /note="S -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045296" FT VARIANT 260 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045297" FT VARIANT 260 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045298" FT VARIANT 260 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045299" FT VARIANT 260 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045300" FT VARIANT 260 FT /note="S -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs876658916)" FT /id="VAR_045301" FT VARIANT 261 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045302" FT VARIANT 261 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045303" FT VARIANT 261 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045304" FT VARIANT 261 FT /note="S -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045305" FT VARIANT 261 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045306" FT VARIANT 262..263 FT /note="GN -> PD (in a sporadic cancer; somatic mutation)" FT /id="VAR_047195" FT VARIANT 262 FT /note="G -> C (in a sporadic cancer; somatic mutation; FT dbSNP:rs200579969)" FT /id="VAR_045307" FT VARIANT 262 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_047196" FT VARIANT 262 FT /note="G -> H (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045863" FT VARIANT 262 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs200579969)" FT /id="VAR_045308" FT VARIANT 262 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691025)" FT /evidence="ECO:0000269|Ref.23" FT /id="VAR_045309" FT VARIANT 263 FT /note="N -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs72661119)" FT /id="VAR_045310" FT VARIANT 263 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045311" FT VARIANT 263 FT /note="N -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045312" FT VARIANT 263 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045313" FT VARIANT 263 FT /note="N -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045314" FT VARIANT 264 FT /note="L -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045315" FT VARIANT 264 FT /note="L -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555525353)" FT /id="VAR_045316" FT VARIANT 264 FT /note="L -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045317" FT VARIANT 264 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045318" FT VARIANT 264 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045319" FT VARIANT 265 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045320" FT VARIANT 265 FT /note="L -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs879253942)" FT /id="VAR_045321" FT VARIANT 265 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045322" FT VARIANT 265 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_047197" FT VARIANT 266 FT /note="G -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045323" FT VARIANT 266 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs193920774)" FT /id="VAR_045324" FT VARIANT 266 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519990)" FT /id="VAR_045325" FT VARIANT 266 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs193920774)" FT /id="VAR_045326" FT VARIANT 267 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045327" FT VARIANT 267 FT /note="R -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045328" FT VARIANT 267 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs587780075)" FT /id="VAR_045329" FT VARIANT 267 FT /note="R -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587780075)" FT /id="VAR_045330" FT VARIANT 267 FT /note="R -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs55832599)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036507" FT VARIANT 268 FT /note="N -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045864" FT VARIANT 268 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045331" FT VARIANT 268 FT /note="N -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045332" FT VARIANT 268 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045333" FT VARIANT 268 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045334" FT VARIANT 268 FT /note="N -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045335" FT VARIANT 269 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045336" FT VARIANT 269 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045337" FT VARIANT 269 FT /note="S -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_047198" FT VARIANT 269 FT /note="S -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045338" FT VARIANT 269 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045339" FT VARIANT 269 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045340" FT VARIANT 270 FT /note="F -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519986)" FT /id="VAR_045341" FT VARIANT 270 FT /note="F -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519988)" FT /id="VAR_045342" FT VARIANT 270 FT /note="F -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519987)" FT /id="VAR_045343" FT VARIANT 270 FT /note="F -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519986)" FT /id="VAR_045344" FT VARIANT 270 FT /note="F -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519988)" FT /id="VAR_045345" FT VARIANT 270 FT /note="F -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045346" FT VARIANT 271 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045347" FT VARIANT 271 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045348" FT VARIANT 271 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045349" FT VARIANT 271 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501191)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036508" FT VARIANT 271 FT /note="E -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045865" FT VARIANT 271 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045350" FT VARIANT 271 FT /note="E -> R (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045866" FT VARIANT 271 FT /note="E -> V (in an osteosarcoma with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_047199" FT VARIANT 272 FT /note="V -> A (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045351" FT VARIANT 272 FT /note="V -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs876660333)" FT /id="VAR_045352" FT VARIANT 272 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs876660333)" FT /id="VAR_045353" FT VARIANT 272 FT /note="V -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912657)" FT /evidence="ECO:0000269|PubMed:1737852" FT /id="VAR_005992" FT VARIANT 272 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs121912657)" FT /id="VAR_045354" FT VARIANT 273 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121913343)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17224074, ECO:0000269|PubMed:7887414, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005993" FT VARIANT 273 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_005994" FT VARIANT 273 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; abolishes sequence-specific DNA FT binding; does not induce SNAI1 degradation; FT dbSNP:rs28934576)" FT /evidence="ECO:0000269|PubMed:10570149, FT ECO:0000269|PubMed:1394225, ECO:0000269|PubMed:1565144, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:1699228, FT ECO:0000269|PubMed:1868473, ECO:0000269|PubMed:20385133, FT ECO:0000269|PubMed:7682763, ECO:0000269|Ref.14" FT /id="VAR_005995" FT VARIANT 273 FT /note="R -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934576)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036509" FT VARIANT 273 FT /note="R -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045867" FT VARIANT 273 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs28934576)" FT /evidence="ECO:0000269|PubMed:27657329" FT /id="VAR_045355" FT VARIANT 273 FT /note="R -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045356" FT VARIANT 273 FT /note="R -> S (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121913343)" FT /id="VAR_045357" FT VARIANT 273 FT /note="R -> Y (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045868" FT VARIANT 274 FT /note="V -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520006)" FT /id="VAR_045358" FT VARIANT 274 FT /note="V -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520006)" FT /id="VAR_045359" FT VARIANT 274 FT /note="V -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520005)" FT /id="VAR_005997" FT VARIANT 274 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520006)" FT /id="VAR_047200" FT VARIANT 274 FT /note="V -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045360" FT VARIANT 274 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520005)" FT /id="VAR_045361" FT VARIANT 275 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs863224451)" FT /id="VAR_045362" FT VARIANT 275 FT /note="C -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045363" FT VARIANT 275 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519983)" FT /id="VAR_045364" FT VARIANT 275 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs863224451)" FT /id="VAR_045365" FT VARIANT 275 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525279)" FT /id="VAR_005999" FT VARIANT 275 FT /note="C -> Y (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs863224451)" FT /evidence="ECO:0000269|PubMed:7887414" FT /id="VAR_005998" FT VARIANT 276 FT /note="A -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs786202082)" FT /id="VAR_045366" FT VARIANT 276 FT /note="A -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs786202082)" FT /id="VAR_045367" FT VARIANT 276 FT /note="A -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691029)" FT /id="VAR_045368" FT VARIANT 276 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045369" FT VARIANT 276 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045370" FT VARIANT 276 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045371" FT VARIANT 277 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs763098116)" FT /id="VAR_045372" FT VARIANT 277 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795369)" FT /id="VAR_006000" FT VARIANT 277 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795369)" FT /id="VAR_045373" FT VARIANT 277 FT /note="C -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045374" FT VARIANT 277 FT /note="C -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_047201" FT VARIANT 277 FT /note="C -> Y (in an osteosarcoma with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs763098116)" FT /id="VAR_045375" FT VARIANT 278 FT /note="P -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs17849781)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_006001" FT VARIANT 278 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045869" FT VARIANT 278 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs876659802)" FT /id="VAR_006002" FT VARIANT 278 FT /note="P -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs876659802)" FT /evidence="ECO:0000269|PubMed:2263646" FT /id="VAR_006003" FT VARIANT 278 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs876659802)" FT /id="VAR_045376" FT VARIANT 278 FT /note="P -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs17849781)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:2263646, ECO:0000269|PubMed:9450901" FT /id="VAR_006004" FT VARIANT 278 FT /note="P -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs17849781)" FT /id="VAR_006005" FT VARIANT 279 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1064793881)" FT /id="VAR_006006" FT VARIANT 279 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525248)" FT /id="VAR_045377" FT VARIANT 279 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045378" FT VARIANT 279 FT /note="G -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_045379" FT VARIANT 280 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs753660142)" FT /id="VAR_045380" FT VARIANT 280 FT /note="R -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs121912660)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_006008" FT VARIANT 280 FT /note="R -> K (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; no effect on interaction with CCAR2; FT dbSNP:rs121912660)" FT /evidence="ECO:0000269|PubMed:1694291, FT ECO:0000269|PubMed:25732823" FT /id="VAR_006007" FT VARIANT 280 FT /note="R -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045381" FT VARIANT 280 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045382" FT VARIANT 280 FT /note="R -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs121912660)" FT /evidence="ECO:0000269|PubMed:1631151" FT /id="VAR_006009" FT VARIANT 281..282 FT /note="DR -> EW (in sporadic cancers; somatic mutation)" FT /id="VAR_047203" FT VARIANT 281 FT /note="D -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs587781525)" FT /id="VAR_006010" FT VARIANT 281 FT /note="D -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519984)" FT /evidence="ECO:0000269|PubMed:1459726" FT /id="VAR_006011" FT VARIANT 281 FT /note="D -> G (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs587781525)" FT /id="VAR_006012" FT VARIANT 281 FT /note="D -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs764146326)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_006013" FT VARIANT 281 FT /note="D -> N (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs764146326)" FT /id="VAR_047202" FT VARIANT 281 FT /note="D -> R (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045870" FT VARIANT 281 FT /note="D -> V (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs587781525)" FT /id="VAR_006014" FT VARIANT 281 FT /note="D -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs764146326)" FT /id="VAR_045383" FT VARIANT 282 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934574)" FT /id="VAR_045384" FT VARIANT 282 FT /note="R -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045385" FT VARIANT 282 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730882008)" FT /id="VAR_006015" FT VARIANT 282 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs730882008)" FT /id="VAR_045386" FT VARIANT 282 FT /note="R -> Q (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs730882008)" FT /evidence="ECO:0000269|PubMed:18453682, ECO:0000269|Ref.22" FT /id="VAR_045387" FT VARIANT 282 FT /note="R -> W (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; does not induce SNAI1 FT degradation; dbSNP:rs28934574)" FT /evidence="ECO:0000269|PubMed:20385133, FT ECO:0000269|PubMed:8829627" FT /id="VAR_006016" FT VARIANT 283 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs149633775)" FT /id="VAR_006017" FT VARIANT 283 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_006018" FT VARIANT 283 FT /note="R -> H (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs371409680)" FT /id="VAR_006019" FT VARIANT 283 FT /note="R -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045388" FT VARIANT 283 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_006020" FT VARIANT 283 FT /note="R -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs149633775)" FT /id="VAR_045389" FT VARIANT 284 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:20959462" FT /id="VAR_006021" FT VARIANT 284 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs863224685)" FT /id="VAR_045390" FT VARIANT 284 FT /note="T -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045391" FT VARIANT 284 FT /note="T -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1204379654)" FT /id="VAR_006022" FT VARIANT 285 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045392" FT VARIANT 285 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045393" FT VARIANT 285 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045394" FT VARIANT 285 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs112431538)" FT /evidence="ECO:0000269|PubMed:1459726, FT ECO:0000269|PubMed:1694291" FT /id="VAR_006023" FT VARIANT 285 FT /note="E -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_006024" FT VARIANT 285 FT /note="E -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs121912667)" FT /id="VAR_006025" FT VARIANT 286 FT /note="E -> A (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1057519985)" FT /id="VAR_006026" FT VARIANT 286 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_006027" FT VARIANT 286 FT /note="E -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519985)" FT /id="VAR_006028" FT VARIANT 286 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs786201059)" FT /evidence="ECO:0000269|PubMed:11023613, FT ECO:0000269|PubMed:8316628" FT /id="VAR_006029" FT VARIANT 286 FT /note="E -> L (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045871" FT VARIANT 286 FT /note="E -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs786201059)" FT /evidence="ECO:0000269|PubMed:8829627" FT /id="VAR_006030" FT VARIANT 286 FT /note="E -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519985)" FT /id="VAR_045395" FT VARIANT 287 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_047204" FT VARIANT 287 FT /note="E -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs748891343)" FT /id="VAR_045396" FT VARIANT 287 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045397" FT VARIANT 287 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs587782006)" FT /id="VAR_045398" FT VARIANT 287 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045399" FT VARIANT 288 FT /note="N -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045400" FT VARIANT 288 FT /note="N -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045401" FT VARIANT 288 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045402" FT VARIANT 288 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045403" FT VARIANT 288 FT /note="N -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045404" FT VARIANT 289 FT /note="L -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045405" FT VARIANT 289 FT /note="L -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045406" FT VARIANT 289 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045407" FT VARIANT 289 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045408" FT VARIANT 289 FT /note="L -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525154)" FT /id="VAR_045409" FT VARIANT 290 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs770374782)" FT /id="VAR_045410" FT VARIANT 290 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs55819519)" FT /id="VAR_045411" FT VARIANT 290 FT /note="R -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_045412" FT VARIANT 291 FT /note="K -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525126)" FT /id="VAR_045413" FT VARIANT 291 FT /note="K -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045414" FT VARIANT 291 FT /note="K -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs372613518)" FT /id="VAR_045415" FT VARIANT 291 FT /note="K -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_047205" FT VARIANT 291 FT /note="K -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs781490101)" FT /id="VAR_045416" FT VARIANT 291 FT /note="K -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045417" FT VARIANT 292 FT /note="K -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045418" FT VARIANT 292 FT /note="K -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045872" FT VARIANT 292 FT /note="K -> I (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation; dbSNP:rs121912663)" FT /evidence="ECO:0000269|PubMed:10484981" FT /id="VAR_015819" FT VARIANT 292 FT /note="K -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045419" FT VARIANT 292 FT /note="K -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045420" FT VARIANT 292 FT /note="K -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs121912663)" FT /id="VAR_045421" FT VARIANT 292 FT /note="K -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045422" FT VARIANT 293 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045423" FT VARIANT 293 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs587780076)" FT /id="VAR_045424" FT VARIANT 293 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045425" FT VARIANT 293 FT /note="G -> W (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs587780076)" FT /id="VAR_045426" FT VARIANT 294 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045427" FT VARIANT 294 FT /note="E -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1305324490)" FT /id="VAR_045428" FT VARIANT 294 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045429" FT VARIANT 294 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_047206" FT VARIANT 294 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045430" FT VARIANT 294 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045431" FT VARIANT 295 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045432" FT VARIANT 295 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs751713111)" FT /id="VAR_045433" FT VARIANT 295 FT /note="P -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs751713111)" FT /id="VAR_045434" FT VARIANT 295 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691006)" FT /id="VAR_045435" FT VARIANT 296 FT /note="H -> C (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045873" FT VARIANT 296 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045436" FT VARIANT 296 FT /note="H -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_047207" FT VARIANT 296 FT /note="H -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045437" FT VARIANT 296 FT /note="H -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_006031" FT VARIANT 296 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045438" FT VARIANT 296 FT /note="H -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs483352696)" FT /id="VAR_045439" FT VARIANT 296 FT /note="H -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs672601296)" FT /id="VAR_045440" FT VARIANT 297 FT /note="H -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045441" FT VARIANT 297 FT /note="H -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045442" FT VARIANT 297 FT /note="H -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045443" FT VARIANT 297 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs876659477)" FT /id="VAR_045444" FT VARIANT 297 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045445" FT VARIANT 298 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045446" FT VARIANT 298 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045447" FT VARIANT 298 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs201744589)" FT /id="VAR_045448" FT VARIANT 298 FT /note="E -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs201744589)" FT /id="VAR_045449" FT VARIANT 298 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045450" FT VARIANT 299 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045451" FT VARIANT 299 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045452" FT VARIANT 299 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045453" FT VARIANT 299 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045454" FT VARIANT 300 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045455" FT VARIANT 300 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs909643864)" FT /id="VAR_045456" FT VARIANT 300 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_006032" FT VARIANT 300 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045457" FT VARIANT 301 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045458" FT VARIANT 301 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525067)" FT /id="VAR_006033" FT VARIANT 301 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045459" FT VARIANT 301 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045460" FT VARIANT 301 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_047208" FT VARIANT 302 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045461" FT VARIANT 302 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501202)" FT /id="VAR_006034" FT VARIANT 302 FT /note="G -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs863224686)" FT /id="VAR_045462" FT VARIANT 302 FT /note="G -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_006035" FT VARIANT 303 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045463" FT VARIANT 303 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045464" FT VARIANT 303 FT /note="S -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs876658714)" FT /id="VAR_045465" FT VARIANT 303 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045466" FT VARIANT 304 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs587782654)" FT /id="VAR_045467" FT VARIANT 304 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045468" FT VARIANT 304 FT /note="T -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045469" FT VARIANT 304 FT /note="T -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_047209" FT VARIANT 305 FT /note="K -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045470" FT VARIANT 305 FT /note="K -> M (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045471" FT VARIANT 305 FT /note="K -> N (in sporadic cancers; somatic mutation; loss FT of nuclear localization)" FT /evidence="ECO:0000269|PubMed:10551826" FT /id="VAR_045472" FT VARIANT 305 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045473" FT VARIANT 305 FT /note="K -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045474" FT VARIANT 306 FT /note="R -> P (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_045475" FT VARIANT 306 FT /note="R -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs1048095040)" FT /id="VAR_006036" FT VARIANT 307 FT /note="A -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045476" FT VARIANT 307 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045477" FT VARIANT 307 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_006037" FT VARIANT 308 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045478" FT VARIANT 308 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045479" FT VARIANT 309 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045480" FT VARIANT 309 FT /note="P -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1555525012)" FT /evidence="ECO:0000269|Ref.14" FT /id="VAR_006038" FT VARIANT 310 FT /note="N -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045481" FT VARIANT 310 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045482" FT VARIANT 311 FT /note="N -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525007)" FT /id="VAR_045483" FT VARIANT 311 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045484" FT VARIANT 311 FT /note="N -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs56184981)" FT /id="VAR_045485" FT VARIANT 311 FT /note="N -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs56184981)" FT /id="VAR_045486" FT VARIANT 312 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045487" FT VARIANT 312 FT /note="T -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs145151284)" FT /id="VAR_045488" FT VARIANT 313 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045489" FT VARIANT 313 FT /note="S -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045490" FT VARIANT 313 FT /note="S -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045491" FT VARIANT 313 FT /note="S -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs1367492395)" FT /id="VAR_045492" FT VARIANT 314 FT /note="S -> F (in a sporadic cancer; somatic mutation; FT dbSNP:rs751440465)" FT /id="VAR_045493" FT VARIANT 315 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045494" FT VARIANT 315 FT /note="S -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045495" FT VARIANT 315 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045496" FT VARIANT 316 FT /note="P -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555524979)" FT /id="VAR_045497" FT VARIANT 316 FT /note="P -> T (in a sporadic cancer; somatic mutation; FT dbSNP:rs772773208)" FT /id="VAR_045498" FT VARIANT 317 FT /note="Q -> H (in a kidney cancer with no family history; FT germline mutation and in a sporadic cancer; somatic FT mutation; dbSNP:rs1060501199)" FT /id="VAR_045499" FT VARIANT 317 FT /note="Q -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs764735889)" FT /id="VAR_045500" FT VARIANT 317 FT /note="Q -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_047210" FT VARIANT 317 FT /note="Q -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045501" FT VARIANT 317 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1159579789)" FT /id="VAR_045502" FT VARIANT 318 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555524975)" FT /id="VAR_045503" FT VARIANT 319 FT /note="K -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045504" FT VARIANT 319 FT /note="K -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045505" FT VARIANT 319 FT /note="K -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045506" FT VARIANT 320 FT /note="K -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045507" FT VARIANT 321 FT /note="K -> E (in kidney cancer; germline mutation)" FT /id="VAR_045508" FT VARIANT 321 FT /note="K -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045509" FT VARIANT 322 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045510" FT VARIANT 322 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045511" FT VARIANT 323 FT /note="L -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045874" FT VARIANT 323 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_045512" FT VARIANT 323 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045513" FT VARIANT 323 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045514" FT VARIANT 323 FT /note="L -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs1432281680)" FT /id="VAR_047211" FT VARIANT 324 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045515" FT VARIANT 324 FT /note="D -> S (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045875" FT VARIANT 324 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045516" FT VARIANT 325 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045517" FT VARIANT 325 FT /note="G -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045518" FT VARIANT 325 FT /note="G -> V (in LFS; germline mutation; FT dbSNP:rs121912659)" FT /evidence="ECO:0000269|PubMed:1565144" FT /id="VAR_006039" FT VARIANT 326 FT /note="E -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045519" FT VARIANT 327 FT /note="Y -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045520" FT VARIANT 327 FT /note="Y -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045521" FT VARIANT 328 FT /note="F -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045522" FT VARIANT 328 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045523" FT VARIANT 328 FT /note="F -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045524" FT VARIANT 329 FT /note="T -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs969930693)" FT /id="VAR_045525" FT VARIANT 329 FT /note="T -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045526" FT VARIANT 330 FT /note="L -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045527" FT VARIANT 330 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_047212" FT VARIANT 330 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045528" FT VARIANT 331 FT /note="Q -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs11575996)" FT /id="VAR_045529" FT VARIANT 331 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045530" FT VARIANT 331 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795056)" FT /id="VAR_045531" FT VARIANT 332 FT /note="I -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045532" FT VARIANT 334 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_006040" FT VARIANT 334 FT /note="G -> W (in a sporadic cancer; somatic mutation; FT dbSNP:rs730882028)" FT /id="VAR_045533" FT VARIANT 335 FT /note="R -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045534" FT VARIANT 335 FT /note="R -> H (in a sporadic cancer; somatic mutation; FT dbSNP:rs771939956)" FT /id="VAR_045535" FT VARIANT 335 FT /note="R -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045536" FT VARIANT 337 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; impaired ability to tetramerize FT and undergo liquid-liquid phase separation; FT dbSNP:rs587782529)" FT /evidence="ECO:0000269|PubMed:36108750, FT ECO:0000269|PubMed:9452042" FT /id="VAR_006041" FT VARIANT 337 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; impaired ability to tetramerize FT and undergo liquid-liquid phase separation; FT dbSNP:rs121912664)" FT /evidence="ECO:0000269|PubMed:11481490, FT ECO:0000269|PubMed:36108750" FT /id="VAR_035016" FT VARIANT 337 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs121912664)" FT /id="VAR_045537" FT VARIANT 337 FT /note="R -> P (in sporadic cancers; somatic mutation; FT impaired ability to tetramerize and undergo liquid-liquid FT phase separation; dbSNP:rs121912664)" FT /evidence="ECO:0000269|PubMed:36108750" FT /id="VAR_045538" FT VARIANT 338 FT /note="F -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045539" FT VARIANT 338 FT /note="F -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs150293825)" FT /id="VAR_045540" FT VARIANT 339 FT /note="E -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs17882252)" FT /evidence="ECO:0000269|Ref.12" FT /id="VAR_022316" FT VARIANT 339 FT /note="E -> Q (in a sporadic cancer; somatic mutation; FT dbSNP:rs17882252)" FT /id="VAR_045541" FT VARIANT 341 FT /note="F -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045542" FT VARIANT 342 FT /note="R -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045543" FT VARIANT 342 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs375338359)" FT /id="VAR_045544" FT VARIANT 342 FT /note="R -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs375338359)" FT /id="VAR_047213" FT VARIANT 343 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045545" FT VARIANT 344 FT /note="L -> P (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation; impaired ability to tetramerize FT and undergo liquid-liquid phase separation; FT dbSNP:rs121912662)" FT /evidence="ECO:0000269|PubMed:36108750" FT /id="VAR_045546" FT VARIANT 344 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045547" FT VARIANT 346 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045548" FT VARIANT 347 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045549" FT VARIANT 347 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045550" FT VARIANT 348 FT /note="L -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045551" FT VARIANT 348 FT /note="L -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045552" FT VARIANT 349 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045553" FT VARIANT 352 FT /note="D -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045554" FT VARIANT 353 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045555" FT VARIANT 354 FT /note="Q -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045556" FT VARIANT 354 FT /note="Q -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs755394212)" FT /id="VAR_045557" FT VARIANT 354 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs752142489)" FT /id="VAR_047214" FT VARIANT 356 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045558" FT VARIANT 356 FT /note="G -> W (in a sporadic cancer; somatic mutation)" FT /id="VAR_045559" FT VARIANT 358 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045560" FT VARIANT 358 FT /note="E -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs587782237)" FT /id="VAR_045561" FT VARIANT 360 FT /note="G -> A (in dbSNP:rs35993958)" FT /id="VAR_045562" FT VARIANT 360 FT /note="G -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs35993958)" FT /id="VAR_045563" FT VARIANT 363 FT /note="R -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs876660285)" FT /id="VAR_045564" FT VARIANT 364 FT /note="A -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045565" FT VARIANT 364 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045566" FT VARIANT 364 FT /note="A -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045567" FT VARIANT 365 FT /note="H -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_047215" FT VARIANT 365 FT /note="H -> Y (in a familial cancer not matching LFS; FT germline mutation and in a sporadic cancer; somatic FT mutation; dbSNP:rs267605075)" FT /id="VAR_045568" FT VARIANT 366 FT /note="S -> A (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs17881470)" FT /evidence="ECO:0000269|Ref.12" FT /id="VAR_022317" FT VARIANT 370 FT /note="K -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045569" FT VARIANT 376 FT /note="S -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045570" FT VARIANT 376 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045571" FT VARIANT 379 FT /note="R -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs863224682)" FT /id="VAR_045572" FT VARIANT 385 FT /note="F -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555524094)" FT /id="VAR_045573" FT VARIANT 389 FT /note="G -> W (in a sporadic cancer; somatic mutation; FT dbSNP:rs587783064)" FT /id="VAR_045574" FT VARIANT 392 FT /note="S -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045575" FT MUTAGEN 15 FT /note="S->A: Loss of interaction with PPP2R5C, PPP2CA AND FT PPP2R1A." FT /evidence="ECO:0000269|PubMed:17967874" FT MUTAGEN 18 FT /note="T->A: No effect on interaction with MDM2 and FT increase in protein levels after DNA damage." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 20 FT /note="S->A: Abolishes phosphorylation site. Abolishes FT increase in protein levels after DNA damage." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 20 FT /note="S->D: Constitutively increased TP53 protein levels." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 22..23 FT /note="LW->QS: Loss of interaction with MDM2, leading to FT constitutively increased TP53 protein levels." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 24 FT /note="K->R: Abolishes ubiquitination by MUL1." FT /evidence="ECO:0000269|PubMed:21597459" FT MUTAGEN 37 FT /note="S->D: Abolishes phosphorylation by MAPKAPK5." FT /evidence="ECO:0000269|PubMed:17254968" FT MUTAGEN 46 FT /note="S->A: Abolishes phosphorylation by DYRK2 and HIPK2 FT and acetylation of K-382 by CREBBP." FT /evidence="ECO:0000269|PubMed:11740489, FT ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:17349958" FT MUTAGEN 46 FT /note="Missing: Alters interaction with WWOX." FT /evidence="ECO:0000269|PubMed:11740489, FT ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:17349958" FT MUTAGEN 55 FT /note="T->A: Blocks phosphorylation by TAF1." FT /evidence="ECO:0000269|PubMed:15053879" FT MUTAGEN 183 FT /note="S->A: Abolishes strongly phosphorylation." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 183 FT /note="S->E: Inhibits slightly its transcriptional FT activity." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 248 FT /note="R->S: Does not induce SNAI1 degradation." FT /evidence="ECO:0000269|PubMed:20385133" FT MUTAGEN 269 FT /note="S->A: Abolishes phosphorylation." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 269 FT /note="S->E: Inhibits strongly its transcriptional FT activity." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 284 FT /note="T->E: Inhibits strongly its transcriptional FT activity." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 291..292 FT /note="KK->RR: Abolishes polyubiquitination by MKRN1." FT /evidence="ECO:0000269|PubMed:19536131" FT MUTAGEN 319 FT /note="K->A: Loss of nuclear localization; when associated FT with A-320 and A-321." FT /evidence="ECO:0000269|PubMed:2156209" FT MUTAGEN 320 FT /note="K->A: Loss of nuclear localization; when associated FT with A-319 and A-321." FT /evidence="ECO:0000269|PubMed:2156209" FT MUTAGEN 321 FT /note="K->A: Loss of nuclear localization; when associated FT with A-319 and A-320." FT /evidence="ECO:0000269|PubMed:2156209" FT MUTAGEN 333..337 FT /note="RGRER->KGKEK: Reduced methylation by PRMT5. Reduced FT nuclear localization. Decreased binding to promoters of FT target genes. Reduced transcriptional activity. Decrease in FT cell cycle arrest." FT /evidence="ECO:0000269|PubMed:19011621" FT MUTAGEN 359 FT /note="P->D: Abolishes binding to USP7." FT /evidence="ECO:0000269|PubMed:16402859" FT MUTAGEN 361 FT /note="G->E: Abolishes binding to USP7." FT /evidence="ECO:0000269|PubMed:16402859" FT MUTAGEN 362 FT /note="S->A: Abolishes binding to USP7." FT /evidence="ECO:0000269|PubMed:16402859" FT MUTAGEN 370 FT /note="K->R: Induces a decrease in methylation by SMYD2." FT /evidence="ECO:0000269|PubMed:17108971" FT MUTAGEN 372 FT /note="K->R: Induces a decrease in protein stabilization." FT /evidence="ECO:0000269|PubMed:15525938" FT MUTAGEN 373 FT /note="K->R: Abolishes dimethylation by EHMT1 and EHMT2." FT /evidence="ECO:0000269|PubMed:20118233" FT MUTAGEN 381 FT /note="K->Q: Mimics acetylation, leading to increased FT stability." FT /evidence="ECO:0000269|PubMed:29474172" FT MUTAGEN 381 FT /note="K->R: Decreased acetylation." FT /evidence="ECO:0000269|PubMed:29474172" FT MUTAGEN 382 FT /note="K->A: Abolishes acetylation by CREBBP." FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725" FT MUTAGEN 382 FT /note="K->R: Abolishes monomethylation by KMT5A." FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725" FT MUTAGEN 383 FT /note="L->A: Abolishes S-315 phosphorylation by CDK2/cyclin FT A." FT /evidence="ECO:0000269|PubMed:10884347" FT MUTAGEN 385 FT /note="F->A: Reduced SUMO1 conjugation." FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11124955" FT MUTAGEN 386 FT /note="K->A: Abolishes SUMO1 conjugation, in vitro and in FT vivo." FT /evidence="ECO:0000269|PubMed:11124955, ECO:0000269|Ref.37" FT MUTAGEN 387 FT /note="T->A: No effect SUMO1 conjugation." FT /evidence="ECO:0000269|PubMed:11124955" FT MUTAGEN 388 FT /note="E->A: Abolishes SUMO1 conjugation." FT /evidence="ECO:0000269|PubMed:11124955" FT MUTAGEN 392 FT /note="S->D: Mimics phosphorylation; promotes ability to FT undergo liquid-liquid phase separation." FT /evidence="ECO:0000269|PubMed:35618207" FT MUTAGEN 392 FT /note="S->E: Abolished ability to undergo liquid-liquid FT phase separation." FT /evidence="ECO:0000269|PubMed:31953488" FT HELIX 3..6 FT /evidence="ECO:0007829|PDB:5HOU" FT TURN 8..10 FT /evidence="ECO:0007829|PDB:5HOU" FT HELIX 19..29 FT /evidence="ECO:0007829|PDB:9C5S" FT HELIX 30..32 FT /evidence="ECO:0007829|PDB:5HPD" FT STRAND 33..35 FT /evidence="ECO:0007829|PDB:2L14" FT HELIX 36..38 FT /evidence="ECO:0007829|PDB:2B3G" FT HELIX 41..44 FT /evidence="ECO:0007829|PDB:2B3G" FT HELIX 47..55 FT /evidence="ECO:0007829|PDB:2B3G" FT STRAND 95..97 FT /evidence="ECO:0007829|PDB:7B49" FT TURN 105..108 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 110..112 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 118..120 FT /evidence="ECO:0007829|PDB:3Q05" FT TURN 121..123 FT /evidence="ECO:0007829|PDB:3Q05" FT STRAND 124..127 FT /evidence="ECO:0007829|PDB:3D06" FT TURN 128..131 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 132..135 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 141..146 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 148..150 FT /evidence="ECO:0007829|PDB:5UN8" FT STRAND 156..165 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 166..168 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 177..180 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 181..183 FT /evidence="ECO:0007829|PDB:4KVP" FT STRAND 187..189 FT /evidence="ECO:0007829|PDB:6GGC" FT STRAND 194..199 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 204..207 FT /evidence="ECO:0007829|PDB:3D06" FT TURN 209..211 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 214..219 FT /evidence="ECO:0007829|PDB:3D06" FT TURN 225..227 FT /evidence="ECO:0007829|PDB:2FEJ" FT STRAND 228..236 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 240..242 FT /evidence="ECO:0007829|PDB:3D07" FT TURN 243..248 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 251..258 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 260..262 FT /evidence="ECO:0007829|PDB:2ADY" FT STRAND 264..274 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 278..287 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 288..290 FT /evidence="ECO:0007829|PDB:4HJE" FT HELIX 322..324 FT /evidence="ECO:0007829|PDB:3Q01" FT STRAND 327..334 FT /evidence="ECO:0007829|PDB:3Q01" FT HELIX 335..354 FT /evidence="ECO:0007829|PDB:1AIE" FT HELIX 375..380 FT /evidence="ECO:0007829|PDB:1YC5" SQ SEQUENCE 393 AA; 43653 MW; AD5C149FD8106131 CRC64; MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI EQWFTEDPGP DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ KTYQGSYGFR LGFLHSGTAK SVTCTYSPAL NKMFCQLAKT CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE RCSDSDGLAP PQHLIRVEGN LRVEYLDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENLR KKGEPHHELP PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPG GSRAHSSHLK SKKGQSTSRH KKLMFKTEGP DSD // ID PLPP1_HUMAN Reviewed; 284 AA. AC O14494; B7ZKN8; G3XA95; O60457; O60463; Q17RZ4; DT 15-MAR-2004, integrated into UniProtKB/Swiss-Prot. DT 01-JAN-1998, sequence version 1. DT 28-JAN-2026, entry version 198. DE RecName: Full=Phospholipid phosphatase 1 {ECO:0000305}; DE EC=3.1.3.- {ECO:0000269|PubMed:10962286, ECO:0000269|PubMed:17379599, ECO:0000269|PubMed:9305923, ECO:0000269|PubMed:9607309, ECO:0000269|PubMed:9705349}; DE EC=3.1.3.106 {ECO:0000250|UniProtKB:Q61469}; DE EC=3.1.3.4 {ECO:0000269|PubMed:10962286, ECO:0000269|PubMed:9305923, ECO:0000269|PubMed:9607309, ECO:0000269|PubMed:9705349}; DE EC=3.6.1.75 {ECO:0000250|UniProtKB:Q61469}; DE AltName: Full=Lipid phosphate phosphohydrolase 1; DE AltName: Full=PAP2-alpha; DE AltName: Full=Phosphatidate phosphohydrolase type 2a; DE AltName: Full=Phosphatidic acid phosphatase 2a; DE Short=PAP-2a; DE Short=PAP2a; GN Name=PLPP1 {ECO:0000312|HGNC:HGNC:9228}; Synonyms=LPP1, PPAP2A; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY, RP SUBSTRATE SPECIFICITY, ACTIVITY REGULATION, PATHWAY, SUBCELLULAR LOCATION, RP GLYCOSYLATION, TISSUE SPECIFICITY, AND CAUTION. RX PubMed=9305923; DOI=10.1074/jbc.272.39.24572; RA Kai M., Wada I., Imai S., Sakane F., Kanoh H.; RT "Cloning and characterization of two human isozymes of Mg2+-independent RT phosphatidic acid phosphatase."; RL J. Biol. Chem. 272:24572-24578(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND TISSUE SPECIFICITY. RC TISSUE=Lung; RX PubMed=9570154; DOI=10.1089/dna.1998.17.377; RA Leung D.W., Tompkins C.K., White T.; RT "Molecular cloning of two alternatively spliced forms of human phosphatidic RT acid phosphatase cDNAs that are differentially expressed in normal and RT tumor cells."; RL DNA Cell Biol. 17:377-385(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INDUCTION. RC TISSUE=Prostate; RX PubMed=9468526; DOI=10.1074/jbc.273.8.4660; RA Ulrix W.E.J., Swinnen J., Heyns W., Verhoeven G.; RT "Identification of the phosphatidic acid phosphatase type 2a isozyme as an RT androgen-regulated gene in the human prostatic Adenocarcinoma cell line RT LNCaP."; RL J. Biol. Chem. 273:4660-4665(1998). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY, RP BIOPHYSICOCHEMICAL PROPERTIES, SUBSTRATE SPECIFICITY, ACTIVITY REGULATION, RP PATHWAY, AND SUBCELLULAR LOCATION. RX PubMed=9705349; DOI=10.1074/jbc.273.34.22059; RA Roberts R., Sciorra V.A., Morris A.J.; RT "Human type 2 phosphatidic acid phosphohydrolases. Substrate specificity of RT the type 2a, 2b, and 2c enzymes and cell surface activity of the 2a RT isoform."; RL J. Biol. Chem. 273:22059-22067(1998). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBSTRATE RP SPECIFICITY, AND PATHWAY. RX PubMed=9607309; DOI=10.1016/s0014-5793(98)00421-9; RA Hooks S.B., Ragan S.P., Lynch K.R.; RT "Identification of a novel human phosphatidic acid phosphatase type 2 RT isoform."; RL FEBS Lett. 427:188-192(1998). RN [9] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, PATHWAY, SUBCELLULAR RP LOCATION, AND GLYCOSYLATION. RX PubMed=10962286; DOI=10.1016/s1388-1981(00)00081-0; RA Roberts R.Z., Morris A.J.; RT "Role of phosphatidic acid phosphatase 2a in uptake of extracellular lipid RT phosphate mediators."; RL Biochim. Biophys. Acta 1487:33-49(2000). RN [10] RP SUBCELLULAR LOCATION, AND MOTIF. RX PubMed=14527693; DOI=10.1016/s0014-5793(03)00931-1; RA Jia Y.J., Kai M., Wada I., Sakane F., Kanoh H.; RT "Differential localization of lipid phosphate phosphatases 1 and 3 to cell RT surface subdomains in polarized MDCK cells."; RL FEBS Lett. 552:240-246(2003). RN [11] RP FUNCTION. RX PubMed=12909631; DOI=10.1074/jbc.m306709200; RA Smyth S.S., Sciorra V.A., Sigal Y.J., Pamulkar Z., Wang Z., Xu Y., RA Prestwich G.D., Morris A.J.; RT "Lipid phosphate phosphatases regulate lysophosphatidic acid production and RT signaling in platelets: studies using chemical inhibitors of lipid RT phosphate phosphatase activity."; RL J. Biol. Chem. 278:43214-43223(2003). RN [12] RP FUNCTION, AND MUTAGENESIS OF ARG-217. RX PubMed=15461590; DOI=10.1042/bj20041160; RA Zhao Y., Usatyuk P.V., Cummings R., Saatian B., He D., Watkins T., RA Morris A., Spannhake E.W., Brindley D.N., Natarajan V.; RT "Lipid phosphate phosphatase-1 regulates lysophosphatidic acid-induced RT calcium release, NF-kappaB activation and interleukin-8 secretion in human RT bronchial epithelial cells."; RL Biochem. J. 385:493-502(2005). RN [13] RP SUBCELLULAR LOCATION. RX PubMed=17005594; DOI=10.1093/jb/mvj195; RA Kai M., Sakane F., Jia Y.J., Imai S., Yasuda S., Kanoh H.; RT "Lipid phosphate phosphatases 1 and 3 are localized in distinct lipid RT rafts."; RL J. Biochem. 140:677-686(2006). RN [14] RP FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY. RX PubMed=17379599; DOI=10.1074/jbc.m701279200; RA Zhao Y., Kalari S.K., Usatyuk P.V., Gorshkova I., He D., Watkins T., RA Brindley D.N., Sun C., Bittman R., Garcia J.G., Berdyshev E.V., RA Natarajan V.; RT "Intracellular generation of sphingosine 1-phosphate in human lung RT endothelial cells: role of lipid phosphate phosphatase-1 and sphingosine RT kinase 1."; RL J. Biol. Chem. 282:14165-14177(2007). CC -!- FUNCTION: Magnesium-independent phospholipid phosphatase of the plasma CC membrane that catalyzes the dephosphorylation of a variety of CC glycerolipid and sphingolipid phosphate esters including CC phosphatidate/PA, lysophosphatidate/LPA, diacylglycerol CC pyrophosphate/DGPP, sphingosine 1-phosphate/S1P and ceramide 1- CC phosphate/C1P (PubMed:10962286, PubMed:17379599, PubMed:9305923, CC PubMed:9607309, PubMed:9705349). Also acts on N-oleoyl ethanolamine CC phosphate/N-(9Z-octadecenoyl)-ethanolamine phosphate, a potential CC physiological compound (PubMed:9607309). Through its extracellular CC phosphatase activity allows both the hydrolysis and the cellular uptake CC of these bioactive lipid mediators from the milieu, regulating signal CC transduction in different cellular processes (PubMed:10962286, CC PubMed:12909631, PubMed:15461590, PubMed:17379599). It is for instance CC essential for the extracellular hydrolysis of S1P and subsequent CC conversion into intracellular S1P (PubMed:17379599). Involved in the CC regulation of inflammation, platelets activation, cell proliferation CC and migration among other processes (PubMed:12909631, PubMed:15461590). CC May also have an intracellular activity to regulate phospholipid- CC mediated signaling pathways (By similarity). CC {ECO:0000250|UniProtKB:O08564, ECO:0000269|PubMed:10962286, CC ECO:0000269|PubMed:12909631, ECO:0000269|PubMed:15461590, CC ECO:0000269|PubMed:17379599, ECO:0000269|PubMed:9305923, CC ECO:0000269|PubMed:9607309, ECO:0000269|PubMed:9705349}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycero-3-phosphate + H2O = a 1,2-diacyl-sn- CC glycerol + phosphate; Xref=Rhea:RHEA:27429, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:17815, ChEBI:CHEBI:43474, ChEBI:CHEBI:58608; EC=3.1.3.4; CC Evidence={ECO:0000269|PubMed:10962286, ECO:0000269|PubMed:9305923, CC ECO:0000269|PubMed:9607309, ECO:0000269|PubMed:9705349}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:27430; CC Evidence={ECO:0000305|PubMed:9305923}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-dihexadecanoyl-sn-glycero-3-phosphate + H2O = 1,2- CC dihexadecanoyl-sn-glycerol + phosphate; Xref=Rhea:RHEA:43236, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:72859, CC ChEBI:CHEBI:82929; Evidence={ECO:0000269|PubMed:9705349}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43237; CC Evidence={ECO:0000305|PubMed:9705349}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphate + H2O = 1,2- CC di-(9Z-octadecenoyl)-sn-glycerol + phosphate; Xref=Rhea:RHEA:43244, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:52333, CC ChEBI:CHEBI:74546; Evidence={ECO:0000269|PubMed:9305923, CC ECO:0000269|PubMed:9607309}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43245; CC Evidence={ECO:0000305|PubMed:9305923}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a monoacyl-sn-glycero-3-phosphate + H2O = a monoacylglycerol + CC phosphate; Xref=Rhea:RHEA:46736, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:17408, ChEBI:CHEBI:43474, ChEBI:CHEBI:77589; CC Evidence={ECO:0000269|PubMed:10962286, ECO:0000269|PubMed:9305923, CC ECO:0000269|PubMed:9607309, ECO:0000269|PubMed:9705349}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46737; CC Evidence={ECO:0000305|PubMed:9305923}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(9Z)-octadecenoyl-sn-glycero-3-phosphate + H2O = (9Z- CC octadecenoyl)-glycerol + phosphate; Xref=Rhea:RHEA:50884, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:75937, CC ChEBI:CHEBI:84973; Evidence={ECO:0000269|PubMed:9305923, CC ECO:0000269|PubMed:9607309, ECO:0000269|PubMed:9705349}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50885; CC Evidence={ECO:0000305|PubMed:9305923}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1-acyl-sn-glycero-3-phosphate + H2O = a 1-acyl-sn-glycerol + CC phosphate; Xref=Rhea:RHEA:33155, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:57970, ChEBI:CHEBI:64683; CC EC=3.1.3.106; Evidence={ECO:0000250|UniProtKB:Q61469}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33156; CC Evidence={ECO:0000250|UniProtKB:Q61469}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1-(9Z-octadecenoyl)-sn-glycero-3-phosphate + H2O = 1-(9Z- CC octadecenoyl)-sn-glycerol + phosphate; Xref=Rhea:RHEA:39835, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:74544, CC ChEBI:CHEBI:75757; Evidence={ECO:0000250|UniProtKB:Q61469}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:39836; CC Evidence={ECO:0000250|UniProtKB:Q61469}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycerol 3-diphosphate + H2O = a 1,2-diacyl- CC sn-glycero-3-phosphate + phosphate + H(+); Xref=Rhea:RHEA:27449, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:58608, ChEBI:CHEBI:59996; EC=3.6.1.75; CC Evidence={ECO:0000250|UniProtKB:Q61469}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:27450; CC Evidence={ECO:0000250|UniProtKB:Q61469}; CC -!- CATALYTIC ACTIVITY: CC Reaction=sphing-4-enine 1-phosphate + H2O = sphing-4-enine + phosphate; CC Xref=Rhea:RHEA:27518, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:57756, ChEBI:CHEBI:60119; CC Evidence={ECO:0000269|PubMed:17379599, ECO:0000269|PubMed:9705349}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:27519; CC Evidence={ECO:0000305|PubMed:9705349}; CC -!- CATALYTIC ACTIVITY: CC Reaction=an N-acylsphing-4-enine 1-phosphate + H2O = an N-acylsphing-4- CC enine + phosphate; Xref=Rhea:RHEA:33743, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:52639, ChEBI:CHEBI:57674; CC Evidence={ECO:0000269|PubMed:9305923, ECO:0000269|PubMed:9705349}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33744; CC Evidence={ECO:0000305|PubMed:9305923}; CC -!- CATALYTIC ACTIVITY: CC Reaction=N-(octanoyl)-sphing-4-enine-1-phosphate + H2O = N- CC octanoylsphing-4-enine + phosphate; Xref=Rhea:RHEA:62040, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:45815, CC ChEBI:CHEBI:85376; Evidence={ECO:0000269|PubMed:9705349}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:62041; CC Evidence={ECO:0000305|PubMed:9705349}; CC -!- CATALYTIC ACTIVITY: CC Reaction=N-(9Z-octadecenoyl)-ethanolamine phosphate + H2O = N-(9Z- CC octadecenoyl) ethanolamine + phosphate; Xref=Rhea:RHEA:62160, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:71466, CC ChEBI:CHEBI:145465; Evidence={ECO:0000269|PubMed:9607309}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:62161; CC Evidence={ECO:0000305|PubMed:9607309}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphate + CC H2O = 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycerol + phosphate; CC Xref=Rhea:RHEA:41255, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:64839, ChEBI:CHEBI:75466; CC Evidence={ECO:0000250|UniProtKB:O08564}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41256; CC Evidence={ECO:0000250|UniProtKB:O08564}; CC -!- ACTIVITY REGULATION: Magnesium-independent phospholipid phosphatase CC (PubMed:9305923). Insensitive to N-ethylmaleimide (PubMed:9305923). CC Inhibited by sphingosine, zinc ions and modestly by propanolol CC (PubMed:9305923, PubMed:9705349). Inhibited by vanadate CC (PubMed:10962286). {ECO:0000269|PubMed:10962286, CC ECO:0000269|PubMed:9305923, ECO:0000269|PubMed:9705349}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=98 uM for 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphate CC {ECO:0000269|PubMed:9607309}; CC KM=170 uM for (9Z)-octadecenoyl-sn-glycero-3-phosphate CC {ECO:0000269|PubMed:9607309}; CC KM=116 uM for N-(9Z-octadecenoyl)-ethanolamine phosphate CC {ECO:0000269|PubMed:9607309}; CC Vmax=0.54 nmol/min/mg enzyme with 1,2-dihexadecanoyl-sn-glycero-3- CC phosphate as substrate {ECO:0000269|PubMed:9705349}; CC Vmax=0.50 nmol/min/mg enzyme with (9Z)-octadecenoyl-sn-glycero-3- CC phosphate as substrate {ECO:0000269|PubMed:9705349}; CC Vmax=0.30 nmol/min/mg enzyme with N-(octanoyl)-sphing-4-enine-1- CC phosphate as substrate {ECO:0000269|PubMed:9705349}; CC Vmax=0.32 nmol/min/mg enzyme with sphing-4-enine 1-phosphate as CC substrate {ECO:0000269|PubMed:9705349}; CC Vmax=41 nmol/min/mg enzyme with 1,2-di-(9Z-octadecenoyl)-sn-glycero- CC 3-phosphate as substrate {ECO:0000269|PubMed:9607309}; CC Vmax=33 nmol/min/mg enzyme with (9Z)-octadecenoyl-sn-glycero-3- CC phosphate as substrate {ECO:0000269|PubMed:9607309}; CC Vmax=29 nmol/min/mg enzyme with N-(9Z-octadecenoyl)-ethanolamine CC phosphate as substrate {ECO:0000269|PubMed:9607309}; CC -!- PATHWAY: Lipid metabolism; phospholipid metabolism. CC {ECO:0000269|PubMed:10962286, ECO:0000269|PubMed:9305923, CC ECO:0000269|PubMed:9607309, ECO:0000269|PubMed:9705349}. CC -!- SUBUNIT: Forms functional homodimers and homooligomers that are not CC required for substrate recognition and catalytic activity (By CC similarity). Can also form heterooligomers with PLPP2 and PLPP3 (By CC similarity). {ECO:0000250|UniProtKB:O88956, CC ECO:0000250|UniProtKB:Q61469}. CC -!- INTERACTION: CC O14494; P05067: APP; NbExp=3; IntAct=EBI-2865290, EBI-77613; CC O14494; Q9UQM7: CAMK2A; NbExp=3; IntAct=EBI-2865290, EBI-1383687; CC O14494; P29466-3: CASP1; NbExp=3; IntAct=EBI-2865290, EBI-12248206; CC O14494; P48730-2: CSNK1D; NbExp=3; IntAct=EBI-2865290, EBI-9087876; CC O14494; O15529: GPR42; NbExp=3; IntAct=EBI-2865290, EBI-18076404; CC O14494; P17612: PRKACA; NbExp=3; IntAct=EBI-2865290, EBI-476586; CC O14494; P49768-2: PSEN1; NbExp=3; IntAct=EBI-2865290, EBI-11047108; CC O14494; Q8WWF3: SSMEM1; NbExp=3; IntAct=EBI-2865290, EBI-17280858; CC O14494; Q15583: TGIF1; NbExp=3; IntAct=EBI-2865290, EBI-714215; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10962286, CC ECO:0000269|PubMed:9705349}; Multi-pass membrane protein {ECO:0000255}. CC Apical cell membrane {ECO:0000269|PubMed:14527693}; Multi-pass membrane CC protein {ECO:0000255}. Membrane raft {ECO:0000269|PubMed:17005594}; CC Multi-pass membrane protein {ECO:0000255}. Membrane, caveola CC {ECO:0000250|UniProtKB:Q61469}; Multi-pass membrane protein CC {ECO:0000255}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Comment=Additional isoforms seem to exist.; CC Name=1; Synonyms=Alpha-1, hLPP1, PAP2-a1; CC IsoId=O14494-1; Sequence=Displayed; CC Name=2; Synonyms=Alpha-2, hLPP1-a, PAP2-a2; CC IsoId=O14494-2; Sequence=VSP_009651; CC -!- TISSUE SPECIFICITY: Widely expressed with highest expression found in CC prostate (PubMed:9305923). Found to be down-regulated in colon CC adenocarcinomas (PubMed:9570154). {ECO:0000269|PubMed:9305923, CC ECO:0000269|PubMed:9570154}. CC -!- TISSUE SPECIFICITY: [Isoform 1]: Predominant in kidney, lung, placenta CC and liver. {ECO:0000269|PubMed:9570154}. CC -!- TISSUE SPECIFICITY: [Isoform 2]: Predominant in heart and pancreas. CC {ECO:0000269|PubMed:9570154}. CC -!- INDUCTION: By androgens. {ECO:0000269|PubMed:9468526}. CC -!- PTM: N-glycosylated (PubMed:10962286, PubMed:9305923). N-linked sugars CC are of the complex type. N-glycosylation is not required for the CC phosphatase activity (By similarity). {ECO:0000250|UniProtKB:Q61469, CC ECO:0000269|PubMed:10962286, ECO:0000269|PubMed:9305923}. CC -!- SIMILARITY: Belongs to the PA-phosphatase related phosphoesterase CC family. {ECO:0000305}. CC -!- CAUTION: Some reports could not detect a significant activity with CC sphingosine 1-phosphate as substrate. {ECO:0000269|PubMed:9305923}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB000888; BAA22593.1; -; mRNA. DR EMBL; AF014402; AAC16032.1; -; mRNA. DR EMBL; AF014403; AAC16033.1; -; mRNA. DR EMBL; Y14436; CAC14588.1; -; mRNA. DR EMBL; AF017116; AAC32041.1; -; mRNA. DR EMBL; AC010480; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC025777; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471123; EAW54920.1; -; Genomic_DNA. DR EMBL; CH471123; EAW54922.1; -; Genomic_DNA. DR EMBL; BC039847; AAH39847.1; -; mRNA. DR EMBL; BC117133; AAI17134.1; -; mRNA. DR EMBL; BC143281; AAI43282.1; -; mRNA. DR CCDS; CCDS34159.1; -. [O14494-1] DR CCDS; CCDS34160.1; -. [O14494-2] DR RefSeq; NP_003702.2; NM_003711.3. [O14494-1] DR RefSeq; NP_795714.1; NM_176895.3. [O14494-2] DR AlphaFoldDB; O14494; -. DR BioGRID; 114169; 41. DR FunCoup; O14494; 507. DR IntAct; O14494; 23. DR MINT; O14494; -. DR STRING; 9606.ENSP00000264775; -. DR SwissLipids; SLP:000000160; -. DR DEPOD; PLPP1; -. DR GlyCosmos; O14494; 1 site, No reported glycans. DR GlyGen; O14494; 1 site. DR iPTMnet; O14494; -. DR PhosphoSitePlus; O14494; -. DR SwissPalm; O14494; -. DR BioMuta; PLPP1; -. DR jPOST; O14494; -. DR MassIVE; O14494; -. DR PeptideAtlas; O14494; -. DR ProteomicsDB; 33687; -. DR ProteomicsDB; 48037; -. [O14494-1] DR ProteomicsDB; 48038; -. [O14494-2] DR Pumba; O14494; -. DR Antibodypedia; 11159; 186 antibodies from 27 providers. DR DNASU; 8611; -. DR Ensembl; ENST00000264775.9; ENSP00000264775.5; ENSG00000067113.18. [O14494-2] DR Ensembl; ENST00000307259.9; ENSP00000302229.8; ENSG00000067113.18. [O14494-1] DR GeneID; 8611; -. DR KEGG; hsa:8611; -. DR MANE-Select; ENST00000307259.9; ENSP00000302229.8; NM_003711.4; NP_003702.2. DR UCSC; uc003jpz.5; human. [O14494-1] DR AGR; HGNC:9228; -. DR ClinPGx; PA33552; -. DR CTD; 8611; -. DR DisGeNET; 8611; -. DR GeneCards; PLPP1; -. DR HGNC; HGNC:9228; PLPP1. DR HPA; ENSG00000067113; Low tissue specificity. DR MIM; 607124; gene. DR OpenTargets; ENSG00000067113; -. DR VEuPathDB; HostDB:ENSG00000067113; -. DR GeneTree; ENSGT00940000156730; -. DR HOGENOM; CLU_021458_3_1_1; -. DR InParanoid; O14494; -. DR OMA; NQHRYIE; -. DR OrthoDB; 8907274at2759; -. DR PAN-GO; O14494; 6 GO annotations based on evolutionary models. DR PhylomeDB; O14494; -. DR PathwayCommons; O14494; -. DR Reactome; R-HSA-9845614; Sphingolipid catabolism. DR SignaLink; O14494; -. DR UniPathway; UPA00085; -. DR Agora; ENSG00000067113; -. DR BioGRID-ORCS; 8611; 19 hits in 1152 CRISPR screens. DR ChiTaRS; PLPP1; human. DR GeneWiki; PPAP2A; -. DR GenomeRNAi; 8611; -. DR Pharos; O14494; Tbio. DR PRO; PR:O14494; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; O14494; protein. DR Bgee; ENSG00000067113; Expressed in decidua and 202 other cell types or tissues. DR ExpressionAtlas; O14494; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB. DR GO; GO:0005901; C:caveola; ISS:UniProtKB. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0045121; C:membrane raft; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0106235; F:ceramide-1-phosphate phosphatase activity; IDA:UniProtKB. DR GO; GO:0000810; F:diacylglycerol diphosphate phosphatase activity; ISS:UniProtKB. DR GO; GO:0042577; F:lipid phosphatase activity; IDA:UniProtKB. DR GO; GO:0052642; F:lysophosphatidic acid phosphatase activity; IEA:UniProtKB-EC. DR GO; GO:0008195; F:phosphatidate phosphatase activity; IDA:UniProtKB. DR GO; GO:0042392; F:sphingosine-1-phosphate phosphatase activity; IDA:UniProtKB. DR GO; GO:0030521; P:androgen receptor signaling pathway; NAS:UniProtKB. DR GO; GO:0006672; P:ceramide metabolic process; IDA:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; NAS:UniProtKB. DR GO; GO:0030518; P:nuclear receptor-mediated steroid hormone signaling pathway; TAS:UniProtKB. DR GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; TAS:UniProtKB. DR GO; GO:0046839; P:phospholipid dephosphorylation; IDA:UniProtKB. DR GO; GO:0006644; P:phospholipid metabolic process; IDA:UniProtKB. DR GO; GO:0019216; P:regulation of lipid metabolic process; NAS:UniProtKB. DR GO; GO:0007165; P:signal transduction; IMP:UniProtKB. DR GO; GO:0030149; P:sphingolipid catabolic process; TAS:Reactome. DR GO; GO:0006670; P:sphingosine metabolic process; IDA:UniProtKB. DR CDD; cd03384; PAP2_wunen; 1. DR FunFam; 1.20.144.10:FF:000007; phospholipid phosphatase 1 isoform X2; 1. DR Gene3D; 1.20.144.10; Phosphatidic acid phosphatase type 2/haloperoxidase; 1. DR InterPro; IPR043216; PAP-like. DR InterPro; IPR000326; PAP2/HPO. DR InterPro; IPR036938; PAP2/HPO_sf. DR PANTHER; PTHR10165; LIPID PHOSPHATE PHOSPHATASE; 1. DR PANTHER; PTHR10165:SF26; PHOSPHOLIPID PHOSPHATASE 1; 1. DR Pfam; PF01569; PAP2; 1. DR SMART; SM00014; acidPPc; 1. DR SUPFAM; SSF48317; Acid phosphatase/Vanadium-dependent haloperoxidase; 1. PE 1: Evidence at protein level; KW Alternative splicing; Cell membrane; Glycoprotein; Hydrolase; KW Lipid metabolism; Membrane; Proteomics identification; Reference proteome; KW Transmembrane; Transmembrane helix. FT CHAIN 1..284 FT /note="Phospholipid phosphatase 1" FT /id="PRO_0000220905" FT TOPO_DOM 1..6 FT /note="Cytoplasmic" FT /evidence="ECO:0000250|UniProtKB:Q61469" FT TRANSMEM 7..27 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 28..53 FT /note="Extracellular" FT /evidence="ECO:0000250|UniProtKB:Q61469" FT TRANSMEM 54..74 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 75..94 FT /note="Cytoplasmic" FT /evidence="ECO:0000250|UniProtKB:Q61469" FT TRANSMEM 95..115 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 116..164 FT /note="Extracellular" FT /evidence="ECO:0000250|UniProtKB:Q61469" FT TRANSMEM 165..185 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 186..199 FT /note="Cytoplasmic" FT /evidence="ECO:0000250|UniProtKB:Q61469" FT TRANSMEM 200..220 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 221..229 FT /note="Extracellular" FT /evidence="ECO:0000250|UniProtKB:Q61469" FT TRANSMEM 230..250 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 251..284 FT /note="Cytoplasmic" FT /evidence="ECO:0000250|UniProtKB:Q61469" FT REGION 120..128 FT /note="Phosphatase sequence motif I" FT /evidence="ECO:0000250|UniProtKB:O34349" FT REGION 168..171 FT /note="Phosphatase sequence motif II" FT /evidence="ECO:0000250|UniProtKB:O34349" FT REGION 216..227 FT /note="Phosphatase sequence motif III" FT /evidence="ECO:0000250|UniProtKB:O34349" FT REGION 260..284 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 5..7 FT /note="PDZ-binding; involved in localization to the apical FT cell membrane" FT /evidence="ECO:0000269|PubMed:14527693" FT COMPBIAS 269..284 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 171 FT /note="Proton donors" FT /evidence="ECO:0000250|UniProtKB:O34349" FT ACT_SITE 223 FT /note="Nucleophile" FT /evidence="ECO:0000250|UniProtKB:O34349" FT SITE 227 FT /note="Stabilizes the active site histidine for FT nucleophilic attack" FT /evidence="ECO:0000250|UniProtKB:O34349" FT CARBOHYD 142 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 21..70 FT /note="GLPFAILTSRHTPFQRGVFCNDESIKYPYKEDTIPYALLGGIIIPFSIIV FT -> SMPMAVLKLGQIYPFQRGFFCKDNSINYPYHDSTVTSTVLILVGVGLPISS (in FT isoform 2)" FT /evidence="ECO:0000303|PubMed:9570154" FT /id="VSP_009651" FT MUTAGEN 217 FT /note="R->K: Decreased lipid phosphatase activity." FT /evidence="ECO:0000269|PubMed:15461590" FT CONFLICT 27 FT /note="L -> FTSRHI (in Ref. 4; AAC32041)" FT /evidence="ECO:0000305" FT CONFLICT 91 FT /note="R -> S (in Ref. 2; AAC16033)" FT /evidence="ECO:0000305" FT CONFLICT O14494-2:55 FT /note="V -> A (in Ref. 2; AAC16033)" FT /evidence="ECO:0000305" FT CONFLICT O14494-2:56 FT /note="T -> A (in Ref. 2; AAC16033)" FT /evidence="ECO:0000305" FT CONFLICT O14494-2:69 FT /note="I -> V (in Ref. 2; AAC16033)" FT /evidence="ECO:0000305" SQ SEQUENCE 284 AA; 32156 MW; FC2F00617EE07EB3 CRC64; MFDKTRLPYV ALDVLCVLLA GLPFAILTSR HTPFQRGVFC NDESIKYPYK EDTIPYALLG GIIIPFSIIV IILGETLSVY CNLLHSNSFI RNNYIATIYK AIGTFLFGAA ASQSLTDIAK YSIGRLRPHF LDVCDPDWSK INCSDGYIEY YICRGNAERV KEGRLSFYSG HSSFSMYCML FVALYLQARM KGDWARLLRP TLQFGLVAVS IYVGLSRVSD YKHHWSDVLT GLIQGALVAI LVAVYVSDFF KERTSFKERK EEDSHTTLHE TPTTGNHYPS NHQP // ID RNZ2_HUMAN Reviewed; 826 AA. AC Q9BQ52; B4DPL9; Q6IA94; Q9HAS8; Q9HAS9; Q9NVT1; DT 16-JAN-2004, integrated into UniProtKB/Swiss-Prot. DT 16-JAN-2004, sequence version 2. DT 28-JAN-2026, entry version 203. DE RecName: Full=Zinc phosphodiesterase ELAC protein 2; DE EC=3.1.26.11; DE AltName: Full=ElaC homolog protein 2; DE AltName: Full=Heredity prostate cancer protein 2; DE AltName: Full=Ribonuclease Z 2; DE Short=RNase Z 2; DE AltName: Full=tRNA 3 endonuclease 2; DE AltName: Full=tRNase Z 2; DE Flags: Precursor; GN Name=ELAC2; Synonyms=HPC2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANTS RP HPC2 LEU-217; THR-541 AND HIS-781. RX PubMed=11175785; DOI=10.1038/84808; RA Tavtigian S.V., Simard J., Teng D.H.F., Abtin V., Baumgard M., Beck A., RA Camp N.J., Carillo A.R., Chen Y., Dayananth P., Desrochers M., Dumont M., RA Farnham J.M., Frank D., Frye C., Ghaffari S., Gupte J.S., Hu R., Iliev D., RA Janecki T., Kort E.N., Laity K.E., Leavitt A., Leblanc G., RA McArthur-Morrison J., Pederson A., Penn B., Peterson K.T., Reid J.E., RA Richards S., Schroeder M., Smith R., Snyder S.C., Swedlund B., Swensen J., RA Thomas A., Tranchant M., Woodland A.-M., Labrie F., Skolnick M.H., RA Neuhausen S., Rommens J., Cannon-Albright L.A.; RT "A candidate prostate cancer susceptibility gene at chromosome 17p."; RL Nat. Genet. 27:172-180(2001). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2; 3 AND 4). RC TISSUE=Hippocampus, Liver, Teratocarcinoma, and Thalamus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT HPC2 RP LEU-217. RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT HPC2 RP LEU-217. RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP ENZYME ACTIVITY, AND CHARACTERIZATION OF VARIANTS HPC2 LEU-217; THR-541 AND RP HIS-781. RX PubMed=12711671; DOI=10.1093/nar/gkg337; RA Takaku H., Minagawa A., Takagi M., Nashimoto M.; RT "A candidate prostate cancer susceptibility gene encodes tRNA 3' processing RT endoribonuclease."; RL Nucleic Acids Res. 31:2272-2278(2003). RN [7] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-199, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [8] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [9] RP INTERACTION WITH PTCD1. RX PubMed=21857155; DOI=10.4161/cc.10.17.17060; RA Sanchez M.I., Mercer T.R., Davies S.M., Shearwood A.M., Nygard K.K., RA Richman T.R., Mattick J.S., Rackham O., Filipovska A.; RT "RNA processing in human mitochondria."; RL Cell Cycle 10:2904-2916(2011). RN [10] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=21593607; DOI=10.4161/rna.8.4.15393; RA Brzezniak L.K., Bijata M., Szczesny R.J., Stepien P.P.; RT "Involvement of human ELAC2 gene product in 3' end processing of RT mitochondrial tRNAs."; RL RNA Biol. 8:616-626(2011). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-199; SER-208; SER-229; RP SER-618 AND SER-736, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=24703694; DOI=10.1016/j.cmet.2014.03.013; RA Bogenhagen D.F., Martin D.W., Koller A.; RT "Initial steps in RNA processing and ribosome assembly occur at RT mitochondrial DNA nucleoids."; RL Cell Metab. 19:618-629(2014). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-208 AND SER-212, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [15] RP VARIANTS HPC2 LEU-217 AND THR-541. RX PubMed=10986046; DOI=10.1086/303096; RA Rebbeck T.R., Walker A.H., Zeigler-Johnson C., Weisburg S., Martin A.-M., RA Nathanson K.L., Wein A.J., Malkowicz S.B.; RT "Association of HPC2/ELAC2 genotypes and prostate cancer."; RL Am. J. Hum. Genet. 67:1014-1019(2000). RN [16] RP VARIANT HPC2 VAL-622. RX PubMed=11507049; RA Roekman A., Ikonen T., Mononen N., Autio V., Matikainen M.P., RA Koivisto P.A., Tammela T.L.J., Kallioniemi O.-P., Schleutker J.; RT "ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer."; RL Cancer Res. 61:6038-6041(2001). RN [17] RP VARIANTS HPC2 GLN-211; LEU-217; ARG-487; THR-541 AND ARG-806. RX PubMed=11522646; RA Wang L., McDonnell S.K., Elkins D.A., Slager S.L., Christensen E., RA Marks A.F., Cunningham J.M., Peterson B.J., Jacobsen S.J., Cerhan J.R., RA Blute M.L., Schaid D.J., Thibodeau S.N.; RT "Role of HPC2/ELAC2 in hereditary prostate cancer."; RL Cancer Res. 61:6494-6499(2001). RN [18] RP VARIANTS HPC2 LEU-217 AND THR-541. RX PubMed=12522685; DOI=10.1007/s100380200099; RA Fujiwara H., Emi M., Nagai H., Nishimura T., Konishi N., Kubota Y., RA Ichikawa T., Takahashi S., Shuin T., Habuchi T., Ogawa O., Inoue K., RA Skolnick M.H., Swensen J., Camp N.J., Tavtigian S.V.; RT "Association of common missense changes in ELAC2 (HPC2) with prostate RT cancer in a Japanese case-control series."; RL J. Hum. Genet. 47:641-648(2002). RN [19] RP VARIANTS HPC2 LEU-217 AND THR-541. RX PubMed=12515253; DOI=10.1086/344516; RA Camp N.J., Tavtigian S.V.; RT "Meta-analysis of associations of the Ser217Leu and Ala541Thr variants in RT ELAC2 (HPC2) and prostate cancer."; RL Am. J. Hum. Genet. 71:1475-1478(2002). RN [20] RP VARIANT LEU-627. RX PubMed=12949798; DOI=10.1002/ijc.11347; RA Takahashi H., Lu W., Watanabe M., Katoh T., Furusato M., Tsukino H., RA Nakao H., Sudo A., Suzuki H., Akakura K., Ikemoto I., Asano K., Ito T., RA Wakui S., Muto T., Hano H.; RT "Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic RT cancer risk in Japanese men."; RL Int. J. Cancer 107:224-228(2003). RN [21] RP VARIANTS HPC2 LEU-217 AND THR-541. RX PubMed=12783937; DOI=10.1093/jnci/95.11.818; RA Severi G., Giles G.G., Southey M.C., Tesoriero A., Tilley W., Neufing P., RA Morris H., English D.R., McCredie M.R., Boyle P., Hopper J.L.; RT "ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate RT cancer."; RL J. Natl. Cancer Inst. 95:818-824(2003). RN [22] RP VARIANT [LARGE SCALE ANALYSIS] HPC2 LEU-217. RX PubMed=18987736; DOI=10.1038/nature07485; RA Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K., RA Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L., RA Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A., RA Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V., RA Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R., RA Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E., RA Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J., Heath S., RA Shannon W.D., Nagarajan R., Walter M.J., Link D.C., Graubert T.A., RA DiPersio J.F., Wilson R.K.; RT "DNA sequencing of a cytogenetically normal acute myeloid leukaemia RT genome."; RL Nature 456:66-72(2008). RN [23] RP VARIANTS COXPD17 LEU-154; PHE-423 AND ILE-520. RX PubMed=23849775; DOI=10.1016/j.ajhg.2013.06.006; RA Haack T.B., Kopajtich R., Freisinger P., Wieland T., Rorbach J., RA Nicholls T.J., Baruffini E., Walther A., Danhauser K., Zimmermann F.A., RA Husain R.A., Schum J., Mundy H., Ferrero I., Strom T.M., Meitinger T., RA Taylor R.W., Minczuk M., Mayr J.A., Prokisch H.; RT "ELAC2 mutations cause a mitochondrial RNA processing defect associated RT with hypertrophic cardiomyopathy."; RL Am. J. Hum. Genet. 93:211-223(2013). CC -!- FUNCTION: Zinc phosphodiesterase, which displays mitochondrial tRNA 3'- CC processing endonuclease activity. Involved in tRNA maturation, by CC removing a 3'-trailer from precursor tRNA (PubMed:21593607). Associates CC with mitochondrial DNA complexes at the nucleoids to initiate RNA CC processing and ribosome assembly (PubMed:24703694). CC {ECO:0000269|PubMed:21593607, ECO:0000269|PubMed:24703694}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Endonucleolytic cleavage of RNA, removing extra 3' nucleotides CC from tRNA precursor, generating 3' termini of tRNAs. A 3'-hydroxy CC group is left at the tRNA terminus and a 5'-phosphoryl group is left CC at the trailer molecule.; EC=3.1.26.11; CC Evidence={ECO:0000269|PubMed:12711671}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000305}; CC -!- SUBUNIT: Homodimer (By similarity). Interacts with PTCD1. {ECO:0000250, CC ECO:0000269|PubMed:21857155}. CC -!- SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:21593607}. CC Mitochondrion matrix, mitochondrion nucleoid CC {ECO:0000269|PubMed:24703694}. Nucleus {ECO:0000269|PubMed:21593607}. CC Note=Mainly mitochondrial. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=Q9BQ52-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9BQ52-2; Sequence=VSP_009169, VSP_009171, VSP_009172; CC Name=3; CC IsoId=Q9BQ52-3; Sequence=VSP_009168, VSP_009170; CC Name=4; CC IsoId=Q9BQ52-4; Sequence=VSP_043449; CC -!- TISSUE SPECIFICITY: Widely expressed. Highly expressed in heart, CC placenta, liver, skeletal muscle, kidney, pancreas, testis and ovary. CC Weakly expressed in brain, lung, spleen, thymus, prostate, small CC intestine, colon and leukocytes. {ECO:0000269|PubMed:11175785}. CC -!- DISEASE: Prostate cancer, hereditary, 2 (HPC2) [MIM:614731]: A CC condition associated with familial predisposition to cancer of the CC prostate. Most prostate cancers are adenocarcinomas that develop in the CC acini of the prostatic ducts. Other rare histopathologic types of CC prostate cancer that occur in approximately 5% of patients include CC small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, CC transitional cell carcinoma, squamous cell carcinoma, basal cell CC carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:10986046, CC ECO:0000269|PubMed:11175785, ECO:0000269|PubMed:11507049, CC ECO:0000269|PubMed:11522646, ECO:0000269|PubMed:12515253, CC ECO:0000269|PubMed:12522685, ECO:0000269|PubMed:12711671, CC ECO:0000269|PubMed:12783937, ECO:0000269|PubMed:15489334, CC ECO:0000269|PubMed:18987736, ECO:0000269|Ref.3}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- DISEASE: Combined oxidative phosphorylation deficiency 17 (COXPD17) CC [MIM:615440]: An autosomal recessive disorder of mitochondrial CC dysfunction characterized by onset of severe hypertrophic CC cardiomyopathy in the first year of life. Other features include CC hypotonia, poor growth, lactic acidosis, and failure to thrive. The CC disorder may be fatal in early childhood. CC {ECO:0000269|PubMed:23849775}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the RNase Z family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40437/ELAC2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF304369; AAG24440.1; -; Genomic_DNA. DR EMBL; AF304370; AAG24441.1; -; mRNA. DR EMBL; AK001392; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AK124838; BAC85964.1; -; mRNA. DR EMBL; AK125030; BAC86026.1; -; mRNA. DR EMBL; AK298397; BAG60631.1; -; mRNA. DR EMBL; CR457261; CAG33542.1; -; mRNA. DR EMBL; AC005277; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC001939; AAH01939.1; -; mRNA. DR EMBL; BC004158; AAH04158.1; -; mRNA. DR CCDS; CCDS11164.1; -. [Q9BQ52-1] DR CCDS; CCDS54093.1; -. [Q9BQ52-4] DR RefSeq; NP_001159434.1; NM_001165962.2. [Q9BQ52-4] DR RefSeq; NP_060597.4; NM_018127.6. [Q9BQ52-1] DR RefSeq; NP_776065.1; NM_173717.1. DR PDB; 8CBL; EM; 2.79 A; E=1-826. DR PDB; 8RR1; EM; 2.93 A; E=32-826. DR PDB; 8RR3; EM; 3.40 A; E=32-826. DR PDB; 8RR4; EM; 3.20 A; E=32-826. DR PDB; 8Z0P; EM; 3.10 A; A=1-826. DR PDB; 8Z1F; EM; 4.30 A; A=1-826. DR PDB; 8Z1G; EM; 3.70 A; A=1-826. DR PDB; 9EY0; EM; 2.78 A; E=31-826. DR PDB; 9EY1; EM; 2.90 A; E=31-826. DR PDB; 9EY2; EM; 2.96 A; E=31-826. DR PDBsum; 8CBL; -. DR PDBsum; 8RR1; -. DR PDBsum; 8RR3; -. DR PDBsum; 8RR4; -. DR PDBsum; 8Z0P; -. DR PDBsum; 8Z1F; -. DR PDBsum; 8Z1G; -. DR PDBsum; 9EY0; -. DR PDBsum; 9EY1; -. DR PDBsum; 9EY2; -. DR AlphaFoldDB; Q9BQ52; -. DR EMDB; EMD-16544; -. DR EMDB; EMD-19453; -. DR EMDB; EMD-19455; -. DR EMDB; EMD-19457; -. DR EMDB; EMD-39710; -. DR EMDB; EMD-39726; -. DR EMDB; EMD-39727; -. DR EMDB; EMD-50050; -. DR EMDB; EMD-50051; -. DR EMDB; EMD-50052; -. DR SMR; Q9BQ52; -. DR BioGRID; 121937; 198. DR ComplexPortal; CPX-2240; Mitochondrial RNase Z complex. DR FunCoup; Q9BQ52; 3637. DR IntAct; Q9BQ52; 55. DR MINT; Q9BQ52; -. DR STRING; 9606.ENSP00000337445; -. DR GlyGen; Q9BQ52; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q9BQ52; -. DR MetOSite; Q9BQ52; -. DR PhosphoSitePlus; Q9BQ52; -. DR SwissPalm; Q9BQ52; -. DR BioMuta; ELAC2; -. DR DMDM; 41017788; -. DR jPOST; Q9BQ52; -. DR MassIVE; Q9BQ52; -. DR PaxDb; 9606-ENSP00000337445; -. DR PeptideAtlas; Q9BQ52; -. DR ProteomicsDB; 78627; -. [Q9BQ52-1] DR ProteomicsDB; 78628; -. [Q9BQ52-2] DR ProteomicsDB; 78629; -. [Q9BQ52-3] DR ProteomicsDB; 78630; -. [Q9BQ52-4] DR Pumba; Q9BQ52; -. DR Antibodypedia; 13065; 203 antibodies from 30 providers. DR DNASU; 60528; -. DR Ensembl; ENST00000338034.9; ENSP00000337445.4; ENSG00000006744.20. [Q9BQ52-1] DR Ensembl; ENST00000426905.7; ENSP00000405223.3; ENSG00000006744.20. [Q9BQ52-4] DR GeneID; 60528; -. DR KEGG; hsa:60528; -. DR MANE-Select; ENST00000338034.9; ENSP00000337445.4; NM_018127.7; NP_060597.4. DR UCSC; uc002gnz.5; human. [Q9BQ52-1] DR AGR; HGNC:14198; -. DR ClinPGx; PA27739; -. DR CTD; 60528; -. DR DisGeNET; 60528; -. DR GeneCards; ELAC2; -. DR HGNC; HGNC:14198; ELAC2. DR HPA; ENSG00000006744; Low tissue specificity. DR MalaCards; ELAC2; -. DR MIM; 176807; phenotype. DR MIM; 605367; gene. DR MIM; 614731; phenotype. DR MIM; 615440; phenotype. DR OpenTargets; ENSG00000006744; -. DR Orphanet; 369913; Combined oxidative phosphorylation defect type 17. DR Orphanet; 1331; Familial prostate cancer. DR VEuPathDB; HostDB:ENSG00000006744; -. DR eggNOG; KOG2121; Eukaryota. DR GeneTree; ENSGT00730000111191; -. DR HOGENOM; CLU_006220_2_0_1; -. DR InParanoid; Q9BQ52; -. DR OMA; INYICQL; -. DR OrthoDB; 527344at2759; -. DR PAN-GO; Q9BQ52; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q9BQ52; -. DR BRENDA; 3.1.26.11; 2681. DR PathwayCommons; Q9BQ52; -. DR Reactome; R-HSA-6784531; tRNA processing in the nucleus. DR Reactome; R-HSA-6785470; tRNA processing in the mitochondrion. DR Reactome; R-HSA-8868766; rRNA processing in the mitochondrion. DR Reactome; R-HSA-9708296; tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis. DR SignaLink; Q9BQ52; -. DR Agora; ENSG00000006744; -. DR BioGRID-ORCS; 60528; 738 hits in 1175 CRISPR screens. DR CD-CODE; F701F3BC; PcG body. DR ChiTaRS; ELAC2; human. DR GeneWiki; ELAC2; -. DR GenomeRNAi; 60528; -. DR Pharos; Q9BQ52; Tbio. DR PRO; PR:Q9BQ52; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q9BQ52; protein. DR Bgee; ENSG00000006744; Expressed in adrenal tissue and 202 other cell types or tissues. DR ExpressionAtlas; Q9BQ52; baseline and differential. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005759; C:mitochondrial matrix; IDA:FlyBase. DR GO; GO:0042645; C:mitochondrial nucleoid; IDA:UniProtKB. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0042781; F:3'-tRNA processing endoribonuclease activity; IBA:GO_Central. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0003723; F:RNA binding; HDA:UniProtKB. DR GO; GO:0004521; F:RNA endonuclease activity; TAS:Reactome. DR GO; GO:0004549; F:tRNA-specific ribonuclease activity; EXP:Reactome. DR GO; GO:1990180; P:mitochondrial tRNA 3'-end processing; IMP:UniProtKB. DR GO; GO:0090646; P:mitochondrial tRNA processing; TAS:Reactome. DR GO; GO:0042780; P:tRNA 3'-end processing; TAS:Reactome. DR GO; GO:0016078; P:tRNA decay; TAS:Reactome. DR CDD; cd07718; RNaseZ_ELAC1_ELAC2-C-term-like_MBL-fold; 1. DR CDD; cd16296; RNaseZ_ELAC2-N-term-like_MBL-fold; 1. DR FunFam; 3.60.15.10:FF:000014; Zinc phosphodiesterase ELAC protein 2; 1. DR Gene3D; 3.60.15.10; Ribonuclease Z/Hydroxyacylglutathione hydrolase-like; 2. DR InterPro; IPR036866; RibonucZ/Hydroxyglut_hydro. DR InterPro; IPR047151; RNZ2-like. DR InterPro; IPR027794; tRNase_Z_dom. DR PANTHER; PTHR12553; ZINC PHOSPHODIESTERASE ELAC PROTEIN 2; 1. DR PANTHER; PTHR12553:SF49; ZINC PHOSPHODIESTERASE ELAC PROTEIN 2; 1. DR Pfam; PF23023; Anti-Pycsar_Apyc1; 1. DR Pfam; PF13691; Lactamase_B_4; 1. DR SUPFAM; SSF56281; Metallo-hydrolase/oxidoreductase; 2. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Disease variant; Endonuclease; KW Hydrolase; Metal-binding; Mitochondrion; Mitochondrion nucleoid; Nuclease; KW Nucleus; Phosphoprotein; Primary mitochondrial disease; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Transit peptide; tRNA processing; Zinc. FT TRANSIT 1..16 FT /note="Mitochondrion" FT /evidence="ECO:0000255" FT CHAIN 17..826 FT /note="Zinc phosphodiesterase ELAC protein 2" FT /id="PRO_0000155828" FT REGION 16..51 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 188..231 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 798..826 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 27..38 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 208..224 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 808..820 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 199 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 208 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 212 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 229 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 618 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 736 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..372 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_009168" FT VAR_SEQ 1..94 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_009169" FT VAR_SEQ 188..227 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_043449" FT VAR_SEQ 373..406 FT /note="NCASVHNLRSHKIQTQLNLIHPDIFPLLTSFRCK -> MRTVPQFTTFAATR FT FKPSSTSSTRTSSPCSPVSA (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_009170" FT VAR_SEQ 554..595 FT /note="GLPSILLQRERALASLGKPLHPLLVVAPNQLKAWLQQYHNQC -> VSVGLD FT HKAGAWRRHCHVELALWLRLFLRFQTCPELLLLISG (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_009171" FT VAR_SEQ 596..826 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_009172" FT VARIANT 52 FT /note="S -> F (in dbSNP:rs9895963)" FT /id="VAR_038210" FT VARIANT 154 FT /note="F -> L (in COXPD17; dbSNP:rs397515465)" FT /evidence="ECO:0000269|PubMed:23849775" FT /id="VAR_070844" FT VARIANT 211 FT /note="R -> Q (in HPC2; dbSNP:rs148419785)" FT /evidence="ECO:0000269|PubMed:11522646" FT /id="VAR_017425" FT VARIANT 217 FT /note="S -> L (in HPC2; risk factor for disease FT development; does not affect the enzymatic activity; FT dbSNP:rs4792311)" FT /evidence="ECO:0000269|PubMed:10986046, FT ECO:0000269|PubMed:11175785, ECO:0000269|PubMed:11522646, FT ECO:0000269|PubMed:12515253, ECO:0000269|PubMed:12522685, FT ECO:0000269|PubMed:12711671, ECO:0000269|PubMed:12783937, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:18987736, FT ECO:0000269|Ref.3" FT /id="VAR_017426" FT VARIANT 423 FT /note="L -> F (in COXPD17; dbSNP:rs397515466)" FT /evidence="ECO:0000269|PubMed:23849775" FT /id="VAR_070845" FT VARIANT 436 FT /note="D -> N (in dbSNP:rs3760317)" FT /id="VAR_038211" FT VARIANT 487 FT /note="G -> R (in HPC2; dbSNP:rs752234492)" FT /evidence="ECO:0000269|PubMed:11522646" FT /id="VAR_017427" FT VARIANT 520 FT /note="T -> I (in COXPD17; dbSNP:rs397515463)" FT /evidence="ECO:0000269|PubMed:23849775" FT /id="VAR_070846" FT VARIANT 541 FT /note="A -> T (in HPC2; risk factor for disease FT development; does not affect the enzymatic activity; FT dbSNP:rs5030739)" FT /evidence="ECO:0000269|PubMed:10986046, FT ECO:0000269|PubMed:11175785, ECO:0000269|PubMed:11522646, FT ECO:0000269|PubMed:12515253, ECO:0000269|PubMed:12522685, FT ECO:0000269|PubMed:12711671, ECO:0000269|PubMed:12783937" FT /id="VAR_017428" FT VARIANT 622 FT /note="E -> V (in HPC2; higher frequency in prostate cancer FT cases; dbSNP:rs119484087)" FT /evidence="ECO:0000269|PubMed:11507049" FT /id="VAR_017429" FT VARIANT 627 FT /note="S -> L (in dbSNP:rs78105154)" FT /evidence="ECO:0000269|PubMed:12949798" FT /id="VAR_017430" FT VARIANT 781 FT /note="R -> H (in HPC2; does not affect the enzymatic FT activity; dbSNP:rs119484086)" FT /evidence="ECO:0000269|PubMed:11175785, FT ECO:0000269|PubMed:12711671" FT /id="VAR_017431" FT VARIANT 806 FT /note="G -> R (in HPC2; dbSNP:rs770669443)" FT /evidence="ECO:0000269|PubMed:11522646" FT /id="VAR_017432" FT CONFLICT 165 FT /note="V -> M (in Ref. 2; AK001392)" FT /evidence="ECO:0000305" FT CONFLICT 406 FT /note="Missing (in Ref. 2; AK001392)" FT /evidence="ECO:0000305" FT CONFLICT 592 FT /note="H -> Y (in Ref. 2; AK001392)" FT /evidence="ECO:0000305" FT CONFLICT 754 FT /note="F -> L (in Ref. 2; AK001392)" FT /evidence="ECO:0000305" FT HELIX 38..46 FT /evidence="ECO:0007829|PDB:9EY0" FT TURN 47..49 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 58..65 FT /evidence="ECO:0007829|PDB:9EY0" FT TURN 68..70 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 72..80 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 82..85 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 91..97 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 102..104 FT /evidence="ECO:0007829|PDB:9EY2" FT STRAND 107..109 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 111..114 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 115..118 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 121..131 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 134..141 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 144..155 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 161..167 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 176..186 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 239..247 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 256..262 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 268..270 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 272..279 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 284..286 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 289..291 FT /evidence="ECO:0007829|PDB:9EY0" FT TURN 293..296 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 305..310 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 314..316 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 317..321 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 324..330 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 333..335 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 338..343 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 346..349 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 352..360 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 365..369 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 380..392 FT /evidence="ECO:0007829|PDB:9EY0" FT TURN 394..396 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 416..418 FT /evidence="ECO:0007829|PDB:9EY2" FT STRAND 424..429 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 432..434 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 443..451 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 453..455 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 456..468 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 481..487 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 489..492 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 495..497 FT /evidence="ECO:0007829|PDB:8Z0P" FT STRAND 499..507 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 510..514 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 520..528 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 529..531 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 532..537 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 539..543 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 546..548 FT /evidence="ECO:0007829|PDB:8Z0P" FT HELIX 549..552 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 555..569 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 576..580 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 584..594 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 599..601 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 602..608 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 619..632 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 634..639 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 643..647 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 651..655 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 660..663 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 671..676 FT /evidence="ECO:0007829|PDB:9EY0" FT TURN 677..679 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 681..686 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 691..693 FT /evidence="ECO:0007829|PDB:8RR1" FT HELIX 694..700 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 705..715 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 720..723 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 729..731 FT /evidence="ECO:0007829|PDB:9EY0" FT TURN 740..742 FT /evidence="ECO:0007829|PDB:9EY2" FT STRAND 743..745 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 750..753 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 754..763 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 764..770 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 772..790 FT /evidence="ECO:0007829|PDB:9EY0" SQ SEQUENCE 826 AA; 92219 MW; 4AE701C755EC7339 CRC64; MWALCSLLRS AAGRTMSQGR TISQAPARRE RPRKDPLRHL RTREKRGPSG CSGGPNTVYL QVVAAGSRDS GAALYVFSEF NRYLFNCGEG VQRLMQEHKL KVARLDNIFL TRMHWSNVGG LSGMILTLKE TGLPKCVLSG PPQLEKYLEA IKIFSGPLKG IELAVRPHSA PEYEDETMTV YQIPIHSEQR RGKHQPWQSP ERPLSRLSPE RSSDSESNEN EPHLPHGVSQ RRGVRDSSLV VAFICKLHLK RGNFLVLKAK EMGLPVGTAA IAPIIAAVKD GKSITHEGRE ILAEELCTPP DPGAAFVVVE CPDESFIQPI CENATFQRYQ GKADAPVALV VHMAPASVLV DSRYQQWMER FGPDTQHLVL NENCASVHNL RSHKIQTQLN LIHPDIFPLL TSFRCKKEGP TLSVPMVQGE CLLKYQLRPR REWQRDAIIT CNPEEFIVEA LQLPNFQQSV QEYRRSAQDG PAPAEKRSQY PEIIFLGTGS AIPMKIRNVS ATLVNISPDT SLLLDCGEGT FGQLCRHYGD QVDRVLGTLA AVFVSHLHAD HHTGLPSILL QRERALASLG KPLHPLLVVA PNQLKAWLQQ YHNQCQEVLH HISMIPAKCL QEGAEISSPA VERLISSLLR TCDLEEFQTC LVRHCKHAFG CALVHTSGWK VVYSGDTMPC EALVRMGKDA TLLIHEATLE DGLEEEAVEK THSTTSQAIS VGMRMNAEFI MLNHFSQRYA KVPLFSPNFS EKVGVAFDHM KVCFGDFPTM PKLIPPLKAL FAGDIEEMEE RREKRELRQV RAALLSRELA GGLEDGEPQQ KRAHTEEPQA KKVRAQ // ID S39A6_HUMAN Reviewed; 755 AA. AC Q13433; B4DR49; B4E224; Q8IXR3; Q96HP5; DT 05-JUL-2005, integrated into UniProtKB/Swiss-Prot. DT 23-MAR-2010, sequence version 3. DT 28-JAN-2026, entry version 187. DE RecName: Full=Zinc transporter ZIP6 {ECO:0000305}; DE AltName: Full=Estrogen-regulated protein LIV-1; DE AltName: Full=Solute carrier family 39 member 6; DE AltName: Full=Zrt- and Irt-like protein 6; DE Short=ZIP-6; DE Flags: Precursor; GN Name=SLC39A6 {ECO:0000312|HGNC:HGNC:18607}; Synonyms=LIV1, ZIP6; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ASP-119. RA Green C., Morgan H.E.; RL Submitted (FEB-2001) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ASP-119. RC TISSUE=Teratocarcinoma, and Trachea; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16177791; DOI=10.1038/nature03983; RA Nusbaum C., Zody M.C., Borowsky M.L., Kamal M., Kodira C.D., Taylor T.D., RA Whittaker C.A., Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., RA Abouelleil A., Allen N.R., Anderson S., Bloom T., Bugalter B., Butler J., RA Cook A., DeCaprio D., Engels R., Garber M., Gnirke A., Hafez N., Hall J.L., RA Norman C.H., Itoh T., Jaffe D.B., Kuroki Y., Lehoczky J., Lui A., RA Macdonald P., Mauceli E., Mikkelsen T.S., Naylor J.W., Nicol R., Nguyen C., RA Noguchi H., O'Leary S.B., Piqani B., Smith C.L., Talamas J.A., Topham K., RA Totoki Y., Toyoda A., Wain H.M., Young S.K., Zeng Q., Zimmer A.R., RA Fujiyama A., Hattori M., Birren B.W., Sakaki Y., Lander E.S.; RT "DNA sequence and analysis of human chromosome 18."; RL Nature 437:551-555(2005). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASP-119. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND NUCLEOTIDE SEQUENCE RP [LARGE SCALE MRNA] OF 382-755 (ISOFORM 1). RC TISSUE=Eye, and Lymph; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP PROTEIN SEQUENCE OF 29-43. RX PubMed=15340161; DOI=10.1110/ps.04682504; RA Zhang Z., Henzel W.J.; RT "Signal peptide prediction based on analysis of experimentally verified RT cleavage sites."; RL Protein Sci. 13:2819-2824(2004). RN [7] RP INDUCTION. RX PubMed=2903103; DOI=10.1016/0303-7207(88)90105-0; RA Manning D.L., Daly R.J., Lord P.G., Kelly K.F., Green C.D.; RT "Effects of oestrogen on the expression of a 4.4 kb mRNA in the ZR-75-1 RT human breast cancer cell line."; RL Mol. Cell. Endocrinol. 59:205-212(1988). RN [8] RP FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, TOPOLOGY, TISSUE RP SPECIFICITY, AND GLYCOSYLATION. RX PubMed=12839489; DOI=10.1042/bj20030478; RA Taylor K.M., Morgan H.E., Johnson A., Hadley L.J., Nicholson R.I.; RT "Structure-function analysis of LIV-1, the breast cancer-associated protein RT that belongs to a new subfamily of zinc transporters."; RL Biochem. J. 375:51-59(2003). RN [9] RP FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, AND INDUCTION. RX PubMed=18272141; DOI=10.1016/j.brainres.2008.01.015; RA Chowanadisai W., Loennerdal B., Kelleher S.L.; RT "Zip6 (LIV-1) regulates zinc uptake in neuroblastoma cells under resting RT but not depolarizing conditions."; RL Brain Res. 1199:10-19(2008). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [12] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-67 AND ASN-241. RC TISSUE=Leukemic T-cell; RX PubMed=19349973; DOI=10.1038/nbt.1532; RA Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M., RA Schiess R., Aebersold R., Watts J.D.; RT "Mass-spectrometric identification and relative quantification of N-linked RT cell surface glycoproteins."; RL Nat. Biotechnol. 27:378-386(2009). RN [13] RP FUNCTION, AND TRANSPORTER ACTIVITY. RX PubMed=21422171; DOI=10.1084/jem.20100031; RA Yu M., Lee W.W., Tomar D., Pryshchep S., Czesnikiewicz-Guzik M., RA Lamar D.L., Li G., Singh K., Tian L., Weyand C.M., Goronzy J.J.; RT "Regulation of T cell receptor signaling by activation-induced zinc RT influx."; RL J. Exp. Med. 208:775-785(2011). RN [14] RP FUNCTION, PROTEOLYTIC CLEAVAGE, GLYCOSYLATION, AND INDUCTION. RX PubMed=23919497; DOI=10.1042/bj20130483; RA Hogstrand C., Kille P., Ackland M.L., Hiscox S., Taylor K.M.; RT "A mechanism for epithelial-mesenchymal transition and anoikis resistance RT in breast cancer triggered by zinc channel ZIP6 and STAT3 (signal RT transducer and activator of transcription 3)."; RL Biochem. J. 455:229-237(2013). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-471 AND SER-478, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [16] RP FUNCTION. RX PubMed=25143461; DOI=10.1093/molehr/gau066; RA Kong B.Y., Duncan F.E., Que E.L., Kim A.M., O'Halloran T.V., Woodruff T.K.; RT "Maternally-derived zinc transporters ZIP6 and ZIP10 drive the mammalian RT oocyte-to-egg transition."; RL Mol. Hum. Reprod. 20:1077-1089(2014). RN [17] RP INTERACTION WITH SLC39A10, FUNCTION, AND TRANSPORTER ACTIVITY. RX PubMed=27274087; DOI=10.1042/bcj20160388; RA Taylor K.M., Muraina I.A., Brethour D., Schmitt-Ulms G., Nimmanon T., RA Ziliotto S., Kille P., Hogstrand C.; RT "Zinc transporter ZIP10 forms a heteromer with ZIP6 which regulates RT embryonic development and cell migration."; RL Biochem. J. 473:2531-2544(2016). RN [18] RP INDUCTION, FUNCTION, AND TRANSPORTER ACTIVITY. RX PubMed=30552163; DOI=10.4049/jimmunol.1800689; RA Colomar-Carando N., Meseguer A., Company-Garrido I., Jutz S., RA Herrera-Fernandez V., Olvera A., Kiefer K., Brander C., Steinberger P., RA Vicente R.; RT "Zip6 Transporter Is an Essential Component of the Lymphocyte Activation RT Machinery."; RL J. Immunol. 202:441-450(2019). RN [19] RP FUNCTION, AND IDENTIFICATION IN A COMPLEX WITH SLC39A10 AND STAT3. RX PubMed=32797246; DOI=10.1007/s00018-020-03616-6; RA Nimmanon T., Ziliotto S., Ogle O., Burt A., Gee J.M.W., Andrews G.K., RA Kille P., Hogstrand C., Maret W., Taylor K.M.; RT "The ZIP6/ZIP10 heteromer is essential for the zinc-mediated trigger of RT mitosis."; RL Cell. Mol. Life Sci. 78:1781-1798(2021). RN [20] RP FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, AND PHOSPHORYLATION. RX PubMed=34394081; DOI=10.3389/fimmu.2021.687367; RA Kim B., Kim H.Y., Lee W.W.; RT "Zap70 Regulates TCR-Mediated Zip6 Activation at the Immunological RT Synapse."; RL Front. Immunol. 12:687367-687367(2021). CC -!- FUNCTION: Zinc-influx transporter which plays a role in zinc CC homeostasis and in the induction of epithelial-to-mesenchymal CC transition (EMT) (PubMed:12839489, PubMed:18272141, PubMed:21422171, CC PubMed:23919497, PubMed:27274087, PubMed:34394081). When associated CC with SLC39A10, the heterodimer formed by SLC39A10 and SLC39A6 mediates CC cellular zinc uptake to trigger cells to undergo epithelial- to- CC mesenchymal transition (EMT) (PubMed:27274087). The SLC39A10-SLC39A6 CC heterodimer also controls NCAM1 phosphorylation and its integration CC into focal adhesion complexes during EMT (By similarity). Zinc influx CC inactivates GSK3B, enabling unphosphorylated SNAI1 in the nucleus to CC down-regulate adherence genes such as CDH1, causing loss of cell CC adherence (PubMed:23919497). In addition, the SLC39A10-SLC39A6 CC heterodimer plays an essentiel role in initiating mitosis by importing CC zinc into cells to initiate a pathway resulting in the onset of mitosis CC (PubMed:32797246). Participates in the T-cell receptor signaling CC regulation by mediating cellular zinc uptake into activated lymphocytes CC (PubMed:21422171, PubMed:30552163, PubMed:34394081). Regulates the zinc CC influx necessary for proper meiotic progression to metaphase II (MII) CC that allows the oocyte-to-egg transition (PubMed:25143461). CC {ECO:0000250|UniProtKB:Q8C145, ECO:0000269|PubMed:12839489, CC ECO:0000269|PubMed:18272141, ECO:0000269|PubMed:21422171, CC ECO:0000269|PubMed:23919497, ECO:0000269|PubMed:25143461, CC ECO:0000269|PubMed:27274087, ECO:0000269|PubMed:30552163, CC ECO:0000269|PubMed:32797246, ECO:0000269|PubMed:34394081}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Zn(2+)(in) = Zn(2+)(out); Xref=Rhea:RHEA:29351, CC ChEBI:CHEBI:29105; Evidence={ECO:0000269|PubMed:12839489, CC ECO:0000269|PubMed:18272141, ECO:0000269|PubMed:21422171, CC ECO:0000269|PubMed:27274087, ECO:0000269|PubMed:30552163, CC ECO:0000269|PubMed:34394081}; CC -!- SUBUNIT: Interacts with SLC39A10; which triggers cells to undergo EMT CC and mitosis (PubMed:27274087). Found in a complex with SLC39A6, CC SLC39A10 and with the 'Ser-727' phosphorylated form of STAT3 throughout CC mitosis (PubMed:32797246). Found in a complex with SLC39A6, SLC39A10 CC and with NCAM1; this complex controls NCAM1 phosphorylation and CC integration into focal adhesion complexes during epithelial-to- CC mesenchymal transition (EMT) (By similarity). Found in a complex with CC SLC39A6, SLC39A10 and with GSK3B that controls NCAM1 phosphorylation CC (By similarity). {ECO:0000250|UniProtKB:Q8C145, CC ECO:0000269|PubMed:27274087, ECO:0000269|PubMed:32797246}. CC -!- INTERACTION: CC Q13433-2; Q92843: BCL2L2; NbExp=3; IntAct=EBI-12956703, EBI-707714; CC Q13433-2; Q86VR2: RETREG3; NbExp=3; IntAct=EBI-12956703, EBI-10192441; CC Q13433-2; Q3KNW5: SLC10A6; NbExp=3; IntAct=EBI-12956703, EBI-18159983; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18272141}; CC Multi-pass membrane protein {ECO:0000255}. Cell projection, CC lamellipodium membrane {ECO:0000269|PubMed:12839489}; Multi-pass CC membrane protein {ECO:0000269|PubMed:12839489}. Membrane raft CC {ECO:0000269|PubMed:34394081}; Multi-pass membrane protein CC {ECO:0000255}. Apical cell membrane {ECO:0000250|UniProtKB:Q4V887}. CC Note=Localizes to lipid rafts in T cells and is recruited into the CC immunological synapse in response to TCR stimulation (PubMed:34394081). CC In the choroid plexus is limited to the apical membrane in epithelial CC cells (By similarity). {ECO:0000250|UniProtKB:Q4V887, CC ECO:0000269|PubMed:34394081}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q13433-1; Sequence=Displayed; CC Name=2; CC IsoId=Q13433-2; Sequence=VSP_014309, VSP_014310, VSP_014311; CC -!- TISSUE SPECIFICITY: Highly expressed in the breast, prostate, placenta, CC kidney, pituitary and corpus callosum (PubMed:12839489). Weakly CC expressed in heart and intestine. Also highly expressed in cells CC derived from an adenocarcinoma of the cervix and lung carcinoma CC (PubMed:12839489). {ECO:0000269|PubMed:12839489}. CC -!- INDUCTION: Up-regulated by estrogen in breast cancer cells lines CC (PubMed:23919497, PubMed:2903103). Decreased protein level in response CC to zinc treatment (PubMed:18272141). Increased upon T cell activation CC (PubMed:30552163). Induced by STAT3 (PubMed:23919497). CC {ECO:0000269|PubMed:18272141, ECO:0000269|PubMed:23919497, CC ECO:0000269|PubMed:2903103, ECO:0000269|PubMed:30552163}. CC -!- PTM: Cleaved on the N-terminus before locating to the plasma membrane. CC {ECO:0000269|PubMed:23919497}. CC -!- PTM: N-glycosylated. {ECO:0000269|PubMed:12839489, CC ECO:0000269|PubMed:19349973, ECO:0000269|PubMed:23919497}. CC -!- PTM: Phosphorylated by ZAP70 in response to TCR stimulation leading to CC its activation. {ECO:0000269|PubMed:34394081}. CC -!- SIMILARITY: Belongs to the ZIP transporter (TC 2.A.5) family. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAG61161.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/44189/SLC39A6"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U41060; AAA96258.2; -; mRNA. DR EMBL; AK299102; BAG61161.1; ALT_INIT; mRNA. DR EMBL; AK304079; BAG64986.1; -; mRNA. DR EMBL; AC091060; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471088; EAX01372.1; -; Genomic_DNA. DR EMBL; BC008317; AAH08317.2; -; mRNA. DR EMBL; BC039498; AAH39498.1; -; mRNA. DR CCDS; CCDS42428.1; -. [Q13433-1] DR CCDS; CCDS45854.1; -. [Q13433-2] DR PIR; G02273; G02273. DR RefSeq; NP_001092876.1; NM_001099406.2. [Q13433-2] DR AlphaFoldDB; Q13433; -. DR BioGRID; 117332; 184. DR FunCoup; Q13433; 1178. DR IntAct; Q13433; 82. DR MINT; Q13433; -. DR STRING; 9606.ENSP00000269187; -. DR ChEMBL; CHEMBL4523581; -. DR DrugBank; DB14533; Zinc chloride. DR DrugBank; DB14548; Zinc sulfate, unspecified form. DR MEROPS; X40.001; -. DR TCDB; 2.A.5.4.13; the zinc (zn(2+))-iron (fe(2+)) permease (zip) family. DR GlyConnect; 1908; 8 N-Linked glycans (3 sites). DR GlyCosmos; Q13433; 7 sites, 10 glycans. DR GlyGen; Q13433; 22 sites, 15 N-linked glycans (4 sites), 4 O-linked glycans (15 sites). DR iPTMnet; Q13433; -. DR PhosphoSitePlus; Q13433; -. DR SwissPalm; Q13433; -. DR BioMuta; SLC39A6; -. DR DMDM; 292495066; -. DR jPOST; Q13433; -. DR MassIVE; Q13433; -. DR PaxDb; 9606-ENSP00000269187; -. DR PeptideAtlas; Q13433; -. DR ProteomicsDB; 59428; -. [Q13433-1] DR ProteomicsDB; 59429; -. [Q13433-2] DR Pumba; Q13433; -. DR ABCD; Q13433; 1 sequenced antibody. DR Antibodypedia; 5245; 295 antibodies from 38 providers. DR DNASU; 25800; -. DR Ensembl; ENST00000269187.10; ENSP00000269187.4; ENSG00000141424.13. [Q13433-1] DR Ensembl; ENST00000440549.6; ENSP00000401139.1; ENSG00000141424.13. [Q13433-2] DR Ensembl; ENST00000590986.5; ENSP00000465915.1; ENSG00000141424.13. [Q13433-1] DR GeneID; 25800; -. DR KEGG; hsa:25800; -. DR MANE-Select; ENST00000269187.10; ENSP00000269187.4; NM_012319.4; NP_036451.4. DR UCSC; uc002kzj.3; human. [Q13433-1] DR AGR; HGNC:18607; -. DR ClinPGx; PA134905551; -. DR CTD; 25800; -. DR DisGeNET; 25800; -. DR GeneCards; SLC39A6; -. DR HGNC; HGNC:18607; SLC39A6. DR HPA; ENSG00000141424; Low tissue specificity. DR MIM; 608731; gene. DR OpenTargets; ENSG00000141424; -. DR VEuPathDB; HostDB:ENSG00000141424; -. DR eggNOG; KOG2693; Eukaryota. DR GeneTree; ENSGT00940000156387; -. DR HOGENOM; CLU_015114_13_2_1; -. DR InParanoid; Q13433; -. DR OMA; LLMSHGM; -. DR OrthoDB; 200954at2759; -. DR PAN-GO; Q13433; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q13433; -. DR PathwayCommons; Q13433; -. DR Reactome; R-HSA-442380; Zinc influx into cells by the SLC39 gene family. DR SignaLink; Q13433; -. DR Agora; ENSG00000141424; -. DR BioGRID-ORCS; 25800; 15 hits in 1165 CRISPR screens. DR ChiTaRS; SLC39A6; human. DR GeneWiki; SLC39A6; -. DR GenomeRNAi; 25800; -. DR Pharos; Q13433; Tbio. DR PRO; PR:Q13433; -. DR Proteomes; UP000005640; Chromosome 18. DR RNAct; Q13433; protein. DR Bgee; ENSG00000141424; Expressed in secondary oocyte and 210 other cell types or tissues. DR ExpressionAtlas; Q13433; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; ISS:UniProtKB. DR GO; GO:0009986; C:cell surface; HDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IEA:Ensembl. DR GO; GO:0031258; C:lamellipodium membrane; IDA:UniProtKB. DR GO; GO:0045121; C:membrane raft; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0140410; F:monoatomic cation:bicarbonate symporter activity; IBA:GO_Central. DR GO; GO:0005385; F:zinc ion transmembrane transporter activity; IDA:UniProtKB. DR GO; GO:0001837; P:epithelial to mesenchymal transition; IDA:UniProtKB. DR GO; GO:0030003; P:intracellular monoatomic cation homeostasis; IBA:GO_Central. DR GO; GO:0006882; P:intracellular zinc ion homeostasis; IDA:BHF-UCL. DR GO; GO:0046649; P:lymphocyte activation; IMP:UniProtKB. DR GO; GO:0050852; P:T cell receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0071578; P:zinc ion import across plasma membrane; IDA:UniProtKB. DR GO; GO:0071577; P:zinc ion transmembrane transport; IMP:UniProtKB. DR InterPro; IPR003689; ZIP. DR InterPro; IPR050799; ZIP_Transporter. DR PANTHER; PTHR12191; SOLUTE CARRIER FAMILY 39; 1. DR PANTHER; PTHR12191:SF22; ZINC TRANSPORTER ZIP6; 1. DR Pfam; PF02535; Zip; 2. PE 1: Evidence at protein level; KW Alternative splicing; Cell membrane; Cell projection; Coiled coil; KW Direct protein sequencing; Glycoprotein; Ion transport; Membrane; KW Phosphoprotein; Proteomics identification; Reference proteome; Signal; KW Transmembrane; Transmembrane helix; Transport; Zinc; Zinc transport. FT SIGNAL 1..28 FT /evidence="ECO:0000269|PubMed:15340161" FT CHAIN 29..755 FT /note="Zinc transporter ZIP6" FT /id="PRO_0000041650" FT TOPO_DOM 29..325 FT /note="Extracellular" FT /evidence="ECO:0000269|PubMed:12839489" FT TRANSMEM 326..346 FT /note="Helical; Name=1" FT /evidence="ECO:0000255" FT TOPO_DOM 347..355 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 356..376 FT /note="Helical; Name=2" FT /evidence="ECO:0000255" FT TOPO_DOM 377..423 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 424..444 FT /note="Helical; Name=3" FT /evidence="ECO:0000255" FT TOPO_DOM 445..657 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 658..678 FT /note="Helical; Name=4" FT /evidence="ECO:0000255" FT TOPO_DOM 679..686 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 687..707 FT /note="Helical; Name=5" FT /evidence="ECO:0000255" FT TOPO_DOM 708..724 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 725..745 FT /note="Helical; Name=6" FT /evidence="ECO:0000255" FT TOPO_DOM 746..755 FT /note="Extracellular" FT /evidence="ECO:0000269|PubMed:12839489" FT REGION 95..186 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 202..246 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 464..480 FT /evidence="ECO:0000255" FT COMPBIAS 95..128 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 129..144 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 145..159 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 167..179 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 219..234 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 471 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 478 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CARBOHYD 67 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973" FT CARBOHYD 241 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973" FT CARBOHYD 266 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 283 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 684 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 1..275 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_014309" FT VAR_SEQ 707..708 FT /note="PE -> SF (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_014310" FT VAR_SEQ 709..755 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_014311" FT VARIANT 119 FT /note="E -> D (in dbSNP:rs1789528)" FT /evidence="ECO:0000269|PubMed:14702039, ECO:0000269|Ref.1, FT ECO:0000269|Ref.4" FT /id="VAR_059964" FT CONFLICT 127..132 FT /note="Missing (in Ref. 1; AAA96258)" FT /evidence="ECO:0000305" SQ SEQUENCE 755 AA; 85047 MW; 8BC1D02CA116DD25 CRC64; MARKLSVILI LTFALSVTNP LHELKAAAFP QTTEKISPNW ESGINVDLAI STRQYHLQQL FYRYGENNSL SVEGFRKLLQ NIGIDKIKRI HIHHDHDHHS DHEHHSDHER HSDHEHHSEH EHHSDHDHHS HHNHAASGKN KRKALCPDHD SDSSGKDPRN SQGKGAHRPE HASGRRNVKD SVSASEVTST VYNTVSEGTH FLETIETPRP GKLFPKDVSS STPPSVTSKS RVSRLAGRKT NESVSEPRKG FMYSRNTNEN PQECFNASKL LTSHGMGIQV PLNATEFNYL CPAIINQIDA RSCLIHTSEK KAEIPPKTYS LQIAWVGGFI AISIISFLSL LGVILVPLMN RVFFKFLLSF LVALAVGTLS GDAFLHLLPH SHASHHHSHS HEEPAMEMKR GPLFSHLSSQ NIEESAYFDS TWKGLTALGG LYFMFLVEHV LTLIKQFKDK KKKNQKKPEN DDDVEIKKQL SKYESQLSTN EEKVDTDDRT EGYLRADSQE PSHFDSQQPA VLEEEEVMIA HAHPQEVYNE YVPRGCKNKC HSHFHDTLGQ SDDLIHHHHD YHHILHHHHH QNHHPHSHSQ RYSREELKDA GVATLAWMVI MGDGLHNFSD GLAIGAAFTE GLSSGLSTSV AVFCHELPHE LGDFAVLLKA GMTVKQAVLY NALSAMLAYL GMATGIFIGH YAENVSMWIF ALTAGLFMYV ALVDMVPEML HNDASDHGCS RWGYFFLQNA GMLLGFGIML LISIFEHKIV FRINF // ID SMAD3_HUMAN Reviewed; 425 AA. AC P84022; A8K4B6; B7Z4Z5; B7Z6M9; B7Z9Q2; F5H383; O09064; O09144; O14510; AC O35273; Q92940; Q93002; Q9GKR4; DT 05-JUL-2004, integrated into UniProtKB/Swiss-Prot. DT 05-JUL-2004, sequence version 1. DT 28-JAN-2026, entry version 216. DE RecName: Full=SMAD family member 3 {ECO:0000312|HGNC:HGNC:6769}; DE Short=SMAD 3 {ECO:0000305}; DE Short=hSMAD3; DE AltName: Full=JV15-2; DE AltName: Full=Mothers against decapentaplegic homolog 3; DE Short=MAD homolog 3; DE Short=Mad3; DE Short=Mothers against DPP homolog 3; DE Short=hMAD-3; GN Name=SMAD3 {ECO:0000312|HGNC:HGNC:6769}; Synonyms=MADH3; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PHOSPHORYLATION. RC TISSUE=Placenta; RX PubMed=8774881; DOI=10.1038/383168a0; RA Zhang Y., Feng X.-H., Wu R.-Y., Derynck R.; RT "Receptor-associated Mad homologues synergize as effectors of the TGF-beta RT response."; RL Nature 383:168-172(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=8673135; DOI=10.1038/ng0796-347; RA Riggins G.J., Thiagalingam S., Rosenblum E., Weinstein C.L., Kern S.E., RA Hamilton S.R., Willson J.K.V., Markowitz S.D., Kinzler K.W., RA Vogelstein B.V.; RT "Mad-related genes in the human."; RL Nat. Genet. 13:347-349(1996). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RC TISSUE=Colon carcinoma; RX PubMed=9464505; DOI=10.1016/s0304-3835(97)00384-4; RA Arai T., Akiyama Y., Okabe S., Ando M., Endo M., Yuasa Y.; RT "Genomic structure of the human Smad3 gene and its infrequent alterations RT in colorectal cancers."; RL Cancer Lett. 122:157-163(1998). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Hagiwara K., Yang K., McMenamin M.G., Freeman A.H., Bennett W.P., RA Nagashima M., Minter A.R., Miyazono K., Takenoshita S., Harris C.C.; RL Submitted (SEP-1997) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2; 3 AND 4). RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16572171; DOI=10.1038/nature04601; RA Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K., RA Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K., RA FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N., RA Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S., RA Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K., RA DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J., RA Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E., RA Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B., RA Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R., RA O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B., RA Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S., RA Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.; RT "Analysis of the DNA sequence and duplication history of human chromosome RT 15."; RL Nature 440:671-675(2006). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Pancreas; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP INTERACTION WITH TGFBR1. RX PubMed=9311995; DOI=10.1093/emboj/16.17.5353; RA Nakao A., Imamura T., Souchelnytskyi S., Kawabata M., Ishisaki A., Oeda E., RA Tamaki K., Hanai J., Heldin C.H., Miyazono K., ten Dijke P.; RT "TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4."; RL EMBO J. 16:5353-5362(1997). RN [10] RP INTERACTION WITH ZFYVE9. RX PubMed=9865696; DOI=10.1016/s0092-8674(00)81701-8; RA Tsukazaki T., Chiang T.A., Davison A.F., Attisano L., Wrana J.L.; RT "SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor."; RL Cell 95:779-791(1998). RN [11] RP SUBUNIT. RX PubMed=9670020; DOI=10.1093/emboj/17.14.4056; RA Kawabata M., Inoue H., Hanyu A., Imamura T., Miyazono K.; RT "Smad proteins exist as monomers in vivo and undergo homo- and hetero- RT oligomerization upon activation by serine/threonine kinase receptors."; RL EMBO J. 17:4056-4065(1998). RN [12] RP PHOSPHORYLATION, AND INTERACTION WITH EP300. RX PubMed=9843571; DOI=10.1091/mbc.9.12.3309; RA Shen X., Hu P.P., Liberati N.T., Datto M.B., Frederick J.P., Wang X.F.; RT "TGF-beta-induced phosphorylation of Smad3 regulates its interaction with RT coactivator p300/CREB-binding protein."; RL Mol. Biol. Cell 9:3309-3319(1998). RN [13] RP INTERACTION WITH MECOM. RX PubMed=9665135; DOI=10.1038/27945; RA Kurokawa M., Mitani K., Irie K., Matsuyama T., Takahashi T., Chiba S., RA Yazaki Y., Matsumoto K., Hirai H.; RT "The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3."; RL Nature 394:92-96(1998). RN [14] RP IDENTIFICATION AS A COMPONENT OF THE SMAD3/SMAD4/JUN/FOS COMPLEX, RP INTERACTION WITH JUN AND FOS, DNA-BINDING, AND FUNCTION. RX PubMed=9732876; DOI=10.1038/29814; RA Zhang Y., Feng X.H., Derynck R.; RT "Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced RT transcription."; RL Nature 394:909-913(1998). RN [15] RP INTERACTION WITH ACVR1B, AND FUNCTION. RX PubMed=9892009; DOI=10.1210/mend.13.1.0218; RA Lebrun J.J., Takabe K., Chen Y., Vale W.; RT "Roles of pathway-specific and inhibitory Smads in activin receptor RT signaling."; RL Mol. Endocrinol. 13:15-23(1999). RN [16] RP INTERACTION WITH JUN IN THE SMAD3/SMAD4/JUN/FOS COMPLEX, DNA-BINDING, RP FUNCTION, AND MUTAGENESIS OF LYS-40; LYS-41; LYS-43; LYS-44 AND ARG-74. RX PubMed=10995748; DOI=10.1074/jbc.m004731200; RA Qing J., Zhang Y., Derynck R.; RT "Structural and functional characterization of the transforming growth RT factor-beta -induced Smad3/c-Jun transcriptional cooperativity."; RL J. Biol. Chem. 275:38802-38812(2000). RN [17] RP INTERACTION WITH DAB2. RX PubMed=11387212; DOI=10.1093/emboj/20.11.2789; RA Hocevar B.A., Smine A., Xu X.X., Howe P.H.; RT "The adaptor molecule Disabled-2 links the transforming growth factor beta RT receptors to the Smad pathway."; RL EMBO J. 20:2789-2801(2001). RN [18] RP INTERACTION WITH SNW1. RX PubMed=11278756; DOI=10.1074/jbc.m010815200; RA Leong G.M., Subramaniam N., Figueroa J., Flanagan J.L., Hayman M.J., RA Eisman J.A., Kouzmenko A.P.; RT "Ski-interacting protein interacts with Smad proteins to augment RT transforming growth factor-beta-dependent transcription."; RL J. Biol. Chem. 276:18243-18248(2001). RN [19] RP INTERACTION WITH TGIF2. RX PubMed=11427533; DOI=10.1074/jbc.m103377200; RA Melhuish T.A., Gallo C.M., Wotton D.; RT "TGIF2 interacts with histone deacetylase 1 and represses transcription."; RL J. Biol. Chem. 276:32109-32114(2001). RN [20] RP SUBUNIT, PHOSPHORYLATION, AND MUTAGENESIS OF 422-SER--SER-425. RX PubMed=11224571; DOI=10.1038/84995; RA Chacko B.M., Qin B., Correia J.J., Lam S.S., de Caestecker M.P., Lin K.; RT "The L3 loop and C-terminal phosphorylation jointly define Smad protein RT trimerization."; RL Nat. Struct. Biol. 8:248-253(2001). RN [21] RP INTERACTION WITH MEN1. RX PubMed=11274402; DOI=10.1073/pnas.061358098; RA Kaji H., Canaff L., Lebrun J.J., Goltzman D., Hendy G.N.; RT "Inactivation of menin, a Smad3-interacting protein, blocks transforming RT growth factor type beta signaling."; RL Proc. Natl. Acad. Sci. U.S.A. 98:3837-3842(2001). RN [22] RP INTERACTION WITH ZNF8. RX PubMed=12370310; DOI=10.1128/mcb.22.21.7633-7644.2002; RA Jiao K., Zhou Y., Hogan B.L.M.; RT "Identification of mZnf8, a mouse Kruppel-like transcriptional repressor, RT as a novel nuclear interaction partner of Smad1."; RL Mol. Cell. Biol. 22:7633-7644(2002). RN [23] RP INTERACTION WITH DACH1. RX PubMed=14525983; DOI=10.1074/jbc.m310021200; RA Wu K., Yang Y., Wang C., Davoli M.A., D'Amico M., Li A., Cveklova K., RA Kozmik Z., Lisanti M.P., Russell R.G., Cvekl A., Pestell R.G.; RT "DACH1 inhibits transforming growth factor-beta signaling through binding RT Smad4."; RL J. Biol. Chem. 278:51673-51684(2003). RN [24] RP IDENTIFICATION IN A COMPLEX WITH NEDD9 AND ITCH, AND INTERACTION WITH RP NEDD9. RX PubMed=15051726; DOI=10.1074/jbc.m403221200; RA Feng L., Guedes S., Wang T.; RT "Atrophin-1-interacting protein 4/human Itch is a ubiquitin E3 ligase for RT human enhancer of filamentation 1 in transforming growth factor-beta RT signaling pathways."; RL J. Biol. Chem. 279:29681-29690(2004). RN [25] RP PHOSPHORYLATION AT THR-8; THR-179; SER-204; SER-208 AND SER-213, FUNCTION, RP AND MUTAGENESIS OF THR-8; THR-179; SER-204; SER-208 AND SER-213. RX PubMed=15241418; DOI=10.1038/nature02650; RA Matsuura I., Denissova N.G., Wang G., He D., Long J., Liu F.; RT "Cyclin-dependent kinases regulate the antiproliferative function of RT Smads."; RL Nature 430:226-231(2004). RN [26] RP TRANSCRIPTIONAL ACTIVATION DOMAIN, FUNCTION, PHOSPHORYLATION, SUBUNIT, AND RP INTERACTION WITH EP300. RX PubMed=15588252; DOI=10.1042/bj20041820; RA Wang G., Long J., Matsuura I., He D., Liu F.; RT "The Smad3 linker region contains a transcriptional activation domain."; RL Biochem. J. 386:29-34(2005). RN [27] RP PHOSPHORYLATION AT THR-179; SER-204 AND SER-208, SUBCELLULAR LOCATION, RP FUNCTION, AND MUTAGENESIS OF THR-179; SER-204 AND SER-208. RX PubMed=16156666; DOI=10.1021/bi050560g; RA Matsuura I., Wang G., He D., Liu F.; RT "Identification and characterization of ERK MAP kinase phosphorylation RT sites in Smad3."; RL Biochemistry 44:12546-12553(2005). RN [28] RP SUBCELLULAR LOCATION, AND INTERACTION WITH LEMD3. RX PubMed=15601644; DOI=10.1093/hmg/ddi040; RA Lin F., Morrison J.M., Wu W., Worman H.J.; RT "MAN1, an integral protein of the inner nuclear membrane, binds Smad2 and RT Smad3 and antagonizes transforming growth factor-beta signaling."; RL Hum. Mol. Genet. 14:437-445(2005). RN [29] RP INTERACTION WITH TGFB1I1. RX PubMed=15561701; DOI=10.1074/jbc.m411575200; RA Wang H., Song K., Sponseller T.L., Danielpour D.; RT "Novel function of androgen receptor-associated protein 55/Hic-5 as a RT negative regulator of Smad3 signaling."; RL J. Biol. Chem. 280:5154-5162(2005). RN [30] RP INTERACTION WITH LEMD3. RX PubMed=15647271; DOI=10.1074/jbc.m411234200; RA Pan D., Estevez-Salmeron L.D., Stroschein S.L., Zhu X., He J., Zhou S., RA Luo K.; RT "The integral inner nuclear membrane protein MAN1 physically interacts with RT the R-Smad proteins to repress signaling by the transforming growth RT factor-{beta} superfamily of cytokines."; RL J. Biol. Chem. 280:15992-16001(2005). RN [31] RP SUBUNIT, AND SUBCELLULAR LOCATION. RX PubMed=15799969; DOI=10.1074/jbc.m500362200; RA Chen H.B., Rud J.G., Lin K., Xu L.; RT "Nuclear targeting of transforming growth factor-beta-activated Smad RT complexes."; RL J. Biol. Chem. 280:21329-21336(2005). RN [32] RP INTERACTION WITH SKOR2. RX PubMed=16200078; DOI=10.1038/labinvest.3700344; RA Arndt S., Poser I., Schubert T., Moser M., Bosserhoff A.-K.; RT "Cloning and functional characterization of a new Ski homolog, Fussel-18, RT specifically expressed in neuronal tissues."; RL Lab. Invest. 85:1330-1341(2005). RN [33] RP INTERACTION WITH MECOM. RX PubMed=15897867; DOI=10.1038/sj.onc.1208754; RA Nitta E., Izutsu K., Yamaguchi Y., Imai Y., Ogawa S., Chiba S., RA Kurokawa M., Hirai H.; RT "Oligomerization of Evi-1 regulated by the PR domain contributes to RT recruitment of corepressor CtBP."; RL Oncogene 24:6165-6173(2005). RN [34] RP INTERACTION WITH PPM1A, DEPHOSPHORYLATION, FUNCTION, AND SUBCELLULAR RP LOCATION. RX PubMed=16751101; DOI=10.1016/j.cell.2006.03.044; RA Lin X., Duan X., Liang Y.Y., Su Y., Wrighton K.H., Long J., Hu M., RA Davis C.M., Wang J., Brunicardi F.C., Shi Y., Chen Y.G., Meng A., RA Feng X.H.; RT "PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling."; RL Cell 125:915-928(2006). RN [35] RP IDENTIFICATION IN A COMPLEX WITH SMAD2 AND TRIM33, AND INTERACTION WITH RP SMAD2 AND TRIM33. RX PubMed=16751102; DOI=10.1016/j.cell.2006.03.045; RA He W., Dorn D.C., Erdjument-Bromage H., Tempst P., Moore M.A., Massague J.; RT "Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the RT TGFbeta pathway."; RL Cell 125:929-941(2006). RN [36] RP INTERACTION WITH ZMIZ1. RX PubMed=16777850; DOI=10.1074/jbc.m508365200; RA Li X., Thyssen G., Beliakoff J., Sun Z.; RT "The novel PIAS-like protein hZimp10 enhances Smad transcriptional RT activity."; RL J. Biol. Chem. 281:23748-23756(2006). RN [37] RP IDENTIFICATION IN A COMPLEX WITH RAN AND XPO4, INTERACTION WITH XPO4, AND RP MUTAGENESIS OF 422-SER--SER-425. RX PubMed=16449645; DOI=10.1128/mcb.26.4.1318-1332.2006; RA Kurisaki A., Kurisaki K., Kowanetz M., Sugino H., Yoneda Y., Heldin C.-H., RA Moustakas A.; RT "The mechanism of nuclear export of Smad3 involves exportin 4 and Ran."; RL Mol. Cell. Biol. 26:1318-1332(2006). RN [38] RP INTERACTION WITH RBPMS. RX PubMed=17099224; DOI=10.1093/nar/gkl914; RA Sun Y., Ding L., Zhang H., Han J., Yang X., Yan J., Zhu Y., Li J., Song H., RA Ye Q.; RT "Potentiation of Smad-mediated transcriptional activation by the RNA- RT binding protein RBPMS."; RL Nucleic Acids Res. 34:6314-6326(2006). RN [39] RP FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION BY PDPK1, AND INTERACTION RP WITH PDPK1. RX PubMed=17327236; DOI=10.1074/jbc.m609279200; RA Seong H.A., Jung H., Kim K.T., Ha H.; RT "3-Phosphoinositide-dependent PDK1 negatively regulates transforming growth RT factor-beta-induced signaling in a kinase-dependent manner through physical RT interaction with Smad proteins."; RL J. Biol. Chem. 282:12272-12289(2007). RN [40] RP INTERACTION WITH SKOR1. RX PubMed=17292623; DOI=10.1016/j.mcn.2007.01.002; RA Arndt S., Poser I., Moser M., Bosserhoff A.-K.; RT "Fussel-15, a novel Ski/Sno homolog protein, antagonizes BMP signaling."; RL Mol. Cell. Neurosci. 34:603-611(2007). RN [41] RP ACETYLATION AT LYS-378, FUNCTION, AND MUTAGENESIS OF LYS-333; LYS-341; RP LYS-378; LYS-409 AND 422-SER--SER-425. RX PubMed=16862174; DOI=10.1038/sj.onc.1209826; RA Inoue Y., Itoh Y., Abe K., Okamoto T., Daitoku H., Fukamizu A., Onozaki K., RA Hayashi H.; RT "Smad3 is acetylated by p300/CBP to regulate its transactivation RT activity."; RL Oncogene 26:500-508(2007). RN [42] RP INTERACTION WITH WWTR1. RX PubMed=18568018; DOI=10.1038/ncb1748; RA Varelas X., Sakuma R., Samavarchi-Tehrani P., Peerani R., Rao B.M., RA Dembowy J., Yaffe M.B., Zandstra P.W., Wrana J.L.; RT "TAZ controls Smad nucleocytoplasmic shuttling and regulates human RT embryonic stem-cell self-renewal."; RL Nat. Cell Biol. 10:837-848(2008). RN [43] RP INTERACTION WITH SARS-COV NUCLEOPROTEIN (MICROBIAL INFECTION). RX PubMed=18055455; DOI=10.1074/jbc.m708033200; RA Zhao X., Nicholls J.M., Chen Y.G.; RT "Severe acute respiratory syndrome-associated coronavirus nucleocapsid RT protein interacts with Smad3 and modulates transforming growth factor-beta RT signaling."; RL J. Biol. Chem. 283:3272-3280(2008). RN [44] RP INTERACTION WITH CSNK1G2, UBIQUITINATION, PHOSPHORYLATION AT SER-418 BY RP CSNK1G2/CK1, AND MUTAGENESIS OF SER-418. RX PubMed=18794808; DOI=10.1038/onc.2008.337; RA Guo X., Waddell D.S., Wang W., Wang Z., Liberati N.T., Yong S., Liu X., RA Wang X.-F.; RT "Ligand-dependent ubiquitination of Smad3 is regulated by casein kinase 1 RT gamma 2, an inhibitor of TGF-beta signaling."; RL Oncogene 27:7235-7247(2008). RN [45] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-416, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [46] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [47] RP INTERACTION WITH RANBP3, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=19289081; DOI=10.1016/j.devcel.2009.01.022; RA Dai F., Lin X., Chang C., Feng X.H.; RT "Nuclear export of Smad2 and Smad3 by RanBP3 facilitates termination of RT TGF-beta signaling."; RL Dev. Cell 16:345-357(2009). RN [48] RP INTERACTION WITH PRDM16; SKI AND HDAC1. RX PubMed=19049980; DOI=10.1074/jbc.m808989200; RA Takahata M., Inoue Y., Tsuda H., Imoto I., Koinuma D., Hayashi M., RA Ichikura T., Yamori T., Nagasaki K., Yoshida M., Matsuoka M., Morishita K., RA Yuki K., Hanyu A., Miyazawa K., Inazawa J., Miyazono K., Imamura T.; RT "SKI and MEL1 cooperate to inhibit transforming growth factor-beta signal RT in gastric cancer cells."; RL J. Biol. Chem. 284:3334-3344(2009). RN [49] RP PHOSPHORYLATION AT THR-179; SER-204 AND SER-208, SUBCELLULAR LOCATION, RP FUNCTION, AND MUTAGENESIS OF THR-179; SER-204 AND SER-208. RX PubMed=19218245; DOI=10.1074/jbc.m809281200; RA Wang G., Matsuura I., He D., Liu F.; RT "Transforming growth factor-{beta}-inducible phosphorylation of Smad3."; RL J. Biol. Chem. 284:9663-9673(2009). RN [50] RP SUBCELLULAR LOCATION. RX PubMed=21145499; DOI=10.1016/j.devcel.2010.11.012; RA Varelas X., Samavarchi-Tehrani P., Narimatsu M., Weiss A., Cockburn K., RA Larsen B.G., Rossant J., Wrana J.L.; RT "The Crumbs complex couples cell density sensing to Hippo-dependent control RT of the TGF-beta-SMAD pathway."; RL Dev. Cell 19:831-844(2010). RN [51] RP INTERACTION WITH MTMR4. RX PubMed=20061380; DOI=10.1074/jbc.m109.075036; RA Yu J., Pan L., Qin X., Chen H., Xu Y., Chen Y., Tang H.; RT "MTMR4 attenuates transforming growth factor beta (TGFbeta) signaling by RT dephosphorylating R-Smads in endosomes."; RL J. Biol. Chem. 285:8454-8462(2010). RN [52] RP INTERACTION WITH PMEPA1. RX PubMed=20129061; DOI=10.1016/j.molcel.2009.10.028; RA Watanabe Y., Itoh S., Goto T., Ohnishi E., Inamitsu M., Itoh F., Satoh K., RA Wiercinska E., Yang W., Shi L., Tanaka A., Nakano N., Mommaas A.M., RA Shibuya H., Ten Dijke P., Kato M.; RT "TMEPAI, a transmembrane TGF-beta-inducible protein, sequesters Smad RT proteins from active participation in TGF-beta signaling."; RL Mol. Cell 37:123-134(2010). RN [53] RP INTERACTION WITH IL1F7. RX PubMed=20935647; DOI=10.1038/ni.1944; RA Nold M.F., Nold-Petry C.A., Zepp J.A., Palmer B.E., Bufler P., RA Dinarello C.A.; RT "IL-37 is a fundamental inhibitor of innate immunity."; RL Nat. Immunol. 11:1014-1022(2010). RN [54] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [55] RP UBIQUITINATION, DEUBIQUITINATION BY USP15, DNA-BINDING, INTERACTION WITH RP USP15, UBIQUITINATION AT LYS-33 AND LYS-81, AND MUTAGENESIS OF LYS-33; RP LYS-53 AND LYS-81. RX PubMed=21947082; DOI=10.1038/ncb2346; RA Inui M., Manfrin A., Mamidi A., Martello G., Morsut L., Soligo S., Enzo E., RA Moro S., Polo S., Dupont S., Cordenonsi M., Piccolo S.; RT "USP15 is a deubiquitylating enzyme for receptor-activated SMADs."; RL Nat. Cell Biol. 13:1368-1375(2011). RN [56] RP INTERACTION WITH PPP5C, AND SUBCELLULAR LOCATION. RX PubMed=22781750; DOI=10.1016/j.cellsig.2012.07.003; RA Bruce D.L., Macartney T., Yong W., Shou W., Sapkota G.P.; RT "Protein phosphatase 5 modulates SMAD3 function in the transforming growth RT factor-beta pathway."; RL Cell. Signal. 24:1999-2006(2012). RN [57] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [58] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-416, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [59] RP INTERACTION WITH STUB1; HSPA1A; HSPA1B; HSP90AA1 AND HSP90AB1, RP UBIQUITINATION, AND PROTEASOMAL DEGRADATION. RX PubMed=24613385; DOI=10.1016/j.bbrc.2014.02.124; RA Shang Y., Xu X., Duan X., Guo J., Wang Y., Ren F., He D., Chang Z.; RT "Hsp70 and Hsp90 oppositely regulate TGF-beta signaling through RT CHIP/Stub1."; RL Biochem. Biophys. Res. Commun. 446:387-392(2014). RN [60] RP INTERACTION WITH ZNF451, AND IDENTIFICATION IN A COMPLEX WITH ZNF451; SMAD2 RP AND SMAD4. RX PubMed=24324267; DOI=10.1074/jbc.m113.526905; RA Feng Y., Wu H., Xu Y., Zhang Z., Liu T., Lin X., Feng X.H.; RT "Zinc finger protein 451 is a novel Smad corepressor in transforming growth RT factor-beta signaling."; RL J. Biol. Chem. 289:2072-2083(2014). RN [61] RP INTERACTION WITH LDLRAD4. RX PubMed=24627487; DOI=10.1074/jbc.m114.558981; RA Nakano N., Maeyama K., Sakata N., Itoh F., Akatsu R., Nakata M., Katsu Y., RA Ikeno S., Togawa Y., Vo Nguyen T.T., Watanabe Y., Kato M., Itoh S.; RT "C18 ORF1, a novel negative regulator of transforming growth factor-beta RT signaling."; RL J. Biol. Chem. 289:12680-12692(2014). RN [62] RP INTERACTION WITH ZFHX3. RX PubMed=25105025; DOI=10.1155/2014/970346; RA Sakata N., Kaneko S., Ikeno S., Miura Y., Nakabayashi H., Dong X.Y., RA Dong J.T., Tamaoki T., Nakano N., Itoh S.; RT "TGF-beta signaling cooperates with AT motif-binding factor-1 for RT repression of the alpha -fetoprotein promoter."; RL J. Signal Transduct. 2014:970346-970346(2014). RN [63] RP ADP-RIBOSYLATION. RX PubMed=25133494; DOI=10.1371/journal.pone.0103651; RA Dahl M., Maturi V., Lonn P., Papoutsoglou P., Zieba A., Vanlandewijck M., RA van der Heide L.P., Watanabe Y., Soderberg O., Hottiger M.O., Heldin C.H., RA Moustakas A.; RT "Fine-tuning of Smad protein function by poly(ADP-ribose) polymerases and RT poly(ADP-ribose) glycohydrolase during transforming growth factor beta RT Signaling."; RL PLoS ONE 9:E103651-E103651(2014). RN [64] RP INTERACTION WITH NEDD9. RX PubMed=29899023; DOI=10.1126/scitranslmed.aap7294; RA Samokhin A.O., Stephens T., Wertheim B.M., Wang R.S., Vargas S.O., RA Yung L.M., Cao M., Brown M., Arons E., Dieffenbach P.B., Fewell J.G., RA Matar M., Bowman F.P., Haley K.J., Alba G.A., Marino S.M., Kumar R., RA Rosas I.O., Waxman A.B., Oldham W.M., Khanna D., Graham B.B., Seo S., RA Gladyshev V.N., Yu P.B., Fredenburgh L.E., Loscalzo J., Leopold J.A., RA Maron B.A.; RT "NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary RT arterial hypertension."; RL Sci. Transl. Med. 10:0-0(2018). RN [65] RP X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 1-144. RX PubMed=9741623; DOI=10.1016/s0092-8674(00)81600-1; RA Shi Y., Wang Y.-F., Jayaraman L., Yang H., Massague J., Pavletich N.P.; RT "Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA RT binding in TGF-beta signaling."; RL Cell 94:585-594(1998). RN [66] RP X-RAY CRYSTALLOGRAPHY (2.74 ANGSTROMS) OF 220-425 IN COMPLEX WITH ZFYVE9. RX PubMed=12154125; DOI=10.1101/gad.1002002; RA Qin B.Y., Lam S.S., Correia J.J., Lin K.; RT "Smad3 allostery links TGF-beta receptor kinase activation to RT transcriptional control."; RL Genes Dev. 16:1950-1963(2002). RN [67] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 1-144 IN COMPLEX WITH DNA, AND RP ZINC. RX PubMed=12686552; DOI=10.1074/jbc.c300134200; RA Chai J., Wu J.W., Yan N., Massague J., Pavletich N.P., Shi Y.; RT "Features of a Smad3 MH1-DNA complex. Roles of water and zinc in DNA RT binding."; RL J. Biol. Chem. 278:20327-20331(2003). RN [68] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 228-424 IN COMPLEX WITH SMAD4, AND RP SUBUNIT. RX PubMed=15350224; DOI=10.1016/j.molcel.2004.07.016; RA Chacko B.M., Qin B.Y., Tiwari A., Shi G., Lam S., Hayward L.J., RA De Caestecker M., Lin K.; RT "Structural basis of heteromeric smad protein assembly in TGF-beta RT signaling."; RL Mol. Cell 15:813-823(2004). RN [69] RP VARIANT [LARGE SCALE ANALYSIS] LEU-393, AND INVOLVEMENT IN COLORECTAL RP CANCER. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [70] RP VARIANTS LDS3 VAL-112; LYS-239 AND LYS-279. RX PubMed=21778426; DOI=10.1161/circresaha.111.248161; RA Regalado E.S., Guo D.C., Villamizar C., Avidan N., Gilchrist D., RA McGillivray B., Clarke L., Bernier F., Santos-Cortez R.L., Leal S.M., RA Bertoli-Avella A.M., Shendure J., Rieder M.J., Nickerson D.A., RA Milewicz D.M.; RT "Exome sequencing identifies SMAD3 mutations as a cause of familial RT thoracic aortic aneurysm and dissection with intracranial and other RT arterial aneurysms."; RL Circ. Res. 109:680-686(2011). RN [71] RP VARIANTS LDS3 ILE-261 AND TRP-287. RX PubMed=21217753; DOI=10.1038/ng.744; RA van de Laar I.M., Oldenburg R.A., Pals G., Roos-Hesselink J.W., RA de Graaf B.M., Verhagen J.M., Hoedemaekers Y.M., Willemsen R., RA Severijnen L.A., Venselaar H., Vriend G., Pattynama P.M., Collee M., RA Majoor-Krakauer D., Poldermans D., Frohn-Mulder I.M., Micha D., RA Timmermans J., Hilhorst-Hofstee Y., Bierma-Zeinstra S.M., Willems P.J., RA Kros J.M., Oei E.H., Oostra B.A., Wessels M.W., Bertoli-Avella A.M.; RT "Mutations in SMAD3 cause a syndromic form of aortic aneurysms and RT dissections with early-onset osteoarthritis."; RL Nat. Genet. 43:121-126(2011). CC -!- FUNCTION: Receptor-regulated SMAD (R-SMAD) that is an intracellular CC signal transducer and transcriptional modulator activated by TGF-beta CC (transforming growth factor) and activin type 1 receptor kinases. Binds CC the TRE element in the promoter region of many genes that are regulated CC by TGF-beta and, on formation of the SMAD3/SMAD4 complex, activates CC transcription. Also can form a SMAD3/SMAD4/JUN/FOS complex at the AP- CC 1/SMAD site to regulate TGF-beta-mediated transcription. Has an CC inhibitory effect on wound healing probably by modulating both growth CC and migration of primary keratinocytes and by altering the TGF-mediated CC chemotaxis of monocytes. This effect on wound healing appears to be CC hormone-sensitive. Regulator of chondrogenesis and osteogenesis and CC inhibits early healing of bone fractures. Positively regulates PDPK1 CC kinase activity by stimulating its dissociation from the 14-3-3 protein CC YWHAQ which acts as a negative regulator. {ECO:0000269|PubMed:10995748, CC ECO:0000269|PubMed:15241418, ECO:0000269|PubMed:15588252, CC ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:16751101, CC ECO:0000269|PubMed:16862174, ECO:0000269|PubMed:17327236, CC ECO:0000269|PubMed:19218245, ECO:0000269|PubMed:19289081, CC ECO:0000269|PubMed:9732876, ECO:0000269|PubMed:9892009}. CC -!- SUBUNIT: Monomer; in the absence of TGF-beta (PubMed:9670020). CC Homooligomer; in the presence of TGF-beta (PubMed:9670020). CC Heterotrimer; forms a heterotrimer in the presence of TGF-beta CC consisting of two molecules of C-terminally phosphorylated SMAD2 or CC SMAD3 and one of SMAD4 to form the transcriptionally active CC SMAD2/SMAD3-SMAD4 complex (PubMed:11224571, PubMed:15350224, CC PubMed:15799969, PubMed:9670020). Part of a complex consisting of CC MAGI2/ARIP1, ACVR2A, ACVR1B and SMAD3 (PubMed:9892009). Forms a complex CC with SMAD2 and TRIM33 upon addition of TGF-beta (PubMed:16751102). CC Found in a complex composed of SMAD3, RAN and XPO4; within the complex CC interacts directly with XPO4 (PubMed:16449645). Component of the CC multimeric complex SMAD3/SMAD4/JUN/FOS which forms at the AP1 promoter CC site; required for synergistic transcriptional activity in response to CC TGF-beta (PubMed:10995748, PubMed:9732876). Part of a ternary complex CC composed of SMAD3, ITCH/AIP4 and NEDD9/HEF1; within the complex CC NEDD9/HEF1 interacts (via N-terminus) with ITCH/AIP4; the complex CC mediates ubiquitination and proteasomal degradation of NEDD9/HEF1 CC (PubMed:15051726). Interacts with NEDD9; the interaction promotes NEDD9 CC ubiquitination and proteasomal degradation (PubMed:15051726). Interacts CC (via an N-terminal domain) with JUN (via its basic DNA binding and CC leucine zipper domains); this interaction is essential for DNA binding CC and cooperative transcriptional activity in response to TGF-beta CC (PubMed:10995748, PubMed:9732876). Identified in a complex that CC contains at least ZNF451, SMAD2, SMAD3 and SMAD4 (PubMed:24324267). CC Interacts with PPM1A; the interaction dephosphorylates SMAD3 in the C- CC terminal SXS motif leading to disruption of the SMAD2/3-SMAD4 complex, CC nuclear export and termination of TGF-beta signaling (PubMed:16751101). CC Interacts (via MH2 domain) with ZMIZ1 (via SP-RING-type domain); in the CC TGF-beta signaling pathway increases the activity of the SMAD3/SMAD4 CC transcriptional complex (PubMed:16777850). Interacts (when CC phosphorylated) with RNF111; RNF111 acts as an enhancer of the CC transcriptional responses by mediating ubiquitination and degradation CC of SMAD3 inhibitors (PubMed:9311995). Interacts (dephosphorylated form CC via the MH1 and MH2 domains) with RANBP3 (via its C-terminal R domain); CC the interaction results in the export of dephosphorylated SMAD3 out of CC the nucleus and termination of the TGF-beta signaling CC (PubMed:19289081). Interacts (via MH2 domain) with LEMD3; the CC interaction represses SMAD3 transcriptional activity through preventing CC the formation of the heteromeric complex with SMAD4 and translocation CC to the nucleus (PubMed:15601644, PubMed:15647271). Interacts (via the CC linker region) with EP300 (C-terminal); the interaction promotes SMAD3 CC acetylation and is enhanced by TGF-beta phosphorylation in the C- CC terminal of SMAD3 (PubMed:15588252, PubMed:9843571). This interaction CC can be blocked by competitive binding of adenovirus oncoprotein E1A to CC the same C-terminal site on EP300, which then results in partially CC inhibited SMAD3/SMAD4 transcriptional activity (PubMed:15588252, CC PubMed:9843571). Interacts with TGFBR1 (PubMed:9311995). Interacts with CC TGFB1I1 (PubMed:15561701). Interacts with PRDM16 (PubMed:19049980). CC Interacts with SNW1 (PubMed:11278756). Interacts (via MH2 domain) with CC ZFYVE9 (PubMed:12154125, PubMed:9865696). Interacts with HDAC1 CC (PubMed:19049980). Interacts with TGIF2 (PubMed:11427533). Interacts CC with SKOR1 (PubMed:17292623). Interacts with SKOR2 (PubMed:16200078). CC Interacts with DACH1; the interaction inhibits the TGF-beta signaling CC (PubMed:14525983). Interacts with RBPMS (PubMed:17099224). Interacts CC (via MH2 domain) with MECOM (PubMed:15897867, PubMed:9665135). CC Interacts with WWTR1 (via its coiled-coil domain) (PubMed:18568018). CC Interacts with SKI; the interaction represses SMAD3 transcriptional CC activity (PubMed:19049980). Interacts with MEN1 (PubMed:11274402). CC Interacts with IL1F7 (PubMed:20935647). Interaction with CSNK1G2 CC (PubMed:18794808). Interacts with PDPK1 (via PH domain) CC (PubMed:17327236). Interacts with DAB2; the interactions are enhanced CC upon TGF-beta stimulation (PubMed:11387212). Interacts with USP15 CC (PubMed:21947082). Interacts with PPP5C; the interaction decreases CC SMAD3 phosphorylation and protein levels (PubMed:22781750). Interacts CC with LDLRAD4 (via the SMAD interaction motif) (PubMed:24627487). CC Interacts with PMEPA1 (PubMed:20129061). Interacts with ZNF451 CC (PubMed:24324267). Interacts with ZFHX3 (PubMed:25105025). Interacts CC weakly with ZNF8 (PubMed:12370310). Interacts with STUB1, HSPA1A, CC HSPA1B, HSP90AA1 and HSP90AB1 (PubMed:24613385). Interacts with YAP1 CC (when phosphorylated at 'Ser-127') (By similarity). Interacts with CC MAGI2/ARIP1 (By similarity). Interacts (via MH2 domain) with CITED2 CC (via C-terminus) (By similarity). Interacts with HGS (By similarity). CC Interacts with WWP1 (By similarity). Interacts with TTRAP (By CC similarity). Interacts with FOXL2 (By similarity). Interacts with PML CC (By similarity). Interacts with NEDD4L; the interaction requires TGF- CC beta stimulation (By similarity). Interacts with ZC3H3 (By similarity). CC Interacts with TGIF. Interacts with CREBBP. Interacts with ATF2. CC Interacts with NEDD9; the interaction is inhibited by oxidation of CC NEDD9 (PubMed:29899023). Interacts with MTMR4; negatively regulates CC TGF-beta signaling through SMAD3 dephosphorylation and retention in CC endosomes (PubMed:20061380). {ECO:0000250|UniProtKB:P84025, CC ECO:0000250|UniProtKB:Q8BUN5, ECO:0000269|PubMed:10995748, CC ECO:0000269|PubMed:11224571, ECO:0000269|PubMed:11274402, CC ECO:0000269|PubMed:11278756, ECO:0000269|PubMed:11387212, CC ECO:0000269|PubMed:11427533, ECO:0000269|PubMed:12154125, CC ECO:0000269|PubMed:12370310, ECO:0000269|PubMed:14525983, CC ECO:0000269|PubMed:15051726, ECO:0000269|PubMed:15350224, CC ECO:0000269|PubMed:15561701, ECO:0000269|PubMed:15588252, CC ECO:0000269|PubMed:15601644, ECO:0000269|PubMed:15647271, CC ECO:0000269|PubMed:15799969, ECO:0000269|PubMed:15897867, CC ECO:0000269|PubMed:16200078, ECO:0000269|PubMed:16449645, CC ECO:0000269|PubMed:16751101, ECO:0000269|PubMed:16751102, CC ECO:0000269|PubMed:16777850, ECO:0000269|PubMed:17099224, CC ECO:0000269|PubMed:17292623, ECO:0000269|PubMed:17327236, CC ECO:0000269|PubMed:18568018, ECO:0000269|PubMed:18794808, CC ECO:0000269|PubMed:19049980, ECO:0000269|PubMed:19289081, CC ECO:0000269|PubMed:20061380, ECO:0000269|PubMed:20129061, CC ECO:0000269|PubMed:20935647, ECO:0000269|PubMed:21947082, CC ECO:0000269|PubMed:22781750, ECO:0000269|PubMed:24324267, CC ECO:0000269|PubMed:24613385, ECO:0000269|PubMed:24627487, CC ECO:0000269|PubMed:25105025, ECO:0000269|PubMed:29899023, CC ECO:0000269|PubMed:9311995, ECO:0000269|PubMed:9665135, CC ECO:0000269|PubMed:9670020, ECO:0000269|PubMed:9732876, CC ECO:0000269|PubMed:9843571, ECO:0000269|PubMed:9865696, CC ECO:0000269|PubMed:9892009}. CC -!- SUBUNIT: (Microbial infection) Interacts with SARS-CoV nucleoprotein. CC {ECO:0000269|PubMed:18055455}. CC -!- INTERACTION: CC P84022; P60709: ACTB; NbExp=3; IntAct=EBI-347161, EBI-353944; CC P84022; Q06481-5: APLP2; NbExp=3; IntAct=EBI-347161, EBI-25646567; CC P84022; P05067: APP; NbExp=3; IntAct=EBI-347161, EBI-77613; CC P84022; Q9H2G9: BLZF1; NbExp=9; IntAct=EBI-347161, EBI-2548012; CC P84022; Q9UQM7: CAMK2A; NbExp=3; IntAct=EBI-347161, EBI-1383687; CC P84022; P29466-3: CASP1; NbExp=3; IntAct=EBI-347161, EBI-12248206; CC P84022; E9PSE9: CCDC198; NbExp=3; IntAct=EBI-347161, EBI-11748295; CC P84022; Q8N5R6: CCDC33; NbExp=4; IntAct=EBI-347161, EBI-740841; CC P84022; Q9H2X0: CHRD; NbExp=2; IntAct=EBI-347161, EBI-947551; CC P84022; Q8N684: CPSF7; NbExp=3; IntAct=EBI-347161, EBI-746909; CC P84022; Q8N684-3: CPSF7; NbExp=3; IntAct=EBI-347161, EBI-11523759; CC P84022; O43186: CRX; NbExp=3; IntAct=EBI-347161, EBI-748171; CC P84022; Q96PZ7: CSMD1; NbExp=3; IntAct=EBI-347161, EBI-766158; CC P84022; P48730-2: CSNK1D; NbExp=3; IntAct=EBI-347161, EBI-9087876; CC P84022; P98082: DAB2; NbExp=3; IntAct=EBI-347161, EBI-1171238; CC P84022; P17844: DDX5; NbExp=2; IntAct=EBI-347161, EBI-351962; CC P84022; Q9BZ29: DOCK9; NbExp=3; IntAct=EBI-347161, EBI-2695893; CC P84022; Q86YD7: FAM90A1; NbExp=3; IntAct=EBI-347161, EBI-6658203; CC P84022; Q01543: FLI1; NbExp=3; IntAct=EBI-347161, EBI-2271018; CC P84022; O75593: FOXH1; NbExp=4; IntAct=EBI-347161, EBI-1759806; CC P84022; O43524: FOXO3; NbExp=5; IntAct=EBI-347161, EBI-1644164; CC P84022; P10070: GLI2; NbExp=4; IntAct=EBI-347161, EBI-10821567; CC P84022; Q16665: HIF1A; NbExp=6; IntAct=EBI-347161, EBI-447269; CC P84022; O15397: IPO8; NbExp=2; IntAct=EBI-347161, EBI-358808; CC P84022; Q8WXH2: JPH3; NbExp=3; IntAct=EBI-347161, EBI-1055254; CC P84022; P50222: MEOX2; NbExp=6; IntAct=EBI-347161, EBI-748397; CC P84022; Q9NYA4: MTMR4; NbExp=2; IntAct=EBI-347161, EBI-1052346; CC P84022; Q99836: MYD88; NbExp=3; IntAct=EBI-347161, EBI-447677; CC P84022; P46934-3: NEDD4; NbExp=3; IntAct=EBI-347161, EBI-11980721; CC P84022; Q16822: PCK2; NbExp=2; IntAct=EBI-347161, EBI-2825219; CC P84022; Q8IXK0: PHC2; NbExp=3; IntAct=EBI-347161, EBI-713786; CC P84022; Q8IXK0-5: PHC2; NbExp=3; IntAct=EBI-347161, EBI-11527347; CC P84022; P27986-2: PIK3R1; NbExp=3; IntAct=EBI-347161, EBI-9090282; CC P84022; Q9BZL4: PPP1R12C; NbExp=2; IntAct=EBI-347161, EBI-721802; CC P84022; P17612: PRKACA; NbExp=3; IntAct=EBI-347161, EBI-476586; CC P84022; P24158: PRTN3; NbExp=2; IntAct=EBI-347161, EBI-465028; CC P84022; P20618: PSMB1; NbExp=3; IntAct=EBI-347161, EBI-372273; CC P84022; Q96EP0: RNF31; NbExp=2; IntAct=EBI-347161, EBI-948111; CC P84022; P0C264: SBK3; NbExp=3; IntAct=EBI-347161, EBI-17181801; CC P84022; Q9BYW2: SETD2; NbExp=2; IntAct=EBI-347161, EBI-945869; CC P84022; P12755: SKI; NbExp=11; IntAct=EBI-347161, EBI-347281; CC P84022; Q15796: SMAD2; NbExp=3; IntAct=EBI-347161, EBI-1040141; CC P84022; P84022: SMAD3; NbExp=3; IntAct=EBI-347161, EBI-347161; CC P84022; Q13485: SMAD4; NbExp=43; IntAct=EBI-347161, EBI-347263; CC P84022; Q9HAU4: SMURF2; NbExp=8; IntAct=EBI-347161, EBI-396727; CC P84022; Q13573: SNW1; NbExp=5; IntAct=EBI-347161, EBI-632715; CC P84022; Q13501: SQSTM1; NbExp=3; IntAct=EBI-347161, EBI-307104; CC P84022; Q12772: SREBF2; NbExp=3; IntAct=EBI-347161, EBI-465059; CC P84022; Q05066: SRY; NbExp=3; IntAct=EBI-347161, EBI-464987; CC P84022; Q8WW24: TEKT4; NbExp=3; IntAct=EBI-347161, EBI-750487; CC P84022; Q15583: TGIF1; NbExp=3; IntAct=EBI-347161, EBI-714215; CC P84022; Q08117: TLE5; NbExp=4; IntAct=EBI-347161, EBI-717810; CC P84022; Q08117-2: TLE5; NbExp=3; IntAct=EBI-347161, EBI-11741437; CC P84022; Q9Y3Q8: TSC22D4; NbExp=2; IntAct=EBI-347161, EBI-739485; CC P84022; Q93009: USP7; NbExp=2; IntAct=EBI-347161, EBI-302474; CC P84022; Q9H0M0: WWP1; NbExp=9; IntAct=EBI-347161, EBI-742157; CC P84022; O00308: WWP2; NbExp=7; IntAct=EBI-347161, EBI-743923; CC P84022; Q5D1E8: ZC3H12A; NbExp=2; IntAct=EBI-347161, EBI-747793; CC P84022; O95405: ZFYVE9; NbExp=7; IntAct=EBI-347161, EBI-296817; CC P84022; Q6NX45: ZNF774; NbExp=3; IntAct=EBI-347161, EBI-10251462; CC P84022; P51141: Dvl1; Xeno; NbExp=2; IntAct=EBI-347161, EBI-1538407; CC P84022; Q64729: Tgfbr1; Xeno; NbExp=6; IntAct=EBI-347161, EBI-2899393; CC P84022; PRO_0000278742 [O92972]; Xeno; NbExp=6; IntAct=EBI-347161, EBI-9213553; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15799969, CC ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:16751101, CC ECO:0000269|PubMed:17327236, ECO:0000269|PubMed:19218245, CC ECO:0000269|PubMed:19289081, ECO:0000269|PubMed:21145499, CC ECO:0000269|PubMed:22781750}. Nucleus {ECO:0000269|PubMed:15601644, CC ECO:0000269|PubMed:15799969, ECO:0000269|PubMed:16156666, CC ECO:0000269|PubMed:16751101, ECO:0000269|PubMed:19218245, CC ECO:0000269|PubMed:19289081, ECO:0000269|PubMed:21145499, CC ECO:0000269|PubMed:22781750}. Note=Cytoplasmic and nuclear in the CC absence of TGF-beta. On TGF-beta stimulation, migrates to the nucleus CC when complexed with SMAD4 (PubMed:15799969, PubMed:21145499). Through CC the action of the phosphatase PPM1A, released from the SMAD2/SMAD4 CC complex, and exported out of the nucleus by interaction with RANBP1 CC (PubMed:16751101, PubMed:19289081). Co-localizes with LEMD3 at the CC nucleus inner membrane (PubMed:15601644). MAPK-mediated phosphorylation CC appears to have no effect on nuclear import (PubMed:19218245). PDPK1 CC prevents its nuclear translocation in response to TGF-beta CC (PubMed:17327236). Localized mainly to the nucleus in the early stages CC of embryo development with expression becoming evident in the cytoplasm CC of the inner cell mass at the blastocyst stage (By similarity). CC {ECO:0000250|UniProtKB:Q8BUN5, ECO:0000269|PubMed:15601644, CC ECO:0000269|PubMed:15799969, ECO:0000269|PubMed:16751101, CC ECO:0000269|PubMed:17327236, ECO:0000269|PubMed:19218245, CC ECO:0000269|PubMed:19289081, ECO:0000269|PubMed:21145499}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=P84022-1; Sequence=Displayed; CC Name=2; CC IsoId=P84022-2; Sequence=VSP_042900; CC Name=3; CC IsoId=P84022-3; Sequence=VSP_043793; CC Name=4; CC IsoId=P84022-4; Sequence=VSP_045348; CC -!- DOMAIN: The MH1 domain is required for DNA binding. Also binds zinc CC ions which are necessary for the DNA binding. CC -!- DOMAIN: The MH2 domain is required for both homomeric and heteromeric CC interactions and for transcriptional regulation. Sufficient for nuclear CC import. CC -!- DOMAIN: The linker region is required for the TGFbeta-mediated CC transcriptional activity and acts synergistically with the MH2 domain. CC -!- PTM: Phosphorylated on serine and threonine residues. Enhanced CC phosphorylation in the linker region on Thr-179, Ser-204 and Ser-208 on CC EGF and TGF-beta treatment. Ser-208 is the main site of MAPK-mediated CC phosphorylation. CDK-mediated phosphorylation occurs in a cell-cycle CC dependent manner and inhibits both the transcriptional activity and CC antiproliferative functions of SMAD3. This phosphorylation is inhibited CC by flavopiridol. Maximum phosphorylation at the G(1)/S junction. Also CC phosphorylated on serine residues in the C-terminal SXS motif by TGFBR1 CC and ACVR1. TGFBR1-mediated phosphorylation at these C-terminal sites is CC required for interaction with SMAD4, nuclear location and CC transactivational activity, and appears to be a prerequisite for the CC TGF-beta mediated phosphorylation in the linker region. CC Dephosphorylated in the C-terminal SXS motif by PPM1A. This CC dephosphorylation disrupts the interaction with SMAD4, promotes nuclear CC export and terminates TGF-beta-mediated signaling. Phosphorylation at CC Ser-418 by CSNK1G2/CK1 promotes ligand-dependent ubiquitination and CC subsequent proteasome degradation, thus inhibiting SMAD3-mediated TGF- CC beta responses. Phosphorylated by PDPK1. {ECO:0000269|PubMed:11224571, CC ECO:0000269|PubMed:15241418, ECO:0000269|PubMed:15588252, CC ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:17327236, CC ECO:0000269|PubMed:18794808, ECO:0000269|PubMed:19218245, CC ECO:0000269|PubMed:21947082, ECO:0000269|PubMed:8774881, CC ECO:0000269|PubMed:9843571}. CC -!- PTM: Acetylation in the nucleus by EP300 in the MH2 domain regulates CC positively its transcriptional activity and is enhanced by TGF-beta. CC {ECO:0000269|PubMed:16862174}. CC -!- PTM: Poly-ADP-ribosylated by PARP1 and PARP2. ADP-ribosylation CC negatively regulates SMAD3 transcriptional responses during the course CC of TGF-beta signaling. {ECO:0000269|PubMed:25133494}. CC -!- PTM: Ubiquitinated. Monoubiquitinated, leading to prevent DNA-binding CC (PubMed:21947082). Deubiquitination by USP15 alleviates inhibition and CC promotes activation of TGF-beta target genes (PubMed:21947082). CC Ubiquitinated by RNF111, leading to its degradation: only SMAD3 CC proteins that are 'in use' are targeted by RNF111, RNF111 playing a key CC role in activating SMAD3 and regulating its turnover (By similarity). CC Undergoes STUB1-mediated ubiquitination and degradation CC (PubMed:24613385). {ECO:0000250|UniProtKB:Q8BUN5, CC ECO:0000269|PubMed:21947082, ECO:0000269|PubMed:24613385}. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:16959974}. Note=The disease CC may be caused by variants affecting the gene represented in this entry. CC -!- DISEASE: Loeys-Dietz syndrome 3 (LDS3) [MIM:613795]: An aortic aneurysm CC syndrome with widespread systemic involvement. The disorder is CC characterized by the triad of arterial tortuosity and aneurysms, CC hypertelorism, and bifid uvula or cleft palate. Patients with LDS3 also CC manifest early-onset osteoarthritis. They lack craniosynostosis and CC intellectual disability. {ECO:0000269|PubMed:21217753, CC ECO:0000269|PubMed:21778426}. Note=The disease is caused by variants CC affecting the gene represented in this entry. SMAD3 mutations have been CC reported to be also associated with thoracic aortic aneurysms and CC dissection (TAAD) (PubMed:21778426). This phenotype is distinguised CC from LDS3 by having aneurysms restricted to thoracic aorta. As CC individuals carrying these mutations also exhibit aneurysms of other CC arteries, including abdominal aorta, iliac, and/or intracranial CC arteries (PubMed:21778426), they have been classified as LDS3 by the CC OMIM resource. {ECO:0000269|PubMed:21778426}. CC -!- SIMILARITY: Belongs to the dwarfin/SMAD family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U68019; AAB80960.1; -; mRNA. DR EMBL; U76622; AAB18967.1; -; mRNA. DR EMBL; AB004930; BAA22032.1; -; Genomic_DNA. DR EMBL; AF025300; AAL68976.1; -; Genomic_DNA. DR EMBL; AF025293; AAL68976.1; JOINED; Genomic_DNA. DR EMBL; AF025294; AAL68976.1; JOINED; Genomic_DNA. DR EMBL; AF025295; AAL68976.1; JOINED; Genomic_DNA. DR EMBL; AF025296; AAL68976.1; JOINED; Genomic_DNA. DR EMBL; AF025297; AAL68976.1; JOINED; Genomic_DNA. DR EMBL; AF025298; AAL68976.1; JOINED; Genomic_DNA. DR EMBL; AF025299; AAL68976.1; JOINED; Genomic_DNA. DR EMBL; AK290881; BAF83570.1; -; mRNA. DR EMBL; AK298139; BAH12731.1; -; mRNA. DR EMBL; AK300614; BAH13315.1; -; mRNA. DR EMBL; AK316017; BAH14388.1; -; mRNA. DR EMBL; AC012568; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC087482; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471082; EAW77788.1; -; Genomic_DNA. DR EMBL; BC050743; AAH50743.1; -; mRNA. DR CCDS; CCDS10222.1; -. [P84022-1] DR CCDS; CCDS45288.1; -. [P84022-2] DR CCDS; CCDS53950.1; -. [P84022-3] DR CCDS; CCDS53951.1; -. [P84022-4] DR PIR; S71798; S71798. DR RefSeq; NP_001138574.1; NM_001145102.2. [P84022-3] DR RefSeq; NP_001138575.1; NM_001145103.2. [P84022-2] DR RefSeq; NP_001138576.1; NM_001145104.2. [P84022-4] DR RefSeq; NP_001393945.1; NM_001407016.1. [P84022-3] DR RefSeq; NP_001393946.1; NM_001407017.1. [P84022-4] DR RefSeq; NP_005893.1; NM_005902.4. [P84022-1] DR RefSeq; XP_054233890.1; XM_054377915.1. [P84022-3] DR PDB; 1MHD; X-ray; 2.80 A; A/B=1-132. DR PDB; 1MJS; X-ray; 1.91 A; A=229-425. DR PDB; 1MK2; X-ray; 2.74 A; A=220-425. DR PDB; 1OZJ; X-ray; 2.40 A; A/B=1-144. DR PDB; 1U7F; X-ray; 2.60 A; A/C=228-425. DR PDB; 2LAJ; NMR; -; B=202-211. DR PDB; 2LB2; NMR; -; B=178-189. DR PDB; 5OD6; X-ray; 2.00 A; A/B=11-135. DR PDB; 5ODG; X-ray; 2.12 A; A/B=11-135. DR PDB; 5XOC; X-ray; 2.40 A; A=220-416. DR PDB; 6YIB; X-ray; 1.70 A; P=417-425. DR PDB; 6ZMN; X-ray; 2.33 A; A/B=10-136. DR PDBsum; 1MHD; -. DR PDBsum; 1MJS; -. DR PDBsum; 1MK2; -. DR PDBsum; 1OZJ; -. DR PDBsum; 1U7F; -. DR PDBsum; 2LAJ; -. DR PDBsum; 2LB2; -. DR PDBsum; 5OD6; -. DR PDBsum; 5ODG; -. DR PDBsum; 5XOC; -. DR PDBsum; 6YIB; -. DR PDBsum; 6ZMN; -. DR AlphaFoldDB; P84022; -. DR SMR; P84022; -. DR BioGRID; 110263; 430. DR ComplexPortal; CPX-1; SMAD2-SMAD3-SMAD4 complex. DR ComplexPortal; CPX-10345; IL37-SMAD3 transcriptional repressor complex. DR ComplexPortal; CPX-12; SMAD3 homotrimer. DR ComplexPortal; CPX-3252; SMAD3-SMAD4 complex. DR ComplexPortal; CPX-6062; SMAD3-TTF-1 complex. DR CORUM; P84022; -. DR DIP; DIP-29720N; -. DR FunCoup; P84022; 2136. DR IntAct; P84022; 245. DR MINT; P84022; -. DR STRING; 9606.ENSP00000332973; -. DR BindingDB; P84022; -. DR ChEMBL; CHEMBL1293258; -. DR MoonDB; P84022; Predicted. DR GlyGen; P84022; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P84022; -. DR PhosphoSitePlus; P84022; -. DR SwissPalm; P84022; -. DR BioMuta; SMAD3; -. DR DMDM; 51338669; -. DR jPOST; P84022; -. DR MassIVE; P84022; -. DR PaxDb; 9606-ENSP00000332973; -. DR PeptideAtlas; P84022; -. DR ProteomicsDB; 26192; -. DR ProteomicsDB; 57743; -. [P84022-1] DR ProteomicsDB; 57744; -. [P84022-2] DR ProteomicsDB; 57745; -. [P84022-3] DR Pumba; P84022; -. DR ABCD; P84022; 2 sequenced antibodies. DR Antibodypedia; 26224; 2325 antibodies from 46 providers. DR DNASU; 4088; -. DR Ensembl; ENST00000327367.9; ENSP00000332973.4; ENSG00000166949.18. [P84022-1] DR Ensembl; ENST00000439724.7; ENSP00000401133.3; ENSG00000166949.18. [P84022-2] DR Ensembl; ENST00000537194.6; ENSP00000445348.2; ENSG00000166949.18. [P84022-4] DR Ensembl; ENST00000540846.6; ENSP00000437757.2; ENSG00000166949.18. [P84022-3] DR Ensembl; ENST00000558428.6; ENSP00000454165.2; ENSG00000166949.18. [P84022-4] DR Ensembl; ENST00000558739.2; ENSP00000453684.2; ENSG00000166949.18. [P84022-3] DR Ensembl; ENST00000558827.2; ENSP00000452767.2; ENSG00000166949.18. [P84022-4] DR Ensembl; ENST00000559460.6; ENSP00000453082.2; ENSG00000166949.18. [P84022-3] DR Ensembl; ENST00000679624.1; ENSP00000505445.1; ENSG00000166949.18. [P84022-3] DR Ensembl; ENST00000681239.1; ENSP00000505641.1; ENSG00000166949.18. [P84022-3] DR GeneID; 4088; -. DR KEGG; hsa:4088; -. DR MANE-Select; ENST00000327367.9; ENSP00000332973.4; NM_005902.4; NP_005893.1. DR UCSC; uc002aqj.4; human. [P84022-1] DR AGR; HGNC:6769; -. DR CIViC; 4088; 1 evidence item across 1 molecular profile. DR ClinPGx; PA30526; -. DR CTD; 4088; -. DR DisGeNET; 4088; -. DR GeneCards; SMAD3; -. DR GeneReviews; SMAD3; -. DR HGNC; HGNC:6769; SMAD3. DR HPA; ENSG00000166949; Low tissue specificity. DR MalaCards; SMAD3; -. DR MIM; 114500; phenotype. DR MIM; 603109; gene. DR MIM; 613795; phenotype. DR OpenTargets; ENSG00000166949; -. DR Orphanet; 284984; Aneurysm-osteoarthritis syndrome. DR Orphanet; 91387; Familial thoracic aortic aneurysm and aortic dissection. DR Orphanet; 60030; Loeys-Dietz syndrome. DR VEuPathDB; HostDB:ENSG00000166949; -. DR eggNOG; KOG3701; Eukaryota. DR GeneTree; ENSGT00940000153499; -. DR HOGENOM; CLU_026736_0_0_1; -. DR InParanoid; P84022; -. DR OMA; VENCRYS; -. DR OrthoDB; 5794312at2759; -. DR PAN-GO; P84022; 10 GO annotations based on evolutionary models. DR PhylomeDB; P84022; -. DR PathwayCommons; P84022; -. DR Reactome; R-HSA-1181150; Signaling by NODAL. DR Reactome; R-HSA-1502540; Signaling by Activin. DR Reactome; R-HSA-2173788; Downregulation of TGF-beta receptor signaling. DR Reactome; R-HSA-2173789; TGF-beta receptor signaling activates SMADs. DR Reactome; R-HSA-2173795; Downregulation of SMAD2/3:SMAD4 transcriptional activity. DR Reactome; R-HSA-2173796; SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription. DR Reactome; R-HSA-3304356; SMAD2/3 Phosphorylation Motif Mutants in Cancer. DR Reactome; R-HSA-3311021; SMAD4 MH2 Domain Mutants in Cancer. DR Reactome; R-HSA-3315487; SMAD2/3 MH2 Domain Mutants in Cancer. DR Reactome; R-HSA-3656532; TGFBR1 KD Mutants in Cancer. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-8941855; RUNX3 regulates CDKN1A transcription. DR Reactome; R-HSA-8952158; RUNX3 regulates BCL2L11 (BIM) transcription. DR Reactome; R-HSA-9008059; Interleukin-37 signaling. DR Reactome; R-HSA-9013695; NOTCH4 Intracellular Domain Regulates Transcription. DR Reactome; R-HSA-9615017; FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes. DR Reactome; R-HSA-9617828; FOXO-mediated transcription of cell cycle genes. DR Reactome; R-HSA-9735871; SARS-CoV-1 targets host intracellular signalling and regulatory pathways. DR Reactome; R-HSA-9754189; Germ layer formation at gastrulation. DR Reactome; R-HSA-9796292; Formation of axial mesoderm. DR Reactome; R-HSA-9823730; Formation of definitive endoderm. DR Reactome; R-HSA-9839394; TGFBR3 expression. DR SignaLink; P84022; -. DR SIGNOR; P84022; -. DR Agora; ENSG00000166949; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 4088; 18 hits in 1191 CRISPR screens. DR CD-CODE; 38EC0B30; Transcriptional condensate. DR CD-CODE; 804901D1; Nuclear speckle. DR ChiTaRS; SMAD3; human. DR EvolutionaryTrace; P84022; -. DR GeneWiki; Mothers_against_decapentaplegic_homolog_3; -. DR GenomeRNAi; 4088; -. DR Pharos; P84022; Tchem. DR PRO; PR:P84022; -. DR Proteomes; UP000005640; Chromosome 15. DR RNAct; P84022; protein. DR Bgee; ENSG00000166949; Expressed in tendon of biceps brachii and 204 other cell types or tissues. DR ExpressionAtlas; P84022; baseline and differential. DR GO; GO:0000785; C:chromatin; IDA:BHF-UCL. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0035869; C:ciliary transition zone; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IGI:ARUK-UCL. DR GO; GO:0071144; C:heteromeric SMAD protein complex; IDA:BHF-UCL. DR GO; GO:0005637; C:nuclear inner membrane; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IEA:Ensembl. DR GO; GO:0043235; C:receptor complex; IMP:BHF-UCL. DR GO; GO:0071141; C:SMAD protein complex; IDA:UniProtKB. DR GO; GO:0005667; C:transcription regulator complex; IDA:UniProtKB. DR GO; GO:0008013; F:beta-catenin binding; IEA:Ensembl. DR GO; GO:0043425; F:bHLH transcription factor binding; IPI:BHF-UCL. DR GO; GO:0031490; F:chromatin DNA binding; IEA:Ensembl. DR GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; IDA:UniProtKB. DR GO; GO:0070410; F:co-SMAD binding; IPI:BHF-UCL. DR GO; GO:0005518; F:collagen binding; IEA:Ensembl. DR GO; GO:0017151; F:DEAD/H-box RNA helicase binding; IPI:BHF-UCL. DR GO; GO:0003677; F:DNA binding; IDA:ARUK-UCL. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:BHF-UCL. DR GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:NTNU_SB. DR GO; GO:0140297; F:DNA-binding transcription factor binding; IPI:BHF-UCL. DR GO; GO:0001217; F:DNA-binding transcription repressor activity; IDA:ARUK-UCL. DR GO; GO:0070411; F:I-SMAD binding; IBA:GO_Central. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0035259; F:nuclear glucocorticoid receptor binding; IPI:CAFA. DR GO; GO:0031962; F:nuclear mineralocorticoid receptor binding; IPI:CAFA. DR GO; GO:0016922; F:nuclear receptor binding; IPI:BHF-UCL. DR GO; GO:0019902; F:phosphatase binding; IPI:UniProtKB. DR GO; GO:1990841; F:promoter-specific chromatin binding; IEA:Ensembl. DR GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL. DR GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB. DR GO; GO:0070412; F:R-SMAD binding; IPI:UniProtKB. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:GO_Central. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:BHF-UCL. DR GO; GO:0043565; F:sequence-specific DNA binding; IDA:BHF-UCL. DR GO; GO:0032810; F:sterol response element binding; IGI:ARUK-UCL. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:BHF-UCL. DR GO; GO:0001223; F:transcription coactivator binding; IPI:UniProtKB. DR GO; GO:0001222; F:transcription corepressor binding; IPI:HGNC-UCL. DR GO; GO:0005160; F:transforming growth factor beta receptor binding; IPI:BHF-UCL. DR GO; GO:0043130; F:ubiquitin binding; IDA:UniProtKB. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:BHF-UCL. DR GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB. DR GO; GO:0032924; P:activin receptor signaling pathway; IMP:BHF-UCL. DR GO; GO:0030325; P:adrenal gland development; IEA:Ensembl. DR GO; GO:0009653; P:anatomical structure morphogenesis; IBA:GO_Central. DR GO; GO:0097190; P:apoptotic signaling pathway; IMP:BHF-UCL. DR GO; GO:0030154; P:cell differentiation; IBA:GO_Central. DR GO; GO:0008283; P:cell population proliferation; IEA:Ensembl. DR GO; GO:0045216; P:cell-cell junction organization; IMP:BHF-UCL. DR GO; GO:0071333; P:cellular response to glucose stimulus; IEA:Ensembl. DR GO; GO:0036120; P:cellular response to platelet-derived growth factor stimulus; IEA:Ensembl. DR GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IDA:CAFA. DR GO; GO:0098586; P:cellular response to virus; IEA:Ensembl. DR GO; GO:0048589; P:developmental growth; IEA:Ensembl. DR GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; IEA:Ensembl. DR GO; GO:0048617; P:embryonic foregut morphogenesis; IEA:Ensembl. DR GO; GO:0009880; P:embryonic pattern specification; IEA:Ensembl. DR GO; GO:0007492; P:endoderm development; IEA:Ensembl. DR GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IMP:BHF-UCL. DR GO; GO:0001947; P:heart looping; IEA:Ensembl. DR GO; GO:0006955; P:immune response; IMP:BHF-UCL. DR GO; GO:0002520; P:immune system development; IEA:Ensembl. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0007254; P:JNK cascade; IEA:Ensembl. DR GO; GO:0070306; P:lens fiber cell differentiation; IEA:Ensembl. DR GO; GO:0001889; P:liver development; IEA:Ensembl. DR GO; GO:0001707; P:mesoderm formation; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl. DR GO; GO:1903243; P:negative regulation of cardiac muscle hypertrophy in response to stress; IEA:Ensembl. DR GO; GO:0045596; P:negative regulation of cell differentiation; ISS:UniProt. DR GO; GO:0030308; P:negative regulation of cell growth; IDA:BHF-UCL. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:BHF-UCL. DR GO; GO:0051481; P:negative regulation of cytosolic calcium ion concentration; IDA:BHF-UCL. DR GO; GO:0045599; P:negative regulation of fat cell differentiation; IDA:BHF-UCL. DR GO; GO:0010629; P:negative regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0050728; P:negative regulation of inflammatory response; IEA:Ensembl. DR GO; GO:0061767; P:negative regulation of lung blood pressure; IEA:Ensembl. DR GO; GO:1902894; P:negative regulation of miRNA transcription; IMP:BHF-UCL. DR GO; GO:0030279; P:negative regulation of ossification; IDA:UniProt. DR GO; GO:0045668; P:negative regulation of osteoblast differentiation; IEA:Ensembl. DR GO; GO:0033689; P:negative regulation of osteoblast proliferation; IEA:Ensembl. DR GO; GO:0042177; P:negative regulation of protein catabolic process; IEA:Ensembl. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:ARUK-UCL. DR GO; GO:0061045; P:negative regulation of wound healing; IEA:Ensembl. DR GO; GO:0038092; P:nodal signaling pathway; IMP:BHF-UCL. DR GO; GO:0002076; P:osteoblast development; IEA:Ensembl. DR GO; GO:0048340; P:paraxial mesoderm morphogenesis; IEA:Ensembl. DR GO; GO:0060039; P:pericardium development; IEA:Ensembl. DR GO; GO:0030501; P:positive regulation of bone mineralization; IEA:Ensembl. DR GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IEA:Ensembl. DR GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl. DR GO; GO:0032332; P:positive regulation of chondrocyte differentiation; IEA:Ensembl. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:BHF-UCL. DR GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IDA:BHF-UCL. DR GO; GO:1901203; P:positive regulation of extracellular matrix assembly; IDA:BHF-UCL. DR GO; GO:0051894; P:positive regulation of focal adhesion assembly; IEA:Ensembl. DR GO; GO:0010628; P:positive regulation of gene expression; IDA:BHF-UCL. DR GO; GO:0032731; P:positive regulation of interleukin-1 beta production; IEA:Ensembl. DR GO; GO:1902895; P:positive regulation of miRNA transcription; IDA:BHF-UCL. DR GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IDA:BHF-UCL. DR GO; GO:0050927; P:positive regulation of positive chemotaxis; IEA:Ensembl. DR GO; GO:0042307; P:positive regulation of protein import into nucleus; NAS:BHF-UCL. DR GO; GO:0060391; P:positive regulation of SMAD protein signal transduction; IMP:BHF-UCL. DR GO; GO:0051496; P:positive regulation of stress fiber assembly; IEA:Ensembl. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0032916; P:positive regulation of transforming growth factor beta3 production; IEA:Ensembl. DR GO; GO:0031053; P:primary miRNA processing; TAS:BHF-UCL. DR GO; GO:0050821; P:protein stabilization; IEA:Ensembl. DR GO; GO:0061001; P:regulation of dendritic spine morphogenesis; IEA:Ensembl. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:ComplexPortal. DR GO; GO:0050678; P:regulation of epithelial cell proliferation; IEA:Ensembl. DR GO; GO:0050776; P:regulation of immune response; IEA:Ensembl. DR GO; GO:1902893; P:regulation of miRNA transcription; IC:ARUK-UCL. DR GO; GO:0051881; P:regulation of mitochondrial membrane potential; IEA:Ensembl. DR GO; GO:0016202; P:regulation of striated muscle tissue development; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:NTNU_SB. DR GO; GO:0017015; P:regulation of transforming growth factor beta receptor signaling pathway; IEA:Ensembl. DR GO; GO:0032909; P:regulation of transforming growth factor beta2 production; IMP:BHF-UCL. DR GO; GO:0001836; P:release of cytochrome c from mitochondria; IEA:Ensembl. DR GO; GO:0097305; P:response to alcohol; IEA:Ensembl. DR GO; GO:1990776; P:response to angiotensin; IMP:BHF-UCL. DR GO; GO:0042220; P:response to cocaine; IEA:Ensembl. DR GO; GO:0010332; P:response to gamma radiation; IEA:Ensembl. DR GO; GO:0001666; P:response to hypoxia; IMP:BHF-UCL. DR GO; GO:0023019; P:signal transduction involved in regulation of gene expression; IEA:Ensembl. DR GO; GO:0060395; P:SMAD protein signal transduction; IDA:BHF-UCL. DR GO; GO:0001756; P:somitogenesis; IEA:Ensembl. DR GO; GO:0042110; P:T cell activation; IEA:Ensembl. DR GO; GO:0030878; P:thyroid gland development; IEA:Ensembl. DR GO; GO:0060290; P:transdifferentiation; IEA:Ensembl. DR GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0061450; P:trophoblast cell migration; IDA:UniProt. DR GO; GO:0001657; P:ureteric bud development; IEA:Ensembl. DR GO; GO:0042060; P:wound healing; TAS:BHF-UCL. DR CDD; cd10491; MH1_SMAD_2_3; 1. DR CDD; cd10985; MH2_SMAD_2_3; 1. DR DisProt; DP01648; -. DR FunFam; 2.60.200.10:FF:000001; Mothers against decapentaplegic homolog; 1. DR FunFam; 3.90.520.10:FF:000001; Mothers against decapentaplegic homolog; 1. DR Gene3D; 2.60.200.10; -; 1. DR Gene3D; 3.90.520.10; SMAD MH1 domain; 1. DR IDEAL; IID00113; -. DR InterPro; IPR013790; Dwarfin. DR InterPro; IPR003619; MAD_homology1_Dwarfin-type. DR InterPro; IPR013019; MAD_homology_MH1. DR InterPro; IPR017855; SMAD-like_dom_sf. DR InterPro; IPR001132; SMAD_dom_Dwarfin-type. DR InterPro; IPR008984; SMAD_FHA_dom_sf. DR InterPro; IPR036578; SMAD_MH1_sf. DR PANTHER; PTHR13703:SF53; MOTHERS AGAINST DECAPENTAPLEGIC HOMOLOG 3; 1. DR PANTHER; PTHR13703; SMAD; 1. DR Pfam; PF03165; MH1; 1. DR Pfam; PF03166; MH2; 1. DR SMART; SM00523; DWA; 1. DR SMART; SM00524; DWB; 1. DR SUPFAM; SSF56366; SMAD MH1 domain; 1. DR SUPFAM; SSF49879; SMAD/FHA domain; 1. DR PROSITE; PS51075; MH1; 1. DR PROSITE; PS51076; MH2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; ADP-ribosylation; Alternative splicing; KW Aortic aneurysm; Cytoplasm; Disease variant; DNA-binding; KW Host-virus interaction; Isopeptide bond; Metal-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Transcription; Transcription regulation; Ubl conjugation; Zinc. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT CHAIN 2..425 FT /note="SMAD family member 3" FT /id="PRO_0000090856" FT DOMAIN 10..136 FT /note="MH1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00438" FT DOMAIN 232..425 FT /note="MH2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00439" FT REGION 137..231 FT /note="Linker" FT REGION 165..208 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 271..324 FT /note="Sufficient for interaction with XPO4" FT /evidence="ECO:0000269|PubMed:16449645" FT COMPBIAS 165..177 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 64 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT BINDING 109 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT BINDING 121 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT BINDING 126 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT SITE 40 FT /note="Required for trimerization" FT SITE 41 FT /note="Required for interaction with DNA and JUN and for FT functional cooperation with JUN" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT MOD_RES 8 FT /note="Phosphothreonine; by CDK2 and CDK4" FT /evidence="ECO:0000269|PubMed:15241418" FT MOD_RES 179 FT /note="Phosphothreonine; by CDK2, CDK4 and MAPK" FT /evidence="ECO:0000269|PubMed:15241418, FT ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:19218245" FT MOD_RES 204 FT /note="Phosphoserine; by GSK3 and MAPK" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00439, FT ECO:0000269|PubMed:15241418, ECO:0000269|PubMed:16156666, FT ECO:0000269|PubMed:19218245" FT MOD_RES 208 FT /note="Phosphoserine; by MAPK" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00439, FT ECO:0000269|PubMed:15241418, ECO:0000269|PubMed:16156666, FT ECO:0000269|PubMed:19218245" FT MOD_RES 213 FT /note="Phosphoserine; by CDK2 and CDK4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00439, FT ECO:0000269|PubMed:15241418" FT MOD_RES 378 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:16862174" FT MOD_RES 416 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 418 FT /note="Phosphoserine; by CK1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00439, FT ECO:0000269|PubMed:18794808" FT MOD_RES 422 FT /note="Phosphoserine; by TGFBR1" FT /evidence="ECO:0000250|UniProtKB:Q8BUN5, FT ECO:0000255|PROSITE-ProRule:PRU00439" FT MOD_RES 423 FT /note="Phosphoserine; by TGFBR1" FT /evidence="ECO:0000250|UniProtKB:Q8BUN5, FT ECO:0000255|PROSITE-ProRule:PRU00439" FT MOD_RES 425 FT /note="Phosphoserine; by TGFBR1" FT /evidence="ECO:0000250|UniProtKB:Q8BUN5, FT ECO:0000255|PROSITE-ProRule:PRU00439" FT CROSSLNK 33 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000305|PubMed:21947082" FT CROSSLNK 81 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000305|PubMed:21947082" FT VAR_SEQ 1..195 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045348" FT VAR_SEQ 1..105 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_043793" FT VAR_SEQ 1..68 FT /note="MSSILPFTPPIVKRLLGWKKGEQNGQEEKWCEKAVKSLVKKLKKTGQLDELE FT KAITTQNVNTKCITIP -> MSCLHPRQTWKGAALVHRKAWWMG (in isoform FT 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_042900" FT VARIANT 112 FT /note="A -> V (in LDS3; dbSNP:rs387906854)" FT /evidence="ECO:0000269|PubMed:21778426" FT /id="VAR_067051" FT VARIANT 170 FT /note="I -> V (in dbSNP:rs35874463)" FT /id="VAR_052021" FT VARIANT 239 FT /note="E -> K (in LDS3; dbSNP:rs387906853)" FT /evidence="ECO:0000269|PubMed:21778426" FT /id="VAR_067047" FT VARIANT 261 FT /note="T -> I (in LDS3; dbSNP:rs387906851)" FT /evidence="ECO:0000269|PubMed:21217753" FT /id="VAR_065578" FT VARIANT 279 FT /note="R -> K (in LDS3; dbSNP:rs387906852)" FT /evidence="ECO:0000269|PubMed:21778426" FT /id="VAR_067048" FT VARIANT 287 FT /note="R -> W (in LDS3; dbSNP:rs387906850)" FT /evidence="ECO:0000269|PubMed:21217753" FT /id="VAR_065579" FT VARIANT 393 FT /note="P -> L (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036474" FT MUTAGEN 8 FT /note="T->V: Reduced phosphorylation, increased FT transcriptional and antiproliferative activities. Further FT increase in transcriptional and antiproliferative FT activities; when associated with V-179 and A-213." FT /evidence="ECO:0000269|PubMed:15241418" FT MUTAGEN 33 FT /note="K->R: Slightly decreased monoubiquitination." FT /evidence="ECO:0000269|PubMed:21947082" FT MUTAGEN 40 FT /note="K->A: Little effect on interaction with DNA or JUN. FT Abolishes interaction with DNA and JUN; when associated FT with A-41; A-43 and A-44." FT /evidence="ECO:0000269|PubMed:10995748" FT MUTAGEN 41 FT /note="K->A: Greatly reduced interaction with DNA and JUN. FT Abolishes interaction with DNA and JUN; when associated FT with A-40; A-44 and A-43." FT /evidence="ECO:0000269|PubMed:10995748" FT MUTAGEN 43 FT /note="K->A: Little effect on interaction with DNA or JUN. FT Abolishes interaction with DNA and JUN; when associated FT with A-40; A-41 and A-44." FT /evidence="ECO:0000269|PubMed:10995748" FT MUTAGEN 44 FT /note="K->A: Little effect on interaction with DNA or JUN. FT Abolishes interaction with JUN; when associated with A-40; FT A-41 and A-43." FT /evidence="ECO:0000269|PubMed:10995748" FT MUTAGEN 53 FT /note="K->R: Slightly decreased monoubiquitination." FT /evidence="ECO:0000269|PubMed:21947082" FT MUTAGEN 74 FT /note="R->D: Reduced interaction with JUN. Loss of FT transcriptional activity and cooperation with JUN." FT /evidence="ECO:0000269|PubMed:10995748" FT MUTAGEN 81 FT /note="K->R: Decreased monoubiquitination." FT /evidence="ECO:0000269|PubMed:21947082" FT MUTAGEN 179 FT /note="T->V: Reduced phosphorylation, increased FT transcriptional and increased antiproliferative activities. FT Further increase in transcriptional and antiproliferative FT activities; when associated with V-8 and A-213." FT /evidence="ECO:0000269|PubMed:15241418, FT ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:19218245" FT MUTAGEN 204 FT /note="S->A: Increased transcriptional activity. Further FT increased transcriptional activity; when associated with S- FT 208." FT /evidence="ECO:0000269|PubMed:15241418, FT ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:19218245" FT MUTAGEN 208 FT /note="S->A: Increased transcriptional activity. Further FT increased transcriptional activity; when associated with S- FT 208." FT /evidence="ECO:0000269|PubMed:15241418, FT ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:19218245" FT MUTAGEN 213 FT /note="S->A: Reduced phosphorylation. Increased FT transcriptional and antiproliferative activities. Further FT increase in transcriptional and antiproliferative FT activities; when associated with V-8 and V-179." FT /evidence="ECO:0000269|PubMed:15241418" FT MUTAGEN 333 FT /note="K->R: No effect on acetylation. Completely abolishes FT acetylation and 97% reduction in transcriptional activity; FT when associated with R-341; R-378 and R-409." FT /evidence="ECO:0000269|PubMed:16862174" FT MUTAGEN 341 FT /note="K->R: No effect on acetylation. Completely abolishes FT acetylation and 97% reduction in transcriptional activity; FT when associated with R-333; R-378 and R-409." FT /evidence="ECO:0000269|PubMed:16862174" FT MUTAGEN 378 FT /note="K->Q: Increased transcriptional activity. No further FT increase in transcriptional activity with EP300." FT /evidence="ECO:0000269|PubMed:16862174" FT MUTAGEN 378 FT /note="K->R: Greatly reduced acetylation and 85% reduction FT in transcriptional activity. Completely abolishes FT acetylation and 97% reduction in transcriptional activity; FT when associated with R-333; R-341 and R-409." FT /evidence="ECO:0000269|PubMed:16862174" FT MUTAGEN 409 FT /note="K->R: No effect on acetylation. Completely abolishes FT acetylation and 97% reduction in transcriptional activity; FT when associated with R-333; R-341 and R-378." FT /evidence="ECO:0000269|PubMed:16862174" FT MUTAGEN 418 FT /note="S->A: Increased constitutive activity." FT /evidence="ECO:0000269|PubMed:18794808" FT MUTAGEN 418 FT /note="S->D: Decreased activity." FT /evidence="ECO:0000269|PubMed:18794808" FT MUTAGEN 422..425 FT /note="SSVS->AAVA: Does not abolish protein nuclear export. FT Abolishes almost completely acetylation." FT /evidence="ECO:0000269|PubMed:11224571, FT ECO:0000269|PubMed:16449645, ECO:0000269|PubMed:16862174" FT MUTAGEN 422..425 FT /note="SSVS->EEVE: Forms heterotrimers." FT /evidence="ECO:0000269|PubMed:11224571, FT ECO:0000269|PubMed:16449645, ECO:0000269|PubMed:16862174" FT MUTAGEN 422..425 FT /note="SSVS->RRVR: Diminishes cargo protein export." FT /evidence="ECO:0000269|PubMed:11224571, FT ECO:0000269|PubMed:16449645, ECO:0000269|PubMed:16862174" FT CONFLICT 178 FT /note="E -> EVGTWAAQAGL (in Ref. 3; BAA22032)" FT /evidence="ECO:0000305" FT CONFLICT 360 FT /note="F -> L (in Ref. 5; BAH13315)" FT /evidence="ECO:0000305" FT HELIX 11..17 FT /evidence="ECO:0007829|PDB:5OD6" FT HELIX 25..44 FT /evidence="ECO:0007829|PDB:5OD6" FT HELIX 48..57 FT /evidence="ECO:0007829|PDB:5OD6" FT STRAND 60..62 FT /evidence="ECO:0007829|PDB:5OD6" FT STRAND 66..68 FT /evidence="ECO:0007829|PDB:5OD6" FT STRAND 71..73 FT /evidence="ECO:0007829|PDB:6ZMN" FT STRAND 75..77 FT /evidence="ECO:0007829|PDB:5OD6" FT STRAND 80..82 FT /evidence="ECO:0007829|PDB:5OD6" FT HELIX 84..92 FT /evidence="ECO:0007829|PDB:5OD6" FT HELIX 100..102 FT /evidence="ECO:0007829|PDB:5OD6" FT STRAND 103..105 FT /evidence="ECO:0007829|PDB:5OD6" FT HELIX 113..115 FT /evidence="ECO:0007829|PDB:5OD6" FT STRAND 118..121 FT /evidence="ECO:0007829|PDB:5OD6" FT HELIX 124..126 FT /evidence="ECO:0007829|PDB:5OD6" FT STRAND 127..129 FT /evidence="ECO:0007829|PDB:5OD6" FT STRAND 221..225 FT /evidence="ECO:0007829|PDB:1MK2" FT STRAND 231..239 FT /evidence="ECO:0007829|PDB:1MJS" FT STRAND 242..250 FT /evidence="ECO:0007829|PDB:1MJS" FT STRAND 252..258 FT /evidence="ECO:0007829|PDB:1MJS" FT STRAND 268..270 FT /evidence="ECO:0007829|PDB:1MJS" FT HELIX 271..273 FT /evidence="ECO:0007829|PDB:1U7F" FT HELIX 281..290 FT /evidence="ECO:0007829|PDB:1MJS" FT STRAND 294..299 FT /evidence="ECO:0007829|PDB:1MJS" FT STRAND 302..307 FT /evidence="ECO:0007829|PDB:1MJS" FT STRAND 309..311 FT /evidence="ECO:0007829|PDB:1MJS" FT STRAND 313..316 FT /evidence="ECO:0007829|PDB:1MJS" FT HELIX 318..321 FT /evidence="ECO:0007829|PDB:1MJS" FT HELIX 323..325 FT /evidence="ECO:0007829|PDB:1MK2" FT STRAND 332..334 FT /evidence="ECO:0007829|PDB:1MJS" FT STRAND 339..343 FT /evidence="ECO:0007829|PDB:1MJS" FT HELIX 345..358 FT /evidence="ECO:0007829|PDB:1MJS" FT HELIX 360..364 FT /evidence="ECO:0007829|PDB:1MJS" FT HELIX 365..370 FT /evidence="ECO:0007829|PDB:1MJS" FT STRAND 371..377 FT /evidence="ECO:0007829|PDB:1MJS" FT STRAND 384..386 FT /evidence="ECO:0007829|PDB:1MK2" FT HELIX 389..391 FT /evidence="ECO:0007829|PDB:5XOC" FT STRAND 392..400 FT /evidence="ECO:0007829|PDB:1MJS" FT HELIX 401..413 FT /evidence="ECO:0007829|PDB:1MJS" SQ SEQUENCE 425 AA; 48081 MW; 46DF5E8B371321AC CRC64; MSSILPFTPP IVKRLLGWKK GEQNGQEEKW CEKAVKSLVK KLKKTGQLDE LEKAITTQNV NTKCITIPRS LDGRLQVSHR KGLPHVIYCR LWRWPDLHSH HELRAMELCE FAFNMKKDEV CVNPYHYQRV ETPVLPPVLV PRHTEIPAEF PPLDDYSHSI PENTNFPAGI EPQSNIPETP PPGYLSEDGE TSDHQMNHSM DAGSPNLSPN PMSPAHNNLD LQPVTYCEPA FWCSISYYEL NQRVGETFHA SQPSMTVDGF TDPSNSERFC LGLLSNVNRN AAVELTRRHI GRGVRLYYIG GEVFAECLSD SAIFVQSPNC NQRYGWHPAT VCKIPPGCNL KIFNNQEFAA LLAQSVNQGF EAVYQLTRMC TIRMSFVKGW GAEYRRQTVT STPCWIELHL NGPLQWLDKV LTQMGSPSIR CSSVS // ID SMAD4_HUMAN Reviewed; 552 AA. AC Q13485; A8K405; DT 04-MAY-2001, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 255. DE RecName: Full=SMAD family member 4 {ECO:0000312|HGNC:HGNC:6770}; DE Short=SMAD 4 {ECO:0000305}; DE Short=hSMAD4; DE AltName: Full=Deletion target in pancreatic carcinoma 4; DE AltName: Full=Mothers against decapentaplegic homolog 4; DE Short=MAD homolog 4; DE Short=Mothers against DPP homolog 4; GN Name=SMAD4 {ECO:0000312|HGNC:HGNC:6770}; Synonyms=DPC4, MADH4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND VARIANT PANCREATIC CARCINOMA RP HIS-493. RC TISSUE=Fetal brain; RX PubMed=8553070; DOI=10.1126/science.271.5247.350; RA Hahn S.A., Schutte M., Shamsul Hoque A.T.M., Moskaluk C.A., da Costa L.T., RA Rozenblum E., Weinstein C.L., Fischer A., Yeo C.J., Hruban R.H., Kern S.E.; RT "DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1."; RL Science 271:350-353(1996). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RC TISSUE=Placenta; RX PubMed=8774881; DOI=10.1038/383168a0; RA Zhang Y., Feng X.-H., Wu R.-Y., Derynck R.; RT "Receptor-associated Mad homologues synergize as effectors of the TGF-beta RT response."; RL Nature 383:168-172(1996). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9098646; DOI=10.1097/00019606-199704000-00003; RA Moskaluk C.A., Hruban R.H., Schutte M., Lietman A.S., Smyrk T., Fusaro L., RA Fusaro R., Lynch J., Yeo C.J., Jackson C.E., Lynch H.T., Kern S.E.; RT "Genomic sequencing of DPC4 in the analysis of familial pancreatic RT carcinoma."; RL Diagn. Mol. Pathol. 6:85-90(1997). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP FUNCTION. RX PubMed=9389648; DOI=10.1101/gad.11.23.3157; RA Liu F., Pouponnot C., Massague J.; RT "Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible RT transcriptional complexes."; RL Genes Dev. 11:3157-3167(1997). RN [8] RP SUBUNIT. RX PubMed=9670020; DOI=10.1093/emboj/17.14.4056; RA Kawabata M., Inoue H., Hanyu A., Imamura T., Miyazono K.; RT "Smad proteins exist as monomers in vivo and undergo homo- and hetero- RT oligomerization upon activation by serine/threonine kinase receptors."; RL EMBO J. 17:4056-4065(1998). RN [9] RP INTERACTION WITH CITED1. RX PubMed=9707553; DOI=10.1073/pnas.95.17.9785; RA Shioda T., Lechleider R.J., Dunwoodie S.L., Li H., Yahata T., RA de Caestecker M.P., Fenner M.H., Roberts A.B., Isselbacher K.J.; RT "Transcriptional activating activity of Smad4: roles of SMAD hetero- RT oligomerization and enhancement by an associating transactivator."; RL Proc. Natl. Acad. Sci. U.S.A. 95:9785-9790(1998). RN [10] RP INTERACTION WITH ZNF423. RX PubMed=10660046; DOI=10.1016/s0092-8674(00)81561-5; RA Hata A., Seoane J., Lagna G., Montalvo E., Hemmati-Brivanlou A., RA Massague J.; RT "OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP- RT Smad and Olf signaling pathways."; RL Cell 100:229-240(2000). RN [11] RP CHARACTERIZATION OF SAD DOMAIN. RX PubMed=10636916; DOI=10.1074/jbc.275.3.2115; RA de Caestecker M.P., Yahata T., Wang D., Parks W.T., Huang S., Hill C.S., RA Shioda T., Roberts A.B., Lechleider R.J.; RT "The Smad4 activation domain (SAD) is a proline-rich, p300-dependent RT transcriptional activation domain."; RL J. Biol. Chem. 275:2115-2122(2000). RN [12] RP IDENTIFICATION IN A TERNARY COMPLEX COMPOSED OF STK11/LKB1 AND STK11IP, AND RP INTERACTION WITH STK11/LKB1 AND STK11IP. RX PubMed=11741830; DOI=10.1093/hmg/10.25.2869; RA Smith D.P., Rayter S.I., Niederlander C., Spicer J., Jones C.M., RA Ashworth A.; RT "LIP1, a cytoplasmic protein functionally linked to the Peutz-Jeghers RT syndrome kinase LKB1."; RL Hum. Mol. Genet. 10:2869-2877(2001). RN [13] RP INTERACTION WITH COPS5. RX PubMed=11818334; DOI=10.1093/embo-reports/kvf024; RA Wan M., Cao X., Wu Y., Bai S., Wu L., Shi X., Wang N., Cao X.; RT "Jab1 antagonizes TGF-beta signaling by inducing Smad4 degradation."; RL EMBO Rep. 3:171-176(2002). RN [14] RP INTERACTION WITH ZNF8. RX PubMed=12370310; DOI=10.1128/mcb.22.21.7633-7644.2002; RA Jiao K., Zhou Y., Hogan B.L.M.; RT "Identification of mZnf8, a mouse Kruppel-like transcriptional repressor, RT as a novel nuclear interaction partner of Smad1."; RL Mol. Cell. Biol. 22:7633-7644(2002). RN [15] RP INTERACTION WITH VPS39. RX PubMed=12941698; DOI=10.1093/emboj/cdg428; RA Felici A., Wurthner J.U., Parks W.T., Giam L.R., Reiss M., Karpova T.S., RA McNally J.G., Roberts A.B.; RT "TLP, a novel modulator of TGF-beta signaling, has opposite effects on RT Smad2- and Smad3-dependent signaling."; RL EMBO J. 22:4465-4477(2003). RN [16] RP INTERACTION WITH DACH1. RX PubMed=14525983; DOI=10.1074/jbc.m310021200; RA Wu K., Yang Y., Wang C., Davoli M.A., D'Amico M., Li A., Cveklova K., RA Kozmik Z., Lisanti M.P., Russell R.G., Cvekl A., Pestell R.G.; RT "DACH1 inhibits transforming growth factor-beta signaling through binding RT Smad4."; RL J. Biol. Chem. 278:51673-51684(2003). RN [17] RP INTERACTION WITH DLX1. RX PubMed=14671321; DOI=10.1073/pnas.2536757100; RA Chiba S., Takeshita K., Imai Y., Kumano K., Kurokawa M., Masuda S., RA Shimizu K., Nakamura S., Ruddle F.H., Hirai H.; RT "Homeoprotein DLX-1 interacts with Smad4 and blocks a signaling pathway RT from activin A in hematopoietic cells."; RL Proc. Natl. Acad. Sci. U.S.A. 100:15577-15582(2003). RN [18] RP INTERACTION WITH ZNF521. RX PubMed=14630787; DOI=10.1182/blood-2003-07-2388; RA Bond H.M., Mesuraca M., Carbone E., Bonelli P., Agosti V., Amodio N., RA De Rosa G., Di Nicola M., Gianni A.M., Moore M.A., Hata A., Grieco M., RA Morrone G., Venuta S.; RT "Early hematopoietic zinc finger protein (EHZF), the human homolog to mouse RT Evi3, is highly expressed in primitive human hematopoietic cells."; RL Blood 103:2062-2070(2004). RN [19] RP INTERACTION WITH TRIM33. RX PubMed=15820681; DOI=10.1016/j.cell.2005.01.033; RA Dupont S., Zacchigna L., Cordenonsi M., Soligo S., Adorno M., Rugge M., RA Piccolo S.; RT "Germ-layer specification and control of cell growth by Ectodermin, a Smad4 RT ubiquitin ligase."; RL Cell 121:87-99(2005). RN [20] RP SUBUNIT, AND SUBCELLULAR LOCATION. RX PubMed=15799969; DOI=10.1074/jbc.m500362200; RA Chen H.B., Rud J.G., Lin K., Xu L.; RT "Nuclear targeting of transforming growth factor-beta-activated Smad RT complexes."; RL J. Biol. Chem. 280:21329-21336(2005). RN [21] RP INTERACTION WITH TSC22D1. RX PubMed=15881652; DOI=10.1007/s11010-005-3456-7; RA Choi S.J., Moon J.H., Ahn Y.W., Ahn J.H., Kim D.U., Han T.H.; RT "Tsc-22 enhances TGF-beta signaling by associating with Smad4 and induces RT erythroid cell differentiation."; RL Mol. Cell. Biochem. 271:23-28(2005). RN [22] RP INTERACTION WITH ZMIZ1. RX PubMed=16777850; DOI=10.1074/jbc.m508365200; RA Li X., Thyssen G., Beliakoff J., Sun Z.; RT "The novel PIAS-like protein hZimp10 enhances Smad transcriptional RT activity."; RL J. Biol. Chem. 281:23748-23756(2006). RN [23] RP INTERACTION WITH RBPMS. RX PubMed=17099224; DOI=10.1093/nar/gkl914; RA Sun Y., Ding L., Zhang H., Han J., Yang X., Yan J., Zhu Y., Li J., Song H., RA Ye Q.; RT "Potentiation of Smad-mediated transcriptional activation by the RNA- RT binding protein RBPMS."; RL Nucleic Acids Res. 34:6314-6326(2006). RN [24] RP FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION BY PDPK1, AND INTERACTION RP WITH PDPK1. RX PubMed=17327236; DOI=10.1074/jbc.m609279200; RA Seong H.A., Jung H., Kim K.T., Ha H.; RT "3-Phosphoinositide-dependent PDK1 negatively regulates transforming growth RT factor-beta-induced signaling in a kinase-dependent manner through physical RT interaction with Smad proteins."; RL J. Biol. Chem. 282:12272-12289(2007). RN [25] RP INTERACTION WITH WWTR1. RX PubMed=18568018; DOI=10.1038/ncb1748; RA Varelas X., Sakuma R., Samavarchi-Tehrani P., Peerani R., Rao B.M., RA Dembowy J., Yaffe M.B., Zandstra P.W., Wrana J.L.; RT "TAZ controls Smad nucleocytoplasmic shuttling and regulates human RT embryonic stem-cell self-renewal."; RL Nat. Cell Biol. 10:837-848(2008). RN [26] RP INTERACTION WITH USP9X, UBIQUITINATION, AND MUTAGENESIS OF LYS-519. RX PubMed=19135894; DOI=10.1016/j.cell.2008.10.051; RA Dupont S., Mamidi A., Cordenonsi M., Montagner M., Zacchigna L., Adorno M., RA Martello G., Stinchfield M.J., Soligo S., Morsut L., Inui M., Moro S., RA Modena N., Argenton F., Newfeld S.J., Piccolo S.; RT "FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, RT controls Smad4 monoubiquitination."; RL Cell 136:123-135(2009). RN [27] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-37; LYS-428 AND LYS-507, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [28] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [29] RP POSSIBLE INVOLVEMENT IN PULMONARY HYPERTENSION, AND VARIANT SER-13. RX PubMed=21898662; DOI=10.1002/humu.21605; RA Nasim M.T., Ogo T., Ahmed M., Randall R., Chowdhury H.M., Snape K.M., RA Bradshaw T.Y., Southgate L., Lee G.J., Jackson I., Lord G.M., Gibbs J.S., RA Wilkins M.R., Ohta-Ogo K., Nakamura K., Girerd B., Coulet F., Soubrier F., RA Humbert M., Morrell N.W., Trembath R.C., Machado R.D.; RT "Molecular genetic characterization of SMAD signaling molecules in RT pulmonary arterial hypertension."; RL Hum. Mutat. 32:1385-1389(2011). RN [30] RP INTERACTION WITH ZNF451, IDENTIFICATION IN A COMPLEX WITH ZNF451; SMAD3 AND RP SMAD2, AND SUBUNIT. RX PubMed=24324267; DOI=10.1074/jbc.m113.526905; RA Feng Y., Wu H., Xu Y., Zhang Z., Liu T., Lin X., Feng X.H.; RT "Zinc finger protein 451 is a novel Smad corepressor in transforming growth RT factor-beta signaling."; RL J. Biol. Chem. 289:2072-2083(2014). RN [31] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [32] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-113, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25218447; DOI=10.1038/nsmb.2890; RA Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M., RA Vertegaal A.C.; RT "Uncovering global SUMOylation signaling networks in a site-specific RT manner."; RL Nat. Struct. Mol. Biol. 21:927-936(2014). RN [33] RP INTERACTION WITH CREB3L1. RX PubMed=25310401; DOI=10.1371/journal.pone.0108528; RA Chen Q., Lee C.E., Denard B., Ye J.; RT "Sustained induction of collagen synthesis by TGF-beta requires regulated RT intramembrane proteolysis of CREB3L1."; RL PLoS ONE 9:E108528-E108528(2014). RN [34] RP FUNCTION, INTERACTION WITH CREBBP; EP300; HDAC1 AND ZBTB7A, AND REGION. RX PubMed=25514493; DOI=10.1016/j.bbagrm.2014.12.008; RA Yang Y., Cui J., Xue F., Zhang C., Mei Z., Wang Y., Bi M., Shan D., RA Meredith A., Li H., Xu Z.Q.; RT "Pokemon (FBI-1) interacts with Smad4 to repress TGF-beta-induced RT transcriptional responses."; RL Biochim. Biophys. Acta 1849:270-281(2015). RN [35] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-113, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25755297; DOI=10.1074/mcp.o114.044792; RA Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V., RA Vertegaal A.C.; RT "System-wide analysis of SUMOylation dynamics in response to replication RT stress reveals novel small ubiquitin-like modified target proteins and RT acceptor lysines relevant for genome stability."; RL Mol. Cell. Proteomics 14:1419-1434(2015). RN [36] RP INTERACTION WITH NUP93 AND IPO7. RX PubMed=26878725; DOI=10.1038/ng.3512; RA Braun D.A., Sadowski C.E., Kohl S., Lovric S., Astrinidis S.A., Pabst W.L., RA Gee H.Y., Ashraf S., Lawson J.A., Shril S., Airik M., Tan W., Schapiro D., RA Rao J., Choi W.I., Hermle T., Kemper M.J., Pohl M., Ozaltin F., Konrad M., RA Bogdanovic R., Buescher R., Helmchen U., Serdaroglu E., Lifton R.P., RA Antonin W., Hildebrandt F.; RT "Mutations in nuclear pore genes NUP93, NUP205 and XPO5 cause steroid- RT resistant nephrotic syndrome."; RL Nat. Genet. 48:457-465(2016). RN [37] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-113, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 319-543. RX PubMed=9214508; DOI=10.1038/40431; RA Shi Y., Hata A., Lo R.S., Massague J., Pavletich N.P.; RT "A structural basis for mutational inactivation of the tumour suppressor RT Smad4."; RL Nature 388:87-93(1997). RN [39] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 285-552. RX PubMed=10647180; DOI=10.1016/s0969-2126(00)88340-9; RA Qin B., Lam S.S., Lin K.; RT "Crystal structure of a transcriptionally active Smad4 fragment."; RL Structure 7:1493-1503(1999). RN [40] RP X-RAY CRYSTALLOGRAPHY (3 ANGSTROMS) OF 273-552 OF WILD TYPE AND MUTANTS RP ARG-416; ARG-502 AND ARG-515 IN COMPLEX WITH SMAD3, SUBUNIT, AND RP MUTAGENESIS OF ARG-416; ARG-496; ARG-502 AND ARG-515. RX PubMed=11224571; DOI=10.1038/84995; RA Chacko B.M., Qin B., Correia J.J., Lam S.S., de Caestecker M.P., Lin K.; RT "The L3 loop and C-terminal phosphorylation jointly define Smad protein RT trimerization."; RL Nat. Struct. Biol. 8:248-253(2001). RN [41] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 314-552 IN COMPLEX WITH SMAD2 OR RP SMAD3, AND SUBUNIT. RX PubMed=15350224; DOI=10.1016/j.molcel.2004.07.016; RA Chacko B.M., Qin B.Y., Tiwari A., Shi G., Lam S., Hayward L.J., RA De Caestecker M., Lin K.; RT "Structural basis of heteromeric smad protein assembly in TGF-beta RT signaling."; RL Mol. Cell 15:813-823(2004). RN [42] RP VARIANT JPS CYS-361. RX PubMed=9811934; DOI=10.1093/hmg/7.12.1907; RA Houlston R., Bevan S., Williams A., Young J., Dunlop M., Rozen P., Eng C., RA Markie D., Woodford-Richens K., Rodriguez-Bigas M.A., Leggett B., Neale K., RA Phillips R., Sheridan E., Hodgson S., Iwama T., Eccles D., Bodmer W., RA Tomlinson I.; RT "Mutations in DPC4 (SMAD4) cause juvenile polyposis syndrome, but only RT account for a minority of cases."; RL Hum. Mol. Genet. 7:1907-1912(1998). RN [43] RP VARIANTS JPS GLY-330 AND ARG-352. RX PubMed=12417513; DOI=10.1007/bf02557528; RA Sayed M.G., Ahmed A.F., Ringold J.R., Anderson M.E., Bair J.L., RA Mitros F.A., Lynch H.T., Tinley S.T., Petersen G.M., Giardiello F.M., RA Vogelstein B., Howe J.R.; RT "Germline SMAD4 or BMPR1A mutations and phenotype of juvenile polyposis."; RL Ann. Surg. Oncol. 9:901-906(2002). RN [44] RP VARIANTS JP/HHT ARG-352 AND ASP-386. RX PubMed=15031030; DOI=10.1016/s0140-6736(04)15732-2; RA Gallione C.J., Repetto G.M., Legius E., Rustgi A.K., Schelley S.L., RA Tejpar S., Mitchell G., Drouin E., Westermann C.J.J., Marchuk D.A.; RT "A combined syndrome of juvenile polyposis and hereditary haemorrhagic RT telangiectasia associated with mutations in MADH4 (SMAD4)."; RL Lancet 363:852-859(2004). RN [45] RP VARIANTS [LARGE SCALE ANALYSIS] SER-130; ASN-351 AND HIS-361, AND RP INVOLVEMENT IN COLORECTAL CANCER. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [46] RP VARIANTS MYHRS THR-500 AND VAL-500. RX PubMed=22243968; DOI=10.1016/j.ajhg.2011.12.011; RA Caputo V., Cianetti L., Niceta M., Carta C., Ciolfi A., Bocchinfuso G., RA Carrani E., Dentici M.L., Biamino E., Belligni E., Garavelli L., RA Boccone L., Melis D., Andria G., Gelb B.D., Stella L., Silengo M., RA Dallapiccola B., Tartaglia M.; RT "A restricted spectrum of mutations in the SMAD4 tumor-suppressor gene RT underlies Myhre syndrome."; RL Am. J. Hum. Genet. 90:161-169(2012). RN [47] RP VARIANTS MYHRS MET-500; THR-500 AND VAL-500, AND CHARACTERIZATION OF RP VARIANT MYHRS THR-500. RX PubMed=22158539; DOI=10.1038/ng.1016; RA Le Goff C., Mahaut C., Abhyankar A., Le Goff W., Serre V., Afenjar A., RA Destree A., di Rocco M., Heron D., Jacquemont S., Marlin S., Simon M., RA Tolmie J., Verloes A., Casanova J.L., Munnich A., Cormier-Daire V.; RT "Mutations at a single codon in Mad homology 2 domain of SMAD4 cause Myhre RT syndrome."; RL Nat. Genet. 44:85-88(2012). CC -!- FUNCTION: In muscle physiology, plays a central role in the balance CC between atrophy and hypertrophy. When recruited by MSTN, promotes CC atrophy response via phosphorylated SMAD2/4. MSTN decrease causes SMAD4 CC release and subsequent recruitment by the BMP pathway to promote CC hypertrophy via phosphorylated SMAD1/5/8. Acts synergistically with CC SMAD1 and YY1 in bone morphogenetic protein (BMP)-mediated cardiac- CC specific gene expression. Binds to SMAD binding elements (SBEs) (5'- CC GTCT/AGAC-3') within BMP response element (BMPRE) of cardiac activating CC regions (By similarity). Common SMAD (co-SMAD) is the coactivator and CC mediator of signal transduction by TGF-beta (transforming growth CC factor). Component of the heterotrimeric SMAD2/SMAD3-SMAD4 complex that CC forms in the nucleus and is required for the TGF-mediated signaling CC (PubMed:25514493). Promotes binding of the SMAD2/SMAD4/FAST-1 complex CC to DNA and provides an activation function required for SMAD1 or SMAD2 CC to stimulate transcription. Component of the multimeric CC SMAD3/SMAD4/JUN/FOS complex which forms at the AP1 promoter site; CC required for synergistic transcriptional activity in response to TGF- CC beta. May act as a tumor suppressor. Positively regulates PDPK1 kinase CC activity by stimulating its dissociation from the 14-3-3 protein YWHAQ CC which acts as a negative regulator. {ECO:0000250, CC ECO:0000269|PubMed:17327236, ECO:0000269|PubMed:25514493, CC ECO:0000269|PubMed:9389648}. CC -!- SUBUNIT: Monomer; in the absence of TGF-beta activation CC (PubMed:9670020). Heterotrimer; on TGF-beta activation CC (PubMed:15799969). Heterotrimer composed of two molecules of a C- CC terminally phosphorylated R-SMAD molecule, SMAD2 or SMAD3, and one CC molecule of SMAD4 to form the transcriptional active SMAD2/SMAD3-SMAD4 CC complex (PubMed:15350224, PubMed:15799969). Found in a ternary complex CC composed of SMAD4, STK11/LKB1 and STK11IP. Found in a complex with CC SMAD1 and YY1 (By similarity). Identified in a complex that contains at CC least ZNF451, SMAD2, SMAD3 and SMAD4 (PubMed:24324267). Interacts with CC ATF2, COPS5, DACH1, MSG1, SKI, STK11/LKB1, STK11IP and TRIM33. CC Associates with ZNF423 or ZNF521 in response to BMP2 leading to CC activate transcription of BMP target genes. Interacts with USP9X. CC Interacts (via the MH1 and MH2 domains) with RBPMS. Interacts with CC WWTR1 (via coiled-coil domain). Interacts with CITED1 and CITED2. CC Interacts with PDPK1 (via PH domain) (By similarity). Interacts with CC VPS39; this interaction affects heterodimer formation with SMAD3, but CC not with SMAD2, and leads to inhibition of SMAD3-dependent CC transcription activation. Interactions with VPS39 and SMAD2 may be CC mutually exclusive. Interacts (via MH2 domain) with ZNF451 (via N- CC terminal zinc-finger domains) (PubMed:24324267). Interacts with ZC3H3 CC (By similarity). Interacts weakly with ZNF8 (PubMed:12370310). CC Interacts with NUP93 and IPO7; translocates SMAD4 to the nucleus CC through the NPC upon BMP7 stimulation resulting in activation of SMAD4 CC signaling (PubMed:26878725). Interacts with CREB3L1, the interaction CC takes place upon TGFB1 induction and SMAD4 acts as a CREB3L1 CC coactivator to induce the expression of genes involved in the assembly CC of collagen extracellular matrix (PubMed:25310401). Interacts with DLX1 CC (PubMed:14671321). Interacts with ZBTB7A; the interaction is direct and CC stimulated by TGFB1 (PubMed:25514493). Interacts with CREBBP; the CC recruitment of this transcriptional coactivator is negatively regulated CC by ZBTB7A (PubMed:25514493). Interacts with EP300; the interaction with CC this transcriptional coactivator is negatively regulated by ZBTB7A CC (PubMed:25514493). Interacts with HDAC1 (PubMed:25514493). Interacts CC (via MH2 domain) with ZMIZ1 (via SP-RING-type domain); in the TGF-beta CC signaling pathway increases the activity of the SMAD3/SMAD4 CC transcriptional complex (PubMed:16777850). Interacts (via N-terminus) CC with TSC22D1 (PubMed:15881652). {ECO:0000250|UniProtKB:O70437, CC ECO:0000250|UniProtKB:P97471, ECO:0000269|PubMed:10660046, CC ECO:0000269|PubMed:11224571, ECO:0000269|PubMed:11741830, CC ECO:0000269|PubMed:11818334, ECO:0000269|PubMed:12370310, CC ECO:0000269|PubMed:12941698, ECO:0000269|PubMed:14525983, CC ECO:0000269|PubMed:14630787, ECO:0000269|PubMed:14671321, CC ECO:0000269|PubMed:15350224, ECO:0000269|PubMed:15799969, CC ECO:0000269|PubMed:15820681, ECO:0000269|PubMed:15881652, CC ECO:0000269|PubMed:16777850, ECO:0000269|PubMed:17099224, CC ECO:0000269|PubMed:17327236, ECO:0000269|PubMed:18568018, CC ECO:0000269|PubMed:19135894, ECO:0000269|PubMed:24324267, CC ECO:0000269|PubMed:25310401, ECO:0000269|PubMed:25514493, CC ECO:0000269|PubMed:26878725, ECO:0000269|PubMed:9670020, CC ECO:0000269|PubMed:9707553}. CC -!- INTERACTION: CC Q13485; P36896: ACVR1B; NbExp=4; IntAct=EBI-347263, EBI-1384128; CC Q13485; P31749: AKT1; NbExp=6; IntAct=EBI-347263, EBI-296087; CC Q13485; P05067: APP; NbExp=3; IntAct=EBI-347263, EBI-77613; CC Q13485; P10398: ARAF; NbExp=6; IntAct=EBI-347263, EBI-365961; CC Q13485; Q92747: ARPC1A; NbExp=6; IntAct=EBI-347263, EBI-1020827; CC Q13485; Q9Y2T1: AXIN2; NbExp=4; IntAct=EBI-347263, EBI-4400025; CC Q13485; Q9NXR7: BABAM2; NbExp=5; IntAct=EBI-347263, EBI-949389; CC Q13485; P62324: BTG1; NbExp=4; IntAct=EBI-347263, EBI-742279; CC Q13485; Q9Y297: BTRC; NbExp=2; IntAct=EBI-347263, EBI-307461; CC Q13485; Q96HB5: CCDC120; NbExp=4; IntAct=EBI-347263, EBI-744556; CC Q13485; P24385: CCND1; NbExp=4; IntAct=EBI-347263, EBI-375001; CC Q13485; Q00534: CDK6; NbExp=3; IntAct=EBI-347263, EBI-295663; CC Q13485; P17676: CEBPB; NbExp=2; IntAct=EBI-347263, EBI-969696; CC Q13485; Q969H4: CNKSR1; NbExp=5; IntAct=EBI-347263, EBI-741671; CC Q13485; Q9UI36: DACH1; NbExp=7; IntAct=EBI-347263, EBI-347111; CC Q13485; Q9NPI6: DCP1A; NbExp=5; IntAct=EBI-347263, EBI-374238; CC Q13485; Q92988: DLX4; NbExp=5; IntAct=EBI-347263, EBI-1752755; CC Q13485; P29320: EPHA3; NbExp=6; IntAct=EBI-347263, EBI-1641575; CC Q13485; P21860: ERBB3; NbExp=6; IntAct=EBI-347263, EBI-720706; CC Q13485; P43268-3: ETV4; NbExp=3; IntAct=EBI-347263, EBI-12130722; CC Q13485; Q01844: EWSR1; NbExp=3; IntAct=EBI-347263, EBI-739737; CC Q13485; Q00597: FANCC; NbExp=5; IntAct=EBI-347263, EBI-81625; CC Q13485; Q9NW38: FANCL; NbExp=6; IntAct=EBI-347263, EBI-2339898; CC Q13485; Q9GZV9: FGF23; NbExp=3; IntAct=EBI-347263, EBI-6594125; CC Q13485; Q12778: FOXO1; NbExp=5; IntAct=EBI-347263, EBI-1108782; CC Q13485; O43524: FOXO3; NbExp=12; IntAct=EBI-347263, EBI-1644164; CC Q13485; P98177: FOXO4; NbExp=2; IntAct=EBI-347263, EBI-4481939; CC Q13485; P23769: GATA2; NbExp=10; IntAct=EBI-347263, EBI-2806671; CC Q13485; Q14344: GNA13; NbExp=5; IntAct=EBI-347263, EBI-465387; CC Q13485; P78333: GPC5; NbExp=5; IntAct=EBI-347263, EBI-2558325; CC Q13485; P49841: GSK3B; NbExp=5; IntAct=EBI-347263, EBI-373586; CC Q13485; Q13547: HDAC1; NbExp=7; IntAct=EBI-347263, EBI-301834; CC Q13485; P20823: HNF1A; NbExp=5; IntAct=EBI-347263, EBI-636034; CC Q13485; P01112: HRAS; NbExp=5; IntAct=EBI-347263, EBI-350145; CC Q13485; P23458: JAK1; NbExp=5; IntAct=EBI-347263, EBI-1383438; CC Q13485; P52333: JAK3; NbExp=3; IntAct=EBI-347263, EBI-518246; CC Q13485; Q8WZ60: KLHL6; NbExp=6; IntAct=EBI-347263, EBI-6426464; CC Q13485; Q9P2J3: KLHL9; NbExp=3; IntAct=EBI-347263, EBI-2510152; CC Q13485; O95835: LATS1; NbExp=7; IntAct=EBI-347263, EBI-444209; CC Q13485; P61968: LMO4; NbExp=8; IntAct=EBI-347263, EBI-2798728; CC Q13485; Q8N653: LZTR1; NbExp=5; IntAct=EBI-347263, EBI-2350056; CC Q13485; Q96RN5: MED15; NbExp=2; IntAct=EBI-347263, EBI-394506; CC Q13485; Q8NI38: NFKBID; NbExp=3; IntAct=EBI-347263, EBI-10271199; CC Q13485; Q9UBE8: NLK; NbExp=6; IntAct=EBI-347263, EBI-366978; CC Q13485; P29474: NOS3; NbExp=4; IntAct=EBI-347263, EBI-1391623; CC Q13485; Q04721: NOTCH2; NbExp=5; IntAct=EBI-347263, EBI-2652733; CC Q13485; P24468: NR2F2; NbExp=4; IntAct=EBI-347263, EBI-2795198; CC Q13485; Q16620: NTRK2; NbExp=4; IntAct=EBI-347263, EBI-3904881; CC Q13485; Q8TE49: OTUD7A; NbExp=4; IntAct=EBI-347263, EBI-1049564; CC Q13485; Q9Y6X2: PIAS3; NbExp=3; IntAct=EBI-347263, EBI-2803703; CC Q13485; P42338: PIK3CB; NbExp=3; IntAct=EBI-347263, EBI-2609540; CC Q13485; P28340: POLD1; NbExp=7; IntAct=EBI-347263, EBI-716569; CC Q13485; Q16633: POU2AF1; NbExp=3; IntAct=EBI-347263, EBI-943588; CC Q13485; O00743: PPP6C; NbExp=4; IntAct=EBI-347263, EBI-359751; CC Q13485; P04049: RAF1; NbExp=6; IntAct=EBI-347263, EBI-365996; CC Q13485; Q8WWW0: RASSF5; NbExp=7; IntAct=EBI-347263, EBI-367390; CC Q13485; Q8NHQ8: RASSF8; NbExp=5; IntAct=EBI-347263, EBI-306805; CC Q13485; Q04206: RELA; NbExp=5; IntAct=EBI-347263, EBI-73886; CC Q13485; P21912: SDHB; NbExp=5; IntAct=EBI-347263, EBI-1056481; CC Q13485; O95754: SEMA4F; NbExp=5; IntAct=EBI-347263, EBI-20855345; CC Q13485; P29353: SHC1; NbExp=5; IntAct=EBI-347263, EBI-78835; CC Q13485; P12755: SKI; NbExp=16; IntAct=EBI-347263, EBI-347281; CC Q13485; P12757: SKIL; NbExp=6; IntAct=EBI-347263, EBI-2902468; CC Q13485; Q13309: SKP2; NbExp=5; IntAct=EBI-347263, EBI-456291; CC Q13485; Q15797: SMAD1; NbExp=18; IntAct=EBI-347263, EBI-1567153; CC Q13485; Q15796: SMAD2; NbExp=31; IntAct=EBI-347263, EBI-1040141; CC Q13485; P84022: SMAD3; NbExp=43; IntAct=EBI-347263, EBI-347161; CC Q13485; Q13485: SMAD4; NbExp=7; IntAct=EBI-347263, EBI-347263; CC Q13485; O15198: SMAD9; NbExp=4; IntAct=EBI-347263, EBI-748763; CC Q13485; O15198-2: SMAD9; NbExp=3; IntAct=EBI-347263, EBI-12273450; CC Q13485; O15524: SOCS1; NbExp=4; IntAct=EBI-347263, EBI-968198; CC Q13485; P08047: SP1; NbExp=2; IntAct=EBI-347263, EBI-298336; CC Q13485; Q08117-2: TLE5; NbExp=3; IntAct=EBI-347263, EBI-11741437; CC Q13485; Q9UPN9: TRIM33; NbExp=6; IntAct=EBI-347263, EBI-2214398; CC Q13485; P16473: TSHR; NbExp=6; IntAct=EBI-347263, EBI-13939599; CC Q13485; P63279: UBE2I; NbExp=6; IntAct=EBI-347263, EBI-80168; CC Q13485; Q93008: USP9X; NbExp=2; IntAct=EBI-347263, EBI-302524; CC Q13485; Q9UPY6: WASF3; NbExp=6; IntAct=EBI-347263, EBI-3907133; CC Q13485; Q15915: ZIC1; NbExp=3; IntAct=EBI-347263, EBI-11963196; CC Q13485; P70056: foxh1; Xeno; NbExp=2; IntAct=EBI-347263, EBI-9969973; CC Q13485; P70398: Usp9x; Xeno; NbExp=4; IntAct=EBI-347263, EBI-2214043; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15799969, CC ECO:0000269|PubMed:17327236}. Nucleus {ECO:0000269|PubMed:15799969}. CC Note=Cytoplasmic in the absence of ligand. Migrates to the nucleus when CC complexed with R-SMAD (PubMed:15799969). PDPK1 prevents its nuclear CC translocation in response to TGF-beta (PubMed:17327236). CC {ECO:0000269|PubMed:15799969, ECO:0000269|PubMed:17327236}. CC -!- DOMAIN: The MH1 domain is required for DNA binding. CC -!- DOMAIN: The MH2 domain is required for both homomeric and heteromeric CC interactions and for transcriptional regulation. Sufficient for nuclear CC import. CC -!- PTM: Phosphorylated by PDPK1. {ECO:0000269|PubMed:17327236}. CC -!- PTM: Monoubiquitinated on Lys-519 by E3 ubiquitin-protein ligase CC TRIM33. Monoubiquitination hampers its ability to form a stable complex CC with activated SMAD2/3 resulting in inhibition of TGF-beta/BMP CC signaling cascade. Deubiquitination by USP9X restores its competence to CC mediate TGF-beta signaling. {ECO:0000269|PubMed:19135894}. CC -!- DISEASE: Pancreatic cancer (PNCA) [MIM:260350]: A malignant neoplasm of CC the pancreas. Tumors can arise from both the exocrine and endocrine CC portions of the pancreas, but 95% of them develop from the exocrine CC portion, including the ductal epithelium, acinar cells, connective CC tissue, and lymphatic tissue. {ECO:0000269|PubMed:8553070}. Note=The CC gene represented in this entry may be involved in disease pathogenesis. CC -!- DISEASE: Juvenile polyposis syndrome (JPS) [MIM:174900]: Autosomal CC dominant gastrointestinal hamartomatous polyposis syndrome in which CC patients are at risk for developing gastrointestinal cancers. The CC lesions are typified by a smooth histological appearance, predominant CC stroma, cystic spaces and lack of a smooth muscle core. Multiple CC juvenile polyps usually occur in a number of Mendelian disorders. CC Sometimes, these polyps occur without associated features as in JPS; CC here, polyps tend to occur in the large bowel and are associated with CC an increased risk of colon and other gastrointestinal cancers. CC {ECO:0000269|PubMed:12417513, ECO:0000269|PubMed:9811934}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Juvenile polyposis/hereditary hemorrhagic telangiectasia CC syndrome (JP/HHT) [MIM:175050]: JP/HHT syndrome phenotype consists of CC the coexistence of juvenile polyposis (JIP) and hereditary hemorrhagic CC telangiectasia (HHT) [MIM:187300] in a single individual. JIP and HHT CC are autosomal dominant disorders with distinct and non-overlapping CC clinical features. The former, an inherited gastrointestinal malignancy CC predisposition, is caused by mutations in SMAD4 or BMPR1A, and the CC latter is a vascular malformation disorder caused by mutations in ENG CC or ACVRL1. All four genes encode proteins involved in the transforming- CC growth-factor-signaling pathway. Although there are reports of patients CC and families with phenotypes of both disorders combined, the genetic CC etiology of this association is unknown. {ECO:0000269|PubMed:15031030}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:16959974}. Note=The disease CC may be caused by variants affecting the gene represented in this entry. CC -!- DISEASE: Note=SMAD4 variants may be associated with susceptibility to CC pulmonary hypertension, a disorder characterized by plexiform lesions CC of proliferating endothelial cells in pulmonary arterioles. The lesions CC lead to elevated pulmonary arterial pression, right ventricular CC failure, and death. The disease can occur from infancy throughout life CC and it has a mean age at onset of 36 years. Penetrance is reduced. CC Although familial pulmonary hypertension is rare, cases secondary to CC known etiologies are more common and include those associated with the CC appetite-suppressant drugs. {ECO:0000269|PubMed:21898662}. CC -!- DISEASE: Myhre syndrome (MYHRS) [MIM:139210]: An autosomal dominant CC syndrome characterized by pre- and postnatal growth deficiency, CC intellectual disability, generalized muscle hypertrophy and striking CC muscular build, decreased joint mobility, cryptorchidism, and unusual CC facies. Dysmorphic facial features include microcephaly, midface CC hypoplasia, prognathism, and blepharophimosis. Typical skeletal CC anomalies are short stature, square body shape, broad ribs, iliac CC hypoplasia, brachydactyly, flattened vertebrae, and thickened calvaria. CC Other features, such as congenital heart disease, may also occur. CC {ECO:0000269|PubMed:22158539, ECO:0000269|PubMed:22243968}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the dwarfin/SMAD family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/371/SMAD4"; CC -!- WEB RESOURCE: Name=Mendelian genes SMAD family member 4 (SMAD4); CC Note=Leiden Open Variation Database (LOVD); CC URL="https://databases.lovd.nl/shared/genes/SMAD4"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF045447; AAC03051.1; -; Genomic_DNA. DR EMBL; AF045438; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; AF045439; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; AF045440; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; AF045441; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; AF045442; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; AF045443; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; AF045444; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; AF045445; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; AF045446; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; U44378; AAA91041.1; -; mRNA. DR EMBL; AK290770; BAF83459.1; -; mRNA. DR EMBL; CH471096; EAW62985.1; -; Genomic_DNA. DR EMBL; BC002379; AAH02379.1; -; mRNA. DR CCDS; CCDS11950.1; -. DR PIR; S71811; S71811. DR RefSeq; NP_001393970.1; NM_001407041.1. DR RefSeq; NP_001393971.1; NM_001407042.1. DR RefSeq; NP_005350.1; NM_005359.6. DR PDB; 1DD1; X-ray; 2.62 A; A/B/C=285-552. DR PDB; 1G88; X-ray; 3.00 A; A/B/C=285-552. DR PDB; 1MR1; X-ray; 2.85 A; A/B=319-552. DR PDB; 1U7F; X-ray; 2.60 A; B=314-552. DR PDB; 1U7V; X-ray; 2.70 A; B=314-549. DR PDB; 1YGS; X-ray; 2.10 A; A=319-552. DR PDB; 5C4V; X-ray; 2.60 A; A/C/E=314-549. DR PDB; 5MEY; X-ray; 2.05 A; A=10-140. DR PDB; 5MEZ; X-ray; 2.98 A; A/B=10-140. DR PDB; 5MF0; X-ray; 3.03 A; A/B=10-140. DR PDB; 5UWU; X-ray; 2.24 A; D=133-149. DR PDB; 6YIC; X-ray; 1.60 A; P=398-406. DR PDBsum; 1DD1; -. DR PDBsum; 1G88; -. DR PDBsum; 1MR1; -. DR PDBsum; 1U7F; -. DR PDBsum; 1U7V; -. DR PDBsum; 1YGS; -. DR PDBsum; 5C4V; -. DR PDBsum; 5MEY; -. DR PDBsum; 5MEZ; -. DR PDBsum; 5MF0; -. DR PDBsum; 5UWU; -. DR PDBsum; 6YIC; -. DR AlphaFoldDB; Q13485; -. DR SASBDB; Q13485; -. DR SMR; Q13485; -. DR BioGRID; 110264; 532. DR ComplexPortal; CPX-1; SMAD2-SMAD3-SMAD4 complex. DR ComplexPortal; CPX-3208; SMAD2-SMAD4 complex. DR ComplexPortal; CPX-3252; SMAD3-SMAD4 complex. DR ComplexPortal; CPX-54; SMAD1-SMAD4 complex. DR CORUM; Q13485; -. DR DIP; DIP-31512N; -. DR FunCoup; Q13485; 4708. DR IntAct; Q13485; 524. DR MINT; Q13485; -. DR STRING; 9606.ENSP00000341551; -. DR GlyCosmos; Q13485; 5 sites, 1 glycan. DR GlyGen; Q13485; 10 sites, 1 O-linked glycan (10 sites). DR iPTMnet; Q13485; -. DR MetOSite; Q13485; -. DR PhosphoSitePlus; Q13485; -. DR SwissPalm; Q13485; -. DR BioMuta; SMAD4; -. DR DMDM; 13959561; -. DR CPTAC; CPTAC-1268; -. DR CPTAC; CPTAC-1269; -. DR jPOST; Q13485; -. DR MassIVE; Q13485; -. DR PaxDb; 9606-ENSP00000341551; -. DR PeptideAtlas; Q13485; -. DR ProteomicsDB; 59479; -. DR Pumba; Q13485; -. DR Antibodypedia; 3711; 1151 antibodies from 45 providers. DR DNASU; 4089; -. DR Ensembl; ENST00000342988.8; ENSP00000341551.3; ENSG00000141646.18. DR Ensembl; ENST00000398417.6; ENSP00000381452.1; ENSG00000141646.18. DR Ensembl; ENST00000588860.6; ENSP00000465878.2; ENSG00000141646.18. DR Ensembl; ENST00000589076.6; ENSP00000466934.2; ENSG00000141646.18. DR Ensembl; ENST00000589941.2; ENSP00000465874.2; ENSG00000141646.18. DR Ensembl; ENST00000590061.2; ENSP00000464772.2; ENSG00000141646.18. DR GeneID; 4089; -. DR KEGG; hsa:4089; -. DR MANE-Select; ENST00000342988.8; ENSP00000341551.3; NM_005359.6; NP_005350.1. DR UCSC; uc010xdp.3; human. DR AGR; HGNC:6770; -. DR CIViC; 4089; 29 evidence items across 22 molecular profiles. DR ClinPGx; PA30527; -. DR CTD; 4089; -. DR DisGeNET; 4089; -. DR GeneCards; SMAD4; -. DR GeneReviews; SMAD4; -. DR HGNC; HGNC:6770; SMAD4. DR HPA; ENSG00000141646; Low tissue specificity. DR MalaCards; SMAD4; -. DR MIM; 114500; phenotype. DR MIM; 139210; phenotype. DR MIM; 174900; phenotype. DR MIM; 175050; phenotype. DR MIM; 260350; phenotype. DR MIM; 600993; gene. DR OpenTargets; ENSG00000141646; -. DR Orphanet; 1333; Familial pancreatic carcinoma. DR Orphanet; 91387; Familial thoracic aortic aneurysm and aortic dissection. DR Orphanet; 329971; Generalized juvenile polyposis/juvenile polyposis coli. DR Orphanet; 774; Hereditary hemorrhagic telangiectasia. DR Orphanet; 2588; Myhre syndrome. DR VEuPathDB; HostDB:ENSG00000141646; -. DR eggNOG; KOG3701; Eukaryota. DR GeneTree; ENSGT00940000157435; -. DR InParanoid; Q13485; -. DR OMA; CWIEVQI; -. DR OrthoDB; 5875866at2759; -. DR PAN-GO; Q13485; 10 GO annotations based on evolutionary models. DR PhylomeDB; Q13485; -. DR PathwayCommons; Q13485; -. DR Reactome; R-HSA-1181150; Signaling by NODAL. DR Reactome; R-HSA-1502540; Signaling by Activin. DR Reactome; R-HSA-201451; Signaling by BMP. DR Reactome; R-HSA-2173789; TGF-beta receptor signaling activates SMADs. DR Reactome; R-HSA-2173795; Downregulation of SMAD2/3:SMAD4 transcriptional activity. DR Reactome; R-HSA-2173796; SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription. DR Reactome; R-HSA-3311021; SMAD4 MH2 Domain Mutants in Cancer. DR Reactome; R-HSA-3315487; SMAD2/3 MH2 Domain Mutants in Cancer. DR Reactome; R-HSA-452723; Transcriptional regulation of pluripotent stem cells. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-8941326; RUNX2 regulates bone development. DR Reactome; R-HSA-8941855; RUNX3 regulates CDKN1A transcription. DR Reactome; R-HSA-8952158; RUNX3 regulates BCL2L11 (BIM) transcription. DR Reactome; R-HSA-9615017; FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes. DR Reactome; R-HSA-9617828; FOXO-mediated transcription of cell cycle genes. DR Reactome; R-HSA-9733709; Cardiogenesis. DR Reactome; R-HSA-9735871; SARS-CoV-1 targets host intracellular signalling and regulatory pathways. DR Reactome; R-HSA-9754189; Germ layer formation at gastrulation. DR Reactome; R-HSA-9823730; Formation of definitive endoderm. DR Reactome; R-HSA-9839394; TGFBR3 expression. DR Reactome; R-HSA-9844594; Transcriptional regulation of brown and beige adipocyte differentiation by EBF2. DR SignaLink; Q13485; -. DR SIGNOR; Q13485; -. DR Agora; ENSG00000141646; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 4089; 81 hits in 1216 CRISPR screens. DR ChiTaRS; SMAD4; human. DR EvolutionaryTrace; Q13485; -. DR GeneWiki; Mothers_against_decapentaplegic_homolog_4; -. DR GenomeRNAi; 4089; -. DR Pharos; Q13485; Tbio. DR PRO; PR:Q13485; -. DR Proteomes; UP000005640; Chromosome 18. DR RNAct; Q13485; protein. DR Bgee; ENSG00000141646; Expressed in ventricular zone and 198 other cell types or tissues. DR ExpressionAtlas; Q13485; baseline and differential. DR GO; GO:0032444; C:activin responsive factor complex; IDA:BHF-UCL. DR GO; GO:0005813; C:centrosome; IDA:HPA. DR GO; GO:0000785; C:chromatin; IDA:BHF-UCL. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0097542; C:ciliary tip; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0071144; C:heteromeric SMAD protein complex; IPI:ComplexPortal. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:BHF-UCL. DR GO; GO:0071141; C:SMAD protein complex; IDA:UniProtKB. DR GO; GO:0005667; C:transcription regulator complex; IDA:BHF-UCL. DR GO; GO:0003682; F:chromatin binding; IEA:Ensembl. DR GO; GO:0005518; F:collagen binding; IEA:Ensembl. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:GO_Central. DR GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:BHF-UCL. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB. DR GO; GO:0031005; F:filamin binding; IEA:Ensembl. DR GO; GO:0070411; F:I-SMAD binding; IPI:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL. DR GO; GO:0070412; F:R-SMAD binding; IPI:BHF-UCL. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:GO_Central. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IEA:Ensembl. DR GO; GO:0043565; F:sequence-specific DNA binding; IDA:BHF-UCL. DR GO; GO:0043199; F:sulfate binding; IMP:CAFA. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:BHF-UCL. DR GO; GO:0001223; F:transcription coactivator binding; IPI:UniProtKB. DR GO; GO:0001222; F:transcription corepressor binding; IPI:HGNC-UCL. DR GO; GO:0032924; P:activin receptor signaling pathway; NAS:ComplexPortal. DR GO; GO:0030325; P:adrenal gland development; IEA:Ensembl. DR GO; GO:0009653; P:anatomical structure morphogenesis; IBA:GO_Central. DR GO; GO:0036302; P:atrioventricular canal development; ISS:BHF-UCL. DR GO; GO:0003190; P:atrioventricular valve formation; ISS:BHF-UCL. DR GO; GO:0007411; P:axon guidance; IEA:Ensembl. DR GO; GO:0030509; P:BMP signaling pathway; IDA:BHF-UCL. DR GO; GO:0003360; P:brainstem development; IEA:Ensembl. DR GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IEA:Ensembl. DR GO; GO:0003161; P:cardiac conduction system development; NAS:BHF-UCL. DR GO; GO:0014898; P:cardiac muscle hypertrophy in response to stress; IEA:Ensembl. DR GO; GO:0030154; P:cell differentiation; IBA:GO_Central. DR GO; GO:0008283; P:cell population proliferation; IEA:Ensembl. DR GO; GO:0071773; P:cellular response to BMP stimulus; NAS:BHF-UCL. DR GO; GO:0071333; P:cellular response to glucose stimulus; IEA:Ensembl. DR GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IMP:BHF-UCL. DR GO; GO:0048589; P:developmental growth; IEA:Ensembl. DR GO; GO:0006351; P:DNA-templated transcription; IDA:ComplexPortal. DR GO; GO:0042733; P:embryonic digit morphogenesis; IEA:Ensembl. DR GO; GO:0060956; P:endocardial cell differentiation; ISS:BHF-UCL. DR GO; GO:0042118; P:endothelial cell activation; IEA:Ensembl. DR GO; GO:0010631; P:epithelial cell migration; IMP:BHF-UCL. DR GO; GO:0001837; P:epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0003198; P:epithelial to mesenchymal transition involved in endocardial cushion formation; IEA:Ensembl. DR GO; GO:0070371; P:ERK1 and ERK2 cascade; IEA:Ensembl. DR GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IMP:BHF-UCL. DR GO; GO:0061040; P:female gonad morphogenesis; IEA:Ensembl. DR GO; GO:0048859; P:formation of anatomical boundary; IEA:Ensembl. DR GO; GO:0001702; P:gastrulation with mouth forming second; IEA:Ensembl. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0070102; P:interleukin-6-mediated signaling pathway; ISS:BHF-UCL. DR GO; GO:0006879; P:intracellular iron ion homeostasis; ISS:BHF-UCL. DR GO; GO:0035556; P:intracellular signal transduction; IMP:CACAO. DR GO; GO:0003220; P:left ventricular cardiac muscle tissue morphogenesis; ISS:BHF-UCL. DR GO; GO:0048382; P:mesendoderm development; IEA:Ensembl. DR GO; GO:0072133; P:metanephric mesenchyme morphogenesis; IEA:Ensembl. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:BHF-UCL. DR GO; GO:0010614; P:negative regulation of cardiac muscle hypertrophy; ISS:BHF-UCL. DR GO; GO:1905305; P:negative regulation of cardiac myofibril assembly; ISS:BHF-UCL. DR GO; GO:0030308; P:negative regulation of cell growth; IDA:BHF-UCL. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:BHF-UCL. DR GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; ISS:BHF-UCL. DR GO; GO:0042177; P:negative regulation of protein catabolic process; IEA:Ensembl. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISS:BHF-UCL. DR GO; GO:0072134; P:nephrogenic mesenchyme morphogenesis; IEA:Ensembl. DR GO; GO:0014033; P:neural crest cell differentiation; IEA:Ensembl. DR GO; GO:0048665; P:neuron fate specification; IMP:BHF-UCL. DR GO; GO:0001649; P:osteoblast differentiation; IEA:Ensembl. DR GO; GO:0003148; P:outflow tract septum morphogenesis; ISS:BHF-UCL. DR GO; GO:0001541; P:ovarian follicle development; IEA:Ensembl. DR GO; GO:0010666; P:positive regulation of cardiac muscle cell apoptotic process; IEA:Ensembl. DR GO; GO:0003251; P:positive regulation of cell proliferation involved in heart valve morphogenesis; ISS:BHF-UCL. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; ISS:BHF-UCL. DR GO; GO:1901203; P:positive regulation of extracellular matrix assembly; IMP:BHF-UCL. DR GO; GO:0046881; P:positive regulation of follicle-stimulating hormone secretion; IEA:Ensembl. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0033686; P:positive regulation of luteinizing hormone secretion; IEA:Ensembl. DR GO; GO:1902895; P:positive regulation of miRNA transcription; IEA:Ensembl. DR GO; GO:0060391; P:positive regulation of SMAD protein signal transduction; ISS:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:GO_Central. DR GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0006355; P:regulation of DNA-templated transcription; NAS:ComplexPortal. DR GO; GO:0051797; P:regulation of hair follicle development; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central. DR GO; GO:0032909; P:regulation of transforming growth factor beta2 production; IMP:BHF-UCL. DR GO; GO:0001666; P:response to hypoxia; IMP:BHF-UCL. DR GO; GO:0071559; P:response to transforming growth factor beta; IDA:UniProtKB. DR GO; GO:0048733; P:sebaceous gland development; IEA:Ensembl. DR GO; GO:0062009; P:secondary palate development; ISS:BHF-UCL. DR GO; GO:0072520; P:seminiferous tubule development; IEA:Ensembl. DR GO; GO:0007338; P:single fertilization; IEA:Ensembl. DR GO; GO:0060395; P:SMAD protein signal transduction; IDA:BHF-UCL. DR GO; GO:0032525; P:somite rostral/caudal axis specification; IEA:Ensembl. DR GO; GO:0007283; P:spermatogenesis; IEA:Ensembl. DR GO; GO:0006366; P:transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0060065; P:uterus development; IEA:Ensembl. DR GO; GO:0060412; P:ventricular septum morphogenesis; ISS:BHF-UCL. DR CDD; cd10492; MH1_SMAD_4; 1. DR CDD; cd10498; MH2_SMAD_4; 1. DR DisProt; DP00464; -. DR FunFam; 2.60.200.10:FF:000002; Mothers against decapentaplegic homolog; 1. DR FunFam; 3.90.520.10:FF:000002; Mothers against decapentaplegic homolog; 1. DR Gene3D; 2.60.200.10; -; 1. DR Gene3D; 3.90.520.10; SMAD MH1 domain; 1. DR IDEAL; IID00132; -. DR InterPro; IPR013790; Dwarfin. DR InterPro; IPR003619; MAD_homology1_Dwarfin-type. DR InterPro; IPR013019; MAD_homology_MH1. DR InterPro; IPR017855; SMAD-like_dom_sf. DR InterPro; IPR001132; SMAD_dom_Dwarfin-type. DR InterPro; IPR008984; SMAD_FHA_dom_sf. DR InterPro; IPR036578; SMAD_MH1_sf. DR PANTHER; PTHR13703:SF63; MOTHERS AGAINST DECAPENTAPLEGIC HOMOLOG 4; 1. DR PANTHER; PTHR13703; SMAD; 1. DR Pfam; PF03165; MH1; 1. DR Pfam; PF03166; MH2; 1. DR SMART; SM00523; DWA; 1. DR SMART; SM00524; DWB; 1. DR SUPFAM; SSF56366; SMAD MH1 domain; 1. DR SUPFAM; SSF49879; SMAD/FHA domain; 1. DR PROSITE; PS51075; MH1; 1. DR PROSITE; PS51076; MH2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Cytoplasm; Disease variant; DNA-binding; KW Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Transcription; KW Transcription regulation; Ubl conjugation; Zinc. FT CHAIN 1..552 FT /note="SMAD family member 4" FT /id="PRO_0000090861" FT DOMAIN 18..142 FT /note="MH1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00438" FT DOMAIN 323..552 FT /note="MH2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00439" FT REGION 1..322 FT /note="Mediates interaction with ZBTB7A" FT /evidence="ECO:0000269|PubMed:25514493" FT REGION 44..69 FT /note="Required for interaction with TSC22D1" FT /evidence="ECO:0000269|PubMed:15881652" FT REGION 168..194 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 236..256 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 275..320 FT /note="SAD" FT COMPBIAS 170..194 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 245..256 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 71 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250" FT BINDING 115 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250" FT BINDING 127 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250" FT BINDING 132 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250" FT SITE 515 FT /note="Necessary for heterotrimerization" FT MOD_RES 37 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 428 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 507 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT CROSSLNK 113 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:28112733" FT CROSSLNK 519 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19135894" FT VARIANT 13 FT /note="N -> S (rare variant; found in a patient with FT pulmonary hypertension; uncertain significance; FT dbSNP:rs281875323)" FT /evidence="ECO:0000269|PubMed:21898662" FT /id="VAR_066870" FT VARIANT 130 FT /note="P -> S (in a colorectal cancer sample; somatic FT mutation; dbSNP:rs1555685186)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036475" FT VARIANT 330 FT /note="E -> G (in JPS; dbSNP:rs281875324)" FT /evidence="ECO:0000269|PubMed:12417513" FT /id="VAR_022833" FT VARIANT 351 FT /note="D -> N (in a colorectal cancer sample; somatic FT mutation; dbSNP:rs1057519739)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036476" FT VARIANT 352 FT /note="G -> R (in JP/HHT and JPS; dbSNP:rs121912581)" FT /evidence="ECO:0000269|PubMed:12417513, FT ECO:0000269|PubMed:15031030" FT /id="VAR_019571" FT VARIANT 361 FT /note="R -> C (in JPS; dbSNP:rs80338963)" FT /evidence="ECO:0000269|PubMed:9811934" FT /id="VAR_019572" FT VARIANT 361 FT /note="R -> H (in a colorectal cancer sample; somatic FT mutation; dbSNP:rs377767347)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036477" FT VARIANT 386 FT /note="G -> D (in JP/HHT; dbSNP:rs121912580)" FT /evidence="ECO:0000269|PubMed:15031030" FT /id="VAR_019573" FT VARIANT 493 FT /note="D -> H (in pancreatic carcinoma; dbSNP:rs121912578)" FT /evidence="ECO:0000269|PubMed:8553070" FT /id="VAR_011380" FT VARIANT 500 FT /note="I -> M (in MYHRS; dbSNP:rs281875320)" FT /evidence="ECO:0000269|PubMed:22158539" FT /id="VAR_067602" FT VARIANT 500 FT /note="I -> T (in MYHRS; there is an enhanced levels of FT SMAD4 protein with lower levels of ubiquitinated SMAD4 FT fibroblasts compared to controls suggesting stabilization FT of the mutant protein; 8-fold increase in phosphorylated FT SMAD2 and SMAD3; 11-fold increase in phosphorylated SMAD1, FT SMAD5 and SMAD8 in cell nuclei compared to controls; FT dbSNP:rs281875321)" FT /evidence="ECO:0000269|PubMed:22158539, FT ECO:0000269|PubMed:22243968" FT /id="VAR_067603" FT VARIANT 500 FT /note="I -> V (in MYHRS; dbSNP:rs281875322)" FT /evidence="ECO:0000269|PubMed:22158539, FT ECO:0000269|PubMed:22243968" FT /id="VAR_067604" FT MUTAGEN 416 FT /note="R->S: No effect on heterotrimerization. Partially FT diminished transcriptional activation." FT /evidence="ECO:0000269|PubMed:11224571" FT MUTAGEN 496 FT /note="R->S: No effect on heterotrimerization. Partially FT diminished transcriptional activation." FT MUTAGEN 502 FT /note="R->S: No effect on heterotrimerization. Greatly FT reduced transcriptional activation." FT /evidence="ECO:0000269|PubMed:11224571" FT MUTAGEN 515 FT /note="R->S: Reduced heterotrimerization." FT /evidence="ECO:0000269|PubMed:11224571" FT MUTAGEN 519 FT /note="K->R: Abolishes ubiquitination." FT /evidence="ECO:0000269|PubMed:19135894" FT HELIX 16..24 FT /evidence="ECO:0007829|PDB:5MEY" FT STRAND 29..31 FT /evidence="ECO:0007829|PDB:5MEY" FT HELIX 33..47 FT /evidence="ECO:0007829|PDB:5MEY" FT HELIX 51..62 FT /evidence="ECO:0007829|PDB:5MEY" FT TURN 63..65 FT /evidence="ECO:0007829|PDB:5MEY" FT STRAND 73..75 FT /evidence="ECO:0007829|PDB:5MEY" FT STRAND 78..80 FT /evidence="ECO:0007829|PDB:5MEY" FT STRAND 82..84 FT /evidence="ECO:0007829|PDB:5MEY" FT STRAND 87..89 FT /evidence="ECO:0007829|PDB:5MEY" FT HELIX 91..99 FT /evidence="ECO:0007829|PDB:5MEY" FT STRAND 109..111 FT /evidence="ECO:0007829|PDB:5MEY" FT HELIX 119..121 FT /evidence="ECO:0007829|PDB:5MEY" FT STRAND 124..127 FT /evidence="ECO:0007829|PDB:5MEY" FT HELIX 130..132 FT /evidence="ECO:0007829|PDB:5MEY" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:5MEY" FT HELIX 143..145 FT /evidence="ECO:0007829|PDB:5UWU" FT STRAND 288..291 FT /evidence="ECO:0007829|PDB:1DD1" FT STRAND 321..330 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 333..342 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 346..353 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 359..363 FT /evidence="ECO:0007829|PDB:1YGS" FT HELIX 364..366 FT /evidence="ECO:0007829|PDB:1U7F" FT HELIX 374..380 FT /evidence="ECO:0007829|PDB:1YGS" FT TURN 381..385 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 387..392 FT /evidence="ECO:0007829|PDB:1YGS" FT TURN 393..395 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 396..401 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 403..405 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 407..410 FT /evidence="ECO:0007829|PDB:1YGS" FT HELIX 412..416 FT /evidence="ECO:0007829|PDB:1YGS" FT TURN 417..419 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 427..429 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 434..438 FT /evidence="ECO:0007829|PDB:1YGS" FT HELIX 440..454 FT /evidence="ECO:0007829|PDB:1YGS" FT TURN 455..458 FT /evidence="ECO:0007829|PDB:1DD1" FT HELIX 461..464 FT /evidence="ECO:0007829|PDB:1DD1" FT HELIX 493..497 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 500..506 FT /evidence="ECO:0007829|PDB:1YGS" FT HELIX 518..520 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 521..529 FT /evidence="ECO:0007829|PDB:1YGS" FT HELIX 530..541 FT /evidence="ECO:0007829|PDB:1YGS" SQ SEQUENCE 552 AA; 60439 MW; 7EE3C4647712DA90 CRC64; MDNMSITNTP TSNDACLSIV HSLMCHRQGG ESETFAKRAI ESLVKKLKEK KDELDSLITA ITTNGAHPSK CVTIQRTLDG RLQVAGRKGF PHVIYARLWR WPDLHKNELK HVKYCQYAFD LKCDSVCVNP YHYERVVSPG IDLSGLTLQS NAPSSMMVKD EYVHDFEGQP SLSTEGHSIQ TIQHPPSNRA STETYSTPAL LAPSESNATS TANFPNIPVA STSQPASILG GSHSEGLLQI ASGPQPGQQQ NGFTGQPATY HHNSTTTWTG SRTAPYTPNL PHHQNGHLQH HPPMPPHPGH YWPVHNELAF QPPISNHPAP EYWCSIAYFE MDVQVGETFK VPSSCPIVTV DGYVDPSGGD RFCLGQLSNV HRTEAIERAR LHIGKGVQLE CKGEGDVWVR CLSDHAVFVQ SYYLDREAGR APGDAVHKIY PSAYIKVFDL RQCHRQMQQQ AATAQAAAAA QAAAVAGNIP GPGSVGGIAP AISLSAAAGI GVDDLRRLCI LRMSFVKGWG PDYPRQSIKE TPCWIEIHLH RALQLLDEVL HTMPIADPQP LD // ID SP1_HUMAN Reviewed; 785 AA. AC P08047; E4Z9M7; G5E9M8; Q86TN8; Q9H3Q5; Q9NR51; Q9NY21; Q9NYE7; DT 01-AUG-1988, integrated into UniProtKB/Swiss-Prot. DT 27-APR-2001, sequence version 3. DT 28-JAN-2026, entry version 268. DE RecName: Full=Transcription factor Sp1; GN Name=SP1; Synonyms=TSFP1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION, AND TISSUE SPECIFICITY. RX PubMed=21798247; DOI=10.1016/j.bbrc.2011.07.047; RA Infantino V., Convertini P., Iacobazzi F., Pisano I., Scarcia P., RA Iacobazzi V.; RT "Identification of a novel Sp1 splice variant as a strong transcriptional RT activator."; RL Biochem. Biophys. Res. Commun. 412:86-91(2011). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16541075; DOI=10.1038/nature04569; RA Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y., RA Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C., RA Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C., RA Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., RA Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E., RA Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., RA Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., RA Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., RA Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., RA Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., RA Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., RA Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., RA Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., RA Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., RA Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K., RA Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D., RA Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R., RA David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E., RA D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N., RA Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N., RA Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R., RA Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S., RA LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H., RA Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P., RA Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G., RA Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E., RA Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S., RA Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., RA Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J., RA Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A., RA Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M., RA Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I., RA Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A., RA Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y., RA Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A., RA Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F., RA Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L., RA Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G., RA Gibbs R.A.; RT "The finished DNA sequence of human chromosome 12."; RL Nature 440:346-351(2006). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain, and Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 4-785 (ISOFORM 1). RC TISSUE=Cervix carcinoma; RA Haggart M.H., Ladurner A.G.; RL Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-558 (ISOFORM 1), AND TRANS-SPLICING. RX PubMed=10973950; DOI=10.1074/jbc.m002010200; RA Takahara T., Kanazu S., Yanagisawa S., Akanuma H.; RT "Heterogeneous Sp1 mRNAs in human HepG2 cells include a product of RT homotypic trans-splicing."; RL J. Biol. Chem. 275:38067-38072(2000). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 90-785 (ISOFORM 1/2), AND PROTEIN SEQUENCE OF RP 359-375 AND 670-675. RX PubMed=3319186; DOI=10.1016/0092-8674(87)90594-0; RA Kadonaga J.T., Carner K.R., Masiarz F.R., Tjian R.; RT "Isolation of cDNA encoding transcription factor Sp1 and functional RT analysis of the DNA binding domain."; RL Cell 51:1079-1090(1987). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-109 (ISOFORM 1). RA Nicolas M., Noe V., Ciudad C.J.; RT "Expression of transcription factor Sp1 mRNA in mammalian cells."; RL Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-98 (ISOFORM 1). RA Handschug K., Huebner A.; RT "Sequencing of the 5' end of human transcription factor SP1 mRNA."; RL Submitted (FEB-2000) to the EMBL/GenBank/DDBJ databases. RN [10] RP GLYCOSYLATION. RX PubMed=3139301; DOI=10.1016/0092-8674(88)90015-3; RA Jackson S.P., Tjian R.; RT "O-glycosylation of eukaryotic transcription factors: implications for RT mechanisms of transcriptional regulation."; RL Cell 55:125-133(1988). RN [11] RP TRANSACTIVATION DOMAINS. RX PubMed=3142690; DOI=10.1016/0092-8674(88)90144-4; RA Courey A.J., Tjian R.; RT "Analysis of Sp1 in vivo reveals multiple transcriptional domains, RT including a novel glutamine-rich activation motif."; RL Cell 55:887-898(1988). RN [12] RP INTERACTION WITH HIV-1 VPR (MICROBIAL INFECTION). RX PubMed=7592727; DOI=10.1074/jbc.270.43.25564; RA Wang L., Mukherjee S., Jia F., Narayan O., Zhao L.J.; RT "Interaction of virion protein Vpr of human immunodeficiency virus type 1 RT with cellular transcription factor Sp1 and trans-activation of viral long RT terminal repeat."; RL J. Biol. Chem. 270:25564-25569(1995). RN [13] RP IDENTIFICATION OF SEROTONIN 1A RECEPTOR PROMOTER BINDING SITES. RX PubMed=8626793; DOI=10.1074/jbc.271.8.4417; RA Parks C.L., Shenk T.; RT "The serotonin 1a receptor gene contains a TATA-less promoter that responds RT to MAZ and Sp1."; RL J. Biol. Chem. 271:4417-4430(1996). RN [14] RP GLYCOSYLATION AT SER-491, MUTAGENESIS OF SER-491, AND IDENTIFICATION BY RP MASS SPECTROMETRY. RX PubMed=9343410; DOI=10.1128/mcb.17.11.6472; RA Roos M.D., Su K., Baker J.R., Kudlow J.E.; RT "O glycosylation of an Sp1-derived peptide blocks known Sp1 protein RT interactions."; RL Mol. Cell. Biol. 17:6472-6480(1997). RN [15] RP INTERACTION WITH SV40 VP2/3 (MICROBIAL INFECTION). RX PubMed=9466902; DOI=10.1006/jmbi.1997.1461; RA Gordon-Shaag A., Ben-Nun-Shaul O., Kasamatsu H., Oppenheim A.B., RA Oppenheim A.; RT "The SV40 capsid protein VP3 cooperates with the cellular transcription RT factor Sp1 in DNA-binding and in regulating viral promoter activity."; RL J. Mol. Biol. 275:187-195(1998). RN [16] RP FUNCTION, AND INTERACTION WITH HLTF. RX PubMed=10391891; DOI=10.1074/jbc.274.28.19573; RA Ding H., Benotmane A.M., Suske G., Collen D., Belayew A.; RT "Functional interactions between Sp1 or Sp3 and the helicase-like RT transcription factor mediate basal expression from the human plasminogen RT activator inhibitor-1 gene."; RL J. Biol. Chem. 274:19573-19580(1999). RN [17] RP INTERACTION WITH ATF7IP; PHC2; POGZ AND HCFC1. RC TISSUE=Colon; RX PubMed=10976766; DOI=10.1023/a:1007177623283; RA Gunther M., Laithier M., Brison O.; RT "A set of proteins interacting with transcription factor Sp1 identified in RT a two-hybrid screening."; RL Mol. Cell. Biochem. 210:131-142(2000). RN [18] RP GLYCOSYLATION AT SER-491, FUNCTION, AND MUTAGENESIS OF SER-491. RX PubMed=11371615; DOI=10.1073/pnas.111099998; RA Yang X., Su K., Roos M.D., Chang Q., Paterson A.J., Kudlow J.E.; RT "O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its RT transcriptional capability."; RL Proc. Natl. Acad. Sci. U.S.A. 98:6611-6616(2001). RN [19] RP PHOSPHORYLATION AT THR-453 AND THR-739, FUNCTION, AND MUTAGENESIS OF RP THR-355; THR-453 AND THR-739. RX PubMed=11904305; DOI=10.1074/jbc.m201753200; RA Milanini-Mongiat J., Pouyssegur J., Pages G.; RT "Identification of two Sp1 phosphorylation sites for p42/p44 mitogen- RT activated protein kinases: their implication in vascular endothelial growth RT factor gene transcription."; RL J. Biol. Chem. 277:20631-20639(2002). RN [20] RP INTERACTION WITH ZBTB7A. RX PubMed=12004059; DOI=10.1074/jbc.m202078200; RA Lee D.K., Suh D., Edenberg H.J., Hur M.W.; RT "POZ domain transcription factor, FBI-1, represses transcription of RT ADH5/FDH by interacting with the zinc finger and interfering with DNA RT binding activity of Sp1."; RL J. Biol. Chem. 277:26761-26768(2002). RN [21] RP INTERACTION WITH SV40 VP1 (MICROBIAL INFECTION). RX PubMed=12021324; DOI=10.1128/jvi.76.12.5915-5924.2002; RA Gordon-Shaag A., Ben-Nun-Shaul O., Roitman V., Yosef Y., Oppenheim A.; RT "Cellular transcription factor Sp1 recruits simian virus 40 capsid proteins RT to the viral packaging signal, ses."; RL J. Virol. 76:5915-5924(2002). RN [22] RP INTERACTION WITH AATF. RX PubMed=12847090; DOI=10.1074/jbc.m306694200; RA Di Padova M., Bruno T., De Nicola F., Iezzi S., D'Angelo C., Gallo R., RA Nicosia D., Corbi N., Biroccio A., Floridi A., Passananti C., Fanciulli M.; RT "Che-1 arrests human colon carcinoma cell proliferation by displacing HDAC1 RT from the p21WAF1/CIP1 promoter."; RL J. Biol. Chem. 278:36496-36504(2003). RN [23] RP INTERACTION WITH VARICELLA-ZOSTER VIRUS IE62 PROTEIN (MICROBIAL INFECTION). RX PubMed=12855699; DOI=10.1074/jbc.m302259200; RA Peng H., He H., Hay J., Ruyechan W.T.; RT "Interaction between the varicella zoster virus IE62 major transactivator RT and cellular transcription factor Sp1."; RL J. Biol. Chem. 278:38068-38075(2003). RN [24] RP PHOSPHORYLATION AT THR-453 AND THR-739, FUNCTION, AND MUTAGENESIS OF RP THR-453 AND THR-739. RX PubMed=14593115; DOI=10.1074/jbc.m308254200; RA Bonello M.R., Khachigian L.M.; RT "Fibroblast growth factor-2 represses platelet-derived growth factor RT receptor-alpha (PDGFR-alpha) transcription via ERK1/2-dependent Sp1 RT phosphorylation and an atypical cis-acting element in the proximal PDGFR- RT alpha promoter."; RL J. Biol. Chem. 279:2377-2382(2004). RN [25] RP INTERACTION WITH ATF7IP AND ATF7IP2. RX PubMed=15691849; DOI=10.1074/jbc.m413654200; RA Ichimura T., Watanabe S., Sakamoto Y., Aoto T., Fujita N., Nakao M.; RT "Transcriptional repression and heterochromatin formation by MBD1 and RT MCAF/AM family proteins."; RL J. Biol. Chem. 280:13928-13935(2005). RN [26] RP INTERACTION WITH DDX3X. RX PubMed=16818630; DOI=10.1158/0008-5472.can-05-2415; RA Chao C.H., Chen C.M., Cheng P.L., Shih J.W., Tsou A.P., Lee Y.H.; RT "DDX3, a DEAD box RNA helicase with tumor growth-suppressive property and RT transcriptional regulation activity of the p21waf1/cip1 promoter, is a RT candidate tumor suppressor."; RL Cancer Res. 66:6579-6588(2006). RN [27] RP GLYCOSYLATION AT SER-612; THR-640; SER-641; SER-698 AND SER-702, RP PHOSPHORYLATION AT SER-612; THR-640; SER-641; SER-698 AND SER-702, RP INDUCTION, SUBCELLULAR LOCATION, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=16332679; DOI=10.1074/jbc.m511223200; RA Majumdar G., Harrington A., Hungerford J., Martinez-Hernandez A., RA Gerling I.C., Raghow R., Solomon S.; RT "Insulin dynamically regulates calmodulin gene expression by sequential O- RT glycosylation and phosphorylation of SP1 and its subcellular RT compartmentalization in liver cells."; RL J. Biol. Chem. 281:3642-3650(2006). RN [28] RP PHOSPHORYLATION AT THR-453 AND THR-739, AND FUNCTION. RX PubMed=16377629; DOI=10.1074/jbc.m510937200; RA Hsu M.C., Chang H.C., Hung W.C.; RT "HER-2/neu represses the metastasis suppressor RECK via ERK and Sp RT transcription factors to promote cell invasion."; RL J. Biol. Chem. 281:4718-4725(2006). RN [29] RP SUMOYLATION AT LYS-16, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF LYS-16; RP GLU-18 AND LYS-19. RX PubMed=16407261; DOI=10.1074/jbc.m600035200; RA Spengler M.L., Brattain M.G.; RT "Sumoylation inhibits cleavage of Sp1 N-terminal negative regulatory domain RT and inhibits Sp1-dependent transcription."; RL J. Biol. Chem. 281:5567-5574(2006). RN [30] RP PHOSPHORYLATION AT SER-59 AND THR-681, DEPHOSPHORYLATION, GLYCOSYLATION, RP FUNCTION, AND MUTAGENESIS OF SER-59; SER-220; THR-355; THR-453; THR-651; RP THR-681 AND THR-739. RX PubMed=17049555; DOI=10.1016/j.jmb.2006.09.036; RA Vicart A., Lefebvre T., Imbert J., Fernandez A., Kahn-Perles B.; RT "Increased chromatin association of Sp1 in interphase cells by PP2A- RT mediated dephosphorylations."; RL J. Mol. Biol. 364:897-908(2006). RN [31] RP ACETYLATION AT LYS-703, INTERACTION WITH HDAC1; EP300 AND JUN, FUNCTION, RP AND MUTAGENESIS OF LYS-703. RX PubMed=16478997; DOI=10.1128/mcb.26.5.1770-1785.2006; RA Hung J.J., Wang Y.T., Chang W.C.; RT "Sp1 deacetylation induced by phorbol ester recruits p300 to activate RT 12(S)-lipoxygenase gene transcription."; RL Mol. Cell. Biol. 26:1770-1785(2006). RN [32] RP PHOSPHORYLATION AT SER-641, FUNCTION, AND MUTAGENESIS OF SER-641. RX PubMed=16943418; DOI=10.1128/mcb.00560-06; RA Zhang Y., Liao M., Dufau M.L.; RT "Phosphatidylinositol 3-kinase/protein kinase Czeta-induced phosphorylation RT of Sp1 and p107 repressor release have a critical role in histone RT deacetylase inhibitor-mediated derepression of transcription of the RT luteinizing hormone receptor gene."; RL Mol. Cell. Biol. 26:6748-6761(2006). RN [33] RP ERRATUM OF PUBMED:16943418. RA Zhang Y., Liao M., Dufau M.L.; RL Mol. Cell. Biol. 26:8214-8214(2006). RN [34] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-59, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [35] RP PHOSPHORYLATION AT SER-101, FUNCTION, AND MUTAGENESIS OF SER-101. RX PubMed=18171990; DOI=10.1158/1541-7786.mcr-07-0374; RA Olofsson B.A., Kelly C.M., Kim J., Hornsby S.M., Azizkhan-Clifford J.; RT "Phosphorylation of Sp1 in response to DNA damage by ataxia telangiectasia- RT mutated kinase."; RL Mol. Cancer Res. 5:1319-1330(2007). RN [36] RP GLYCOSYLATION, FUNCTION, AND MUTAGENESIS OF SER-612; THR-640; SER-641; RP SER-698 AND SER-702. RX PubMed=18513490; DOI=10.1016/j.bbrc.2008.05.096; RA Chung S.S., Kim J.H., Park H.S., Choi H.H., Lee K.W., Cho Y.M., Lee H.K., RA Park K.S.; RT "Activation of PPARgamma negatively regulates O-GlcNAcylation of Sp1."; RL Biochem. Biophys. Res. Commun. 372:713-718(2008). RN [37] RP PHOSPHORYLATION AT SER-7 AND SER-59, SUMOYLATION AT LYS-16, PROTEOLYTIC RP PROCESSING, UBIQUITINATION, FUNCTION, AND MUTAGENESIS OF SER-7; SER-59; RP SER-728 AND SER-732. RX PubMed=18239466; DOI=10.4161/cc.7.5.5402; RA Spengler M.L., Guo L.W., Brattain M.G.; RT "Phosphorylation mediates Sp1 coupled activities of proteolytic processing, RT desumoylation and degradation."; RL Cell Cycle 7:623-630(2008). RN [38] RP PHOSPHORYLATION AT SER-101, FUNCTION, AND MUTAGENESIS OF SER-36; SER-56; RP SER-81; SER-85; THR-98; SER-101; THR-250; SER-281; SER-291; SER-296; RP SER-313; SER-351; THR-394; THR-427 AND SER-431. RX PubMed=18619531; DOI=10.1016/j.cellsig.2008.06.007; RA Iwahori S., Yasui Y., Kudoh A., Sato Y., Nakayama S., Murata T., RA Isomura H., Tsurumi T.; RT "Identification of phosphorylation sites on transcription factor Sp1 in RT response to DNA damage and its accumulation at damaged sites."; RL Cell. Signal. 20:1795-1803(2008). RN [39] RP PHOSPHORYLATION AT THR-668; SER-670 AND THR-681, AND MUTAGENESIS OF RP THR-668; SER-670 AND THR-681. RX PubMed=18258854; DOI=10.1161/circresaha.107.167395; RA Tan N.Y., Midgley V.C., Kavurma M.M., Santiago F.S., Luo X., Peden R., RA Fahmy R.G., Berndt M.C., Molloy M.P., Khachigian L.M.; RT "Angiotensin II-inducible platelet-derived growth factor-D transcription RT requires specific Ser/Thr residues in the second zinc finger region of RT Sp1."; RL Circ. Res. 102:38-51(2008). RN [40] RP PHOSPHORYLATION AT SER-59 AND THR-278, FUNCTION, SUBCELLULAR LOCATION, AND RP MUTAGENESIS OF SER-59; SER-73; THR-117; THR-278 AND THR-739. RX PubMed=18199680; DOI=10.1091/mbc.e07-09-0881; RA Chuang J.-Y., Wang Y.-T., Yeh S.-H., Liu Y.-W., Chang W.-C., Hung J.-J.; RT "Phosphorylation by c-Jun NH2-terminal kinase 1 regulates the stability of RT transcription factor Sp1 during mitosis."; RL Mol. Biol. Cell 19:1139-1151(2008). RN [41] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-651, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [42] RP GLYCOSYLATION, AND INTERACTION WITH ELF1. RX PubMed=19285002; DOI=10.1016/j.bbrc.2009.01.121; RA Lim K., Chang H.I.; RT "O-GlcNAc inhibits interaction between Sp1 and Elf-1 transcription RT factors."; RL Biochem. Biophys. Res. Commun. 380:569-574(2009). RN [43] RP GLYCOSYLATION, AND INTERACTION WITH NFYA. RX PubMed=19302979; DOI=10.1016/j.bbrc.2009.03.075; RA Lim K., Chang H.I.; RT "O-GlcNAcylation of Sp1 interrupts Sp1 interaction with NF-Y."; RL Biochem. Biophys. Res. Commun. 382:593-597(2009). RN [44] RP INTERACTION WITH ATF7IP AND TBP. RX PubMed=19106100; DOI=10.1074/jbc.m807098200; RA Liu L., Ishihara K., Ichimura T., Fujita N., Hino S., Tomita S., RA Watanabe S., Saitoh N., Ito T., Nakao M.; RT "MCAF1/AM is involved in Sp1-mediated maintenance of cancer-associated RT telomerase activity."; RL J. Biol. Chem. 284:5165-5174(2009). RN [45] RP GLYCOSYLATION, AND FUNCTION. RX PubMed=19193796; DOI=10.1128/jvi.01384-08; RA Jochmann R., Thurau M., Jung S., Hofmann C., Naschberger E., Kremmer E., RA Harrer T., Miller M., Schaft N., Stuerzl M.; RT "O-linked N-acetylglucosaminylation of Sp1 inhibits the human RT immunodeficiency virus type 1 promoter."; RL J. Virol. 83:3704-3718(2009). RN [46] RP INTERACTION WITH BAHD1. RX PubMed=19666599; DOI=10.1073/pnas.0901259106; RA Bierne H., Tham T.N., Batsche E., Dumay A., Leguillou M., RA Kerneis-Golsteyn S., Regnault B., Seeler J.S., Muchardt C., Feunteun J., RA Cossart P.; RT "Human BAHD1 promotes heterochromatic gene silencing."; RL Proc. Natl. Acad. Sci. U.S.A. 106:13826-13831(2009). RN [47] RP INTERACTION WITH EGR1. RX PubMed=20121949; DOI=10.1111/j.1742-4658.2009.07553.x; RA Hu C.T., Chang T.Y., Cheng C.C., Liu C.S., Wu J.R., Li M.C., Wu W.S.; RT "Snail associates with EGR-1 and SP-1 to upregulate transcriptional RT activation of p15INK4b."; RL FEBS J. 277:1202-1218(2010). RN [48] RP FUNCTION. RX PubMed=20091743; DOI=10.1002/jcb.22457; RA Yu H.T., Chan W.W., Chai K.H., Lee C.W., Chang R.C., Yu M.S., RA McLoughlin D.M., Miller C.C., Lau K.F.; RT "Transcriptional regulation of human FE65, a ligand of Alzheimer's disease RT amyloid precursor protein, by Sp1."; RL J. Cell. Biochem. 109:782-793(2010). RN [49] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, PHOSPHORYLATION [LARGE SCALE RP ANALYSIS] AT SER-2 AND SER-7, CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE RP ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [50] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [51] RP PHOSPHORYLATION AT SER-702. RX PubMed=20953893; DOI=10.1007/s00018-010-0541-1; RA Alemu E.A., Sjoettem E., Outzen H., Larsen K.B., Holm T., Bjoerkoey G., RA Johansen T.; RT "Transforming growth factor-beta-inducible early response gene 1 is a novel RT substrate for atypical protein kinase Cs."; RL Cell. Mol. Life Sci. 68:1953-1968(2011). RN [52] RP INTERACTION WITH MEIS2 AND PBX1. RX PubMed=21746878; DOI=10.1128/mcb.01456-10; RA Bjerke G.A., Hyman-Walsh C., Wotton D.; RT "Cooperative transcriptional activation by Klf4, Meis2, and Pbx1."; RL Mol. Cell. Biol. 31:3723-3733(2011). RN [53] RP FUNCTION. RX PubMed=21046154; DOI=10.1007/s00438-010-0586-8; RA Sachrajda I., Ratajewski M.; RT "Mithramycin A suppresses expression of the human melanoma-associated gene RT ABCB8."; RL Mol. Genet. Genomics 285:57-65(2011). RN [54] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, PHOSPHORYLATION [LARGE SCALE RP ANALYSIS] AT SER-7, CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE RP ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [55] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2; SER-7 AND SER-59, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [56] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-16, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25218447; DOI=10.1038/nsmb.2890; RA Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M., RA Vertegaal A.C.; RT "Uncovering global SUMOylation signaling networks in a site-specific RT manner."; RL Nat. Struct. Mol. Biol. 21:927-936(2014). RN [57] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-16, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [58] RP 9AATAD MOTIF. RX PubMed=31375868; DOI=10.1007/s00018-019-03251-w; RA Piskacek M., Havelka M., Jendruchova K., Knight A., Keegan L.P.; RT "The evolution of the 9aaTAD domain in Sp2 proteins: inactivation with RT valines and intron reservoirs."; RL Cell. Mol. Life Sci. 77:1793-1810(2020). RN [59] RP ACETYLATION, AND DEACETYLATION BY HDAC6. RX PubMed=38534334; DOI=10.3390/cells13060490; RA Sun C., Xie K., Yang L., Cai S., Wang M., Zhu Y., Tao B., Zhu Y.; RT "HDAC6 Enhances Endoglin Expression through Deacetylation of Transcription RT Factor SP1, Potentiating BMP9-Induced Angiogenesis."; RL Cells 13:0-0(2024). RN [60] RP STRUCTURE BY NMR OF 654-684 AND 684-712. RX PubMed=9065444; DOI=10.1074/jbc.272.12.7801; RA Narayan V.A., Kriwacki R.W., Caradonna J.P.; RT "Structures of zinc finger domains from transcription factor Sp1. Insights RT into sequence-specific protein-DNA recognition."; RL J. Biol. Chem. 272:7801-7809(1997). CC -!- FUNCTION: Transcription factor that can activate or repress CC transcription in response to physiological and pathological stimuli. CC Binds with high affinity to GC-rich motifs and regulates the expression CC of a large number of genes involved in a variety of processes such as CC cell growth, apoptosis, differentiation and immune responses. Highly CC regulated by post-translational modifications (phosphorylations, CC sumoylation, proteolytic cleavage, glycosylation and acetylation). Also CC binds the PDGFR-alpha G-box promoter. May have a role in modulating the CC cellular response to DNA damage. Implicated in chromatin remodeling. CC Plays an essential role in the regulation of FE65 gene expression. In CC complex with ATF7IP, maintains telomerase activity in cancer cells by CC inducing TERT and TERC gene expression. Isoform 3 is a stronger CC activator of transcription than isoform 1. Positively regulates the CC transcription of the core clock component BMAL1 (PubMed:10391891, CC PubMed:11371615, PubMed:11904305, PubMed:14593115, PubMed:16377629, CC PubMed:16478997, PubMed:16943418, PubMed:17049555, PubMed:18171990, CC PubMed:18199680, PubMed:18239466, PubMed:18513490, PubMed:18619531, CC PubMed:19193796, PubMed:20091743, PubMed:21046154, PubMed:21798247). CC Plays a role in the recruitment of SMARCA4/BRG1 on the c-FOS promoter. CC Plays a role in protecting cells against oxidative stress following CC brain injury by regulating the expression of RNF112 (By similarity). CC {ECO:0000250|UniProtKB:O89090, ECO:0000250|UniProtKB:Q01714, CC ECO:0000269|PubMed:10391891, ECO:0000269|PubMed:11371615, CC ECO:0000269|PubMed:11904305, ECO:0000269|PubMed:14593115, CC ECO:0000269|PubMed:16377629, ECO:0000269|PubMed:16478997, CC ECO:0000269|PubMed:16943418, ECO:0000269|PubMed:17049555, CC ECO:0000269|PubMed:18171990, ECO:0000269|PubMed:18199680, CC ECO:0000269|PubMed:18239466, ECO:0000269|PubMed:18513490, CC ECO:0000269|PubMed:18619531, ECO:0000269|PubMed:19193796, CC ECO:0000269|PubMed:20091743, ECO:0000269|PubMed:21046154, CC ECO:0000269|PubMed:21798247}. CC -!- SUBUNIT: Interacts with ATF7IP, ATF7IP2, BAHD1, POGZ, HCFC1, AATF and CC PHC2. Interacts with HLTF; the interaction may be required for basal CC transcriptional activity of HLTF. Interacts (deacetylated form) with CC EP300; the interaction enhances gene expression. Interacts with HDAC1 CC and JUN. Interacts with ELF1; the interaction is inhibited by CC glycosylation of SP1. Interaction with NFYA; the interaction is CC inhibited by glycosylation of SP1. Interacts with ATF7IP and TBP. CC Interacts with MEIS2 isoform 4 and PBX1 isoform PBX1a. Interacts with CC EGR1 (PubMed:10391891, PubMed:10976766, PubMed:12021324, CC PubMed:12847090, PubMed:12855699, PubMed:15691849, PubMed:16478997, CC PubMed:19106100, PubMed:19285002, PubMed:19302979, PubMed:19666599, CC PubMed:20121949, PubMed:21746878, PubMed:7592727, PubMed:9466902). CC Interacts with SMARCA4/BRG1. Interacts with RNF112 in an oxidative CC stress-regulated manner (By similarity). Interacts with ZBTB7A; ZBTB7A CC prevents the binding to GC-rich motifs in promoters and represses the CC transcriptional activity of SP1 (PubMed:12004059). Interacts with CC DDX3X; this interaction potentiates SP1-induced CDKN1A/WAF1/CIP1 CC transcription (PubMed:16818630). Interacts with MSX1; the interaction CC may inhibit MSX1 autoinactivation (By similarity). CC {ECO:0000250|UniProtKB:O89090, ECO:0000250|UniProtKB:Q01714, CC ECO:0000269|PubMed:10391891, ECO:0000269|PubMed:10976766, CC ECO:0000269|PubMed:12004059, ECO:0000269|PubMed:12847090, CC ECO:0000269|PubMed:15691849, ECO:0000269|PubMed:16478997, CC ECO:0000269|PubMed:16818630, ECO:0000269|PubMed:19106100, CC ECO:0000269|PubMed:19285002, ECO:0000269|PubMed:19302979, CC ECO:0000269|PubMed:19666599, ECO:0000269|PubMed:20121949, CC ECO:0000269|PubMed:21746878}. CC -!- SUBUNIT: (Microbial infection) Interacts with varicella-zoster virus CC IE62 protein. {ECO:0000269|PubMed:12855699}. CC -!- SUBUNIT: (Microbial infection) Interacts with SV40 VP2/3 proteins. CC Interacts with SV40 major capsid protein VP1; this interaction leads to CC a cooperativity between the 2 proteins in DNA binding. CC {ECO:0000269|PubMed:12021324, ECO:0000269|PubMed:9466902}. CC -!- SUBUNIT: (Microbial infection) Interacts with HIV-1 Vpr; the CC interaction is inhibited by SP1 O-glycosylation. CC {ECO:0000269|PubMed:7592727}. CC -!- INTERACTION: CC P08047; Q9NY61: AATF; NbExp=2; IntAct=EBI-298336, EBI-372428; CC P08047; Q8N726: CDKN2A; NbExp=4; IntAct=EBI-298336, EBI-625922; CC P08047; Q92988: DLX4; NbExp=4; IntAct=EBI-298336, EBI-1752755; CC P08047; Q01094: E2F1; NbExp=2; IntAct=EBI-298336, EBI-448924; CC P08047; P32519: ELF1; NbExp=2; IntAct=EBI-298336, EBI-765526; CC P08047; Q99814: EPAS1; NbExp=2; IntAct=EBI-298336, EBI-447470; CC P08047; P03372: ESR1; NbExp=2; IntAct=EBI-298336, EBI-78473; CC P08047; Q14192: FHL2; NbExp=3; IntAct=EBI-298336, EBI-701903; CC P08047; Q06546: GABPA; NbExp=2; IntAct=EBI-298336, EBI-638925; CC P08047; P51610: HCFC1; NbExp=4; IntAct=EBI-298336, EBI-396176; CC P08047; Q13547: HDAC1; NbExp=2; IntAct=EBI-298336, EBI-301834; CC P08047; Q16665: HIF1A; NbExp=3; IntAct=EBI-298336, EBI-447269; CC P08047; P17096: HMGA1; NbExp=4; IntAct=EBI-298336, EBI-746843; CC P08047; P42858: HTT; NbExp=2; IntAct=EBI-298336, EBI-466029; CC P08047; Q13118: KLF10; NbExp=2; IntAct=EBI-298336, EBI-1389509; CC P08047; P01106: MYC; NbExp=4; IntAct=EBI-298336, EBI-447544; CC P08047; P16333: NCK1; NbExp=2; IntAct=EBI-298336, EBI-389883; CC P08047; Q8IXK0: PHC2; NbExp=2; IntAct=EBI-298336, EBI-713786; CC P08047; Q7Z3K3: POGZ; NbExp=2; IntAct=EBI-298336, EBI-1389308; CC P08047; P14859: POU2F1; NbExp=7; IntAct=EBI-298336, EBI-624770; CC P08047; Q06455: RUNX1T1; NbExp=2; IntAct=EBI-298336, EBI-743342; CC P08047; Q15459: SF3A1; NbExp=2; IntAct=EBI-298336, EBI-1054743; CC P08047; Q13485: SMAD4; NbExp=2; IntAct=EBI-298336, EBI-347263; CC P08047; P08047: SP1; NbExp=2; IntAct=EBI-298336, EBI-298336; CC P08047; Q12772: SREBF2; NbExp=3; IntAct=EBI-298336, EBI-465059; CC P08047; P40763: STAT3; NbExp=4; IntAct=EBI-298336, EBI-518675; CC P08047; Q9UL17: TBX21; NbExp=4; IntAct=EBI-298336, EBI-3922312; CC P08047; P04637: TP53; NbExp=6; IntAct=EBI-298336, EBI-366083; CC P08047; Q8N680: ZBTB2; NbExp=4; IntAct=EBI-298336, EBI-2515601; CC P08047; P23708: Nfya; Xeno; NbExp=18; IntAct=EBI-298336, EBI-862337; CC P08047; O92837: vp3; Xeno; NbExp=2; IntAct=EBI-298336, EBI-7196689; CC P08047; P03070; Xeno; NbExp=2; IntAct=EBI-298336, EBI-617698; CC -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear location is CC governed by glycosylated/phosphorylated states. Insulin promotes CC nuclear location, while glucagon favors cytoplasmic location. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=Sp1a; CC IsoId=P08047-1; Sequence=Displayed; CC Name=2; Synonyms=Sp1b; CC IsoId=P08047-2; Sequence=VSP_053934; CC Name=3; Synonyms=Sp1c; CC IsoId=P08047-3; Sequence=VSP_053935; CC -!- TISSUE SPECIFICITY: Up-regulated in adenocarcinomas of the stomach (at CC protein level). Isoform 3 is ubiquitously expressed at low levels. CC {ECO:0000269|PubMed:21798247}. CC -!- INDUCTION: By insulin. {ECO:0000269|PubMed:16332679}. CC -!- DOMAIN: The 9aaTAD motif is a transactivation domain present in a large CC number of yeast and animal transcription factors. CC {ECO:0000269|PubMed:31375868}. CC -!- PTM: Phosphorylated on multiple serine and threonine residues. CC Phosphorylation is coupled to ubiquitination, sumoylation and CC proteolytic processing. Phosphorylation on Ser-59 enhances proteolytic CC cleavage. Phosphorylation on Ser-7 enhances ubiquitination and protein CC degradation. Hyperphosphorylation on Ser-101 in response to DNA damage CC has no effect on transcriptional activity. MAPK1/MAPK3-mediated CC phosphorylation on Thr-453 and Thr-739 enhances VEGF transcription but, CC represses FGF2-triggered PDGFR-alpha transcription. Also implicated in CC the repression of RECK by ERBB2. Hyperphosphorylated on Thr-278 and CC Thr-739 during mitosis by MAPK8 shielding SP1 from degradation by the CC ubiquitin-dependent pathway. Phosphorylated in the zinc-finger domain CC by calmodulin-activated PKCzeta. Phosphorylation on Ser-641 by PKCzeta CC is critical for TSA-activated LHR gene expression through release of CC its repressor, p107. Phosphorylation on Thr-668, Ser-670 and Thr-681 is CC stimulated by angiotensin II via the AT1 receptor inducing increased CC binding to the PDGF-D promoter. This phosphorylation is increased in CC injured artey wall. Ser-59 and Thr-681 can both be dephosphorylated by CC PP2A during cell-cycle interphase. Dephosphorylation on Ser-59 leads to CC increased chromatin association during interphase and increases the CC transcriptional activity. On insulin stimulation, sequentially CC glycosylated and phosphorylated on several C-terminal serine and CC threonine residues. {ECO:0000269|PubMed:11904305, CC ECO:0000269|PubMed:14593115, ECO:0000269|PubMed:16332679, CC ECO:0000269|PubMed:16377629, ECO:0000269|PubMed:16943418, CC ECO:0000269|PubMed:17049555, ECO:0000269|PubMed:18171990, CC ECO:0000269|PubMed:18199680, ECO:0000269|PubMed:18239466, CC ECO:0000269|PubMed:18258854, ECO:0000269|PubMed:18619531}. CC -!- PTM: Acetylated (PubMed:16478997, PubMed:38534334). CC Acetylation/deacetylation events affect transcriptional activity CC (PubMed:16478997, PubMed:38534334). Deacetylation leads to an increase CC in the expression of the 12(s)-lipooxygenase gene through recruitment CC of p300 to the promoter (PubMed:16478997). Deacetylated by HDAC6 which CC leads to increased expression of ENG and positive regulation of CC angiogenesis (PubMed:38534334). {ECO:0000269|PubMed:16478997, CC ECO:0000269|PubMed:38534334}. CC -!- PTM: Ubiquitinated. Ubiquitination occurs on the C-terminal CC proteolytically-cleaved peptide and is triggered by phosphorylation. CC {ECO:0000269|PubMed:18239466}. CC -!- PTM: Sumoylated with SUMO1. Sumoylation modulates proteolytic cleavage CC of the N-terminal repressor domain. Sumoylation levels are attenuated CC during tumorigenesis. Phosphorylation mediates SP1 desumoylation. CC -!- PTM: Proteolytic cleavage in the N-terminal repressor domain is CC prevented by sumoylation. The C-terminal cleaved product is susceptible CC to degradation. CC -!- PTM: O-glycosylated; Contains 8 N-acetylglucosamine side chains. Levels CC are controlled by insulin and the SP1 phosphorylation states. Insulin- CC mediated O-glycosylation locates SP1 to the nucleus, where it is CC sequentially deglycosylated and phosphorylated. O-glycosylation affects CC transcriptional activity through disrupting the interaction with a CC number of transcription factors including ELF1 and NFYA. Also inhibits CC interaction with the HIV1 promoter. Inhibited by peroxisomome CC proliferator receptor gamma (PPARgamma). CC -!- MISCELLANEOUS: In the hepatoma cell line Hep-G2, SP1 precursor mRNA may CC undergo homotype trans-splicing leading to the duplication of exons 2 CC and 3. CC -!- SIMILARITY: Belongs to the Sp1 C2H2-type zinc-finger protein family. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH43224.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; FN908228; CBM42955.1; -; mRNA. DR EMBL; AC068889; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC073611; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471054; EAW96699.1; -; Genomic_DNA. DR EMBL; BC043224; AAH43224.1; ALT_INIT; mRNA. DR EMBL; BC062539; AAH62539.1; -; mRNA. DR EMBL; AF252284; AAF67726.1; -; mRNA. DR EMBL; AB039286; BAB13476.1; -; Genomic_DNA. DR EMBL; J03133; AAA61154.1; -; mRNA. DR EMBL; AF255682; AAF78781.1; -; mRNA. DR EMBL; AJ272134; CAB75345.1; -; mRNA. DR CCDS; CCDS44898.1; -. [P08047-2] DR CCDS; CCDS8857.1; -. [P08047-1] DR PIR; A29635; A29635. DR RefSeq; NP_001238754.1; NM_001251825.2. [P08047-3] DR RefSeq; NP_003100.1; NM_003109.1. [P08047-2] DR RefSeq; NP_612482.2; NM_138473.2. [P08047-1] DR PDB; 1SP1; NMR; -; A=684-712. DR PDB; 1SP2; NMR; -; A=654-684. DR PDB; 1VA1; NMR; -; A=619-654. DR PDB; 1VA2; NMR; -; A=654-684. DR PDB; 1VA3; NMR; -; A=684-712. DR PDB; 6PV0; NMR; -; A=654-684. DR PDB; 6PV1; NMR; -; A=654-684. DR PDB; 6PV2; NMR; -; A=654-684. DR PDB; 6PV3; NMR; -; A=655-684. DR PDB; 6UCO; NMR; -; A=654-684. DR PDB; 6UCP; NMR; -; A=654-684. DR PDBsum; 1SP1; -. DR PDBsum; 1SP2; -. DR PDBsum; 1VA1; -. DR PDBsum; 1VA2; -. DR PDBsum; 1VA3; -. DR PDBsum; 6PV0; -. DR PDBsum; 6PV1; -. DR PDBsum; 6PV2; -. DR PDBsum; 6PV3; -. DR PDBsum; 6UCO; -. DR PDBsum; 6UCP; -. DR AlphaFoldDB; P08047; -. DR BMRB; P08047; -. DR SMR; P08047; -. DR BioGRID; 112550; 352. DR CORUM; P08047; -. DR DIP; DIP-36N; -. DR ELM; P08047; -. DR FunCoup; P08047; 4420. DR IntAct; P08047; 134. DR MINT; P08047; -. DR STRING; 9606.ENSP00000329357; -. DR BindingDB; P08047; -. DR ChEMBL; CHEMBL6103; -. DR DrugBank; DB12226; Terameprocol. DR GlyConnect; 605; 1 O-GlcNAc glycan. DR GlyCosmos; P08047; 25 sites, 2 glycans. DR GlyGen; P08047; 28 sites, 2 O-linked glycans (27 sites). DR iPTMnet; P08047; -. DR PhosphoSitePlus; P08047; -. DR BioMuta; SP1; -. DR DMDM; 13638437; -. DR jPOST; P08047; -. DR MassIVE; P08047; -. DR PaxDb; 9606-ENSP00000329357; -. DR PeptideAtlas; P08047; -. DR ProteomicsDB; 33987; -. DR ProteomicsDB; 52061; -. [P08047-1] DR Pumba; P08047; -. DR Antibodypedia; 892; 1093 antibodies from 47 providers. DR DNASU; 6667; -. DR Ensembl; ENST00000327443.9; ENSP00000329357.4; ENSG00000185591.11. [P08047-1] DR Ensembl; ENST00000426431.2; ENSP00000404263.2; ENSG00000185591.11. [P08047-2] DR GeneID; 6667; -. DR KEGG; hsa:6667; -. DR MANE-Select; ENST00000327443.9; ENSP00000329357.4; NM_138473.3; NP_612482.2. DR UCSC; uc001scw.4; human. [P08047-1] DR AGR; HGNC:11205; -. DR ClinPGx; PA36042; -. DR CTD; 6667; -. DR DisGeNET; 6667; -. DR GeneCards; SP1; -. DR HGNC; HGNC:11205; SP1. DR HPA; ENSG00000185591; Low tissue specificity. DR MIM; 189906; gene. DR OpenTargets; ENSG00000185591; -. DR VEuPathDB; HostDB:ENSG00000185591; -. DR eggNOG; KOG1721; Eukaryota. DR GeneTree; ENSGT00940000157804; -. DR HOGENOM; CLU_019688_2_0_1; -. DR InParanoid; P08047; -. DR OMA; IMNFAPS; -. DR OrthoDB; 6365676at2759; -. DR PAN-GO; P08047; 3 GO annotations based on evolutionary models. DR PhylomeDB; P08047; -. DR PathwayCommons; P08047; -. DR Reactome; R-HSA-1989781; PPARA activates gene expression. DR Reactome; R-HSA-2173796; SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription. DR Reactome; R-HSA-2426168; Activation of gene expression by SREBF (SREBP). DR Reactome; R-HSA-2559585; Oncogene Induced Senescence. DR Reactome; R-HSA-6807505; RNA polymerase II transcribes snRNA genes. DR Reactome; R-HSA-9018519; Estrogen-dependent gene expression. DR Reactome; R-HSA-9735871; SARS-CoV-1 targets host intracellular signalling and regulatory pathways. DR Reactome; R-HSA-9762293; Regulation of CDH11 gene transcription. DR Reactome; R-HSA-9764790; Positive Regulation of CDH1 Gene Transcription. DR Reactome; R-HSA-9818030; NFE2L2 regulating tumorigenic genes. DR Reactome; R-HSA-9839394; TGFBR3 expression. DR SignaLink; P08047; -. DR SIGNOR; P08047; -. DR Agora; ENSG00000185591; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 6667; 167 hits in 1197 CRISPR screens. DR CD-CODE; 38EC0B30; Transcriptional condensate. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; B5B9A610; PML body. DR ChiTaRS; SP1; human. DR EvolutionaryTrace; P08047; -. DR GeneWiki; Sp1_transcription_factor; -. DR GenomeRNAi; 6667; -. DR Pharos; P08047; Tbio. DR PRO; PR:P08047; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; P08047; protein. DR Bgee; ENSG00000185591; Expressed in nipple and 188 other cell types or tissues. DR ExpressionAtlas; P08047; baseline and differential. DR GO; GO:0000785; C:chromatin; IDA:BHF-UCL. DR GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0000791; C:euchromatin; IDA:ARUK-UCL. DR GO; GO:0005654; C:nucleoplasm; IDA:ParkinsonsUK-UCL. DR GO; GO:0005634; C:nucleus; IDA:HGNC-UCL. DR GO; GO:0032993; C:protein-DNA complex; ISS:ARUK-UCL. DR GO; GO:0017053; C:transcription repressor complex; IDA:CAFA. DR GO; GO:0043425; F:bHLH transcription factor binding; ISS:BHF-UCL. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:ARUK-UCL. DR GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:BHF-UCL. DR GO; GO:0003690; F:double-stranded DNA binding; IDA:BHF-UCL. DR GO; GO:0035035; F:histone acetyltransferase binding; IEA:Ensembl. DR GO; GO:0042826; F:histone deacetylase binding; IPI:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0060090; F:molecular adaptor activity; EXP:DisProt. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:ARUK-UCL. DR GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:UniProtKB. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; ISS:BHF-UCL. DR GO; GO:0043565; F:sequence-specific DNA binding; IDA:HGNC-UCL. DR GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:BHF-UCL. DR GO; GO:0001221; F:transcription coregulator binding; IPI:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0071391; P:cellular response to estrogen stimulus; IEA:Ensembl. DR GO; GO:0032869; P:cellular response to insulin stimulus; IEA:Ensembl. DR GO; GO:1904568; P:cellular response to wortmannin; IEA:Ensembl. DR GO; GO:0034224; P:cellular response to zinc ion starvation; IEA:Ensembl. DR GO; GO:0043923; P:host-mediated activation of viral transcription; IDA:UniProtKB. DR GO; GO:1902004; P:positive regulation of amyloid-beta formation; IMP:ARUK-UCL. DR GO; GO:0045766; P:positive regulation of angiogenesis; IMP:BHF-UCL. DR GO; GO:2001235; P:positive regulation of apoptotic signaling pathway; IDA:BHF-UCL. DR GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IMP:BHF-UCL. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:1904828; P:positive regulation of hydrogen sulfide biosynthetic process; IDA:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:1905564; P:positive regulation of vascular endothelial cell proliferation; IMP:BHF-UCL. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central. DR GO; GO:0033194; P:response to hydroperoxide; ISS:UniProtKB. DR GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW. DR CDD; cd22539; SP1_N; 1. DR DisProt; DP00378; -. DR FunFam; 3.30.160.60:FF:000014; Transcription factor Sp3; 1. DR FunFam; 3.30.160.60:FF:000026; Transcription factor Sp3; 1. DR FunFam; 3.30.160.60:FF:000061; Transcription factor Sp3; 1. DR Gene3D; 3.30.160.60; Classic Zinc Finger; 3. DR IDEAL; IID00266; -. DR InterPro; IPR036236; Znf_C2H2_sf. DR InterPro; IPR013087; Znf_C2H2_type. DR PANTHER; PTHR23235; KRUEPPEL-LIKE TRANSCRIPTION FACTOR; 1. DR PANTHER; PTHR23235:SF16; TRANSCRIPTION FACTOR SP1; 1. DR Pfam; PF00096; zf-C2H2; 2. DR SMART; SM00355; ZnF_C2H2; 3. DR SUPFAM; SSF57667; beta-beta-alpha zinc fingers; 1. DR PROSITE; PS00028; ZINC_FINGER_C2H2_1; 3. DR PROSITE; PS50157; ZINC_FINGER_C2H2_2; 3. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Activator; Alternative splicing; KW Biological rhythms; Cytoplasm; Direct protein sequencing; DNA-binding; KW Glycoprotein; Host-virus interaction; Isopeptide bond; Metal-binding; KW Nucleus; Phosphoprotein; Proteomics identification; Reference proteome; KW Repeat; Repressor; Transcription; Transcription regulation; KW Ubl conjugation; Zinc; Zinc-finger. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692" FT CHAIN 2..785 FT /note="Transcription factor Sp1" FT /id="PRO_0000047137" FT ZN_FING 626..650 FT /note="C2H2-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00042" FT ZN_FING 656..680 FT /note="C2H2-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00042" FT ZN_FING 686..708 FT /note="C2H2-type 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00042" FT REGION 1..93 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2..82 FT /note="Repressor domain" FT REGION 109..141 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 146..251 FT /note="Transactivation domain A (Gln-rich)" FT REGION 261..495 FT /note="Transactivation domain B (Gln-rich)" FT REGION 329..395 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 496..610 FT /note="Transactivation domain C (highly charged)" FT REGION 567..598 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 619..785 FT /note="VZV IE62-binding" FT REGION 708..785 FT /note="Domain D" FT MOTIF 462..470 FT /note="9aaTAD" FT /evidence="ECO:0000269|PubMed:31375868" FT COMPBIAS 20..34 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 72..85 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 109..123 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 124..136 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 342..357 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 358..379 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 381..395 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT SITE 63..64 FT /note="Cleavage" FT /evidence="ECO:0000305" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692" FT MOD_RES 2 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 7 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:18239466, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 59 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17049555, FT ECO:0000269|PubMed:18199680, ECO:0000269|PubMed:18239466, FT ECO:0007744|PubMed:16964243, ECO:0007744|PubMed:23186163" FT MOD_RES 101 FT /note="Phosphoserine; by ATM" FT /evidence="ECO:0000269|PubMed:18171990, FT ECO:0000269|PubMed:18619531" FT MOD_RES 278 FT /note="Phosphothreonine; by MAPK8" FT /evidence="ECO:0000305|PubMed:18199680" FT MOD_RES 453 FT /note="Phosphothreonine; by MAPK1 and MAPK3" FT /evidence="ECO:0000269|PubMed:11904305, FT ECO:0000269|PubMed:14593115, ECO:0000269|PubMed:16377629" FT MOD_RES 612 FT /note="Phosphoserine; alternate" FT /evidence="ECO:0000269|PubMed:16332679" FT MOD_RES 640 FT /note="Phosphothreonine; alternate" FT /evidence="ECO:0000269|PubMed:16332679" FT MOD_RES 641 FT /note="Phosphoserine; by PKC/PRKCZ; alternate" FT /evidence="ECO:0000269|PubMed:16332679, FT ECO:0000269|PubMed:16943418" FT MOD_RES 651 FT /note="Phosphothreonine; by PKC/PRKCZ" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 668 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:18258854" FT MOD_RES 670 FT /note="Phosphoserine; by PKC/PRKCZ" FT /evidence="ECO:0000269|PubMed:18258854" FT MOD_RES 681 FT /note="Phosphothreonine; by PKC/PRKCZ" FT /evidence="ECO:0000269|PubMed:17049555, FT ECO:0000269|PubMed:18258854" FT MOD_RES 698 FT /note="Phosphoserine; alternate" FT /evidence="ECO:0000269|PubMed:16332679" FT MOD_RES 702 FT /note="Phosphoserine; alternate" FT /evidence="ECO:0000269|PubMed:16332679, FT ECO:0000305|PubMed:20953893" FT MOD_RES 703 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:16478997" FT MOD_RES 739 FT /note="Phosphothreonine; by MAPK1, MAPK3 and MAPK8" FT /evidence="ECO:0000269|PubMed:11904305, FT ECO:0000269|PubMed:14593115, ECO:0000269|PubMed:16377629" FT CARBOHYD 491 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:11371615, FT ECO:0000269|PubMed:9343410" FT CARBOHYD 612 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000269|PubMed:16332679" FT CARBOHYD 640 FT /note="O-linked (GlcNAc) threonine; alternate" FT /evidence="ECO:0000269|PubMed:16332679" FT CARBOHYD 641 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000269|PubMed:16332679" FT CARBOHYD 698 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000269|PubMed:16332679" FT CARBOHYD 702 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000269|PubMed:16332679" FT CROSSLNK 16 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO); alternate" FT CROSSLNK 16 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2); alternate" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:28112733" FT VAR_SEQ 1..7 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_053934" FT VAR_SEQ 54..101 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:21798247" FT /id="VSP_053935" FT VARIANT 737 FT /note="T -> A (in dbSNP:rs3741665)" FT /id="VAR_019971" FT MUTAGEN 7 FT /note="S->A: Increase in protein stability. No change in FT sumoylation." FT /evidence="ECO:0000269|PubMed:18239466" FT MUTAGEN 15 FT /note="V->R: Enhanced transcriptional activity." FT MUTAGEN 16 FT /note="K->R: Loss of sumoylation. No cleavage and reduced FT transcriptional activity." FT /evidence="ECO:0000269|PubMed:16407261" FT MUTAGEN 18 FT /note="E->A: Loss of sumoylation. Increased cleavage and FT enhanced transcriptional activity." FT /evidence="ECO:0000269|PubMed:16407261" FT MUTAGEN 19 FT /note="K->R: No effect on sumoylation nor on proteolytic FT cleavage." FT /evidence="ECO:0000269|PubMed:16407261" FT MUTAGEN 36 FT /note="S->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 56 FT /note="S->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 59 FT /note="S->A: Loss of phosphorylation. No effect on FT activated MAPK8-mediated phosphorylation. Similar loss of FT phosphorylation as by dephosphorylation by PP2AC. Reduced FT proteolytic processing." FT /evidence="ECO:0000269|PubMed:17049555, FT ECO:0000269|PubMed:18199680, ECO:0000269|PubMed:18239466" FT MUTAGEN 59 FT /note="S->E: Some association with chromatin, increased FT phosphorylation levels and decreased glycosylation." FT /evidence="ECO:0000269|PubMed:17049555, FT ECO:0000269|PubMed:18199680, ECO:0000269|PubMed:18239466" FT MUTAGEN 73 FT /note="S->A: Little effect on activated MAPK8-mediated FT phosphorylation." FT /evidence="ECO:0000269|PubMed:18199680" FT MUTAGEN 81 FT /note="S->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 85 FT /note="S->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 98 FT /note="T->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 101 FT /note="S->A: Significant reduction of phosphorylation on FT DNA damage." FT /evidence="ECO:0000269|PubMed:18171990, FT ECO:0000269|PubMed:18619531" FT MUTAGEN 101 FT /note="S->D: Increase in phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18171990, FT ECO:0000269|PubMed:18619531" FT MUTAGEN 117 FT /note="T->A: No effect on activated MAPK8-mediated FT phosphorylation." FT /evidence="ECO:0000269|PubMed:18199680" FT MUTAGEN 220 FT /note="S->A: No effect on dephosphorylation by PP2A." FT /evidence="ECO:0000269|PubMed:17049555" FT MUTAGEN 250 FT /note="T->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 278 FT /note="T->A: Almost complete abolition of activated MAPK8- FT mediated phosphorylation and 40% reduction in protein FT levels during mitosis. Protein levels reduced by 70% during FT mitosis; when associated with A-739." FT /evidence="ECO:0000269|PubMed:18199680" FT MUTAGEN 278 FT /note="T->D: Increased protein stability during mitosis; FT when associated with D-739." FT /evidence="ECO:0000269|PubMed:18199680" FT MUTAGEN 281 FT /note="S->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 291 FT /note="S->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 296 FT /note="S->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 313 FT /note="S->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 351 FT /note="S->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 355 FT /note="T->A: No effect on dephosphorylation by PP2A." FT /evidence="ECO:0000269|PubMed:11904305, FT ECO:0000269|PubMed:17049555" FT MUTAGEN 394 FT /note="T->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 427 FT /note="T->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 431 FT /note="S->A: No effect on phosphorylation on DNA damage." FT /evidence="ECO:0000269|PubMed:18619531" FT MUTAGEN 453 FT /note="T->A: Abolishes MAPK-mediated phosphorylation, 50% FT reduction in MAPK1/MAPK3-mediated activity on VEGF promoter FT and no effect on dephosphorylation by PP2A. Greatly reduced FT MAPK1-mediated activity on VEGF promoter; when associated FT with A-739." FT /evidence="ECO:0000269|PubMed:11904305, FT ECO:0000269|PubMed:14593115, ECO:0000269|PubMed:17049555" FT MUTAGEN 491 FT /note="S->A: Loss of O-glycosylation. Increase in FT transcriptional activity." FT /evidence="ECO:0000269|PubMed:11371615, FT ECO:0000269|PubMed:9343410" FT MUTAGEN 612 FT /note="S->A: Diminished glycosylation. Inhibits FT transcriptional activity; when associated with A-640; A- FT 641; A-698 and A-702." FT /evidence="ECO:0000269|PubMed:18513490" FT MUTAGEN 640 FT /note="T->A: Diminished glycosylation. Inhibits FT transcriptional activity; when associated with A-612; A- FT 641; A-698 and A-702." FT /evidence="ECO:0000269|PubMed:18513490" FT MUTAGEN 641 FT /note="S->A: Abolishes PRKCzeta-mediated phosphorylation. FT Diminished glycosylation. Inhibits transcriptional FT activity; when associated with A-612; A-640; A-641 and A- FT 702." FT /evidence="ECO:0000269|PubMed:16943418, FT ECO:0000269|PubMed:18513490" FT MUTAGEN 651 FT /note="T->A: No effect on dephosphorylation by PP2A." FT /evidence="ECO:0000269|PubMed:17049555" FT MUTAGEN 668 FT /note="T->A: Abolishes PRKCzeta-mediated but not PKCdelta- FT mediated phosphorylation. No effect on DNA binding; when FT associated with A-670 and A-681." FT /evidence="ECO:0000269|PubMed:18258854" FT MUTAGEN 670 FT /note="S->A: Abolishes PRKCzeta-mediated but not PKCdelta- FT mediated phosphorylation. No effect on DNA binding; when FT associated with A-668 and A-681." FT /evidence="ECO:0000269|PubMed:18258854" FT MUTAGEN 681 FT /note="T->A: Abolishes PRKCzeta-mediated but not PKCdelta- FT mediated phosphorylation. Some effect on dephosphorylation FT by PP2A. No effect on DNA binding; when associated with A- FT 668 and A-681." FT /evidence="ECO:0000269|PubMed:17049555, FT ECO:0000269|PubMed:18258854" FT MUTAGEN 698 FT /note="S->A: Diminished glycosylation. Inhibits FT transcriptional activity; when associated with A-612; A- FT 640; A-641 and A-702." FT /evidence="ECO:0000269|PubMed:18513490" FT MUTAGEN 702 FT /note="S->A: Diminished glycosylation. Inhibits FT transcriptional activity; when associated with A-612; A- FT 640; A-641 and A-698." FT /evidence="ECO:0000269|PubMed:18513490" FT MUTAGEN 703 FT /note="K->A: Abolishes acetylation. Increases recruitment FT of p300 to the promoter and enhances gene transcription." FT /evidence="ECO:0000269|PubMed:16478997" FT MUTAGEN 728 FT /note="S->A: Exhibits attenuated endoproteolytic cleavage; FT when associated with A-732." FT /evidence="ECO:0000269|PubMed:18239466" FT MUTAGEN 732 FT /note="S->A: Exhibits attenuated endoproteolytic cleavage; FT when associated with A-728." FT /evidence="ECO:0000269|PubMed:18239466" FT MUTAGEN 739 FT /note="T->A: Abolishes MAPK-mediated phosphorylation. 50% FT reduction in MAPK1/MAPK3-mediated activity on VEGF FT promoter, 40% reduction in protein levels during mitosis FT and no effect on dephosphorylation by PP2A. Greatly reduced FT MAPK1-mediated activity on VEGF promoter; when associated FT with A-453. Protein levels during mitosis reduced by 70%; FT when associated with A-278." FT /evidence="ECO:0000269|PubMed:11904305, FT ECO:0000269|PubMed:14593115, ECO:0000269|PubMed:17049555, FT ECO:0000269|PubMed:18199680" FT MUTAGEN 739 FT /note="T->D: Increased protein stability during mitosis; FT when associated with D-278." FT /evidence="ECO:0000269|PubMed:11904305, FT ECO:0000269|PubMed:14593115, ECO:0000269|PubMed:17049555, FT ECO:0000269|PubMed:18199680" FT CONFLICT 366 FT /note="D -> G (in Ref. 7; AA sequence)" FT /evidence="ECO:0000305" FT CONFLICT 670 FT /note="S -> F (in Ref. 7; AA sequence)" FT /evidence="ECO:0000305" FT STRAND 620..622 FT /evidence="ECO:0007829|PDB:1VA1" FT STRAND 636..638 FT /evidence="ECO:0007829|PDB:1VA1" FT HELIX 640..651 FT /evidence="ECO:0007829|PDB:1VA1" FT STRAND 656..658 FT /evidence="ECO:0007829|PDB:6UCO" FT TURN 661..663 FT /evidence="ECO:0007829|PDB:1VA2" FT STRAND 666..668 FT /evidence="ECO:0007829|PDB:1VA2" FT HELIX 670..677 FT /evidence="ECO:0007829|PDB:1SP2" FT TURN 678..680 FT /evidence="ECO:0007829|PDB:1SP2" FT TURN 681..683 FT /evidence="ECO:0007829|PDB:6PV0" FT TURN 689..692 FT /evidence="ECO:0007829|PDB:1SP1" FT HELIX 699..706 FT /evidence="ECO:0007829|PDB:1SP1" FT HELIX 707..709 FT /evidence="ECO:0007829|PDB:1SP1" SQ SEQUENCE 785 AA; 80693 MW; 43893DBF6518B9EA CRC64; MSDQDHSMDE MTAVVKIEKG VGGNNGGNGN GGGAFSQARS SSTGSSSSTG GGGQESQPSP LALLAATCSR IESPNENSNN SQGPSQSGGT GELDLTATQL SQGANGWQII SSSSGATPTS KEQSGSSTNG SNGSESSKNR TVSGGQYVVA AAPNLQNQQV LTGLPGVMPN IQYQVIPQFQ TVDGQQLQFA ATGAQVQQDG SGQIQIIPGA NQQIITNRGS GGNIIAAMPN LLQQAVPLQG LANNVLSGQT QYVTNVPVAL NGNITLLPVN SVSAATLTPS SQAVTISSSG SQESGSQPVT SGTTISSASL VSSQASSSSF FTNANSYSTT TTTSNMGIMN FTTSGSSGTN SQGQTPQRVS GLQGSDALNI QQNQTSGGSL QAGQQKEGEQ NQQTQQQQIL IQPQLVQGGQ ALQALQAAPL SGQTFTTQAI SQETLQNLQL QAVPNSGPII IRTPTVGPNG QVSWQTLQLQ NLQVQNPQAQ TITLAPMQGV SLGQTSSSNT TLTPIASAAS IPAGTVTVNA AQLSSMPGLQ TINLSALGTS GIQVHPIQGL PLAIANAPGD HGAQLGLHGA GGDGIHDDTA GGEEGENSPD AQPQAGRRTR REACTCPYCK DSEGRGSGDP GKKKQHICHI QGCGKVYGKT SHLRAHLRWH TGERPFMCTW SYCGKRFTRS DELQRHKRTH TGEKKFACPE CPKRFMRSDH LSKHIKTHQN KKGGPGVALS VGTLPLDSGA GSEGSGTATP SALITTNMVA MEAICPEGIA RLANSGINVM QVADLQSINI SGNGF // ID TEC_HUMAN Reviewed; 631 AA. AC P42680; B7ZKZ6; Q3MIS5; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 11-SEP-2007, sequence version 2. DT 28-JAN-2026, entry version 221. DE RecName: Full=Tyrosine-protein kinase Tec; DE EC=2.7.10.2; GN Name=TEC; Synonyms=PSCTK4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Blood; RX PubMed=7934162; RA Sato K., Mano H., Ariyama T., Inazawa J., Yazaki Y., Hirai H.; RT "Molecular cloning and analysis of the human Tec protein-tyrosine kinase."; RL Leukemia 8:1663-1672(1994). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Liver; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP PROTEIN SEQUENCE OF 203-206, AND PHOSPHORYLATION AT TYR-206. RX PubMed=12573241; DOI=10.1016/s1570-9639(02)00524-1; RA Nore B.F., Mattsson P.T., Antonsson P., Backesjo C.-M., Westlund A., RA Lennartsson J., Hansson H., Low P., Ronnstrand L., Smith C.I.E.; RT "Identification of phosphorylation sites within the SH3 domains of Tec RT family tyrosine kinases."; RL Biochim. Biophys. Acta 1645:123-132(2003). RN [5] RP PHOSPHORYLATION, INTERACTION WITH KIT, AND ACTIVITY REGULATION. RX PubMed=7526158; DOI=10.1128/mcb.14.12.8432-8437.1994; RA Tang B., Mano H., Yi T., Ihle J.N.; RT "Tec kinase associates with c-kit and is tyrosine phosphorylated and RT activated following stem cell factor binding."; RL Mol. Cell. Biol. 14:8432-8437(1994). RN [6] RP PHOSPHORYLATION, AND SUBCELLULAR LOCATION. RX PubMed=9299487; DOI=10.1006/bbrc.1997.7269; RA Laffargue M., Monnereau L., Tuech J., Ragab A., Ragab-Thomas J., RA Payrastre B., Raynal P., Chap H.; RT "Integrin-dependent tyrosine phosphorylation and cytoskeletal translocation RT of Tec in thrombin-activated platelets."; RL Biochem. Biophys. Res. Commun. 238:247-251(1997). RN [7] RP ACTIVITY REGULATION. RX PubMed=9341160; DOI=10.1074/jbc.272.43.27178; RA Ohya K., Kajigaya S., Yamashita Y., Miyazato A., Hatake K., Miura Y., RA Ikeda U., Shimada K., Ozawa K., Mano H.; RT "SOCS-1/JAB/SSI-1 can bind to and suppress Tec protein-tyrosine kinase."; RL J. Biol. Chem. 272:27178-27182(1997). RN [8] RP INTERACTION WITH GRB10, AND FUNCTION IN PHOSPHORYLATION OF GRB10. RX PubMed=9753425; DOI=10.1046/j.1365-2443.1998.00201.x; RA Mano H., Ohya K., Miyazato A., Yamashita Y., Ogawa W., Inazawa J., RA Ikeda U., Shimada K., Hatake K., Kasuga M., Ozawa K., Kajigaya S.; RT "Grb10/GrbIR as an in vivo substrate of Tec tyrosine kinase."; RL Genes Cells 3:431-441(1998). RN [9] RP PHOSPHORYLATION, ACTIVITY REGULATION, AND SUBCELLULAR LOCATION. RX PubMed=9652744; DOI=10.1038/sj.onc.1201799; RA Hamazaki Y., Kojima H., Mano H., Nagata Y., Todokoro K., Abe T., RA Nagasawa T.; RT "Tec is involved in G protein-coupled receptor- and integrin-mediated RT signalings in human blood platelets."; RL Oncogene 16:2773-2779(1998). RN [10] RP FUNCTION IN PHOSPHORYLATION OF STAP1, AND ACTIVITY REGULATION. RX PubMed=10518561; DOI=10.1073/pnas.96.21.11976; RA Ohya K., Kajigaya S., Kitanaka A., Yoshida K., Miyazato A., Yamashita Y., RA Yamanaka T., Ikeda U., Shimada K., Ozawa K., Mano H.; RT "Molecular cloning of a docking protein, BRDG1, that acts downstream of the RT Tec tyrosine kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 96:11976-11981(1999). RN [11] RP INTERACTION WITH INPP5D AND INPPL1. RX PubMed=15492005; DOI=10.1074/jbc.m408141200; RA Tomlinson M.G., Heath V.L., Turck C.W., Watson S.P., Weiss A.; RT "SHIP family inositol phosphatases interact with and negatively regulate RT the Tec tyrosine kinase."; RL J. Biol. Chem. 279:55089-55096(2004). RN [12] RP INTERACTION WITH FASLG. RX PubMed=19807924; DOI=10.1186/1471-2172-10-53; RA Voss M., Lettau M., Janssen O.; RT "Identification of SH3 domain interaction partners of human FasL (CD178) by RT phage display screening."; RL BMC Immunol. 10:53-53(2009). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-206 AND TYR-228, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-519, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [15] RP FUNCTION. RX PubMed=19883687; DOI=10.1016/j.imlet.2009.10.009; RA Susaki K., Kitanaka A., Dobashi H., Kubota Y., Kittaka K., Kameda T., RA Yamaoka G., Mano H., Mihara K., Ishida T.; RT "Tec protein tyrosine kinase inhibits CD25 expression in human T- RT lymphocyte."; RL Immunol. Lett. 127:135-142(2010). RN [16] RP FUNCTION IN PHOSPHORYLATION OF FGF2, AND INTERACTION WITH FGF2. RX PubMed=20230531; DOI=10.1111/j.1600-0854.2010.01059.x; RA Ebert A.D., Laussmann M., Wegehingel S., Kaderali L., Erfle H., RA Reichert J., Lechner J., Beer H.D., Pepperkok R., Nickel W.; RT "Tec-kinase-mediated phosphorylation of fibroblast growth factor 2 is RT essential for unconventional secretion."; RL Traffic 11:813-826(2010). RN [17] RP VARIANTS [LARGE SCALE ANALYSIS] GLN-44 AND LYS-563. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Non-receptor tyrosine kinase that contributes to signaling CC from many receptors and participates as a signal transducer in multiple CC downstream pathways, including regulation of the actin cytoskeleton. CC Plays a redundant role to ITK in regulation of the adaptive immune CC response. Regulates the development, function and differentiation of CC conventional T-cells and nonconventional NKT-cells. Required for TCR- CC dependent IL2 gene induction. Phosphorylates DOK1, one CD28-specific CC substrate, and contributes to CD28-signaling. Mediates signals that CC negatively regulate IL2RA expression induced by TCR cross-linking. CC Plays a redundant role to BTK in BCR-signaling for B-cell development CC and activation, especially by phosphorylating STAP1, a BCR-signaling CC protein. Required in mast cells for efficient cytokine production. CC Involved in both growth and differentiation mechanisms of myeloid cells CC through activation by the granulocyte colony-stimulating factor CSF3, a CC critical cytokine to promoting the growth, differentiation, and CC functional activation of myeloid cells. Participates in platelet CC signaling downstream of integrin activation. Cooperates with JAK2 CC through reciprocal phosphorylation to mediate cytokine-driven CC activation of FOS transcription. GRB10, a negative modifier of the FOS CC activation pathway, is another substrate of TEC. TEC is involved in G CC protein-coupled receptor- and integrin-mediated signalings in blood CC platelets. Plays a role in hepatocyte proliferation and liver CC regeneration and is involved in HGF-induced ERK signaling pathway. TEC CC also regulates FGF2 unconventional secretion (endoplasmic reticulum CC (ER)/Golgi-independent mechanism) under various physiological CC conditions through phosphorylation of FGF2 'Tyr-215'. May also be CC involved in the regulation of osteoclast differentiation. CC {ECO:0000269|PubMed:10518561, ECO:0000269|PubMed:19883687, CC ECO:0000269|PubMed:20230531, ECO:0000269|PubMed:9753425}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250}; CC Note=Binds 1 zinc ion per subunit. {ECO:0000250}; CC -!- ACTIVITY REGULATION: Activated by tyrosine phosphorylation by a wide CC range of cytokine stimulations. When T-cells or B-cells receptors are CC activated, a series of phosphorylation leads to the recruitment of TEC CC to the cell membrane, where it is phosphorylated at Tyr-519. Also CC activated in response to SCF. Integrin engagement induces tyrosine CC phosphorylation of TEC in platelets. STAP1 participates in a positive CC feedback loop by increasing the activity of TEC. SOCS1 is an inhibitor CC of TEC kinase activity. {ECO:0000269|PubMed:10518561, CC ECO:0000269|PubMed:7526158, ECO:0000269|PubMed:9341160, CC ECO:0000269|PubMed:9652744}. CC -!- SUBUNIT: Part of a complex composed of EEIG1, TNFRSF11A/RANK, PLCG2, CC GAB2, TEC and BTK; complex formation increases in the presence of CC TNFSF11/RANKL (By similarity). Interacts with INPP5D/SHIP1 and CC INPPL1/SHIP2. Interacts with CD28, FASLG, FGF2, GRB10, LYN and KIT. CC Interacts with VAV1 and JAK2 (By similarity). {ECO:0000250, CC ECO:0000250|UniProtKB:P24604}. CC -!- INTERACTION: CC P42680; P78325: ADAM8; NbExp=2; IntAct=EBI-1383480, EBI-2625954; CC P42680; Q13480: GAB1; NbExp=2; IntAct=EBI-1383480, EBI-517684; CC P42680; P08581: MET; NbExp=2; IntAct=EBI-1383480, EBI-1039152; CC -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane; Peripheral membrane CC protein. Cytoplasm, cytoskeleton. Note=Following B-cell or T-cell CC receptors activation by antigen, translocates to the plasma membrane CC through its PH domain. Thrombin and integrin engagement induces CC translocation of TEC to the cytoskeleton during platelet activation. In CC cardiac myocytes, assumes a diffuse intracellular localization under CC basal conditions but is recruited to striated structures upon various CC stimuli, including ATP (By similarity). {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Expressed in a wide range of cells, including CC hematopoietic cell lines like myeloid, B-, and T-cell lineages. CC -!- DOMAIN: The PH domain mediates the binding to inositol polyphosphate CC and phosphoinositides, leading to its targeting to the plasma membrane. CC It is extended in the BTK kinase family by a region designated the TH CC (Tec homology) domain, which consists of about 80 residues preceding CC the SH3 domain. CC -!- DOMAIN: The SH3 domain is essential for its targeting to activated CD28 CC costimulatory molecule. {ECO:0000250}. CC -!- PTM: Following B-cell or T-cell receptors engagement, translocates to CC the plasma membrane where it gets phosphorylated at Tyr-519. Undergoes CC also tyrosine phosphorylation during platelet activation. CC {ECO:0000269|PubMed:12573241, ECO:0000269|PubMed:7526158, CC ECO:0000269|PubMed:9299487, ECO:0000269|PubMed:9652744}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. TEC subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- CAUTION: It is uncertain whether Met-1 is the initiator. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D29767; BAA06171.1; -; mRNA. DR EMBL; CH471069; EAW93055.1; -; Genomic_DNA. DR EMBL; BC101711; AAI01712.1; -; mRNA. DR EMBL; BC101713; AAI01714.1; -; mRNA. DR EMBL; BC143487; AAI43488.1; -; mRNA. DR CCDS; CCDS3481.1; -. DR PIR; I38268; I38268. DR PIR; I56997; I56997. DR RefSeq; NP_003206.2; NM_003215.3. DR PDB; 2LUL; NMR; -; A=1-154. DR PDBsum; 2LUL; -. DR AlphaFoldDB; P42680; -. DR BMRB; P42680; -. DR SMR; P42680; -. DR BioGRID; 112865; 61. DR FunCoup; P42680; 655. DR IntAct; P42680; 47. DR MINT; P42680; -. DR STRING; 9606.ENSP00000370912; -. DR BindingDB; P42680; -. DR ChEMBL; CHEMBL4246; -. DR DrugBank; DB06616; Bosutinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB14924; Ritlecitinib. DR DrugBank; DB15035; Zanubrutinib. DR DrugCentral; P42680; -. DR GuidetoPHARMACOLOGY; 2238; -. DR iPTMnet; P42680; -. DR PhosphoSitePlus; P42680; -. DR BioMuta; TEC; -. DR DMDM; 158518392; -. DR CPTAC; CPTAC-3135; -. DR CPTAC; CPTAC-3136; -. DR CPTAC; CPTAC-3137; -. DR jPOST; P42680; -. DR MassIVE; P42680; -. DR PaxDb; 9606-ENSP00000370912; -. DR PeptideAtlas; P42680; -. DR ProteomicsDB; 55526; -. DR Pumba; P42680; -. DR ABCD; P42680; 3 sequenced antibodies. DR Antibodypedia; 715; 347 antibodies from 34 providers. DR DNASU; 7006; -. DR Ensembl; ENST00000381501.8; ENSP00000370912.3; ENSG00000135605.14. DR GeneID; 7006; -. DR KEGG; hsa:7006; -. DR MANE-Select; ENST00000381501.8; ENSP00000370912.3; NM_003215.3; NP_003206.2. DR UCSC; uc003gxz.4; human. DR AGR; HGNC:11719; -. DR ClinPGx; PA36436; -. DR CTD; 7006; -. DR DisGeNET; 7006; -. DR GeneCards; TEC; -. DR HGNC; HGNC:11719; TEC. DR HPA; ENSG00000135605; Low tissue specificity. DR MalaCards; TEC; -. DR MIM; 600583; gene. DR OpenTargets; ENSG00000135605; -. DR VEuPathDB; HostDB:ENSG00000135605; -. DR eggNOG; KOG0197; Eukaryota. DR GeneTree; ENSGT00940000155951; -. DR HOGENOM; CLU_000288_7_2_1; -. DR InParanoid; P42680; -. DR OMA; NVTGHAH; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P42680; 7 GO annotations based on evolutionary models. DR PhylomeDB; P42680; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; P42680; -. DR Reactome; R-HSA-1433557; Signaling by SCF-KIT. DR Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization. DR Reactome; R-HSA-512988; Interleukin-3, Interleukin-5 and GM-CSF signaling. DR SignaLink; P42680; -. DR SIGNOR; P42680; -. DR Agora; ENSG00000135605; -. DR BioGRID-ORCS; 7006; 19 hits in 1180 CRISPR screens. DR ChiTaRS; TEC; human. DR EvolutionaryTrace; P42680; -. DR GeneWiki; TEC_(gene); -. DR GenomeRNAi; 7006; -. DR Pharos; P42680; Tchem. DR PRO; PR:P42680; -. DR Proteomes; UP000005640; Chromosome 4. DR RNAct; P42680; protein. DR Bgee; ENSG00000135605; Expressed in primordial germ cell in gonad and 97 other cell types or tissues. DR ExpressionAtlas; P42680; baseline and differential. DR GO; GO:0005856; C:cytoskeleton; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0005543; F:phospholipid binding; NAS:BHF-UCL. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0002250; P:adaptive immune response; IBA:GO_Central. DR GO; GO:0050853; P:B cell receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0007229; P:integrin-mediated signaling pathway; IDA:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; TAS:ProtInc. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0010543; P:regulation of platelet activation; IDA:UniProtKB. DR GO; GO:0050852; P:T cell receptor signaling pathway; IBA:GO_Central. DR GO; GO:0042246; P:tissue regeneration; IEA:Ensembl. DR CDD; cd01238; PH_Btk; 1. DR CDD; cd05114; PTKc_Tec_Rlk; 1. DR CDD; cd10396; SH2_Tec_Itk; 1. DR CDD; cd11905; SH3_Tec; 1. DR FunFam; 1.10.510.10:FF:000052; Tyrosine-protein kinase; 1. DR FunFam; 2.30.29.30:FF:000210; Tyrosine-protein kinase; 1. DR FunFam; 2.30.30.40:FF:000151; Tyrosine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000053; Tyrosine-protein kinase; 1. DR FunFam; 3.30.505.10:FF:000041; Tyrosine-protein kinase; 1. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR Gene3D; 3.30.505.10; SH2 domain; 1. DR Gene3D; 2.30.30.40; SH3 Domains; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR050198; Non-receptor_tyrosine_kinases. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR001849; PH_domain. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR000980; SH2. DR InterPro; IPR036860; SH2_dom_sf. DR InterPro; IPR036028; SH3-like_dom_sf. DR InterPro; IPR001452; SH3_domain. DR InterPro; IPR035572; Tec_SH3. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR001562; Znf_Btk_motif. DR PANTHER; PTHR24418; TYROSINE-PROTEIN KINASE; 1. DR Pfam; PF00779; BTK; 1. DR Pfam; PF00169; PH; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00017; SH2; 1. DR Pfam; PF00018; SH3_1; 1. DR PRINTS; PR00401; SH2DOMAIN. DR PRINTS; PR00452; SH3DOMAIN. DR PRINTS; PR00402; TECBTKDOMAIN. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00107; BTK; 1. DR SMART; SM00233; PH; 1. DR SMART; SM00252; SH2; 1. DR SMART; SM00326; SH3; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF50729; PH domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF55550; SH2 domain; 1. DR SUPFAM; SSF50044; SH3-domain; 1. DR PROSITE; PS50003; PH_DOMAIN; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS50001; SH2; 1. DR PROSITE; PS50002; SH3; 1. DR PROSITE; PS51113; ZF_BTK; 1. PE 1: Evidence at protein level; KW 3D-structure; Adaptive immunity; ATP-binding; Cell membrane; Cytoplasm; KW Cytoskeleton; Direct protein sequencing; Immunity; Kinase; Lipid-binding; KW Membrane; Metal-binding; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; SH2 domain; SH3 domain; KW Transferase; Tyrosine-protein kinase; Zinc; Zinc-finger. FT CHAIN 1..631 FT /note="Tyrosine-protein kinase Tec" FT /id="PRO_0000088170" FT DOMAIN 4..111 FT /note="PH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00145" FT DOMAIN 179..239 FT /note="SH3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00192" FT DOMAIN 247..345 FT /note="SH2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00191" FT DOMAIN 370..623 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ZN_FING 113..149 FT /note="Btk-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT REGION 157..178 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 489 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 121 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT BINDING 132 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT BINDING 133 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT BINDING 143 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT BINDING 376..384 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 398 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 206 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12573241, FT ECO:0007744|PubMed:19369195" FT MOD_RES 228 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 519 FT /note="Phosphotyrosine; by autocatalysis, LYN and JAK2" FT /evidence="ECO:0007744|PubMed:19690332" FT VARIANT 44 FT /note="R -> Q (in dbSNP:rs35374286)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041850" FT VARIANT 563 FT /note="R -> K (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041851" FT CONFLICT 514 FT /note="V -> F (in Ref. 1; BAA06171)" FT /evidence="ECO:0000305" FT STRAND 3..14 FT /evidence="ECO:0007829|PDB:2LUL" FT STRAND 19..21 FT /evidence="ECO:0007829|PDB:2LUL" FT STRAND 26..41 FT /evidence="ECO:0007829|PDB:2LUL" FT STRAND 45..47 FT /evidence="ECO:0007829|PDB:2LUL" FT STRAND 53..55 FT /evidence="ECO:0007829|PDB:2LUL" FT HELIX 56..58 FT /evidence="ECO:0007829|PDB:2LUL" FT STRAND 61..64 FT /evidence="ECO:0007829|PDB:2LUL" FT STRAND 69..71 FT /evidence="ECO:0007829|PDB:2LUL" FT STRAND 74..76 FT /evidence="ECO:0007829|PDB:2LUL" FT STRAND 78..83 FT /evidence="ECO:0007829|PDB:2LUL" FT STRAND 88..92 FT /evidence="ECO:0007829|PDB:2LUL" FT HELIX 96..110 FT /evidence="ECO:0007829|PDB:2LUL" FT STRAND 118..120 FT /evidence="ECO:0007829|PDB:2LUL" FT STRAND 132..134 FT /evidence="ECO:0007829|PDB:2LUL" FT STRAND 143..145 FT /evidence="ECO:0007829|PDB:2LUL" SQ SEQUENCE 631 AA; 73581 MW; F55DECBF9916E1F9 CRC64; MNFNTILEEI LIKRSQQKKK TSPLNYKERL FVLTKSMLTY YEGRAEKKYR KGFIDVSKIK CVEIVKNDDG VIPCQNKYPF QVVHDANTLY IFAPSPQSRD LWVKKLKEEI KNNNNIMIKY HPKFWTDGSY QCCRQTEKLA PGCEKYNLFE SSIRKALPPA PETKKRRPPP PIPLEEEDNS EEIVVAMYDF QAAEGHDLRL ERGQEYLILE KNDVHWWRAR DKYGNEGYIP SNYVTGKKSN NLDQYEWYCR NMNRSKAEQL LRSEDKEGGF MVRDSSQPGL YTVSLYTKFG GEGSSGFRHY HIKETTTSPK KYYLAEKHAF GSIPEIIEYH KHNAAGLVTR LRYPVSVKGK NAPTTAGFSY EKWEINPSEL TFMRELGSGL FGVVRLGKWR AQYKVAIKAI REGAMCEEDF IEEAKVMMKL THPKLVQLYG VCTQQKPIYI VTEFMERGCL LNFLRQRQGH FSRDVLLSMC QDVCEGMEYL ERNSFIHRDL AARNCLVSEA GVVKVSDFGM ARYVLDDQYT SSSGAKFPVK WCPPEVFNYS RFSSKSDVWS FGVLMWEVFT EGRMPFEKYT NYEVVTMVTR GHRLYQPKLA SNYVYEVMLR CWQEKPEGRP SFEDLLRTID ELVECEETFG R // ID TRPM7_HUMAN Reviewed; 1865 AA. AC Q96QT4; Q6ZMF5; Q86VJ4; Q8NBW2; Q9BXB2; Q9NXQ2; DT 07-DEC-2004, integrated into UniProtKB/Swiss-Prot. DT 01-DEC-2001, sequence version 1. DT 28-JAN-2026, entry version 188. DE RecName: Full=Transient receptor potential cation channel subfamily M member 7; DE EC=2.7.11.1 {ECO:0000269|PubMed:15485879, ECO:0000269|PubMed:18365021, ECO:0000269|PubMed:18394644}; DE AltName: Full=Channel-kinase 1; DE AltName: Full=Long transient receptor potential channel 7 {ECO:0000303|PubMed:11385574}; DE Short=LTrpC-7; DE Short=LTrpC7; DE Contains: DE RecName: Full=TRPM7 kinase, cleaved form {ECO:0000250|UniProtKB:Q923J1}; DE Short=M7CK; DE Contains: DE RecName: Full=TRPM7 channel, cleaved form {ECO:0000250|UniProtKB:Q923J1}; GN Name=TRPM7; Synonyms=CHAK1, LTRPC7 {ECO:0000303|PubMed:11385574}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TRANSPORTER ACTIVITY, AND ACTIVITY RP REGULATION. RX PubMed=11385574; DOI=10.1038/35079092; RA Nadler M.J.S., Hermosura M.C., Inabe K., Perraud A.-L., Zhu Q., RA Stokes A.J., Kurosaki T., Kinet J.-P., Penner R., Scharenberg A.M., RA Fleig A.; RT "LTRPC7 is a Mg.ATP-regulated divalent cation channel required for cell RT viability."; RL Nature 411:590-595(2001). RN [2] RP ERRATUM OF PUBMED:11385574. RA Nadler M.J.S., Hermosura M.C., Inabe K., Perraud A.-L., Zhu Q., RA Stokes A.J., Kurosaki T., Kinet J.-P., Penner R., Scharenberg A.M., RA Fleig A.; RL Nature 412:660-660(2001). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION. RX PubMed=14594813; DOI=10.1074/jbc.m308820200; RA Ryazanova L.V., Dorovkov M.V., Ansari A., Ryazanov A.G.; RT "Characterization of the protein kinase activity of TRPM7/ChaK1, a protein RT kinase fused to the transient receptor potential ion channel."; RL J. Biol. Chem. 279:3708-3716(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-575 AND 1096-1865, AND VARIANT RP ILE-1482. RC TISSUE=Colon, and Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 464-998. RC TISSUE=Liver; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP FUNCTION, TRANSPORTER ACTIVITY, AND MUTAGENESIS OF LYS-1648 AND GLY-1799. RX PubMed=12887921; DOI=10.1016/s0092-8674(03)00556-7; RA Schmitz C., Perraud A.-L., Johnson C.O., Inabe K., Smith M.K., Penner R., RA Kurosaki T., Fleig A., Scharenberg A.M.; RT "Regulation of vertebrate cellular Mg2+ homeostasis by TRPM7."; RL Cell 114:191-200(2003). RN [7] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=15485879; DOI=10.1074/jbc.c400441200; RA Dorovkov M.V., Ryazanov A.G.; RT "Phosphorylation of annexin I by TRPM7 channel-kinase."; RL J. Biol. Chem. 279:50643-50646(2004). RN [8] RP INTERACTION WITH TRPM6. RX PubMed=14976260; DOI=10.1073/pnas.0305252101; RA Chubanov V., Waldegger S., Mederos y Schnitzler M., Vitzthum H., RA Sassen M.C., Seyberth H.W., Konrad M., Gudermann T.; RT "Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 RT gene causes hypomagnesemia with secondary hypocalcemia."; RL Proc. Natl. Acad. Sci. U.S.A. 101:2894-2899(2004). RN [9] RP INTERACTION WITH TRPM6. RX PubMed=16636202; DOI=10.1085/jgp.200609502; RA Li M., Jiang J., Yue L.; RT "Functional characterization of homo- and heteromeric channel kinases TRPM6 RT and TRPM7."; RL J. Gen. Physiol. 127:525-537(2006). RN [10] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=18394644; DOI=10.1016/j.jmb.2008.02.057; RA Clark K., Middelbeek J., Lasonder E., Dulyaninova N.G., Morrice N.A., RA Ryazanov A.G., Bresnick A.R., Figdor C.G., van Leeuwen F.N.; RT "TRPM7 regulates myosin IIA filament stability and protein localization by RT heavy chain phosphorylation."; RL J. Mol. Biol. 378:790-803(2008). RN [11] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND PHOSPHORYLATION AT RP THR-1163; SER-1191; SER-1193; SER-1255; SER-1258; THR-1265; SER-1287; RP SER-1358; SER-1361; SER-1387; SER-1390; SER-1396; SER-1404; THR-1405; RP SER-1407; THR-1435; SER-1446; THR-1455; SER-1456; SER-1463; SER-1468; RP THR-1471; SER-1476; SER-1477; THR-1482; SER-1493; SER-1504; THR-1508; RP SER-1513; SER-1527; SER-1533; THR-1537; THR-1542; SER-1543; THR-1551; RP SER-1567; SER-1569; THR-1583; SER-1598; SER-1615; SER-1660; THR-1685; RP SER-1779; THR-1830 AND SER-1860. RX PubMed=18365021; DOI=10.1371/journal.pone.0001876; RA Clark K., Middelbeek J., Morrice N.A., Figdor C.G., Lasonder E., RA van Leeuwen F.N.; RT "Massive autophosphorylation of the Ser/Thr-rich domain controls protein RT kinase activity of TRPM6 and TRPM7."; RL PLoS ONE 3:e1876-e1876(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [14] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-101; SER-1387; SER-1390; RP SER-1395; SER-1404; SER-1477; SER-1527 AND SER-1569, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [16] RP FUNCTION. RX PubMed=24316671; DOI=10.1038/ncb2883; RA Cai Z., Jitkaew S., Zhao J., Chiang H.C., Choksi S., Liu J., Ward Y., RA Wu L.G., Liu Z.G.; RT "Plasma membrane translocation of trimerized MLKL protein is required for RT TNF-induced necroptosis."; RL Nat. Cell Biol. 16:55-65(2014). RN [17] RP PALMITOYLATION AT CYS-1143; CYS-1144 AND CYS-1146, FUNCTION, AND RP TRANSPORTER ACTIVITY. RX PubMed=36027648; DOI=10.1016/j.ceca.2022.102639; RA Gao X., Kuo C.W., Main A., Brown E., Rios F.J., Camargo L.L., Mary S., RA Wypijewski K., Goek C., Touyz R.M., Fuller W.; RT "Palmitoylation regulates cellular distribution of and transmembrane Ca RT flux through TrpM7."; RL Cell Calcium 106:102639-102639(2022). RN [18] RP VARIANT ILE-1482, CHARACTERIZATION OF VARIANT ILE-1482, AND ACTIVITY RP REGULATION. RX PubMed=16051700; DOI=10.1073/pnas.0505149102; RA Hermosura M.C., Nayakanti H., Dorovkov M.V., Calderon F.R., Ryazanov A.G., RA Haymer D.S., Garruto R.M.; RT "A TRPM7 variant shows altered sensitivity to magnesium that may contribute RT to the pathogenesis of two Guamanian neurodegenerative disorders."; RL Proc. Natl. Acad. Sci. U.S.A. 102:11510-11515(2005). RN [19] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-68; CYS-406; THR-459; ASN-574; SER-720; RP VAL-830; TYR-949; ARG-1064; THR-1211; VAL-1254; GLU-1306; LYS-1444 AND RP ILE-1482. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [20] RP FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, VARIANT ASP-1046, RP CHARACTERIZATION OF VARIANT ASP-1046, AND INVOLVEMENT IN HYPOMAGNESEMIA RP WITH SECONDARY HYPOCALCEMIA. RX PubMed=35561741; DOI=10.1093/ndt/gfac182; RA Vargas-Poussou R., Claverie-Martin F., Prot-Bertoye C., Carotti V., RA van der Wijst J., Perdomo-Ramirez A., Fraga-Rodriguez G.M., Hureaux M., RA Bos C., Latta F., Houillier P., Hoenderop J., de Baaij J.; RT "Possible role for rare TRPM7 variants in patients with hypomagnesemia with RT secondary hypocalcemia."; RL Nephrol. Dial. Transplant. 0:0-0(2022). CC -!- FUNCTION: Bifunctional protein that combines an ion channel with an CC intrinsic kinase domain, enabling it to modulate cellular functions CC either by conducting ions through the pore or by phosphorylating CC downstream proteins via its kinase domain. The channel is highly CC permeable to divalent cations, specifically calcium (Ca2+), magnesium CC (Mg2+) and zinc (Zn2+) and mediates their influx (PubMed:11385574, CC PubMed:12887921, PubMed:15485879, PubMed:24316671, PubMed:35561741, CC PubMed:36027648). Controls a wide range of biological processes such as CC Ca2(+), Mg(2+) and Zn(2+) homeostasis, vesicular Zn(2+) release channel CC and intracellular Ca(2+) signaling, embryonic development, immune CC responses, cell motility, proliferation and differentiation (By CC similarity). The C-terminal alpha-kinase domain autophosphorylates CC cytoplasmic residues of TRPM7 (PubMed:18365021). In vivo, TRPM7 CC phosphorylates SMAD2, suggesting that TRPM7 kinase may play a role in CC activating SMAD signaling pathways. In vitro, TRPM7 kinase CC phosphorylates ANXA1 (annexin A1), myosin II isoforms and a variety of CC proteins with diverse cellular functions (PubMed:15485879, CC PubMed:18394644). {ECO:0000250|UniProtKB:Q923J1, CC ECO:0000269|PubMed:11385574, ECO:0000269|PubMed:12887921, CC ECO:0000269|PubMed:15485879, ECO:0000269|PubMed:18365021, CC ECO:0000269|PubMed:18394644, ECO:0000269|PubMed:24316671, CC ECO:0000269|PubMed:35561741, ECO:0000269|PubMed:36027648}. CC -!- FUNCTION: [TRPM7 channel, cleaved form]: The cleaved channel exhibits CC substantially higher current and potentiates Fas receptor signaling. CC {ECO:0000250|UniProtKB:Q923J1}. CC -!- FUNCTION: [TRPM7 kinase, cleaved form]: The C-terminal kinase domain CC can be cleaved from the channel segment in a cell-type-specific CC fashion. In immune cells, the TRPM7 kinase domain is clipped from the CC channel domain by caspases in response to Fas-receptor stimulation. The CC cleaved kinase fragments can translocate to the nucleus, and bind CC chromatin-remodeling complex proteins in a Zn(2+)-dependent manner to CC ultimately phosphorylate specific Ser/Thr residues of histones known to CC be functionally important for cell differentiation and embryonic CC development. {ECO:0000250|UniProtKB:Q923J1}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:15485879, ECO:0000269|PubMed:18365021, CC ECO:0000269|PubMed:18394644}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:18365021, ECO:0000269|PubMed:18394644}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Mg(2+)(in) = Mg(2+)(out); Xref=Rhea:RHEA:29827, CC ChEBI:CHEBI:18420; Evidence={ECO:0000269|PubMed:11385574, CC ECO:0000269|PubMed:12887921, ECO:0000269|PubMed:35561741}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:11385574, CC ECO:0000269|PubMed:36027648}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Zn(2+)(in) = Zn(2+)(out); Xref=Rhea:RHEA:29351, CC ChEBI:CHEBI:29105; Evidence={ECO:0000250|UniProtKB:Q923J1}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; CC Evidence={ECO:0000250|UniProtKB:Q923J1}; CC Note=Binds 1 zinc ion per subunit. {ECO:0000250|UniProtKB:Q923J1}; CC -!- ACTIVITY REGULATION: Channel displays constitutive activity. Channel CC activity is negatively regulated by cytosolic Mg(2+) and Mg-ATP CC (PubMed:11385574, PubMed:16051700). Channel activity is negatively CC regulated by low intracellular pH (By similarity). Resting free CC cytosolic Mg(2+) and Mg-ATP concentrations seem to be sufficient to CC block native TRPM7 channel activity (By similarity). TRPM7 channel CC activity is highly dependent on membrane levels of phosphatidylinositol CC 4,5 bisphosphate (PIP2). PIP2 hydrolysis negatively regulates TRPM7 CC channel activity (By similarity). TRPM7 kinase activity does not affect CC channel activity (By similarity). The kinase activity is controlled CC through the autophosphorylation of a serine/threonine-rich region CC located N-terminal to the catalytic domain (PubMed:18365021). CC {ECO:0000250|UniProtKB:Q923J1, ECO:0000250|UniProtKB:Q925B3, CC ECO:0000269|PubMed:11385574, ECO:0000269|PubMed:16051700, CC ECO:0000269|PubMed:18365021}. CC -!- SUBUNIT: Homotetramer (By similarity). Interacts with PLCB1 (By CC similarity). Forms heteromers with TRPM6; heteromeric channels are CC functionally different from the homomeric channels (PubMed:14976260, CC PubMed:16636202). {ECO:0000250|UniProtKB:Q923J1, CC ECO:0000250|UniProtKB:Q925B3, ECO:0000269|PubMed:14976260, CC ECO:0000269|PubMed:16636202}. CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:24316671, CC ECO:0000269|PubMed:35561741}; Multi-pass membrane protein CC {ECO:0000250|UniProtKB:Q923J1}. Cytoplasmic vesicle membrane CC {ECO:0000250|UniProtKB:Q923J1}; Multi-pass membrane protein CC {ECO:0000250|UniProtKB:Q923J1}. Note=Localized largely in intracellular CC Zn(2+)-storage vesicles. {ECO:0000250|UniProtKB:Q923J1}. CC -!- SUBCELLULAR LOCATION: [TRPM7 kinase, cleaved form]: Nucleus CC {ECO:0000250|UniProtKB:Q923J1}. CC -!- PTM: Palmitoylated; palmitoylation at Cys-1143, Cys-1144 and Cys-1146 CC promotes TRPM7 trafficking from the Golgi to the surface membrane. CC {ECO:0000269|PubMed:36027648}. CC -!- PTM: Autophosphorylated; autophosphorylation of C-terminus regulates CC TRPM7 kinase activity towards its substrates. CC {ECO:0000269|PubMed:18365021}. CC -!- PTM: The C-terminal kinase domain can be cleaved from the channel CC segment in a cell-type-specific fashion. TRPM7 is cleaved by caspase-8, CC dissociating the kinase from the ion-conducting pore. The cleaved CC kinase fragments (M7CKs) can translocate to the cell nucleus and binds CC chromatin-remodeling complex proteins in a Zn(2+)-dependent manner to CC ultimately phosphorylate specific Ser/Thr residues of histones. CC {ECO:0000250|UniProtKB:Q923J1}. CC -!- DISEASE: Amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 CC (ALS-PDC1) [MIM:105500]: A neurodegenerative disorder characterized by CC chronic, progressive and uniformly fatal amyotrophic lateral sclerosis CC and parkinsonism-dementia. Both diseases are known to occur in the same CC kindred, the same sibship and even the same individual. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Note=TRPM7 variants have been identified as a potential cause CC of disease in patients suffering from seizures and muscle cramps due to CC magnesium deficiency and episodes of hypocalcemia. CC {ECO:0000269|PubMed:35561741}. CC -!- SIMILARITY: In the C-terminal section; belongs to the protein kinase CC superfamily. Alpha-type protein kinase family. ALPK subfamily. CC {ECO:0000305}. CC -!- SIMILARITY: In the N-terminal section; belongs to the transient CC receptor (TC 1.A.4) family. LTrpC subfamily. TRPM7 sub-subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAC11462.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC Sequence=BAD18773.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY032950; AAK44211.1; -; mRNA. DR EMBL; AF346629; AAK19738.2; -; mRNA. DR EMBL; AK000124; BAA90958.1; -; mRNA. DR EMBL; AK172800; BAD18773.1; ALT_INIT; mRNA. DR EMBL; AK075193; BAC11462.1; ALT_INIT; mRNA. DR EMBL; BC051024; AAH51024.1; -; mRNA. DR CCDS; CCDS42035.1; -. DR RefSeq; NP_001288141.1; NM_001301212.1. DR RefSeq; NP_060142.3; NM_017672.5. DR AlphaFoldDB; Q96QT4; -. DR SMR; Q96QT4; -. DR BioGRID; 120177; 153. DR CORUM; Q96QT4; -. DR FunCoup; Q96QT4; 1775. DR IntAct; Q96QT4; 44. DR MINT; Q96QT4; -. DR STRING; 9606.ENSP00000495860; -. DR BindingDB; Q96QT4; -. DR ChEMBL; CHEMBL1250412; -. DR DrugBank; DB04447; 1,4-Dithiothreitol. DR DrugBank; DB14513; Magnesium. DR DrugBank; DB09481; Magnesium carbonate. DR DrugBank; DB06757; Manganese cation. DR DrugBank; DB00179; Masoprocol. DR DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester. DR GuidetoPHARMACOLOGY; 499; -. DR TCDB; 1.A.4.5.1; the transient receptor potential ca2+/cation channel (trp-cc) family. DR CarbonylDB; Q96QT4; -. DR iPTMnet; Q96QT4; -. DR PhosphoSitePlus; Q96QT4; -. DR SwissPalm; Q96QT4; -. DR BioMuta; TRPM7; -. DR DMDM; 56404941; -. DR jPOST; Q96QT4; -. DR MassIVE; Q96QT4; -. DR PaxDb; 9606-ENSP00000320239; -. DR PeptideAtlas; Q96QT4; -. DR ProteomicsDB; 77898; -. DR Pumba; Q96QT4; -. DR Antibodypedia; 24755; 465 antibodies from 40 providers. DR DNASU; 54822; -. DR Ensembl; ENST00000646667.1; ENSP00000495860.1; ENSG00000092439.16. DR GeneID; 54822; -. DR KEGG; hsa:54822; -. DR MANE-Select; ENST00000646667.1; ENSP00000495860.1; NM_017672.6; NP_060142.3. DR UCSC; uc001zyt.5; human. DR AGR; HGNC:17994; -. DR ClinPGx; PA38273; -. DR CTD; 54822; -. DR DisGeNET; 54822; -. DR GeneCards; TRPM7; -. DR HGNC; HGNC:17994; TRPM7. DR HPA; ENSG00000092439; Tissue enriched (parathyroid). DR MalaCards; TRPM7; -. DR MIM; 105500; phenotype. DR MIM; 605692; gene. DR OpenTargets; ENSG00000092439; -. DR Orphanet; 140957; Autosomal dominant macrothrombocytopenia. DR Orphanet; 90020; Parkinson-dementia complex of Guam. DR VEuPathDB; HostDB:ENSG00000092439; -. DR eggNOG; KOG3614; Eukaryota. DR GeneTree; ENSGT00940000157091; -. DR InParanoid; Q96QT4; -. DR OMA; SSKDPHX; -. DR OrthoDB; 301415at2759; -. DR PAN-GO; Q96QT4; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q96QT4; -. DR PathwayCommons; Q96QT4; -. DR Reactome; R-HSA-3295583; TRP channels. DR SignaLink; Q96QT4; -. DR SIGNOR; Q96QT4; -. DR Agora; ENSG00000092439; -. DR BioGRID-ORCS; 54822; 406 hits in 1198 CRISPR screens. DR ChiTaRS; TRPM7; human. DR GeneWiki; TRPM7; -. DR GenomeRNAi; 54822; -. DR Pharos; Q96QT4; Tchem. DR PRO; PR:Q96QT4; -. DR Proteomes; UP000005640; Chromosome 15. DR RNAct; Q96QT4; protein. DR Bgee; ENSG00000092439; Expressed in left ventricle myocardium and 179 other cell types or tissues. DR ExpressionAtlas; Q96QT4; baseline and differential. DR GO; GO:0031410; C:cytoplasmic vesicle; ISS:UniProtKB. DR GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0001726; C:ruffle; IEA:Ensembl. DR GO; GO:0003779; F:actin binding; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005262; F:calcium channel activity; IDA:UniProtKB. DR GO; GO:0015095; F:magnesium ion transmembrane transporter activity; IDA:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0017022; F:myosin binding; IEA:Ensembl. DR GO; GO:0004672; F:protein kinase activity; IBA:GO_Central. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0005385; F:zinc ion transmembrane transporter activity; IEA:Ensembl. DR GO; GO:0031032; P:actomyosin structure organization; IEA:Ensembl. DR GO; GO:0070588; P:calcium ion transmembrane transport; IDA:UniProtKB. DR GO; GO:0006816; P:calcium ion transport; IBA:GO_Central. DR GO; GO:0016340; P:calcium-dependent cell-matrix adhesion; IEA:Ensembl. DR GO; GO:0010961; P:intracellular magnesium ion homeostasis; ISS:UniProtKB. DR GO; GO:0010960; P:magnesium ion homeostasis; IDA:UniProtKB. DR GO; GO:0015693; P:magnesium ion transport; IDA:UniProtKB. DR GO; GO:0098655; P:monoatomic cation transmembrane transport; IBA:GO_Central. DR GO; GO:0070266; P:necroptotic process; IMP:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0051289; P:protein homotetramerization; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0006829; P:zinc ion transport; ISS:UniProtKB. DR CDD; cd16971; Alpha_kinase_ChaK1_TRMP7; 1. DR FunFam; 1.20.5.1010:FF:000002; Transient receptor potential cation channel subfamily M member 7; 1. DR FunFam; 3.20.200.10:FF:000001; Transient receptor potential cation channel, subfamily M, member 7; 1. DR FunFam; 3.30.200.20:FF:000129; Transient receptor potential cation channel, subfamily M, member 7; 1. DR Gene3D; 3.20.200.10; MHCK/EF2 kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.20.5.1010; TRPM, tetramerisation domain; 1. DR InterPro; IPR004166; a-kinase_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR050927; TRPM. DR InterPro; IPR057366; TRPM-like. DR InterPro; IPR029601; TRPM7_a-kinase_dom. DR InterPro; IPR041491; TRPM_SLOG. DR InterPro; IPR032415; TRPM_tetra. DR InterPro; IPR037162; TRPM_tetra_sf. DR PANTHER; PTHR13800:SF8; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL SUBFAMILY M MEMBER 7; 1. DR PANTHER; PTHR13800; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY M, MEMBER 6; 1. DR Pfam; PF02816; Alpha_kinase; 1. DR Pfam; PF18139; LSDAT_euk; 1. DR Pfam; PF25508; TRPM2; 2. DR Pfam; PF16519; TRPM_tetra; 1. DR SMART; SM00811; Alpha_kinase; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51158; ALPHA_KINASE; 1. PE 1: Evidence at protein level; KW Acetylation; Amyotrophic lateral sclerosis; ATP-binding; Calcium; KW Calcium channel; Calcium transport; Cell membrane; Coiled coil; KW Cytoplasmic vesicle; Disease variant; Ion channel; Ion transport; Kinase; KW Lipoprotein; Membrane; Metal-binding; Necrosis; Neurodegeneration; KW Nucleotide-binding; Nucleus; Palmitate; Parkinsonism; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Transmembrane; KW Transmembrane helix; Transport; Zinc. FT CHAIN 1..1865 FT /note="Transient receptor potential cation channel FT subfamily M member 7" FT /id="PRO_0000215331" FT CHAIN 1..? FT /note="TRPM7 channel, cleaved form" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT /id="PRO_0000461294" FT CHAIN ?..1865 FT /note="TRPM7 kinase, cleaved form" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT /id="PRO_0000461295" FT TOPO_DOM 1..850 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 851..876 FT /note="Helical; Name=1" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 877..882 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 883..904 FT /note="Helical; Name=2" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 905..923 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 924..943 FT /note="Helical; Name=3" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 944..956 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 957..980 FT /note="Helical; Name=4" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 981..999 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 1000..1023 FT /note="Helical; Name=5" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 1024..1025 FT /note="Extracellular" FT /evidence="ECO:0000305" FT INTRAMEM 1026..1066 FT /note="Pore-forming" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 1067..1069 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 1070..1098 FT /note="Helical; Name=6" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT TOPO_DOM 1099..1865 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT DOMAIN 1594..1824 FT /note="Alpha-type protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00501" FT REGION 544..575 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1386..1407 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1492..1511 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1524..1543 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1836..1865 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 1198..1250 FT /evidence="ECO:0000250" FT COMPBIAS 544..555 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 560..573 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1386..1398 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1494..1511 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1844..1865 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 1767 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT BINDING 1621 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1622 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1623 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1624 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1648 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1720 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1721 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1723 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1753 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1777 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1810 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1812 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1816 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 101 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1163 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1191 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1193 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1224 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1255 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1258 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1265 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1287 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1301 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1358 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1361 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1386 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1387 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1390 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1395 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1396 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1404 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1405 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1407 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1435 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1446 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1455 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1456 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1463 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1467 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1468 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1471 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1476 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1477 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 1482 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1493 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1500 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1504 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1508 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1513 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1527 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1533 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1537 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1542 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1543 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1551 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1567 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1569 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1583 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1598 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1615 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1660 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1685 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1779 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1830 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT MOD_RES 1851 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1860 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18365021" FT LIPID 1143 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:36027648" FT LIPID 1144 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:36027648" FT LIPID 1146 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:36027648" FT VARIANT 68 FT /note="G -> V (in dbSNP:rs56064201)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042395" FT VARIANT 406 FT /note="S -> C (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042396" FT VARIANT 459 FT /note="I -> T (in dbSNP:rs55924090)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042397" FT VARIANT 574 FT /note="K -> N (in dbSNP:rs56040619)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042398" FT VARIANT 720 FT /note="T -> S (in a breast infiltrating ductal carcinoma FT sample; somatic mutation; dbSNP:rs1040254222)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042399" FT VARIANT 830 FT /note="M -> V (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042400" FT VARIANT 949 FT /note="F -> Y (in dbSNP:rs55681028)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042401" FT VARIANT 1033 FT /note="A -> G (in dbSNP:rs34530969)" FT /id="VAR_052381" FT VARIANT 1046 FT /note="G -> D (found in a patient with hypomagnesemia and FT secondary hypocalcemia; likely pathogenic; de novo variant; FT causes severely reduced Mg(2+) uptake in transfected cells; FT dbSNP:rs2059709974)" FT /evidence="ECO:0000269|PubMed:35561741" FT /id="VAR_086707" FT VARIANT 1064 FT /note="Q -> R (in dbSNP:rs56298128)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042402" FT VARIANT 1145 FT /note="I -> V (in dbSNP:rs34711809)" FT /id="VAR_052382" FT VARIANT 1211 FT /note="I -> T (in dbSNP:rs56090496)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042403" FT VARIANT 1254 FT /note="A -> V (in dbSNP:rs56288221)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042404" FT VARIANT 1306 FT /note="D -> E (in dbSNP:rs55970334)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042405" FT VARIANT 1444 FT /note="R -> K (in dbSNP:rs55840070)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042406" FT VARIANT 1482 FT /note="T -> I (mutant channels are functional but show FT increased susceptibility to inhibition by intracellular FT Mg(2+) concentrations compared to wild-type channels; FT dbSNP:rs8042919)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:16051700, ECO:0000269|PubMed:17344846" FT /id="VAR_019967" FT MUTAGEN 1648 FT /note="K->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:12887921" FT MUTAGEN 1799 FT /note="G->D: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:12887921" FT CONFLICT 573..575 FT /note="EKM -> KKK (in Ref. 4; BAD18773)" FT /evidence="ECO:0000305" FT CONFLICT 998 FT /note="A -> S (in Ref. 5)" FT /evidence="ECO:0000305" FT CONFLICT 1496 FT /note="Missing (in Ref. 3; AAK19738)" FT /evidence="ECO:0000305" FT CONFLICT 1520 FT /note="D -> V (in Ref. 3; AAK19738)" FT /evidence="ECO:0000305" SQ SEQUENCE 1865 AA; 212697 MW; BE732674D52D7485 CRC64; MSQKSWIEST LTKRECVYII PSSKDPHRCL PGCQICQQLV RCFCGRLVKQ HACFTASLAM KYSDVKLGDH FNQAIEEWSV EKHTEQSPTD AYGVINFQGG SHSYRAKYVR LSYDTKPEVI LQLLLKEWQM ELPKLVISVH GGMQKFELHP RIKQLLGKGL IKAAVTTGAW ILTGGVNTGV AKHVGDALKE HASRSSRKIC TIGIAPWGVI ENRNDLVGRD VVAPYQTLLN PLSKLNVLNN LHSHFILVDD GTVGKYGAEV RLRRELEKTI NQQRIHARIG QGVPVVALIF EGGPNVILTV LEYLQESPPV PVVVCEGTGR AADLLAYIHK QTEEGGNLPD AAEPDIISTI KKTFNFGQNE ALHLFQTLME CMKRKELITV FHIGSDEHQD IDVAILTALL KGTNASAFDQ LILTLAWDRV DIAKNHVFVY GQQWLVGSLE QAMLDALVMD RVAFVKLLIE NGVSMHKFLT IPRLEELYNT KQGPTNPMLF HLVRDVKQGN LPPGYKITLI DIGLVIEYLM GGTYRCTYTR KRFRLIYNSL GGNNRRSGRN TSSSTPQLRK SHESFGNRAD KKEKMRHNHF IKTAQPYRPK IDTVMEEGKK KRTKDEIVDI DDPETKRFPY PLNELLIWAC LMKRQVMARF LWQHGEESMA KALVACKIYR SMAYEAKQSD LVDDTSEELK QYSNDFGQLA VELLEQSFRQ DETMAMKLLT YELKNWSNST CLKLAVSSRL RPFVAHTCTQ MLLSDMWMGR LNMRKNSWYK VILSILVPPA ILLLEYKTKA EMSHIPQSQD AHQMTMDDSE NNFQNITEEI PMEVFKEVRI LDSNEGKNEM EIQMKSKKLP ITRKFYAFYH APIVKFWFNT LAYLGFLMLY TFVVLVQMEQ LPSVQEWIVI AYIFTYAIEK VREIFMSEAG KVNQKIKVWF SDYFNISDTI AIISFFIGFG LRFGAKWNFA NAYDNHVFVA GRLIYCLNII FWYVRLLDFL AVNQQAGPYV MMIGKMVANM FYIVVIMALV LLSFGVPRKA ILYPHEAPSW TLAKDIVFHP YWMIFGEVYA YEIDVCANDS VIPQICGPGT WLTPFLQAVY LFVQYIIMVN LLIAFFNNVY LQVKAISNIV WKYQRYHFIM AYHEKPVLPP PLIILSHIVS LFCCICKRRK KDKTSDGPKL FLTEEDQKKL HDFEEQCVEM YFNEKDDKFH SGSEERIRVT FERVEQMCIQ IKEVGDRVNY IKRSLQSLDS QIGHLQDLSA LTVDTLKTLT AQKASEASKV HNEITRELSI SKHLAQNLID DGPVRPSVWK KHGVVNTLSS SLPQGDLESN NPFHCNILMK DDKDPQCNIF GQDLPAVPQR KEFNFPEAGS SSGALFPSAV SPPELRQRLH GVELLKIFNK NQKLGSSSTS IPHLSSPPTK FFVSTPSQPS CKSHLETGTK DQETVCSKAT EGDNTEFGAF VGHRDSMDLQ RFKETSNKIK ILSNNNTSEN TLKRVSSLAG FTDCHRTSIP VHSKQAEKIS RRPSTEDTHE VDSKAALIPD WLQDRPSNRE MPSEEGTLNG LTSPFKPAMD TNYYYSAVER NNLMRLSQSI PFTPVPPRGE PVTVYRLEES SPNILNNSMS SWSQLGLCAK IEFLSKEEMG GGLRRAVKVQ CTWSEHDILK SGHLYIIKSF LPEVVNTWSS IYKEDTVLHL CLREIQQQRA AQKLTFAFNQ MKPKSIPYSP RFLEVFLLYC HSAGQWFAVE ECMTGEFRKY NNNNGDEIIP TNTLEEIMLA FSHWTYEYTR GELLVLDLQG VGENLTDPSV IKAEEKRSCD MVFGPANLGE DAIKNFRAKH HCNSCCRKLK LPDLKRNDYT PDKIIFPQDE PSDLNLQPGN STKESESTNS VRLML // ID UHRF1_HUMAN Reviewed; 793 AA. AC Q96T88; A0JBR2; A8K024; B2RBA9; Q2HIX7; Q8J022; Q9H6S6; Q9P115; Q9P1U7; DT 07-JUN-2005, integrated into UniProtKB/Swiss-Prot. DT 01-DEC-2001, sequence version 1. DT 28-JAN-2026, entry version 210. DE RecName: Full=E3 ubiquitin-protein ligase UHRF1; DE EC=2.3.2.27 {ECO:0000269|PubMed:22945642, ECO:0000269|PubMed:27595565, ECO:0000269|PubMed:30392929, ECO:0000269|PubMed:30392931, ECO:0000269|PubMed:37728657}; DE AltName: Full=Inverted CCAAT box-binding protein of 90 kDa {ECO:0000303|PubMed:17967883}; DE AltName: Full=Nuclear zinc finger protein Np95 {ECO:0000303|PubMed:17067204}; DE Short=HuNp95 {ECO:0000303|PubMed:17067204}; DE Short=Nuclear protein 95 {ECO:0000303|PubMed:17067204}; DE Short=hNp95 {ECO:0000303|PubMed:17067204}; DE AltName: Full=RING finger protein 106; DE AltName: Full=Transcription factor ICBP90 {ECO:0000303|PubMed:17967883}; DE AltName: Full=Ubiquitin-like PHD and RING finger domain-containing protein 1 {ECO:0000303|PubMed:17673620}; DE Short=hUHRF1 {ECO:0000303|PubMed:17673620}; GN Name=UHRF1 {ECO:0000303|PubMed:17673620, ECO:0000312|HGNC:HGNC:12556}; GN Synonyms=ICBP90 {ECO:0000303|PubMed:17967883}, GN NP95 {ECO:0000303|PubMed:17067204}, RNF106; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, DEVELOPMENTAL RP STAGE, SUBCELLULAR LOCATION, DNA-BINDING, INDUCTION, AND FUNCTION. RC TISSUE=Thymus; RX PubMed=10646863; RA Hopfner R., Mousli M., Jeltsch J.-M., Voulgaris A., Lutz Y., Marin C., RA Bellocq J.-P., Oudet P., Bronner C.; RT "ICBP90, a novel human CCAAT binding protein, involved in the regulation of RT topoisomerase IIa expression."; RL Cancer Res. 60:121-128(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=17067204; DOI=10.1667/rr0459.1; RA Muto M., Fujimori A., Nenoi M., Daino K., Matsuda Y., Kuroiwa A., Kubo E., RA Kanari Y., Utsuno M., Tsuji H., Ukai H., Mita K., Takahagi M., Tatsumi K.; RT "Isolation and characterization of a novel human radiosusceptibility gene, RT NP95."; RL Radiat. Res. 166:723-733(2006). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Davenport J.W., Fernandes E.R., Neale G.A.M., Goorha R.M.; RT "LMO2-induced T cell leukemias overexpress Np95, a gene containing RING and RT PHD zinc fingers and an ubiquitin-like domain."; RL Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS LYS-379 RP AND THR-638. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HIS-240; LYS-379; THR-638; RP MET-642 AND PHE-713. RG NIEHS SNPs program; RL Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP INDUCTION, AND TISSUE SPECIFICITY. RX PubMed=12838312; DOI=10.1038/sj.bjc.6601068; RA Mousli M., Hopfner R., Abbady A.-Q., Monte D., Jeanblanc M., Oudet P., RA Louis B., Bronner C.; RT "ICBP90 belongs to a new family of proteins with an expression that is RT deregulated in cancer cells."; RL Br. J. Cancer 89:120-127(2003). RN [11] RP PHOSPHORYLATION, PHOSPHORYLATION AT SER-298, AND MUTAGENESIS OF SER-298; RP SER-651 AND SER-666. RX PubMed=15178447; DOI=10.1016/j.bbrc.2004.05.028; RA Trotzier M.-A., Bronner C., Bathami K., Mathieu E., Abbady A.-Q., RA Jeanblanc M., Muller C.D., Rochette-Egly C., Mousli M.; RT "Phosphorylation of ICBP90 by protein kinase A enhances topoisomerase RT IIalpha expression."; RL Biochem. Biophys. Res. Commun. 319:590-595(2004). RN [12] RP INDUCTION, UBIQUITINATION, AND FUNCTION. RX PubMed=15009091; DOI=10.1111/j.1356-9597.2004.00710.x; RA Arima Y., Hirota T., Bronner C., Mousli M., Fujiwara T., Niwa S., RA Ishikawa H., Saya H.; RT "Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent RT DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S RT transition."; RL Genes Cells 9:131-142(2004). RN [13] RP FUNCTION, INDUCTION, TISSUE SPECIFICITY, DNA-BINDING, AND INTERACTION WITH RP HDAC1 AND BLTP3A. RX PubMed=15361834; DOI=10.1038/sj.onc.1208053; RA Unoki M., Nishidate T., Nakamura Y.; RT "ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through RT its SRA domain."; RL Oncogene 23:7601-7610(2004). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287 AND SER-639, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-639, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [16] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH DNMT1. RX PubMed=17673620; DOI=10.1126/science.1147939; RA Bostick M., Kim J.K., Esteve P.O., Clark A., Pradhan S., Jacobsen S.E.; RT "UHRF1 plays a role in maintaining DNA methylation in mammalian cells."; RL Science 317:1760-1764(2007). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [18] RP FUNCTION, SUBCELLULAR LOCATION, AND AUTOUBIQUITINATION. RX PubMed=17967883; DOI=10.1128/mcb.01598-07; RA Karagianni P., Amazit L., Qin J., Wong J.; RT "ICBP90, a novel methyl K9 H3 binding protein linking protein RT ubiquitination with heterochromatin formation."; RL Mol. Cell. Biol. 28:705-717(2008). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-76; SER-91 AND SER-707, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [20] RP INVOLVEMENT IN CANCER. RX PubMed=19491893; DOI=10.1038/sj.bjc.6605123; RA Unoki M., Kelly J.D., Neal D.E., Ponder B.A., Nakamura Y., Hamamoto R.; RT "UHRF1 is a novel molecular marker for diagnosis and the prognosis of RT bladder cancer."; RL Br. J. Cancer 101:98-105(2009). RN [21] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH EHMT2. RX PubMed=19056828; DOI=10.1093/nar/gkn961; RA Kim J.K., Esteve P.O., Jacobsen S.E., Pradhan S.; RT "UHRF1 binds G9a and participates in p21 transcriptional regulation in RT mammalian cells."; RL Nucleic Acids Res. 37:493-505(2009). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [23] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-399 AND LYS-546, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [24] RP MUTAGENESIS OF TYR-188 AND TYR-191. RX PubMed=20026581; DOI=10.1093/nar/gkp1152; RA Rottach A., Frauer C., Pichler G., Bonapace I.M., Spada F., Leonhardt H.; RT "The multi-domain protein Np95 connects DNA methylation and histone RT modification."; RL Nucleic Acids Res. 38:1796-1804(2010). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-76; SER-287; SER-639 AND RP SER-707, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [27] RP FUNCTION, AUTOUBIQUITINATION, AND INTERACTION WITH DNMT1. RX PubMed=21745816; DOI=10.1093/nar/gkr528; RA Felle M., Joppien S., Nemeth A., Diermeier S., Thalhammer V., Dobner T., RA Kremmer E., Kappler R., Langst G.; RT "The USP7/Dnmt1 complex stimulates the DNA methylation activity of Dnmt1 RT and regulates the stability of UHRF1."; RL Nucleic Acids Res. 39:8355-8365(2011). RN [28] RP HYDROXYMETHYLCYTOSINE-BINDING. RX PubMed=21731699; DOI=10.1371/journal.pone.0021306; RA Frauer C., Hoffmann T., Bultmann S., Casa V., Cardoso M.C., Antes I., RA Leonhardt H.; RT "Recognition of 5-hydroxymethylcytosine by the Uhrf1 SRA domain."; RL PLoS ONE 6:E21306-E21306(2011). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287 AND SER-651, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [30] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASN-147 AND TYR-188. RX PubMed=23022729; DOI=10.1038/nsmb.2391; RA Rothbart S.B., Krajewski K., Nady N., Tempel W., Xue S., Badeaux A.I., RA Barsyte-Lovejoy D., Martinez J.Y., Bedford M.T., Fuchs S.M., RA Arrowsmith C.H., Strahl B.D.; RT "Association of UHRF1 with methylated H3K9 directs the maintenance of DNA RT methylation."; RL Nat. Struct. Mol. Biol. 19:1155-1160(2012). RN [31] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-76; SER-91; SER-287; SER-368; RP SER-639; SER-707 AND SER-709, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [32] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND MUTAGENESIS OF 724-CYS--CYS-727. RX PubMed=24013172; DOI=10.1038/nature12488; RA Nishiyama A., Yamaguchi L., Sharif J., Johmura Y., Kawamura T., RA Nakanishi K., Shimamura S., Arita K., Kodama T., Ishikawa F., Koseki H., RA Nakanishi M.; RT "Uhrf1-dependent H3K23 ubiquitylation couples maintenance DNA methylation RT and replication."; RL Nature 502:249-253(2013). RN [33] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND MUTAGENESIS OF HIS-741. RX PubMed=22945642; DOI=10.1038/onc.2012.406; RA Guan D., Factor D., Liu Y., Wang Z., Kao H.Y.; RT "The epigenetic regulator UHRF1 promotes ubiquitination-mediated RT degradation of the tumor-suppressor protein promyelocytic leukemia RT protein."; RL Oncogene 32:3819-3828(2013). RN [34] RP INVOLVEMENT IN CANCER. RX PubMed=22286757; DOI=10.1038/onc.2012.3; RA Sabatino L., Fucci A., Pancione M., Carafa V., Nebbioso A., Pistore C., RA Babbio F., Votino C., Laudanna C., Ceccarelli M., Altucci L., RA Bonapace I.M., Colantuoni V.; RT "UHRF1 coordinates peroxisome proliferator activated receptor gamma (PPARG) RT epigenetic silencing and mediates colorectal cancer progression."; RL Oncogene 31:5061-5072(2012). RN [35] RP INVOLVEMENT IN CANCER. RX PubMed=22330138; DOI=10.1038/onc.2011.641; RA Babbio F., Pistore C., Curti L., Castiglioni I., Kunderfranco P., Brino L., RA Oudet P., Seiler R., Thalman G.N., Roggero E., Sarti M., Pinton S., RA Mello-Grand M., Chiorino G., Catapano C.V., Carbone G.M., Bonapace I.M.; RT "The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in RT prostate cancer progression."; RL Oncogene 31:4878-4887(2012). RN [36] RP AUTOUBIQUITINATION, DEUBIQUITINATION BY USP7, PHOSPHORYLATION AT SER-639, RP AND MUTAGENESIS OF SER-639. RX PubMed=22411829; DOI=10.1073/pnas.1116349109; RA Ma H., Chen H., Guo X., Wang Z., Sowa M.E., Zheng L., Hu S., Zeng P., RA Guo R., Diao J., Lan F., Harper J.W., Shi Y.G., Xu Y., Shi Y.; RT "M phase phosphorylation of the epigenetic regulator UHRF1 regulates its RT physical association with the deubiquitylase USP7 and stability."; RL Proc. Natl. Acad. Sci. U.S.A. 109:4828-4833(2012). RN [37] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-385; LYS-546 AND LYS-670, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25218447; DOI=10.1038/nsmb.2890; RA Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M., RA Vertegaal A.C.; RT "Uncovering global SUMOylation signaling networks in a site-specific RT manner."; RL Nat. Struct. Mol. Biol. 21:927-936(2014). RN [38] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, SUBCELLULAR LOCATION, AND RP MUTAGENESIS OF GLY-448; ASP-469 AND HIS-741. RX PubMed=27595565; DOI=10.7554/elife.17101; RA Harrison J.S., Cornett E.M., Goldfarb D., DaRosa P.A., Li Z.M., Yan F., RA Dickson B.M., Guo A.H., Cantu D.V., Kaustov L., Brown P.J., RA Arrowsmith C.H., Erie D.A., Major M.B., Klevit R.E., Krajewski K., RA Kuhlman B., Strahl B.D., Rothbart S.B.; RT "Hemi-methylated DNA regulates DNA methylation inheritance through RT allosteric activation of H3 ubiquitylation by UHRF1."; RL Elife 5:0-0(2016). RN [39] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-279 AND LYS-670, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [40] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND DOMAIN. RX PubMed=30392929; DOI=10.1016/j.molcel.2018.09.028; RA Foster B.M., Stolz P., Mulholland C.B., Montoya A., Kramer H., Bultmann S., RA Bartke T.; RT "Critical role of the UBL domain in stimulating the E3 ubiquitin ligase RT activity of UHRF1 toward chromatin."; RL Mol. Cell 72:739-752(2018). RN [41] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, DOMAIN, AND MUTAGENESIS OF TRP-2; RP ARG-6; MET-8; PHE-46; ARG-48; LYS-50; HIS-56; PHE-59; GLU-62; ARG-64; RP LEU-65; GLN-70 AND LEU-72. RX PubMed=30392931; DOI=10.1016/j.molcel.2018.09.029; RA DaRosa P.A., Harrison J.S., Zelter A., Davis T.N., Brzovic P., Kuhlman B., RA Klevit R.E.; RT "A bifunctional role for the UHRF1 UBL domain in the control of hemi- RT methylated DNA-dependent histone ubiquitylation."; RL Mol. Cell 72:753-765(2018). RN [42] RP FUNCTION, INTERACTION WITH UHRF2 AND FANCD2, AND SUBCELLULAR LOCATION. RX PubMed=30335751; DOI=10.1371/journal.pgen.1007643; RA Motnenko A., Liang C.C., Yang D., Lopez-Martinez D., Yoshikawa Y., Zhan B., RA Ward K.E., Tian J., Haas W., Spingardi P., Kessler B.M., Kriaucionis S., RA Gygi S.P., Cohn M.A.; RT "Identification of UHRF2 as a novel DNA interstrand crosslink sensor RT protein."; RL PLoS Genet. 14:e1007643-e1007643(2018). RN [43] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF 334-ASP-GLU-335 AND RP GLY-448. RX PubMed=30104358; DOI=10.1073/pnas.1806373115; RA Vaughan R.M., Dickson B.M., Whelihan M.F., Johnstone A.L., Cornett E.M., RA Cheek M.A., Ausherman C.A., Cowles M.W., Sun Z.W., Rothbart S.B.; RT "Chromatin structure and its chemical modifications regulate the ubiquitin RT ligase substrate selectivity of UHRF1."; RL Proc. Natl. Acad. Sci. U.S.A. 115:8775-8780(2018). RN [44] RP INTERACTION WITH ZNF263. RX PubMed=32051553; DOI=10.1038/s41388-020-1206-7; RA Yu Z., Feng J., Wang W., Deng Z., Zhang Y., Xiao L., Wang Z., Liu C., RA Liu Q., Chen S., Wu M.; RT "The EGFR-ZNF263 signaling axis silences SIX3 in glioblastoma RT epigenetically."; RL Oncogene 39:3163-3178(2020). RN [45] RP FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY. RX PubMed=37728657; DOI=10.1083/jcb.202210093; RA Qi X., Liu Y., Peng Y., Fu Y., Fu Y., Yin L., Li X.; RT "UHRF1 promotes spindle assembly and chromosome congression by catalyzing RT EG5 polyubiquitination."; RL J. Cell Biol. 222:0-0(2023). RN [46] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND MUTAGENESIS OF PHE-59; GLY-448 RP AND HIS-741. RX PubMed=39607687; DOI=10.1093/nar/gkae1105; RA Tiedemann R.L., Hrit J., Du Q., Wiseman A.K., Eden H.E., Dickson B.M., RA Kong X., Chomiak A.A., Vaughan R.M., Tibben B.M., Hebert J.M., David Y., RA Zhou W., Baylin S.B., Jones P.A., Clark S.J., Rothbart S.B.; RT "UHRF1 ubiquitin ligase activity supports the maintenance of low-density RT CpG methylation."; RL Nucleic Acids Res. 52:13733-13756(2024). RN [47] RP FUNCTION, AND MUTAGENESIS OF TYR-188. RX PubMed=39631394; DOI=10.1016/j.molcel.2024.11.009; RA Liu Y., Hrit J.A., Chomiak A.A., Stransky S., Hoffman J.R., Tiedemann R.L., RA Wiseman A.K., Kariapper L.S., Dickson B.M., Worden E.J., Fry C.J., RA Sidoli S., Rothbart S.B.; RT "DNA hypomethylation promotes UHRF1-and SUV39H1/H2-dependent crosstalk RT between H3K18ub and H3K9me3 to reinforce heterochromatin states."; RL Mol. Cell 85:394-412(2025). RN [48] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1-76. RG Structural genomics consortium (SGC); RT "Ubiquitin-like domain of human nuclear zinc finger protein NP95."; RL Submitted (JAN-2006) to the PDB data bank. RN [49] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 408-643. RX PubMed=18931436; DOI=10.1107/s1744309108027462; RA Delagoutte B., Lallous N., Birck C., Oudet P., Samama J.P.; RT "Expression, purification, crystallization and preliminary crystallographic RT study of the SRA domain of the human UHRF1 protein."; RL Acta Crystallogr. F 64:922-925(2008). RN [50] RP X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 414-617, AND MUTAGENESIS OF RP ARG-433; ARG-443; TYR-466 AND ARG-491. RX PubMed=18945682; DOI=10.1074/jbc.c800169200; RA Qian C., Li S., Jakoncic J., Zeng L., Walsh M.J., Zhou M.M.; RT "Structure and hemimethylated CpG binding of the SRA domain from human RT UHRF1."; RL J. Biol. Chem. 283:34490-34494(2008). RN [51] {ECO:0007744|PDB:3BI7, ECO:0007744|PDB:3CLZ} RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 414-617 IN COMPLEX WITH RP HEMIMETHYLATED DNA, FUNCTION, AND MUTAGENESIS OF GLY-448; ASP-469; ASN-489 RP AND ARG-491. RX PubMed=18772889; DOI=10.1038/nature07273; RA Avvakumov G.V., Walker J.R., Xue S., Li Y., Duan S., Bronner C., RA Arrowsmith C.H., Dhe-Paganon S.; RT "Structural basis for recognition of hemi-methylated DNA by the SRA domain RT of human UHRF1."; RL Nature 455:822-825(2008). RN [52] {ECO:0007744|PDB:3FL2} RP X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 672-793 IN COMPLEX WITH ZN(2+). RA Walker J.R., Avvakumov G.V., Xue S., Li Y., Bountra C., Weigelt J., RA Arrowsmith C.H., Edwards A.M., Bochkarev A., Dhe-Paganon S.; RT "Structure of the Ring domain of the E3 ubiquitin-protein ligase Uhrf1."; RL Submitted (DEC-2008) to the PDB data bank. RN [53] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 298-366 IN COMPLEX WITH ZINC, AND RP MUTAGENESIS OF ASP-334 AND ASP-337. RX PubMed=21808300; DOI=10.1038/cr.2011.124; RA Hu L., Li Z., Wang P., Lin Y., Xu Y.; RT "Crystal structure of PHD domain of UHRF1 and insights into recognition of RT unmodified histone H3 arginine residue 2."; RL Cell Res. 21:1374-1378(2011). RN [54] RP STRUCTURE BY NMR OF 298-366, AND MUTAGENESIS OF ASP-334 AND ASP-337. RX PubMed=21808299; DOI=10.1038/cr.2011.123; RA Wang C., Shen J., Yang Z., Chen P., Zhao B., Hu W., Lan W., Tong X., Wu H., RA Li G., Cao C.; RT "Structural basis for site-specific reading of unmodified R2 of histone H3 RT tail by UHRF1 PHD finger."; RL Cell Res. 21:1379-1382(2011). RN [55] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 126-285, STRUCTURE BY NMR OF RP 126-285, AND MUTAGENESIS OF ASP-142; ASP-145; PHE-152; GLU-153; TYR-188 AND RP ASP-190. RX PubMed=21489993; DOI=10.1074/jbc.m111.234104; RA Nady N., Lemak A., Walker J.R., Avvakumov G.V., Kareta M.S., Achour M., RA Xue S., Duan S., Allali-Hassani A., Zuo X., Wang Y.X., Bronner C., RA Chedin F., Arrowsmith C.H., Dhe-Paganon S.; RT "Recognition of multivalent histone states associated with heterochromatin RT by UHRF1 protein."; RL J. Biol. Chem. 286:24300-24311(2011). RN [56] {ECO:0007744|PDB:3SOU, ECO:0007744|PDB:3SOW, ECO:0007744|PDB:3SOX} RP X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 298-367 IN COMPLEX WITH ZINC AND RP HISTONE H3 PEPTIDE, FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP 334-ASP-GLU-335. RX PubMed=21777816; DOI=10.1016/j.molcel.2011.07.006; RA Rajakumara E., Wang Z., Ma H., Hu L., Chen H., Lin Y., Guo R., Wu F., RA Li H., Lan F., Shi Y.G., Xu Y., Patel D.J., Shi Y.; RT "PHD finger recognition of unmodified histone H3R2 links UHRF1 to RT regulation of euchromatic gene expression."; RL Mol. Cell 43:275-284(2011). RN [57] RP X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 314-367, AND MUTAGENESIS OF RP GLN-330; ASP-334 AND ASP-337. RX PubMed=22096602; DOI=10.1371/journal.pone.0027599; RA Lallous N., Legrand P., McEwen A.G., Ramon-Maiques S., Samama J.P., RA Birck C.; RT "The PHD finger of human UHRF1 reveals a new subgroup of unmethylated RT histone H3 tail readers."; RL PLoS ONE 6:E27599-E27599(2011). RN [58] RP X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 299-364 IN COMPLEX WITH HISTONE RP H3 PEPTIDE, AND FUNCTION. RX PubMed=22100450; DOI=10.1016/j.jmb.2011.11.012; RA Xie S., Jakoncic J., Qian C.; RT "UHRF1 double tudor domain and the adjacent PHD finger act together to RT recognize K9me3-containing histone H3 tail."; RL J. Mol. Biol. 415:318-328(2012). RN [59] {ECO:0007744|PDB:3ASK, ECO:0007744|PDB:3ASL} RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 134-367 IN COMPLEX WITH ZINC AND RP HISTONE H3 PEPTIDE, FUNCTION, PHOSPHORYLATION AT SER-298, AND MUTAGENESIS RP OF 295-ARG-ARG-296. RX PubMed=22837395; DOI=10.1073/pnas.1203701109; RA Arita K., Isogai S., Oda T., Unoki M., Sugita K., Sekiyama N., Kuwata K., RA Hamamoto R., Tochio H., Sato M., Ariyoshi M., Shirakawa M.; RT "Recognition of modification status on a histone H3 tail by linked histone RT reader modules of the epigenetic regulator UHRF1."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12950-12955(2012). CC -!- FUNCTION: E3 ubiquitin-protein ligase that acts as a key epigenetic CC regulator by bridging DNA methylation and chromatin modification CC (PubMed:10646863, PubMed:15009091, PubMed:19056828, PubMed:23022729, CC PubMed:24013172, PubMed:27595565, PubMed:30104358, PubMed:30392929, CC PubMed:30392931, PubMed:39607687). Plays a key role in DNA methylation CC inheritance by promoting recruitment of DNMT1 to hemimethylated DNA and CC ensure faithful propagation of the DNA methylation patterns through DNA CC replication (PubMed:23022729, PubMed:24013172, PubMed:27595565, CC PubMed:30104358, PubMed:30392929, PubMed:30392931, PubMed:39607687). CC Acts both as a histone reader and writer: specifically recognizes and CC binds (1) hemimethylated DNA at replication forks and (2) histone H3 CC trimethylated at 'Lys-9' and unmethylated at 'Arg-2' (H3K9me3 and CC H3R2me0, respectively), thereby activating its E3 ubiquitin-protein CC ligase activity (PubMed:15361834, PubMed:17673620, PubMed:17967883, CC PubMed:18772889, PubMed:21745816, PubMed:21777816, PubMed:22100450, CC PubMed:22837395, PubMed:23022729, PubMed:27595565, PubMed:30104358). CC UHRF1 then mediates histone H3 'Lys-18' monoubiquitination (H3K18ub), a CC docking site for DNMT1, leading to DNMT1 recruitment and replication- CC coupled DNA methylation maintenance (PubMed:27595565). Also mediates CC histone H3 'Lys-14' and 'Lys-23' ubiquitination (H3K14ub and H3K23ub) CC at lower level (PubMed:24013172, PubMed:27595565). Histone ubiquitin CC ligase activity also stimulates the methyltransferase activity of CC SUV39H1 and/or SUV39H2, promoting accumulation of H3K9me3 histone mark CC to reinformce heterochromatin state (PubMed:39631394). Enriched in CC pericentric heterochromatin where it recruits different chromatin CC modifiers required for this chromatin replication. Also localizes to CC euchromatic regions where it negatively regulates transcription CC possibly by impacting DNA methylation and histone modifications CC (PubMed:21777816). Plays a role in DNA repair by cooperating with UHRF2 CC to ensure recruitment of FANCD2 to interstrand cross-links (ICLs) CC leading to FANCD2 activation (PubMed:30335751). Also ubiquitinates non- CC histone proteins, such as histone H3, KIF11 and PML (PubMed:22945642, CC PubMed:37728657). Acts as a critical player of proper spindle CC architecture by catalyzing the 'Lys-63'-linked ubiquitination of KIF11, CC thereby controlling KIF11 localization on the spindle CC (PubMed:37728657). {ECO:0000269|PubMed:10646863, CC ECO:0000269|PubMed:15009091, ECO:0000269|PubMed:15361834, CC ECO:0000269|PubMed:17673620, ECO:0000269|PubMed:17967883, CC ECO:0000269|PubMed:18772889, ECO:0000269|PubMed:19056828, CC ECO:0000269|PubMed:21745816, ECO:0000269|PubMed:21777816, CC ECO:0000269|PubMed:22100450, ECO:0000269|PubMed:22837395, CC ECO:0000269|PubMed:22945642, ECO:0000269|PubMed:23022729, CC ECO:0000269|PubMed:24013172, ECO:0000269|PubMed:27595565, CC ECO:0000269|PubMed:30104358, ECO:0000269|PubMed:30335751, CC ECO:0000269|PubMed:30392929, ECO:0000269|PubMed:30392931, CC ECO:0000269|PubMed:37728657, ECO:0000269|PubMed:39607687, CC ECO:0000269|PubMed:39631394}. CC -!- CATALYTIC ACTIVITY: CC Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine + CC [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L- CC cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.; CC EC=2.3.2.27; Evidence={ECO:0000269|PubMed:22945642, CC ECO:0000269|PubMed:24013172, ECO:0000269|PubMed:27595565, CC ECO:0000269|PubMed:30392929, ECO:0000269|PubMed:30392931, CC ECO:0000269|PubMed:37728657, ECO:0000269|PubMed:39607687}; CC -!- PATHWAY: Protein modification; protein ubiquitination. CC {ECO:0000269|PubMed:22945642, ECO:0000269|PubMed:24013172, CC ECO:0000269|PubMed:27595565, ECO:0000269|PubMed:30392929, CC ECO:0000269|PubMed:30392931, ECO:0000269|PubMed:37728657, CC ECO:0000269|PubMed:39607687}. CC -!- SUBUNIT: Interacts with DNMT1; the interaction is direct CC (PubMed:17673620, PubMed:21745816). Interacts with DNMT3A and DNMT3B CC (By similarity). Interacts with HDAC1, but not with HDAC2 CC (PubMed:15361834). Interacts with BLTP3A (PubMed:15361834). Interacts CC with EHMT2 (PubMed:19056828). Interacts with ZNF263; recruited to the CC SIX3 promoter along with other proteins involved in chromatin CC modification and transcriptional corepression where it contributes to CC transcriptional repression (PubMed:32051553). Interacts with UHRF2 CC (PubMed:30335751). Interacts with FANCD2 (PubMed:30335751). Interacts CC with TET1 isoform 2; this interaction induces the recruitment of TET1 CC isoform 2 to replicating heterochromatin (By similarity). CC {ECO:0000250|UniProtKB:Q8VDF2, ECO:0000269|PubMed:15361834, CC ECO:0000269|PubMed:17673620, ECO:0000269|PubMed:19056828, CC ECO:0000269|PubMed:21745816, ECO:0000269|PubMed:30335751, CC ECO:0000269|PubMed:32051553}. CC -!- INTERACTION: CC Q96T88; P26358: DNMT1; NbExp=12; IntAct=EBI-1548946, EBI-719459; CC Q96T88; Q9Y6K1: DNMT3A; NbExp=7; IntAct=EBI-1548946, EBI-923653; CC Q96T88; Q9UBC3: DNMT3B; NbExp=7; IntAct=EBI-1548946, EBI-80125; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00358, CC ECO:0000269|PubMed:10646863, ECO:0000269|PubMed:17673620, CC ECO:0000269|PubMed:17967883, ECO:0000269|PubMed:19056828, CC ECO:0000269|PubMed:21777816, ECO:0000269|PubMed:30335751}. Chromosome CC {ECO:0000269|PubMed:17673620, ECO:0000269|PubMed:17967883, CC ECO:0000269|PubMed:21777816, ECO:0000269|PubMed:23022729, CC ECO:0000269|PubMed:27595565, ECO:0000269|PubMed:30104358}. CC Note=Associated with replicating DNA from early to late S phase, CC including at replicating pericentric heterochromatin (PubMed:17673620). CC Also localizes to euchromatic regions (PubMed:21777816). In non-S-phase CC cells, homogenously distributed through the nucleus (By similarity). CC {ECO:0000250|UniProtKB:Q8VDF2, ECO:0000269|PubMed:17673620, CC ECO:0000269|PubMed:21777816}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q96T88-1; Sequence=Displayed; CC Name=2; CC IsoId=Q96T88-2; Sequence=VSP_044394; CC -!- TISSUE SPECIFICITY: Expressed in thymus, bone marrow, testis, lung and CC heart. Overexpressed in breast cancer. {ECO:0000269|PubMed:10646863, CC ECO:0000269|PubMed:12838312, ECO:0000269|PubMed:15361834}. CC -!- DEVELOPMENTAL STAGE: Expressed in fetal thymus, liver and kidney. CC {ECO:0000269|PubMed:10646863}. CC -!- INDUCTION: Up-regulated in proliferating cells, and down-regulated in CC quiescent cells. Down-regulated upon adriamycin-induced DNA damage, in CC a p53/TP53 and CDKN1A-dependent way. Induced by E2F1 transcription CC factor. {ECO:0000269|PubMed:10646863, ECO:0000269|PubMed:12838312, CC ECO:0000269|PubMed:15009091, ECO:0000269|PubMed:15361834}. CC -!- DOMAIN: The UBL domain is required for the E3 histone H3 ubiquitin- CC protein ligase activity: it binds the backside of UBE2D E2 ubiquitin- CC conjugating enzymes (UBE2D1, UBE2D2, UBE2D3 or UBE2D4) and coordinates CC with other domains that recognize epigenetic marks on DNA and histone CC H3 to direct ubiquitin to H3. {ECO:0000269|PubMed:30392929, CC ECO:0000269|PubMed:30392931}. CC -!- DOMAIN: The PHD-type zinc finger specifically recognizes and binds CC histone H3 unmethylated at 'Arg-2' (H3R2me0), while the tudor-like CC regions specifically recognize and bind histone H3 trimethylated at CC 'Lys-9' (H3K9me3) (PubMed:21489993, PubMed:21777816, PubMed:22100450). CC The tudor-like regions simultaneously recognizes H3K9me3 through a CC conserved aromatic cage in the first tudor-like subdomain and CC unmodified H3K4 (H3K4me0) within a groove between the tandem subdomains CC (PubMed:21489993, PubMed:21777816, PubMed:22100450). The linker region CC plays a role in the formation of a histone H3-binding hole between the CC reader modules formed by the tudor-like regions and the PHD-type zinc CC finger by making extended contacts with the tandem tudor-like regions CC (PubMed:22837395). {ECO:0000269|PubMed:21489993, CC ECO:0000269|PubMed:21777816, ECO:0000269|PubMed:22100450, CC ECO:0000269|PubMed:22837395}. CC -!- DOMAIN: The YDG domain (also named SRA domain) specifically recognizes CC and binds hemimethylated DNA at replication forks (DNA that is only CC methylated on the mother strand of replicating DNA) (PubMed:17673620). CC It contains a binding pocket that accommodates the 5-methylcytosine CC that is flipped out of the duplex DNA. 2 specialized loops reach CC through the resulting gap in the DNA from both the major and the minor CC grooves to read the other 3 bases of the CpG duplex. The major groove CC loop confers both specificity for the CpG dinucleotide and CC discrimination against methylation of deoxycytidine of the CC complementary strand (PubMed:18772889). The YDG domain also recognizes CC and binds 5-hydroxymethylcytosine (5hmC) (PubMed:21731699). CC {ECO:0000269|PubMed:17673620, ECO:0000269|PubMed:18772889, CC ECO:0000269|PubMed:21731699}. CC -!- PTM: Phosphorylation at Ser-298 of the linker region by PKA decreases CC the binding to H3K9me3 (PubMed:15178447, PubMed:22837395). CC Phosphorylation at Ser-639 by CDK1 during M phase impairs interaction CC with USP7, preventing deubiquitination and leading to degradation by CC the proteasome (PubMed:22411829). {ECO:0000269|PubMed:15178447, CC ECO:0000269|PubMed:22411829, ECO:0000269|PubMed:22837395}. CC -!- PTM: Ubiquitinated; which leads to proteasomal degradation CC (PubMed:15009091). Autoubiquitinated; interaction with USP7 leads to CC deubiquitination and prevents degradation (PubMed:17967883, CC PubMed:21745816, PubMed:22411829). Ubiquitination and degradation takes CC place during M phase, when phosphorylation at Ser-639 prevents CC interaction with USP7 and subsequent deubiquitination CC (PubMed:22411829). Polyubiquitination may be stimulated by DNA damage CC (PubMed:15009091). {ECO:0000269|PubMed:15009091, CC ECO:0000269|PubMed:17967883, ECO:0000269|PubMed:21745816, CC ECO:0000269|PubMed:22411829}. CC -!- DISEASE: Note=Defects in UHRF1 may be a cause of cancers. Overexpressed CC in many different forms of human cancers, including bladder, breast, CC cervical, colorectal and prostate cancers, as well as pancreatic CC adenocarcinomas, rhabdomyosarcomas and gliomas. Plays an important role CC in the correlation of histone modification and gene silencing in cancer CC progression. Expression is associated with a poor prognosis in patients CC with various cancers, suggesting that it participates in cancer CC progression. {ECO:0000269|PubMed:19491893, ECO:0000269|PubMed:22286757, CC ECO:0000269|PubMed:22330138}. CC -!- SEQUENCE CAUTION: CC Sequence=BAB15177.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF129507; AAF28469.1; -; mRNA. DR EMBL; AB177623; BAF36719.1; -; mRNA. DR EMBL; AB177624; BAF36720.1; -; mRNA. DR EMBL; AB075601; BAC20576.1; -; mRNA. DR EMBL; AF274048; AAK55744.1; -; mRNA. DR EMBL; EF560733; ABQ59043.1; -; mRNA. DR EMBL; AK025578; BAB15177.1; ALT_INIT; mRNA. DR EMBL; AK289389; BAF82078.1; -; mRNA. DR EMBL; AK314579; BAG37156.1; -; mRNA. DR EMBL; AY787925; AAV40831.1; -; Genomic_DNA. DR EMBL; AC027319; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC053467; AAF64067.1; -; Genomic_DNA. DR EMBL; CH471139; EAW69187.1; -; Genomic_DNA. DR EMBL; BC113875; AAI13876.2; -; mRNA. DR CCDS; CCDS74262.1; -. [Q96T88-2] DR CCDS; CCDS74263.1; -. [Q96T88-1] DR RefSeq; NP_001041666.1; NM_001048201.3. [Q96T88-1] DR RefSeq; NP_001276979.1; NM_001290050.2. [Q96T88-1] DR RefSeq; NP_001276980.1; NM_001290051.2. [Q96T88-1] DR RefSeq; NP_001276981.1; NM_001290052.2. [Q96T88-1] DR RefSeq; NP_037414.3; NM_013282.4. DR PDB; 2FAZ; X-ray; 2.00 A; A/B=1-76. DR PDB; 2L3R; NMR; -; A=126-285. DR PDB; 2LGG; NMR; -; A=298-366. DR PDB; 2LGK; NMR; -; A=298-366. DR PDB; 2LGL; NMR; -; A=298-366. DR PDB; 2PB7; X-ray; 1.90 A; A=408-643. DR PDB; 3ASK; X-ray; 2.90 A; A/B/C/D=134-367. DR PDB; 3ASL; X-ray; 1.41 A; A=298-367. DR PDB; 3BI7; X-ray; 1.70 A; A=414-617. DR PDB; 3CLZ; X-ray; 2.20 A; A/B/C/D=414-617. DR PDB; 3DB3; X-ray; 2.40 A; A=126-285. DR PDB; 3DB4; X-ray; 2.40 A; A=126-285. DR PDB; 3DWH; X-ray; 1.95 A; A=414-617. DR PDB; 3FL2; X-ray; 1.75 A; A=672-793. DR PDB; 3SHB; X-ray; 1.80 A; A=298-366. DR PDB; 3SOU; X-ray; 1.80 A; A/B=298-367. DR PDB; 3SOW; X-ray; 1.95 A; A/B=298-367. DR PDB; 3SOX; X-ray; 2.65 A; A/B=298-367. DR PDB; 3T6R; X-ray; 1.95 A; A/B=299-364. DR PDB; 3ZVY; X-ray; 1.95 A; A/B=296-367. DR PDB; 3ZVZ; X-ray; 1.45 A; B=314-367. DR PDB; 4GY5; X-ray; 2.96 A; A/B/C/D=134-366. DR PDB; 4QQD; X-ray; 2.28 A; A/B=126-285. DR PDB; 5C6D; X-ray; 2.29 A; C/D=634-665. DR PDB; 5IAY; NMR; -; A=134-285, B=642-657. DR PDB; 5XPI; X-ray; 2.20 A; A=127-283. DR PDB; 5YY9; X-ray; 2.65 A; A/B=123-285. DR PDB; 5YYA; X-ray; 1.70 A; A=123-285. DR PDB; 6B9M; X-ray; 1.68 A; D=638-678. DR PDB; 6IIW; X-ray; 1.70 A; A=299-366. DR PDB; 6VCS; X-ray; 1.70 A; A/B/E=414-617. DR PDB; 6VED; NMR; -; A=133-300. DR PDB; 6VYJ; X-ray; 1.39 A; A=122-283. DR PDB; 6W92; X-ray; 1.30 A; A=122-283. DR PDB; 7FB7; X-ray; 1.45 A; A/B=123-285. DR PDB; 8JIG; X-ray; 2.40 A; A/B=413-617. DR PDB; 8WMS; X-ray; 2.40 A; A=299-366. DR PDB; 8XV4; X-ray; 3.20 A; A/B=134-366. DR PDB; 8XV6; X-ray; 1.60 A; A/C=298-367. DR PDB; 8XV7; X-ray; 2.25 A; A/C/E/G=134-366. DR PDB; 8XV8; X-ray; 2.05 A; A/C/E/G=298-367. DR PDBsum; 2FAZ; -. DR PDBsum; 2L3R; -. DR PDBsum; 2LGG; -. DR PDBsum; 2LGK; -. DR PDBsum; 2LGL; -. DR PDBsum; 2PB7; -. DR PDBsum; 3ASK; -. DR PDBsum; 3ASL; -. DR PDBsum; 3BI7; -. DR PDBsum; 3CLZ; -. DR PDBsum; 3DB3; -. DR PDBsum; 3DB4; -. DR PDBsum; 3DWH; -. DR PDBsum; 3FL2; -. DR PDBsum; 3SHB; -. DR PDBsum; 3SOU; -. DR PDBsum; 3SOW; -. DR PDBsum; 3SOX; -. DR PDBsum; 3T6R; -. DR PDBsum; 3ZVY; -. DR PDBsum; 3ZVZ; -. DR PDBsum; 4GY5; -. DR PDBsum; 4QQD; -. DR PDBsum; 5C6D; -. DR PDBsum; 5IAY; -. DR PDBsum; 5XPI; -. DR PDBsum; 5YY9; -. DR PDBsum; 5YYA; -. DR PDBsum; 6B9M; -. DR PDBsum; 6IIW; -. DR PDBsum; 6VCS; -. DR PDBsum; 6VED; -. DR PDBsum; 6VYJ; -. DR PDBsum; 6W92; -. DR PDBsum; 7FB7; -. DR PDBsum; 8JIG; -. DR PDBsum; 8WMS; -. DR PDBsum; 8XV4; -. DR PDBsum; 8XV6; -. DR PDBsum; 8XV7; -. DR PDBsum; 8XV8; -. DR AlphaFoldDB; Q96T88; -. DR BMRB; Q96T88; -. DR SASBDB; Q96T88; -. DR SMR; Q96T88; -. DR BioGRID; 118893; 235. DR CORUM; Q96T88; -. DR FunCoup; Q96T88; 1543. DR IntAct; Q96T88; 82. DR MINT; Q96T88; -. DR STRING; 9606.ENSP00000479617; -. DR BindingDB; Q96T88; -. DR ChEMBL; CHEMBL2424510; -. DR GlyGen; Q96T88; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q96T88; -. DR PhosphoSitePlus; Q96T88; -. DR SwissPalm; Q96T88; -. DR BioMuta; UHRF1; -. DR DMDM; 67462077; -. DR jPOST; Q96T88; -. DR MassIVE; Q96T88; -. DR PaxDb; 9606-ENSP00000479617; -. DR PeptideAtlas; Q96T88; -. DR ProteomicsDB; 78215; -. [Q96T88-1] DR Pumba; Q96T88; -. DR Antibodypedia; 72541; 412 antibodies from 35 providers. DR DNASU; 29128; -. DR Ensembl; ENST00000612630.4; ENSP00000484739.1; ENSG00000276043.6. [Q96T88-1] DR Ensembl; ENST00000615884.4; ENSP00000478601.1; ENSG00000276043.6. [Q96T88-1] DR Ensembl; ENST00000616255.1; ENSP00000478348.1; ENSG00000276043.6. [Q96T88-1] DR Ensembl; ENST00000624301.3; ENSP00000485604.1; ENSG00000276043.6. [Q96T88-1] DR Ensembl; ENST00000650932.1; ENSP00000498698.1; ENSG00000276043.6. [Q96T88-1] DR GeneID; 29128; -. DR KEGG; hsa:29128; -. DR MANE-Select; ENST00000650932.1; ENSP00000498698.1; NM_001048201.3; NP_001041666.1. DR UCSC; uc032hkj.2; human. [Q96T88-1] DR AGR; HGNC:12556; -. DR ClinPGx; PA37196; -. DR CTD; 29128; -. DR DisGeNET; 29128; -. DR GeneCards; UHRF1; -. DR HGNC; HGNC:12556; UHRF1. DR HPA; ENSG00000276043; Group enriched (bone marrow, lymphoid tissue). DR MalaCards; UHRF1; -. DR MIM; 607990; gene. DR OpenTargets; ENSG00000276043; -. DR Orphanet; 2268; ICF syndrome. DR VEuPathDB; HostDB:ENSG00000276043; -. DR eggNOG; ENOG502QRDQ; Eukaryota. DR GeneTree; ENSGT00390000008296; -. DR HOGENOM; CLU_022357_0_0_1; -. DR InParanoid; Q96T88; -. DR OrthoDB; 2270193at2759; -. DR PAN-GO; Q96T88; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q96T88; -. DR PathwayCommons; Q96T88; -. DR Reactome; R-HSA-5334118; DNA methylation. DR Reactome; R-HSA-9821002; Chromatin modifications during the maternal to zygotic transition (MZT). DR SignaLink; Q96T88; -. DR SIGNOR; Q96T88; -. DR UniPathway; UPA00143; -. DR Agora; ENSG00000276043; -. DR BioGRID-ORCS; 29128; 65 hits in 331 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; UHRF1; human. DR EvolutionaryTrace; Q96T88; -. DR GeneWiki; UHRF1; -. DR GenomeRNAi; 29128; -. DR Pharos; Q96T88; Tbio. DR PRO; PR:Q96T88; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q96T88; protein. DR Bgee; ENSG00000276043; Expressed in oocyte and 139 other cell types or tissues. DR ExpressionAtlas; Q96T88; baseline and differential. DR GO; GO:0000785; C:chromatin; IDA:UniProtKB. DR GO; GO:0000791; C:euchromatin; IDA:UniProtKB. DR GO; GO:0000792; C:heterochromatin; IDA:UniProtKB. DR GO; GO:0016363; C:nuclear matrix; ISS:BHF-UCL. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:BHF-UCL. DR GO; GO:0005657; C:replication fork; IDA:UniProtKB. DR GO; GO:0005819; C:spindle; IC:UniProt. DR GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; IDA:BHF-UCL. DR GO; GO:0140612; F:DNA damage sensor activity; TAS:BHF-UCL. DR GO; GO:0044729; F:hemi-methylated DNA-binding; IDA:UniProtKB. DR GO; GO:0042393; F:histone binding; IDA:UniProtKB. DR GO; GO:0141055; F:histone H3 ubiquitin ligase activity; IDA:UniProtKB. DR GO; GO:0140851; F:histone H3K14 ubiquitin ligase activity; IDA:UniProtKB. DR GO; GO:0140248; F:histone H3K18 ubiquitin ligase activity; IDA:UniProtKB. DR GO; GO:0140234; F:histone H3K23 ubiquitin ligase activity; IDA:UniProtKB. DR GO; GO:0062072; F:histone H3K9me2/3 reader activity; IDA:UniProtKB. DR GO; GO:0042802; F:identical protein binding; ISS:BHF-UCL. DR GO; GO:0008327; F:methyl-CpG binding; IDA:UniProtKB. DR GO; GO:0003676; F:nucleic acid binding; EXP:DisProt. DR GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:UniProt. DR GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB. DR GO; GO:0141119; P:chromosomal DNA methylation maintenance following DNA replication; IDA:UniProtKB. DR GO; GO:0006974; P:DNA damage response; TAS:BHF-UCL. DR GO; GO:0000724; P:double-strand break repair via homologous recombination; TAS:BHF-UCL. DR GO; GO:0040029; P:epigenetic regulation of gene expression; TAS:BHF-UCL. DR GO; GO:0031507; P:heterochromatin formation; IDA:UniProtKB. DR GO; GO:0035825; P:homologous recombination; TAS:BHF-UCL. DR GO; GO:0090307; P:mitotic spindle assembly; IDA:UniProt. DR GO; GO:0044027; P:negative regulation of gene expression via chromosomal CpG island methylation; IMP:UniProtKB. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0051247; P:positive regulation of protein metabolic process; IDA:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL. DR GO; GO:0051865; P:protein autoubiquitination; IDA:UniProtKB. DR GO; GO:0071168; P:protein localization to chromatin; IDA:UniProt. DR GO; GO:0016567; P:protein ubiquitination; IBA:GO_Central. DR GO; GO:0050678; P:regulation of epithelial cell proliferation; IMP:BHF-UCL. DR GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:UniProtKB. DR CDD; cd15616; PHD_UHRF1; 1. DR CDD; cd16769; RING-HC_UHRF1; 1. DR CDD; cd20455; Tudor_UHRF1_rpt1; 1. DR CDD; cd20457; Tudor_UHRF1_rpt2; 1. DR CDD; cd17122; Ubl_UHRF1; 1. DR DisProt; DP01651; -. DR FunFam; 2.30.280.10:FF:000001; E3 ubiquitin-protein ligase UHRF1 isoform 1; 1. DR FunFam; 2.30.30.140:FF:000068; E3 ubiquitin-protein ligase UHRF1 isoform 1; 1. DR FunFam; 3.10.20.90:FF:000143; E3 ubiquitin-protein ligase UHRF1 isoform 1; 1. DR FunFam; 2.30.30.1150:FF:000001; E3 ubiquitin-protein ligase UHRF2 isoform X1; 1. DR FunFam; 3.30.40.10:FF:000066; E3 ubiquitin-protein ligase UHRF2 isoform X1; 1. DR Gene3D; 2.30.30.1150; -; 1. DR Gene3D; 2.30.30.140; -; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR Gene3D; 2.30.280.10; SRA-YDG; 1. DR Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1. DR IDEAL; IID00327; -. DR InterPro; IPR015947; PUA-like_sf. DR InterPro; IPR036987; SRA-YDG_sf. DR InterPro; IPR003105; SRA_YDG. DR InterPro; IPR021991; TTD_dom. DR InterPro; IPR000626; Ubiquitin-like_dom. DR InterPro; IPR029071; Ubiquitin-like_domsf. DR InterPro; IPR047406; Ubl_UHRF1. DR InterPro; IPR045134; UHRF1/2-like. DR InterPro; IPR011011; Znf_FYVE_PHD. DR InterPro; IPR001965; Znf_PHD. DR InterPro; IPR019787; Znf_PHD-finger. DR InterPro; IPR001841; Znf_RING. DR InterPro; IPR013083; Znf_RING/FYVE/PHD. DR InterPro; IPR017907; Znf_RING_CS. DR PANTHER; PTHR14140; E3 UBIQUITIN-PROTEIN LIGASE UHRF-RELATED; 1. DR PANTHER; PTHR14140:SF2; E3 UBIQUITIN-PROTEIN LIGASE UHRF1; 1. DR Pfam; PF00628; PHD; 1. DR Pfam; PF02182; SAD_SRA; 1. DR Pfam; PF12148; TTD; 1. DR Pfam; PF00240; ubiquitin; 1. DR SMART; SM00249; PHD; 1. DR SMART; SM00184; RING; 2. DR SMART; SM00466; SRA; 1. DR SMART; SM00213; UBQ; 1. DR SUPFAM; SSF57903; FYVE/PHD zinc finger; 1. DR SUPFAM; SSF88697; PUA domain-like; 1. DR SUPFAM; SSF57850; RING/U-box; 1. DR SUPFAM; SSF54236; Ubiquitin-like; 1. DR PROSITE; PS50053; UBIQUITIN_2; 1. DR PROSITE; PS51015; YDG; 1. DR PROSITE; PS01359; ZF_PHD_1; 1. DR PROSITE; PS50016; ZF_PHD_2; 1. DR PROSITE; PS00518; ZF_RING_1; 1. DR PROSITE; PS50089; ZF_RING_2; 2. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Cell cycle; KW Chromatin regulator; Chromosome; DNA damage; DNA repair; DNA-binding; KW Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; Repressor; KW Transcription; Transcription regulation; Transferase; Ubl conjugation; KW Ubl conjugation pathway; Zinc; Zinc-finger. FT CHAIN 1..793 FT /note="E3 ubiquitin-protein ligase UHRF1" FT /id="PRO_0000056144" FT DOMAIN 1..78 FT /note="Ubiquitin-like" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00214" FT DOMAIN 419..582 FT /note="YDG" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00358" FT ZN_FING 310..366 FT /note="PHD-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00146" FT ZN_FING 724..763 FT /note="RING-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00175" FT REGION 82..124 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 133..209 FT /note="Tudor-like 1" FT /evidence="ECO:0000269|PubMed:21489993" FT REGION 216..283 FT /note="Tudor-like 2" FT /evidence="ECO:0000269|PubMed:21489993" FT REGION 296..301 FT /note="Linker" FT /evidence="ECO:0000269|PubMed:22837395" FT REGION 333..337 FT /note="Histone H3R2me0 binding" FT /evidence="ECO:0000269|PubMed:21777816" FT REGION 353..355 FT /note="Histone H3R2me0 binding" FT /evidence="ECO:0000269|PubMed:21777816" FT REGION 445..446 FT /note="Required to promote base flipping" FT /evidence="ECO:0000250|UniProtKB:Q8VDF2" FT REGION 466..469 FT /note="Required for formation of a 5-methylcytosine-binding FT pocket" FT /evidence="ECO:0000269|PubMed:18772889" FT REGION 478..481 FT /note="Required for formation of a 5-methylcytosine-binding FT pocket" FT /evidence="ECO:0000269|PubMed:18772889" FT REGION 618..673 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 618..629 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 302 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:22837395, ECO:0007744|PDB:3ASK, FT ECO:0007744|PDB:3ASL, ECO:0007744|PDB:3SOU" FT BINDING 305 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:22837395, ECO:0007744|PDB:3ASK, FT ECO:0007744|PDB:3ASL, ECO:0007744|PDB:3SOU" FT BINDING 313 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:22837395, ECO:0007744|PDB:3ASK, FT ECO:0007744|PDB:3ASL, ECO:0007744|PDB:3SOU" FT BINDING 316 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:22837395, ECO:0007744|PDB:3ASK, FT ECO:0007744|PDB:3ASL, ECO:0007744|PDB:3SOU" FT BINDING 318 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:22837395, ECO:0007744|PDB:3ASK, FT ECO:0007744|PDB:3ASL, ECO:0007744|PDB:3SOU" FT BINDING 319 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:22837395, ECO:0007744|PDB:3ASL, FT ECO:0007744|PDB:3SOU" FT BINDING 321 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:22837395, ECO:0007744|PDB:3ASL, FT ECO:0007744|PDB:3SOU" FT BINDING 333 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:22837395, ECO:0007744|PDB:3ASK, FT ECO:0007744|PDB:3ASL, ECO:0007744|PDB:3SOU" FT BINDING 336 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:22837395, FT ECO:0007744|PDB:3ASK, ECO:0007744|PDB:3ASL" FT BINDING 341 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:22837395, FT ECO:0007744|PDB:3ASK, ECO:0007744|PDB:3ASL" FT BINDING 344 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:22837395, FT ECO:0007744|PDB:3ASK, ECO:0007744|PDB:3ASL" FT BINDING 360 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:22837395, FT ECO:0007744|PDB:3ASL" FT BINDING 362 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:22837395, FT ECO:0007744|PDB:3ASL" FT BINDING 363 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:22837395, FT ECO:0007744|PDB:3ASL" FT BINDING 463..464 FT /ligand="DNA" FT /ligand_id="ChEBI:CHEBI:16991" FT /ligand_part="5-methylcytosine group" FT /ligand_part_id="ChEBI:CHEBI:65274" FT /evidence="ECO:0000269|PubMed:18772889" FT BINDING 469 FT /ligand="DNA" FT /ligand_id="ChEBI:CHEBI:16991" FT /ligand_part="5-methylcytosine group" FT /ligand_part_id="ChEBI:CHEBI:65274" FT /evidence="ECO:0000269|PubMed:18772889" FT BINDING 724 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="5" FT /evidence="ECO:0000269|Ref.52, ECO:0007744|PDB:3FL2" FT BINDING 727 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="5" FT /evidence="ECO:0000269|Ref.52, ECO:0007744|PDB:3FL2" FT BINDING 739 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="6" FT /evidence="ECO:0000269|Ref.52, ECO:0007744|PDB:3FL2" FT BINDING 741 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="6" FT /evidence="ECO:0000269|Ref.52, ECO:0007744|PDB:3FL2" FT BINDING 744 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="5" FT /evidence="ECO:0000269|Ref.52, ECO:0007744|PDB:3FL2" FT BINDING 747 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="5" FT /evidence="ECO:0000269|Ref.52, ECO:0007744|PDB:3FL2" FT BINDING 759 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="6" FT /evidence="ECO:0000269|Ref.52, ECO:0007744|PDB:3FL2" FT BINDING 762 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="6" FT /evidence="ECO:0000269|Ref.52, ECO:0007744|PDB:3FL2" FT SITE 316 FT /note="Histone H3K4me0 binding" FT /evidence="ECO:0000269|PubMed:21777816" FT SITE 327 FT /note="Histone H3R2me0 binding" FT /evidence="ECO:0000269|PubMed:21777816" FT SITE 330 FT /note="Histone H3R2me0 binding" FT /evidence="ECO:0000269|PubMed:21777816" FT SITE 479 FT /note="Required to confer preferential recognition of FT cytosine over thymine" FT /evidence="ECO:0000269|PubMed:18772889" FT SITE 489 FT /note="Required to discriminate between hemimethylated DNA FT versus symmetrically methylated DNA" FT /evidence="ECO:0000269|PubMed:18772889" FT SITE 491 FT /note="Required for affinity and specificity for 5-mCpG FT sequence" FT /evidence="ECO:0000269|PubMed:18772889" FT MOD_RES 76 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 91 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 95 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q7TPK1" FT MOD_RES 165 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8VDF2" FT MOD_RES 287 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18220336, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 298 FT /note="Phosphoserine; by PKA" FT /evidence="ECO:0000269|PubMed:15178447, FT ECO:0000269|PubMed:22837395" FT MOD_RES 368 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 399 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 546 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 639 FT /note="Phosphoserine; by CDK1" FT /evidence="ECO:0000269|PubMed:22411829, FT ECO:0007744|PubMed:16964243, ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 651 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 707 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 709 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 279 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 385 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447" FT CROSSLNK 546 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2); alternate" FT /evidence="ECO:0007744|PubMed:25218447" FT CROSSLNK 670 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:28112733" FT VAR_SEQ 1 FT /note="M -> MGVFAVPPLSSDTM (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_044394" FT VARIANT 240 FT /note="D -> H (in dbSNP:rs17886098)" FT /evidence="ECO:0000269|Ref.6" FT /id="VAR_022554" FT VARIANT 379 FT /note="E -> K (in dbSNP:rs17885791)" FT /evidence="ECO:0000269|PubMed:14702039, ECO:0000269|Ref.6" FT /id="VAR_022555" FT VARIANT 638 FT /note="A -> T (in dbSNP:rs2307209)" FT /evidence="ECO:0000269|PubMed:14702039, ECO:0000269|Ref.6" FT /id="VAR_022556" FT VARIANT 642 FT /note="T -> M (in dbSNP:rs17884843)" FT /evidence="ECO:0000269|Ref.6" FT /id="VAR_022557" FT VARIANT 713 FT /note="L -> F (in dbSNP:rs17883563)" FT /evidence="ECO:0000269|Ref.6" FT /id="VAR_022558" FT MUTAGEN 2 FT /note="W->V: Decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 6 FT /note="R->D: Strongly decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 8 FT /note="M->R: Strongly decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 46 FT /note="F->V: Strongly decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 48 FT /note="R->E: Strongly decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 50 FT /note="K->R: Decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 56 FT /note="H->A: No effect on histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 59 FT /note="F->V: Decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931, FT ECO:0000269|PubMed:39607687" FT MUTAGEN 62 FT /note="E->K: No effect on histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 64 FT /note="R->E: Strongly decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 65 FT /note="L->A: Decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 70 FT /note="Q->E: Abolished binding to UBE2D E2 ubiquitin FT conjugating enzymes, leading to strongly decreased histone FT H3 ubiquitin ligase activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 72 FT /note="L->A: No effect on histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 142 FT /note="D->A: Impaired binding to histone H3 without FT affecting the protein folding; when associated with A-153." FT /evidence="ECO:0000269|PubMed:21489993" FT MUTAGEN 145 FT /note="D->A: Impaired binding to histone H3." FT /evidence="ECO:0000269|PubMed:21489993" FT MUTAGEN 147 FT /note="N->D,E: Reduced binding to H3K9me3." FT /evidence="ECO:0000269|PubMed:23022729" FT MUTAGEN 152 FT /note="F->A: Impaired binding to histone H3." FT /evidence="ECO:0000269|PubMed:21489993" FT MUTAGEN 153 FT /note="E->A: Impaired binding to histone H3 without FT affecting the protein folding; when associated with A-142." FT /evidence="ECO:0000269|PubMed:21489993" FT MUTAGEN 188 FT /note="Y->A: Abolished binding to H3K9me3." FT /evidence="ECO:0000269|PubMed:20026581, FT ECO:0000269|PubMed:21489993, ECO:0000269|PubMed:23022729, FT ECO:0000269|PubMed:39631394" FT MUTAGEN 190 FT /note="D->A: Slightly impaired binding to histone H3." FT /evidence="ECO:0000269|PubMed:21489993" FT MUTAGEN 191 FT /note="Y->A: Impaired binding to histone H3." FT /evidence="ECO:0000269|PubMed:20026581" FT MUTAGEN 295..296 FT /note="RR->AA: Disrupts the simultaneous binding to H3R2me0 FT and H3K9me3." FT /evidence="ECO:0000269|PubMed:22837395" FT MUTAGEN 298 FT /note="S->A: Diminishes phosphorylation by PKA." FT /evidence="ECO:0000269|PubMed:15178447" FT MUTAGEN 330 FT /note="Q->A,K: Does not affect ability to bind histone H3 FT peptide." FT /evidence="ECO:0000269|PubMed:22096602" FT MUTAGEN 334..335 FT /note="DE->AA: Abolishes binding to histone H3. Abolished FT binding to H3K9me3." FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:30104358" FT MUTAGEN 334 FT /note="D->A: Impaired binding to histone H3." FT /evidence="ECO:0000269|PubMed:21808299, FT ECO:0000269|PubMed:21808300, ECO:0000269|PubMed:22096602" FT MUTAGEN 337 FT /note="D->A: Impaired binding to histone H3." FT /evidence="ECO:0000269|PubMed:21808299, FT ECO:0000269|PubMed:21808300, ECO:0000269|PubMed:22096602" FT MUTAGEN 433 FT /note="R->A: Does not affect ability to bind DNA." FT /evidence="ECO:0000269|PubMed:18945682" FT MUTAGEN 443 FT /note="R->A: Decreased ability to bind DNA." FT /evidence="ECO:0000269|PubMed:18945682" FT MUTAGEN 448 FT /note="G->D: Decreased affinity for DNA." FT /evidence="ECO:0000269|PubMed:18772889, FT ECO:0000269|PubMed:27595565, ECO:0000269|PubMed:30104358, FT ECO:0000269|PubMed:39607687" FT MUTAGEN 466 FT /note="Y->G: Decreased ability to bind DNA." FT /evidence="ECO:0000269|PubMed:18945682" FT MUTAGEN 469 FT /note="D->G: Abolishes ability to bind hemimethylated DNA." FT /evidence="ECO:0000269|PubMed:18772889, FT ECO:0000269|PubMed:27595565" FT MUTAGEN 489 FT /note="N->A: Abolishes specificity to hemimethylated DNA." FT /evidence="ECO:0000269|PubMed:18772889" FT MUTAGEN 491 FT /note="R->A: Decreased binding to methylated DNA but does FT not affect ability to bind DNA." FT /evidence="ECO:0000269|PubMed:18772889, FT ECO:0000269|PubMed:18945682" FT MUTAGEN 639 FT /note="S->A: Prevents phosphorylation by CDK1 during M FT phase, leading to increased stability." FT /evidence="ECO:0000269|PubMed:22411829" FT MUTAGEN 639 FT /note="S->D: Mimics phosphorylation; impaired interaction FT with USP7, leading to decreased stability." FT /evidence="ECO:0000269|PubMed:22411829" FT MUTAGEN 651 FT /note="S->A: No effect on in vitro phosphorylation by PKA." FT /evidence="ECO:0000269|PubMed:15178447" FT MUTAGEN 666 FT /note="S->A: No effect on in vitro phosphorylation by PKA." FT /evidence="ECO:0000269|PubMed:15178447" FT MUTAGEN 724..727 FT /note="CICC->AIAA: Abolished E3 ubiquitin-protein ligase FT activity." FT /evidence="ECO:0000269|PubMed:24013172" FT MUTAGEN 741 FT /note="H->A: Abolished E3 ubiquitin-protein ligase FT activity." FT /evidence="ECO:0000269|PubMed:22945642, FT ECO:0000269|PubMed:27595565, ECO:0000269|PubMed:39607687" FT CONFLICT 383 FT /note="K -> E (in Ref. 5; BAF82078)" FT /evidence="ECO:0000305" FT CONFLICT 383 FT /note="K -> N (in Ref. 1; AAF28469)" FT /evidence="ECO:0000305" FT CONFLICT 457 FT /note="A -> S (in Ref. 1; AAF28469)" FT /evidence="ECO:0000305" FT CONFLICT 675 FT /note="S -> N (in Ref. 5; BAF82078)" FT /evidence="ECO:0000305" FT STRAND 1..7 FT /evidence="ECO:0007829|PDB:2FAZ" FT STRAND 13..19 FT /evidence="ECO:0007829|PDB:2FAZ" FT HELIX 25..36 FT /evidence="ECO:0007829|PDB:2FAZ" FT HELIX 40..42 FT /evidence="ECO:0007829|PDB:2FAZ" FT STRAND 43..47 FT /evidence="ECO:0007829|PDB:2FAZ" FT TURN 58..62 FT /evidence="ECO:0007829|PDB:2FAZ" FT STRAND 68..73 FT /evidence="ECO:0007829|PDB:2FAZ" FT STRAND 126..128 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 130..132 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:7FB7" FT STRAND 140..144 FT /evidence="ECO:0007829|PDB:6W92" FT TURN 146..148 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 151..162 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 164..167 FT /evidence="ECO:0007829|PDB:2L3R" FT STRAND 173..175 FT /evidence="ECO:0007829|PDB:6W92" FT HELIX 179..181 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 183..190 FT /evidence="ECO:0007829|PDB:6W92" FT HELIX 192..194 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 196..200 FT /evidence="ECO:0007829|PDB:6W92" FT HELIX 201..203 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 204..206 FT /evidence="ECO:0007829|PDB:7FB7" FT STRAND 210..212 FT /evidence="ECO:0007829|PDB:2L3R" FT HELIX 214..216 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 222..227 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 229..231 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 237..248 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 253..260 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 262..264 FT /evidence="ECO:0007829|PDB:8XV4" FT STRAND 266..270 FT /evidence="ECO:0007829|PDB:6W92" FT HELIX 274..276 FT /evidence="ECO:0007829|PDB:2L3R" FT STRAND 277..279 FT /evidence="ECO:0007829|PDB:2L3R" FT STRAND 283..286 FT /evidence="ECO:0007829|PDB:3ASK" FT TURN 303..307 FT /evidence="ECO:0007829|PDB:3ASL" FT STRAND 309..311 FT /evidence="ECO:0007829|PDB:2LGG" FT TURN 314..316 FT /evidence="ECO:0007829|PDB:3ASL" FT TURN 319..321 FT /evidence="ECO:0007829|PDB:3ASL" FT STRAND 323..325 FT /evidence="ECO:0007829|PDB:2LGL" FT HELIX 327..329 FT /evidence="ECO:0007829|PDB:3ASL" FT STRAND 330..332 FT /evidence="ECO:0007829|PDB:3ASL" FT TURN 334..336 FT /evidence="ECO:0007829|PDB:3ASL" FT STRAND 339..341 FT /evidence="ECO:0007829|PDB:3ASL" FT HELIX 342..344 FT /evidence="ECO:0007829|PDB:3ASL" FT STRAND 345..347 FT /evidence="ECO:0007829|PDB:3ASL" FT STRAND 354..356 FT /evidence="ECO:0007829|PDB:3ASL" FT TURN 361..363 FT /evidence="ECO:0007829|PDB:3ASL" FT STRAND 417..419 FT /evidence="ECO:0007829|PDB:3DWH" FT STRAND 429..432 FT /evidence="ECO:0007829|PDB:3BI7" FT HELIX 433..438 FT /evidence="ECO:0007829|PDB:3BI7" FT TURN 439..442 FT /evidence="ECO:0007829|PDB:3DWH" FT STRAND 448..452 FT /evidence="ECO:0007829|PDB:3BI7" FT TURN 453..455 FT /evidence="ECO:0007829|PDB:3BI7" FT STRAND 456..462 FT /evidence="ECO:0007829|PDB:3BI7" FT STRAND 473..479 FT /evidence="ECO:0007829|PDB:3BI7" FT TURN 487..489 FT /evidence="ECO:0007829|PDB:3CLZ" FT HELIX 503..511 FT /evidence="ECO:0007829|PDB:3BI7" FT STRAND 512..514 FT /evidence="ECO:0007829|PDB:3BI7" FT TURN 518..520 FT /evidence="ECO:0007829|PDB:3BI7" FT HELIX 527..529 FT /evidence="ECO:0007829|PDB:3BI7" FT STRAND 533..538 FT /evidence="ECO:0007829|PDB:3BI7" FT HELIX 539..544 FT /evidence="ECO:0007829|PDB:3BI7" FT STRAND 546..548 FT /evidence="ECO:0007829|PDB:3CLZ" FT STRAND 550..568 FT /evidence="ECO:0007829|PDB:3BI7" FT STRAND 572..582 FT /evidence="ECO:0007829|PDB:3BI7" FT HELIX 592..601 FT /evidence="ECO:0007829|PDB:3BI7" FT HELIX 611..617 FT /evidence="ECO:0007829|PDB:3BI7" FT HELIX 678..686 FT /evidence="ECO:0007829|PDB:3FL2" FT HELIX 688..690 FT /evidence="ECO:0007829|PDB:3FL2" FT HELIX 691..699 FT /evidence="ECO:0007829|PDB:3FL2" FT STRAND 706..708 FT /evidence="ECO:0007829|PDB:3FL2" FT HELIX 710..721 FT /evidence="ECO:0007829|PDB:3FL2" FT TURN 725..727 FT /evidence="ECO:0007829|PDB:3FL2" FT STRAND 728..730 FT /evidence="ECO:0007829|PDB:3FL2" FT STRAND 732..736 FT /evidence="ECO:0007829|PDB:3FL2" FT STRAND 742..744 FT /evidence="ECO:0007829|PDB:3FL2" FT HELIX 745..753 FT /evidence="ECO:0007829|PDB:3FL2" FT TURN 760..762 FT /evidence="ECO:0007829|PDB:3FL2" FT HELIX 776..785 FT /evidence="ECO:0007829|PDB:3FL2" FT TURN 787..792 FT /evidence="ECO:0007829|PDB:3FL2" SQ SEQUENCE 793 AA; 89814 MW; E65B15657525C89F CRC64; MWIQVRTMDG RQTHTVDSLS RLTKVEELRR KIQELFHVEP GLQRLFYRGK QMEDGHTLFD YEVRLNDTIQ LLVRQSLVLP HSTKERDSEL SDTDSGCCLG QSESDKSSTH GEAAAETDSR PADEDMWDET ELGLYKVNEY VDARDTNMGA WFEAQVVRVT RKAPSRDEPC SSTSRPALEE DVIYHVKYDD YPENGVVQMN SRDVRARART IIKWQDLEVG QVVMLNYNPD NPKERGFWYD AEISRKRETR TARELYANVV LGDDSLNDCR IIFVDEVFKI ERPGEGSPMV DNPMRRKSGP SCKHCKDDVN RLCRVCACHL CGGRQDPDKQ LMCDECDMAF HIYCLDPPLS SVPSEDEWYC PECRNDASEV VLAGERLRES KKKAKMASAT SSSQRDWGKG MACVGRTKEC TIVPSNHYGP IPGIPVGTMW RFRVQVSESG VHRPHVAGIH GRSNDGAYSL VLAGGYEDDV DHGNFFTYTG SGGRDLSGNK RTAEQSCDQK LTNTNRALAL NCFAPINDQE GAEAKDWRSG KPVRVVRNVK GGKNSKYAPA EGNRYDGIYK VVKYWPEKGK SGFLVWRYLL RRDDDEPGPW TKEGKDRIKK LGLTMQYPEG YLEALANRER EKENSKREEE EQQEGGFASP RTGKGKWKRK SAGGGPSRAG SPRRTSKKTK VEPYSLTAQQ SSLIREDKSN AKLWNEVLAS LKDRPASGSP FQLFLSKVEE TFQCICCQEL VFRPITTVCQ HNVCKDCLDR SFRAQVFSCP ACRYDLGRSY AMQVNQPLQT VLNQLFPGYG NGR //